{"data": [{"Element": "<div class=\"WordSection1\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span style=\"font-size:10.0pt\">\u00a0</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span style=\"font-size:10.0pt\">\u00a0</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span style=\"font-size:10.0pt\">\u00a0</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\">\u00a0</p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\">\u00a0</p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\">\u00a0</p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\">\u00a0</p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\">\u00a0</p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\">\u00a0</p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\">\u00a0</p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\">\u00a0</p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b>\u00a0</b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b>\u00a0</b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b>\u00a0</b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b>\u00a0</b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b>\u00a0</b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b>\u00a0</b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b>\u00a0</b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b>\u00a0</b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b>\u00a0</b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b>\u00a0</b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b>\u00a0</b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b>\u00a0</b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b>ANNEX I</b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\">\u00a0</p>\n<p class=\"Annex\">SUMMARY OF PRODUCT CHARACTERISTICS</p>\n<b><span style='font-size:10.0pt;font-family:\"Times New Roman\",serif;\ncolor:green'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span></b>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></b></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME OF THE MEDICINAL PRODUCT</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Perjeta 420\u00a0mg concentrate for\nsolution for infusion</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 QUALITATIVE AND QUANTITATIVE\nCOMPOSITION</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">One 14\u00a0ml vial of concentrate contains\n420\u00a0mg of pertuzumab at a concentration of 30\u00a0mg/ml.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">After dilution, one ml of solution contains\napproximately 3.02 mg of pertuzumab for the initial dose and approximately 1.59\nmg of pertuzumab for the maintenance dose (see section 6.6).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Pertuzumab is a humanised IgG1 monoclonal\nantibody produced in mammalian (Chinese hamster ovary) cells by recombinant DNA\ntechnology.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">For the full list of excipients, see\nsection 6.1.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL FORM</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Concentrate for solution for infusion.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Clear to slightly opalescent, colourless to\npale yellow, liquid.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"text-transform:uppercase\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span></b><b><span lang=\"EN-GB\">CLINICAL PARTICULARS</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">4.1\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Therapeutic indications</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Early breast cancer</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Perjeta is indicated for use in combination\nwith trastuzumab and chemotherapy in:</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:35.7pt;text-indent:-17.85pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0 </span><span lang=\"EN-GB\">the neoadjuvant treatment of adult patients with HER2-positive,\nlocally advanced, inflammatory, or early stage breast cancer at high risk of\nrecurrence (see section 5.1)</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:35.7pt;text-indent:-17.85pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0 </span><span lang=\"EN-GB\">the adjuvant treatment of adult patients with HER2-positive early\nbreast cancer at high risk of recurrence (see section 5.1)</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Metastatic breast cancer</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Perjeta is indicated for use in combination\nwith trastuzumab and docetaxel in adult patients with HER2-positive metastatic\nor locally recurrent unresectable breast cancer,</span><b><i><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif'> </span></i></b><span lang=\"EN-GB\">who\nhave not received previous anti-HER2 therapy or chemotherapy for their\nmetastatic disease.</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">4.2\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Posology and method of\nadministration</span></b></p>\n<p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">\u00a0</span></i></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Perjeta should only be initiated under the\nsupervision of a physician experienced in the administration of anti-cancer\nagents. Perjeta should be administered by a healthcare professional prepared to\nmanage anaphylaxis and </span><span lang=\"EN-GB\">in an environment where full\nresuscitation facilities are immediately available</span><span lang=\"EN-GB\">.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Posology</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Patients treated with Perjeta must have\nHER2-positive tumour status, defined as a score of 3+ by immunohistochemistry\n(IHC) and/or a ratio of \u2265\u00a02.0 by in situ hybridisation (ISH)\nassessed by a validated test.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">To ensure accurate and reproducible\nresults, the testing must be performed in a specialised laboratory, which can\nensure validation of the testing procedures. For full instructions on assay\nperformance and interpretation please refer to the package leaflets of\nvalidated HER2 testing assays.</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">The recommended initial loading dose of pertuzumab\nis 840\u00a0mg administered as a 60 minute intravenous infusion, followed every\n3 weeks thereafter by a maintenance dose of 420\u00a0mg administered over a\nperiod of 30 to 60 minutes. An observation period of 30 - 60 minutes is\nrecommended after completion of each infusion.\u00a0 The observation period should\nbe completed prior to any subsequent infusion of trastuzumab or chemotherapy\n(see section 4.4).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Perjeta and trastuzumab should be\nadministered sequentially and not mixed in the same infusion bag. Perjeta and\ntrastuzumab can be given in any order. When administered with Perjeta the </span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">recommendation is to follow a 3 weekly\nschedule for trastuzumab administered as either:</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:35.7pt;text-indent:-17.85pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0 an IV\ninfusion with an initial loading dose of trastuzumab 8\u00a0mg/kg body weight\nfollowed every 3 weeks thereafter by a maintenance dose of 6\u00a0mg/kg body\nweight</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:35.7pt;text-indent:-17.85pt\"><span lang=\"EN-GB\">or </span></p>\n<p class=\"MsoNormal\" style=\"margin-left:35.7pt;text-indent:-17.85pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0 a fixed\nsubcutaneous dose of trastuzumab by injection (600\u00a0mg) every 3 weeks irrespective\nof the patient\u2019s body weight.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">In patients receiving a taxane, Perjeta and\ntrastuzumab should be administered prior to the taxane. </span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\">When administered with Perjeta, docetaxel can be started at\n75 mg/m2, and subsequently escalated to 100 mg/m2 depending on the chosen\nregimen and tolerability of the initial dose. Alternatively, docetaxel can be\ngiven at 100 mg/m2 on a 3 weekly schedule from the start, again depending on\nthe chosen regimen. If a carboplatin-based regimen is used, the recommended dose\nfor docetaxel is 75 mg/m2 throughout (no dose escalation). <span lang=\"EN-GB\">When\nadministered with Perjeta in the adjuvant setting, the recommended dose of\npaclitaxel is 80 mg/m2 once weekly for 12 weekly cycles.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">In patients receiving an anthracycline-based\nregimen, Perjeta and trastuzumab should be administered following completion of\nthe entire anthracycline regimen (see section 4.4). </span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">Metastatic breast cancer</span></i></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Perjeta should be administered in\ncombination with trastuzumab and docetaxel . Treatment with Perjeta and\ntrastuzumab may continue until disease progression or unmanageable toxicity\neven if treatment with docetaxel is discontinued.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">Early breast cancer</span></i></p>\n<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">\u00a0</span></i></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">In the neoadjuvant setting, Perjeta should\nbe administered for 3 to 6 cycles in combination with </span><span lang=\"EN-GB\">trastuzumab\nand chemotherapy, as part of a complete treatment regimen for early breast\ncancer (see section 5.1). </span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\">In the adjuvant setting, Perjeta should be administered in\ncombination with trastuzumab for a total of one year (up to 18 cycles or until\ndisease recurrence, or unmanageable toxicity, whichever occurs first) as part\nof a complete regimen for early breast cancer and regardless of the timing of\nsurgery.\u00a0 Treatment should include standard anthracycline- and/or taxane-based\nchemotherapy. Perjeta and trastuzumab should start on Day 1 of the first\ntaxane-containing cycle and should continue even if chemotherapy is\ndiscontinued<span lang=\"EN-GB\">. </span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Delayed\nor missed doses</span></i></p>\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\" style=\"color:black\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\" style=\"color:black\">For\nrecommendations on delayed or missed doses, please refer to Table 1 below.</span></p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"margin-left:.75in;text-indent:-.75in;page-break-after:\navoid\"><b><span lang=\"EN-GB\">Table 1\u00a0\u00a0\u00a0\u00a0\u00a0 Recommendations regarding delayed or\nmissed doses</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-left:.75in;text-indent:-.75in;page-break-after:\navoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr>\n<td rowspan=\"2\" style=\"width:103.05pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"137\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Time between two\n  sequential infusions</b></p>\n</td>\n<td rowspan=\"2\" style=\"width:126.1pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"168\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Perjeta </b></p>\n</td>\n<td colspan=\"2\" style=\"width:235.2pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"314\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b>trastuzumab</b></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:123.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"165\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>IV</b></p>\n</td>\n<td style=\"width:111.65pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"149\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>SC</b></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:103.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"137\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">&lt; 6 weeks</p>\n</td>\n<td style=\"width:126.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"168\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">The 420 mg dose of\n  pertuzumab should be administered as soon as possible. Do not wait until the\n  next planned dose. Thereafter, revert to the original planned schedule.</p>\n</td>\n<td style=\"width:123.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"165\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">The 6\u00a0mg/kg dose of trastuzumab\n  IV should be administered as soon as possible. Do not wait until the next\n  planned dose. Thereafter, revert to the original planned schedule.</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n<td rowspan=\"2\" style=\"width:111.65pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"149\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">The fixed dose of 600mg\n  trastuzumab SC should be administered as soon as possible. </p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Do not wait until the next\n  planned dose.</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n</tr>\n<tr>\n<td style=\"width:103.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"137\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"ZH-CN\" style=\"font-family:SimSun\">\u2265</span> 6 weeks</p>\n</td>\n<td style=\"width:126.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"168\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">The 840 mg loading dose of\n  pertuzumab should be re-administered\u00a0as a 60 minute infusion, followed\n  by a maintenance dose of 420 mg IV administered every 3 weeks thereafter.</p>\n</td>\n<td style=\"width:123.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"165\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">The\u00a0loading dose of\n  8\u00a0mg/kg of trastuzumab IV should be re- administered\u00a0over\n  approximately 90\u00a0minutes, followed by a maintenance dose of 6\u00a0mg/kg\n  IV\u00a0administered every 3 weeks thereafter.</p>\n</td>\n</tr>\n</table>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">Dose modification</span></i></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Dose reductions are not recommended for Perjeta\nor trastuzumab.\u00a0 For details regarding trastuzumab, please refer to the summary\nof product characteristics (SmPC). </span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Patients may continue\ntherapy during periods of reversible chemotherapy-induced myelosuppression but\nthey should be monitored carefully for complications of neutropenia during this\ntime. </span><span lang=\"EN-GB\">For docetaxel </span><span lang=\"EN-GB\">and other\nchemotherapy </span><span lang=\"EN-GB\">dose modifications, see </span><span lang=\"EN-GB\">relevant</span><span lang=\"EN-GB\"> SmPC.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">If trastuzumab treatment is discontinued,\ntreatment with Perjeta should be discontinued. </span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">Left ventricular dysfunction </span></i></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Perjeta and trastuzumab should be withheld\nfor at least 3 <span style=\"color:black\">weeks for </span></span><span lang=\"EN-GB\" style=\"color:black\">any </span><span lang=\"EN-GB\">signs and symptoms\nsuggestive of congestive heart failure. Perjeta should be discontinued if\nsymptomatic heart failure is confirmed (see section 4.4 for more details).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Patients with metastatic breast cancer</span></u></p>\n<p class=\"MsoNormal\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Patients should have a pre-treatment left\nventricular ejection fraction (LVEF) of \u2265 50%. Perjeta and trastuzumab\nshould be withheld for at least 3 weeks for:</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:35.7pt;text-indent:-17.85pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0 a drop in\nLVEF to less than 40% </span></p>\n<p class=\"MsoNormal\" style=\"margin-left:35.7pt;text-indent:-17.85pt\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:35.7pt;text-indent:-17.85pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0 a LVEF of\n40%-45% associated with a fall of \u2265\u00a010% points below pre-treatment\nvalue.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Perjeta and trastuzumab may be resumed if\nthe LVEF has recovered to &gt;\u00a045%, or to 40-45% associated with a\ndifference of &lt;\u00a010% points below pre-treatment values. </span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Patients\nwith early breast cancer</span></u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Patients\nshould have a pre-treatment LVEF of \u2265 55% (\u2265 50% after completion\nof the anthracycline component of chemotherapy, if given). Perjeta and\ntrastuzumab should be withheld for at least 3 weeks for: </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:35.7pt;text-indent:-17.85pt;page-break-after:\navoid\"><span style=\"font-family:Symbol;color:black\">\u00b7</span><span lang=\"BG\" style=\"color:black\">\u00a0\u00a0\u00a0 </span><span lang=\"EN-GB\">a drop in LVEF to less than 50%\nassociated with a fall of\u00a0 \u2265 10% points below pre-treatment values.</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Perjeta and trastuzumab may be resumed if\nthe LVEF has recovered to \u226550% or to a difference of &lt;\u00a010% points\nbelow pre-treatment values. </span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Elderly\npatients</span></i></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">No overall differences in efficacy\nof Perjeta were observed in patients \u2265 65 and &lt; 65 years of age. <span lang=\"EN-GB\">No dose adjustment is necessary in the elderly population \u2265\u00a065\nyears of age. Limited data are available in patients &gt;\u00a075 years of age.\nPlease see section 4.8 for assessment of safety of Perjeta in elderly patients.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">Renal impairment</span></i></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Dose adjustments of pertuzumab are not\nneeded in patients with mild or moderate renal impairment. No dose\nrecommendations can be made for patients with severe renal impairment because\nof the limited pharmacokinetic data available (see section 5.2).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">Hepatic impairment</span></i></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">The safety and efficacy of Perjeta have not\nbeen studied in patients with hepatic impairment.\u00a0 No specific dose\nrecommendations can be made.</span></p>\n<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">\u00a0</span></i></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Paediatric\npopulation</span></i></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">The safety and efficacy of Perjeta in\nchildren and adolescents below 18 years of age have not been established.</span><span lang=\"EN-GB\"> There is no relevant use of Perjeta in the paediatric population in\nthe indication of breast cancer.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\" style=\"color:black\">Method of administration</span></u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><i><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></i></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Perjeta is administered intravenously by\ninfusion. It should not be administered as an intravenous push or bolus. For\ninstructions on dilution of Perjeta prior to administration, see sections 6.2\nand 6.6.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">For the initial dose, the recommended\ninfusion period is 60 minutes. If the first infusion is well tolerated,\nsubsequent infusions may be administered over a period of 30 minutes to 60\nminutes (see section 4.4).</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Infusion\nreactions</span></i></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">\u00a0</span></i></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">The infusion rate may be slowed or\ninterrupted if the patient develops an infusion reaction (see section 4.8). The\ninfusion may be resumed when symptoms abate. Treatment including oxygen, beta\nagonists, antihistamines, rapid i.v. fluids and antipyretics may also help\nalleviate symptoms. </span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">Hypersensitivity reactions/anaphylaxis </span></i></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">The infusion should be discontinued\nimmediately and permanently if the patient experiences a NCI-CTCAE Grade 4\nreaction (anaphylaxis), </span><span lang=\"EN-GB\">bronchospasm or acute\nrespiratory distress syndrome (see section 4.4).</span></p>\n<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">\u00a0</span></i></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">4.3\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Contraindications</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Hypersensitivity\nto the active substance or to any of the excipients listed in section 6.1.</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">4.4\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Special\nwarnings and precautions for use</span></b><b><span lang=\"EN-GB\"> </span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Traceability</span></u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">In order to improve the traceability of\nbiological medicinal products, the name and batch number of the administered\nproduct should be clearly recorded.</span></p>\n<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">\u00a0</span></i></p>\n<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Left ventricular dysfunction (including\ncongestive heart failure)</span></u></p>\n<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">\u00a0</span></i></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Decreases in LVEF have been reported with\nmedicinal products that block HER2 activity, including Perjeta. The incidence\nof symptomatic left ventricular systolic dysfunction (LVD) [congestive heart\nfailure] was higher in patients treated with Perjeta in combination with trastuzumab\nand chemotherapy compared with trastuzumab and chemotherapy . Patients who have\nreceived prior anthracyclines or prior radiotherapy to the chest area may be at\nhigher risk of LVEF declines. The majority of cases of symptomatic heart\nfailure reported in the adjuvant setting were in patients who received\nanthracycline-based chemotherapy (see section 4.8).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Perjeta</span><span lang=\"EN-GB\"> has not\nbeen studied in patients with:\u00a0a pre-treatment LVEF value of &lt;\u00a050%;\na prior history of congestive heart failure (CHF); LVEF declines to &lt;\u00a050%\nduring prior trastuzumab adjuvant therapy; or conditions that could impair left\nventricular function such as uncontrolled hypertension, recent myocardial\ninfarction, serious cardiac arrhythmia requiring treatment or a cumulative\nprior anthracycline exposure to &gt;\u00a0360\u00a0mg/m<sup>2</sup> of\ndoxorubicin or its equivalent.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Assess LVEF prior to initiation of Perjeta\nand at regular intervals during treatment </span><span lang=\"EN-GB\">with Perjeta\n(e.g. once during neoadjuvant treatment and every 12 weeks in the adjuvant or\nmetastatic setting) </span><span lang=\"EN-GB\">to ensure that LVEF is within\nnormal limits. If the LVEF has declined as indicated in section 4.2 and has not\nimproved, or has declined further at the subsequent assessment, discontinuation\nof Perjeta and trastuzumab should be strongly considered, unless the benefits\nfor the individual patient are deemed to outweigh the risks. </span></p>\n<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">\u00a0</span></i></p>\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\"><span lang=\"EN-GB\">Cardiac risk should be carefully considered and balanced against the\nmedical need of the individual patient before use of Perjeta with an anthracycline.\n</span><span lang=\"EN-GB\">Based on the pharmacological actions of <br/>\nHER2-targeted agents and anthracyclines, the risk of cardiac toxicity might be\nexpected to be higher with concomitant\u00a0use of Perjeta and anthracyclines\nthan with sequential use. </span></p>\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Sequential use of Perjeta (in combination\nwith trastuzumab and a taxane) has been evaluated following the epirubicin or\ndoxorubicin component of many anthracycline-based regimens in the APHINITY and\nBERENICE studies. However, only limited safety data are available on concurrent\nuse of Perjeta and an anthracycline. In the TRYPHAENA study, Perjeta was given concurrently\nwith epirubicin, as part of the FEC</span><span lang=\"EN-GB\"> </span>(5-fluorouracil,\nepirubicin, cyclophosphamide) <span lang=\"EN-GB\">regimen (see sections 4.8 and\n5.1). Only chemotherapy-naive patients were treated and they received low\ncumulative doses of epirubicin (up to 300 mg/m<sup>2</sup>). In this study,\ncardiac safety was similar to that observed in patients given the same regimen but\nwith Perjeta administered sequentially (following FEC chemotherapy).</span></p>\n<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">\u00a0</span></i></p>\n<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Infusion reactions</span></u></p>\n<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">\u00a0</span></i></p>\n<p class=\"MsoNormal\" style=\"background:white\"><span lang=\"EN-GB\" style=\"color:black\">Perjeta\nhas been associated with infusion reactions, including events with a fatal\noutcome (</span><span lang=\"EN-GB\" style=\"color:black\">see section 4.8</span><span lang=\"EN-GB\" style=\"color:black\">). Close observation of the patient during and\nfor 60 minutes after the first infusion and during and for 30-60 minutes after\nsubsequent infusions of Perjeta is recommended. If a significant infusion</span><span lang=\"EN-GB\" style=\"color:black\"> </span><span lang=\"EN-GB\" style=\"color:black\">reaction\noccurs, the infusion should be slowed down or interrupted and appropriate\nmedical therapies should be administered. Patients should be evaluated and\ncarefully monitored until complete resolution of signs and symptoms.</span><span lang=\"EN-GB\" style=\"color:black\"> Permanent discontinuation should be considered\nin patients with severe infusion reactions. This clinical assessment should be\nbased on the severity of the preceding reaction and response to administered\ntreatment for the adverse reaction (see section 4.2).</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">\u00a0</span></i></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Hypersensitivity\nreactions/anaphylaxis</span></u></p>\n<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">\u00a0</span></i></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Patients should be observed closely for\nhypersensitivity reactions. Severe hypersensitivity, including anaphylaxis and\nevents with a fatal outcome, has been observed with Perjeta (see section 4.8).\nMedicinal products to treat such reactions, as well as emergency equipment,\nshould be available for immediate use. Perjeta must be permanently discontinued\nin case of NCI-CTCAE Grade 4 hypersensitivity reactions (anaphylaxis), bronchospasm\nor acute respiratory distress syndrome (see section 4.2). </span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Febrile neutropenia</span></u></p>\n<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">\u00a0</span></i></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Patients treated with Perjeta, trastuzumab\nand docetaxel are at increased risk of febrile neutropenia compared with\npatients treated with placebo, trastuzumab and docetaxel, especially during the\nfirst 3 cycles of treatment (see section 4.8). </span><span lang=\"EN-GB\">In the\nCLEOPATRA trial in metastatic breast cancer,</span><span lang=\"EN-GB\"> nadir\nneutrophil counts were similar in Perjeta-treated and placebo-treated patients</span><span lang=\"EN-GB\">. The</span><span lang=\"EN-GB\"> higher incidence of febrile\nneutropenia in Perjeta-treated patients </span><span lang=\"EN-GB\">was</span><span lang=\"EN-GB\"> associated with the higher incidence of mucositis and diarrhoea in\nthese patients. Symptomatic treatment for mucositis and diarrhoea should be\nconsidered. </span><span lang=\"EN-GB\">No</span><span lang=\"EN-GB\"> events of\nfebrile neutropenia were reported after cessation of docetaxel.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><u><span lang=\"ES\">Diarrhoea</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"ES\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"ES\">Perjeta may elicit severe diarrhoea. </span><span lang=\"EN-GB\">Diarrhoea is most frequent during concurrent administration with\ntaxane therapy.</span> Elderly patients (<u>&gt;</u> 65 years) have a higher\nrisk of diarrhoea compared with younger patients (&lt;<u> </u>65 years). Treat\ndiarrhoea according to standard practice and guidelines. Early intervention\nwith loperamide, fluids and electrolyte replacement should be considered,\nparticularly in elderly patients, and in case of severe or prolonged\ndiarrhoea.\u00a0 <span lang=\"EN-GB\">Interruption of treatment with pertuzumab should\nbe considered if no improvement in the patient\u2019s condition is achieved. When\nthe diarrhoea is under control treatment with pertuzumab may be reinstated.</span></p>\n<p class=\"MsoNormal\"><b><i><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></i></b></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">4.5\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Interaction with other\nmedicinal products and other forms of interaction</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">No pharmacokinetic (PK) interactions were\nobserved between </span><span lang=\"EN-GB\">pertuzumab</span><span lang=\"EN-GB\"> and\ntrastuzumab, or between </span><span lang=\"EN-GB\">pertuzumab</span><span lang=\"EN-GB\"> and docetaxel in a sub-study of 37 patients in the randomised,\npivotal trial CLEOPATRA</span><span lang=\"EN-GB\"> in metastatic breast cancer</span><span lang=\"EN-GB\">. In addition, in the population PK analysis, no evidence of a\ndrug-drug interaction has been shown between </span><span lang=\"EN-GB\">pertuzumab</span><span lang=\"EN-GB\"> and trastuzumab </span><span lang=\"EN-GB\">or</span><span lang=\"EN-GB\">\nbetween </span><span lang=\"EN-GB\">pertuzumab</span><span lang=\"EN-GB\"> and\ndocetaxel</span><span lang=\"EN-GB\">. This absence of drug-drug interaction was\nconfirmed by pharmacokinetic data from the NEOSPHERE and APHINITY studies</span><span lang=\"EN-GB\">.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Five studies evaluated the effects of </span><span lang=\"EN-GB\">pertuzumab</span><span lang=\"EN-GB\"> on the PK of co-administered\ncytotoxic agents, docetaxel, paclitaxel, gemcitabine, capecitabine, carboplatin\nand erlotinib. There was no evidence of any PK interaction between </span><span lang=\"EN-GB\">pertuzumab</span><span lang=\"EN-GB\"> and any of these agents. The PK\nof </span><span lang=\"EN-GB\">pertuzumab</span><span lang=\"EN-GB\"> in these studies was\ncomparable to those observed in single-agent studies.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">4.6\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Fertility,\np</span></b><b><span lang=\"EN-GB\">regnancy and lactation</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Contraception\n</span></u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Women of\nchildbearing potential should use effective contraception while receiving\nPerjeta and for 6 months following the last dose of pertuzumab.</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Pregnancy</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">There is limited amount of data from the\nuse of pertuzumab in pregnant women. </span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Studies in animals have shown reproductive\ntoxicity (see section 5.3).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Perjeta is not recommended during pregnancy\nand in women of childbearing potential not using contraception. </span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>\n<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Breast-feeding</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Because human IgG is secreted in human milk\nand the potential for absorption and harm to the infant is unknown, a decision\nshould be made to discontinue breast-feeding or to discontinue treatment,\ntaking into account the benefit of breast-feeding for the child and the benefit\nof Perjeta therapy for the woman (see section 5.2).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Fertility</span></u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">No specific fertility studies in animals\nhave been performed to evaluate the effect of </span><span lang=\"EN-GB\">pertuzumab</span><span lang=\"EN-GB\">.</span><span lang=\"EN-GB\"> In repeated dose toxicity studies in\ncynomolgus monkeys, no definitive conclusions could be drawn on the adverse\neffect on male reproductive organs. </span><span lang=\"EN-GB\">No adverse reactions\nwere observed in sexually mature female cynomolgus monkeys exposed to\npertuzumab (see section 5.3).</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">4.7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Effects\non ability to drive and use machines</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">On the basis\nof reported adverse reactions, Perjeta has a minor influence on the ability to\ndrive or use machines. </span>Dizziness may occur during treatment with Perjeta\n(see section\u00a04.8). <span lang=\"EN-GB\">Patients experiencing infusion\nreactions should be advised not to drive and use machines until symptoms abate.\n</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">4.8\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Undesirable effects</span></b><b><span lang=\"EN-GB\"> </span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Summary of the safety profile</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">The safety of Perjeta has been evaluated in\nmore than 6,000 patients in </span><span lang=\"EN-GB\">Phase</span><span lang=\"EN-GB\"> I, II, and III trials in patients with various malignancies and\npredominantly treated with Perjeta in combination with other antineoplastic\nagents. </span>Those studies included the pivotal trials CLEOPATRA (n=808),\nNEOSPHERE (n=417), TRYPHAENA (n=225), and APHINITY (n=4804) [pooled in Table\n2]. <span lang=\"EN-GB\">The safety of Perjeta was generally consistent across\nstudies, although the incidence and most common adverse drug reactions (ADRs)\nvaried depending on whether Perjeta was administered as monotherapy or with\nconcomitant anti-neoplastic agents. </span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Tabulated\nlist of adverse reactions</span></u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Table 2 summarizes\nthe ADRs from the Perjeta-treated groups of the following pivotal clinical\ntrials:</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:35.7pt;text-indent:-17.85pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0 CLEOPATRA,\nin which Perjeta was given in combination with docetaxel and trastuzumab</span><span lang=\"EN-GB\"> to patients with metastatic breast cancer (n=453)</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:35.7pt;text-indent:-17.85pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0 </span><span lang=\"EN-GB\" style=\"color:black\">NEOSPHERE (n=309) and TRYPHAENA (n=218), in\nwhich neoadjuvant Perjeta was given in combination with trastuzumab and\nchemotherapy to patients with locally advanced, inflammatory, or early breast\ncancer</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:35.7pt;text-indent:-17.85pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0 </span>APHINITY,\nin which adjuvant Perjeta was given in combination with trastuzumab and\nanthracycline-based or non-anthracycline-based, taxane-containing chemotherapy\nto patients with early breast cancer (n=2364)</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">In addition,\nADRs reported in the post-marketing setting are included in Table 2. As Perjeta\nwas used with trastuzumab and </span><span lang=\"EN-GB\">chemotherapy in these\ntrials</span><span lang=\"EN-GB\">, it is difficult to ascertain the causal\nrelationship of an adverse event to a particular medicinal product. </span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">The ADRs are\nlisted below by MedDRA system organ class (SOC) and categories of frequency: </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Very common\n(\u2265\u00a01/10)</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Common\n(\u2265\u00a01/100 to &lt;\u00a01/10)</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Uncommon(\n\u2265\u00a01/1,000 to &lt;\u00a01/100)</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Rare (</span><span lang=\"EN-GB\">\u2265\u00a0</span><span lang=\"EN-GB\">1/10,000 to &lt;\u00a01/1,000)</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Very rare\n(&lt;\u00a01/10,000)</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Not known (cannot be estimated from the\navailable data)</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Within each frequency grouping and SOC, ADRs\nare presented in the order of decreasing seriousness.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">The most common ADRs (\u226530%) from this\npooled data were diarrhoea, alopecia, nausea, fatigue, neutropenia, and\nvomiting. The most common NCI-CTCAE Grade 3-4 ADRs (\u226510%) were\nneutropenia and febrile neutropenia.</span></p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"margin-left:.75in;text-indent:-.75in;page-break-after:\navoid\"><b><span lang=\"EN-GB\">Table 2\u00a0\u00a0\u00a0\u00a0\u00a0 Summary of ADRs </span></b><b><span lang=\"EN-GB\">in patients treated with Perjeta in clinical trials^, and in the Post-marketing\nsetting</span></b><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u2020</span><b><span lang=\"EN-GB\"> </span></b><b><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">\u00a0</span></i></p>\n<div align=\"center\">\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\" width=\"723\">\n<thead>\n<tr style=\"height:31.65pt\">\n<td nowrap=\"\" style=\"width:120.45pt;border:solid windowtext 1.5pt;\n   padding:0in 4.25pt 0in 4.25pt;height:31.65pt\" width=\"161\">\n<p class=\"MsoNormal\" style=\"margin-left:-.05pt;text-indent:.05pt;page-break-after:\n   avoid;text-autospace:none\"><b><span lang=\"EN-GB\" style=\"color:black\">System </span></b><b><span lang=\"EN-GB\" style=\"color:black\">organ class</span></b></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border:solid windowtext 1.5pt;\n   border-left:none;padding:0in 4.25pt 0in 4.25pt;height:31.65pt\" width=\"141\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><i><u><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Very Common</span></u></i></b></p>\n</td>\n<td nowrap=\"\" style=\"width:105.5pt;border:solid windowtext 1.5pt;\n   border-left:none;padding:0in 4.25pt 0in 4.25pt;height:31.65pt\" width=\"141\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><i><u><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Common</span></u></i></b></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border:solid windowtext 1.5pt;\n   border-left:none;padding:0in 4.25pt 0in 4.25pt;height:31.65pt\" width=\"141\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><i><u><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Uncommon</span></u></i></b></p>\n</td>\n<td style=\"width:105.5pt;border:solid windowtext 1.5pt;border-left:\n   none;padding:0in 4.25pt 0in 4.25pt;height:31.65pt\" width=\"141\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><i><u><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Rare</span></u></i></b></p>\n</td>\n</tr>\n</thead>\n<tr style=\"height:29.6pt\">\n<td nowrap=\"\" style=\"width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:29.6pt\" valign=\"top\" width=\"161\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Infections and infestations</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:29.6pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Nasopharyngitis</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:29.6pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Paronychia</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Upper respiratory tract\n  infection</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:29.6pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td style=\"width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:29.6pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"height:27.05pt\">\n<td nowrap=\"\" style=\"width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:27.05pt\" valign=\"top\" width=\"161\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Blood and lymphatic system</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">disorders</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:27.05pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"IT\" style=\"font-size:10.0pt;color:black\">Febrile neutropenia*</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"IT\" style=\"font-size:10.0pt;color:black\">Neutropenia</span><span lang=\"IT\" style=\"font-size:10.0pt;color:black\"> </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"IT\" style=\"font-size:10.0pt;color:black\">Leucopenia </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"IT\" style=\"font-size:10.0pt;color:black\">Anaemia</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:27.05pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"IT\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:27.05pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"IT\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td style=\"width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:27.05pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"IT\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"height:27.05pt\">\n<td nowrap=\"\" style=\"width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:27.05pt\" valign=\"top\" width=\"161\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Immune system disorders</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:27.05pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Infusion reaction\u00b0\u00b0, *</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:27.05pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Hypersensitivity</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00b0, *</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Drug hypersensitivity\u00b0, *</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:27.05pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Anaphylactic reaction\u00b0, *</span></p>\n</td>\n<td style=\"width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:27.05pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Cytokine release syndrome\u00b0\u00b0</span></p>\n</td>\n</tr>\n<tr style=\"height:27.05pt\">\n<td nowrap=\"\" style=\"width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:27.05pt\" valign=\"top\" width=\"161\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Metabolism and nutrition\n  disorders</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:27.05pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Decreased appetite</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:27.05pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:27.05pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td style=\"width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:27.05pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Tumour lysis syndrome\u2020</span></p>\n</td>\n</tr>\n<tr style=\"height:15.55pt\">\n<td nowrap=\"\" style=\"width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:15.55pt\" valign=\"top\" width=\"161\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Psychiatric disorders</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:15.55pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Insomnia</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:15.55pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:15.55pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td style=\"width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:15.55pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"height:13.05pt\">\n<td nowrap=\"\" style=\"width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"161\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Nervous system disorders</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Neuropathy peripheral</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Headache\u00a0 </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Dysgeusia</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Peripheral sensory neuropathy</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Dizziness</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Paraesthesia</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td style=\"width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"height:18.2pt\">\n<td nowrap=\"\" style=\"width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"161\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Eye disorders</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Lacrimation increased</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td style=\"width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"height:18.2pt\">\n<td nowrap=\"\" style=\"width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"161\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Cardiac disorders</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Left ventricular dysfunction</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">**</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Cardiac failure congestive</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">**</span></p>\n</td>\n<td style=\"width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"height:18.2pt\">\n<td nowrap=\"\" style=\"width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"161\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Vascular disorders</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Hot flush</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td style=\"width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"height:18.2pt\">\n<td nowrap=\"\" style=\"width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"161\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Respiratory, thoracic and mediastinal\n  disorders</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Cough </span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Epistaxis</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Dyspnoea</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Interstitial lung disease </span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Pleural effusion</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td style=\"width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"height:11.6pt\">\n<td nowrap=\"\" style=\"width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:11.6pt\" valign=\"top\" width=\"161\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Gastrointestinal disorders</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:11.6pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Diarrhoea</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Vomiting\u00a0 </span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Stomatitis</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Nausea </span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Constipation </span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Dyspepsia </span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Abdominal pain</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:11.6pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></b></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:11.6pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></b></p>\n</td>\n<td style=\"width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:11.6pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></b></p>\n</td>\n</tr>\n<tr style=\"height:37.4pt\">\n<td nowrap=\"\" style=\"width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:37.4pt\" valign=\"top\" width=\"161\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Skin and subcutaneous tissue\n  disorders</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:37.4pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Alopecia</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Rash </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Nail disorder</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Pruritus</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Dry skin</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:37.4pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:37.4pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td style=\"width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:37.4pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"height:26.45pt\">\n<td nowrap=\"\" style=\"width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:26.45pt\" valign=\"top\" width=\"161\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Musculoskeletal and connective tissue disorders</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:26.45pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Myalgia</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Arthralgia</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Pain in extremity</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:26.45pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:26.45pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td style=\"width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:26.45pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"height:12.55pt\">\n<td nowrap=\"\" style=\"width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:12.55pt\" valign=\"top\" width=\"161\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">General disorders and\n  administration site conditions </span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:12.55pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Mucosal inflammation</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"PT-BR\" style=\"font-size:10.0pt;color:black\">Oedema peripheral</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"PT-BR\" style=\"font-size:10.0pt;color:black\">Pyrexia</span><span lang=\"PT-BR\" style=\"font-size:10.0pt;color:black\"> </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"PT-BR\" style=\"font-size:10.0pt;color:black\">Fatigue</span><span lang=\"PT-BR\" style=\"font-size:10.0pt;color:black\"> </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"PT-BR\" style=\"font-size:10.0pt;color:black\">Asthenia </span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:12.55pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Chills</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Pain</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Oedema</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:12.55pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td style=\"width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:12.55pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n</tr>\n</table>\n</div>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><b><sup><span lang=\"EN-GB\" style=\"font-size:10.0pt\">^\u00a0 </span></sup></b><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Table 2 shows pooled data from the overall treatment\nperiod in CLEOPATRA (data cutoff 11 February 2014; median number of cycles of\nPerjeta was 24); and from the neoadjuvant\u00a0 treatment period in NEOSPHERE\n(median number of cycles of Perjeta was 4, across all treatment arms) and\nTRYPHAENA (median number of cycles of Perjeta was 3 \u2013 6 across treatment arms) </span><span style=\"font-size:10.0pt\">and from the treatment period of APHINITY (median\nnumber of cycles of Perjeta was 18). <sup>\u00a0</sup></span><span style=\"font-size:\n10.0pt\">\u00a0<sup>\u00a0\u00a0</sup></span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">* ADRs with a fatal outcome have been\nreported</span><span lang=\"EN-GB\" style=\"font-size:10.0pt\">.\u00a0 </span></p>\n<p class=\"MsoNormal\" style=\"margin-left:9.0pt;text-indent:-9.0pt;page-break-after:\navoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">** For the\noverall treatment period across the 4 studies. The incidence of left\nventricular dysfunction and cardiac failure congestive reflect the MedDRA\nPreferred Terms reported in the individual studies.</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00b0 </span><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Hypersensitivity/anaphylactic\nreaction is based on a group of terms.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:9.0pt;text-indent:-9.0pt;page-break-after:\navoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00b0\u00b0 Infusion reaction includes\na range of different terms within a time window, see \u201cDescription of selected\nadverse reactions\u201d below. </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u2020 ADRs reported in the post marketing setting</span><u><span lang=\"EN-GB\">-</span></u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Description\nof selected adverse reactions</span></u></p>\n<p class=\"MsoNormal\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\"><i><span lang=\"EN-GB\">Left ventricular dysfunction (LVD)</span></i></p>\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\"><span lang=\"EN-GB\">In the pivotal trial CLEOPATRA in metastatic breast cancer, the\nincidence of LVD during study treatment was higher in the placebo-treated group\nthan in the Perjeta-treated group (8.6% and 6.6%, respectively). The incidence\nof symptomatic LVD was also lower in the Perjeta-treated group (1.8% in the\nplacebo-treated group vs. 1.5% in the Perjeta-treated group) (see section 4.4).\n</span></p>\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\"><span lang=\"EN-GB\">In the neoadjuvant trial NEOSPHERE, in which patients received 4\ncycles of Perjeta as neoadjuvant treatment, the incidence of LVD (during the\noverall treatment period) was higher in the Perjeta, trastuzumab and\ndocetaxel-treated group (7.5%) compared to the trastuzumab and\ndocetaxel-treated group (1.9%). There was one case of symptomatic LVD in the\nPerjeta and trastuzumab-treated group. </span></p>\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\"><span lang=\"EN-GB\">In the neoadjuvant trial TRYPHAENA, the incidence of LVD (during the\noverall treatment period) was 8.3% in the group treated with Perjeta plus\ntrastuzumab and FEC </span>(5-fluorouracil, epirubicin, cyclophosphamide)<span lang=\"EN-GB\"> followed by Perjeta plus trastuzumab and docetaxel; 9.3% in the\ngroup treated with Perjeta plus trastuzumab and docetaxel following FEC; and\n6.6% in the group treated with Perjeta in combination with TCH </span>(docetaxel,\ncarboplatin and trastuzumab)<span lang=\"EN-GB\">. The incidence of symptomatic LVD\n(congestive heart failure) was 1.3% in the group treated with Perjeta plus\ntrastuzumab and docetaxel following FEC (this excludes a patient who\nexperienced symptomatic LVD during FEC treatment prior to receiving Perjeta\nplus trastuzumab and docetaxel) and also 1.3% in the group treated with Perjeta\nin combination with TCH. No patients in the group treated with Perjeta plus\ntrastuzumab and FEC followed by Perjeta plus trastuzumab and docetaxel\nexperienced symptomatic LVD.</span></p>\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">In the neoadjuvant period of the BERENICE\ntrial, the incidence of NYHA Class III/IV symptomatic LVD (congestive heart\nfailure</span><span lang=\"EN-CARRIBEAN\"> according to </span>NCI-CTCAE v.4<span lang=\"EN-GB\">) was 1.5% in the group treated with dose dense doxorubicin and\ncyclophosphamide (AC) followed by Perjeta plus trastuzumab and paclitaxel and none\nof the patients (0%) experienced symptomatic LVD in the group treated with FEC\nfollowed by Perjeta in combination with trastuzumab and docetaxel. The\nincidence of asymptomatic LVD (ejection fraction decrease </span><span lang=\"EN-CARRIBEAN\">according to </span>NCI-CTCAE v.4)<span lang=\"EN-GB\"> was 7% in\nthe group treated with dose dense AC followed by Perjeta plus trastuzumab and\npaclitaxel and 3.5% in the group treated with FEC followed by Perjeta plus\ntrastuzumab and docetaxel.</span></p>\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\">In\nAPHINITY, the incidence of symptomatic heart failure (NYHA class III or IV)\nwith a LVEF decline of at least 10% points from baseline and to &lt;50% was\n&lt;1% (0.6% of Perjeta-treated patients vs 0.3% of placebo-treated patients).\nOf the patients who experienced symptomatic heart failure, 46.7% of\nPerjeta-treated patients and 57.1% of placebo-treated patients had recovered\n(defined as 2 consecutive LVEF measurements above 50%) at the data cutoff. The\nmajority of the events were reported in anthracycline-treated patients. Asymptomatic\nor mildly symptomatic (NYHA class II) declines in LVEF of at least 10% points\nfrom baseline and to &lt;50% were reported in 2.7% of Perjeta-treated patients\nand 2.8% of placebo-treated patients, of whom 79.7% of Perjeta-treated patients\nand 80.6% of placebo-treated patients had recovered at the data cutoff. </p>\n<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">\u00a0</span></i></p>\n<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">Infusion reactions</span></i></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">An infusion reaction was defined in the\npivotal trials as any event reported as hypersensitivity, anaphylactic\nreaction, acute infusion reaction or cytokine release syndrome occurring during\nan infusion or on the same day as the infusion. In the pivotal trial CLEOPATRA,\nthe initial dose of Perjeta was given the day before trastuzumab and docetaxel\nto allow for the examination of Perjeta-associated reactions. On the first day\nwhen only Perjeta was administered, the overall frequency of infusion reactions\nwas 9.8% in the placebo-treated group and 13.2% in the Perjeta-treated group,\nwith the majority of infusion reactions being mild or moderate. The most common\ninfusion reactions (</span><span lang=\"EN-GB\">\u2265</span><span lang=\"EN-GB\">\u00a01.0%)\nin the Perjeta-treated group were pyrexia, chills, fatigue, headache, asthenia,\nhypersensitivity and vomiting.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">During the second cycle when all medicinal\nproducts were administered on the same day, the most common infusion reactions\nin the Perjeta-treated group (</span><span lang=\"EN-GB\">\u2265</span><span lang=\"EN-GB\">\u00a01.0%) were fatigue, dysgeusia, </span><span lang=\"EN-GB\">drug </span><span lang=\"EN-GB\">hypersensitivity, myalgia and vomiting (see section 4.4).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">In neoadjuvant and adjuvant trials, Perjeta\nwas administered on the same day as other study treatments in all cycles.\nInfusion reactions occurred in 18.6% - 25.0% of patients on the first day of\nPerjeta administration (in combination with trastuzumab and chemotherapy). The\ntype and severity of events were consistent with those observed in CLEOPATRA at\nthe cycles when Perjeta was given on the same day as trastuzumab and docetaxel,\nwith the majority of reactions being mild or moderate in severity.</span></p>\n<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">\u00a0</span></i></p>\n<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">Hypersensitivity reactions/anaphylaxis</span></i></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">In the pivotal trial CLEOPATRA</span><span lang=\"EN-GB\"> in metastatic breast cancer</span><span lang=\"EN-GB\">, the overall\nfrequency of investigator reported hypersensitivity/anaphylaxis events during\nthe entire treatment period was 9.3% in the placebo-treated group and 11.3% in\nthe Perjeta-treated group, of which 2.5% and 2.0% were <br/>\nNCI-CTCAE Grade 3-4, respectively. Overall, 2 patients in the placebo-treated\ngroup and 4 patients in the Perjeta-treated group experienced </span><span lang=\"EN-GB\">events described as </span><span lang=\"EN-GB\">anaphylaxis </span><span lang=\"EN-GB\">by the investigator </span><span lang=\"EN-GB\">(see section 4.4). </span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Overall, the majority of hypersensitivity\nreactions were mild or moderate in severity and resolved upon treatment. Based\non modifications made to the study treatment, most reactions were assessed as\nsecondary to docetaxel infusions.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">In the neoadjuvant and adjuvant trials,\nhypersensitivity/anaphylaxis events were consistent with those observed in\nCLEOPATRA. In NEOSPHERE, two patients in the Perjeta and docetaxel-treated\ngroup experienced anaphylaxis. In both the TRYPHAENA and APHINITY trials, the\noverall frequency of hypersensitivity/anaphylaxis was highest in the Perjeta\nand TCH treated group (13.2% and 7.6%, respectively), of which 2.6% and 1.3% of\nevents, respectively, were NCI-CTCAE Grade 3-4.</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">\u00a0</span></i></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Febrile\nneutropenia</span></i></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">In the pivotal trial CLEOPATRA, the\nmajority of patients in both treatment groups experienced at least one\nleucopenic event (63.0% of patients in the Perjeta-treated group and 58.3% of\npatients in the placebo-treated group), of which the majority were neutropenic\nevents (see section 4.4). Febrile neutropenia occurred in 13.7% of Perjeta-treated\npatients and 7.6% of placebo-treated patients. In both treatment groups, the\nproportion of patients experiencing febrile neutropenia was highest in the\nfirst cycle of therapy and declined steadily thereafter. An increased incidence\nof febrile neutropenia was observed </span><span lang=\"EN-GB\">among</span><span lang=\"EN-GB\"> Asian patients in both treatment groups compared with patients of\nother races and from other geographic regions. Among Asian patients, the\nincidence of febrile neutropenia was higher in the Perjeta-treated group (25.8%)\ncompared with the placebo-treated group (11.3%).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">In the NEOSPHERE trial, 8.4% of patients\ntreated with neoadjuvant Perjeta, trastuzumab and docetaxel experienced febrile\nneutropenia compared with 7.5% of patients treated with trastuzumab and\ndocetaxel. In the TRYPHAENA trial, febrile neutropenia occurred in 17.1% of\npatients treated with neoadjuvant Perjeta + TCH, and 9.3% of patients treated\nwith neoadjuvant Perjeta, trastuzumab and docetaxel following FEC. In TRYPHAENA,\nthe incidence of febrile neutropenia was higher in patients who received six\ncycles of Perjeta compared with patients who received three cycles of Perjeta,\nindependent of the chemotherapy given. As in the CLEOPATRA trial, a higher\nincidence of neutropenia and febrile neutropenia was observed among Asian\npatients compared with other patients in both neoadjuvant trials. In NEOSPHERE,\n8.3% of Asian patients treated with neoadjuvant Perjeta, trastuzumab and\ndocetaxel experienced febrile neutropenia compared with 4.0% of Asian patients\ntreated with neoadjuvant trastuzumab and docetaxel.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">In the APHINITY trial, febrile neutropenia\noccurred in 12.1% of Perjeta-treated patients and 11.1% of placebo-treated\npatients. As in the CLEOPATRA, TRYPHAENA, and NEOSPHERE trials, a higher\nincidence of febrile neutropenia was observed among Perjeta-treated Asian\npatients compared with other races in the APHINITY trial (15.9% of\nPerjeta-treated patients and 9.9% of placebo-treated patients).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">Diarrhoea</span></i></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">In the pivotal trial CLEOPATRA</span><span lang=\"EN-GB\"> in metastatic breast cancer</span><span lang=\"EN-GB\">, diarrhoea\noccurred in 68.4% of Perjeta-treated patients and 48.7% of placebo-treated\npatients (see section 4.4). Most events were mild</span><span lang=\"EN-GB\"> to </span><span lang=\"EN-GB\">moderate in severity and occurred in the first few cycles of\ntreatment. The incidence of NCI-CTCAE Grade 3-4 diarrhoea was 9.3% in Perjeta-treated\npatients vs 5.1% in placebo-treated patients. The median duration of the longest\nepisode was 18 days in Perjeta-treated patients and 8 days in placebo-treated\npatients. Diarrhoeal events responded well to proactive management with\nanti-diarrhoeal agents.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">In the NEOSPHERE trial, diarrhoea occurred\nin 45.8% of patients treated with neoadjuvant Perjeta, trastuzumab and\ndocetaxel compared with 33.6% of patients treated with trastuzumab and\ndocetaxel. In the TRYPHAENA trial, diarrhoea occurred in 72.3% of patients\ntreated with neoadjuvant Perjeta+TCH and 61.4% of patients treated with\nneoadjuvant Perjeta, trastuzumab and docetaxel following FEC. In both studies\nmost events were mild to moderate in severity. </span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">In the APHINITY trial, a higher incidence\nof diarrhoea was reported in the Perjeta-treated arm (71.2%) compared to the\nplacebo arm (45.2%).\u00a0 Grade \u2265 3 diarrhoea was reported in 9.8% of\npatients in the Perjeta arm vs. 3.7% in the placebo arm. The majority of the\nreported events were Grade 1 or 2 in severity. The highest incidence of\ndiarrhoea (all Grades) was reported during the targeted therapy+taxane\nchemotherapy period (61.4% of patients in the Perjeta arm vs. 33.8% of patients\nin the placebo arm).The incidence of diarrhoea was much lower after\nchemotherapy cessation, affecting 18.1% of patients in the Perjeta arm vs. 9.2%\nof patients in the placebo arm in the post-chemotherapy targeted therapy\nperiod.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">Rash</span></i></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">In the pivotal trial CLEOPATRA in\nmetastatic breast cancer, r</span><span lang=\"EN-GB\">ash occurred in 51.7% of Perjeta-treated\npatients, compared with 38.9% of placebo-treated patients. Most events were\nGrade 1 or 2 in severity, occurred in the first two cycles, and responded to\nstandard therapies, such as topical or oral treatment for acne.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">In the NEOSPHERE trial, rash occurred in\n40.2% of patients treated with neoadjuvant Perjeta, trastuzumab and docetaxel\ncompared with 29.0% of patients treated with trastuzumab and docetaxel. In the\nTRYPHAENA trial, rash occurred in 36.8% of patients treated with neoadjuvant\nPerjeta + TCH and 20.0% of patients treated with neoadjuvant Perjeta,\ntrastuzumab and docetaxel following FEC. The incidence of rash was higher in\npatients who received six cycles of Perjeta compared with patients who received\nthree cycles of Perjeta, independent of the chemotherapy given.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">In the APHINITY trial, the adverse event of\nrash occurred in 25.8% of patients in Perjeta arm vs.\u00a0 20.3% of patients in\nplacebo arm. The majority of rash events were Grade 1 or 2.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">Laboratory abnormalities</span></i></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">In the pivotal trial CLEOPATRA in\nmetastatic breast cancer, the</span><span lang=\"EN-GB\"> incidence of NCI-CTCAE </span><span lang=\"EN-GB\">v.</span><span lang=\"EN-GB\">3 Grade 3-4 neutropenia was balanced in\nthe two treatment groups (86.3% of Perjeta-treated patients and 86.6% of\nplacebo-treated patients, including 60.7% and 64.8% Grade 4 neutropenia,\nrespectively).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">In the NEOSPHERE trial, the incidence of\nNCI-CTCAE v.3 Grade 3-4 neutropenia was 74.5% in patients treated with\nneoadjuvant Perjeta, trastuzumab and docetaxel compared with 84.5% in patients\ntreated with trastuzumab and docetaxel, including 50.9% and 60.2% Grade 4\nneutropenia, respectively. In the TRYPHAENA trial, the incidence of NCI-CTCAE\nv.3 Grade 3-4 neutropenia was 85.3% in patients treated with neoadjuvant Perjeta\n+ TCH and 77.0% in patients treated with neoadjuvant Perjeta, trastuzumab and\ndocetaxel following FEC, including 66.7% and 59.5% Grade 4 neutropenia,\nrespectively. </span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">In the APHINITY trial, the incidence of\nNCI-CTCAE v.4 Grade 3-4 neutropenia was 40.6% in patients treated with Perjeta,\ntrastuzumab and chemotherapy compared with 39.1% in patients treated with\nplacebo, trastuzumab and chemotherapy, including 28.3% and 26.5% Grade 4\nneutropenia, respectively.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Elderly Patients</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\">The incidence of the following all grade adverse events was\nat least 5% higher in patients \u2265\u00a065\u00a0years of age, compared to\npatients &lt;\u00a065\u00a0years of age: decreased appetite, anaemia, weight\ndecreased, asthenia, dysgeusia, peripheral neuropathy, hypomagnesemia and\ndiarrhoea. Limited data are available in patients &gt; 75 years of age. </p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Reporting of suspected adverse reactions</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:13.0pt;text-autospace:none\"><span lang=\"EN-GB\">Reporting suspected adverse reactions after authorisation of the\nmedicinal product is important. It allows continued monitoring of the\nbenefit/risk balance of the medicinal product. Healthcare professionals are\nasked to report any suspected adverse reactions via </span><span lang=\"EN-GB\" style=\"background:lightgrey\">the national reporting system listed in </span><a href=\"https://www.ema.europa.eu/documents/template-form/appendix-v-adverse-drug-reaction-reporting-details_en.doc\"><span lang=\"EN-GB\" style=\"background:lightgrey\">Appendix V.</span></a></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">4.9\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Overdose</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">The maximum tolerated dose of </span><span lang=\"EN-GB\">pertuzumab has not been determined. In clinical trials, single doses\nhigher than 25\u00a0mg/kg (1727\u00a0mg) have not been tested.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">In case of overdose, patients must be\nclosely monitored for signs or symptoms of adverse reactions and appropriate\nsymptomatic treatment instituted.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACOLOGICAL\nPROPERTIES</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">5.1\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Pharmacodynamic\nproperties</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Pharmacotherapeutic\ngroup: Antineoplastic agents, monoclonal antibodies, ATC code: L01XC13</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Mechanism\nof action</span></u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Pertuzumab</span><span lang=\"EN-GB\"> is a\nrecombinant humanised monoclonal antibody that specifically targets the\nextracellular dimerization domain (subdomain II) of the human epidermal growth\nfactor receptor 2 protein (HER2), and thereby, blocks ligand-dependent\nheterodimerisation of HER2 with other HER family members, including EGFR, HER3\nand HER4. As a result, pertuzumab inhibits ligand\u2011initiated intracellular\nsignalling through two major signal pathways, mitogen\u2011activated protein\n(MAP) kinase and phosphoinositide\u00a03\u2011kinase (PI3K). Inhibition of\nthese signalling pathways can result in cell growth arrest and apoptosis,\nrespectively. In addition, pertuzumab mediates antibody-dependent cell-mediated\ncytotoxicity (ADCC).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">While pertuzumab alone inhibited the\nproliferation of human tumour cells, the combination of pertuzumab and\ntrastuzumab significantly augmented antitumour activity in HER2-overexpressing\nxenograft models.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Clinical\nefficacy and safety</span></u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">The efficacy of Perjeta in HER2-positive\nbreast cancer is supported by a randomised phase III trial and a single-arm\nphase II trial in metastatic breast cancer, two randomised neoadjuvant phase II\n\u00a0trials in early breast cancer (one controlled), a non-randomised neoadjuvant\nphase II trial, and a randomised phase III trial in the adjuvant setting.</span></p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">HER2 overexpression was determined at a\ncentral laboratory and defined as a score of 3+ by IHC or an ISH amplification\nratio \u22652.0 in the trials outlined below.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Metastatic\n</span></u></i><i><u><span lang=\"EN-GB\">breast cancer </span></u></i></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">Perjeta in combination with trastuzumab\nand docetaxel</span></i></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">CLEOPATRA</span><span lang=\"EN-GB\"> (WO20698)</span><span lang=\"EN-GB\"> is a multicentre, randomised, double-blind, placebo-controlled\nphase III clinical trial conducted in 808 patients with HER2-positive\nmetastatic or locally recurrent unresectable breast cancer. Patients with clinically\nimportant cardiac risk factors were not included (see section 4.4). Due to the\nexclusion of patients with brain metastases no data are available on Perjeta\nactivity on brain metastases. There is very limited data available in patients\nwith unresectable locally recurrent disease. Patients were randomised 1:1 to\nreceive placebo + trastuzumab + docetaxel or Perjeta + trastuzumab + docetaxel.\n</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Perjeta and trastuzumab were given at\nstandard doses in a 3-weekly regimen. Patients were treated with Perjeta and trastuzumab\nuntil disease progression, withdrawal of consent or unmanageable toxicity.\nDocetaxel was given as an initial dose of 75\u00a0mg/m<sup>2</sup> as an\nintravenous infusion every three weeks for at least 6 cycles. The dose of\ndocetaxel could be escalated to 100\u00a0mg/m<sup>2</sup> at the investigator\u2019s\ndiscretion if the initial dose was well tolerated. </span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">The primary endpoint of the study was\nprogression-free survival (PFS) as assessed by an independent review facility\n(IRF) and defined as the time from the date of randomisation to the date of\ndisease progression or death (from any cause) if the death occurred within 18\nweeks of the last tumour assessment. </span><span lang=\"EN-GB\">Secondary efficacy\nendpoints were overall survival (OS), PFS (investigator-assessed), objective\nresponse rate (ORR), duration of response, and time to symptom progression\naccording to the FACT B Quality of Life questionnaire.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Approximately half the patients in each\ntreatment group had hormone receptor-positive disease (defined as o</span><span lang=\"EN-GB\">estrogen</span><span lang=\"EN-GB\"> receptor</span><span lang=\"EN-GB\">\n(ER) </span><span lang=\"EN-GB\">positive and/or progesterone receptor</span><span lang=\"EN-GB\"> (PgR) </span><span lang=\"EN-GB\">positive) and approximately half of\nthe patients in each treatment group had received prior adjuvant or neoadjuvant\ntherapy. Most of these patients had received prior anthracycline therapy and 11%\nof all patients had received prior trastuzumab. A total of 43% of patients in\nboth treatment groups had previously received radiotherapy. Patients\u2019 median LVEF\nat baseline was 65.0% (range 50% \u2013 88%) in both groups. </span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">The efficacy results from the CLEOPATRA\nstudy are summarised in Table 3. </span><span lang=\"EN-GB\">A statistically\nsignificant improvement in IRF-assessed PFS was demonstrated in the Perjeta-treated\ngroup compared with the placebo-treated group. The results for investigator-assessed\nPFS were similar to those observed for IRF-assessed PFS. </span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Table 3  Summary\nof efficacy from CLEOPATRA study</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"margin-left:5.4pt;border-collapse:collapse;border:none\">\n<thead>\n<tr>\n<td style=\"width:163.05pt;border:solid windowtext 1.0pt;\n   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"217\">\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\n   page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">Parameter </span></b></p>\n</td>\n<td style=\"width:70.85pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"94\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">Placebo+ </span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">trastuzumab</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">+ docetaxel</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">n=406</span></b></p>\n</td>\n<td style=\"width:70.9pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"95\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">Perjeta+ </span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">trastuzumab</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">+ docetaxel</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">n=402</span></b></p>\n</td>\n<td style=\"width:63.75pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">HR</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">(95% CI)</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n<td style=\"width:70.9pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"95\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">p-value</span></b></p>\n</td>\n</tr>\n</thead>\n<tr>\n<td style=\"width:163.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"217\">\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\n  page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">Progression-Free\n  Survival </span></b></p>\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\n  page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">(independent\n  review) \u2013 primary endpoint*</span></b></p>\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\n  page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\n  page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">no. of patients\n  with an event</span></p>\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\n  page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Median months</span></p>\n</td>\n<td style=\"width:70.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"94\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">242 (59%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">12.4</span></p>\n</td>\n<td style=\"width:70.9pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"95\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">191 (47.5%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">18.5</span></p>\n</td>\n<td style=\"width:63.75pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">0.62</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">[0.51;0.75]</span></p>\n</td>\n<td style=\"width:70.9pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"95\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">&lt;0.0001</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:163.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"217\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">Overall Survival - secondary endpoint**</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">no. of patients with an event</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Median months</span></p>\n</td>\n<td style=\"width:70.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"94\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><s><span lang=\"EN-GB\"><span style=\"text-decoration:\n   none\">\u00a0</span></span></s></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><s><span lang=\"EN-GB\"><span style=\"text-decoration:\n   none\">\u00a0</span></span></s></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><s><span lang=\"EN-GB\"><span style=\"text-decoration:\n   none\">\u00a0</span></span></s></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">221 (54.4%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">40.8</span></p>\n</td>\n<td style=\"width:70.9pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"95\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><s><span lang=\"EN-GB\"><span style=\"text-decoration:\n   none\">\u00a0</span></span></s></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><s><span lang=\"EN-GB\"><span style=\"text-decoration:\n   none\">\u00a0</span></span></s></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><s><span lang=\"EN-GB\"><span style=\"text-decoration:\n   none\">\u00a0</span></span></s></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">168 (41.8%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">56.5</span></p>\n</td>\n<td style=\"width:63.75pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><s><span lang=\"EN-GB\"><span style=\"text-decoration:\n   none\">\u00a0</span></span></s></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">0.68</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">[0.56;0.84]</span></p>\n</td>\n<td style=\"width:70.9pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"95\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><s><span lang=\"EN-GB\"><span style=\"text-decoration:\n   none\">\u00a0</span></span></s></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><s><span lang=\"EN-GB\"><span style=\"text-decoration:\n   none\">\u00a0</span></span></s></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><s><span lang=\"EN-GB\"><span style=\"text-decoration:\n   none\">\u00a0</span></span></s></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">0.0002</span></p>\n</td>\n</tr>\n<tr style=\"height:21.0pt\">\n<td style=\"width:163.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:21.0pt\" valign=\"top\" width=\"217\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">Objective Response Rate (ORR)^ - secondary endpoint</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">no. of patients with measurable disease</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Responders***\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n  </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">95% CI for\n  ORR\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Complete\n  response (CR)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Partial\n  Response (PR)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Stable\n  disease (SD)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Progressive\n  disease (PD)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span></p>\n</td>\n<td style=\"width:70.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:21.0pt\" valign=\"top\" width=\"94\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">336</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">233 (69.3%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">[64.1; 74.2]</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">14 (4.2%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">219 (65.2%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">70 (20.8%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">28 (8.3%)</span></p>\n</td>\n<td style=\"width:70.9pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:21.0pt\" valign=\"top\" width=\"95\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">343</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">275 (80.2%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">[75.6; 84.3]</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">19 (5.5%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">256 (74.6%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">50 (14.6%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">13 (3.8 %)</span></p>\n</td>\n<td style=\"width:63.75pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:21.0pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">Difference in ORR:</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">10.8%</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">[4.2,17.5]</span></p>\n</td>\n<td style=\"width:70.9pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:21.0pt\" valign=\"top\" width=\"95\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">0.0011</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:163.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"217\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><b><span lang=\"EN-GB\">Duration\n  of Response </span></b><span lang=\"EN-GB\">\u2020<b>^</b></span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">n=</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Median weeks </span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">95% CI for\n  Median</span></p>\n</td>\n<td style=\"width:70.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"94\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-autospace:none\"><span lang=\"EN-GB\">233</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-autospace:none\"><span lang=\"EN-GB\">54.1</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-autospace:none\"><span lang=\"EN-GB\">[46;64]</span></p>\n</td>\n<td style=\"width:70.9pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"95\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-autospace:none\"><span lang=\"EN-GB\">275</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-autospace:none\"><span lang=\"EN-GB\">87.6</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-autospace:none\"><span lang=\"EN-GB\">[71;106]</span></p>\n</td>\n<td style=\"width:63.75pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:70.9pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"95\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n</table>\n<p class=\"MsoNormal\" style=\"margin-left:9.0pt;text-indent:-9.0pt\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">* Primary progression-free survival\nanalysis, cutoff date 13<sup>th</sup> May 2011.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:9.0pt;text-indent:-9.0pt\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">**</span><span lang=\"EN-GB\" style=\"font-size:\n10.0pt\"> Event-driven final overall survival analysis, cutoff date 11<sup>th</sup>\nFebruary 2014.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">*** Patients with\nbest overall response of confirmed CR or PR by RECIST.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u2020 Evaluated in\npatients with Best Overall Response of CR or PR</span><span lang=\"EN-GB\" style=\"font-size:10.0pt\">.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">^ Objective\nresponse rate and duration of response are based on IRF-assessed tumour\nassessments</span><span lang=\"EN-GB\" style=\"font-size:10.0pt\">.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Consistent results were observed across\npre-specified patient subgroups including the subgroups based on stratification\nfactors of geographic region and prior adjuvant/neoadjuvant therapy or de novo\nmetastatic breast cancer (see Figure 1). A post hoc exploratory analysis\nrevealed that for patients who had received prior trastuzumab (n = 88), the\nhazard ratio for IRF-assessed PFS was 0.62 (95% CI 0.35, 1.07), compared with\n0.60 (95% CI 0.43, 0.83) for patients who had received prior therapy which did\nnot include trastuzumab (n = 288).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.75in;text-indent:-.75in;page-break-after:\navoid\"><b><span lang=\"EN-GB\">Figure 1\u00a0\u00a0\u00a0\u00a0 IRF-assessed PFS by patient subgroup</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-bottom:6.0pt;line-height:12.0pt;page-break-after:\navoid\"><img alt=\"picutre-01\" border=\"0\" height=\"385\" id=\"Picture 2\" src=\"Perjeta-II-48%20EN%20PI%20clean_files/image002.jpg\" width=\"651\"/></p>\n<p class=\"MsoNormal\" style=\"margin-bottom:6.0pt;line-height:12.0pt;page-break-after:\navoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">The event-driven final analysis of OS was\nperformed when 389 patients had died (221 in the placebo-treated group and 168\nin the Perjeta-treated group). The statistically significant OS benefit in favour\nof the Perjeta-treated group, </span><span style=\"color:#222222;background:\nwhite\">previously observed at an interim analysis of OS (performed one year\nafter the primary analysis),\u00a0</span><span lang=\"EN-GB\">was maintained (HR\n0.68, p = 0.0002 log-rank test). The median time to death was 40.8 months in\nthe placebo-treated group and 56.5 months in the Perjeta-treated group </span><span lang=\"EN-GB\">(see Table 3, Figure\u00a02).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">A descriptive analysis of OS performed at\nthe end of the study when 515 patients had died (280 in the placebo-treated\ngroup and 235 in the Perjeta-treated group) showed that the statistically\nsignificant OS benefit in favour of the Perjeta-treated group was maintained over\ntime after a median follow-up of 99 months (HR 0.69, p &lt; 0.0001 log-rank\ntest; median time to death 40.8 months [placebo-treated group] versus 57.1\nmonths [Perjeta-treated group]). Landmark survival estimates at 8 years were\n37% in the Perjeta-treated group and 23% in the placebo-treated group.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:62.95pt;text-indent:-62.95pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">Figure 2\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Kaplan-Meier Curve of Event\u2011Driven\nOverall Survival</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:10.0pt;text-align:center;\nline-height:115%;page-break-after:avoid\"><img border=\"0\" height=\"354\" id=\"Picture 1\" src=\"Perjeta-II-48%20EN%20PI%20clean_files/image003.jpg\" width=\"580\"/></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:10.0pt;text-align:center;\nline-height:115%\"><span lang=\"EN-GB\" style=\"font-size:8.0pt;line-height:115%\">HR=\nhazard ratio; CI= confidence interval; Pla= placebo; Ptz= pertuzumab (Perjeta);\nT= trastuzumab (Herceptin); D= docetaxel</span><span lang=\"EN-GB\" style=\"font-size:8.0pt;line-height:115%\">.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">No statistically significant differences\nwere found between the two treatment groups in Health Related Quality of Life\nas assessed by FACT-B TOI-PFB scores. </span></p>\n<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">\u00a0</span></i></p>\n<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">Additional </span></i><i><span lang=\"EN-GB\">supportive clinical trial</span></i><i><span lang=\"EN-GB\"> information</span></i></p>\n<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">\u00a0</span></i></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">BO17929</span></b><span lang=\"EN-GB\"> -<b>\n</b>single-arm trial in metastatic breast cancer</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">BO17929 was a phase II, non-randomised study\nin patients with metastatic breast cancer whose tumours had progressed during\ntreatment with trastuzumab. Treatment with Perjeta and trastuzumab resulted in\na response rate of 24.2%, with a further 25.8% of patients experiencing\nstabilisation of disease lasting at least 6 months, indicating that Perjeta is\nactive </span><span lang=\"EN-GB\">following</span><span lang=\"EN-GB\"> progression on\n</span><span lang=\"EN-GB\">trastuzumab.</span>\u00a0 </p>\n<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">\u00a0</span></i></p>\n<p class=\"MsoNormal\"><i><span lang=\"EN-GB\" style=\"color:black\">Early Breast Cancer</span></i></p>\n<p class=\"MsoNormal\"><i><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></i></p>\n<p class=\"MsoNormal\"><i><span lang=\"EN-GB\" style=\"color:black\">Neoadjuvant\nTreatment</span></i></p>\n<p class=\"MsoNormal\"><i><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></i></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">In the neoadjuvant\nsetting, locally advanced and inflammatory breast cancers are considered as\nhigh-risk irrespective of hormone receptor status. In early stage breast cancer,\ntumor size, grade, hormone receptor status and lymph node metastases should be\ntaken into account in the risk assessment.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">The indication in the\nneoadjuvant treatment of breast cancer is based on demonstration of an\nimprovement in pathological complete response rate,</span><span lang=\"EN-GB\"> </span><span lang=\"EN-GB\" style=\"color:black\">and trends to improvement in disease-free\nsurvival that nevertheless do not establish or precisely measure a benefit with\nregard to long-term outcomes, such as overall survival or disease-free\nsurvival. </span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"color:black\">NEOSPHERE (WO20697)</span></b><span lang=\"EN-GB\" style=\"color:black\"> </span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">NEOSPHERE is a phase\nII, multicentre, multinational randomised controlled trial with Perjeta and was\nconducted in 417 adult female patients</span><span lang=\"EN-GB\"> </span><span lang=\"EN-GB\" style=\"color:black\">with newly diagnosed, early, inflammatory or\nlocally advanced HER2-positive breast cancer (T2-4d</span>; <span lang=\"EN-GB\" style=\"color:black\">primary tumour &gt; 2cm in diameter) who had not received\nprior trastuzumab, chemotherapy or radiotherapy. Patients with metastases,\nbilateral breast cancer, clinically important cardiac risk factors (see section\n4.4) or LVEF &lt; 55% were not included. The majority of</span><span lang=\"EN-GB\" style=\"color:black\"> patients were </span><span lang=\"EN-GB\" style=\"color:black\">less than 65 years old. </span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Patients were </span><span lang=\"EN-GB\" style=\"color:black\">randomised\n</span><span lang=\"EN-GB\" style=\"color:black\">to receive</span><span lang=\"EN-GB\" style=\"color:black\"> one of </span><span lang=\"EN-GB\" style=\"color:black\">the\nfollowing neoadjuvant regimens for 4 cycles prior to surgery: </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.25in;page-break-after:avoid\"><span style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0 <span style=\"color:\nblack\">Trastuzumab plus docetaxel </span></span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.25in;page-break-after:avoid\"><span style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0 <span style=\"color:\nblack\">Perjeta plus trastuzumab and docetaxel</span></span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.25in\"><span style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 <span style=\"color:black\">Perjeta plus trastuzumab</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.25in\"><span style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 <span style=\"color:black\">Perjeta plus docetaxel. </span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.5in\"><span style=\"color:black\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Randomisation was\nstratified by breast cancer type (operable, locally advanced, or inflammatory)\nand ER or PgR positivity.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0 </span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Pertuzumab was given\nintravenously at an initial dose of 840 mg, followed by 420 mg every three\nweeks. Trastuzumab was given intravenously at an initial dose of 8 mg/kg,\nfollowed by 6 mg/kg every three weeks. Docetaxel was given intravenously at an\ninitial dose of 75 mg/ m<sup>2</sup> followed by 75 mg/ m<sup>2</sup> or 100\nmg/ m<sup>2</sup> (if tolerated) every 3 weeks. Following surgery all patients\nreceived 3 cycles of 5-fluorouracil (600\u00a0mg/m<sup>2</sup>), epirubicin\n(90\u00a0mg/m<sup>2</sup>), cyclophosphamide (600\u00a0mg/m<sup>2</sup>) (FEC)\ngiven intravenously every three weeks, and trastuzumab administered\nintravenously every three weeks to complete one year of therapy. Patients who\nonly received Perjeta plus trastuzumab prior to surgery subsequently received\nboth FEC and docetaxel post surgery.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">The primary endpoint of\nthe study was pathological complete response (pCR) rate in the breast\n(ypT0/is).\u00a0 Secondary efficacy endpoints were clinical response rate, breast\nconserving surgery rate (T2-3 tumours only), disease-free survival (DFS), and\nPFS. Additional exploratory pCR rates included nodal status (ypT0/isN0 and\nypT0N0).</span></p>\n<p class=\"MsoNormal\"><u><span lang=\"EN-GB\" style=\"color:black\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Demographics were well\nbalanced (median age was 49-50 years, the majority were caucasian (71%)) and\nall patients were female. Overall 7% of patients had inflammatory breast\ncancer, 32% had locally advanced breast cancer and 61% had operable breast\ncancer.\u00a0 Approximately half the patients in each treatment group had hormone\nreceptor-positive disease (defined as ER positive and/or PgR positive). </span></p>\n<p class=\"MsoNormal\"><u><span lang=\"EN-GB\" style=\"color:black\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">The efficacy results are presented in Table\n4. A statistically significant\u00a0 improvement in pCR rate (ypT0/is) was observed\nin patients receiving Perjeta plus trastuzumab and docetaxel compared to\npatients receiving trastuzumab and docetaxel (45.8% vs 29.0%, p value = </span><span lang=\"EN-GB\">0.0141</span><span lang=\"EN-GB\">). A consistent pattern of results was\nobserved regardless of pCR definition. The difference in pCR rate is considered\nlikely to translate into a clinically meaningful difference in long term\noutcomes and is supported by positive trends in PFS (HR 0.69, 95% CI 0.34, 1.40)\nand DFS (HR 0.60, 95% CI 0.28, 1.27).<u> </u></span></p>\n<p class=\"MsoNormal\"><u><span lang=\"EN-GB\" style=\"color:black\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">The pCR rates as well as the magnitude of\nbenefit with Perjeta (Perjeta plus trastuzumab and docetaxel compared to\npatients receiving trastuzumab and docetaxel) were lower in the subgroup of\npatients with hormone receptor-positive tumours (difference of 6% in pCR in the\nbreast) than in patients with hormone receptor-negative tumours (difference of\n26.4% in pCR in the breast).</span><span lang=\"EN-GB\"> </span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">pCR rates were similar in patients with operable\nversus locally advanced disease. There were too few patients with inflammatory\nbreast cancer to draw any firm conclusions but the pCR rate was higher in\npatients who received Perjeta plus trastuzumab and docetaxel.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">TRYPHAENA\n(BO22280)</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">TRYPHAENA is\na multicentre, randomised phase II clinical trial conducted in 225 adult female\npatients with HER2-positive locally advanced, operable, or inflammatory breast\ncancer (T2-4d; primary tumour\u00a0 &gt; 2cm in diameter) who had not received prior\ntrastuzumab, chemotherapy or radiotherapy.\u00a0 Patients with metastases, bilateral\nbreast cancer, clinically important cardiac risk factors (see section 4.4) or\nLVEF\u00a0 &lt;\u00a0 55% were not included. The majority of patients were less than 65\nyears old. Patients were randomised to receive one of three neoadjuvant\nregimens prior to surgery as follows: </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:35.7pt;text-indent:-17.85pt\"><span style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 <span lang=\"EN-GB\" style=\"color:black\">3\ncycles of FEC followed by 3 cycles of docetaxel, all given concurrently with\nPerjeta and trastuzumab</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:35.7pt;text-indent:-17.85pt\"><span style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 <span lang=\"EN-GB\" style=\"color:black\">3\ncycles of FEC alone followed by 3 cycles of docetaxel, with trastuzumab and\nPerjeta given concurrently</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:35.7pt;text-indent:-17.85pt\"><span style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 <span lang=\"EN-GB\" style=\"color:black\">6\ncycles of TCH in combination with Perjeta. </span></p>\n<p class=\"MsoNormal\" style=\"margin-left:35.7pt;text-indent:-17.85pt\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Randomisation was stratified by breast\ncancer type (operable, locally advanced, or inflammatory) and ER and /or PgR\npositivity. </span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Pertuzumab was given intravenously at an\ninitial dose of 840 mg, followed by 420 mg every three weeks.\u00a0 Trastuzumab was\ngiven intravenously at an initial dose of 8 mg/kg, followed by 6 mg/kg every\nthree weeks.\u00a0 FEC (5-fluorouracil [500\u00a0mg/m<sup>2</sup>], epirubicin [100\nmg/m2], cyclophosphamide [600 mg/m2]) were given intravenously every three\nweeks for 3 cycles.\u00a0 Docetaxel was given as an initial dose of 75\u00a0mg/m<sup>2</sup>\nIV infusion every three weeks with the option to escalate to 100 mg/m<sup>2</sup>\nat the investigator\u2019s discretion if the initial dose was well tolerated.\u00a0\nHowever, in the group treated with Perjeta in combination with TCH, docetaxel\nwas given intravenously at 75\u00a0mg/m<sup>2</sup> (no escalation was\npermitted) and carboplatin (AUC 6) was given intravenously every three weeks.\nFollowing surgery all patients received trastuzumab</span><span lang=\"EN-GB\"> to\ncomplete </span><span lang=\"EN-GB\">one year of therapy</span><span lang=\"EN-GB\">.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">The primary endpoint of this study was\ncardiac safety during the neoadjuvant treatment period of the study.\u00a0 Secondary\nefficacy endpoints were pCR rate in the breast (ypT0/is), DFS, PFS and OS. </span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Demographics were well balanced between\narms (median age was 49-50 years, the majority were Caucasian [77%]) and all\npatients were female. Overall 6% of patients had inflammatory breast cancer,\n25% had locally advanced breast cancer and 69% had operable breast cancer.\nApproximately half the patients in each treatment group had ER-positive and/or PgR-positive\ndisease.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Compared with published data for similar\nregimens without pertuzumab, high pCR rates were observed in all 3 treatment arms\n(see Table 4). A consistent pattern of results was observed regardless of pCR\ndefinition used. The pCR rates were lower in the subgroup of patients with\nhormone receptor-positive tumours (range 46.2% to 50.0%) than in patients with\nhormone receptor-negative tumours (range 65.0% to 83.8%).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">pCR rates were similar in patients with\noperable and locally advanced disease. There were too few patients with\ninflammatory breast cancer to draw any firm conclusions. </span></p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"margin-left:.75in;text-indent:-.75in;page-break-after:\navoid\"><b><span lang=\"EN-GB\" style=\"color:black\">Table 4\u00a0\u00a0\u00a0\u00a0\u00a0 NEOSPHERE (WO20697)\nand TRYPHAENA (BO22280): Overview of efficacy (Intent to Treat Population) </span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div align=\"center\">\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\" width=\"108%\">\n<thead>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:10.6%;border:solid windowtext 1.0pt;padding:\n   0in 2.85pt 0in 2.85pt\" width=\"10%\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n   2.5pt;margin-left:0in;line-height:12.0pt;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></b></p>\n</td>\n<td colspan=\"4\" style=\"width:47.48%;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 2.85pt 0in 2.85pt\" width=\"47%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">NEOSPHERE (WO20697)</span></b></p>\n</td>\n<td colspan=\"3\" style=\"width:41.92%;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 2.85pt 0in 2.85pt\" width=\"41%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">TRYPHAENA (BO22280)</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:10.6%;border:solid windowtext 1.0pt;border-top:\n   none;padding:0in 2.85pt 0in 2.85pt\" width=\"10%\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n   2.5pt;margin-left:0in;line-height:12.0pt;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Parameter</span></b></p>\n</td>\n<td style=\"width:11.44%;border-top:none;border-left:none;\n   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n   padding:0in 2.85pt 0in 2.85pt\" width=\"11%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Trastuzumab +Docetaxel</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">N=107</span></b></p>\n</td>\n<td style=\"width:12.1%;border-top:none;border-left:none;\n   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n   padding:0in 2.85pt 0in 2.85pt\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Perjeta+</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Trastuzumab+</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Docetaxel</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">N=107</span></b></p>\n</td>\n<td style=\"width:12.12%;border-top:none;border-left:none;\n   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n   padding:0in 2.85pt 0in 2.85pt\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Perjeta+</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Trastuzumab</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">N=107</span></b></p>\n</td>\n<td style=\"width:11.82%;border-top:none;border-left:none;\n   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n   padding:0in 2.85pt 0in 2.85pt\" width=\"11%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Perjeta</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">+Docetaxel</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">N=96</span></b></p>\n</td>\n<td style=\"width:13.72%;border-top:none;border-left:none;\n   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n   padding:0in 2.85pt 0in 2.85pt\" width=\"13%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:-1.45pt;\n   margin-bottom:2.5pt;margin-left:-1.2pt;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"ES\" style=\"font-size:10.0pt;color:black\">Perjeta+</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:-1.45pt;\n   margin-bottom:2.5pt;margin-left:-1.2pt;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"ES\" style=\"font-size:10.0pt;color:black\">Trastuzumab+</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:-1.45pt;\n   margin-bottom:2.5pt;margin-left:-1.2pt;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"ES\" style=\"font-size:10.0pt;color:black\">FEC</span></b><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Wingdings;color:black\">\u00e0</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"ES\" style=\"font-size:10.0pt;color:black\">Perjeta+</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"ES\" style=\"font-size:10.0pt;color:black\">Trastuzumab+</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Docetaxel</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">N=73</span></b></p>\n</td>\n<td style=\"width:13.44%;border-top:none;border-left:none;\n   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n   padding:0in 2.85pt 0in 2.85pt\" width=\"13%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"ES\" style=\"font-size:10.0pt;color:black\">FEC</span></b><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Wingdings;color:black\">\u00e0</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"ES\" style=\"font-size:10.0pt;color:black\">Perjeta+</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"ES\" style=\"font-size:10.0pt;color:black\">Trastuzumab+</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"ES\" style=\"font-size:10.0pt;color:black\">Docetaxel</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"ES\" style=\"font-size:10.0pt;color:black\">N=75</span></b></p>\n</td>\n<td style=\"width:14.76%;border-top:none;border-left:none;\n   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n   padding:0in 2.85pt 0in 2.85pt\" width=\"14%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Perjeta</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">+TCH</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">N=77</span></b></p>\n</td>\n</tr>\n</thead>\n<tr style=\"page-break-inside:avoid;height:48.2pt\">\n<td style=\"width:10.6%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt;height:48.2pt\" valign=\"top\" width=\"10%\">\n<p class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;margin-bottom:\n  1.0pt;margin-left:0in;line-height:14.0pt;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">pCR rate in the breast\n  (ypT0/is)</span></p>\n<p class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;margin-bottom:\n  1.0pt;margin-left:0in;line-height:14.0pt;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">n (%)</span></p>\n<p class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;margin-bottom:\n  1.0pt;margin-left:0in;line-height:14.0pt;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[95% CI]<sup>1</sup></span></p>\n</td>\n<td style=\"width:11.44%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:48.2pt\" width=\"11%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">31\n  (29.0%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[20.6;\n  38.5]</span></p>\n</td>\n<td style=\"width:12.1%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:48.2pt\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">49\n  (45.8%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[36.1;\n  55.7]</span></p>\n</td>\n<td style=\"width:12.12%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:48.2pt\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">18\n  (16.8%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[10.3;\n  25.3]</span></p>\n</td>\n<td style=\"width:11.82%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:48.2pt\" width=\"11%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">23\n  (24.0%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[15.8;\n  33.7]</span></p>\n</td>\n<td style=\"width:13.72%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:48.2pt\" width=\"13%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">45\n  (61.6%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[49.5;\n  72.8]</span></p>\n</td>\n<td style=\"width:13.44%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:48.2pt\" width=\"13%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">43\n  (57.3%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[45.4;\n  68.7]</span></p>\n</td>\n<td style=\"width:14.76%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:48.2pt\" width=\"14%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">51\n  (66.2%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[54.6;\n  76.6]</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:10.6%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"top\" width=\"10%\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Difference in pCR rates<sup>2</sup></span></p>\n<p class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;margin-bottom:\n  1.0pt;margin-left:0in;line-height:14.0pt;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[95% CI]<sup>3</sup></span></p>\n</td>\n<td style=\"width:11.44%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"11%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td style=\"width:12.1%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">+16.8 %</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[3.5; 30.1]</span></p>\n</td>\n<td style=\"width:12.12%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">-12.2 %</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:-4.05pt;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;text-indent:-4.1pt;\n  line-height:14.0pt;page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[-23.8; -0.5]</span></p>\n</td>\n<td style=\"width:11.82%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"11%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">-21.8 %</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:-2.8pt;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;text-indent:-1.65pt;\n  line-height:14.0pt;page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[-35.1; -8.5]</span></p>\n</td>\n<td style=\"width:13.72%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"13%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">NA</span></p>\n</td>\n<td style=\"width:13.44%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"13%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">NA</span></p>\n</td>\n<td style=\"width:14.76%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"14%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">NA</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:10.6%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"top\" width=\"10%\">\n<p class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;margin-bottom:\n  1.0pt;margin-left:0in;line-height:14.0pt;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">p-value (with Simes corr. for\n  CMH test)<sup>4</sup></span></p>\n</td>\n<td style=\"width:11.44%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"11%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td style=\"width:12.1%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">0.0141</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">(vs.\n  Trastuzumab+Docetaxel)</span></p>\n</td>\n<td style=\"width:12.12%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">0.0198</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">(vs.\n  Trastuzumab+Docetaxel)</span></p>\n</td>\n<td style=\"width:11.82%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"11%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">0.0030</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:-4.45pt;\n  margin-bottom:1.0pt;margin-left:-2.8pt;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">(vs\n  Perjeta+</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:-4.45pt;\n  margin-bottom:1.0pt;margin-left:-2.8pt;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Trastuzumab+Docetaxel)</span></p>\n</td>\n<td style=\"width:13.72%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"13%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">NA</span></p>\n</td>\n<td style=\"width:13.44%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"13%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">NA</span></p>\n</td>\n<td style=\"width:14.76%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"14%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">NA</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:10.6%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"top\" width=\"10%\">\n<p class=\"MsoNormal\" style=\"line-height:14.0pt;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">pCR rate in the breast and\n  lymph node (ypT0/is N0)</span></p>\n<p class=\"MsoNormal\" style=\"margin-bottom:1.0pt;line-height:14.0pt;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">n (%)</span></p>\n<p class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;margin-bottom:\n  1.0pt;margin-left:0in;line-height:14.0pt;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[95% CI]</span></p>\n</td>\n<td style=\"width:11.44%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"11%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">23\n  (21.5%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[14.1;\n  30.5]</span></p>\n</td>\n<td style=\"width:12.1%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">42\n  (39.3%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[30.3;\n  49.2]</span></p>\n</td>\n<td style=\"width:12.12%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">12\n  (11.2%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[5.9;\n  18.8]</span></p>\n</td>\n<td style=\"width:11.82%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"11%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">17\n  (17.7%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[10.7;\n  26.8]</span></p>\n</td>\n<td style=\"width:13.72%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"13%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">41\n  (56.2%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[44.1;\n  67.8]</span></p>\n</td>\n<td style=\"width:13.44%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"13%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">41\n  (54.7%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[42.7;\n  66.2]</span></p>\n</td>\n<td style=\"width:14.76%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"14%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">49\n  (63.6%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[51.9;\n  74.3]</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:10.6%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"top\" width=\"10%\">\n<p class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;margin-bottom:\n  1.0pt;margin-left:0in;line-height:14.0pt;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">ypT0 N0 </span></p>\n<p class=\"MsoNormal\" style=\"margin-bottom:1.0pt;line-height:14.0pt;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">n (%)</span></p>\n<p class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;margin-bottom:\n  1.0pt;margin-left:0in;line-height:14.0pt;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[95% CI]</span></p>\n</td>\n<td style=\"width:11.44%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"11%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">13\n  (12.1%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[6.6;\n  19.9]</span></p>\n</td>\n<td style=\"width:12.1%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">35\n  (32.7%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[24.0;\n  42.5]</span></p>\n</td>\n<td style=\"width:12.12%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">6\n  (5.6%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[2.1;\n  11.8]</span></p>\n</td>\n<td style=\"width:11.82%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"11%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">13\n  (13.2%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[7.4;\n  22.0]</span></p>\n</td>\n<td style=\"width:13.72%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"13%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">37\n  (50.7%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[38.7;\n  62.6]</span></p>\n</td>\n<td style=\"width:13.44%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"13%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">34\n  (45.3%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[33.8;\n  57.3]</span></p>\n</td>\n<td style=\"width:14.76%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"14%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">40\n  (51.9%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[40.3;\n  63.5]</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:10.6%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"top\" width=\"10%\">\n<p class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;margin-bottom:\n  1.0pt;margin-left:0in;line-height:14.0pt;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Clinical Response<sup>5</sup></span></p>\n</td>\n<td style=\"width:11.44%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"11%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">79\n  (79.8%)</span></p>\n</td>\n<td style=\"width:12.1%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">89\n  (88.1%)</span></p>\n</td>\n<td style=\"width:12.12%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">69\n  (67.6%)</span></p>\n</td>\n<td style=\"width:11.82%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"11%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">65\n  (71.4%)</span></p>\n</td>\n<td style=\"width:13.72%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"13%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">67\n  (91.8%)</span></p>\n</td>\n<td style=\"width:13.44%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"13%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">71\n  (94.7%)</span></p>\n</td>\n<td style=\"width:14.76%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"14%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">69\n  (89.6%)</span></p>\n</td>\n</tr>\n</table>\n</div>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">FEC: 5-fluorouracil,\nepirubicin, cyclophosphamide; TCH: docetaxel, carboplatin and trastuzumab, CMH:\nCochran\u2013Mantel\u2013Haenszel</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">1. 95% CI for one sample\nbinomial using Pearson-Clopper method.</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">2. Treatment Perjeta+Trastuzumab+Docetaxel\nand Perjeta+Trastuzumab are compared to Trastuzumab+ Docetaxel while\nPerjeta+Docetaxel\u00a0 is compared to Perjeta+Trastuzumab+Docetaxel.</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">3. Approximate 95% CI for\ndifference of two response rates using Hauck-Anderson method.</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">4. p-value from Cochran-Mantel-Haenszel\u00a0\ntest, with Simes multiplicity adjustment.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">5.\nClinical response represents patients with a best overall response of CR or PR\nduring the neoadjuvant period (in the primary breast lesion).</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:9.0pt;text-indent:-9.0pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">BERENICE\n(WO29217)</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"MsoNormal\">BERENICE is a non-randomized, open-label, multicentre,\nmultinational, Phase II trial conducted in 401 patients with HER2-positive\nlocally advanced, inflammatory, or early-stage breast cancer (with primary\ntumours <span style=\"font-family:Symbol\">&gt;</span>\u00a02cm in diameter or\nnode\u2011positive disease).</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">The BERENICE study included two parallel groups of patients.\nPatients considered suitable for neoadjuvant treatment with trastuzumab plus\nanthracycline/taxane-based chemotherapy were allocated to receive one of the\ntwo following regimens prior to surgery as follows: </p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"margin-left:35.7pt;text-indent:-17.85pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0 </span>Cohort\nA - 4 cycles of two weekly dose-dense doxorubicin and cyclophosphamide followed\nby 4 cycles of Perjeta in combination with trastuzumab and paclitaxel.</p>\n<p class=\"MsoNormal\" style=\"margin-left:35.7pt;text-indent:-17.85pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0 </span>Cohort\nB - 4 cycles of FEC followed by 4 cycles of Perjeta in combination with trastuzumab\nand docetaxel. </p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Following surgery all patients received Perjeta and\ntrastuzumab intravenously every 3 weeks to complete 1 year of therapy.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">The primary endpoint of the BERENICE trial is cardiac safety\nin the neoadjuvant period of the trial. The primary endpoint of cardiac safety,\ni.e. the incidence of NYHA Class III/IV LVD and LVEF declines, was consistent\nwith previous data in the neoadjuvant setting (see section 4.4. and 4.8).</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\"><i>Adjuvant Treatment</i></p>\n<p class=\"MsoNormal\"><i>\u00a0</i></p>\n<p class=\"MsoNormal\">In the adjuvant setting, based on data from the APHINITY\nstudy, HER2-positive early breast cancer patients at high risk of recurrence\nare defined as those with lymph node-positive or hormone receptor-negative\ndisease.</p>\n<p class=\"MsoNormal\"><b>\u00a0</b></p>\n<p class=\"MsoNormal\"><b>APHINITY (BO25126) </b></p>\n<p class=\"MsoNormal\"><b>\u00a0</b></p>\n<p class=\"MsoNormal\">APHINITY is a multicentre, randomised, double-blind,\nplacebo-controlled Phase III trial conducted in 4804 patients with\nHER2-positive early breast cancer who had their primary tumour excised prior to\nrandomisation. Patients were then randomised to receive Perjeta or placebo, in\ncombination with adjuvant trastuzumab and chemotherapy. Investigators selected\none of the following anthracycline-based or non-anthracycline-based\nchemotherapy regimens for individual patients:</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"margin-left:35.7pt;text-indent:-17.85pt\"><span style=\"font-family:Symbol;color:black\">\u00b7</span><span lang=\"BG\" style=\"color:black\">\u00a0\u00a0\u00a0 </span>3\nor 4 cycles of FEC or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC),\nfollowed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel</p>\n<p class=\"MsoNormal\" style=\"margin-left:35.7pt;text-indent:-17.85pt\"><span style=\"font-family:Symbol;color:black\">\u00b7</span><span lang=\"BG\" style=\"color:black\">\u00a0\u00a0\u00a0 </span>4\ncycles of AC or epirubicin and cyclophosphamide (EC), followed by 3 or 4 cycles\nof docetaxel or 12 cycles of weekly paclitaxel </p>\n<p class=\"MsoNormal\" style=\"margin-left:35.7pt;text-indent:-17.85pt\"><span style=\"font-family:Symbol;color:black\">\u00b7</span><span lang=\"BG\" style=\"color:black\">\u00a0\u00a0\u00a0 </span>6\ncycles of docetaxel in combination with carboplatin\u00a0 </p>\n<p class=\"MsoNormal\" style=\"margin-left:.5in\">\u00a0</p>\n<p class=\"MsoNormal\">Pertuzumab and trastuzumab were administered intravenously\n(see section 4.2) every 3 weeks starting<i> </i>on Day 1 of the first\ntaxane-containing cycle, for a total of 52 weeks (up to 18 cycles) or until\nrecurrence, withdrawal of consent or unmanageable toxicity. Standard doses of\n5-fluorouracil, epirubicin, doxorubicin, cyclophosphamide, docetaxel,\npaclitaxel and carboplatin were administered. After completion of chemotherapy,\npatients received radiotherapy and/or hormone therapy as per local clinical\nstandard.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">The primary endpoint of the study was invasive disease-free\nsurvival (IDFS), defined as the time from randomisation to first occurrence of\nipsilateral local or regional invasive breast cancer recurrence, distant\nrecurrence, contralateral invasive breast cancer, or death from any cause.\nSecondary efficacy endpoints were IDFS including second primary non-breast\ncancer, overall survival (OS), disease-free survival (DFS), recurrence-free interval\n(RFI) and distant recurrence-free interval (DRFI).</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Demographics were well\nbalanced between the two treatment arms. The median age was 51 years, and over\n99% of patients were female. The majority of patients had node-positive (63%)\nand/or hormone receptor-positive disease (64%), and were Caucasian (71%).</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">After a median follow-up of\n45.4 months, the APHINITY study showed a 19% (hazard ratio [HR] = 0.81; 95% CI\n0.66, 1.00 p-value 0.0446) reduction in risk of recurrence or death in patients\nrandomised to receive Perjeta compared with patients randomised to receive\nplacebo.</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">The efficacy results from the\nAPHINITY trial are summarised in Table 5 and in Figure 3.</p>\n<p class=\"MsoNormal\"><u><span style=\"text-decoration:none\">\u00a0</span></u></p>\n<p class=\"MsoNormal\" style=\"margin-left:.75in;text-indent:-.75in;page-break-after:\navoid\"><b>Table 5 \u00a0\u00a0\u00a0\u00a0 Overall Efficacy: ITT Population</b></p>\n<p class=\"MsoNormal\" style=\"margin-left:.75in;text-indent:-.75in;page-break-after:\navoid\"><b>\u00a0</b></p>\n<div align=\"right\">\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:457.35pt;border-collapse:collapse;border:none\" width=\"610\">\n<thead>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:238.5pt;border:solid windowtext 1.0pt;\n   padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:112.5pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"150\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Perjeta\n   + trastuzumab + Chemotherapy</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">N=2400</span></b></p>\n</td>\n<td style=\"width:106.35pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"142\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Placebo\n   + trastuzumab + Chemotherapy</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">N=2404</span></b></p>\n</td>\n</tr>\n</thead>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:238.5pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Primary\n  Endpoint</span></i></b></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">\u00a0</span></i></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Invasive\n  Disease Free Survival (IDFS)<sup> </sup></span></b></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Number (%)\n  of patients with event </span></p>\n</td>\n<td style=\"width:112.5pt;border:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"150\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">171 (7.1%)</span></p>\n</td>\n<td style=\"width:106.35pt;border:none;border-right:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"142\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\">210 (8.7%)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">HR [95%\n  CI]</span></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0.81 [0.66, 1.00]</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">p-value\n  (Log-Rank test, stratified<sup>1</sup>)</span></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0.0446</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:238.5pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">3 year\n  event-free rate<sup>2</sup> [95% CI] </span></p>\n</td>\n<td style=\"width:112.5pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"150\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">94.1\n  [93.1, 95.0]</span></p>\n</td>\n<td style=\"width:106.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"142\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\">93.2 [92.2, 94.3]</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:238.5pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Secondary\n  Endpoints<sup>1</sup></span></i></b></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">\u00a0</span></i></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">IDFS</span></b><span lang=\"EN-GB\"> </span><b><span lang=\"EN-GB\">including second primary non-breast\n  cancer</span></b></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Number (%)\n  of patients with event </span></p>\n</td>\n<td style=\"width:112.5pt;border:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"150\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">189 (7.9%)</span></p>\n</td>\n<td style=\"width:106.35pt;border:none;border-right:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"142\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\">230 (9.6%)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"top\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">HR [95%\n  CI]</span></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"top\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0.82 [0.68, 0.99]</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">p-value\n  (Log-Rank test, stratified<sup>1</sup>)</span></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0.0430</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:238.5pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">3 year\n  event-free rate<sup>2</sup> [95% CI] </span></p>\n</td>\n<td style=\"width:112.5pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"150\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">93.5\n  [92.5, 94.5]</span></p>\n</td>\n<td style=\"width:106.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"142\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\">92.5 [91.4, 93.6]</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Disease\n  Free Survival (DFS) </span></b></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Number (%)\n  of patients with event</span></p>\n</td>\n<td style=\"width:112.5pt;border:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"150\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">192 (8.0%)</span></p>\n</td>\n<td style=\"width:106.35pt;border:none;border-right:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"142\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\">236 (9.8%)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">HR [95%\n  CI]</span></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0.81 [0.67, 0.98]</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">p-value (Log-Rank\n  test, stratified<sup>1</sup>)</span></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0.0327</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:238.5pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">3 year\n  event-free rate<sup>2</sup> [95% CI]</span></p>\n</td>\n<td style=\"width:112.5pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"150\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">93.4\n  [92.4, 94.4]</span></p>\n</td>\n<td style=\"width:106.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"142\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\">92.3 [91.2, 93.4]</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid;height:6.1pt\">\n<td style=\"width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:6.1pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Overall\n  Survival (OS)<sup>3</sup></span></b></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt;height:\n  6.1pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid;height:10.9pt\">\n<td style=\"width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:10.9pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Number (%)\n  of patients with event</span></p>\n</td>\n<td style=\"width:112.5pt;border:none;padding:0in 2.85pt 0in 2.85pt;\n  height:10.9pt\" valign=\"bottom\" width=\"150\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">80 (3.3%)</span></p>\n</td>\n<td style=\"width:106.35pt;border:none;border-right:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt;height:10.9pt\" valign=\"bottom\" width=\"142\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\">89 (3.7%)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid;height:10.9pt\">\n<td style=\"width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:10.9pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">HR [95%\n  CI]</span></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt;height:\n  10.9pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0.89 [0.66, 1.21]</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid;height:10.9pt\">\n<td style=\"width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:10.9pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">p-value\n  (Log-Rank test, stratified<sup>1</sup>)</span></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt;height:\n  10.9pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0.4673</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid;height:10.9pt\">\n<td style=\"width:238.5pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt;height:10.9pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">3 year\n  event-free rate<sup>2</sup> [95% CI]</span></p>\n</td>\n<td style=\"width:112.5pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt;height:10.9pt\" valign=\"bottom\" width=\"150\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">97.7\n  [97.0, 98.3]</span></p>\n</td>\n<td style=\"width:106.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:10.9pt\" valign=\"bottom\" width=\"142\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\">97.7 [97.1, 98.3]</span></p>\n</td>\n</tr>\n</table>\n</div>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span style=\"font-size:\n10.0pt\">Key to abbreviations (Table 5): </span></b><span lang=\"EN-GB\" style=\"font-size:10.0pt\">HR: Hazard Ratio; CI: Confidence Interval </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span style=\"font-size:10.0pt\">1.\nAll analyses stratified by nodal status, protocol version, central hormone\nreceptor status, and adjuvant chemotherapy\nregimen.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span style=\"font-size:10.0pt\">2.\n3-year event-free rate derived from Kaplan-Meier estimates.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.75in;text-indent:-.75in;page-break-after:\navoid\"><span style=\"font-size:10.0pt\">3. Data from first interim analysis. </span></p>\n<p class=\"MsoNormal\"><b>\u00a0</b></p>\n<p class=\"MsoNormal\" style=\"margin-left:.75in;text-indent:-.75in;page-break-after:\navoid\"><b>Figure 3\u00a0\u00a0\u00a0\u00a0 Kaplan-Meier Curve of Invasive Disease Free Survival </b></p>\n<p class=\"MsoNormal\" style=\"margin-left:.75in;text-indent:-.75in;page-break-after:\navoid\"><b>\u00a0</b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span style=\"font-size:8.0pt\"><img border=\"0\" height=\"385\" id=\"Picture 8\" src=\"Perjeta-II-48%20EN%20PI%20clean_files/image004.png\" width=\"604\"/></span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span style=\"font-size:8.0pt\">IDFS=\ninvasive disease free survival; CI= confidence interval; Pla= placebo; Ptz=\npertuzumab (Perjeta); T= trastuzumab.</span></p>\n<p class=\"MsoNormal\" style=\"margin-bottom:10.0pt;line-height:115%\"><span style=\"line-height:115%\">\u00a0</span></p>\n<p class=\"MsoNormal\">The estimate of IDFS at 4-years was 92.3% in the\nPerjeta-treated group versus 90.6% in the placebo-treated group. At the time of\nthe estimate the median follow-up was 45.4 months.</p>\n<p class=\"MsoNormal\"><u><span style=\"text-decoration:none\">\u00a0</span></u></p>\n<p class=\"MsoNormal\"><u>Results of Subgroup Analysis </u></p>\n<p class=\"MsoNormal\"><u><span style=\"text-decoration:none\">\u00a0</span></u></p>\n<p class=\"MsoNormal\">At the time of the primary analysis, the benefits of Perjeta\nwere more apparent in subgroups of patients a high risk of recurrence: patients\nwith node-positive or hormone receptor-negative disease (see table 6).</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><u>Table\u00a06\u00a0 Efficacy\nresults in subgroups by nodal status and hormone receptor status<sup>1</sup></u></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><u><span style=\"text-decoration:\n none\">\u00a0</span></u></b></p>\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:460.25pt;border-collapse:collapse;border:none\" width=\"614\">\n<tr style=\"height:11.1pt\">\n<td rowspan=\"2\" style=\"width:126.9pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:11.1pt\" valign=\"top\" width=\"169\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Population</span></b></p>\n</td>\n<td colspan=\"2\" style=\"width:232.9pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:11.1pt\" valign=\"top\" width=\"311\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Number\n  of IDFS events/Total N (%)</span></b></p>\n</td>\n<td rowspan=\"2\" style=\"width:100.45pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:11.1pt\" valign=\"top\" width=\"134\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Unstratified\n  HR (95% CI)</span></b></p>\n</td>\n</tr>\n<tr style=\"height:44.95pt\">\n<td style=\"width:113.6pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:44.95pt\" valign=\"top\" width=\"151\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Perjeta + trastuzumab + chemotherapy</span></b></p>\n</td>\n<td style=\"width:119.3pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:44.95pt\" valign=\"top\" width=\"159\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Placebo + <br/>\n  trastuzumab + chemotherapy</span></b></p>\n</td>\n</tr>\n<tr style=\"height:11.65pt\">\n<td colspan=\"4\" style=\"width:460.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:11.65pt\" valign=\"top\" width=\"614\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Nodal\n  status</span></b></p>\n</td>\n</tr>\n<tr style=\"height:26.75pt\">\n<td style=\"width:126.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:26.75pt\" valign=\"top\" width=\"169\">\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\n  page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0\u00a0 Positive</span></p>\n</td>\n<td style=\"width:113.6pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:26.75pt\" valign=\"top\" width=\"151\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">139/1503</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(9.2%)</span></p>\n</td>\n<td style=\"width:119.3pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:26.75pt\" valign=\"top\" width=\"159\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">181/1502</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(12.1%)</span></p>\n</td>\n<td style=\"width:100.45pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:26.75pt\" valign=\"top\" width=\"134\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0.77</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(0.62, 0.96)</span></p>\n</td>\n</tr>\n<tr style=\"height:23.3pt\">\n<td style=\"width:126.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:23.3pt\" valign=\"top\" width=\"169\">\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\n  page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0\u00a0 Negative </span></p>\n</td>\n<td style=\"width:113.6pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:23.3pt\" valign=\"top\" width=\"151\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">32/897</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(3.6%)</span></p>\n</td>\n<td style=\"width:119.3pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:23.3pt\" valign=\"top\" width=\"159\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">29/902</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(3.2%)</span></p>\n</td>\n<td style=\"width:100.45pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:23.3pt\" valign=\"top\" width=\"134\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">1.13</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(0.68, 1.86)</span></p>\n</td>\n</tr>\n<tr style=\"height:11.25pt\">\n<td style=\"width:126.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:11.25pt\" valign=\"top\" width=\"169\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Hormone\n  receptor status</span></b></p>\n</td>\n<td style=\"width:113.6pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:11.25pt\" valign=\"top\" width=\"151\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:119.3pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:11.25pt\" valign=\"top\" width=\"159\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:100.45pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:11.25pt\" valign=\"top\" width=\"134\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"height:26.75pt\">\n<td style=\"width:126.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:26.75pt\" valign=\"top\" width=\"169\">\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\n  page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0\u00a0 Negative</span></p>\n</td>\n<td style=\"width:113.6pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:26.75pt\" valign=\"top\" width=\"151\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">71/864</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(8.2%)</span></p>\n</td>\n<td style=\"width:119.3pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:26.75pt\" valign=\"top\" width=\"159\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">91/858</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(10.6%)</span></p>\n</td>\n<td style=\"width:100.45pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:26.75pt\" valign=\"top\" width=\"134\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0.76</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(0.56, 1.04)</span></p>\n</td>\n</tr>\n<tr style=\"height:26.75pt\">\n<td style=\"width:126.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:26.75pt\" valign=\"top\" width=\"169\">\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\n  page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0\u00a0 Positive</span></p>\n</td>\n<td style=\"width:113.6pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:26.75pt\" valign=\"top\" width=\"151\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">100/1536</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(6.5%)</span></p>\n</td>\n<td style=\"width:119.3pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:26.75pt\" valign=\"top\" width=\"159\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">119/1546</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(7.7%)</span></p>\n</td>\n<td style=\"width:100.45pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:26.75pt\" valign=\"top\" width=\"134\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0.86</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(0.66, 1.13)</span></p>\n</td>\n</tr>\n</table>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><sup><span style=\"font-size:\n10.0pt\">1</span></sup><span style=\"font-size:10.0pt\"> Prespecified subgroup\nanalyses without adjusting for multiple comparisons, therefore, results are\nconsidered descriptive.</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Estimates of IDFS rates in\nthe lymph node- positive subgroup were 92.0% versus 90.2% at 3\u00a0years and\n89.9% vs. 86.7% at 4 years in Perjeta-treated patients versus placebo-treated\npatients, respectively. In the lymph node- negative subgroup, estimates of IDFS\nrates were 97.5% versus 98.4% at 3\u00a0years and 96.2% versus 96.7% at 4 years\nin Perjeta-treated patients versus placebo-treated patients, respectively. In\nthe hormone receptor-negative subgroup, estimates of IDFS rates were 92.8%\nversus 91.2% at 3 years and 91.0% versus 88.7% at 4 years in Perjeta-treated\npatients versus placebo-treated patients, respectively. In the hormone\nreceptor-positive subgroup estimates of IDFS rates were 94.8% versus 94.4% at 3\nyears and 93.0% versus 91.6% at 4 years in Perjeta-treated patients versus\nplacebo-treated patients, respectively. </p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><u><span style=\"text-decoration:\n none\">\u00a0</span></u></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Patient\nReported Outcomes (PRO)</span></u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Secondary\nendpoints included the assessment of patient-reported global health status,\nrole and physical function, and treatment symptoms using the EORTC QLQ-C30 and\nEORTC QLQ-BR23 questionnaires. In the analyses of patient-reported outcomes, a\n10-point difference was considered clinically meaningful. </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Patients\u2019\nphysical function, global health status and diarrhoea scores showed a\nclinically meaningful change during chemotherapy in both treatment arms. The\nmean decrease from baseline at that time for physical function was -10.7 (95%\nCI-11.4, -10.0) in the Perjeta arm and -10.6 (95% CI -11.4, -9.9) in the\nplacebo arm; global health status was -11.2 (95% CI -12.2, -10.2) in the\nPerjeta arm and -10.2 (95% CI -11.1,-9.2) in the placebo arm. Change in\ndiarrhoea symptoms increased to +22.3 (95% CI 21.0, 23.6) in the Perjeta arm\nversus +9.2 (95% CI 8.2, 10.2) in the placebo arm. </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Thereafter\nin both arms physical function and global health status scores returned to\nbaseline levels during targeted treatment. Diarrhoea symptoms returned to\nbaseline after HER2 therapy in the Perjeta-arm. The addition of Perjeta to\ntrastuzumab plus chemotherapy did not affect patients\u2019 overall role function\nover the course of the study. </span></p>\n<p class=\"MsoNormal\" style=\"margin-left:9.0pt;text-indent:-9.0pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Immunogenicity</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Patients in the pivotal trial CLEOPATRA\nwere tested at multiple time-points for </span><span lang=\"EN-GB\">anti-drug antibodies\n(ADA</span><span lang=\"EN-GB\">) to </span><span lang=\"EN-GB\">Perjeta. </span><span lang=\"EN-GB\">3.3% (13/389 patients) of Perjeta-treated patients and 6.7% (25/372\npatients) of placebo-treated patients tested positive for ADA. </span>In BERENICE,\n4.1% (16/392) of the patients treated with Perjeta tested positive for ADA.\u00a0 <span lang=\"EN-GB\">None of these patients experienced anaphylactic/hypersensitivity\nreactions that were clearly related to ADA.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Paediatric\npopulation</span></u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">The European Medicines Agency has waived\nthe obligation to submit the results of studies with </span><span lang=\"EN-GB\">Perjeta\n</span><span lang=\"EN-GB\">in all subsets of the paediatric population in </span><span lang=\"EN-GB\">breast cancer</span><span lang=\"EN-GB\"> (see section 4.2 for\ninformation on paediatric use).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">5.2\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Pharmacokinetic properties</span></b></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">A population pharmacokinetic analysis was\nperformed with data from 481 patients across different clinical trials (phase\nI, II and III) with various types of advanced malignancies who had received Perjeta\nas a single agent or in combination at pertuzumab doses ranging from 2 to 25\u00a0mg/kg\nadministered every 3 weeks as a 30-60 minutes intravenous infusion.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Absorption</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Perjeta is administered as an intravenous\ninfusion. </span></p>\n<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">\u00a0</span></i></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Distribution</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Across all clinical studies, the volume of\ndistribution of the central (Vc) and the peripheral (Vp) compartment in the\ntypical patient, was 3.11\u00a0litres and 2.46\u00a0litres, respectively.</span></p>\n<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">\u00a0</span></i></p>\n<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Biotransformation</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">The metabolism of pertuzumab has not been directly\nstudied. Antibodies are cleared principally by catabolism.</span></p>\n<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">\u00a0</span></i></p>\n<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Elimination</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">The median clearance (CL) of pertuzumab was\n0.235\u00a0litres/day and the median half-life was 18 days.</span></p>\n<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">\u00a0</span></i></p>\n<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Linearity/non-linearity</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Pertuzumab displayed linear\npharmacokinetics within the recommended dose range.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Elderly patients</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Based on the population\npharmacokinetic analysis, no significant difference was observed in the\npharmacokinetics of pertuzumab between patients &lt;\u00a065 years (n=306) and\npatients \u2265\u00a065 years (n=175).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Renal impairment </span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">No dedicated renal impairment trial for Perjeta\nhas been conducted. Based on the results of the population pharmacokinetic\nanalysis, pertuzumab exposure in patients with mild (creatinine clearance\n[CLcr] 60 to 90\u00a0ml/min, N=200) and moderate renal impairment (CLcr 30 to\n60\u00a0ml/min, N=71) was similar to that in patients with normal renal\nfunction (CLcr greater than 90\u00a0ml/min, N=200). No relationship between\nCLcr and pertuzumab exposure was observed over the range of CLcr (27 to 244\u00a0ml/min).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Other special populations</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">The population PK analysis suggested no PK\ndifferences based on age, gender and ethnicity (Japanese versus non-Japanese).\nBaseline albumin and lean body weight were the most significant covariates\ninfluencing CL. CL decreased in patients with higher baseline albumin\nconcentrations and increased in patients with greater lean body weight. However\nsensitivity analyses performed at the recommended dose and schedule of Perjeta\nshowed that at the extreme values of these two covariates, there was no\nsignificant impact on the ability to achieve target steady-state concentrations\nidentified in preclinical tumour xenograft models. Therefore, there is no need\nto adjust the dosage of pertuzumab based on these covariates.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">The PK results of pertuzumab in the\nNEOSPHERE and APHINITY studies were consistent with the predictions from the\nprevious population PK model. </span>No differences in pertuzumab PK were\nobserved in patients with early breast cancer compared to patients with\nmetastatic breast cancer.</p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><b><span lang=\"EN-GB\">5.3\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Preclinical safety data</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">No specific fertility studies in animals\nhave been performed to evaluate the effect of pertuzumab. No definitive\nconclusion on adverse effects can be drawn on the male reproductive organs in\ncynomolgus monkey repeated dose toxicity study.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Reproductive toxicology studies have been\nconducted in pregnant cynomolgus monkeys (Gestational Day (GD) 19 through to GD\n50) at initial doses of 30 to 150\u00a0mg/kg followed by bi\u2011weekly doses\nof 10\u00a0to\u00a0100\u00a0mg/kg. These dose levels resulted in clinically\nrelevant exposures of 2.5\u00a0to\u00a020-fold greater than the recommended\nhuman dose, based on C<sub>max</sub>. Intravenous administration of pertuzumab from\nGD19 through GD50 (period of organogenesis) was embryotoxic, with\ndose-dependent increases in embryo-foetal death between GD25\u00a0to\u00a0GD70.\nThe incidences of embryo-foetal loss were 33, 50, and 85% for pregnant female\nmonkeys treated with bi\u2011weekly pertuzumab doses of 10, 30, and\n100\u00a0mg/kg, respectively (2.5\u00a0to\u00a020-fold greater than the\nrecommended human dose, based on C<sub>max</sub>). At Caesarean section on\nGD100, oligohydramnios, decreased relative lung and kidney weights and\nmicroscopic evidence of renal hypoplasia consistent with delayed renal\ndevelopment were identified in all pertuzumab dose groups. In addition,\nconsistent with foetal growth restrictions, secondary to oligohydramnios, lung\nhypoplasia (1 of 6 in 30\u00a0mg/kg and 1 of 2 in100\u00a0mg/kg groups),\nventricular septal defects (1 of 6 in 30\u00a0mg/kg group), thin ventricular\nwall (1 of 2 in 100\u00a0mg/kg group) and minor skeletal defects (external - 3\nof 6 in 30\u00a0mg/kg group) were also noted.\u00a0 Pertuzumab exposure was reported\nin offspring from all treated groups, at levels of 29% to 40% of maternal serum\nlevels at GD100. </span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">In cynomolgus monkeys, weekly intravenous\nadministration of </span><span lang=\"EN-GB\">pertuzumab </span><span lang=\"EN-GB\">at\ndoses up to 150\u00a0mg/kg/dose was generally well tolerated. With doses of\n15\u00a0mg/kg and higher, intermittent mild treatment-associated diarrhoea was\nnoted. In a subset of monkeys, chronic dosing (7 to 26 weekly doses) resulted in\nepisodes of severe secretory diarrhoea. The diarrhoea was managed (with the\nexception of euthanasia of one animal, 50\u00a0mg/kg/dose) with supportive care\nincluding intravenous fluid replacement therapy.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL PARTICULARS</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">6.1\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 List of excipients</span></b></p>\n<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">\u00a0</span></i></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Glacial acetic acid</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">L-Histidine</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Sucrose</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Polysorbate 20</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Water for injections</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">6.2\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Incompatibilities</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Glucose (5%)\nsolution should not be used to dilute Perjeta since it is chemically and\nphysically unstable in such solutions.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">This medicinal product must not be mixed\nwith other medicinal products except those mentioned in section 6.6.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">6.3\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Shelf life</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><u><span lang=\"EN-GB\" style=\"color:black\">Unopened vial</span></u><span lang=\"EN-GB\" style=\"color:black\">\n</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">2 years</span><span lang=\"EN-GB\" style=\"color:black\">. </span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>\n<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Diluted solution</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Chemical and physical in-use stability has\nbeen demonstrated for 24 hours at 30\u00b0C. </span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">From a microbiological point of view, the\nproduct should be used immediately. If not used immediately, in-use storage\ntimes and conditions prior to use are the responsibility of the user and would\nnormally not be longer than 24 hours at 2\u00b0C to 8\u00b0C, unless dilution has taken\nplace in controlled and validated aseptic conditions.</span><span lang=\"EN-GB\"> </span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">6.4\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Special precautions for\nstorage</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Store in a refrigerator (2\u00b0C-8\u00b0C).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Do not freeze. </span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Keep the vial in the outer carton in order\nto protect from light.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">For storage conditions after dilution of\nthe medicinal product, see section 6.3.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">6.5\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Nature and contents of\ncontainer</span></b></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Vial (Type I glass) with a stopper (butyl\nrubber) containing 14\u00a0ml of solution. </span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Pack of 1 vial.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><a name=\"OLE_LINK1\"><b><span lang=\"EN-GB\">6.6\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Special precautions for disposal and other handling</span></b></a></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Perjeta does\nnot contain any antimicrobial preservative. Therefore, care must be taken to\nensure the sterility of the prepared solution for infusion and should be\nprepared by a healthcare professional. </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Perjeta is\nfor single use only.</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">The vial\nmust not be shaken. 14 ml of Perjeta concentrate should be withdrawn from the\nvial and diluted into a 250\u00a0ml PVC or non-PVC polyolefin infusion bag of\nsodium chloride 9\u00a0mg/ml (0.9%) solution for infusion. After dilution, one\nml of solution should contain approximately </span><span lang=\"EN-GB\">3.02\u00a0mg\nof pertuzumab (840\u00a0mg/278\u00a0ml) for the initial dose where two vials\nare required and approximately 1.59\u00a0mg of pertuzumab (420\u00a0mg/264 \u00a0ml)\nfor the maintenance dose where one vial is required. </span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">The bag should be gently inverted to mix\nthe solution in order to avoid foaming.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Parenteral medicinal products should be\ninspected visually for particulates and discolouration prior to administration.\nIf particulates or discoloration are observed, the solution should not be used.\nOnce the infusion is prepared it should be administered immediately (see\nsection 6.3). </span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Any unused medicinal product or waste\nmaterial should be disposed of in accordance with local requirements.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Perjeta is compatible with\npolyvinylchloride (PVC) or non-PVC polyolefin bags including polyethylene.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">7.</span></b><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <b>MARKETING AUTHORISATION HOLDER</b></span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Roche Registration GmbH </span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Emil-Barell-Strasse 1</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">79639 Grenzach-Wyhlen</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Germany</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 MARKETING\nAUTHORISATION NUMBER(S) </span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">EU/1/13/813/001</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 DATE OF FIRST\nAUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Date of first authorisation: 4<sup>th</sup>\nMarch 2013</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Date of latest renewal: 8<sup>th</sup>\nDecember 2017</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">10.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 DATE\nOF REVISION OF THE TEXT</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Detailed\ninformation on this medicinal product </span><span lang=\"EN-GB\">is available on\nthe website of the European Medicines Agency </span><a href=\"http://www.ema.europa.eu\"><span lang=\"EN-GB\">http://www.ema.europa.eu</span></a><span lang=\"EN-GB\" style=\"color:blue\">.</span></p>\n<b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span></b>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">ANNEX</span></b><b><span lang=\"EN-GB\"> II</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:70.9pt;margin-bottom:\n0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">A.\u00a0\u00a0\u00a0\u00a0\u00a0 MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND\nMANUFACTURER RESPONSIBLE FOR BATCH RELEASE </span></b></p>\n<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:70.9pt;margin-bottom:\n0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:70.9pt;margin-bottom:\n0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">B.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:70.9pt;margin-bottom:\n0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:70.9pt;margin-bottom:\n0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">C.\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING\nAUTHORISATION</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:70.9pt;margin-bottom:\n0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:70.9pt;margin-bottom:\n0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">D.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND\nEFFECTIVE USE OF THE MEDICINAL PRODUCT</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span></b>\n<p class=\"AnnexHeading\"><span lang=\"EN-GB\">A.\u00a0\u00a0\u00a0\u00a0\u00a0 </span><span lang=\"EN-GB\">MANUFACTURER\nOF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH\nRELEASE</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:10.0pt\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><u><span lang=\"EN-GB\">Name and address of the manufacturer of the biological active\nsubstance(s) </span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Genentech, Inc.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">1000 New Horizons Way</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Vacaville, CA 95688-9431</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">USA</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><u><span lang=\"EN-GB\">Name and address of the manufacturer responsible for batch release</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche Pharma AG</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Emil-Barell-Strasse 1</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">D-79639 Grenzach-Whylen</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Germany</span></p>\n<p class=\"MsoNormal\" style=\"line-height:10.0pt\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:10.0pt\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"AnnexHeading\"><span lang=\"EN-GB\">B.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR RESTRICTIONS\nREGARDING SUPPLY AND USE</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Medicinal product subject to restricted\nmedical prescription (see Annex I: Summary of Product Characteristics, section\n4.2).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:10.0pt\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"AnnexHeading\"><span lang=\"EN-GB\">C. \u00a0\u00a0\u00a0\u00a0 OTHER CONDITIONS AND\nREQUIREMENTS OF THE MARKETING AUTHORISATION </span></p>\n<p class=\"MsoNormal\" style=\"line-height:10.0pt\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:-.05pt;line-height:13.0pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span><b><span lang=\"EN-GB\">Periodic safety update reports </span></b></p>\n<p class=\"MsoNormal\" style=\"margin-right:28.35pt;line-height:13.0pt\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:14.0pt\">The requirements for submission\nof periodic safety update reports for this medicinal product are <span lang=\"EN-GB\">set out in the list of Union reference dates (EURD list) provided\nfor under Article 107c(7) of Directive 2001/83/EC and any subsquent updates published\non the European medicines web-portal.</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:28.35pt;line-height:13.0pt\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:28.35pt;line-height:13.0pt\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"AnnexHeading\"><span lang=\"EN-GB\">D.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR RESTRICTIONS WITH\nREGARD TO THE SAFE AND EFFECTIVE\u00a0 USE OF THE MEDICINAL PRODUCT</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:28.35pt;line-height:11.0pt\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:-.05pt;line-height:13.0pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span><b><span lang=\"EN-GB\">Risk Management Plan (RMP)</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.05pt;margin-bottom:\n0in;margin-left:.5in;margin-bottom:.0001pt;line-height:13.0pt\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-right:28.35pt;line-height:13.0pt\"><span lang=\"EN-GB\">The MAH shall perform the required\u00a0 pharmacovigilance activities and\ninterventions detailed in the\u00a0 agreed RMP presented in Module 1.8.2 of the\nMarketing Authorisation and any agreeed\u00a0 subsequent updates of the RMP.</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:-.05pt;line-height:13.0pt\"><span lang=\"EN-GB\">An updated RMP should be submitted:</span></p>\n<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.05pt;margin-bottom:\n0in;margin-left:14.2pt;margin-bottom:.0001pt;line-height:13.0pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0 </span><span lang=\"EN-GB\">At the request of the European Medicines Agency;</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-12.8pt;line-height:\n13.0pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0 Whenever\nthe risk management system is modified, especially as the result of new\ninformation being received that may lead to a significant change to the\nbenefit/risk profile or as the result of an important (pharmacovigilance or\nrisk minimisation) milestone being reached. </span></p>\n<p class=\"MsoNormal\" style=\"margin-right:28.35pt;line-height:13.0pt\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:-.05pt;line-height:13.0pt;page-break-after:\navoid\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span><b><span lang=\"EN-GB\">Obligation to conduct post-authorisation measures</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-right:-.05pt;line-height:13.0pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-right:28.35pt;line-height:13.0pt;page-break-after:\navoid\"><span lang=\"EN-GB\">The MAH shall complete, within the stated timeframe,\nthe following measures:</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:28.35pt;line-height:13.0pt;page-break-after:\navoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:98.0%;border-collapse:collapse;border:none\" width=\"98%\">\n<tr>\n<td style=\"width:83.62%;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"83%\">\n<p class=\"MsoNormal\" style=\"margin-right:-.05pt\"><b><span lang=\"EN-GB\">Description</span></b></p>\n</td>\n<td style=\"width:16.38%;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16%\">\n<p class=\"MsoBodyText\"><b><span lang=\"EN-GB\" style=\"color:windowtext;font-style:\n  normal\">Due date</span></b></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:83.62%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"83%\">\n<p class=\"MsoNormal\" style=\"line-height:14.0pt\"><span lang=\"EN-GB\">MO28047\n  (PERUSE) </span></p>\n<p class=\"MsoNormal\" style=\"line-height:14.0pt\"><span lang=\"EN-GB\">A multicenter,\n  open-label, single-arm study of pertuzumab in combination with trastuzumab\n  and a taxane in first line treatment of patients with HER2- positive advanced\n  (metastatic or locally recurrent) breast cancer</span></p>\n<p class=\"MsoNormal\" style=\"line-height:14.0pt\"><span lang=\"EN-GB\" style='font-size:9.0pt;font-family:\"Verdana\",sans-serif'>\u00a0</span></p>\n</td>\n<td style=\"width:16.38%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16%\">\n<p class=\"MsoNormal\" style=\"line-height:14.0pt\"><span lang=\"EN-GB\">September 2020</span></p>\n</td>\n</tr>\n</table>\n<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">ANNEX\nIII</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">LABELLING\nAND PACKAGE LEAFLET</span></b></p>\n<b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span></b>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n<p class=\"Annex\"><span lang=\"EN-GB\">A. LABELLING</span></p>\n<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">PARTICULARS\nTO APPEAR ON THE OUTER PACKAGING</span></b></p>\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">CARTON</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME\nOF THE MEDICINAL PRODUCT</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Perjeta 420\u00a0mg concentrate for\nsolution for infusion</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">pertuzumab</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 STATEMENT\nOF ACTIVE SUBSTANCE(S)</span></b></p>\n</div>\n<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">\u00a0</span></i></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">One 14\u00a0ml vial contains 420\u00a0mg of\npertuzumab at a concentration of 30\u00a0mg/ml.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 LIST\nOF EXCIPIENTS</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Glacial acetic acid, L-histidine, sucrose\nand polysorbate 20.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Water for injections</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL\nFORM AND CONTENTS</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Concentrate for solution for infusion</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">420\u00a0mg/14\u00a0ml</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">1 x 14\u00a0ml</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD\nAND ROUTE(S) OF ADMINISTRATION</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">For intravenous use after dilution</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Do not shake</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Read the package leaflet before use</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;border:none;\npadding:0in\"><b><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL WARNING THAT THE MEDICINAL\nPRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Keep out of the sight and reach of children</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER\nSPECIAL WARNING(S), IF NECESSARY</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY\nDATE</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">EXP </span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL STORAGE CONDITIONS</span></b></p>\n</div>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Store in a\nrefrigerator</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Do not\nfreeze</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Keep the vial in the outer carton in order\nto protect from light </span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;border:none;\npadding:0in\"><b><span lang=\"EN-GB\">10.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL PRECAUTIONS FOR DISPOSAL OF\nUNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL\nPRODUCTS, IF APPROPRIATE</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">11.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME\nAND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche Registration GmbH </span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Emil-Barell-Strasse 1</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">79639 Grenzach-Wyhlen</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Germany</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">12.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 MARKETING\nAUTHORISATION NUMBER(S) </span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">EU/1/13/813/001</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">13.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 BATCH\nNUMBER</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Batch</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">14.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 GENERAL\nCLASSIFICATION FOR SUPPLY</span></b></p>\n</div>\n<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">\u00a0</span></i></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Medicinal product subject to medical\nprescription</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">15.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 INSTRUCTIONS\nON USE</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">16.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 INFORMATION\nIN BRAILLE</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span style=\"color:black;background:#D9D9D9\">Justification\nfor not including Braille accepted</span> </p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b>17.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 UNIQUE\nIDENTIFIER \u2013 2D BARCODE</b></p>\n</div>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\"><span style=\"background:lightgrey\">2D barcode carrying the\nunique identifier included.</span></p>\n<p class=\"MsoNormal\"><span style=\"background:#CCCCCC\">\u00a0</span></p>\n<p class=\"MsoNormal\">\u00a0</p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b>18.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 UNIQUE\nIDENTIFIER - HUMAN READABLE DATA</b></p>\n</div>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">PC: </p>\n<p class=\"MsoNormal\">SN: </p>\n<p class=\"MsoNormal\">NN: </p>\n<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">MINIMUM\nPARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS</span></b></p>\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">VIAL\nLABEL</span></b></p>\n</div>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME\nOF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Perjeta 420\u00a0mg concentrate for\nsolution for infusion</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">pertuzumab</span></p>\n<p class=\"MsoNormal\"><span style=\"color:black;background:#D9D9D9\">IV</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD\nOF ADMINISTRATION</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">For intravenous use after dilution</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY\nDATE</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">EXP</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 BATCH\nNUMBER</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Lot</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 CONTENTS\nBY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">420\u00a0mg/14\u00a0ml</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"Annex\"><span lang=\"EN-GB\">B. PACKAGE LEAFLET</span></p>\n<b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span></b>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">Package\nLeaflet: Information for the user</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">Perjeta\n420\u00a0mg concentrate for solution for infusion</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">pertuzumab</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:12.0pt\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Read all of this leaflet carefully\nbefore you start being given this medicine because it contains important\ninformation for you.</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.1pt;text-indent:-28.1pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Keep\nthis leaflet. You may need to read it again.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.1pt;text-indent:-28.1pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 If you\nhave any further questions, ask your doctor or nurse. </span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.1pt;text-indent:-28.1pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 If you\nget any side effects, talk to your doctor or nurse. This includes any possible\nside effects not listed in this leaflet. See section 4.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">What is in this leaflet</span></b><span lang=\"EN-GB\">: </span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-1.45pt;margin-bottom:\n0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What Perjeta<b> </b>is and what it is used for</span></p>\n<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-1.45pt;margin-bottom:\n0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What you need to know before you are given Perjeta</span></p>\n<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-1.45pt;margin-bottom:\n0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How you are given Perjeta </span></p>\n<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-1.45pt;margin-bottom:\n0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Possible side effects</span></p>\n<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-1.45pt;margin-bottom:\n0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How to store Perjeta</span></p>\n<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-1.45pt;margin-bottom:\n0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Contents of the pack and other information</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What Perjeta is and what it\nis used for</span></b></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Perjeta contains the active substance\npertuzumab and is used to treat adult patients with breast cancer when:</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 The breast cancer\nhas been identified to be of the \u201cHER2-positive\u201d form \u2013 your doctor will test\nyou for this.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 The cancer has\nspread to other parts of the body such as the lungs or liver (metastasised) and\nhas not previously been treated with anticancer medicines (chemotherapy) or\nother medicines designed to attach to HER2, or else the cancer has come back in\nthe breast after previous treatment.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 The cancer has\nnot spread to other parts of the body and treatment is going to be given before\nsurgery takes place (treatment before surgery is called neoadjuvant therapy)</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 The cancer has\nnot spread to other parts of the body and treatment is going to be given after\nsurgery (treatment after surgery is called adjuvant therapy)</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">As well as Perjeta you will also receive trastuzumab\nand medicines called chemotherapy Information about these medicines is\ndescribed in separate package leaflets. Ask your doctor or nurse to give you\ninformation about these other medicines.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">How Perjeta\nworks</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Perjeta is a\ntype of medicine called a \u201cmonoclonal antibody\u201d which attaches itself to\nspecific targets in your body and on the cancer cells.<b> </b></span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Perjeta\nrecognises and attaches to a target called \u201chuman epidermal growth factor\u00a0receptor\n2\u201d (HER2). HER2 is found in large amounts on the surface of some cancer cells\nwhere it stimulates their growth. When Perjeta attaches to the HER2 cancer\ncells, it may slow or stop the cancer cells from growing, or may kill them.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What\nyou need to know before you are given Perjeta</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">You must\nnot be given Perjeta</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 If you are\nallergic to pertuzumab, or to any of the other ingredients of this medicine\n(listed in section 6).</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">If you are not sure, talk to your doctor or\nnurse before you are given Perjeta.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Warnings\nand precautions</span></b></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Treatment with Perjeta may affect the heart.\n\u00a0Talk to your doctor or nurse before you are given Perjeta:</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 If you have ever\nhad heart problems (such as heart failure, treatment for serious irregular\nheartbeats, uncontrolled high blood pressure, recent heart attack), your heart\nfunction will be checked before and during treatment with Perjeta and your\ndoctor will run tests to check if your heart is working properly. </span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 If you have ever\nhad heart problems during previous treatment with trastuzumab.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 If you have ever\nhad a chemotherapy medicine from the class called anthracyclines, e.g.\ndoxorubicin or epirubicin \u2013 these medicines can damage heart muscle and\nincrease the risk of heart problems with Perjeta.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">If any of the above applies to you (or you\nare not sure), talk to your doctor or nurse before you are given Perjeta. See\nsection 4 \u201cSerious side effects\u201d for more details about signs of heart problems\nto look out for.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Infusion reactions</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Infusion reactions, allergic or\nanaphylactic (more severe allergic) reactions can happen. Your doctor or nurse\nwill check for side effects during your infusion and for 30 to 60 minutes\nafterwards. If you get any serious reaction, your doctor may stop treatment\nwith Perjeta. Very rarely, patients have died due to anaphylactic reactions\nduring Perjeta infusion. See section 4 \u201cSerious side effects\u201d for more details\nabout infusion reactions to look out for during the infusion and thereafter. </span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Febrile neutropenia (Low white blood\ncells with fever)</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">When Perjeta is given with other cancer\ntreatments (trastuzumab and chemotherapy), the number of white blood cells may\ndrop and fever (raised temperature) may develop. If you have inflammation of\nthe digestive tract (e.g.sore mouth or diarrhoea) you may be more likely to\ndevelop this side effect.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Diarrhoea</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Treatment with Perjeta may cause severe\ndiarrhoea. Patients over 65\u00a0years of age have a higher risk of diarrhoea compared\nwith patients younger than 65 years of age.</span><span lang=\"EN-GB\" style=\"color:black;background:white\"> </span><span lang=\"EN-GB\">Diarrhoea is a\ncondition where your body produces more watery stools than normal. If you\nexperience severe diarrhoea while receiving your anti-cancer treatment, your\ndoctor may start you on anti-diarrhoeal treatment and may stop your treatment\nwith Perjeta until the diarrhoea is under control. </span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Use in children and adolescents</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Perjeta should not be given to patients under\nthe age of 18 years because there is no information on how it works in this age\ngroup.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"background:white\"><b><span lang=\"EN-GB\" style=\"color:black\">Use in the elderly</span></b></p>\n<p class=\"MsoNormal\" style=\"background:white\"><span lang=\"EN-GB\" style=\"color:black\">Patients\nover 65\u00a0years of age who are treated with Perjeta are more likely to\nexperience side effects such as reduced appetite, decrease in the number of red\nblood cells, weight loss, feeling tired, loss or altered taste, weak, numb,\ntingling or prickling sensations mainly affecting the feet and legs and\ndiarrhoea, compared to patients younger than 65\u00a0years of age.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Other medicines and Perjeta</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tell your doctor or nurse if you are\ntaking, have recently taken or might take any other medicines. </span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Pregnancy\nand breast-feeding</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Before starting treatment, you must tell\nyour doctor or nurse if you are pregnant or breast-feeding, </span><span lang=\"EN-GB\">or if you </span><span lang=\"EN-GB\">think you may be pregnant<b> </b>or\nare planning to have a baby. They will advise you about the benefits and risks\nfor you and your baby of taking Perjeta while you are pregnant.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Tell your doctor\nstraight away,<b> </b>if you get pregnant during treatment with<b> </b>Perjeta\nor during the 6 months after stopping treatment.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Ask your doctor\nabout whether you can breast-feed during or after treatment with Perjeta.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Perjeta may harm the unborn baby. You\nshould use effective contraception during treatment with Perjeta and for 6 months\nafter stopping treatment. Talk to your doctor about the best contraception for\nyou.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Driving and using machines</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Perjeta may have a minor effect on you\nbeing able to drive or use machines. However, if you get any dizziness, infusion\nreactions, allergic or anaphylactic reactions, wait until these have gone away\nbefore driving or using machines.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><b>Sodium</b> </p>\n<p class=\"MsoNormal\">Perjeta contains less than 1\u00a0mmol of sodium per dose,\ni.e. it is essentially sodium\u2011free.</p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How\nyou are given Perjeta</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Being\ngiven this medicine</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-right:-.1pt;page-break-after:avoid\"><span lang=\"EN-GB\">Perjeta</span><span lang=\"EN-GB\"> will be given to you by a doctor or\nnurse in a hospital or clinic.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 It is given by a\ndrip into a vein (intravenous infusion) once every three weeks.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 The amount of\nmedicine you are given and how long the infusion will last are different for\nthe first dose and following doses. </span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 The number of\ninfusions you will be given depends on how you respond to treatment</span><span lang=\"EN-GB\"> and whether you are receiving treatment before or after surgery\n(neoadjuvant or adjuvant therapy) or for disease which has spread</span><span lang=\"EN-GB\">.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Perjeta is given with other cancer treatments (trastuzumab\nandchemotherapy).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">For the</span></b><span lang=\"EN-GB\"> <b>first\ninfusion</b>:</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 You will be given\n840\u00a0mg of Perjeta over 60 minutes. Your doctor or nurse will check for\nside effects during your infusion and for 60 minutes afterwards.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 You will also be\ngiven trastuzumab and chemotherapyl.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">For all\nfollowing infusions</span></b><span lang=\"EN-GB\">, if the first infusion was well\ntolerated:</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;page-break-after:\navoid\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 You\nwill be given 420\u00a0mg of Perjeta over 30 to 60 minutes. Your doctor or\nnurse will check for side effects during your infusion and for 30 to 60 minutes\nafterwards.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;page-break-after:\navoid\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 You\nwill also be given trastuzumab and chemotherapy.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">For further information on dosing of trastuzumab\nand chemotherapy (which can cause side effects as well), please refer to the package\nleaflet for these products. If you have questions about these medicines, please\nask your doctor or nurse. </span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">If you forget to have Perjeta</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">If you forget or miss your appointment to\nreceive Perjeta</span><span lang=\"EN-GB\"> </span><span lang=\"EN-GB\">make another\nappointment as soon as possible. If it has been 6 weeks or more since your last\nvisit</span><span lang=\"EN-GB\"> a </span><span lang=\"EN-GB\">higher Perjeta dose of\n840\u00a0mg will be given to you.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">If you stop having Perjeta</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Do not stop having this medicine without\ntalking to your doctor first. It is important that you are given all the\ninfusions that have been recommended.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">If you have any further questions on the\nuse of this medicine, ask your doctor or nurse.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Possible\nside effects</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Like all\nmedicines, this medicine can cause side effects, although not everybody gets\nthem.</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Serious\nside effects</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Tell a\ndoctor or nurse straight away, if you notice any of the following side effects:\n</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Very severe or\npersistent diarrhoea (7 or more stools per day).</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 A decrease in the\nnumber or low amount of white blood cells (shown in a blood test), with or\nwithout fever, which may increase the risk of an infection.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Infusion\nreactions with symptoms that can either be mild or more severe and may include\nfeeling sick (nausea), fever, chills, feeling tired, headache, loss of appetite,\njoint and muscle pains, and hot flushes. </span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span><span lang=\"EN-GB\">Allergic and anaphylactic (more severe allergic) reactions with symptoms\nthat may include swelling of your face and throat, with difficulty </span><span lang=\"EN-GB\">in </span><span lang=\"EN-GB\">breathing. Very rarely, patients have\ndied due to anaphylactic reactions during Perjeta infusion.\u00a0 </span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Heart problems\n(heart failure) with symptoms that can include cough, shortness of breath, and\nswelling (fluid retention) in your legs or arms. </span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span><span lang=\"EN-GB\">Tumour lysis syndrome (a condition which may happen when cancer\ncells die quickly, causing changes in blood levels of </span>minerals and\nmetabolites shown in a blood test). S<span lang=\"EN-GB\">ymptoms may include\nkidney problems (weakness, shortness of breath, fatigue and confusion), heart\nproblems (fluttering of the heart of a faster or slower heartbeat), seizures,\nvomiting or diarrhoea and tingling in the mouth, hands or feet</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tell a doctor or nurse straight away, if\nyou notice any of the side effects above. </span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Other side effects include:</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Very common (may affect more than 1 in\n10 people):</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Diarrhoea</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Hair loss</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Feeling sick or being tired</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Rash</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Inflammation of your digestive tract (e.g. sore mouth)</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Decrease in the number of red blood cells \u2013 shown in a\nblood test</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Joint or muscle pain, muscle weakness</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Constipation</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Reduced appetite</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Loss of or altered taste</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Fever </span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Swollen ankles or other body parts due to your body\nretaining too much water</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Not being able to\nsleep</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Hot flushes </span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Weak, numb,\ntingling or prickling sensations mainly affecting the feet and legs </span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Nose bleeds</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Cough</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Heartburn</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Dry, itchy or acne like skin</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Nail problems </span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Sore throat, red, sore or runny nose, flu-like symptoms\nand fever</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Producing more tears</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Fever associated with dangerously low levels of a type of\nwhite blood cell (neutrophils)</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Pain in the body, arms, legs, and belly</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Shortness of breath</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Feeling dizzy</span></p>\n<p class=\"MsoNormal\"><b><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></b></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Common (may affect up to 1 in 10\npeople):</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 A feeling of\nnumbness, prickling or tingling in feet or hands; sharp jabbing, throbbing,\nfreezing or burning pain; feeling pain from something which should not be\npainful such as a light touch; less able to feel changes in heat or cold; loss\nof balance or coordination</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Inflammation of the nail bed where the nail and skin meet </span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Infection of the ear, nose or throat</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:37.1pt;text-indent:-37.1pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Condition\nin which the left ventricle of the heart is functionally impaired with or\nwithout symptoms </span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Uncommon (may affect up to 1 in 100 people):</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span><span lang=\"EN-GB\">Chest symptoms such as a dry cough or breathlessness </span><span lang=\"EN-GB\">(possible signs of interstitial lung disease, a condition of damage\nto the tissues around the air sacs in the lungs)</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Fluid around the lungs causing difficulty in breathing</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">If you experience any of the above symptoms\nafter treatment with Perjeta has been stopped, you should consult your doctor\nimmediately and inform him or her that you have previously been treated with\nPerjeta.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Some of the side effects which you get may\nbe due to your breast cancer. If you are given Perjeta with trastuzumab and\nchemotherapy at the same time, some side effects may also be due to these other\nmedicines.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Reporting\nof side effects</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">If you get\nany side effects, talk to your doctor or nurse. This includes any possible side\neffects not listed in this leaflet. </span><span lang=\"EN-GB\">You can also report\nside effects directly via </span><span lang=\"EN-GB\" style=\"background:lightgrey\">the\nnational reporting system listed in </span><a href=\"https://www.ema.europa.eu/documents/template-form/appendix-v-adverse-drug-reaction-reporting-details_en.doc\"><span lang=\"EN-GB\" style=\"background:lightgrey\">Appendix V</span><span lang=\"EN-GB\">.</span></a><span lang=\"EN-GB\"> By reporting side effects you can help provide more information on\nthe safety of this medicine.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How\nto store Perjeta</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Perjeta will\nbe stored by the health professionals at the hospital or clinic. The storage\ndetails </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">are as\nfollows:</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Keep this\nmedicine out of the sight and reach of children.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Do not use this\nmedicine after the expiry date which is stated on the outer carton after EXP.\nThe expiry date refers to the last day of that month.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Store in a\nrefrigerator (2\u00b0C-8\u00b0C). </span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Do not freeze.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Keep the vial in\nthe outer carton in order to protect from light.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Do not use this\nmedicine if you notice any particles in the liquid or it is the wrong colour\n(please see section 6). </span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Do not throw away\nany medicines via wastewater or household waste. Ask your pharmacist how to\nthrow away medicines you no longer use. These measures will help to protect the\nenvironment.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Contents of the pack and\nother information</span></b></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">What Perjeta contains</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 The active\nsubstance is pertuzumab. Each vial contains a total of 420\u00a0mg pertuzumab\nat a concentration of 30\u00a0mg/ml</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 The other\ningredients are glacial acetic acid, L-histidine, sucrose, polysorbate 20 and\nwater for injections</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">What Perjeta\nlooks like and contents of the pack</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Perjeta is a\nconcentrate for solution for infusion. It is a clear to slightly pearly\n(opalescent), colourless to pale yellow liquid. It is supplied in a glass vial\ncontaining 14\u00a0ml concentrate.</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Each pack\ncontains one vial.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Marketing\nAuthorisation Holder</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Roche Registration GmbH </span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Emil-Barell-Strasse 1</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">79639 Grenzach-Wyhlen</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Germany</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Manufacturer</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"DE\" style=\"color:black\">Roche Pharma AG </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"DE-CH\" style=\"color:black\">Emil-Barell-Strasse 1</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">D-79639\nGrenzach-Wyhlen</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Germany </span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">For any information about this medicine,\nplease contact the local representative of the Marketing Authorisation Holder:</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse\">\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"FR-CH\">Belgi\u00eb/Belgique/Belgien</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"FR-CH\">N.V. Roche S.A.</span></p>\n<p class=\"MsoNormal\"><span lang=\"FR\">T\u00e9l/Tel: +32 (0) 2 525 82 11</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"FR\">\u00a0</span></b></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">Lietuva</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">UAB \u201cRoche Lietuva\u201d</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Tel: +370 5 2546799</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">\u00a0</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><b><span lang=\"EN-GB\">\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u0420\u043e\u0448</span><span lang=\"EN-GB\"> </span><span lang=\"EN-GB\">\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f</span><span lang=\"EN-GB\"> </span><span lang=\"EN-GB\">\u0415\u041e\u041e\u0414</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u0422\u0435\u043b</span>: +359\n  2\u00a0818 44 44</p>\n<p class=\"MsoNormal\">\u00a0</p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">Luxembourg/Luxemburg</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">(Voir/siehe Belgique/Belgien)</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">\u010cesk\u00e1 republika</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche s. r. o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">Tel: +420 - 2 20382111</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">\u00a0</span></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE\">Magyarorsz\u00e1g</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">Roche (Magyarorsz\u00e1g) Kft.</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">Tel: +36 - 23 446 800</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"DE\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Danmark</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Roche a/s</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tlf: +45 - 36 39 99 99</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Malta</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">(See Ireland)</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">Deutschland</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche Pharma AG</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Tel: +49 (0) 7624 140</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">\u00a0</span></b></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">Nederland</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche Nederland B.V.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +31 (0) 348 438050</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"IT\">Eesti</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Roche Eesti O\u00dc</span></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Tel: + 372 - 6 177 380</span></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Norge</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Roche Norge AS</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tlf: +47 - 22 78 90 00</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u0395\u03bb\u03bb\u03ac\u03b4\u03b1</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Roche (Hellas) A.E. </span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u03a4\u03b7\u03bb: +30 210 61 66 100</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">\u00d6sterreich</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche Austria GmbH</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Tel: +43 (0) 1 27739</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"ES\">Espa\u00f1a</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"ES\">Roche Farma S.A.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +34 - 91 324 81 00</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Polska</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche Polska Sp.z o.o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +48 - 22 345 18 88</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">France</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Roche</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">T\u00e9l: +33\u00a0 (0)1 47 61 40 00</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"PT-BR\">Portugal</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"PT-BR\">Roche Farmac\u00eautica Qu\u00edmica, Lda</span></p>\n<p class=\"MsoNormal\"><span lang=\"PT-BR\">Tel: +351 - 21 425 70 00</span></p>\n<p class=\"MsoNormal\"><span lang=\"PT-BR\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">Hrvatska</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche d.o.o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: + 385 1 47 22 333</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"IT\">Rom\u00e2nia</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Roche Rom\u00e2nia S.R.L.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +40 21 206 47 01</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Ireland</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Roche Products (Ireland) Ltd.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +353 (0) 1 469 0700</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Slovenija</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Roche farmacevtska dru\u017eba d.o.o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +386 - 1 360 26 00</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"PT-BR\">\u00cdsland </span></b></p>\n<p class=\"MsoNormal\"><span lang=\"PT-BR\">Roche a/s</span></p>\n<p class=\"MsoNormal\"><span lang=\"PT-BR\">c/o Icepharma hf</span></p>\n<p class=\"MsoNormal\"><span lang=\"PT-BR\">S\u00edmi: +354 540 8000</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"PT-BR\">\u00a0</span></b></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DA\">Slovensk\u00e1 republika </span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DA\">Roche Slovensko, s.r.o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +421 - 2 52638201</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"IT\">Italia</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Roche S.p.A.</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Tel: +39 - 039 2471</span></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">Suomi/Finland</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche Oy<span style=\"layout-grid-mode:\n  line\"> </span></span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Puh/Tel: +358 (0) 10 554 500</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">K</span></b><b><span lang=\"EN-GB\">\u03cd\u03c0\u03c1\u03bf\u03c2</span></b><span lang=\"EN-GB\" style=\"font-size:10.0pt\"> </span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u0393</span><span lang=\"DE-CH\">.</span><span lang=\"EN-GB\">\u0391</span><span lang=\"DE-CH\">.</span><span lang=\"EN-GB\">\u03a3\u03c4\u03b1\u03bc\u03ac\u03c4\u03b7\u03c2</span><span lang=\"DE-CH\"> &amp; </span><span lang=\"EN-GB\">\u03a3\u03b9\u03b1</span><span lang=\"EN-GB\"> </span><span lang=\"EN-GB\">\u039b\u03c4\u03b4</span><span lang=\"DE-CH\">.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u03a4\u03b7\u03bb: +357 - 22 76 62 76</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Sverige</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Roche AB</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +46 (0) 8 726 1200</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"IT\">Latvija</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Roche Latvija SIA</span></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Tel: +371 - 6 7039831</span></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">United Kingdom</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Roche Products Ltd.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +44 (0) 1707 366000</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n</table>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">This\nleaflet was last revised in. </span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-right:-1.4pt\"><span lang=\"EN-GB\">Detailed\ninformation on this medicine is available on the European Medicines Agency web\nsite: http://www.ema.europa.eu </span></p>\n<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:6.0pt;margin-bottom:0in;\nmargin-left:6.35pt;margin-bottom:.0001pt;text-autospace:none\"><span style=\"color:black\">\u00a0</span></p>\n</div>", "ID": "b1556562-cce0-4cdc-9a84-e7791a4be2a1", "Styles": "None", "Classes": "['WordSection1']", "Text": "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           ", "ParentId": "ac11b3d8-d0c4-4cbe-b8a3-71d536a41493"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span style=\"font-size:10.0pt\">\u00a0</span></b></p>", "ID": "09ba8eed-54d2-401a-9afe-a08c18ce789d", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span style=\"font-size:10.0pt\">\u00a0</span></b>", "ID": "6a52dc18-dd97-45ca-b721-02a7c843ecf4", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "09ba8eed-54d2-401a-9afe-a08c18ce789d"}, {"Element": "<span style=\"font-size:10.0pt\">\u00a0</span>", "ID": "1a2912b8-ebfe-4fa2-b76c-5e63795df40b", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "6a52dc18-dd97-45ca-b721-02a7c843ecf4"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span style=\"font-size:10.0pt\">\u00a0</span></b></p>", "ID": "94fce562-a359-430e-95f6-a8d9c3211b39", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span style=\"font-size:10.0pt\">\u00a0</span></b>", "ID": "9c51182a-ca46-4771-b36e-14958ea89394", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "94fce562-a359-430e-95f6-a8d9c3211b39"}, {"Element": "<span style=\"font-size:10.0pt\">\u00a0</span>", "ID": "eb011d19-d065-4b79-9b12-a8f07cf3fa3a", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "9c51182a-ca46-4771-b36e-14958ea89394"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span style=\"font-size:10.0pt\">\u00a0</span></b></p>", "ID": "0e80dba8-d34e-4b55-8113-ce0126ca775b", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span style=\"font-size:10.0pt\">\u00a0</span></b>", "ID": "ed7344be-8e5e-428d-adca-93bf07f0945b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "0e80dba8-d34e-4b55-8113-ce0126ca775b"}, {"Element": "<span style=\"font-size:10.0pt\">\u00a0</span>", "ID": "fc1a8be3-8f4e-4ac1-b3b8-cad6830eb653", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "ed7344be-8e5e-428d-adca-93bf07f0945b"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\">\u00a0</p>", "ID": "4dcc86fb-905f-47ea-bc59-ffd81f457a47", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\">\u00a0</p>", "ID": "0c0328c0-f631-4c65-9ab8-8a6ba08dc49b", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\">\u00a0</p>", "ID": "0e60cef0-6aa5-4f1b-b1e7-ec7745428e36", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\">\u00a0</p>", "ID": "0f315d28-8d03-4422-ab2b-b3b323ce5b49", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\">\u00a0</p>", "ID": "478ce0b0-8db0-476a-b7f8-de0769c51119", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\">\u00a0</p>", "ID": "0a5ebaba-d6bc-4458-a5ec-7dd1cc9334cb", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\">\u00a0</p>", "ID": "84cf0bf4-2432-4a6f-9e91-f4a150abf269", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\">\u00a0</p>", "ID": "33d30cc2-d5ff-45db-991b-2622ca3eb4d8", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b>\u00a0</b></p>", "ID": "03322512-7586-4892-a06d-57d88946b654", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b>\u00a0</b>", "ID": "fdfd94ae-b213-4bc1-b063-a92035e4c01e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "03322512-7586-4892-a06d-57d88946b654"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b>\u00a0</b></p>", "ID": "3908e53a-ad82-4dc9-93d7-c9ad88eb28ec", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b>\u00a0</b>", "ID": "6c70080c-2c16-45a1-808e-de671e22e345", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3908e53a-ad82-4dc9-93d7-c9ad88eb28ec"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b>\u00a0</b></p>", "ID": "ca3a524d-d9c8-46d4-becb-e82d2564f8dc", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b>\u00a0</b>", "ID": "9a2bb013-8b9b-460c-abeb-6880f3f9304a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ca3a524d-d9c8-46d4-becb-e82d2564f8dc"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b>\u00a0</b></p>", "ID": "52c337e1-bb7b-434d-9b0f-1d046d96a4d3", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b>\u00a0</b>", "ID": "6cdd517a-df19-472a-a956-d26305bf442d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "52c337e1-bb7b-434d-9b0f-1d046d96a4d3"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b>\u00a0</b></p>", "ID": "df17949f-5b2d-4e48-a618-1b98918d07b9", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b>\u00a0</b>", "ID": "51ce7dbb-20f3-4dc4-be7f-d2c5afb78452", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "df17949f-5b2d-4e48-a618-1b98918d07b9"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b>\u00a0</b></p>", "ID": "5005d03d-f3ac-4dae-a882-5f8b468bb668", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b>\u00a0</b>", "ID": "8ea65a4c-421f-4bab-905b-4da86b9c1f96", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5005d03d-f3ac-4dae-a882-5f8b468bb668"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b>\u00a0</b></p>", "ID": "c47514d0-a424-4c6e-9886-d1a648227613", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b>\u00a0</b>", "ID": "d7755837-4ca1-4611-a9bf-b6f3a83ee3f6", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c47514d0-a424-4c6e-9886-d1a648227613"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b>\u00a0</b></p>", "ID": "330e3946-e6b5-44c0-9d7d-9b6c15d71eb7", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b>\u00a0</b>", "ID": "73de1a17-2552-478e-8c5f-03ea968c81fd", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "330e3946-e6b5-44c0-9d7d-9b6c15d71eb7"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b>\u00a0</b></p>", "ID": "7cac098e-04bd-49a0-a931-2ae7ec52ea4f", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b>\u00a0</b>", "ID": "a3aa8dc4-0f9d-4587-a59e-e7c43029ddab", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7cac098e-04bd-49a0-a931-2ae7ec52ea4f"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b>\u00a0</b></p>", "ID": "39528d24-42a6-4f07-9e9e-7a8da07e1046", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b>\u00a0</b>", "ID": "9d82af12-a297-4f3b-a8a4-7e82a3827c5f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "39528d24-42a6-4f07-9e9e-7a8da07e1046"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b>\u00a0</b></p>", "ID": "21a6a180-18e6-45dc-a4b8-8c1d9b245a80", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b>\u00a0</b>", "ID": "d52f793e-d73b-487c-b70c-2f4acaf82e81", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "21a6a180-18e6-45dc-a4b8-8c1d9b245a80"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b>\u00a0</b></p>", "ID": "a655b237-c47e-43f8-abba-9b1542784578", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b>\u00a0</b>", "ID": "069cf3d6-39b6-4cef-bd19-5709387eb2c8", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a655b237-c47e-43f8-abba-9b1542784578"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b>ANNEX I</b></p>", "ID": "b9a6642a-16e0-46bb-833f-decfb2139075", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b>ANNEX I</b>", "ID": "d743da33-f2fd-49e7-a250-28adaed3a4c2", "Styles": "None", "Classes": "None", "Text": "ANNEX I", "ParentId": "b9a6642a-16e0-46bb-833f-decfb2139075"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\">\u00a0</p>", "ID": "b4a24466-a720-4b6b-84d5-f86165b3e92b", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<p class=\"Annex\">SUMMARY OF PRODUCT CHARACTERISTICS</p>", "ID": "c95a321b-e52e-43ca-bbc5-2013e69fb9da", "Styles": "None", "Classes": "['Annex']", "Text": "SUMMARY OF PRODUCT CHARACTERISTICS", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span style='font-size:10.0pt;font-family:\"Times New Roman\",serif;\ncolor:green'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span></b>", "ID": "9a569751-1952-44af-8d12-ee09e2c31860", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span style='font-size:10.0pt;font-family:\"Times New Roman\",serif;\ncolor:green'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>", "ID": "370d64e1-fe58-4230-b73f-4a3ed3e9fdb7", "Styles": "font-size:10.0pt;font-family:\"Times New Roman\",serif;\ncolor:green", "Classes": "None", "Text": " ", "ParentId": "9a569751-1952-44af-8d12-ee09e2c31860"}, {"Element": "<br clear=\"all\" style=\"page-break-before:always\"/>", "ID": "f9e71f68-b7b9-4da3-88dd-2de02d72de88", "Styles": "page-break-before:always", "Classes": "None", "Text": "", "ParentId": "370d64e1-fe58-4230-b73f-4a3ed3e9fdb7"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></b></p>", "ID": "2d13fd4d-3ede-4cac-9806-d6f2c39ccc08", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></b>", "ID": "7ef5c1de-f73d-473a-809e-971e48a827c7", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "2d13fd4d-3ede-4cac-9806-d6f2c39ccc08"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span>", "ID": "88d9c2fd-6de6-473a-b44d-85d49687be0a", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "7ef5c1de-f73d-473a-809e-971e48a827c7"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME OF THE MEDICINAL PRODUCT</span></b></p>", "ID": "d9f6bd4f-c6da-4df4-90e8-d345d19199f3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME OF THE MEDICINAL PRODUCT</span></b>", "ID": "d4cb5177-5643-46b2-b009-04fb80e956a8", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d9f6bd4f-c6da-4df4-90e8-d345d19199f3"}, {"Element": "<span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME OF THE MEDICINAL PRODUCT</span>", "ID": "09bc5e39-fb44-4b6e-b92c-f271ad9e0843", "Styles": "None", "Classes": "None", "Text": "1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME OF THE MEDICINAL PRODUCT", "ParentId": "d4cb5177-5643-46b2-b009-04fb80e956a8"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6c224dba-1a29-47fb-91f5-58a15b0dea4b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0671d1fb-d3ee-478c-b1fb-0b2e6e89903e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6c224dba-1a29-47fb-91f5-58a15b0dea4b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Perjeta 420\u00a0mg concentrate for\nsolution for infusion</span></p>", "ID": "135a34e8-8151-4afa-b518-cd4b41454a43", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Perjeta 420\u00a0mg concentrate for\nsolution for infusion</span>", "ID": "b2dfe78a-11af-4aff-b1f4-0c1ee9489145", "Styles": "None", "Classes": "None", "Text": "Perjeta 420\u00a0mg concentrate for solution for infusion", "ParentId": "135a34e8-8151-4afa-b518-cd4b41454a43"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "489b5ae4-cd49-4fad-aeb9-195ce1b27d84", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "264705dc-aa8c-4009-9f3a-2d18e70fc13b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "489b5ae4-cd49-4fad-aeb9-195ce1b27d84"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6811d607-a5d3-4153-8c0d-e738d746d546", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "cf5e8360-bc2a-4b2d-ac8f-590ee071bd9d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6811d607-a5d3-4153-8c0d-e738d746d546"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 QUALITATIVE AND QUANTITATIVE\nCOMPOSITION</span></b></p>", "ID": "cefcfd76-a21b-4c95-a6fa-4f03cc02ec66", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 QUALITATIVE AND QUANTITATIVE\nCOMPOSITION</span></b>", "ID": "2925ec0c-55e8-44e6-9559-ed332cafba1d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "cefcfd76-a21b-4c95-a6fa-4f03cc02ec66"}, {"Element": "<span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 QUALITATIVE AND QUANTITATIVE\nCOMPOSITION</span>", "ID": "b1f0d32b-2fd1-4b7a-8ffe-ba367b0ee1bc", "Styles": "None", "Classes": "None", "Text": "2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 QUALITATIVE AND QUANTITATIVE COMPOSITION", "ParentId": "2925ec0c-55e8-44e6-9559-ed332cafba1d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9a028f3a-7298-40b2-ba60-462ef98b7aeb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "034ca53a-bdfc-4042-93ca-3be6f8f7f057", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9a028f3a-7298-40b2-ba60-462ef98b7aeb"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">One 14\u00a0ml vial of concentrate contains\n420\u00a0mg of pertuzumab at a concentration of 30\u00a0mg/ml.</span></p>", "ID": "84a332e1-390f-4260-b883-86d83d9609d3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">One 14\u00a0ml vial of concentrate contains\n420\u00a0mg of pertuzumab at a concentration of 30\u00a0mg/ml.</span>", "ID": "60f194e6-c879-4fa8-acd4-4438f74f4809", "Styles": "None", "Classes": "None", "Text": "One 14\u00a0ml vial of concentrate contains 420\u00a0mg of pertuzumab at a concentration of 30\u00a0mg/ml.", "ParentId": "84a332e1-390f-4260-b883-86d83d9609d3"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">After dilution, one ml of solution contains\napproximately 3.02 mg of pertuzumab for the initial dose and approximately 1.59\nmg of pertuzumab for the maintenance dose (see section 6.6).</span></p>", "ID": "59e639e4-744a-43a1-8dce-09b8da0764a6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">After dilution, one ml of solution contains\napproximately 3.02 mg of pertuzumab for the initial dose and approximately 1.59\nmg of pertuzumab for the maintenance dose (see section 6.6).</span>", "ID": "58518a1d-9cf1-49af-94aa-3579cdbaeb8b", "Styles": "None", "Classes": "None", "Text": "After dilution, one ml of solution contains approximately 3.02 mg of pertuzumab for the initial dose and approximately 1.59 mg of pertuzumab for the maintenance dose (see section 6.6).", "ParentId": "59e639e4-744a-43a1-8dce-09b8da0764a6"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "35c3a440-63fc-4d19-8fc1-13535da4a6d8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "81132fa9-61c5-4281-9e7a-e8d09357fd12", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "35c3a440-63fc-4d19-8fc1-13535da4a6d8"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Pertuzumab is a humanised IgG1 monoclonal\nantibody produced in mammalian (Chinese hamster ovary) cells by recombinant DNA\ntechnology.</span></p>", "ID": "a459e2a3-79e2-440c-b276-44c52bf1c034", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Pertuzumab is a humanised IgG1 monoclonal\nantibody produced in mammalian (Chinese hamster ovary) cells by recombinant DNA\ntechnology.</span>", "ID": "021d84c1-57d9-4f9c-bf84-416b01846f16", "Styles": "None", "Classes": "None", "Text": "Pertuzumab is a humanised IgG1 monoclonal antibody produced in mammalian (Chinese hamster ovary) cells by recombinant DNA technology.", "ParentId": "a459e2a3-79e2-440c-b276-44c52bf1c034"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "1e63282e-2977-4e33-8f5c-ac943a49e78d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "27699938-ce44-4391-80ba-42a8a1ef7f57", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1e63282e-2977-4e33-8f5c-ac943a49e78d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">For the full list of excipients, see\nsection 6.1.</span></p>", "ID": "cf87a3ed-5c78-4564-a8e1-b6a0559ac65e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">For the full list of excipients, see\nsection 6.1.</span>", "ID": "2e22a3be-47b8-4117-b502-c28c29639d85", "Styles": "None", "Classes": "None", "Text": "For the full list of excipients, see section 6.1.", "ParentId": "cf87a3ed-5c78-4564-a8e1-b6a0559ac65e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3ad0881c-b209-44dc-84a7-32698e522001", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "98f829df-5add-4e04-8493-2c4df458db31", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3ad0881c-b209-44dc-84a7-32698e522001"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ac4de7bd-65d3-4c13-bee3-38d3a3827ae7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2be677ad-5b8a-40f1-b5e5-b20b2e348f13", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ac4de7bd-65d3-4c13-bee3-38d3a3827ae7"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL FORM</span></b></p>", "ID": "8ec86757-1427-4b55-a235-7dd33555bd4e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL FORM</span></b>", "ID": "289d2a8d-7994-48ad-bf36-1c1bc19319f5", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8ec86757-1427-4b55-a235-7dd33555bd4e"}, {"Element": "<span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL FORM</span>", "ID": "91949809-174f-427f-ab2a-1e38287befc5", "Styles": "None", "Classes": "None", "Text": "3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL FORM", "ParentId": "289d2a8d-7994-48ad-bf36-1c1bc19319f5"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "82555b01-a3f5-4be1-9d02-c2d593050592", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d1fd98a9-3d45-4ba3-a81b-df75fde92711", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "82555b01-a3f5-4be1-9d02-c2d593050592"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Concentrate for solution for infusion.</span></p>", "ID": "37e742a7-9704-4fa5-8db3-bf9300cc38f6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Concentrate for solution for infusion.</span>", "ID": "4eb304ab-c31a-46a3-ac70-389655796d21", "Styles": "None", "Classes": "None", "Text": "Concentrate for solution for infusion.", "ParentId": "37e742a7-9704-4fa5-8db3-bf9300cc38f6"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Clear to slightly opalescent, colourless to\npale yellow, liquid.</span></p>", "ID": "d3e62010-b3eb-4454-972e-9ad601564bbb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Clear to slightly opalescent, colourless to\npale yellow, liquid.</span>", "ID": "bf25328c-60b9-483e-8dae-405ae111d3de", "Styles": "None", "Classes": "None", "Text": "Clear to slightly opalescent, colourless to pale yellow, liquid.", "ParentId": "d3e62010-b3eb-4454-972e-9ad601564bbb"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ed5b388c-187d-448c-8bdc-899a907e152c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4201490a-ec52-4865-a3c6-679f705cf75b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ed5b388c-187d-448c-8bdc-899a907e152c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2993569f-dfd4-4861-ac86-38cb3c7ddbe7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e3aa3650-6181-49bc-9920-23c19c3e6715", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2993569f-dfd4-4861-ac86-38cb3c7ddbe7"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"text-transform:uppercase\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span></b><b><span lang=\"EN-GB\">CLINICAL PARTICULARS</span></b></p>", "ID": "0787fbf5-33a6-4114-ab72-e50a3b912aee", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\" style=\"text-transform:uppercase\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span></b>", "ID": "bc0fd0cd-4982-45b2-9474-ae4e1ad954ad", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "0787fbf5-33a6-4114-ab72-e50a3b912aee"}, {"Element": "<span lang=\"EN-GB\" style=\"text-transform:uppercase\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span>", "ID": "d429518a-d9f2-42a2-894d-37f87d7ba5bf", "Styles": "text-transform:uppercase", "Classes": "None", "Text": "4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "bc0fd0cd-4982-45b2-9474-ae4e1ad954ad"}, {"Element": "<b><span lang=\"EN-GB\">CLINICAL PARTICULARS</span></b>", "ID": "afb6142c-e0d8-4607-8871-abc6b16a652f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "0787fbf5-33a6-4114-ab72-e50a3b912aee"}, {"Element": "<span lang=\"EN-GB\">CLINICAL PARTICULARS</span>", "ID": "2b1e48a7-3986-474e-984a-cddbbd02e627", "Styles": "None", "Classes": "None", "Text": "CLINICAL PARTICULARS", "ParentId": "afb6142c-e0d8-4607-8871-abc6b16a652f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "48cad417-94c2-41e9-a13b-70ed7c04e422", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "59e60f20-5813-4cba-ae24-7160ca537d53", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "48cad417-94c2-41e9-a13b-70ed7c04e422"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">4.1\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Therapeutic indications</span></b></p>", "ID": "8c36893a-4fc2-4a30-88a3-c314cafaf506", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">4.1\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Therapeutic indications</span></b>", "ID": "3fbf30c5-e51f-48fb-b64c-8887759be359", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8c36893a-4fc2-4a30-88a3-c314cafaf506"}, {"Element": "<span lang=\"EN-GB\">4.1\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Therapeutic indications</span>", "ID": "b286e90b-d1b7-4ddc-9e41-1135d51b68db", "Styles": "None", "Classes": "None", "Text": "4.1\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Therapeutic indications", "ParentId": "3fbf30c5-e51f-48fb-b64c-8887759be359"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d683f35e-071c-494e-b35f-332a5c0bf809", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "84dafd43-33cd-47f6-989d-169b70941d28", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d683f35e-071c-494e-b35f-332a5c0bf809"}, {"Element": "<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Early breast cancer</span></u></p>", "ID": "797ef8bc-cbed-4795-9b1b-50ecdc36ef9d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<u><span lang=\"EN-GB\">Early breast cancer</span></u>", "ID": "8bbbcd8e-6aa9-47ed-9f02-ebbdb863be6d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "797ef8bc-cbed-4795-9b1b-50ecdc36ef9d"}, {"Element": "<span lang=\"EN-GB\">Early breast cancer</span>", "ID": "15fbd8ee-1fd2-4044-be67-6ff0e4404fbe", "Styles": "None", "Classes": "None", "Text": "Early breast cancer", "ParentId": "8bbbcd8e-6aa9-47ed-9f02-ebbdb863be6d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Perjeta is indicated for use in combination\nwith trastuzumab and chemotherapy in:</span></p>", "ID": "1f3b7ef7-a06f-4e04-a092-ee7ab008acc2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Perjeta is indicated for use in combination\nwith trastuzumab and chemotherapy in:</span>", "ID": "b32018fd-3e95-40f7-be81-9b0e94b07295", "Styles": "None", "Classes": "None", "Text": "Perjeta is indicated for use in combination with trastuzumab and chemotherapy in:", "ParentId": "1f3b7ef7-a06f-4e04-a092-ee7ab008acc2"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:35.7pt;text-indent:-17.85pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0 </span><span lang=\"EN-GB\">the neoadjuvant treatment of adult patients with HER2-positive,\nlocally advanced, inflammatory, or early stage breast cancer at high risk of\nrecurrence (see section 5.1)</span></p>", "ID": "f9e730bf-4ab8-4c52-b069-d16e0bc86469", "Styles": "margin-left:35.7pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "d40e2413-08a2-4dea-808a-7d9cd004ed6c", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "f9e730bf-4ab8-4c52-b069-d16e0bc86469"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0 </span>", "ID": "8d8e8f3b-5bf1-468e-91b4-57da4aa4bab1", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "f9e730bf-4ab8-4c52-b069-d16e0bc86469"}, {"Element": "<span lang=\"EN-GB\">the neoadjuvant treatment of adult patients with HER2-positive,\nlocally advanced, inflammatory, or early stage breast cancer at high risk of\nrecurrence (see section 5.1)</span>", "ID": "7662e1cb-476e-4f50-8056-b435ee81eae6", "Styles": "None", "Classes": "None", "Text": "the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence (see section 5.1)", "ParentId": "f9e730bf-4ab8-4c52-b069-d16e0bc86469"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:35.7pt;text-indent:-17.85pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0 </span><span lang=\"EN-GB\">the adjuvant treatment of adult patients with HER2-positive early\nbreast cancer at high risk of recurrence (see section 5.1)</span></p>", "ID": "0ae0e859-b53a-4e4f-8b3b-5f3f5d5d86cb", "Styles": "margin-left:35.7pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "83771038-e305-44f6-b6f2-19e5a62ae230", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "0ae0e859-b53a-4e4f-8b3b-5f3f5d5d86cb"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0 </span>", "ID": "e1aa8e45-e30e-40a9-a848-1294fcf78f94", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "0ae0e859-b53a-4e4f-8b3b-5f3f5d5d86cb"}, {"Element": "<span lang=\"EN-GB\">the adjuvant treatment of adult patients with HER2-positive early\nbreast cancer at high risk of recurrence (see section 5.1)</span>", "ID": "03a6f23c-aa2a-4ce3-a2fc-93680755cd24", "Styles": "None", "Classes": "None", "Text": "the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence (see section 5.1)", "ParentId": "0ae0e859-b53a-4e4f-8b3b-5f3f5d5d86cb"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b96e25d2-2651-4b3a-bfd1-29aeb8be88a3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "40f8232d-4a4a-4c3d-93a5-0d12b43190ad", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b96e25d2-2651-4b3a-bfd1-29aeb8be88a3"}, {"Element": "<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Metastatic breast cancer</span></u></p>", "ID": "e8e42464-96e3-45bf-af9c-46983835421d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<u><span lang=\"EN-GB\">Metastatic breast cancer</span></u>", "ID": "b1d93438-9848-4ee1-861e-d02d6d3fc633", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e8e42464-96e3-45bf-af9c-46983835421d"}, {"Element": "<span lang=\"EN-GB\">Metastatic breast cancer</span>", "ID": "6d72e981-e1a1-46b4-a86d-e23b7b17cdc4", "Styles": "None", "Classes": "None", "Text": "Metastatic breast cancer", "ParentId": "b1d93438-9848-4ee1-861e-d02d6d3fc633"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Perjeta is indicated for use in combination\nwith trastuzumab and docetaxel in adult patients with HER2-positive metastatic\nor locally recurrent unresectable breast cancer,</span><b><i><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif'> </span></i></b><span lang=\"EN-GB\">who\nhave not received previous anti-HER2 therapy or chemotherapy for their\nmetastatic disease.</span></p>", "ID": "3b844b2f-2b4a-43f2-a2f7-20e1c901909c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Perjeta is indicated for use in combination\nwith trastuzumab and docetaxel in adult patients with HER2-positive metastatic\nor locally recurrent unresectable breast cancer,</span>", "ID": "c513c74f-89bc-4fc5-8e26-98442e4ce563", "Styles": "None", "Classes": "None", "Text": "Perjeta is indicated for use in combination with trastuzumab and docetaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer,", "ParentId": "3b844b2f-2b4a-43f2-a2f7-20e1c901909c"}, {"Element": "<b><i><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif'> </span></i></b>", "ID": "2f25a521-d24e-45ae-bbe4-5be1d9606ee5", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3b844b2f-2b4a-43f2-a2f7-20e1c901909c"}, {"Element": "<i><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif'> </span></i>", "ID": "7af19677-a4c7-4f2f-ba50-7c25237f9131", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "2f25a521-d24e-45ae-bbe4-5be1d9606ee5"}, {"Element": "<span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif'> </span>", "ID": "950d2409-0286-4c85-8db0-d07702c0b686", "Styles": "font-family:\"Arial\",sans-serif", "Classes": "None", "Text": " ", "ParentId": "7af19677-a4c7-4f2f-ba50-7c25237f9131"}, {"Element": "<span lang=\"EN-GB\">who\nhave not received previous anti-HER2 therapy or chemotherapy for their\nmetastatic disease.</span>", "ID": "3000807a-c315-4b46-bceb-1f1d23e12707", "Styles": "None", "Classes": "None", "Text": "who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.", "ParentId": "3b844b2f-2b4a-43f2-a2f7-20e1c901909c"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "a957d2cf-d1c6-419e-8b4f-3573d8dfdc4b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "2f4d7b60-7ee6-4ed8-adfd-ffc7b5484a7e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a957d2cf-d1c6-419e-8b4f-3573d8dfdc4b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "df97baa6-b100-4a8c-89e7-ef8a97a47473", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2f4d7b60-7ee6-4ed8-adfd-ffc7b5484a7e"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">4.2\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Posology and method of\nadministration</span></b></p>", "ID": "cc75f8a1-04f0-41b0-b1e9-d486cace5555", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">4.2\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Posology and method of\nadministration</span></b>", "ID": "e7ea8284-8c54-460f-9f86-a8c99eefc3f4", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "cc75f8a1-04f0-41b0-b1e9-d486cace5555"}, {"Element": "<span lang=\"EN-GB\">4.2\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Posology and method of\nadministration</span>", "ID": "2758c31c-0e16-459e-85c9-f310602486b8", "Styles": "None", "Classes": "None", "Text": "4.2\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Posology and method of administration", "ParentId": "e7ea8284-8c54-460f-9f86-a8c99eefc3f4"}, {"Element": "<p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">\u00a0</span></i></b></p>", "ID": "74ee4fec-d4ec-4ab2-a663-ef8c458c885a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><i><span lang=\"EN-GB\">\u00a0</span></i></b>", "ID": "ade2f3e3-5fb2-4a92-b66e-f719933bd2d2", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "74ee4fec-d4ec-4ab2-a663-ef8c458c885a"}, {"Element": "<i><span lang=\"EN-GB\">\u00a0</span></i>", "ID": "678ec398-f72b-4b28-82b6-3c2abeefe188", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ade2f3e3-5fb2-4a92-b66e-f719933bd2d2"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "bb6e713b-96e2-49be-a8be-661e5193bbc2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "678ec398-f72b-4b28-82b6-3c2abeefe188"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Perjeta should only be initiated under the\nsupervision of a physician experienced in the administration of anti-cancer\nagents. Perjeta should be administered by a healthcare professional prepared to\nmanage anaphylaxis and </span><span lang=\"EN-GB\">in an environment where full\nresuscitation facilities are immediately available</span><span lang=\"EN-GB\">.</span></p>", "ID": "e36a4c9c-f202-46bb-a923-472234bc40c4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Perjeta should only be initiated under the\nsupervision of a physician experienced in the administration of anti-cancer\nagents. Perjeta should be administered by a healthcare professional prepared to\nmanage anaphylaxis and </span>", "ID": "51603c2a-d32a-44b1-b6f5-691a256d544f", "Styles": "None", "Classes": "None", "Text": "Perjeta should only be initiated under the supervision of a physician experienced in the administration of anti-cancer agents. Perjeta should be administered by a healthcare professional prepared to manage anaphylaxis and ", "ParentId": "e36a4c9c-f202-46bb-a923-472234bc40c4"}, {"Element": "<span lang=\"EN-GB\">in an environment where full\nresuscitation facilities are immediately available</span>", "ID": "aaa19916-c40e-4992-b895-907334e16527", "Styles": "None", "Classes": "None", "Text": "in an environment where full resuscitation facilities are immediately available", "ParentId": "e36a4c9c-f202-46bb-a923-472234bc40c4"}, {"Element": "<span lang=\"EN-GB\">.</span>", "ID": "f2c705b0-d6ab-414e-98a3-c1f858326843", "Styles": "None", "Classes": "None", "Text": ".", "ParentId": "e36a4c9c-f202-46bb-a923-472234bc40c4"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "81c0ba0c-19a5-4fa2-a403-661559cde66b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b0be5965-ecc5-4e7d-a53a-ff216f557d22", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "81c0ba0c-19a5-4fa2-a403-661559cde66b"}, {"Element": "<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Posology</span></u></p>", "ID": "e25005f3-3abf-4a6a-8e12-01e3f52d7cdf", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<u><span lang=\"EN-GB\">Posology</span></u>", "ID": "35ac7865-05da-489b-b9c7-ee3f0a65714d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e25005f3-3abf-4a6a-8e12-01e3f52d7cdf"}, {"Element": "<span lang=\"EN-GB\">Posology</span>", "ID": "0f6b06db-527f-44e9-906c-60f427e2989e", "Styles": "None", "Classes": "None", "Text": "Posology", "ParentId": "35ac7865-05da-489b-b9c7-ee3f0a65714d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "1cdae34d-f921-470c-b97a-478845698675", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e98abb8e-9df0-4d33-8656-bba83e665f07", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1cdae34d-f921-470c-b97a-478845698675"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Patients treated with Perjeta must have\nHER2-positive tumour status, defined as a score of 3+ by immunohistochemistry\n(IHC) and/or a ratio of \u2265\u00a02.0 by in situ hybridisation (ISH)\nassessed by a validated test.</span></p>", "ID": "e681d117-6f07-4d14-893d-c69c814b69c6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Patients treated with Perjeta must have\nHER2-positive tumour status, defined as a score of 3+ by immunohistochemistry\n(IHC) and/or a ratio of \u2265\u00a02.0 by in situ hybridisation (ISH)\nassessed by a validated test.</span>", "ID": "7f170448-9cd7-4426-8742-9c10d414b437", "Styles": "None", "Classes": "None", "Text": "Patients treated with Perjeta must have HER2-positive tumour status, defined as a score of 3+ by immunohistochemistry (IHC) and/or a ratio of \u2265\u00a02.0 by in situ hybridisation (ISH) assessed by a validated test.", "ParentId": "e681d117-6f07-4d14-893d-c69c814b69c6"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a8b3780a-7569-49c0-a14d-c06a14c9f217", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "fcc9c6b5-5856-498e-859c-167d8c9a9085", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a8b3780a-7569-49c0-a14d-c06a14c9f217"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">To ensure accurate and reproducible\nresults, the testing must be performed in a specialised laboratory, which can\nensure validation of the testing procedures. For full instructions on assay\nperformance and interpretation please refer to the package leaflets of\nvalidated HER2 testing assays.</span></p>", "ID": "c2f01cee-3dab-44db-a724-aaeb50f08120", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">To ensure accurate and reproducible\nresults, the testing must be performed in a specialised laboratory, which can\nensure validation of the testing procedures. For full instructions on assay\nperformance and interpretation please refer to the package leaflets of\nvalidated HER2 testing assays.</span>", "ID": "730ff2d1-9a1d-4086-9ae3-9582eee70c6a", "Styles": "None", "Classes": "None", "Text": "To ensure accurate and reproducible results, the testing must be performed in a specialised laboratory, which can ensure validation of the testing procedures. For full instructions on assay performance and interpretation please refer to the package leaflets of validated HER2 testing assays.", "ParentId": "c2f01cee-3dab-44db-a724-aaeb50f08120"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>", "ID": "569424db-cf3d-4772-afe1-dc997b6e9f92", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u>", "ID": "d921e55a-e165-45fd-a480-89073a00e746", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "569424db-cf3d-4772-afe1-dc997b6e9f92"}, {"Element": "<span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span>", "ID": "5cfb50cf-b431-4cb6-bc2a-1024337215b7", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d921e55a-e165-45fd-a480-89073a00e746"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "05b4b14d-50fa-4446-8af7-6a028c7a40af", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "5cfb50cf-b431-4cb6-bc2a-1024337215b7"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The recommended initial loading dose of pertuzumab\nis 840\u00a0mg administered as a 60 minute intravenous infusion, followed every\n3 weeks thereafter by a maintenance dose of 420\u00a0mg administered over a\nperiod of 30 to 60 minutes. An observation period of 30 - 60 minutes is\nrecommended after completion of each infusion.\u00a0 The observation period should\nbe completed prior to any subsequent infusion of trastuzumab or chemotherapy\n(see section 4.4).</span></p>", "ID": "0864ff67-5f79-453e-a0d4-75ce31228507", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">The recommended initial loading dose of pertuzumab\nis 840\u00a0mg administered as a 60 minute intravenous infusion, followed every\n3 weeks thereafter by a maintenance dose of 420\u00a0mg administered over a\nperiod of 30 to 60 minutes. An observation period of 30 - 60 minutes is\nrecommended after completion of each infusion.\u00a0 The observation period should\nbe completed prior to any subsequent infusion of trastuzumab or chemotherapy\n(see section 4.4).</span>", "ID": "9d3fe01e-9092-4c50-8075-8cfa427c4cf3", "Styles": "None", "Classes": "None", "Text": "The recommended initial loading dose of pertuzumab is 840\u00a0mg administered as a 60 minute intravenous infusion, followed every 3 weeks thereafter by a maintenance dose of 420\u00a0mg administered over a period of 30 to 60 minutes. An observation period of 30 - 60 minutes is recommended after completion of each infusion.\u00a0 The observation period should be completed prior to any subsequent infusion of trastuzumab or chemotherapy (see section 4.4).", "ParentId": "0864ff67-5f79-453e-a0d4-75ce31228507"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5bcdff92-598e-4c1d-898a-4f6925389fa6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0bfaddbe-9e37-4a49-acf0-8bb6a3753d08", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5bcdff92-598e-4c1d-898a-4f6925389fa6"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Perjeta and trastuzumab should be\nadministered sequentially and not mixed in the same infusion bag. Perjeta and\ntrastuzumab can be given in any order. When administered with Perjeta the </span></p>", "ID": "4a4e0927-e352-4135-9214-de41fabe5c3b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Perjeta and trastuzumab should be\nadministered sequentially and not mixed in the same infusion bag. Perjeta and\ntrastuzumab can be given in any order. When administered with Perjeta the </span>", "ID": "69c4fb93-82c5-4723-a81d-4e98d81fc5e4", "Styles": "None", "Classes": "None", "Text": "Perjeta and trastuzumab should be administered sequentially and not mixed in the same infusion bag. Perjeta and trastuzumab can be given in any order. When administered with Perjeta the ", "ParentId": "4a4e0927-e352-4135-9214-de41fabe5c3b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">recommendation is to follow a 3 weekly\nschedule for trastuzumab administered as either:</span></p>", "ID": "f041e4a9-22e4-44fd-99b8-fc778f779b74", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">recommendation is to follow a 3 weekly\nschedule for trastuzumab administered as either:</span>", "ID": "0f880fd1-c994-47fa-a42e-bc95c057b9e5", "Styles": "None", "Classes": "None", "Text": "recommendation is to follow a 3 weekly schedule for trastuzumab administered as either:", "ParentId": "f041e4a9-22e4-44fd-99b8-fc778f779b74"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a7dcb435-8eb0-437b-9ed9-e9aec824c3d4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "81a8231d-59ea-4823-ab5f-1dabd50cbf91", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a7dcb435-8eb0-437b-9ed9-e9aec824c3d4"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:35.7pt;text-indent:-17.85pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0 an IV\ninfusion with an initial loading dose of trastuzumab 8\u00a0mg/kg body weight\nfollowed every 3 weeks thereafter by a maintenance dose of 6\u00a0mg/kg body\nweight</span></p>", "ID": "e0ad1221-11c0-4da8-9582-952910abb678", "Styles": "margin-left:35.7pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "4348d1af-544b-411b-962d-8320be853dd3", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "e0ad1221-11c0-4da8-9582-952910abb678"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0 an IV\ninfusion with an initial loading dose of trastuzumab 8\u00a0mg/kg body weight\nfollowed every 3 weeks thereafter by a maintenance dose of 6\u00a0mg/kg body\nweight</span>", "ID": "2e4aff06-edbb-47b1-8a75-8d4641491b38", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 an IV infusion with an initial loading dose of trastuzumab 8\u00a0mg/kg body weight followed every 3 weeks thereafter by a maintenance dose of 6\u00a0mg/kg body weight", "ParentId": "e0ad1221-11c0-4da8-9582-952910abb678"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:35.7pt;text-indent:-17.85pt\"><span lang=\"EN-GB\">or </span></p>", "ID": "90502d56-311e-4d07-9460-afc5b0e209f3", "Styles": "margin-left:35.7pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">or </span>", "ID": "e81ff492-c419-4f12-9f49-1215ce96d401", "Styles": "None", "Classes": "None", "Text": "or ", "ParentId": "90502d56-311e-4d07-9460-afc5b0e209f3"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:35.7pt;text-indent:-17.85pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0 a fixed\nsubcutaneous dose of trastuzumab by injection (600\u00a0mg) every 3 weeks irrespective\nof the patient\u2019s body weight.</span></p>", "ID": "371eb155-4da9-4162-89ae-fdfc77f1a74e", "Styles": "margin-left:35.7pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "ec0338c4-0d2e-4050-a759-31ffb9ab1e70", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "371eb155-4da9-4162-89ae-fdfc77f1a74e"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0 a fixed\nsubcutaneous dose of trastuzumab by injection (600\u00a0mg) every 3 weeks irrespective\nof the patient\u2019s body weight.</span>", "ID": "96c2c4a1-603b-416a-aeaa-275db8af1a18", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 a fixed subcutaneous dose of trastuzumab by injection (600\u00a0mg) every 3 weeks irrespective of the patient\u2019s body weight.", "ParentId": "371eb155-4da9-4162-89ae-fdfc77f1a74e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4ec230ca-12f8-49d4-b510-bd2c4a53f9ca", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "521af21b-8699-4ee5-954f-af5e4c21f692", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4ec230ca-12f8-49d4-b510-bd2c4a53f9ca"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In patients receiving a taxane, Perjeta and\ntrastuzumab should be administered prior to the taxane. </span></p>", "ID": "bed0e65a-c784-4e05-8401-0d2ca9891b08", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">In patients receiving a taxane, Perjeta and\ntrastuzumab should be administered prior to the taxane. </span>", "ID": "72abc879-8340-40bd-927d-8388931170ec", "Styles": "None", "Classes": "None", "Text": "In patients receiving a taxane, Perjeta and trastuzumab should be administered prior to the taxane. ", "ParentId": "bed0e65a-c784-4e05-8401-0d2ca9891b08"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6240329f-ed82-436a-8954-6e5088ec2742", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "744c8f8f-5c17-4f6e-9934-fd4dcab6f561", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6240329f-ed82-436a-8954-6e5088ec2742"}, {"Element": "<p class=\"MsoNormal\">When administered with Perjeta, docetaxel can be started at\n75 mg/m2, and subsequently escalated to 100 mg/m2 depending on the chosen\nregimen and tolerability of the initial dose. Alternatively, docetaxel can be\ngiven at 100 mg/m2 on a 3 weekly schedule from the start, again depending on\nthe chosen regimen. If a carboplatin-based regimen is used, the recommended dose\nfor docetaxel is 75 mg/m2 throughout (no dose escalation). <span lang=\"EN-GB\">When\nadministered with Perjeta in the adjuvant setting, the recommended dose of\npaclitaxel is 80 mg/m2 once weekly for 12 weekly cycles.</span></p>", "ID": "9b9b86bf-5747-43fc-84b2-b1d08d13b9ad", "Styles": "None", "Classes": "['MsoNormal']", "Text": "When administered with Perjeta, docetaxel can be started at 75 mg/m2, and subsequently escalated to 100 mg/m2 depending on the chosen regimen and tolerability of the initial dose. Alternatively, docetaxel can be given at 100 mg/m2 on a 3 weekly schedule from the start, again depending on the chosen regimen. If a carboplatin-based regimen is used, the recommended dose for docetaxel is 75 mg/m2 throughout (no dose escalation). ", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">When\nadministered with Perjeta in the adjuvant setting, the recommended dose of\npaclitaxel is 80 mg/m2 once weekly for 12 weekly cycles.</span>", "ID": "722d9d54-1411-4164-a800-51cc8afe901d", "Styles": "None", "Classes": "None", "Text": "When administered with Perjeta in the adjuvant setting, the recommended dose of paclitaxel is 80 mg/m2 once weekly for 12 weekly cycles.", "ParentId": "9b9b86bf-5747-43fc-84b2-b1d08d13b9ad"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4118a94f-a98d-434c-83bb-7ac27d544872", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "688c8578-5a37-4b4a-81f2-1d8b0d24161a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4118a94f-a98d-434c-83bb-7ac27d544872"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">In patients receiving an anthracycline-based\nregimen, Perjeta and trastuzumab should be administered following completion of\nthe entire anthracycline regimen (see section 4.4). </span></p>", "ID": "c69c1201-c527-4b31-9b5f-50dabd10ffd0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-CARRIBEAN\">In patients receiving an anthracycline-based\nregimen, Perjeta and trastuzumab should be administered following completion of\nthe entire anthracycline regimen (see section 4.4). </span>", "ID": "f0bfcf33-6acb-4c2c-991c-a54e5475d169", "Styles": "None", "Classes": "None", "Text": "In patients receiving an anthracycline-based regimen, Perjeta and trastuzumab should be administered following completion of the entire anthracycline regimen (see section 4.4). ", "ParentId": "c69c1201-c527-4b31-9b5f-50dabd10ffd0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "db228812-d8ee-4292-a95e-4fa5d13b2381", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8e46d57e-3c99-4c48-b8fa-13d0cc11b8be", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "db228812-d8ee-4292-a95e-4fa5d13b2381"}, {"Element": "<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">Metastatic breast cancer</span></i></p>", "ID": "afec1499-320c-4120-a40b-db13923d63b0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<i><span lang=\"EN-GB\">Metastatic breast cancer</span></i>", "ID": "6d576acc-5de7-4587-90ca-dc38d1001148", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "afec1499-320c-4120-a40b-db13923d63b0"}, {"Element": "<span lang=\"EN-GB\">Metastatic breast cancer</span>", "ID": "8b87e9ec-f4bf-4aaf-9b3a-edf399b5dde3", "Styles": "None", "Classes": "None", "Text": "Metastatic breast cancer", "ParentId": "6d576acc-5de7-4587-90ca-dc38d1001148"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "84f73b6f-bd26-420d-b979-ab7ff29632af", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "96754c76-cff2-4724-ab94-0a647b528e82", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "84f73b6f-bd26-420d-b979-ab7ff29632af"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Perjeta should be administered in\ncombination with trastuzumab and docetaxel . Treatment with Perjeta and\ntrastuzumab may continue until disease progression or unmanageable toxicity\neven if treatment with docetaxel is discontinued.</span></p>", "ID": "5f1742ab-303a-4cd1-918a-35ac72941e89", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Perjeta should be administered in\ncombination with trastuzumab and docetaxel . Treatment with Perjeta and\ntrastuzumab may continue until disease progression or unmanageable toxicity\neven if treatment with docetaxel is discontinued.</span>", "ID": "80269cfd-0b8e-4807-b14d-c8bf26e1b19c", "Styles": "None", "Classes": "None", "Text": "Perjeta should be administered in combination with trastuzumab and docetaxel . Treatment with Perjeta and trastuzumab may continue until disease progression or unmanageable toxicity even if treatment with docetaxel is discontinued.", "ParentId": "5f1742ab-303a-4cd1-918a-35ac72941e89"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e5d1359d-14bd-4423-8c07-a01a2c63b76f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1486fddf-0ee9-476b-a606-63d775408f06", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e5d1359d-14bd-4423-8c07-a01a2c63b76f"}, {"Element": "<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">Early breast cancer</span></i></p>", "ID": "09a1f2f2-60cb-483c-bdea-74d9d176304b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<i><span lang=\"EN-GB\">Early breast cancer</span></i>", "ID": "1c3c1864-09dd-4025-b189-5ceee18c048c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "09a1f2f2-60cb-483c-bdea-74d9d176304b"}, {"Element": "<span lang=\"EN-GB\">Early breast cancer</span>", "ID": "2ba5ca32-5583-432e-9a9d-cf2f6b9ed972", "Styles": "None", "Classes": "None", "Text": "Early breast cancer", "ParentId": "1c3c1864-09dd-4025-b189-5ceee18c048c"}, {"Element": "<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">\u00a0</span></i></p>", "ID": "539eb223-fe80-4660-8cf1-573e6526386b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<i><span lang=\"EN-GB\">\u00a0</span></i>", "ID": "804c515c-ce18-4cba-b13d-56a02e1766d1", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "539eb223-fe80-4660-8cf1-573e6526386b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c226b116-263c-4c34-af8d-3041df36e316", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "804c515c-ce18-4cba-b13d-56a02e1766d1"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In the neoadjuvant setting, Perjeta should\nbe administered for 3 to 6 cycles in combination with </span><span lang=\"EN-GB\">trastuzumab\nand chemotherapy, as part of a complete treatment regimen for early breast\ncancer (see section 5.1). </span></p>", "ID": "4b2d0c35-cd41-47c2-9170-dd07b038875b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">In the neoadjuvant setting, Perjeta should\nbe administered for 3 to 6 cycles in combination with </span>", "ID": "370f1549-0233-486b-8df2-0c27dc482c53", "Styles": "None", "Classes": "None", "Text": "In the neoadjuvant setting, Perjeta should be administered for 3 to 6 cycles in combination with ", "ParentId": "4b2d0c35-cd41-47c2-9170-dd07b038875b"}, {"Element": "<span lang=\"EN-GB\">trastuzumab\nand chemotherapy, as part of a complete treatment regimen for early breast\ncancer (see section 5.1). </span>", "ID": "341a7b83-3b00-40a7-8e08-d4dd70e171f7", "Styles": "None", "Classes": "None", "Text": "trastuzumab and chemotherapy, as part of a complete treatment regimen for early breast cancer (see section 5.1). ", "ParentId": "4b2d0c35-cd41-47c2-9170-dd07b038875b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c5d23661-5134-43a1-9e34-66540fd4acb8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "99a461d9-dd21-4eee-81a3-9e5f3c774d84", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c5d23661-5134-43a1-9e34-66540fd4acb8"}, {"Element": "<p class=\"MsoNormal\">In the adjuvant setting, Perjeta should be administered in\ncombination with trastuzumab for a total of one year (up to 18 cycles or until\ndisease recurrence, or unmanageable toxicity, whichever occurs first) as part\nof a complete regimen for early breast cancer and regardless of the timing of\nsurgery.\u00a0 Treatment should include standard anthracycline- and/or taxane-based\nchemotherapy. Perjeta and trastuzumab should start on Day 1 of the first\ntaxane-containing cycle and should continue even if chemotherapy is\ndiscontinued<span lang=\"EN-GB\">. </span></p>", "ID": "950c7ad4-d46c-4ca5-ba0f-1d314ac46cd6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "In the adjuvant setting, Perjeta should be administered in combination with trastuzumab for a total of one year (up to 18 cycles or until disease recurrence, or unmanageable toxicity, whichever occurs first) as part of a complete regimen for early breast cancer and regardless of the timing of surgery.\u00a0 Treatment should include standard anthracycline- and/or taxane-based chemotherapy. Perjeta and trastuzumab should start on Day 1 of the first taxane-containing cycle and should continue even if chemotherapy is discontinued", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">. </span>", "ID": "b64d0b07-a7a7-428d-b861-5b057ee0d439", "Styles": "None", "Classes": "None", "Text": ". ", "ParentId": "950c7ad4-d46c-4ca5-ba0f-1d314ac46cd6"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f0b0c434-fa24-4a25-ac2e-abb0f628229c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "77e1b7a4-1a34-4e76-b769-6d15dc18a533", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f0b0c434-fa24-4a25-ac2e-abb0f628229c"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Delayed\nor missed doses</span></i></p>", "ID": "5ce2f7c0-ad60-4212-863b-d1b09baab7a0", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<i><span lang=\"EN-GB\">Delayed\nor missed doses</span></i>", "ID": "bcde1640-e7ba-42a2-ab06-60cfdce646c0", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "5ce2f7c0-ad60-4212-863b-d1b09baab7a0"}, {"Element": "<span lang=\"EN-GB\">Delayed\nor missed doses</span>", "ID": "2cd90d1e-0302-49e2-8959-8d654b1467c5", "Styles": "None", "Classes": "None", "Text": "Delayed or missed doses", "ParentId": "bcde1640-e7ba-42a2-ab06-60cfdce646c0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\" style=\"color:black\">\u00a0</span></p>", "ID": "70b190b9-206e-48c5-b55b-4afb31da364f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-CARRIBEAN\" style=\"color:black\">\u00a0</span>", "ID": "fcb1cdb5-3eca-4e21-8cc5-2ce77805d4af", "Styles": "color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "70b190b9-206e-48c5-b55b-4afb31da364f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\" style=\"color:black\">For\nrecommendations on delayed or missed doses, please refer to Table 1 below.</span></p>", "ID": "2f9a6e7f-5e95-471b-8df7-6c2c3cfd4d71", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-CARRIBEAN\" style=\"color:black\">For\nrecommendations on delayed or missed doses, please refer to Table 1 below.</span>", "ID": "ca6de14b-8d37-4ac4-bef7-16e78ce9c6f3", "Styles": "color:black", "Classes": "None", "Text": "For recommendations on delayed or missed doses, please refer to Table 1 below.", "ParentId": "2f9a6e7f-5e95-471b-8df7-6c2c3cfd4d71"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "4e771249-d400-4f22-92dd-6d95f5076c8b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.75in;text-indent:-.75in;page-break-after:\navoid\"><b><span lang=\"EN-GB\">Table 1\u00a0\u00a0\u00a0\u00a0\u00a0 Recommendations regarding delayed or\nmissed doses</span></b></p>", "ID": "cc9c88d9-1aa4-4829-a43b-9a1fb4edf25a", "Styles": "margin-left:.75in;text-indent:-.75in;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">Table 1\u00a0\u00a0\u00a0\u00a0\u00a0 Recommendations regarding delayed or\nmissed doses</span></b>", "ID": "b7292aed-a58d-42f2-94f8-3bd42a78f6e4", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "cc9c88d9-1aa4-4829-a43b-9a1fb4edf25a"}, {"Element": "<span lang=\"EN-GB\">Table 1\u00a0\u00a0\u00a0\u00a0\u00a0 Recommendations regarding delayed or\nmissed doses</span>", "ID": "209e3ca9-b07a-4d77-b3e6-1a9685524d0b", "Styles": "None", "Classes": "None", "Text": "Table 1\u00a0\u00a0\u00a0\u00a0\u00a0 Recommendations regarding delayed or missed doses", "ParentId": "b7292aed-a58d-42f2-94f8-3bd42a78f6e4"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.75in;text-indent:-.75in;page-break-after:\navoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "edacb973-b10a-4df6-8ba7-21de82efe1a0", "Styles": "margin-left:.75in;text-indent:-.75in;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "2a69fd3f-a9d1-4890-8a42-362f31228160", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "edacb973-b10a-4df6-8ba7-21de82efe1a0"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c412045b-eb42-4807-b673-2f39d1dabcba", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2a69fd3f-a9d1-4890-8a42-362f31228160"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr>\n<td rowspan=\"2\" style=\"width:103.05pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"137\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Time between two\n  sequential infusions</b></p>\n</td>\n<td rowspan=\"2\" style=\"width:126.1pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"168\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Perjeta </b></p>\n</td>\n<td colspan=\"2\" style=\"width:235.2pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"314\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b>trastuzumab</b></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:123.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"165\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>IV</b></p>\n</td>\n<td style=\"width:111.65pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"149\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>SC</b></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:103.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"137\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">&lt; 6 weeks</p>\n</td>\n<td style=\"width:126.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"168\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">The 420 mg dose of\n  pertuzumab should be administered as soon as possible. Do not wait until the\n  next planned dose. Thereafter, revert to the original planned schedule.</p>\n</td>\n<td style=\"width:123.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"165\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">The 6\u00a0mg/kg dose of trastuzumab\n  IV should be administered as soon as possible. Do not wait until the next\n  planned dose. Thereafter, revert to the original planned schedule.</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n<td rowspan=\"2\" style=\"width:111.65pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"149\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">The fixed dose of 600mg\n  trastuzumab SC should be administered as soon as possible. </p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Do not wait until the next\n  planned dose.</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n</tr>\n<tr>\n<td style=\"width:103.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"137\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"ZH-CN\" style=\"font-family:SimSun\">\u2265</span> 6 weeks</p>\n</td>\n<td style=\"width:126.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"168\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">The 840 mg loading dose of\n  pertuzumab should be re-administered\u00a0as a 60 minute infusion, followed\n  by a maintenance dose of 420 mg IV administered every 3 weeks thereafter.</p>\n</td>\n<td style=\"width:123.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"165\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">The\u00a0loading dose of\n  8\u00a0mg/kg of trastuzumab IV should be re- administered\u00a0over\n  approximately 90\u00a0minutes, followed by a maintenance dose of 6\u00a0mg/kg\n  IV\u00a0administered every 3 weeks thereafter.</p>\n</td>\n</tr>\n</table>", "ID": "1e5ceace-f7a4-4361-8053-9128c6b083a5", "Styles": "border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Text": "     ", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<tr>\n<td rowspan=\"2\" style=\"width:103.05pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"137\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Time between two\n  sequential infusions</b></p>\n</td>\n<td rowspan=\"2\" style=\"width:126.1pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"168\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Perjeta </b></p>\n</td>\n<td colspan=\"2\" style=\"width:235.2pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"314\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b>trastuzumab</b></p>\n</td>\n</tr>", "ID": "3b941160-fd56-4af8-8344-02abf2338d05", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "1e5ceace-f7a4-4361-8053-9128c6b083a5"}, {"Element": "<td rowspan=\"2\" style=\"width:103.05pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"137\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Time between two\n  sequential infusions</b></p>\n</td>", "ID": "e34c3e71-f21f-4b7b-be61-b6b8932287fc", "Styles": "width:103.05pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "3b941160-fd56-4af8-8344-02abf2338d05"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Time between two\n  sequential infusions</b></p>", "ID": "84ebb66e-3eb3-4b24-bd04-1f6e2b1274fe", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e34c3e71-f21f-4b7b-be61-b6b8932287fc"}, {"Element": "<b>Time between two\n  sequential infusions</b>", "ID": "d80d4e1e-4df4-443b-8576-e42bb99fc6bd", "Styles": "None", "Classes": "None", "Text": "Time between two   sequential infusions", "ParentId": "84ebb66e-3eb3-4b24-bd04-1f6e2b1274fe"}, {"Element": "<td rowspan=\"2\" style=\"width:126.1pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"168\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Perjeta </b></p>\n</td>", "ID": "81390d12-9783-4872-9d5e-e1fb215d4eef", "Styles": "width:126.1pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "3b941160-fd56-4af8-8344-02abf2338d05"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Perjeta </b></p>", "ID": "931fde54-7358-4820-9642-51432ed9b1ed", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "81390d12-9783-4872-9d5e-e1fb215d4eef"}, {"Element": "<b>Perjeta </b>", "ID": "e5b07f47-3d38-43ea-81c2-2998bfa0d102", "Styles": "None", "Classes": "None", "Text": "Perjeta ", "ParentId": "931fde54-7358-4820-9642-51432ed9b1ed"}, {"Element": "<td colspan=\"2\" style=\"width:235.2pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"314\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b>trastuzumab</b></p>\n</td>", "ID": "604d6273-0e56-4772-a437-faf2e8b18784", "Styles": "width:235.2pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "3b941160-fd56-4af8-8344-02abf2338d05"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b>trastuzumab</b></p>", "ID": "3ad14602-bb8f-4425-8f9f-ffc4e5e12bdd", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "604d6273-0e56-4772-a437-faf2e8b18784"}, {"Element": "<b>trastuzumab</b>", "ID": "c4c49380-d733-4f95-95b1-701fef722bb8", "Styles": "None", "Classes": "None", "Text": "trastuzumab", "ParentId": "3ad14602-bb8f-4425-8f9f-ffc4e5e12bdd"}, {"Element": "<tr>\n<td style=\"width:123.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"165\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>IV</b></p>\n</td>\n<td style=\"width:111.65pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"149\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>SC</b></p>\n</td>\n</tr>", "ID": "b92657dd-0719-4955-8ba8-e440617fe5ba", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "1e5ceace-f7a4-4361-8053-9128c6b083a5"}, {"Element": "<td style=\"width:123.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"165\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>IV</b></p>\n</td>", "ID": "536dfde9-6a2c-496d-aa62-db457b18cea8", "Styles": "width:123.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "b92657dd-0719-4955-8ba8-e440617fe5ba"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>IV</b></p>", "ID": "3659db55-c352-4b2f-b79f-ac944c803a58", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "536dfde9-6a2c-496d-aa62-db457b18cea8"}, {"Element": "<b>IV</b>", "ID": "cee2c183-38cf-4247-b35d-ec164fb3ac25", "Styles": "None", "Classes": "None", "Text": "IV", "ParentId": "3659db55-c352-4b2f-b79f-ac944c803a58"}, {"Element": "<td style=\"width:111.65pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"149\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>SC</b></p>\n</td>", "ID": "27ad1f88-8dcf-4b5a-b7d8-a4bd894b7ece", "Styles": "width:111.65pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "b92657dd-0719-4955-8ba8-e440617fe5ba"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>SC</b></p>", "ID": "c7409844-53ac-4b19-b423-0157ab70fc36", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "27ad1f88-8dcf-4b5a-b7d8-a4bd894b7ece"}, {"Element": "<b>SC</b>", "ID": "3d868e61-d981-4fbb-98ec-a548239ba944", "Styles": "None", "Classes": "None", "Text": "SC", "ParentId": "c7409844-53ac-4b19-b423-0157ab70fc36"}, {"Element": "<tr>\n<td style=\"width:103.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"137\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">&lt; 6 weeks</p>\n</td>\n<td style=\"width:126.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"168\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">The 420 mg dose of\n  pertuzumab should be administered as soon as possible. Do not wait until the\n  next planned dose. Thereafter, revert to the original planned schedule.</p>\n</td>\n<td style=\"width:123.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"165\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">The 6\u00a0mg/kg dose of trastuzumab\n  IV should be administered as soon as possible. Do not wait until the next\n  planned dose. Thereafter, revert to the original planned schedule.</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n<td rowspan=\"2\" style=\"width:111.65pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"149\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">The fixed dose of 600mg\n  trastuzumab SC should be administered as soon as possible. </p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Do not wait until the next\n  planned dose.</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n</tr>", "ID": "d86d11ef-c888-493c-8210-13d4c4872295", "Styles": "None", "Classes": "None", "Text": "     ", "ParentId": "1e5ceace-f7a4-4361-8053-9128c6b083a5"}, {"Element": "<td style=\"width:103.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"137\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">&lt; 6 weeks</p>\n</td>", "ID": "a1af87f4-d9d7-4cd7-9399-35611f92b8e1", "Styles": "width:103.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "d86d11ef-c888-493c-8210-13d4c4872295"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">&lt; 6 weeks</p>", "ID": "e935db6f-b921-4941-98b4-806aa9aabcfd", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "< 6 weeks", "ParentId": "a1af87f4-d9d7-4cd7-9399-35611f92b8e1"}, {"Element": "<td style=\"width:126.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"168\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">The 420 mg dose of\n  pertuzumab should be administered as soon as possible. Do not wait until the\n  next planned dose. Thereafter, revert to the original planned schedule.</p>\n</td>", "ID": "714edbb9-83b5-4576-bfc4-fbf3d7eef895", "Styles": "width:126.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "d86d11ef-c888-493c-8210-13d4c4872295"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">The 420 mg dose of\n  pertuzumab should be administered as soon as possible. Do not wait until the\n  next planned dose. Thereafter, revert to the original planned schedule.</p>", "ID": "2d830c75-05f7-4837-acf8-711ab60d12d0", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "The 420 mg dose of   pertuzumab should be administered as soon as possible. Do not wait until the   next planned dose. Thereafter, revert to the original planned schedule.", "ParentId": "714edbb9-83b5-4576-bfc4-fbf3d7eef895"}, {"Element": "<td style=\"width:123.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"165\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">The 6\u00a0mg/kg dose of trastuzumab\n  IV should be administered as soon as possible. Do not wait until the next\n  planned dose. Thereafter, revert to the original planned schedule.</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>", "ID": "84c45f54-8530-477d-ba93-0bbe91f1d2b6", "Styles": "width:123.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "d86d11ef-c888-493c-8210-13d4c4872295"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">The 6\u00a0mg/kg dose of trastuzumab\n  IV should be administered as soon as possible. Do not wait until the next\n  planned dose. Thereafter, revert to the original planned schedule.</p>", "ID": "e086d8df-47df-4b2e-9e84-d02dfa7a3e26", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "The 6\u00a0mg/kg dose of trastuzumab   IV should be administered as soon as possible. Do not wait until the next   planned dose. Thereafter, revert to the original planned schedule.", "ParentId": "84c45f54-8530-477d-ba93-0bbe91f1d2b6"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "a279900a-3087-4075-b06e-cbccfba9ec9c", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "84c45f54-8530-477d-ba93-0bbe91f1d2b6"}, {"Element": "<td rowspan=\"2\" style=\"width:111.65pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"149\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">The fixed dose of 600mg\n  trastuzumab SC should be administered as soon as possible. </p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Do not wait until the next\n  planned dose.</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>", "ID": "de880f02-365a-4eea-8f2f-482d870ec0e9", "Styles": "width:111.65pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "    ", "ParentId": "d86d11ef-c888-493c-8210-13d4c4872295"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">The fixed dose of 600mg\n  trastuzumab SC should be administered as soon as possible. </p>", "ID": "d12e2fd8-5d64-4f7b-a6b9-bd20c330f564", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "The fixed dose of 600mg   trastuzumab SC should be administered as soon as possible. ", "ParentId": "de880f02-365a-4eea-8f2f-482d870ec0e9"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Do not wait until the next\n  planned dose.</p>", "ID": "28c84eab-5b47-47c0-b0de-8d3535b535ea", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "Do not wait until the next   planned dose.", "ParentId": "de880f02-365a-4eea-8f2f-482d870ec0e9"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "6ff4419b-ab8e-4544-b37a-4748cd8fc701", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "de880f02-365a-4eea-8f2f-482d870ec0e9"}, {"Element": "<tr>\n<td style=\"width:103.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"137\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"ZH-CN\" style=\"font-family:SimSun\">\u2265</span> 6 weeks</p>\n</td>\n<td style=\"width:126.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"168\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">The 840 mg loading dose of\n  pertuzumab should be re-administered\u00a0as a 60 minute infusion, followed\n  by a maintenance dose of 420 mg IV administered every 3 weeks thereafter.</p>\n</td>\n<td style=\"width:123.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"165\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">The\u00a0loading dose of\n  8\u00a0mg/kg of trastuzumab IV should be re- administered\u00a0over\n  approximately 90\u00a0minutes, followed by a maintenance dose of 6\u00a0mg/kg\n  IV\u00a0administered every 3 weeks thereafter.</p>\n</td>\n</tr>", "ID": "77d2071b-dc7a-4f73-8aed-e9483f89cd3c", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "1e5ceace-f7a4-4361-8053-9128c6b083a5"}, {"Element": "<td style=\"width:103.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"137\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"ZH-CN\" style=\"font-family:SimSun\">\u2265</span> 6 weeks</p>\n</td>", "ID": "e79bcc23-d047-4705-a402-fc6a0ef3bc1c", "Styles": "width:103.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "77d2071b-dc7a-4f73-8aed-e9483f89cd3c"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"ZH-CN\" style=\"font-family:SimSun\">\u2265</span> 6 weeks</p>", "ID": "e9838bbc-2bec-4cfd-aae7-2afd73be0ce2", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": " 6 weeks", "ParentId": "e79bcc23-d047-4705-a402-fc6a0ef3bc1c"}, {"Element": "<span lang=\"ZH-CN\" style=\"font-family:SimSun\">\u2265</span>", "ID": "08e4f179-b332-4573-af13-11be48d9869f", "Styles": "font-family:SimSun", "Classes": "None", "Text": "\u2265", "ParentId": "e9838bbc-2bec-4cfd-aae7-2afd73be0ce2"}, {"Element": "<td style=\"width:126.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"168\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">The 840 mg loading dose of\n  pertuzumab should be re-administered\u00a0as a 60 minute infusion, followed\n  by a maintenance dose of 420 mg IV administered every 3 weeks thereafter.</p>\n</td>", "ID": "180020db-b87f-4a51-8b17-4cafa1c5b4c6", "Styles": "width:126.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "77d2071b-dc7a-4f73-8aed-e9483f89cd3c"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">The 840 mg loading dose of\n  pertuzumab should be re-administered\u00a0as a 60 minute infusion, followed\n  by a maintenance dose of 420 mg IV administered every 3 weeks thereafter.</p>", "ID": "4e901b9e-d602-4f66-98fe-abb094bb4785", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "The 840 mg loading dose of   pertuzumab should be re-administered\u00a0as a 60 minute infusion, followed   by a maintenance dose of 420 mg IV administered every 3 weeks thereafter.", "ParentId": "180020db-b87f-4a51-8b17-4cafa1c5b4c6"}, {"Element": "<td style=\"width:123.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"165\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">The\u00a0loading dose of\n  8\u00a0mg/kg of trastuzumab IV should be re- administered\u00a0over\n  approximately 90\u00a0minutes, followed by a maintenance dose of 6\u00a0mg/kg\n  IV\u00a0administered every 3 weeks thereafter.</p>\n</td>", "ID": "24aff0d2-85e4-4f46-85b7-65abafcb75bc", "Styles": "width:123.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "77d2071b-dc7a-4f73-8aed-e9483f89cd3c"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">The\u00a0loading dose of\n  8\u00a0mg/kg of trastuzumab IV should be re- administered\u00a0over\n  approximately 90\u00a0minutes, followed by a maintenance dose of 6\u00a0mg/kg\n  IV\u00a0administered every 3 weeks thereafter.</p>", "ID": "07cdb471-1fcb-4887-ad42-4247aa6593a0", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "The\u00a0loading dose of   8\u00a0mg/kg of trastuzumab IV should be re- administered\u00a0over   approximately 90\u00a0minutes, followed by a maintenance dose of 6\u00a0mg/kg   IV\u00a0administered every 3 weeks thereafter.", "ParentId": "24aff0d2-85e4-4f46-85b7-65abafcb75bc"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b3a67735-5eda-437d-b9a6-2d042dfa179f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "cb785b0e-f1d2-4ef7-a044-bc81a84a0706", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b3a67735-5eda-437d-b9a6-2d042dfa179f"}, {"Element": "<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">Dose modification</span></i></p>", "ID": "a6ed4d37-2eef-4b46-970d-292461bb97ba", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<i><span lang=\"EN-GB\">Dose modification</span></i>", "ID": "7187a058-786f-4612-b25d-726e78a15599", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a6ed4d37-2eef-4b46-970d-292461bb97ba"}, {"Element": "<span lang=\"EN-GB\">Dose modification</span>", "ID": "dd32eab6-6e31-4980-9e8d-e84af2d13e04", "Styles": "None", "Classes": "None", "Text": "Dose modification", "ParentId": "7187a058-786f-4612-b25d-726e78a15599"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Dose reductions are not recommended for Perjeta\nor trastuzumab.\u00a0 For details regarding trastuzumab, please refer to the summary\nof product characteristics (SmPC). </span></p>", "ID": "38a85791-f6e8-4daf-920e-28a4d16ae022", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Dose reductions are not recommended for Perjeta\nor trastuzumab.\u00a0 For details regarding trastuzumab, please refer to the summary\nof product characteristics (SmPC). </span>", "ID": "6ea078a2-f6e5-4244-967a-af24caad7ab3", "Styles": "None", "Classes": "None", "Text": "Dose reductions are not recommended for Perjeta or trastuzumab.\u00a0 For details regarding trastuzumab, please refer to the summary of product characteristics (SmPC). ", "ParentId": "38a85791-f6e8-4daf-920e-28a4d16ae022"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0cdb5332-625f-4552-a9b1-5aa352d920b0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e6408442-9151-4ae2-9b9f-5b5aba01bd73", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0cdb5332-625f-4552-a9b1-5aa352d920b0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Patients may continue\ntherapy during periods of reversible chemotherapy-induced myelosuppression but\nthey should be monitored carefully for complications of neutropenia during this\ntime. </span><span lang=\"EN-GB\">For docetaxel </span><span lang=\"EN-GB\">and other\nchemotherapy </span><span lang=\"EN-GB\">dose modifications, see </span><span lang=\"EN-GB\">relevant</span><span lang=\"EN-GB\"> SmPC.</span></p>", "ID": "0b5983d0-9c2d-4fcc-adcc-e654052ce791", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Patients may continue\ntherapy during periods of reversible chemotherapy-induced myelosuppression but\nthey should be monitored carefully for complications of neutropenia during this\ntime. </span>", "ID": "082ed16e-08f2-40b5-a079-62722f5c42ab", "Styles": "color:black", "Classes": "None", "Text": "Patients may continue therapy during periods of reversible chemotherapy-induced myelosuppression but they should be monitored carefully for complications of neutropenia during this time. ", "ParentId": "0b5983d0-9c2d-4fcc-adcc-e654052ce791"}, {"Element": "<span lang=\"EN-GB\">For docetaxel </span>", "ID": "1bfed8f9-80eb-4086-9749-821ef9e22ff9", "Styles": "None", "Classes": "None", "Text": "For docetaxel ", "ParentId": "0b5983d0-9c2d-4fcc-adcc-e654052ce791"}, {"Element": "<span lang=\"EN-GB\">and other\nchemotherapy </span>", "ID": "2402336d-5f9f-44a5-bc03-54aa9c424bf8", "Styles": "None", "Classes": "None", "Text": "and other chemotherapy ", "ParentId": "0b5983d0-9c2d-4fcc-adcc-e654052ce791"}, {"Element": "<span lang=\"EN-GB\">dose modifications, see </span>", "ID": "49aa1505-bc3e-449c-8fc7-f4185d72810b", "Styles": "None", "Classes": "None", "Text": "dose modifications, see ", "ParentId": "0b5983d0-9c2d-4fcc-adcc-e654052ce791"}, {"Element": "<span lang=\"EN-GB\">relevant</span>", "ID": "de521468-d5c2-48cd-9c66-a90e36f7efd9", "Styles": "None", "Classes": "None", "Text": "relevant", "ParentId": "0b5983d0-9c2d-4fcc-adcc-e654052ce791"}, {"Element": "<span lang=\"EN-GB\"> SmPC.</span>", "ID": "70901012-99c4-40b3-872d-96872b6b16d3", "Styles": "None", "Classes": "None", "Text": " SmPC.", "ParentId": "0b5983d0-9c2d-4fcc-adcc-e654052ce791"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d970644f-a6d2-4dce-bd9f-4cbaf4104c10", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8ef68284-46db-49bd-8321-90c6c6858860", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d970644f-a6d2-4dce-bd9f-4cbaf4104c10"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">If trastuzumab treatment is discontinued,\ntreatment with Perjeta should be discontinued. </span></p>", "ID": "00c875e1-1cbe-4884-8606-3e30546f28fa", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">If trastuzumab treatment is discontinued,\ntreatment with Perjeta should be discontinued. </span>", "ID": "10a33fa2-7b5c-4eac-a596-f082f19aa361", "Styles": "None", "Classes": "None", "Text": "If trastuzumab treatment is discontinued, treatment with Perjeta should be discontinued. ", "ParentId": "00c875e1-1cbe-4884-8606-3e30546f28fa"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2299438b-9c5f-4754-ae28-56f62478babd", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6fefd152-a466-4c21-a294-7ba544ad75cd", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2299438b-9c5f-4754-ae28-56f62478babd"}, {"Element": "<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">Left ventricular dysfunction </span></i></p>", "ID": "1f863047-e5dc-4fc4-9c55-453f6fe05070", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<i><span lang=\"EN-GB\">Left ventricular dysfunction </span></i>", "ID": "d5ffeced-a1ea-436d-81d2-e1a024a5bb4a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "1f863047-e5dc-4fc4-9c55-453f6fe05070"}, {"Element": "<span lang=\"EN-GB\">Left ventricular dysfunction </span>", "ID": "bf028244-84b5-411b-8a7b-c186b87f73fd", "Styles": "None", "Classes": "None", "Text": "Left ventricular dysfunction ", "ParentId": "d5ffeced-a1ea-436d-81d2-e1a024a5bb4a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Perjeta and trastuzumab should be withheld\nfor at least 3 <span style=\"color:black\">weeks for </span></span><span lang=\"EN-GB\" style=\"color:black\">any </span><span lang=\"EN-GB\">signs and symptoms\nsuggestive of congestive heart failure. Perjeta should be discontinued if\nsymptomatic heart failure is confirmed (see section 4.4 for more details).</span></p>", "ID": "f9f03bd9-6b5c-4289-ac01-709d891df0b4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Perjeta and trastuzumab should be withheld\nfor at least 3 <span style=\"color:black\">weeks for </span></span>", "ID": "3e70ff78-61b5-41ea-9aa6-46ee0eff36ce", "Styles": "None", "Classes": "None", "Text": "Perjeta and trastuzumab should be withheld for at least 3 ", "ParentId": "f9f03bd9-6b5c-4289-ac01-709d891df0b4"}, {"Element": "<span style=\"color:black\">weeks for </span>", "ID": "13e76145-b8e5-452d-96b0-c570f5a1ecba", "Styles": "color:black", "Classes": "None", "Text": "weeks for ", "ParentId": "3e70ff78-61b5-41ea-9aa6-46ee0eff36ce"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">any </span>", "ID": "5d6729fb-6761-4274-9da9-9741aac2c7cf", "Styles": "color:black", "Classes": "None", "Text": "any ", "ParentId": "f9f03bd9-6b5c-4289-ac01-709d891df0b4"}, {"Element": "<span lang=\"EN-GB\">signs and symptoms\nsuggestive of congestive heart failure. Perjeta should be discontinued if\nsymptomatic heart failure is confirmed (see section 4.4 for more details).</span>", "ID": "5768390b-a504-4d68-952c-a6d454c3565d", "Styles": "None", "Classes": "None", "Text": "signs and symptoms suggestive of congestive heart failure. Perjeta should be discontinued if symptomatic heart failure is confirmed (see section 4.4 for more details).", "ParentId": "f9f03bd9-6b5c-4289-ac01-709d891df0b4"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "bf9c2948-7491-495d-9884-7ab29609f6be", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "46666471-1524-4134-b63c-baadb0893023", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "bf9c2948-7491-495d-9884-7ab29609f6be"}, {"Element": "<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Patients with metastatic breast cancer</span></u></p>", "ID": "e16d3f3d-28ca-4aba-8531-06e653a84399", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<u><span lang=\"EN-GB\">Patients with metastatic breast cancer</span></u>", "ID": "9854c7ea-871a-49ac-8da3-15f423e0ee62", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e16d3f3d-28ca-4aba-8531-06e653a84399"}, {"Element": "<span lang=\"EN-GB\">Patients with metastatic breast cancer</span>", "ID": "6f0cfb68-1abb-4158-aab8-66bdbeef3ef2", "Styles": "None", "Classes": "None", "Text": "Patients with metastatic breast cancer", "ParentId": "9854c7ea-871a-49ac-8da3-15f423e0ee62"}, {"Element": "<p class=\"MsoNormal\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>", "ID": "ef00ceec-684a-425a-9fbd-babdc1fde66a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u>", "ID": "0a0f9fdf-5887-4c7d-afb8-1e7399a4059f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ef00ceec-684a-425a-9fbd-babdc1fde66a"}, {"Element": "<span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span>", "ID": "fa19bfaf-d50a-43d0-817c-fe5c06f3f6b6", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "0a0f9fdf-5887-4c7d-afb8-1e7399a4059f"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "456e4ea2-9806-4460-8c6e-941988ebe9f5", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "fa19bfaf-d50a-43d0-817c-fe5c06f3f6b6"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Patients should have a pre-treatment left\nventricular ejection fraction (LVEF) of \u2265 50%. Perjeta and trastuzumab\nshould be withheld for at least 3 weeks for:</span></p>", "ID": "c441af03-2927-457b-907d-843c7ea14f0a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Patients should have a pre-treatment left\nventricular ejection fraction (LVEF) of \u2265 50%. Perjeta and trastuzumab\nshould be withheld for at least 3 weeks for:</span>", "ID": "cc373fe1-3b31-404b-be12-a3b27e2aefd7", "Styles": "None", "Classes": "None", "Text": "Patients should have a pre-treatment left ventricular ejection fraction (LVEF) of \u2265 50%. Perjeta and trastuzumab should be withheld for at least 3 weeks for:", "ParentId": "c441af03-2927-457b-907d-843c7ea14f0a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b0004fcf-f952-4b57-9025-23629bccbb48", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9a511ad6-1bf1-48bd-986c-906ba40a7f2d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b0004fcf-f952-4b57-9025-23629bccbb48"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:35.7pt;text-indent:-17.85pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0 a drop in\nLVEF to less than 40% </span></p>", "ID": "e63387b4-80b2-469d-ad06-0ef57638d6d2", "Styles": "margin-left:35.7pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "a3cab334-f912-4684-beaa-04ebe62bcad2", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "e63387b4-80b2-469d-ad06-0ef57638d6d2"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0 a drop in\nLVEF to less than 40% </span>", "ID": "cdcc96c5-c006-4339-9f57-7f028b81ef3f", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 a drop in LVEF to less than 40% ", "ParentId": "e63387b4-80b2-469d-ad06-0ef57638d6d2"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:35.7pt;text-indent:-17.85pt\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9fc85a41-953e-49d3-aa90-eea791cd586b", "Styles": "margin-left:35.7pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b24f684e-f138-4ca6-b233-824288b72185", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9fc85a41-953e-49d3-aa90-eea791cd586b"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:35.7pt;text-indent:-17.85pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0 a LVEF of\n40%-45% associated with a fall of \u2265\u00a010% points below pre-treatment\nvalue.</span></p>", "ID": "542df140-ba47-4e5e-8444-584b3107c102", "Styles": "margin-left:35.7pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "55b3256b-76ec-4c85-a4a2-001528b57b75", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "542df140-ba47-4e5e-8444-584b3107c102"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0 a LVEF of\n40%-45% associated with a fall of \u2265\u00a010% points below pre-treatment\nvalue.</span>", "ID": "2853b989-596c-44b7-a817-e8fd4c9b1e4a", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 a LVEF of 40%-45% associated with a fall of \u2265\u00a010% points below pre-treatment value.", "ParentId": "542df140-ba47-4e5e-8444-584b3107c102"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9383c401-41d4-4a3e-937d-629d07ab739f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f10e69ed-da4e-4971-aab4-024d554be166", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9383c401-41d4-4a3e-937d-629d07ab739f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Perjeta and trastuzumab may be resumed if\nthe LVEF has recovered to &gt;\u00a045%, or to 40-45% associated with a\ndifference of &lt;\u00a010% points below pre-treatment values. </span></p>", "ID": "2d4778a3-b22c-42cb-a6af-09fa5bcdfd3f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Perjeta and trastuzumab may be resumed if\nthe LVEF has recovered to &gt;\u00a045%, or to 40-45% associated with a\ndifference of &lt;\u00a010% points below pre-treatment values. </span>", "ID": "f6461bee-1f75-4086-a531-5bd104a144f8", "Styles": "None", "Classes": "None", "Text": "Perjeta and trastuzumab may be resumed if the LVEF has recovered to >\u00a045%, or to 40-45% associated with a difference of <\u00a010% points below pre-treatment values. ", "ParentId": "2d4778a3-b22c-42cb-a6af-09fa5bcdfd3f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "edcbd2dc-205a-4ebc-a2a9-f932511e7cc2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0da24fc3-82ab-4e9d-b00e-ec0304789029", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "edcbd2dc-205a-4ebc-a2a9-f932511e7cc2"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Patients\nwith early breast cancer</span></u></p>", "ID": "a7336673-46b7-4f7d-881d-08e80ead791e", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<u><span lang=\"EN-GB\">Patients\nwith early breast cancer</span></u>", "ID": "4c1fc7ac-04aa-4aca-bc29-60003c7f7639", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a7336673-46b7-4f7d-881d-08e80ead791e"}, {"Element": "<span lang=\"EN-GB\">Patients\nwith early breast cancer</span>", "ID": "0adbb7fd-72a9-49e9-96a5-885af776af42", "Styles": "None", "Classes": "None", "Text": "Patients with early breast cancer", "ParentId": "4c1fc7ac-04aa-4aca-bc29-60003c7f7639"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>", "ID": "d866747d-44c5-4772-84da-162773642dd5", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u>", "ID": "b67ec51b-aed3-4fb9-bb23-415cb131c38f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d866747d-44c5-4772-84da-162773642dd5"}, {"Element": "<span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span>", "ID": "d9ecc133-e502-4b8a-a90e-722ef0ae93ed", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b67ec51b-aed3-4fb9-bb23-415cb131c38f"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "08757b68-b9e8-40e9-aa2c-a973f1974b00", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "d9ecc133-e502-4b8a-a90e-722ef0ae93ed"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Patients\nshould have a pre-treatment LVEF of \u2265 55% (\u2265 50% after completion\nof the anthracycline component of chemotherapy, if given). Perjeta and\ntrastuzumab should be withheld for at least 3 weeks for: </span></p>", "ID": "4007a80e-d1fb-4814-b65a-a55e9c2c22cd", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Patients\nshould have a pre-treatment LVEF of \u2265 55% (\u2265 50% after completion\nof the anthracycline component of chemotherapy, if given). Perjeta and\ntrastuzumab should be withheld for at least 3 weeks for: </span>", "ID": "88fc1141-6870-4fb0-ac6d-b79c1610838b", "Styles": "None", "Classes": "None", "Text": "Patients should have a pre-treatment LVEF of \u2265 55% (\u2265 50% after completion of the anthracycline component of chemotherapy, if given). Perjeta and trastuzumab should be withheld for at least 3 weeks for: ", "ParentId": "4007a80e-d1fb-4814-b65a-a55e9c2c22cd"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "769bbd92-2464-4b80-bc48-99d0a1ff4322", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1a02e110-ca6e-4675-9e20-2f69da6ad9d0", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "769bbd92-2464-4b80-bc48-99d0a1ff4322"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:35.7pt;text-indent:-17.85pt;page-break-after:\navoid\"><span style=\"font-family:Symbol;color:black\">\u00b7</span><span lang=\"BG\" style=\"color:black\">\u00a0\u00a0\u00a0 </span><span lang=\"EN-GB\">a drop in LVEF to less than 50%\nassociated with a fall of\u00a0 \u2265 10% points below pre-treatment values.</span></p>", "ID": "3fed4cfd-22bc-4909-b5e9-4f831b8af672", "Styles": "margin-left:35.7pt;text-indent:-17.85pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span style=\"font-family:Symbol;color:black\">\u00b7</span>", "ID": "62ec447e-22af-4dfa-ae24-5c8ecb4bd564", "Styles": "font-family:Symbol;color:black", "Classes": "None", "Text": "\u00b7", "ParentId": "3fed4cfd-22bc-4909-b5e9-4f831b8af672"}, {"Element": "<span lang=\"BG\" style=\"color:black\">\u00a0\u00a0\u00a0 </span>", "ID": "d75987f0-8947-4919-a42a-00d6e595ceea", "Styles": "color:black", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "3fed4cfd-22bc-4909-b5e9-4f831b8af672"}, {"Element": "<span lang=\"EN-GB\">a drop in LVEF to less than 50%\nassociated with a fall of\u00a0 \u2265 10% points below pre-treatment values.</span>", "ID": "b30519cb-1c86-4e73-af49-2b81b66a6e91", "Styles": "None", "Classes": "None", "Text": "a drop in LVEF to less than 50% associated with a fall of\u00a0 \u2265 10% points below pre-treatment values.", "ParentId": "3fed4cfd-22bc-4909-b5e9-4f831b8af672"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "688a4975-5fc7-4b4c-9ea9-e5168bab3d69", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "95b9d2f2-1079-4c00-a484-2221ad201891", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "688a4975-5fc7-4b4c-9ea9-e5168bab3d69"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Perjeta and trastuzumab may be resumed if\nthe LVEF has recovered to \u226550% or to a difference of &lt;\u00a010% points\nbelow pre-treatment values. </span></p>", "ID": "1a0c6cc0-fc75-4456-b88d-6c3bd0fbb7e0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Perjeta and trastuzumab may be resumed if\nthe LVEF has recovered to \u226550% or to a difference of &lt;\u00a010% points\nbelow pre-treatment values. </span>", "ID": "bb265752-b02a-43a3-b793-cb5c20213c9b", "Styles": "None", "Classes": "None", "Text": "Perjeta and trastuzumab may be resumed if the LVEF has recovered to \u226550% or to a difference of <\u00a010% points below pre-treatment values. ", "ParentId": "1a0c6cc0-fc75-4456-b88d-6c3bd0fbb7e0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "618cf44d-68ae-4bfc-a560-5d956cbec2e2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0b10b4ba-9831-48c2-a534-c42cc99eef30", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "618cf44d-68ae-4bfc-a560-5d956cbec2e2"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Elderly\npatients</span></i></p>", "ID": "06e3c9c9-b474-4897-bcbf-459a6984f705", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<i><span lang=\"EN-GB\">Elderly\npatients</span></i>", "ID": "a730a268-aac7-4ee6-a43d-cd68eca29911", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "06e3c9c9-b474-4897-bcbf-459a6984f705"}, {"Element": "<span lang=\"EN-GB\">Elderly\npatients</span>", "ID": "651d2374-a505-459d-97fe-b9d529499205", "Styles": "None", "Classes": "None", "Text": "Elderly patients", "ParentId": "a730a268-aac7-4ee6-a43d-cd68eca29911"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">No overall differences in efficacy\nof Perjeta were observed in patients \u2265 65 and &lt; 65 years of age. <span lang=\"EN-GB\">No dose adjustment is necessary in the elderly population \u2265\u00a065\nyears of age. Limited data are available in patients &gt;\u00a075 years of age.\nPlease see section 4.8 for assessment of safety of Perjeta in elderly patients.</span></p>", "ID": "17a46dc0-910a-4fd3-926f-233fe43640a0", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "No overall differences in efficacy of Perjeta were observed in patients \u2265 65 and < 65 years of age. ", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">No dose adjustment is necessary in the elderly population \u2265\u00a065\nyears of age. Limited data are available in patients &gt;\u00a075 years of age.\nPlease see section 4.8 for assessment of safety of Perjeta in elderly patients.</span>", "ID": "17b06a37-15b5-4e91-b2fe-05694ac3ad7b", "Styles": "None", "Classes": "None", "Text": "No dose adjustment is necessary in the elderly population \u2265\u00a065 years of age. Limited data are available in patients >\u00a075 years of age. Please see section 4.8 for assessment of safety of Perjeta in elderly patients.", "ParentId": "17a46dc0-910a-4fd3-926f-233fe43640a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "34d643a8-c696-4bc7-a1c5-cc5c5c8422be", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "119b0bfa-383d-4a98-affa-ce03a80f83d4", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "34d643a8-c696-4bc7-a1c5-cc5c5c8422be"}, {"Element": "<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">Renal impairment</span></i></p>", "ID": "2c483061-53e3-4bf9-a560-1e4f2140070d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<i><span lang=\"EN-GB\">Renal impairment</span></i>", "ID": "c4180aa2-ad4f-4dfc-bf8c-577c34489a0f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "2c483061-53e3-4bf9-a560-1e4f2140070d"}, {"Element": "<span lang=\"EN-GB\">Renal impairment</span>", "ID": "30bc6e1a-39cc-4f82-8f51-f00dc5574c8c", "Styles": "None", "Classes": "None", "Text": "Renal impairment", "ParentId": "c4180aa2-ad4f-4dfc-bf8c-577c34489a0f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Dose adjustments of pertuzumab are not\nneeded in patients with mild or moderate renal impairment. No dose\nrecommendations can be made for patients with severe renal impairment because\nof the limited pharmacokinetic data available (see section 5.2).</span></p>", "ID": "b14869c7-e3d9-4269-94f1-12fa94969eae", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Dose adjustments of pertuzumab are not\nneeded in patients with mild or moderate renal impairment. No dose\nrecommendations can be made for patients with severe renal impairment because\nof the limited pharmacokinetic data available (see section 5.2).</span>", "ID": "97a34426-0553-4d30-b7b9-014e964f9f2f", "Styles": "None", "Classes": "None", "Text": "Dose adjustments of pertuzumab are not needed in patients with mild or moderate renal impairment. No dose recommendations can be made for patients with severe renal impairment because of the limited pharmacokinetic data available (see section 5.2).", "ParentId": "b14869c7-e3d9-4269-94f1-12fa94969eae"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "be188d29-113f-4af6-bd9d-c7350961678b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1038f096-a57b-4402-bcd7-217d696cfb62", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "be188d29-113f-4af6-bd9d-c7350961678b"}, {"Element": "<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">Hepatic impairment</span></i></p>", "ID": "d131025f-f0d6-4147-88e2-9e1eacc3e310", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<i><span lang=\"EN-GB\">Hepatic impairment</span></i>", "ID": "88301e54-7325-40d0-b8dd-9e8483aafc20", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d131025f-f0d6-4147-88e2-9e1eacc3e310"}, {"Element": "<span lang=\"EN-GB\">Hepatic impairment</span>", "ID": "7c71d616-dc45-4bef-b4ad-40454e808a27", "Styles": "None", "Classes": "None", "Text": "Hepatic impairment", "ParentId": "88301e54-7325-40d0-b8dd-9e8483aafc20"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The safety and efficacy of Perjeta have not\nbeen studied in patients with hepatic impairment.\u00a0 No specific dose\nrecommendations can be made.</span></p>", "ID": "ab51920b-7c8d-4cf2-9561-0cba86d28cd7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">The safety and efficacy of Perjeta have not\nbeen studied in patients with hepatic impairment.\u00a0 No specific dose\nrecommendations can be made.</span>", "ID": "469bd7c4-9dac-418e-b2ca-e8de9d9a9dc6", "Styles": "None", "Classes": "None", "Text": "The safety and efficacy of Perjeta have not been studied in patients with hepatic impairment.\u00a0 No specific dose recommendations can be made.", "ParentId": "ab51920b-7c8d-4cf2-9561-0cba86d28cd7"}, {"Element": "<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">\u00a0</span></i></p>", "ID": "c511a355-1f0f-43d5-b1f3-158fcc38e749", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<i><span lang=\"EN-GB\">\u00a0</span></i>", "ID": "349ecab1-6b53-42ea-864b-e0d4a42a4599", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c511a355-1f0f-43d5-b1f3-158fcc38e749"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e1247d90-bab9-469c-865d-fbfa28ce123e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "349ecab1-6b53-42ea-864b-e0d4a42a4599"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Paediatric\npopulation</span></i></p>", "ID": "5e03125b-800e-4137-aa9f-a0ff6a285fa7", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<i><span lang=\"EN-GB\">Paediatric\npopulation</span></i>", "ID": "366c3f42-4577-44f3-8d7c-0a684bda418a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "5e03125b-800e-4137-aa9f-a0ff6a285fa7"}, {"Element": "<span lang=\"EN-GB\">Paediatric\npopulation</span>", "ID": "11d5b1f2-3ff8-406c-a0c4-960d4650baf6", "Styles": "None", "Classes": "None", "Text": "Paediatric population", "ParentId": "366c3f42-4577-44f3-8d7c-0a684bda418a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The safety and efficacy of Perjeta in\nchildren and adolescents below 18 years of age have not been established.</span><span lang=\"EN-GB\"> There is no relevant use of Perjeta in the paediatric population in\nthe indication of breast cancer.</span></p>", "ID": "53a2f4c2-8b22-4ff1-b9c1-7862b4121642", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">The safety and efficacy of Perjeta in\nchildren and adolescents below 18 years of age have not been established.</span>", "ID": "10b5ea50-d82e-4085-bc01-92ee5173af68", "Styles": "None", "Classes": "None", "Text": "The safety and efficacy of Perjeta in children and adolescents below 18 years of age have not been established.", "ParentId": "53a2f4c2-8b22-4ff1-b9c1-7862b4121642"}, {"Element": "<span lang=\"EN-GB\"> There is no relevant use of Perjeta in the paediatric population in\nthe indication of breast cancer.</span>", "ID": "077217f3-8fd6-4346-a0eb-a8b8bc5d206d", "Styles": "None", "Classes": "None", "Text": " There is no relevant use of Perjeta in the paediatric population in the indication of breast cancer.", "ParentId": "53a2f4c2-8b22-4ff1-b9c1-7862b4121642"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6a80c661-167c-405e-8270-d11f92064c55", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "093362d3-93fb-4934-a83b-7839c5efa277", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6a80c661-167c-405e-8270-d11f92064c55"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\" style=\"color:black\">Method of administration</span></u></p>", "ID": "4d912d8c-1843-4bb2-947f-58aeb69fd619", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<u><span lang=\"EN-GB\" style=\"color:black\">Method of administration</span></u>", "ID": "89a45017-5e1b-4d35-bda6-9805ac976089", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4d912d8c-1843-4bb2-947f-58aeb69fd619"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Method of administration</span>", "ID": "4ea33f61-2e80-4919-ade6-2bfabf9ea72c", "Styles": "color:black", "Classes": "None", "Text": "Method of administration", "ParentId": "89a45017-5e1b-4d35-bda6-9805ac976089"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><i><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></i></p>", "ID": "8c2c8df8-15d3-419b-be24-65c79c519de9", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<i><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></i>", "ID": "2080e7e5-c6e0-497a-b77a-cea6caf46954", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8c2c8df8-15d3-419b-be24-65c79c519de9"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">\u00a0</span>", "ID": "624c5444-70a0-4681-bea0-d5c0fbe9bd68", "Styles": "color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "2080e7e5-c6e0-497a-b77a-cea6caf46954"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Perjeta is administered intravenously by\ninfusion. It should not be administered as an intravenous push or bolus. For\ninstructions on dilution of Perjeta prior to administration, see sections 6.2\nand 6.6.</span></p>", "ID": "156dc4a3-6701-40cb-8e03-7f12c0fd809f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Perjeta is administered intravenously by\ninfusion. It should not be administered as an intravenous push or bolus. For\ninstructions on dilution of Perjeta prior to administration, see sections 6.2\nand 6.6.</span>", "ID": "2937928c-f337-458d-8f7c-e1755fd9331c", "Styles": "None", "Classes": "None", "Text": "Perjeta is administered intravenously by infusion. It should not be administered as an intravenous push or bolus. For instructions on dilution of Perjeta prior to administration, see sections 6.2 and 6.6.", "ParentId": "156dc4a3-6701-40cb-8e03-7f12c0fd809f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a1755270-798a-4a9a-b040-e9058f5f549a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "711f11b1-ace7-465f-941e-fd72f186748c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a1755270-798a-4a9a-b040-e9058f5f549a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">For the initial dose, the recommended\ninfusion period is 60 minutes. If the first infusion is well tolerated,\nsubsequent infusions may be administered over a period of 30 minutes to 60\nminutes (see section 4.4).</span></p>", "ID": "67e79d20-6422-4f99-8920-64621df54494", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">For the initial dose, the recommended\ninfusion period is 60 minutes. If the first infusion is well tolerated,\nsubsequent infusions may be administered over a period of 30 minutes to 60\nminutes (see section 4.4).</span>", "ID": "71db9338-8706-4f2c-b373-cb036b024e18", "Styles": "None", "Classes": "None", "Text": "For the initial dose, the recommended infusion period is 60 minutes. If the first infusion is well tolerated, subsequent infusions may be administered over a period of 30 minutes to 60 minutes (see section 4.4).", "ParentId": "67e79d20-6422-4f99-8920-64621df54494"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "dcb2bea0-6ef1-48f1-9bda-bf9523e1b0c7", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1e9e764f-025f-46ce-9f36-c790bfe0cd4d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "dcb2bea0-6ef1-48f1-9bda-bf9523e1b0c7"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Infusion\nreactions</span></i></p>", "ID": "3dc62244-beff-414e-b450-f7b1e2e2668b", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<i><span lang=\"EN-GB\">Infusion\nreactions</span></i>", "ID": "4a354172-85e7-46a6-83ca-7c6b1afdf18c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3dc62244-beff-414e-b450-f7b1e2e2668b"}, {"Element": "<span lang=\"EN-GB\">Infusion\nreactions</span>", "ID": "71cea569-7bb0-42ea-a406-fd51fcb8e680", "Styles": "None", "Classes": "None", "Text": "Infusion reactions", "ParentId": "4a354172-85e7-46a6-83ca-7c6b1afdf18c"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">\u00a0</span></i></p>", "ID": "ea9101e0-23b1-496b-a8d9-fdf78623df8f", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<i><span lang=\"EN-GB\">\u00a0</span></i>", "ID": "460bd1e5-fe44-4265-9392-d3aa5dbebd2c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ea9101e0-23b1-496b-a8d9-fdf78623df8f"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b18cc3fe-8834-42f2-877d-e89989633af8", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "460bd1e5-fe44-4265-9392-d3aa5dbebd2c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The infusion rate may be slowed or\ninterrupted if the patient develops an infusion reaction (see section 4.8). The\ninfusion may be resumed when symptoms abate. Treatment including oxygen, beta\nagonists, antihistamines, rapid i.v. fluids and antipyretics may also help\nalleviate symptoms. </span></p>", "ID": "53b309bb-b353-45bc-b35e-89c92b78466b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">The infusion rate may be slowed or\ninterrupted if the patient develops an infusion reaction (see section 4.8). The\ninfusion may be resumed when symptoms abate. Treatment including oxygen, beta\nagonists, antihistamines, rapid i.v. fluids and antipyretics may also help\nalleviate symptoms. </span>", "ID": "53ddc579-d408-44a6-add4-d7c936fccbcb", "Styles": "None", "Classes": "None", "Text": "The infusion rate may be slowed or interrupted if the patient develops an infusion reaction (see section 4.8). The infusion may be resumed when symptoms abate. Treatment including oxygen, beta agonists, antihistamines, rapid i.v. fluids and antipyretics may also help alleviate symptoms. ", "ParentId": "53b309bb-b353-45bc-b35e-89c92b78466b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "50919aea-a9a4-4c7b-be87-f40f5887e2fe", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e9caf312-a86b-4927-9002-2ddd1c73f1b7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "50919aea-a9a4-4c7b-be87-f40f5887e2fe"}, {"Element": "<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">Hypersensitivity reactions/anaphylaxis </span></i></p>", "ID": "4e47acc9-6811-4db9-be87-24653cf0662c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<i><span lang=\"EN-GB\">Hypersensitivity reactions/anaphylaxis </span></i>", "ID": "a5c554cd-44f1-4fab-9959-7bee81977f0d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4e47acc9-6811-4db9-be87-24653cf0662c"}, {"Element": "<span lang=\"EN-GB\">Hypersensitivity reactions/anaphylaxis </span>", "ID": "9f14f10d-345a-402c-870d-f48b52b0e576", "Styles": "None", "Classes": "None", "Text": "Hypersensitivity reactions/anaphylaxis ", "ParentId": "a5c554cd-44f1-4fab-9959-7bee81977f0d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5d8b5a44-6997-4664-bb11-851edbe97fe6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c0609798-4fd9-4bd7-b316-d997d6833bb4", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5d8b5a44-6997-4664-bb11-851edbe97fe6"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The infusion should be discontinued\nimmediately and permanently if the patient experiences a NCI-CTCAE Grade 4\nreaction (anaphylaxis), </span><span lang=\"EN-GB\">bronchospasm or acute\nrespiratory distress syndrome (see section 4.4).</span></p>", "ID": "7f531b0b-c41e-4e76-97c4-70a774b734c9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">The infusion should be discontinued\nimmediately and permanently if the patient experiences a NCI-CTCAE Grade 4\nreaction (anaphylaxis), </span>", "ID": "3de909d0-6876-4d15-96f0-31d61fca463d", "Styles": "None", "Classes": "None", "Text": "The infusion should be discontinued immediately and permanently if the patient experiences a NCI-CTCAE Grade 4 reaction (anaphylaxis), ", "ParentId": "7f531b0b-c41e-4e76-97c4-70a774b734c9"}, {"Element": "<span lang=\"EN-GB\">bronchospasm or acute\nrespiratory distress syndrome (see section 4.4).</span>", "ID": "ab9b780e-5445-48dc-8baa-60fde3577054", "Styles": "None", "Classes": "None", "Text": "bronchospasm or acute respiratory distress syndrome (see section 4.4).", "ParentId": "7f531b0b-c41e-4e76-97c4-70a774b734c9"}, {"Element": "<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">\u00a0</span></i></p>", "ID": "4b4f23e7-bd40-4bcb-bcaf-e44e3a29a01f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<i><span lang=\"EN-GB\">\u00a0</span></i>", "ID": "6f9e8ecc-3f21-4743-af14-576fa849b909", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4b4f23e7-bd40-4bcb-bcaf-e44e3a29a01f"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "588b8b05-aa59-4b4e-b87a-38ea9fc6e0ee", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6f9e8ecc-3f21-4743-af14-576fa849b909"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">4.3\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Contraindications</span></b></p>", "ID": "83b140de-78b7-4ec1-8d7d-461c0459b2ad", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">4.3\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Contraindications</span></b>", "ID": "5bbdb442-2330-4c02-9961-35105780555b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "83b140de-78b7-4ec1-8d7d-461c0459b2ad"}, {"Element": "<span lang=\"EN-GB\">4.3\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Contraindications</span>", "ID": "1f050abb-f5fc-4ee3-93fd-21382aee0e09", "Styles": "None", "Classes": "None", "Text": "4.3\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Contraindications", "ParentId": "5bbdb442-2330-4c02-9961-35105780555b"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "7de5bcf4-436a-40f4-958e-cd3b711a93f1", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "0c9272e4-8233-45ba-8deb-623e51c96a88", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "7de5bcf4-436a-40f4-958e-cd3b711a93f1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "907e9234-28a7-4a5a-9388-4c53d41537f6", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0c9272e4-8233-45ba-8deb-623e51c96a88"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Hypersensitivity\nto the active substance or to any of the excipients listed in section 6.1.</span></p>", "ID": "6c504c23-bce4-4fad-809e-513b5d3d88b4", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Hypersensitivity\nto the active substance or to any of the excipients listed in section 6.1.</span>", "ID": "b56c0f04-3e81-4299-a790-2b803d67e7d5", "Styles": "None", "Classes": "None", "Text": "Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.", "ParentId": "6c504c23-bce4-4fad-809e-513b5d3d88b4"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a5bc5b8c-3da8-4420-afcb-7578fb341818", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4e47a96b-9176-4398-98dc-e6ee38681046", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a5bc5b8c-3da8-4420-afcb-7578fb341818"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">4.4\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Special\nwarnings and precautions for use</span></b><b><span lang=\"EN-GB\"> </span></b></p>", "ID": "cac9596b-9c50-4d88-9356-00cfbffa42c0", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">4.4\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Special\nwarnings and precautions for use</span></b>", "ID": "0ac40c8c-e4d0-4fba-964b-2984c7d0002b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "cac9596b-9c50-4d88-9356-00cfbffa42c0"}, {"Element": "<span lang=\"EN-GB\">4.4\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Special\nwarnings and precautions for use</span>", "ID": "3f704e08-8332-454b-a136-6d87b26740b8", "Styles": "None", "Classes": "None", "Text": "4.4\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Special warnings and precautions for use", "ParentId": "0ac40c8c-e4d0-4fba-964b-2984c7d0002b"}, {"Element": "<b><span lang=\"EN-GB\"> </span></b>", "ID": "3138402d-73af-4541-bb27-e2701d75aaef", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "cac9596b-9c50-4d88-9356-00cfbffa42c0"}, {"Element": "<span lang=\"EN-GB\"> </span>", "ID": "2e6b4b6e-917a-44e4-8cc3-a3a5cc469d16", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "3138402d-73af-4541-bb27-e2701d75aaef"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2f3e0d44-a821-43c2-8330-e9d64f6a3187", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e07d2811-600b-4173-9fc3-046da64ce66d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2f3e0d44-a821-43c2-8330-e9d64f6a3187"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Traceability</span></u></p>", "ID": "bd5780ad-1c6f-42e2-bda1-e335da1746b2", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<u><span lang=\"EN-GB\">Traceability</span></u>", "ID": "fa1d2e7c-ad2f-4010-bf85-8e5d8ba101b6", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "bd5780ad-1c6f-42e2-bda1-e335da1746b2"}, {"Element": "<span lang=\"EN-GB\">Traceability</span>", "ID": "e49f8bb0-c2c1-418a-a9ba-f50d935b9a2a", "Styles": "None", "Classes": "None", "Text": "Traceability", "ParentId": "fa1d2e7c-ad2f-4010-bf85-8e5d8ba101b6"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3ef9cc45-6293-49f8-85b5-69a0680459a2", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9389cf73-75b1-4087-ab60-7e9b84f1eace", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3ef9cc45-6293-49f8-85b5-69a0680459a2"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In order to improve the traceability of\nbiological medicinal products, the name and batch number of the administered\nproduct should be clearly recorded.</span></p>", "ID": "ee116511-673f-4946-8e59-078596f59f35", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">In order to improve the traceability of\nbiological medicinal products, the name and batch number of the administered\nproduct should be clearly recorded.</span>", "ID": "cae631ee-066d-47f6-bdbc-84decc9c44d9", "Styles": "None", "Classes": "None", "Text": "In order to improve the traceability of biological medicinal products, the name and batch number of the administered product should be clearly recorded.", "ParentId": "ee116511-673f-4946-8e59-078596f59f35"}, {"Element": "<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">\u00a0</span></i></p>", "ID": "3974ae94-bd6b-421e-8b24-88107cf68662", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<i><span lang=\"EN-GB\">\u00a0</span></i>", "ID": "9f33ccc8-ebda-4df3-91b4-1f692afd63b3", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3974ae94-bd6b-421e-8b24-88107cf68662"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4b0e47c7-afb2-43ab-bfaa-fe91245ada0f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9f33ccc8-ebda-4df3-91b4-1f692afd63b3"}, {"Element": "<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Left ventricular dysfunction (including\ncongestive heart failure)</span></u></p>", "ID": "63bdeddd-f633-4e7b-867c-8bd5870fb98e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<u><span lang=\"EN-GB\">Left ventricular dysfunction (including\ncongestive heart failure)</span></u>", "ID": "0105325d-8dc4-4ce7-92f8-4cfa6c806343", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "63bdeddd-f633-4e7b-867c-8bd5870fb98e"}, {"Element": "<span lang=\"EN-GB\">Left ventricular dysfunction (including\ncongestive heart failure)</span>", "ID": "c20b8c5e-9bf7-4d9a-93f9-adeac4330ffd", "Styles": "None", "Classes": "None", "Text": "Left ventricular dysfunction (including congestive heart failure)", "ParentId": "0105325d-8dc4-4ce7-92f8-4cfa6c806343"}, {"Element": "<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">\u00a0</span></i></p>", "ID": "7985e015-3b67-45ee-9c75-7b99eb058729", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<i><span lang=\"EN-GB\">\u00a0</span></i>", "ID": "9a298909-7075-413d-8f0f-fba33908876e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "7985e015-3b67-45ee-9c75-7b99eb058729"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2d5c2f85-4159-42ba-999b-df56a13547f6", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9a298909-7075-413d-8f0f-fba33908876e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Decreases in LVEF have been reported with\nmedicinal products that block HER2 activity, including Perjeta. The incidence\nof symptomatic left ventricular systolic dysfunction (LVD) [congestive heart\nfailure] was higher in patients treated with Perjeta in combination with trastuzumab\nand chemotherapy compared with trastuzumab and chemotherapy . Patients who have\nreceived prior anthracyclines or prior radiotherapy to the chest area may be at\nhigher risk of LVEF declines. The majority of cases of symptomatic heart\nfailure reported in the adjuvant setting were in patients who received\nanthracycline-based chemotherapy (see section 4.8).</span></p>", "ID": "49b8d7c5-cb1a-42dd-bff3-a774f0b9eefb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Decreases in LVEF have been reported with\nmedicinal products that block HER2 activity, including Perjeta. The incidence\nof symptomatic left ventricular systolic dysfunction (LVD) [congestive heart\nfailure] was higher in patients treated with Perjeta in combination with trastuzumab\nand chemotherapy compared with trastuzumab and chemotherapy . Patients who have\nreceived prior anthracyclines or prior radiotherapy to the chest area may be at\nhigher risk of LVEF declines. The majority of cases of symptomatic heart\nfailure reported in the adjuvant setting were in patients who received\nanthracycline-based chemotherapy (see section 4.8).</span>", "ID": "efb8b7dd-4965-42c4-8da9-8d32455033f3", "Styles": "None", "Classes": "None", "Text": "Decreases in LVEF have been reported with medicinal products that block HER2 activity, including Perjeta. The incidence of symptomatic left ventricular systolic dysfunction (LVD) [congestive heart failure] was higher in patients treated with Perjeta in combination with trastuzumab and chemotherapy compared with trastuzumab and chemotherapy . Patients who have received prior anthracyclines or prior radiotherapy to the chest area may be at higher risk of LVEF declines. The majority of cases of symptomatic heart failure reported in the adjuvant setting were in patients who received anthracycline-based chemotherapy (see section 4.8).", "ParentId": "49b8d7c5-cb1a-42dd-bff3-a774f0b9eefb"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0faaa34c-1384-4278-9d99-f0d7d3d30288", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d23f8098-b3c1-409d-b49d-4c5ddf6ccadc", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0faaa34c-1384-4278-9d99-f0d7d3d30288"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Perjeta</span><span lang=\"EN-GB\"> has not\nbeen studied in patients with:\u00a0a pre-treatment LVEF value of &lt;\u00a050%;\na prior history of congestive heart failure (CHF); LVEF declines to &lt;\u00a050%\nduring prior trastuzumab adjuvant therapy; or conditions that could impair left\nventricular function such as uncontrolled hypertension, recent myocardial\ninfarction, serious cardiac arrhythmia requiring treatment or a cumulative\nprior anthracycline exposure to &gt;\u00a0360\u00a0mg/m<sup>2</sup> of\ndoxorubicin or its equivalent.</span></p>", "ID": "95ae601a-a254-4a51-882f-b28b5a1caa3b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Perjeta</span>", "ID": "a49351a5-d703-48c1-802d-7c177f5a4275", "Styles": "None", "Classes": "None", "Text": "Perjeta", "ParentId": "95ae601a-a254-4a51-882f-b28b5a1caa3b"}, {"Element": "<span lang=\"EN-GB\"> has not\nbeen studied in patients with:\u00a0a pre-treatment LVEF value of &lt;\u00a050%;\na prior history of congestive heart failure (CHF); LVEF declines to &lt;\u00a050%\nduring prior trastuzumab adjuvant therapy; or conditions that could impair left\nventricular function such as uncontrolled hypertension, recent myocardial\ninfarction, serious cardiac arrhythmia requiring treatment or a cumulative\nprior anthracycline exposure to &gt;\u00a0360\u00a0mg/m<sup>2</sup> of\ndoxorubicin or its equivalent.</span>", "ID": "22edb650-45ab-4cc3-af8b-aa8a9fbb4121", "Styles": "None", "Classes": "None", "Text": " has not been studied in patients with:\u00a0a pre-treatment LVEF value of <\u00a050%; a prior history of congestive heart failure (CHF); LVEF declines to <\u00a050% during prior trastuzumab adjuvant therapy; or conditions that could impair left ventricular function such as uncontrolled hypertension, recent myocardial infarction, serious cardiac arrhythmia requiring treatment or a cumulative prior anthracycline exposure to >\u00a0360\u00a0mg/m of doxorubicin or its equivalent.", "ParentId": "95ae601a-a254-4a51-882f-b28b5a1caa3b"}, {"Element": "<sup>2</sup>", "ID": "39c7002c-2fd8-4412-bf02-9610830406fa", "Styles": "None", "Classes": "None", "Text": "2", "ParentId": "22edb650-45ab-4cc3-af8b-aa8a9fbb4121"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "01d28135-a507-43d8-ae07-ae5060009c39", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7c6b7f04-5076-415c-a560-c58f16734795", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "01d28135-a507-43d8-ae07-ae5060009c39"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Assess LVEF prior to initiation of Perjeta\nand at regular intervals during treatment </span><span lang=\"EN-GB\">with Perjeta\n(e.g. once during neoadjuvant treatment and every 12 weeks in the adjuvant or\nmetastatic setting) </span><span lang=\"EN-GB\">to ensure that LVEF is within\nnormal limits. If the LVEF has declined as indicated in section 4.2 and has not\nimproved, or has declined further at the subsequent assessment, discontinuation\nof Perjeta and trastuzumab should be strongly considered, unless the benefits\nfor the individual patient are deemed to outweigh the risks. </span></p>", "ID": "d30be59c-85b8-4d4b-97ef-de5f0780a0cb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Assess LVEF prior to initiation of Perjeta\nand at regular intervals during treatment </span>", "ID": "90b4a346-658b-4faf-8f99-b490a703fbf7", "Styles": "None", "Classes": "None", "Text": "Assess LVEF prior to initiation of Perjeta and at regular intervals during treatment ", "ParentId": "d30be59c-85b8-4d4b-97ef-de5f0780a0cb"}, {"Element": "<span lang=\"EN-GB\">with Perjeta\n(e.g. once during neoadjuvant treatment and every 12 weeks in the adjuvant or\nmetastatic setting) </span>", "ID": "caa58770-6be7-4e02-889e-7b1425ce19dc", "Styles": "None", "Classes": "None", "Text": "with Perjeta (e.g. once during neoadjuvant treatment and every 12 weeks in the adjuvant or metastatic setting) ", "ParentId": "d30be59c-85b8-4d4b-97ef-de5f0780a0cb"}, {"Element": "<span lang=\"EN-GB\">to ensure that LVEF is within\nnormal limits. If the LVEF has declined as indicated in section 4.2 and has not\nimproved, or has declined further at the subsequent assessment, discontinuation\nof Perjeta and trastuzumab should be strongly considered, unless the benefits\nfor the individual patient are deemed to outweigh the risks. </span>", "ID": "1ff3fe42-7008-40ca-a792-f5f86bd73d01", "Styles": "None", "Classes": "None", "Text": "to ensure that LVEF is within normal limits. If the LVEF has declined as indicated in section 4.2 and has not improved, or has declined further at the subsequent assessment, discontinuation of Perjeta and trastuzumab should be strongly considered, unless the benefits for the individual patient are deemed to outweigh the risks. ", "ParentId": "d30be59c-85b8-4d4b-97ef-de5f0780a0cb"}, {"Element": "<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">\u00a0</span></i></p>", "ID": "0b2e4770-1a4e-4ce1-98a7-984fd78d0c0c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<i><span lang=\"EN-GB\">\u00a0</span></i>", "ID": "8bdd7081-7ea1-4070-9412-3ff9db252d8f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "0b2e4770-1a4e-4ce1-98a7-984fd78d0c0c"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2bae2567-ff18-4543-afd5-74c8f3276b05", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8bdd7081-7ea1-4070-9412-3ff9db252d8f"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\"><span lang=\"EN-GB\">Cardiac risk should be carefully considered and balanced against the\nmedical need of the individual patient before use of Perjeta with an anthracycline.\n</span><span lang=\"EN-GB\">Based on the pharmacological actions of <br/>\nHER2-targeted agents and anthracyclines, the risk of cardiac toxicity might be\nexpected to be higher with concomitant\u00a0use of Perjeta and anthracyclines\nthan with sequential use. </span></p>", "ID": "c7e66a95-dffd-42f7-872d-893c8ae80d77", "Styles": "text-align:justify;text-justify:inter-ideograph", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Cardiac risk should be carefully considered and balanced against the\nmedical need of the individual patient before use of Perjeta with an anthracycline.\n</span>", "ID": "ccd622f6-f5a5-4d08-8db8-25c6bbe903a2", "Styles": "None", "Classes": "None", "Text": "Cardiac risk should be carefully considered and balanced against the medical need of the individual patient before use of Perjeta with an anthracycline. ", "ParentId": "c7e66a95-dffd-42f7-872d-893c8ae80d77"}, {"Element": "<span lang=\"EN-GB\">Based on the pharmacological actions of <br/>\nHER2-targeted agents and anthracyclines, the risk of cardiac toxicity might be\nexpected to be higher with concomitant\u00a0use of Perjeta and anthracyclines\nthan with sequential use. </span>", "ID": "beab4abb-54c6-490f-89c8-69b6664c129b", "Styles": "None", "Classes": "None", "Text": "Based on the pharmacological actions of  HER2-targeted agents and anthracyclines, the risk of cardiac toxicity might be expected to be higher with concomitant\u00a0use of Perjeta and anthracyclines than with sequential use. ", "ParentId": "c7e66a95-dffd-42f7-872d-893c8ae80d77"}, {"Element": "<br/>", "ID": "ae73f095-2e97-46b2-85b6-c210d7019a5d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "beab4abb-54c6-490f-89c8-69b6664c129b"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b9df1df2-d46b-4cc8-a57a-885031f92f3c", "Styles": "text-align:justify;text-justify:inter-ideograph", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "096af1b8-03fd-4664-b5cb-65e27ed4943a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b9df1df2-d46b-4cc8-a57a-885031f92f3c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Sequential use of Perjeta (in combination\nwith trastuzumab and a taxane) has been evaluated following the epirubicin or\ndoxorubicin component of many anthracycline-based regimens in the APHINITY and\nBERENICE studies. However, only limited safety data are available on concurrent\nuse of Perjeta and an anthracycline. In the TRYPHAENA study, Perjeta was given concurrently\nwith epirubicin, as part of the FEC</span><span lang=\"EN-GB\"> </span>(5-fluorouracil,\nepirubicin, cyclophosphamide) <span lang=\"EN-GB\">regimen (see sections 4.8 and\n5.1). Only chemotherapy-naive patients were treated and they received low\ncumulative doses of epirubicin (up to 300 mg/m<sup>2</sup>). In this study,\ncardiac safety was similar to that observed in patients given the same regimen but\nwith Perjeta administered sequentially (following FEC chemotherapy).</span></p>", "ID": "494d0f8a-089b-4180-92f4-d6e5342cfc4d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "(5-fluorouracil, epirubicin, cyclophosphamide) ", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Sequential use of Perjeta (in combination\nwith trastuzumab and a taxane) has been evaluated following the epirubicin or\ndoxorubicin component of many anthracycline-based regimens in the APHINITY and\nBERENICE studies. However, only limited safety data are available on concurrent\nuse of Perjeta and an anthracycline. In the TRYPHAENA study, Perjeta was given concurrently\nwith epirubicin, as part of the FEC</span>", "ID": "688136c7-4ea2-4fee-831e-75d0a52231b1", "Styles": "None", "Classes": "None", "Text": "Sequential use of Perjeta (in combination with trastuzumab and a taxane) has been evaluated following the epirubicin or doxorubicin component of many anthracycline-based regimens in the APHINITY and BERENICE studies. However, only limited safety data are available on concurrent use of Perjeta and an anthracycline. In the TRYPHAENA study, Perjeta was given concurrently with epirubicin, as part of the FEC", "ParentId": "494d0f8a-089b-4180-92f4-d6e5342cfc4d"}, {"Element": "<span lang=\"EN-GB\"> </span>", "ID": "7cd2bc8a-79fb-4a03-8bf5-d1ba7665804b", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "494d0f8a-089b-4180-92f4-d6e5342cfc4d"}, {"Element": "<span lang=\"EN-GB\">regimen (see sections 4.8 and\n5.1). Only chemotherapy-naive patients were treated and they received low\ncumulative doses of epirubicin (up to 300 mg/m<sup>2</sup>). In this study,\ncardiac safety was similar to that observed in patients given the same regimen but\nwith Perjeta administered sequentially (following FEC chemotherapy).</span>", "ID": "b36aba3c-36ab-4f3a-b5fa-55fe9892c6ca", "Styles": "None", "Classes": "None", "Text": "regimen (see sections 4.8 and 5.1). Only chemotherapy-naive patients were treated and they received low cumulative doses of epirubicin (up to 300 mg/m). In this study, cardiac safety was similar to that observed in patients given the same regimen but with Perjeta administered sequentially (following FEC chemotherapy).", "ParentId": "494d0f8a-089b-4180-92f4-d6e5342cfc4d"}, {"Element": "<sup>2</sup>", "ID": "6ffcfbc4-bbd0-4790-bb6b-bd01d7d18ac3", "Styles": "None", "Classes": "None", "Text": "2", "ParentId": "b36aba3c-36ab-4f3a-b5fa-55fe9892c6ca"}, {"Element": "<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">\u00a0</span></i></p>", "ID": "69b4d70e-91ef-4448-a187-3aa77cfe4872", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<i><span lang=\"EN-GB\">\u00a0</span></i>", "ID": "bdaa8631-a169-456d-b716-b862071d08d0", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "69b4d70e-91ef-4448-a187-3aa77cfe4872"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "461b060d-966a-4be6-90dd-7f8b745b3e9c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "bdaa8631-a169-456d-b716-b862071d08d0"}, {"Element": "<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Infusion reactions</span></u></p>", "ID": "af55cc7c-ec70-4c5b-9c3c-abb4dd416082", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<u><span lang=\"EN-GB\">Infusion reactions</span></u>", "ID": "f2369195-363c-44cc-927c-b18f9fdcf746", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "af55cc7c-ec70-4c5b-9c3c-abb4dd416082"}, {"Element": "<span lang=\"EN-GB\">Infusion reactions</span>", "ID": "216c2bd3-5fc5-488b-b94e-07cf73dd04fd", "Styles": "None", "Classes": "None", "Text": "Infusion reactions", "ParentId": "f2369195-363c-44cc-927c-b18f9fdcf746"}, {"Element": "<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">\u00a0</span></i></p>", "ID": "6cc989a1-5dfd-473c-a24b-dc2ad09736a7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<i><span lang=\"EN-GB\">\u00a0</span></i>", "ID": "bcb46aae-a5b6-4fa9-822b-444851e90952", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "6cc989a1-5dfd-473c-a24b-dc2ad09736a7"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "502f6673-6147-4794-8e41-3950059258e7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "bcb46aae-a5b6-4fa9-822b-444851e90952"}, {"Element": "<p class=\"MsoNormal\" style=\"background:white\"><span lang=\"EN-GB\" style=\"color:black\">Perjeta\nhas been associated with infusion reactions, including events with a fatal\noutcome (</span><span lang=\"EN-GB\" style=\"color:black\">see section 4.8</span><span lang=\"EN-GB\" style=\"color:black\">). Close observation of the patient during and\nfor 60 minutes after the first infusion and during and for 30-60 minutes after\nsubsequent infusions of Perjeta is recommended. If a significant infusion</span><span lang=\"EN-GB\" style=\"color:black\"> </span><span lang=\"EN-GB\" style=\"color:black\">reaction\noccurs, the infusion should be slowed down or interrupted and appropriate\nmedical therapies should be administered. Patients should be evaluated and\ncarefully monitored until complete resolution of signs and symptoms.</span><span lang=\"EN-GB\" style=\"color:black\"> Permanent discontinuation should be considered\nin patients with severe infusion reactions. This clinical assessment should be\nbased on the severity of the preceding reaction and response to administered\ntreatment for the adverse reaction (see section 4.2).</span></p>", "ID": "6c5584a9-27e9-4857-90c7-a41daa63f7af", "Styles": "background:white", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Perjeta\nhas been associated with infusion reactions, including events with a fatal\noutcome (</span>", "ID": "fc490b99-b3b9-41e2-ba08-b1ee25df4f5e", "Styles": "color:black", "Classes": "None", "Text": "Perjeta has been associated with infusion reactions, including events with a fatal outcome (", "ParentId": "6c5584a9-27e9-4857-90c7-a41daa63f7af"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">see section 4.8</span>", "ID": "580bf30a-1274-49bb-b2e4-1abbc0540398", "Styles": "color:black", "Classes": "None", "Text": "see section 4.8", "ParentId": "6c5584a9-27e9-4857-90c7-a41daa63f7af"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">). Close observation of the patient during and\nfor 60 minutes after the first infusion and during and for 30-60 minutes after\nsubsequent infusions of Perjeta is recommended. If a significant infusion</span>", "ID": "65ec2b33-b347-4858-a1be-9fb157328445", "Styles": "color:black", "Classes": "None", "Text": "). Close observation of the patient during and for 60 minutes after the first infusion and during and for 30-60 minutes after subsequent infusions of Perjeta is recommended. If a significant infusion", "ParentId": "6c5584a9-27e9-4857-90c7-a41daa63f7af"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\"> </span>", "ID": "6a82ac62-1cfa-4d69-89ee-b8b51cd17cf9", "Styles": "color:black", "Classes": "None", "Text": " ", "ParentId": "6c5584a9-27e9-4857-90c7-a41daa63f7af"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">reaction\noccurs, the infusion should be slowed down or interrupted and appropriate\nmedical therapies should be administered. Patients should be evaluated and\ncarefully monitored until complete resolution of signs and symptoms.</span>", "ID": "1d448c28-9636-4bf3-9b02-bc4ca1828e90", "Styles": "color:black", "Classes": "None", "Text": "reaction occurs, the infusion should be slowed down or interrupted and appropriate medical therapies should be administered. Patients should be evaluated and carefully monitored until complete resolution of signs and symptoms.", "ParentId": "6c5584a9-27e9-4857-90c7-a41daa63f7af"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\"> Permanent discontinuation should be considered\nin patients with severe infusion reactions. This clinical assessment should be\nbased on the severity of the preceding reaction and response to administered\ntreatment for the adverse reaction (see section 4.2).</span>", "ID": "a55c2108-7dc3-46f1-bb63-dffe777b5e6b", "Styles": "color:black", "Classes": "None", "Text": " Permanent discontinuation should be considered in patients with severe infusion reactions. This clinical assessment should be based on the severity of the preceding reaction and response to administered treatment for the adverse reaction (see section 4.2).", "ParentId": "6c5584a9-27e9-4857-90c7-a41daa63f7af"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">\u00a0</span></i></p>", "ID": "4f1ade43-ff3f-4299-9c61-ff48e3e0fba9", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<i><span lang=\"EN-GB\">\u00a0</span></i>", "ID": "82b5fdea-622d-48dc-a109-50d90dde8cc6", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4f1ade43-ff3f-4299-9c61-ff48e3e0fba9"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "15ada74b-be78-4566-935d-f3cc9c5908f1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "82b5fdea-622d-48dc-a109-50d90dde8cc6"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Hypersensitivity\nreactions/anaphylaxis</span></u></p>", "ID": "d028fe7c-1fb7-4f92-b2ea-fa36939361e5", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<u><span lang=\"EN-GB\">Hypersensitivity\nreactions/anaphylaxis</span></u>", "ID": "75c189ea-a376-4e15-abf8-baf51df7a55f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d028fe7c-1fb7-4f92-b2ea-fa36939361e5"}, {"Element": "<span lang=\"EN-GB\">Hypersensitivity\nreactions/anaphylaxis</span>", "ID": "19eb32ff-4e5c-4610-aa79-a94ba952ebf5", "Styles": "None", "Classes": "None", "Text": "Hypersensitivity reactions/anaphylaxis", "ParentId": "75c189ea-a376-4e15-abf8-baf51df7a55f"}, {"Element": "<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">\u00a0</span></i></p>", "ID": "ed7d9aec-ea2f-4a44-86c8-55be53271136", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<i><span lang=\"EN-GB\">\u00a0</span></i>", "ID": "9eb84a75-7391-4970-bb54-d263e75c53e7", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ed7d9aec-ea2f-4a44-86c8-55be53271136"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5d0040bc-8317-4bcf-8c97-42d2226e9fe5", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9eb84a75-7391-4970-bb54-d263e75c53e7"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Patients should be observed closely for\nhypersensitivity reactions. Severe hypersensitivity, including anaphylaxis and\nevents with a fatal outcome, has been observed with Perjeta (see section 4.8).\nMedicinal products to treat such reactions, as well as emergency equipment,\nshould be available for immediate use. Perjeta must be permanently discontinued\nin case of NCI-CTCAE Grade 4 hypersensitivity reactions (anaphylaxis), bronchospasm\nor acute respiratory distress syndrome (see section 4.2). </span></p>", "ID": "0fe9ebac-8b25-4d8b-bdad-5218e0a63e92", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Patients should be observed closely for\nhypersensitivity reactions. Severe hypersensitivity, including anaphylaxis and\nevents with a fatal outcome, has been observed with Perjeta (see section 4.8).\nMedicinal products to treat such reactions, as well as emergency equipment,\nshould be available for immediate use. Perjeta must be permanently discontinued\nin case of NCI-CTCAE Grade 4 hypersensitivity reactions (anaphylaxis), bronchospasm\nor acute respiratory distress syndrome (see section 4.2). </span>", "ID": "02ff8b40-fcdc-4a27-9937-824c72671cef", "Styles": "None", "Classes": "None", "Text": "Patients should be observed closely for hypersensitivity reactions. Severe hypersensitivity, including anaphylaxis and events with a fatal outcome, has been observed with Perjeta (see section 4.8). Medicinal products to treat such reactions, as well as emergency equipment, should be available for immediate use. Perjeta must be permanently discontinued in case of NCI-CTCAE Grade 4 hypersensitivity reactions (anaphylaxis), bronchospasm or acute respiratory distress syndrome (see section 4.2). ", "ParentId": "0fe9ebac-8b25-4d8b-bdad-5218e0a63e92"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "cefbb8eb-0b40-4b21-b35e-932373ec93cf", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ad7f90f1-0aec-4a5c-8e2c-3e52f51a058a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "cefbb8eb-0b40-4b21-b35e-932373ec93cf"}, {"Element": "<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Febrile neutropenia</span></u></p>", "ID": "f9a95cfb-e8e1-4527-b179-9690c3ff0509", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<u><span lang=\"EN-GB\">Febrile neutropenia</span></u>", "ID": "4847c6b8-99db-4860-bd30-5df31b5e9ab0", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f9a95cfb-e8e1-4527-b179-9690c3ff0509"}, {"Element": "<span lang=\"EN-GB\">Febrile neutropenia</span>", "ID": "a2e61d90-bcc8-4950-85fe-2965184221a5", "Styles": "None", "Classes": "None", "Text": "Febrile neutropenia", "ParentId": "4847c6b8-99db-4860-bd30-5df31b5e9ab0"}, {"Element": "<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">\u00a0</span></i></p>", "ID": "1f100bd2-b283-4742-9ce1-e925feb4caa7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<i><span lang=\"EN-GB\">\u00a0</span></i>", "ID": "df5016c4-6bc3-4d0f-acac-4cf477f6c6fe", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "1f100bd2-b283-4742-9ce1-e925feb4caa7"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "811bb6a7-35d1-42be-af53-4311d8f21581", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "df5016c4-6bc3-4d0f-acac-4cf477f6c6fe"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Patients treated with Perjeta, trastuzumab\nand docetaxel are at increased risk of febrile neutropenia compared with\npatients treated with placebo, trastuzumab and docetaxel, especially during the\nfirst 3 cycles of treatment (see section 4.8). </span><span lang=\"EN-GB\">In the\nCLEOPATRA trial in metastatic breast cancer,</span><span lang=\"EN-GB\"> nadir\nneutrophil counts were similar in Perjeta-treated and placebo-treated patients</span><span lang=\"EN-GB\">. The</span><span lang=\"EN-GB\"> higher incidence of febrile\nneutropenia in Perjeta-treated patients </span><span lang=\"EN-GB\">was</span><span lang=\"EN-GB\"> associated with the higher incidence of mucositis and diarrhoea in\nthese patients. Symptomatic treatment for mucositis and diarrhoea should be\nconsidered. </span><span lang=\"EN-GB\">No</span><span lang=\"EN-GB\"> events of\nfebrile neutropenia were reported after cessation of docetaxel.</span></p>", "ID": "8920cea8-c56b-4a91-91e7-6a09123f2cac", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Patients treated with Perjeta, trastuzumab\nand docetaxel are at increased risk of febrile neutropenia compared with\npatients treated with placebo, trastuzumab and docetaxel, especially during the\nfirst 3 cycles of treatment (see section 4.8). </span>", "ID": "c272cf17-ecbd-481f-8189-761daca83fc9", "Styles": "None", "Classes": "None", "Text": "Patients treated with Perjeta, trastuzumab and docetaxel are at increased risk of febrile neutropenia compared with patients treated with placebo, trastuzumab and docetaxel, especially during the first 3 cycles of treatment (see section 4.8). ", "ParentId": "8920cea8-c56b-4a91-91e7-6a09123f2cac"}, {"Element": "<span lang=\"EN-GB\">In the\nCLEOPATRA trial in metastatic breast cancer,</span>", "ID": "3888e690-8bf6-478e-8c6d-9e4c0d0c4ce8", "Styles": "None", "Classes": "None", "Text": "In the CLEOPATRA trial in metastatic breast cancer,", "ParentId": "8920cea8-c56b-4a91-91e7-6a09123f2cac"}, {"Element": "<span lang=\"EN-GB\"> nadir\nneutrophil counts were similar in Perjeta-treated and placebo-treated patients</span>", "ID": "463c7e3f-ad5b-4242-9e3e-ee66d862eba6", "Styles": "None", "Classes": "None", "Text": " nadir neutrophil counts were similar in Perjeta-treated and placebo-treated patients", "ParentId": "8920cea8-c56b-4a91-91e7-6a09123f2cac"}, {"Element": "<span lang=\"EN-GB\">. The</span>", "ID": "aa5f4dfa-732b-472d-9338-67c99ab39722", "Styles": "None", "Classes": "None", "Text": ". The", "ParentId": "8920cea8-c56b-4a91-91e7-6a09123f2cac"}, {"Element": "<span lang=\"EN-GB\"> higher incidence of febrile\nneutropenia in Perjeta-treated patients </span>", "ID": "71ec7e24-f8a0-48c6-a420-dfdf95d08f73", "Styles": "None", "Classes": "None", "Text": " higher incidence of febrile neutropenia in Perjeta-treated patients ", "ParentId": "8920cea8-c56b-4a91-91e7-6a09123f2cac"}, {"Element": "<span lang=\"EN-GB\">was</span>", "ID": "0f966a1c-7d95-4daf-9817-af4561cdfa45", "Styles": "None", "Classes": "None", "Text": "was", "ParentId": "8920cea8-c56b-4a91-91e7-6a09123f2cac"}, {"Element": "<span lang=\"EN-GB\"> associated with the higher incidence of mucositis and diarrhoea in\nthese patients. Symptomatic treatment for mucositis and diarrhoea should be\nconsidered. </span>", "ID": "9945be6f-c7be-45e0-905e-841d126db2c7", "Styles": "None", "Classes": "None", "Text": " associated with the higher incidence of mucositis and diarrhoea in these patients. Symptomatic treatment for mucositis and diarrhoea should be considered. ", "ParentId": "8920cea8-c56b-4a91-91e7-6a09123f2cac"}, {"Element": "<span lang=\"EN-GB\">No</span>", "ID": "a2ffecb5-2409-4d41-96d2-e28c91e77732", "Styles": "None", "Classes": "None", "Text": "No", "ParentId": "8920cea8-c56b-4a91-91e7-6a09123f2cac"}, {"Element": "<span lang=\"EN-GB\"> events of\nfebrile neutropenia were reported after cessation of docetaxel.</span>", "ID": "673af3e2-c706-43b7-b037-4c39099c0f49", "Styles": "None", "Classes": "None", "Text": " events of febrile neutropenia were reported after cessation of docetaxel.", "ParentId": "8920cea8-c56b-4a91-91e7-6a09123f2cac"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "475a90d3-2505-4b80-af37-3e4712f258df", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "13093ab7-e51f-4e2c-b5f0-7f6fa507681c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "475a90d3-2505-4b80-af37-3e4712f258df"}, {"Element": "<p class=\"MsoNormal\"><u><span lang=\"ES\">Diarrhoea</span></u></p>", "ID": "3d50c5c9-4aed-4d3c-8dec-5e52d802741e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<u><span lang=\"ES\">Diarrhoea</span></u>", "ID": "2eeb647c-909f-4087-9ae1-cb17ea6e1757", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3d50c5c9-4aed-4d3c-8dec-5e52d802741e"}, {"Element": "<span lang=\"ES\">Diarrhoea</span>", "ID": "2b3a8d27-c4fe-4e6d-b08c-96c70e9e92f2", "Styles": "None", "Classes": "None", "Text": "Diarrhoea", "ParentId": "2eeb647c-909f-4087-9ae1-cb17ea6e1757"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"ES\">\u00a0</span></p>", "ID": "e56000f1-3c9d-4496-961f-5b43bb095d4a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"ES\">\u00a0</span>", "ID": "750fb214-61b4-4d97-aa9f-bc25025edd5c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e56000f1-3c9d-4496-961f-5b43bb095d4a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"ES\">Perjeta may elicit severe diarrhoea. </span><span lang=\"EN-GB\">Diarrhoea is most frequent during concurrent administration with\ntaxane therapy.</span> Elderly patients (<u>&gt;</u> 65 years) have a higher\nrisk of diarrhoea compared with younger patients (&lt;<u> </u>65 years). Treat\ndiarrhoea according to standard practice and guidelines. Early intervention\nwith loperamide, fluids and electrolyte replacement should be considered,\nparticularly in elderly patients, and in case of severe or prolonged\ndiarrhoea.\u00a0 <span lang=\"EN-GB\">Interruption of treatment with pertuzumab should\nbe considered if no improvement in the patient\u2019s condition is achieved. When\nthe diarrhoea is under control treatment with pertuzumab may be reinstated.</span></p>", "ID": "86d5c2eb-c4c7-4623-81ca-d2a2f4bedd85", "Styles": "None", "Classes": "['MsoNormal']", "Text": " Elderly patients ( 65 years) have a higher risk of diarrhoea compared with younger patients (<65 years). Treat diarrhoea according to standard practice and guidelines. Early intervention with loperamide, fluids and electrolyte replacement should be considered, particularly in elderly patients, and in case of severe or prolonged diarrhoea.\u00a0 ", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"ES\">Perjeta may elicit severe diarrhoea. </span>", "ID": "2927aa7e-ba6c-497b-8551-6bbcf0ad33a2", "Styles": "None", "Classes": "None", "Text": "Perjeta may elicit severe diarrhoea. ", "ParentId": "86d5c2eb-c4c7-4623-81ca-d2a2f4bedd85"}, {"Element": "<span lang=\"EN-GB\">Diarrhoea is most frequent during concurrent administration with\ntaxane therapy.</span>", "ID": "30bc2b14-e858-45f0-b331-d61e92161b38", "Styles": "None", "Classes": "None", "Text": "Diarrhoea is most frequent during concurrent administration with taxane therapy.", "ParentId": "86d5c2eb-c4c7-4623-81ca-d2a2f4bedd85"}, {"Element": "<u>&gt;</u>", "ID": "421b662e-9ae0-4d0b-9aac-6550d7358a70", "Styles": "None", "Classes": "None", "Text": ">", "ParentId": "86d5c2eb-c4c7-4623-81ca-d2a2f4bedd85"}, {"Element": "<u> </u>", "ID": "9f560b3d-54d4-4133-8883-4132fab051f6", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "86d5c2eb-c4c7-4623-81ca-d2a2f4bedd85"}, {"Element": "<span lang=\"EN-GB\">Interruption of treatment with pertuzumab should\nbe considered if no improvement in the patient\u2019s condition is achieved. When\nthe diarrhoea is under control treatment with pertuzumab may be reinstated.</span>", "ID": "8eb7111b-c4dc-4bd7-bb3a-0486e4f5cf81", "Styles": "None", "Classes": "None", "Text": "Interruption of treatment with pertuzumab should be considered if no improvement in the patient\u2019s condition is achieved. When the diarrhoea is under control treatment with pertuzumab may be reinstated.", "ParentId": "86d5c2eb-c4c7-4623-81ca-d2a2f4bedd85"}, {"Element": "<p class=\"MsoNormal\"><b><i><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></i></b></p>", "ID": "34f445e4-c1e2-4db8-b64e-3bb273aaf673", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><i><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></i></b>", "ID": "98d405df-c282-487c-b0fc-a6f237545ebc", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "34f445e4-c1e2-4db8-b64e-3bb273aaf673"}, {"Element": "<i><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></i>", "ID": "d39de081-1078-413f-9a05-7b54247e6646", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "98d405df-c282-487c-b0fc-a6f237545ebc"}, {"Element": "<u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u>", "ID": "98bdb794-b0c8-46c4-a851-716dee4ad290", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d39de081-1078-413f-9a05-7b54247e6646"}, {"Element": "<span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span>", "ID": "15a161e1-b449-49ba-90f1-33dc14985ea9", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "98bdb794-b0c8-46c4-a851-716dee4ad290"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "9090af5b-b7fa-449c-b405-61833850f702", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "15a161e1-b449-49ba-90f1-33dc14985ea9"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">4.5\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Interaction with other\nmedicinal products and other forms of interaction</span></b></p>", "ID": "a4205c1c-e324-4140-a3b7-1143886b2faa", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">4.5\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Interaction with other\nmedicinal products and other forms of interaction</span></b>", "ID": "ea40153d-cbc2-4b64-b264-c18a762a76b3", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a4205c1c-e324-4140-a3b7-1143886b2faa"}, {"Element": "<span lang=\"EN-GB\">4.5\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Interaction with other\nmedicinal products and other forms of interaction</span>", "ID": "e700c3f3-bebe-481d-9dfe-e2c74b30a1ff", "Styles": "None", "Classes": "None", "Text": "4.5\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Interaction with other medicinal products and other forms of interaction", "ParentId": "ea40153d-cbc2-4b64-b264-c18a762a76b3"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6e6d7bf0-3998-421d-9ca7-3833033a85e3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "cae5b20c-9eef-42b5-b748-060e7c82e631", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6e6d7bf0-3998-421d-9ca7-3833033a85e3"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">No pharmacokinetic (PK) interactions were\nobserved between </span><span lang=\"EN-GB\">pertuzumab</span><span lang=\"EN-GB\"> and\ntrastuzumab, or between </span><span lang=\"EN-GB\">pertuzumab</span><span lang=\"EN-GB\"> and docetaxel in a sub-study of 37 patients in the randomised,\npivotal trial CLEOPATRA</span><span lang=\"EN-GB\"> in metastatic breast cancer</span><span lang=\"EN-GB\">. In addition, in the population PK analysis, no evidence of a\ndrug-drug interaction has been shown between </span><span lang=\"EN-GB\">pertuzumab</span><span lang=\"EN-GB\"> and trastuzumab </span><span lang=\"EN-GB\">or</span><span lang=\"EN-GB\">\nbetween </span><span lang=\"EN-GB\">pertuzumab</span><span lang=\"EN-GB\"> and\ndocetaxel</span><span lang=\"EN-GB\">. This absence of drug-drug interaction was\nconfirmed by pharmacokinetic data from the NEOSPHERE and APHINITY studies</span><span lang=\"EN-GB\">.</span></p>", "ID": "bb2c8e50-2c24-40fe-9370-14bfc88228bc", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">No pharmacokinetic (PK) interactions were\nobserved between </span>", "ID": "1c477e81-69a4-41f1-984e-8cf1076ca7ba", "Styles": "None", "Classes": "None", "Text": "No pharmacokinetic (PK) interactions were observed between ", "ParentId": "bb2c8e50-2c24-40fe-9370-14bfc88228bc"}, {"Element": "<span lang=\"EN-GB\">pertuzumab</span>", "ID": "d30ca7ec-fd37-40ab-a021-1a892aa4a417", "Styles": "None", "Classes": "None", "Text": "pertuzumab", "ParentId": "bb2c8e50-2c24-40fe-9370-14bfc88228bc"}, {"Element": "<span lang=\"EN-GB\"> and\ntrastuzumab, or between </span>", "ID": "6f8c7e1c-556d-4e32-a6ce-3d1e80f54f38", "Styles": "None", "Classes": "None", "Text": " and trastuzumab, or between ", "ParentId": "bb2c8e50-2c24-40fe-9370-14bfc88228bc"}, {"Element": "<span lang=\"EN-GB\">pertuzumab</span>", "ID": "cb124614-110f-44f0-b631-ab323ca1b12a", "Styles": "None", "Classes": "None", "Text": "pertuzumab", "ParentId": "bb2c8e50-2c24-40fe-9370-14bfc88228bc"}, {"Element": "<span lang=\"EN-GB\"> and docetaxel in a sub-study of 37 patients in the randomised,\npivotal trial CLEOPATRA</span>", "ID": "8d6d27f7-37b8-435a-87f4-bd80804f3950", "Styles": "None", "Classes": "None", "Text": " and docetaxel in a sub-study of 37 patients in the randomised, pivotal trial CLEOPATRA", "ParentId": "bb2c8e50-2c24-40fe-9370-14bfc88228bc"}, {"Element": "<span lang=\"EN-GB\"> in metastatic breast cancer</span>", "ID": "6ab94fdb-6d59-4630-84b5-782e854c8a2f", "Styles": "None", "Classes": "None", "Text": " in metastatic breast cancer", "ParentId": "bb2c8e50-2c24-40fe-9370-14bfc88228bc"}, {"Element": "<span lang=\"EN-GB\">. In addition, in the population PK analysis, no evidence of a\ndrug-drug interaction has been shown between </span>", "ID": "2dc3cf16-6606-41d4-8c61-45c68248b9c3", "Styles": "None", "Classes": "None", "Text": ". In addition, in the population PK analysis, no evidence of a drug-drug interaction has been shown between ", "ParentId": "bb2c8e50-2c24-40fe-9370-14bfc88228bc"}, {"Element": "<span lang=\"EN-GB\">pertuzumab</span>", "ID": "065f078d-d91d-409e-8f40-5252717f4c6b", "Styles": "None", "Classes": "None", "Text": "pertuzumab", "ParentId": "bb2c8e50-2c24-40fe-9370-14bfc88228bc"}, {"Element": "<span lang=\"EN-GB\"> and trastuzumab </span>", "ID": "280a66c7-2347-462a-ab98-d7331046aadc", "Styles": "None", "Classes": "None", "Text": " and trastuzumab ", "ParentId": "bb2c8e50-2c24-40fe-9370-14bfc88228bc"}, {"Element": "<span lang=\"EN-GB\">or</span>", "ID": "6e91b2d7-3efc-4e34-8410-51260fa6456c", "Styles": "None", "Classes": "None", "Text": "or", "ParentId": "bb2c8e50-2c24-40fe-9370-14bfc88228bc"}, {"Element": "<span lang=\"EN-GB\">\nbetween </span>", "ID": "2bd25b65-9b98-44f2-8ad0-da5914482502", "Styles": "None", "Classes": "None", "Text": " between ", "ParentId": "bb2c8e50-2c24-40fe-9370-14bfc88228bc"}, {"Element": "<span lang=\"EN-GB\">pertuzumab</span>", "ID": "38c8ec8c-b547-4151-9ac1-7c2f0ad4ef22", "Styles": "None", "Classes": "None", "Text": "pertuzumab", "ParentId": "bb2c8e50-2c24-40fe-9370-14bfc88228bc"}, {"Element": "<span lang=\"EN-GB\"> and\ndocetaxel</span>", "ID": "b2282a1b-0eb4-43ba-8bea-7a918eca95a7", "Styles": "None", "Classes": "None", "Text": " and docetaxel", "ParentId": "bb2c8e50-2c24-40fe-9370-14bfc88228bc"}, {"Element": "<span lang=\"EN-GB\">. This absence of drug-drug interaction was\nconfirmed by pharmacokinetic data from the NEOSPHERE and APHINITY studies</span>", "ID": "73886da4-d6ad-4e1f-9fcd-bd3258c2bdfc", "Styles": "None", "Classes": "None", "Text": ". This absence of drug-drug interaction was confirmed by pharmacokinetic data from the NEOSPHERE and APHINITY studies", "ParentId": "bb2c8e50-2c24-40fe-9370-14bfc88228bc"}, {"Element": "<span lang=\"EN-GB\">.</span>", "ID": "8c31ef98-88b6-498f-b723-8aa02bf75bd1", "Styles": "None", "Classes": "None", "Text": ".", "ParentId": "bb2c8e50-2c24-40fe-9370-14bfc88228bc"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "cc491d16-0897-40f1-85ba-5792f5bc4d59", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e12bdb95-528a-42e1-8bfa-665cdf84a2ea", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "cc491d16-0897-40f1-85ba-5792f5bc4d59"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Five studies evaluated the effects of </span><span lang=\"EN-GB\">pertuzumab</span><span lang=\"EN-GB\"> on the PK of co-administered\ncytotoxic agents, docetaxel, paclitaxel, gemcitabine, capecitabine, carboplatin\nand erlotinib. There was no evidence of any PK interaction between </span><span lang=\"EN-GB\">pertuzumab</span><span lang=\"EN-GB\"> and any of these agents. The PK\nof </span><span lang=\"EN-GB\">pertuzumab</span><span lang=\"EN-GB\"> in these studies was\ncomparable to those observed in single-agent studies.</span></p>", "ID": "5e649819-00fd-4437-a362-5a003630a30a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Five studies evaluated the effects of </span>", "ID": "cbfca180-c1c2-4386-9845-08462f5e7309", "Styles": "None", "Classes": "None", "Text": "Five studies evaluated the effects of ", "ParentId": "5e649819-00fd-4437-a362-5a003630a30a"}, {"Element": "<span lang=\"EN-GB\">pertuzumab</span>", "ID": "dfaf0f39-6df1-4776-a717-eab41afd7594", "Styles": "None", "Classes": "None", "Text": "pertuzumab", "ParentId": "5e649819-00fd-4437-a362-5a003630a30a"}, {"Element": "<span lang=\"EN-GB\"> on the PK of co-administered\ncytotoxic agents, docetaxel, paclitaxel, gemcitabine, capecitabine, carboplatin\nand erlotinib. There was no evidence of any PK interaction between </span>", "ID": "12e91d69-bee7-427a-8479-87b6cfbb1c23", "Styles": "None", "Classes": "None", "Text": " on the PK of co-administered cytotoxic agents, docetaxel, paclitaxel, gemcitabine, capecitabine, carboplatin and erlotinib. There was no evidence of any PK interaction between ", "ParentId": "5e649819-00fd-4437-a362-5a003630a30a"}, {"Element": "<span lang=\"EN-GB\">pertuzumab</span>", "ID": "b342bbec-59a6-4193-825d-cd315b6392e8", "Styles": "None", "Classes": "None", "Text": "pertuzumab", "ParentId": "5e649819-00fd-4437-a362-5a003630a30a"}, {"Element": "<span lang=\"EN-GB\"> and any of these agents. The PK\nof </span>", "ID": "0038627b-e908-4a68-b7b1-a4b8fcbd6270", "Styles": "None", "Classes": "None", "Text": " and any of these agents. The PK of ", "ParentId": "5e649819-00fd-4437-a362-5a003630a30a"}, {"Element": "<span lang=\"EN-GB\">pertuzumab</span>", "ID": "5a571bd6-bda1-4067-9559-796036a466b3", "Styles": "None", "Classes": "None", "Text": "pertuzumab", "ParentId": "5e649819-00fd-4437-a362-5a003630a30a"}, {"Element": "<span lang=\"EN-GB\"> in these studies was\ncomparable to those observed in single-agent studies.</span>", "ID": "07e4060d-5a27-4074-8113-a4caa1587c74", "Styles": "None", "Classes": "None", "Text": " in these studies was comparable to those observed in single-agent studies.", "ParentId": "5e649819-00fd-4437-a362-5a003630a30a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6872680c-abc0-434f-bf08-1a22d3c3bab2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "25f95dde-d237-40cf-a5ec-dd905c64cd4e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6872680c-abc0-434f-bf08-1a22d3c3bab2"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">4.6\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Fertility,\np</span></b><b><span lang=\"EN-GB\">regnancy and lactation</span></b></p>", "ID": "10bd96bb-636a-4dd9-9980-bb6bff4123ae", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">4.6\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Fertility,\np</span></b>", "ID": "6c267987-0833-4322-a26b-919135cbdf26", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "10bd96bb-636a-4dd9-9980-bb6bff4123ae"}, {"Element": "<span lang=\"EN-GB\">4.6\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Fertility,\np</span>", "ID": "fc1bbcfa-f6a5-4afe-a2c0-379bca70b79f", "Styles": "None", "Classes": "None", "Text": "4.6\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Fertility, p", "ParentId": "6c267987-0833-4322-a26b-919135cbdf26"}, {"Element": "<b><span lang=\"EN-GB\">regnancy and lactation</span></b>", "ID": "c5bba13a-0716-4dfa-a7f1-6b5a0901b854", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "10bd96bb-636a-4dd9-9980-bb6bff4123ae"}, {"Element": "<span lang=\"EN-GB\">regnancy and lactation</span>", "ID": "287e51a8-e54c-498f-bef9-0df2d7f12880", "Styles": "None", "Classes": "None", "Text": "regnancy and lactation", "ParentId": "c5bba13a-0716-4dfa-a7f1-6b5a0901b854"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "96566da2-7e5d-4175-bf0e-c72af45c9b75", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "459f87c3-1fff-46ac-8520-29528690e388", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "96566da2-7e5d-4175-bf0e-c72af45c9b75"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Contraception\n</span></u></p>", "ID": "a3247812-df19-4834-b9e5-8c35fffc74ff", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<u><span lang=\"EN-GB\">Contraception\n</span></u>", "ID": "c0e673f6-3638-45d1-a891-e893f125d3d4", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a3247812-df19-4834-b9e5-8c35fffc74ff"}, {"Element": "<span lang=\"EN-GB\">Contraception\n</span>", "ID": "724461dc-95c4-43f5-8fcb-434ca3a73ef2", "Styles": "None", "Classes": "None", "Text": "Contraception ", "ParentId": "c0e673f6-3638-45d1-a891-e893f125d3d4"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "308e7fc8-0f29-417d-b9cb-8ae365aa96b1", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f7348d6f-0095-41cd-93bd-3b3df59f539c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "308e7fc8-0f29-417d-b9cb-8ae365aa96b1"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Women of\nchildbearing potential should use effective contraception while receiving\nPerjeta and for 6 months following the last dose of pertuzumab.</span></p>", "ID": "519961ce-2ab5-43a3-a305-8d15eb6d3630", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Women of\nchildbearing potential should use effective contraception while receiving\nPerjeta and for 6 months following the last dose of pertuzumab.</span>", "ID": "73a8529e-76a4-4af0-b34e-21e038fb9103", "Styles": "None", "Classes": "None", "Text": "Women of childbearing potential should use effective contraception while receiving Perjeta and for 6 months following the last dose of pertuzumab.", "ParentId": "519961ce-2ab5-43a3-a305-8d15eb6d3630"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>", "ID": "9211b88b-4add-4225-a38f-b4a70fb6f9b7", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u>", "ID": "2f9ed009-fe64-4aa4-a285-cfcb403dfc30", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "9211b88b-4add-4225-a38f-b4a70fb6f9b7"}, {"Element": "<span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span>", "ID": "1f49826d-57b1-42c0-8835-f1021b7cbc2f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "2f9ed009-fe64-4aa4-a285-cfcb403dfc30"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "e1681f8e-786e-407b-850d-375b535bdf69", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "1f49826d-57b1-42c0-8835-f1021b7cbc2f"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Pregnancy</span></u></p>", "ID": "4411d821-faa8-4ff7-8b07-daef603c4d7e", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<u><span lang=\"EN-GB\">Pregnancy</span></u>", "ID": "d1f68e7a-360d-4449-9c3d-52a5d17794a1", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4411d821-faa8-4ff7-8b07-daef603c4d7e"}, {"Element": "<span lang=\"EN-GB\">Pregnancy</span>", "ID": "2c8052ea-855b-466f-af61-2b8e4f9d7f94", "Styles": "None", "Classes": "None", "Text": "Pregnancy", "ParentId": "d1f68e7a-360d-4449-9c3d-52a5d17794a1"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "17faee0d-98cf-4b3c-9227-e186d96836c9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1c4198e5-50b4-4f37-92cc-07ecb8517e97", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "17faee0d-98cf-4b3c-9227-e186d96836c9"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">There is limited amount of data from the\nuse of pertuzumab in pregnant women. </span></p>", "ID": "f565aa45-b50f-48e2-939a-ae5759d9a2f8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">There is limited amount of data from the\nuse of pertuzumab in pregnant women. </span>", "ID": "b17a8de9-5d1c-40f8-9e92-a6f8ecc582ef", "Styles": "None", "Classes": "None", "Text": "There is limited amount of data from the use of pertuzumab in pregnant women. ", "ParentId": "f565aa45-b50f-48e2-939a-ae5759d9a2f8"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Studies in animals have shown reproductive\ntoxicity (see section 5.3).</span></p>", "ID": "19746cb3-65c8-4eea-bae8-97acd6f91b14", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Studies in animals have shown reproductive\ntoxicity (see section 5.3).</span>", "ID": "4fe10d54-d458-4dae-a9ff-e960306b7bfb", "Styles": "None", "Classes": "None", "Text": "Studies in animals have shown reproductive toxicity (see section 5.3).", "ParentId": "19746cb3-65c8-4eea-bae8-97acd6f91b14"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Perjeta is not recommended during pregnancy\nand in women of childbearing potential not using contraception. </span></p>", "ID": "b9849caf-1bf9-4a18-8986-ba4d8990695c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Perjeta is not recommended during pregnancy\nand in women of childbearing potential not using contraception. </span>", "ID": "c890a4b0-540d-4f75-bd70-bdf0538a398e", "Styles": "None", "Classes": "None", "Text": "Perjeta is not recommended during pregnancy and in women of childbearing potential not using contraception. ", "ParentId": "b9849caf-1bf9-4a18-8986-ba4d8990695c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>", "ID": "3ea3858a-870e-4fdb-8324-efff1513a64c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">\u00a0</span>", "ID": "cfda944a-995c-4f4e-a52c-867d6a3c9985", "Styles": "color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "3ea3858a-870e-4fdb-8324-efff1513a64c"}, {"Element": "<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Breast-feeding</span></u></p>", "ID": "f47959af-af29-4f5e-bf2a-4cdfa6f46111", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<u><span lang=\"EN-GB\">Breast-feeding</span></u>", "ID": "d63c4c7c-586f-43c6-b99a-3afadef469e5", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f47959af-af29-4f5e-bf2a-4cdfa6f46111"}, {"Element": "<span lang=\"EN-GB\">Breast-feeding</span>", "ID": "82b5f229-d709-4bc5-9a29-75da384788ab", "Styles": "None", "Classes": "None", "Text": "Breast-feeding", "ParentId": "d63c4c7c-586f-43c6-b99a-3afadef469e5"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2edc581d-2168-47c4-91cc-342b06adce44", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e72b18a2-c726-4038-8d72-c8bbc28aa8a4", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2edc581d-2168-47c4-91cc-342b06adce44"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Because human IgG is secreted in human milk\nand the potential for absorption and harm to the infant is unknown, a decision\nshould be made to discontinue breast-feeding or to discontinue treatment,\ntaking into account the benefit of breast-feeding for the child and the benefit\nof Perjeta therapy for the woman (see section 5.2).</span></p>", "ID": "33da8bd2-f5da-4951-8ff2-892ba679128c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Because human IgG is secreted in human milk\nand the potential for absorption and harm to the infant is unknown, a decision\nshould be made to discontinue breast-feeding or to discontinue treatment,\ntaking into account the benefit of breast-feeding for the child and the benefit\nof Perjeta therapy for the woman (see section 5.2).</span>", "ID": "9989eb04-98e7-484f-9a52-af0b3f62d6ce", "Styles": "None", "Classes": "None", "Text": "Because human IgG is secreted in human milk and the potential for absorption and harm to the infant is unknown, a decision should be made to discontinue breast-feeding or to discontinue treatment, taking into account the benefit of breast-feeding for the child and the benefit of Perjeta therapy for the woman (see section 5.2).", "ParentId": "33da8bd2-f5da-4951-8ff2-892ba679128c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "72557e1d-70d0-4843-a6c2-d4f4a3c2d19d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a8823488-bdd2-462f-8c25-f8d15354b7bd", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "72557e1d-70d0-4843-a6c2-d4f4a3c2d19d"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Fertility</span></u></p>", "ID": "cc83802e-97c6-4f35-8770-41bdbd09a175", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<u><span lang=\"EN-GB\">Fertility</span></u>", "ID": "af31e6c5-4eb5-4869-b791-6b43d0bcb8f9", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "cc83802e-97c6-4f35-8770-41bdbd09a175"}, {"Element": "<span lang=\"EN-GB\">Fertility</span>", "ID": "c0dd874c-a003-44b6-bc95-065f289b1f03", "Styles": "None", "Classes": "None", "Text": "Fertility", "ParentId": "af31e6c5-4eb5-4869-b791-6b43d0bcb8f9"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7302006a-6ab5-48c3-82e6-41e6d3d6dec1", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "361561d7-e6df-42fc-b3d9-a571485a373b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7302006a-6ab5-48c3-82e6-41e6d3d6dec1"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">No specific fertility studies in animals\nhave been performed to evaluate the effect of </span><span lang=\"EN-GB\">pertuzumab</span><span lang=\"EN-GB\">.</span><span lang=\"EN-GB\"> In repeated dose toxicity studies in\ncynomolgus monkeys, no definitive conclusions could be drawn on the adverse\neffect on male reproductive organs. </span><span lang=\"EN-GB\">No adverse reactions\nwere observed in sexually mature female cynomolgus monkeys exposed to\npertuzumab (see section 5.3).</span></p>", "ID": "894cab38-2ff5-4e36-b55d-5ab901644ec5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">No specific fertility studies in animals\nhave been performed to evaluate the effect of </span>", "ID": "b57e379e-bd99-4b9b-bae0-6f1ca379c109", "Styles": "None", "Classes": "None", "Text": "No specific fertility studies in animals have been performed to evaluate the effect of ", "ParentId": "894cab38-2ff5-4e36-b55d-5ab901644ec5"}, {"Element": "<span lang=\"EN-GB\">pertuzumab</span>", "ID": "55cadd43-fd22-4a0e-b187-a2ce9328e407", "Styles": "None", "Classes": "None", "Text": "pertuzumab", "ParentId": "894cab38-2ff5-4e36-b55d-5ab901644ec5"}, {"Element": "<span lang=\"EN-GB\">.</span>", "ID": "268cd9da-6430-405d-ada2-09e18ba13a25", "Styles": "None", "Classes": "None", "Text": ".", "ParentId": "894cab38-2ff5-4e36-b55d-5ab901644ec5"}, {"Element": "<span lang=\"EN-GB\"> In repeated dose toxicity studies in\ncynomolgus monkeys, no definitive conclusions could be drawn on the adverse\neffect on male reproductive organs. </span>", "ID": "c0bf7179-6da9-4ada-a5fb-c286bfd2fb93", "Styles": "None", "Classes": "None", "Text": " In repeated dose toxicity studies in cynomolgus monkeys, no definitive conclusions could be drawn on the adverse effect on male reproductive organs. ", "ParentId": "894cab38-2ff5-4e36-b55d-5ab901644ec5"}, {"Element": "<span lang=\"EN-GB\">No adverse reactions\nwere observed in sexually mature female cynomolgus monkeys exposed to\npertuzumab (see section 5.3).</span>", "ID": "879f84d1-1131-47d2-b5fe-9653a963ea69", "Styles": "None", "Classes": "None", "Text": "No adverse reactions were observed in sexually mature female cynomolgus monkeys exposed to pertuzumab (see section 5.3).", "ParentId": "894cab38-2ff5-4e36-b55d-5ab901644ec5"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "82765a14-12bf-4413-a1b9-7e8c2f568182", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "246e945f-3e42-40e2-8054-ec0662ca5573", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "82765a14-12bf-4413-a1b9-7e8c2f568182"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "74569619-bac0-4bb2-b162-742ede181d3a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "246e945f-3e42-40e2-8054-ec0662ca5573"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">4.7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Effects\non ability to drive and use machines</span></b></p>", "ID": "4d643a1d-1e99-48f0-920e-f9cc0f9d7123", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">4.7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Effects\non ability to drive and use machines</span></b>", "ID": "a6c693a3-4fe0-4305-8dc5-f32c84b04cf8", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4d643a1d-1e99-48f0-920e-f9cc0f9d7123"}, {"Element": "<span lang=\"EN-GB\">4.7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Effects\non ability to drive and use machines</span>", "ID": "91c8aa4e-6a67-48d0-8177-6b27ce639041", "Styles": "None", "Classes": "None", "Text": "4.7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Effects on ability to drive and use machines", "ParentId": "a6c693a3-4fe0-4305-8dc5-f32c84b04cf8"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "99e3343f-b492-4c8c-9d91-e503ca9e90d4", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b63789fa-3536-45f9-a7c2-8079424bd3e0", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "99e3343f-b492-4c8c-9d91-e503ca9e90d4"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">On the basis\nof reported adverse reactions, Perjeta has a minor influence on the ability to\ndrive or use machines. </span>Dizziness may occur during treatment with Perjeta\n(see section\u00a04.8). <span lang=\"EN-GB\">Patients experiencing infusion\nreactions should be advised not to drive and use machines until symptoms abate.\n</span></p>", "ID": "04165453-dd56-4f55-8bb3-37ce9eab8123", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "Dizziness may occur during treatment with Perjeta (see section\u00a04.8). ", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">On the basis\nof reported adverse reactions, Perjeta has a minor influence on the ability to\ndrive or use machines. </span>", "ID": "56f041fe-773c-4a84-ad7c-47047f3fa474", "Styles": "None", "Classes": "None", "Text": "On the basis of reported adverse reactions, Perjeta has a minor influence on the ability to drive or use machines. ", "ParentId": "04165453-dd56-4f55-8bb3-37ce9eab8123"}, {"Element": "<span lang=\"EN-GB\">Patients experiencing infusion\nreactions should be advised not to drive and use machines until symptoms abate.\n</span>", "ID": "13b55e26-6c0d-4093-b503-304861cdf3d3", "Styles": "None", "Classes": "None", "Text": "Patients experiencing infusion reactions should be advised not to drive and use machines until symptoms abate. ", "ParentId": "04165453-dd56-4f55-8bb3-37ce9eab8123"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7b83c316-66b3-4d7c-8a1b-ad8fcb4f9e4d", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "83204b6e-cdf5-45b3-a993-8c6c3ed78583", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7b83c316-66b3-4d7c-8a1b-ad8fcb4f9e4d"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">4.8\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Undesirable effects</span></b><b><span lang=\"EN-GB\"> </span></b></p>", "ID": "3744142f-69b0-48ff-96d5-06cefff0f17e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">4.8\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Undesirable effects</span></b>", "ID": "c179a591-4a29-493b-a5d7-4577e22dd95e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3744142f-69b0-48ff-96d5-06cefff0f17e"}, {"Element": "<span lang=\"EN-GB\">4.8\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Undesirable effects</span>", "ID": "0ea7724d-6e2c-4db5-a8ff-9f5dab334621", "Styles": "None", "Classes": "None", "Text": "4.8\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Undesirable effects", "ParentId": "c179a591-4a29-493b-a5d7-4577e22dd95e"}, {"Element": "<b><span lang=\"EN-GB\"> </span></b>", "ID": "1e392cc6-b2b2-434f-ae73-9c13acd7435d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3744142f-69b0-48ff-96d5-06cefff0f17e"}, {"Element": "<span lang=\"EN-GB\"> </span>", "ID": "71df47e6-e0d8-4ad9-9a6f-2eaf463d6f5e", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "1e392cc6-b2b2-434f-ae73-9c13acd7435d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c895ca68-3097-4dab-9727-30b588fb8f19", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ef878ccb-a8d4-45c9-aed5-d60bf4e9353b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c895ca68-3097-4dab-9727-30b588fb8f19"}, {"Element": "<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Summary of the safety profile</span></u></p>", "ID": "fd9a40c0-117b-40fa-9c1c-a1d7b19f547d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<u><span lang=\"EN-GB\">Summary of the safety profile</span></u>", "ID": "3d944a6f-320b-42a9-b50d-fa649ce37062", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "fd9a40c0-117b-40fa-9c1c-a1d7b19f547d"}, {"Element": "<span lang=\"EN-GB\">Summary of the safety profile</span>", "ID": "6e2cfd3e-159d-4df5-92e6-a13dd0d2039c", "Styles": "None", "Classes": "None", "Text": "Summary of the safety profile", "ParentId": "3d944a6f-320b-42a9-b50d-fa649ce37062"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0c5bd86b-a0e5-434d-af07-c62dd2d126cd", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7ae5586d-b933-41ab-8ac7-20eb892dd508", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0c5bd86b-a0e5-434d-af07-c62dd2d126cd"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The safety of Perjeta has been evaluated in\nmore than 6,000 patients in </span><span lang=\"EN-GB\">Phase</span><span lang=\"EN-GB\"> I, II, and III trials in patients with various malignancies and\npredominantly treated with Perjeta in combination with other antineoplastic\nagents. </span>Those studies included the pivotal trials CLEOPATRA (n=808),\nNEOSPHERE (n=417), TRYPHAENA (n=225), and APHINITY (n=4804) [pooled in Table\n2]. <span lang=\"EN-GB\">The safety of Perjeta was generally consistent across\nstudies, although the incidence and most common adverse drug reactions (ADRs)\nvaried depending on whether Perjeta was administered as monotherapy or with\nconcomitant anti-neoplastic agents. </span></p>", "ID": "5061ce79-8500-4f55-8f8e-f26ecbc79e62", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Those studies included the pivotal trials CLEOPATRA (n=808), NEOSPHERE (n=417), TRYPHAENA (n=225), and APHINITY (n=4804) [pooled in Table 2]. ", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">The safety of Perjeta has been evaluated in\nmore than 6,000 patients in </span>", "ID": "3d22fd1f-5084-4b3d-a683-e8b4d23f956d", "Styles": "None", "Classes": "None", "Text": "The safety of Perjeta has been evaluated in more than 6,000 patients in ", "ParentId": "5061ce79-8500-4f55-8f8e-f26ecbc79e62"}, {"Element": "<span lang=\"EN-GB\">Phase</span>", "ID": "cdc8fdbc-076f-4a5d-b3ba-a63a6b9523b0", "Styles": "None", "Classes": "None", "Text": "Phase", "ParentId": "5061ce79-8500-4f55-8f8e-f26ecbc79e62"}, {"Element": "<span lang=\"EN-GB\"> I, II, and III trials in patients with various malignancies and\npredominantly treated with Perjeta in combination with other antineoplastic\nagents. </span>", "ID": "f08cb4de-bd6e-46b0-a5f1-e0fddf11ceea", "Styles": "None", "Classes": "None", "Text": " I, II, and III trials in patients with various malignancies and predominantly treated with Perjeta in combination with other antineoplastic agents. ", "ParentId": "5061ce79-8500-4f55-8f8e-f26ecbc79e62"}, {"Element": "<span lang=\"EN-GB\">The safety of Perjeta was generally consistent across\nstudies, although the incidence and most common adverse drug reactions (ADRs)\nvaried depending on whether Perjeta was administered as monotherapy or with\nconcomitant anti-neoplastic agents. </span>", "ID": "d7f4fea1-799b-476c-9d6f-84136c3c039d", "Styles": "None", "Classes": "None", "Text": "The safety of Perjeta was generally consistent across studies, although the incidence and most common adverse drug reactions (ADRs) varied depending on whether Perjeta was administered as monotherapy or with concomitant anti-neoplastic agents. ", "ParentId": "5061ce79-8500-4f55-8f8e-f26ecbc79e62"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "94a7f300-edf7-41f6-bc78-66725deae2f6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b21cedc4-c3b4-436e-a511-f6c7863fcf43", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "94a7f300-edf7-41f6-bc78-66725deae2f6"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Tabulated\nlist of adverse reactions</span></u></p>", "ID": "d2413fc9-50de-4107-9cfe-910d3291f9db", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<u><span lang=\"EN-GB\">Tabulated\nlist of adverse reactions</span></u>", "ID": "78df2440-cfcc-4955-a612-b097de157bc8", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d2413fc9-50de-4107-9cfe-910d3291f9db"}, {"Element": "<span lang=\"EN-GB\">Tabulated\nlist of adverse reactions</span>", "ID": "7d0fe027-d766-4c22-8961-4aa99524f37b", "Styles": "None", "Classes": "None", "Text": "Tabulated list of adverse reactions", "ParentId": "78df2440-cfcc-4955-a612-b097de157bc8"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4729337c-a21e-4ac8-8e82-d6a48f66411d", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5fc3474a-b75b-4504-bcda-e79bafb94f60", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4729337c-a21e-4ac8-8e82-d6a48f66411d"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Table 2 summarizes\nthe ADRs from the Perjeta-treated groups of the following pivotal clinical\ntrials:</span></p>", "ID": "3f16a51c-ee82-4d59-9ee8-61af7f1b58f6", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Table 2 summarizes\nthe ADRs from the Perjeta-treated groups of the following pivotal clinical\ntrials:</span>", "ID": "d6c6f457-fca1-4210-894f-d5739d7ac737", "Styles": "None", "Classes": "None", "Text": "Table 2 summarizes the ADRs from the Perjeta-treated groups of the following pivotal clinical trials:", "ParentId": "3f16a51c-ee82-4d59-9ee8-61af7f1b58f6"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:35.7pt;text-indent:-17.85pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0 CLEOPATRA,\nin which Perjeta was given in combination with docetaxel and trastuzumab</span><span lang=\"EN-GB\"> to patients with metastatic breast cancer (n=453)</span></p>", "ID": "6fb0604c-9968-4fb9-9992-e209683ac935", "Styles": "margin-left:35.7pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "9b3ac371-f6dc-4cae-a5b0-a3f96fe47b59", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "6fb0604c-9968-4fb9-9992-e209683ac935"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0 CLEOPATRA,\nin which Perjeta was given in combination with docetaxel and trastuzumab</span>", "ID": "5f8ac297-62fa-43ce-b0be-6670e86fc343", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 CLEOPATRA, in which Perjeta was given in combination with docetaxel and trastuzumab", "ParentId": "6fb0604c-9968-4fb9-9992-e209683ac935"}, {"Element": "<span lang=\"EN-GB\"> to patients with metastatic breast cancer (n=453)</span>", "ID": "5744e32f-9f93-464d-b85b-0488bb55964d", "Styles": "None", "Classes": "None", "Text": " to patients with metastatic breast cancer (n=453)", "ParentId": "6fb0604c-9968-4fb9-9992-e209683ac935"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:35.7pt;text-indent:-17.85pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0 </span><span lang=\"EN-GB\" style=\"color:black\">NEOSPHERE (n=309) and TRYPHAENA (n=218), in\nwhich neoadjuvant Perjeta was given in combination with trastuzumab and\nchemotherapy to patients with locally advanced, inflammatory, or early breast\ncancer</span></p>", "ID": "92b0efa4-d164-481b-b70d-4b5180c01d6a", "Styles": "margin-left:35.7pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "b4acbea8-af06-4c93-8f79-322bec978617", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "92b0efa4-d164-481b-b70d-4b5180c01d6a"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0 </span>", "ID": "7b0dfe63-9752-4baa-90e9-c3e0614bbc9f", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "92b0efa4-d164-481b-b70d-4b5180c01d6a"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">NEOSPHERE (n=309) and TRYPHAENA (n=218), in\nwhich neoadjuvant Perjeta was given in combination with trastuzumab and\nchemotherapy to patients with locally advanced, inflammatory, or early breast\ncancer</span>", "ID": "33ad6451-87b9-4584-b2f2-21f1d95edb63", "Styles": "color:black", "Classes": "None", "Text": "NEOSPHERE (n=309) and TRYPHAENA (n=218), in which neoadjuvant Perjeta was given in combination with trastuzumab and chemotherapy to patients with locally advanced, inflammatory, or early breast cancer", "ParentId": "92b0efa4-d164-481b-b70d-4b5180c01d6a"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:35.7pt;text-indent:-17.85pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0 </span>APHINITY,\nin which adjuvant Perjeta was given in combination with trastuzumab and\nanthracycline-based or non-anthracycline-based, taxane-containing chemotherapy\nto patients with early breast cancer (n=2364)</p>", "ID": "dac4d071-ab1f-459c-9b20-b55f2dc7dbe4", "Styles": "margin-left:35.7pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "APHINITY, in which adjuvant Perjeta was given in combination with trastuzumab and anthracycline-based or non-anthracycline-based, taxane-containing chemotherapy to patients with early breast cancer (n=2364)", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "e35fbe97-fa25-4aeb-a94e-3e75a4ea5abe", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "dac4d071-ab1f-459c-9b20-b55f2dc7dbe4"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0 </span>", "ID": "407688fe-edb4-4827-b81b-3f5e5776128a", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "dac4d071-ab1f-459c-9b20-b55f2dc7dbe4"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "6cf6c89d-f9df-4b2d-927f-e0c833cbca0a", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">In addition,\nADRs reported in the post-marketing setting are included in Table 2. As Perjeta\nwas used with trastuzumab and </span><span lang=\"EN-GB\">chemotherapy in these\ntrials</span><span lang=\"EN-GB\">, it is difficult to ascertain the causal\nrelationship of an adverse event to a particular medicinal product. </span></p>", "ID": "30e2aef7-2f7c-419f-a433-4a5e8388f8e9", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">In addition,\nADRs reported in the post-marketing setting are included in Table 2. As Perjeta\nwas used with trastuzumab and </span>", "ID": "11ea5eb7-4f2e-4a71-bb94-d8ac4d54ee32", "Styles": "None", "Classes": "None", "Text": "In addition, ADRs reported in the post-marketing setting are included in Table 2. As Perjeta was used with trastuzumab and ", "ParentId": "30e2aef7-2f7c-419f-a433-4a5e8388f8e9"}, {"Element": "<span lang=\"EN-GB\">chemotherapy in these\ntrials</span>", "ID": "0c2b15bf-3ac2-4513-a57d-8e9b3a2d9bb9", "Styles": "None", "Classes": "None", "Text": "chemotherapy in these trials", "ParentId": "30e2aef7-2f7c-419f-a433-4a5e8388f8e9"}, {"Element": "<span lang=\"EN-GB\">, it is difficult to ascertain the causal\nrelationship of an adverse event to a particular medicinal product. </span>", "ID": "8d030313-b99c-4c61-97e1-ea36d600f8a8", "Styles": "None", "Classes": "None", "Text": ", it is difficult to ascertain the causal relationship of an adverse event to a particular medicinal product. ", "ParentId": "30e2aef7-2f7c-419f-a433-4a5e8388f8e9"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "84a87dcd-14c7-48a5-ad41-c9fee35a8523", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0cfa2e0c-1af9-4efa-b386-f392bb7f79c3", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "84a87dcd-14c7-48a5-ad41-c9fee35a8523"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">The ADRs are\nlisted below by MedDRA system organ class (SOC) and categories of frequency: </span></p>", "ID": "eb6d8a8c-b066-47c0-b8a2-82d7d2e55fac", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">The ADRs are\nlisted below by MedDRA system organ class (SOC) and categories of frequency: </span>", "ID": "402988bd-64af-49fb-8a49-5a3b5829318d", "Styles": "None", "Classes": "None", "Text": "The ADRs are listed below by MedDRA system organ class (SOC) and categories of frequency: ", "ParentId": "eb6d8a8c-b066-47c0-b8a2-82d7d2e55fac"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Very common\n(\u2265\u00a01/10)</span></p>", "ID": "778d62b4-d6f3-4dbf-9184-3f54629a2289", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Very common\n(\u2265\u00a01/10)</span>", "ID": "8ef2f9bb-ccdd-4d88-b0f1-2382a50c42ba", "Styles": "None", "Classes": "None", "Text": "Very common (\u2265\u00a01/10)", "ParentId": "778d62b4-d6f3-4dbf-9184-3f54629a2289"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Common\n(\u2265\u00a01/100 to &lt;\u00a01/10)</span></p>", "ID": "28c06ae7-35e6-438f-8565-9dede1e5d5af", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Common\n(\u2265\u00a01/100 to &lt;\u00a01/10)</span>", "ID": "c9e26e4d-d960-406e-839e-81ea35334ee9", "Styles": "None", "Classes": "None", "Text": "Common (\u2265\u00a01/100 to <\u00a01/10)", "ParentId": "28c06ae7-35e6-438f-8565-9dede1e5d5af"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Uncommon(\n\u2265\u00a01/1,000 to &lt;\u00a01/100)</span></p>", "ID": "cdbf5566-0046-4742-8b00-60f94a3864ef", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Uncommon(\n\u2265\u00a01/1,000 to &lt;\u00a01/100)</span>", "ID": "a31ab86e-177a-4dce-a530-1af8b77036bf", "Styles": "None", "Classes": "None", "Text": "Uncommon( \u2265\u00a01/1,000 to <\u00a01/100)", "ParentId": "cdbf5566-0046-4742-8b00-60f94a3864ef"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Rare (</span><span lang=\"EN-GB\">\u2265\u00a0</span><span lang=\"EN-GB\">1/10,000 to &lt;\u00a01/1,000)</span></p>", "ID": "50e9c62b-5697-4354-a214-5bf183602635", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Rare (</span>", "ID": "82d65663-ebd7-4466-ab84-828596355778", "Styles": "None", "Classes": "None", "Text": "Rare (", "ParentId": "50e9c62b-5697-4354-a214-5bf183602635"}, {"Element": "<span lang=\"EN-GB\">\u2265\u00a0</span>", "ID": "13e97f24-f5cb-44b4-a9b4-9e8675a1f946", "Styles": "None", "Classes": "None", "Text": "\u2265\u00a0", "ParentId": "50e9c62b-5697-4354-a214-5bf183602635"}, {"Element": "<span lang=\"EN-GB\">1/10,000 to &lt;\u00a01/1,000)</span>", "ID": "5991276b-ca0e-4b65-a496-84142b4becdb", "Styles": "None", "Classes": "None", "Text": "1/10,000 to <\u00a01/1,000)", "ParentId": "50e9c62b-5697-4354-a214-5bf183602635"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Very rare\n(&lt;\u00a01/10,000)</span></p>", "ID": "c18ae466-bba4-412b-9bcf-7f83bf671209", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Very rare\n(&lt;\u00a01/10,000)</span>", "ID": "e2ec362f-9df4-4abe-93b4-fb51bc0dab54", "Styles": "None", "Classes": "None", "Text": "Very rare (<\u00a01/10,000)", "ParentId": "c18ae466-bba4-412b-9bcf-7f83bf671209"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Not known (cannot be estimated from the\navailable data)</span></p>", "ID": "bf806fe3-9884-49ef-9a61-951b37be80bb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Not known (cannot be estimated from the\navailable data)</span>", "ID": "ad16dc03-9839-4102-8587-30f020cb138b", "Styles": "None", "Classes": "None", "Text": "Not known (cannot be estimated from the available data)", "ParentId": "bf806fe3-9884-49ef-9a61-951b37be80bb"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6245b509-a744-4c8c-9d79-fe21b9925a04", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1c767b26-5958-45c0-9824-0e525d971159", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6245b509-a744-4c8c-9d79-fe21b9925a04"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Within each frequency grouping and SOC, ADRs\nare presented in the order of decreasing seriousness.</span></p>", "ID": "21ad448a-0972-4564-8b1d-fd407c8d71d0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Within each frequency grouping and SOC, ADRs\nare presented in the order of decreasing seriousness.</span>", "ID": "3c78c293-21d4-48fa-878f-4ff8a8ef07ea", "Styles": "None", "Classes": "None", "Text": "Within each frequency grouping and SOC, ADRs are presented in the order of decreasing seriousness.", "ParentId": "21ad448a-0972-4564-8b1d-fd407c8d71d0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "faea40d8-1b9f-40cd-ab6b-493a65c6e79f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1c481846-55f3-4939-be48-62cfb077f8be", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "faea40d8-1b9f-40cd-ab6b-493a65c6e79f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The most common ADRs (\u226530%) from this\npooled data were diarrhoea, alopecia, nausea, fatigue, neutropenia, and\nvomiting. The most common NCI-CTCAE Grade 3-4 ADRs (\u226510%) were\nneutropenia and febrile neutropenia.</span></p>", "ID": "52007b50-2cbf-478b-a562-2066c1b511fc", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">The most common ADRs (\u226530%) from this\npooled data were diarrhoea, alopecia, nausea, fatigue, neutropenia, and\nvomiting. The most common NCI-CTCAE Grade 3-4 ADRs (\u226510%) were\nneutropenia and febrile neutropenia.</span>", "ID": "84aaaaed-c55b-4fbf-ab60-ea897fe35eb1", "Styles": "None", "Classes": "None", "Text": "The most common ADRs (\u226530%) from this pooled data were diarrhoea, alopecia, nausea, fatigue, neutropenia, and vomiting. The most common NCI-CTCAE Grade 3-4 ADRs (\u226510%) were neutropenia and febrile neutropenia.", "ParentId": "52007b50-2cbf-478b-a562-2066c1b511fc"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "2af22d84-5558-49ef-aad5-0a192e24cfb0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.75in;text-indent:-.75in;page-break-after:\navoid\"><b><span lang=\"EN-GB\">Table 2\u00a0\u00a0\u00a0\u00a0\u00a0 Summary of ADRs </span></b><b><span lang=\"EN-GB\">in patients treated with Perjeta in clinical trials^, and in the Post-marketing\nsetting</span></b><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u2020</span><b><span lang=\"EN-GB\"> </span></b><b><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></b></p>", "ID": "85fe61ff-3a1d-4cf9-ad6d-c1b59758e0f7", "Styles": "margin-left:.75in;text-indent:-.75in;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">Table 2\u00a0\u00a0\u00a0\u00a0\u00a0 Summary of ADRs </span></b>", "ID": "dad34c3a-5522-42cf-aab4-dd5a01dee1e5", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "85fe61ff-3a1d-4cf9-ad6d-c1b59758e0f7"}, {"Element": "<span lang=\"EN-GB\">Table 2\u00a0\u00a0\u00a0\u00a0\u00a0 Summary of ADRs </span>", "ID": "733da536-6b90-43be-ac33-dc68e9e55e8a", "Styles": "None", "Classes": "None", "Text": "Table 2\u00a0\u00a0\u00a0\u00a0\u00a0 Summary of ADRs ", "ParentId": "dad34c3a-5522-42cf-aab4-dd5a01dee1e5"}, {"Element": "<b><span lang=\"EN-GB\">in patients treated with Perjeta in clinical trials^, and in the Post-marketing\nsetting</span></b>", "ID": "22df08d5-7d9b-46da-9966-1c904e939c6d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "85fe61ff-3a1d-4cf9-ad6d-c1b59758e0f7"}, {"Element": "<span lang=\"EN-GB\">in patients treated with Perjeta in clinical trials^, and in the Post-marketing\nsetting</span>", "ID": "f98b3985-c3a6-4438-a723-3a881d746171", "Styles": "None", "Classes": "None", "Text": "in patients treated with Perjeta in clinical trials^, and in the Post-marketing setting", "ParentId": "22df08d5-7d9b-46da-9966-1c904e939c6d"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u2020</span>", "ID": "6fc08702-cd7f-47d5-940e-bb3c61c244e6", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u2020", "ParentId": "85fe61ff-3a1d-4cf9-ad6d-c1b59758e0f7"}, {"Element": "<b><span lang=\"EN-GB\"> </span></b>", "ID": "6a1ef794-6ed6-4ab7-96fe-0cef2a9b0b5e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "85fe61ff-3a1d-4cf9-ad6d-c1b59758e0f7"}, {"Element": "<span lang=\"EN-GB\"> </span>", "ID": "c4112da7-416c-4b2d-8205-3431e288a6b4", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "6a1ef794-6ed6-4ab7-96fe-0cef2a9b0b5e"}, {"Element": "<b><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></b>", "ID": "972978fe-0239-48b1-8657-3dae44b98d19", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "85fe61ff-3a1d-4cf9-ad6d-c1b59758e0f7"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">\u00a0</span>", "ID": "e47f08e2-23fe-4dfd-957e-85de0ea6adaf", "Styles": "color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "972978fe-0239-48b1-8657-3dae44b98d19"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">\u00a0</span></i></p>", "ID": "759f8db5-80af-4fe3-bf72-64e9cf1e05ae", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<i><span lang=\"EN-GB\">\u00a0</span></i>", "ID": "586085b8-2221-408e-bbbf-4316384194fd", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "759f8db5-80af-4fe3-bf72-64e9cf1e05ae"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4090ae04-0a95-48f6-b9fd-41c66eef246f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "586085b8-2221-408e-bbbf-4316384194fd"}, {"Element": "<div align=\"center\">\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\" width=\"723\">\n<thead>\n<tr style=\"height:31.65pt\">\n<td nowrap=\"\" style=\"width:120.45pt;border:solid windowtext 1.5pt;\n   padding:0in 4.25pt 0in 4.25pt;height:31.65pt\" width=\"161\">\n<p class=\"MsoNormal\" style=\"margin-left:-.05pt;text-indent:.05pt;page-break-after:\n   avoid;text-autospace:none\"><b><span lang=\"EN-GB\" style=\"color:black\">System </span></b><b><span lang=\"EN-GB\" style=\"color:black\">organ class</span></b></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border:solid windowtext 1.5pt;\n   border-left:none;padding:0in 4.25pt 0in 4.25pt;height:31.65pt\" width=\"141\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><i><u><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Very Common</span></u></i></b></p>\n</td>\n<td nowrap=\"\" style=\"width:105.5pt;border:solid windowtext 1.5pt;\n   border-left:none;padding:0in 4.25pt 0in 4.25pt;height:31.65pt\" width=\"141\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><i><u><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Common</span></u></i></b></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border:solid windowtext 1.5pt;\n   border-left:none;padding:0in 4.25pt 0in 4.25pt;height:31.65pt\" width=\"141\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><i><u><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Uncommon</span></u></i></b></p>\n</td>\n<td style=\"width:105.5pt;border:solid windowtext 1.5pt;border-left:\n   none;padding:0in 4.25pt 0in 4.25pt;height:31.65pt\" width=\"141\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><i><u><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Rare</span></u></i></b></p>\n</td>\n</tr>\n</thead>\n<tr style=\"height:29.6pt\">\n<td nowrap=\"\" style=\"width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:29.6pt\" valign=\"top\" width=\"161\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Infections and infestations</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:29.6pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Nasopharyngitis</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:29.6pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Paronychia</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Upper respiratory tract\n  infection</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:29.6pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td style=\"width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:29.6pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"height:27.05pt\">\n<td nowrap=\"\" style=\"width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:27.05pt\" valign=\"top\" width=\"161\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Blood and lymphatic system</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">disorders</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:27.05pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"IT\" style=\"font-size:10.0pt;color:black\">Febrile neutropenia*</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"IT\" style=\"font-size:10.0pt;color:black\">Neutropenia</span><span lang=\"IT\" style=\"font-size:10.0pt;color:black\"> </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"IT\" style=\"font-size:10.0pt;color:black\">Leucopenia </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"IT\" style=\"font-size:10.0pt;color:black\">Anaemia</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:27.05pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"IT\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:27.05pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"IT\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td style=\"width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:27.05pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"IT\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"height:27.05pt\">\n<td nowrap=\"\" style=\"width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:27.05pt\" valign=\"top\" width=\"161\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Immune system disorders</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:27.05pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Infusion reaction\u00b0\u00b0, *</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:27.05pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Hypersensitivity</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00b0, *</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Drug hypersensitivity\u00b0, *</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:27.05pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Anaphylactic reaction\u00b0, *</span></p>\n</td>\n<td style=\"width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:27.05pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Cytokine release syndrome\u00b0\u00b0</span></p>\n</td>\n</tr>\n<tr style=\"height:27.05pt\">\n<td nowrap=\"\" style=\"width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:27.05pt\" valign=\"top\" width=\"161\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Metabolism and nutrition\n  disorders</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:27.05pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Decreased appetite</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:27.05pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:27.05pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td style=\"width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:27.05pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Tumour lysis syndrome\u2020</span></p>\n</td>\n</tr>\n<tr style=\"height:15.55pt\">\n<td nowrap=\"\" style=\"width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:15.55pt\" valign=\"top\" width=\"161\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Psychiatric disorders</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:15.55pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Insomnia</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:15.55pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:15.55pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td style=\"width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:15.55pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"height:13.05pt\">\n<td nowrap=\"\" style=\"width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"161\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Nervous system disorders</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Neuropathy peripheral</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Headache\u00a0 </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Dysgeusia</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Peripheral sensory neuropathy</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Dizziness</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Paraesthesia</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td style=\"width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"height:18.2pt\">\n<td nowrap=\"\" style=\"width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"161\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Eye disorders</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Lacrimation increased</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td style=\"width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"height:18.2pt\">\n<td nowrap=\"\" style=\"width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"161\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Cardiac disorders</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Left ventricular dysfunction</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">**</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Cardiac failure congestive</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">**</span></p>\n</td>\n<td style=\"width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"height:18.2pt\">\n<td nowrap=\"\" style=\"width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"161\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Vascular disorders</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Hot flush</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td style=\"width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"height:18.2pt\">\n<td nowrap=\"\" style=\"width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"161\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Respiratory, thoracic and mediastinal\n  disorders</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Cough </span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Epistaxis</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Dyspnoea</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Interstitial lung disease </span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Pleural effusion</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td style=\"width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"height:11.6pt\">\n<td nowrap=\"\" style=\"width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:11.6pt\" valign=\"top\" width=\"161\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Gastrointestinal disorders</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:11.6pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Diarrhoea</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Vomiting\u00a0 </span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Stomatitis</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Nausea </span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Constipation </span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Dyspepsia </span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Abdominal pain</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:11.6pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></b></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:11.6pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></b></p>\n</td>\n<td style=\"width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:11.6pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></b></p>\n</td>\n</tr>\n<tr style=\"height:37.4pt\">\n<td nowrap=\"\" style=\"width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:37.4pt\" valign=\"top\" width=\"161\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Skin and subcutaneous tissue\n  disorders</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:37.4pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Alopecia</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Rash </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Nail disorder</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Pruritus</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Dry skin</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:37.4pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:37.4pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td style=\"width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:37.4pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"height:26.45pt\">\n<td nowrap=\"\" style=\"width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:26.45pt\" valign=\"top\" width=\"161\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Musculoskeletal and connective tissue disorders</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:26.45pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Myalgia</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Arthralgia</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Pain in extremity</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:26.45pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:26.45pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td style=\"width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:26.45pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"height:12.55pt\">\n<td nowrap=\"\" style=\"width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:12.55pt\" valign=\"top\" width=\"161\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">General disorders and\n  administration site conditions </span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:12.55pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Mucosal inflammation</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"PT-BR\" style=\"font-size:10.0pt;color:black\">Oedema peripheral</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"PT-BR\" style=\"font-size:10.0pt;color:black\">Pyrexia</span><span lang=\"PT-BR\" style=\"font-size:10.0pt;color:black\"> </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"PT-BR\" style=\"font-size:10.0pt;color:black\">Fatigue</span><span lang=\"PT-BR\" style=\"font-size:10.0pt;color:black\"> </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"PT-BR\" style=\"font-size:10.0pt;color:black\">Asthenia </span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:12.55pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Chills</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Pain</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Oedema</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:12.55pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td style=\"width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:12.55pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n</tr>\n</table>\n</div>", "ID": "e2784162-fde9-4a6c-8d6d-492b632103bc", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\" width=\"723\">\n<thead>\n<tr style=\"height:31.65pt\">\n<td nowrap=\"\" style=\"width:120.45pt;border:solid windowtext 1.5pt;\n   padding:0in 4.25pt 0in 4.25pt;height:31.65pt\" width=\"161\">\n<p class=\"MsoNormal\" style=\"margin-left:-.05pt;text-indent:.05pt;page-break-after:\n   avoid;text-autospace:none\"><b><span lang=\"EN-GB\" style=\"color:black\">System </span></b><b><span lang=\"EN-GB\" style=\"color:black\">organ class</span></b></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border:solid windowtext 1.5pt;\n   border-left:none;padding:0in 4.25pt 0in 4.25pt;height:31.65pt\" width=\"141\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><i><u><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Very Common</span></u></i></b></p>\n</td>\n<td nowrap=\"\" style=\"width:105.5pt;border:solid windowtext 1.5pt;\n   border-left:none;padding:0in 4.25pt 0in 4.25pt;height:31.65pt\" width=\"141\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><i><u><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Common</span></u></i></b></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border:solid windowtext 1.5pt;\n   border-left:none;padding:0in 4.25pt 0in 4.25pt;height:31.65pt\" width=\"141\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><i><u><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Uncommon</span></u></i></b></p>\n</td>\n<td style=\"width:105.5pt;border:solid windowtext 1.5pt;border-left:\n   none;padding:0in 4.25pt 0in 4.25pt;height:31.65pt\" width=\"141\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><i><u><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Rare</span></u></i></b></p>\n</td>\n</tr>\n</thead>\n<tr style=\"height:29.6pt\">\n<td nowrap=\"\" style=\"width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:29.6pt\" valign=\"top\" width=\"161\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Infections and infestations</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:29.6pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Nasopharyngitis</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:29.6pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Paronychia</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Upper respiratory tract\n  infection</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:29.6pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td style=\"width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:29.6pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"height:27.05pt\">\n<td nowrap=\"\" style=\"width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:27.05pt\" valign=\"top\" width=\"161\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Blood and lymphatic system</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">disorders</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:27.05pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"IT\" style=\"font-size:10.0pt;color:black\">Febrile neutropenia*</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"IT\" style=\"font-size:10.0pt;color:black\">Neutropenia</span><span lang=\"IT\" style=\"font-size:10.0pt;color:black\"> </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"IT\" style=\"font-size:10.0pt;color:black\">Leucopenia </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"IT\" style=\"font-size:10.0pt;color:black\">Anaemia</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:27.05pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"IT\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:27.05pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"IT\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td style=\"width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:27.05pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"IT\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"height:27.05pt\">\n<td nowrap=\"\" style=\"width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:27.05pt\" valign=\"top\" width=\"161\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Immune system disorders</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:27.05pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Infusion reaction\u00b0\u00b0, *</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:27.05pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Hypersensitivity</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00b0, *</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Drug hypersensitivity\u00b0, *</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:27.05pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Anaphylactic reaction\u00b0, *</span></p>\n</td>\n<td style=\"width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:27.05pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Cytokine release syndrome\u00b0\u00b0</span></p>\n</td>\n</tr>\n<tr style=\"height:27.05pt\">\n<td nowrap=\"\" style=\"width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:27.05pt\" valign=\"top\" width=\"161\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Metabolism and nutrition\n  disorders</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:27.05pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Decreased appetite</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:27.05pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:27.05pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td style=\"width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:27.05pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Tumour lysis syndrome\u2020</span></p>\n</td>\n</tr>\n<tr style=\"height:15.55pt\">\n<td nowrap=\"\" style=\"width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:15.55pt\" valign=\"top\" width=\"161\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Psychiatric disorders</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:15.55pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Insomnia</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:15.55pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:15.55pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td style=\"width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:15.55pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"height:13.05pt\">\n<td nowrap=\"\" style=\"width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"161\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Nervous system disorders</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Neuropathy peripheral</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Headache\u00a0 </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Dysgeusia</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Peripheral sensory neuropathy</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Dizziness</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Paraesthesia</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td style=\"width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"height:18.2pt\">\n<td nowrap=\"\" style=\"width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"161\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Eye disorders</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Lacrimation increased</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td style=\"width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"height:18.2pt\">\n<td nowrap=\"\" style=\"width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"161\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Cardiac disorders</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Left ventricular dysfunction</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">**</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Cardiac failure congestive</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">**</span></p>\n</td>\n<td style=\"width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"height:18.2pt\">\n<td nowrap=\"\" style=\"width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"161\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Vascular disorders</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Hot flush</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td style=\"width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"height:18.2pt\">\n<td nowrap=\"\" style=\"width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"161\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Respiratory, thoracic and mediastinal\n  disorders</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Cough </span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Epistaxis</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Dyspnoea</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Interstitial lung disease </span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Pleural effusion</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td style=\"width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"height:11.6pt\">\n<td nowrap=\"\" style=\"width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:11.6pt\" valign=\"top\" width=\"161\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Gastrointestinal disorders</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:11.6pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Diarrhoea</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Vomiting\u00a0 </span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Stomatitis</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Nausea </span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Constipation </span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Dyspepsia </span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Abdominal pain</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:11.6pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></b></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:11.6pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></b></p>\n</td>\n<td style=\"width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:11.6pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></b></p>\n</td>\n</tr>\n<tr style=\"height:37.4pt\">\n<td nowrap=\"\" style=\"width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:37.4pt\" valign=\"top\" width=\"161\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Skin and subcutaneous tissue\n  disorders</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:37.4pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Alopecia</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Rash </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Nail disorder</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Pruritus</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Dry skin</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:37.4pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:37.4pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td style=\"width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:37.4pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"height:26.45pt\">\n<td nowrap=\"\" style=\"width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:26.45pt\" valign=\"top\" width=\"161\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Musculoskeletal and connective tissue disorders</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:26.45pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Myalgia</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Arthralgia</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Pain in extremity</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:26.45pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:26.45pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td style=\"width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:26.45pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"height:12.55pt\">\n<td nowrap=\"\" style=\"width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:12.55pt\" valign=\"top\" width=\"161\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">General disorders and\n  administration site conditions </span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:12.55pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Mucosal inflammation</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"PT-BR\" style=\"font-size:10.0pt;color:black\">Oedema peripheral</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"PT-BR\" style=\"font-size:10.0pt;color:black\">Pyrexia</span><span lang=\"PT-BR\" style=\"font-size:10.0pt;color:black\"> </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"PT-BR\" style=\"font-size:10.0pt;color:black\">Fatigue</span><span lang=\"PT-BR\" style=\"font-size:10.0pt;color:black\"> </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"PT-BR\" style=\"font-size:10.0pt;color:black\">Asthenia </span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:12.55pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Chills</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Pain</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Oedema</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:12.55pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td style=\"width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:12.55pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n</tr>\n</table>", "ID": "161b9621-307c-4cd5-b01e-b40713008112", "Styles": "border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Text": "                ", "ParentId": "e2784162-fde9-4a6c-8d6d-492b632103bc"}, {"Element": "<thead>\n<tr style=\"height:31.65pt\">\n<td nowrap=\"\" style=\"width:120.45pt;border:solid windowtext 1.5pt;\n   padding:0in 4.25pt 0in 4.25pt;height:31.65pt\" width=\"161\">\n<p class=\"MsoNormal\" style=\"margin-left:-.05pt;text-indent:.05pt;page-break-after:\n   avoid;text-autospace:none\"><b><span lang=\"EN-GB\" style=\"color:black\">System </span></b><b><span lang=\"EN-GB\" style=\"color:black\">organ class</span></b></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border:solid windowtext 1.5pt;\n   border-left:none;padding:0in 4.25pt 0in 4.25pt;height:31.65pt\" width=\"141\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><i><u><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Very Common</span></u></i></b></p>\n</td>\n<td nowrap=\"\" style=\"width:105.5pt;border:solid windowtext 1.5pt;\n   border-left:none;padding:0in 4.25pt 0in 4.25pt;height:31.65pt\" width=\"141\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><i><u><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Common</span></u></i></b></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border:solid windowtext 1.5pt;\n   border-left:none;padding:0in 4.25pt 0in 4.25pt;height:31.65pt\" width=\"141\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><i><u><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Uncommon</span></u></i></b></p>\n</td>\n<td style=\"width:105.5pt;border:solid windowtext 1.5pt;border-left:\n   none;padding:0in 4.25pt 0in 4.25pt;height:31.65pt\" width=\"141\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><i><u><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Rare</span></u></i></b></p>\n</td>\n</tr>\n</thead>", "ID": "00e9d31e-e317-447a-b6b5-c544b859f76f", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "161b9621-307c-4cd5-b01e-b40713008112"}, {"Element": "<tr style=\"height:31.65pt\">\n<td nowrap=\"\" style=\"width:120.45pt;border:solid windowtext 1.5pt;\n   padding:0in 4.25pt 0in 4.25pt;height:31.65pt\" width=\"161\">\n<p class=\"MsoNormal\" style=\"margin-left:-.05pt;text-indent:.05pt;page-break-after:\n   avoid;text-autospace:none\"><b><span lang=\"EN-GB\" style=\"color:black\">System </span></b><b><span lang=\"EN-GB\" style=\"color:black\">organ class</span></b></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border:solid windowtext 1.5pt;\n   border-left:none;padding:0in 4.25pt 0in 4.25pt;height:31.65pt\" width=\"141\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><i><u><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Very Common</span></u></i></b></p>\n</td>\n<td nowrap=\"\" style=\"width:105.5pt;border:solid windowtext 1.5pt;\n   border-left:none;padding:0in 4.25pt 0in 4.25pt;height:31.65pt\" width=\"141\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><i><u><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Common</span></u></i></b></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border:solid windowtext 1.5pt;\n   border-left:none;padding:0in 4.25pt 0in 4.25pt;height:31.65pt\" width=\"141\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><i><u><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Uncommon</span></u></i></b></p>\n</td>\n<td style=\"width:105.5pt;border:solid windowtext 1.5pt;border-left:\n   none;padding:0in 4.25pt 0in 4.25pt;height:31.65pt\" width=\"141\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><i><u><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Rare</span></u></i></b></p>\n</td>\n</tr>", "ID": "649d6d6e-519c-4d67-9212-dbe66ae6a9a6", "Styles": "height:31.65pt", "Classes": "None", "Text": "      ", "ParentId": "00e9d31e-e317-447a-b6b5-c544b859f76f"}, {"Element": "<td nowrap=\"\" style=\"width:120.45pt;border:solid windowtext 1.5pt;\n   padding:0in 4.25pt 0in 4.25pt;height:31.65pt\" width=\"161\">\n<p class=\"MsoNormal\" style=\"margin-left:-.05pt;text-indent:.05pt;page-break-after:\n   avoid;text-autospace:none\"><b><span lang=\"EN-GB\" style=\"color:black\">System </span></b><b><span lang=\"EN-GB\" style=\"color:black\">organ class</span></b></p>\n</td>", "ID": "50c8fbf0-a4ec-4f55-b079-dc8ee7caa8fb", "Styles": "width:120.45pt;border:solid windowtext 1.5pt;\n   padding:0in 4.25pt 0in 4.25pt;height:31.65pt", "Classes": "None", "Text": "  ", "ParentId": "649d6d6e-519c-4d67-9212-dbe66ae6a9a6"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:-.05pt;text-indent:.05pt;page-break-after:\n   avoid;text-autospace:none\"><b><span lang=\"EN-GB\" style=\"color:black\">System </span></b><b><span lang=\"EN-GB\" style=\"color:black\">organ class</span></b></p>", "ID": "331fd907-0178-41cd-b29b-03713bfbb63b", "Styles": "margin-left:-.05pt;text-indent:.05pt;page-break-after:\n   avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "50c8fbf0-a4ec-4f55-b079-dc8ee7caa8fb"}, {"Element": "<b><span lang=\"EN-GB\" style=\"color:black\">System </span></b>", "ID": "4d935486-aefa-45e0-ab92-1d9f71c69131", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "331fd907-0178-41cd-b29b-03713bfbb63b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">System </span>", "ID": "2237fe1c-44f1-4636-a6eb-5320d1eeb072", "Styles": "color:black", "Classes": "None", "Text": "System ", "ParentId": "4d935486-aefa-45e0-ab92-1d9f71c69131"}, {"Element": "<b><span lang=\"EN-GB\" style=\"color:black\">organ class</span></b>", "ID": "d7bb12df-5f1c-413c-adbd-f6b927858c53", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "331fd907-0178-41cd-b29b-03713bfbb63b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">organ class</span>", "ID": "565fe7ad-8214-4fde-af71-dc125519efdb", "Styles": "color:black", "Classes": "None", "Text": "organ class", "ParentId": "d7bb12df-5f1c-413c-adbd-f6b927858c53"}, {"Element": "<td nowrap=\"\" style=\"width:105.45pt;border:solid windowtext 1.5pt;\n   border-left:none;padding:0in 4.25pt 0in 4.25pt;height:31.65pt\" width=\"141\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><i><u><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Very Common</span></u></i></b></p>\n</td>", "ID": "1fd6a312-ced8-47b0-8d01-0165b83218c0", "Styles": "width:105.45pt;border:solid windowtext 1.5pt;\n   border-left:none;padding:0in 4.25pt 0in 4.25pt;height:31.65pt", "Classes": "None", "Text": "  ", "ParentId": "649d6d6e-519c-4d67-9212-dbe66ae6a9a6"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><i><u><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Very Common</span></u></i></b></p>", "ID": "c60f0b0c-c9e7-4757-84de-d57f0398b385", "Styles": "text-align:center;page-break-after:\n   avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1fd6a312-ced8-47b0-8d01-0165b83218c0"}, {"Element": "<b><i><u><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Very Common</span></u></i></b>", "ID": "9a0236bc-3822-4b26-9871-48bdcaf9895c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c60f0b0c-c9e7-4757-84de-d57f0398b385"}, {"Element": "<i><u><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Very Common</span></u></i>", "ID": "e0d9da9b-6f4f-4e8d-8ae7-15eaf8223d16", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "9a0236bc-3822-4b26-9871-48bdcaf9895c"}, {"Element": "<u><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Very Common</span></u>", "ID": "f09b36ab-7515-4abf-9d7d-00745207536f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e0d9da9b-6f4f-4e8d-8ae7-15eaf8223d16"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Very Common</span>", "ID": "0bb7f4d5-5429-41d1-982c-b4016965b0a2", "Styles": "font-size:10.0pt;\n   color:black", "Classes": "None", "Text": "Very Common", "ParentId": "f09b36ab-7515-4abf-9d7d-00745207536f"}, {"Element": "<td nowrap=\"\" style=\"width:105.5pt;border:solid windowtext 1.5pt;\n   border-left:none;padding:0in 4.25pt 0in 4.25pt;height:31.65pt\" width=\"141\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><i><u><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Common</span></u></i></b></p>\n</td>", "ID": "4273da06-0a89-47e9-8038-f012aea329d2", "Styles": "width:105.5pt;border:solid windowtext 1.5pt;\n   border-left:none;padding:0in 4.25pt 0in 4.25pt;height:31.65pt", "Classes": "None", "Text": "  ", "ParentId": "649d6d6e-519c-4d67-9212-dbe66ae6a9a6"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><i><u><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Common</span></u></i></b></p>", "ID": "c7864852-1b6d-44ae-8ed2-1abd4c654df0", "Styles": "text-align:center;page-break-after:\n   avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4273da06-0a89-47e9-8038-f012aea329d2"}, {"Element": "<b><i><u><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Common</span></u></i></b>", "ID": "1d400b61-2176-4479-a9cb-47df768cdf55", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c7864852-1b6d-44ae-8ed2-1abd4c654df0"}, {"Element": "<i><u><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Common</span></u></i>", "ID": "092b012b-a8fe-4636-bd2d-22950a80959e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "1d400b61-2176-4479-a9cb-47df768cdf55"}, {"Element": "<u><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Common</span></u>", "ID": "df50bd69-9925-4812-a27f-32bdd3b97ede", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "092b012b-a8fe-4636-bd2d-22950a80959e"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Common</span>", "ID": "a63567af-e1ce-40ca-857a-234edc6afbd8", "Styles": "font-size:10.0pt;\n   color:black", "Classes": "None", "Text": "Common", "ParentId": "df50bd69-9925-4812-a27f-32bdd3b97ede"}, {"Element": "<td nowrap=\"\" style=\"width:105.45pt;border:solid windowtext 1.5pt;\n   border-left:none;padding:0in 4.25pt 0in 4.25pt;height:31.65pt\" width=\"141\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><i><u><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Uncommon</span></u></i></b></p>\n</td>", "ID": "568765a0-d66d-48b6-98f1-de6301ab7b50", "Styles": "width:105.45pt;border:solid windowtext 1.5pt;\n   border-left:none;padding:0in 4.25pt 0in 4.25pt;height:31.65pt", "Classes": "None", "Text": "  ", "ParentId": "649d6d6e-519c-4d67-9212-dbe66ae6a9a6"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><i><u><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Uncommon</span></u></i></b></p>", "ID": "59c006c2-7007-4b59-aae7-e4a04db7da05", "Styles": "text-align:center;page-break-after:\n   avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "568765a0-d66d-48b6-98f1-de6301ab7b50"}, {"Element": "<b><i><u><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Uncommon</span></u></i></b>", "ID": "5b46d687-d445-4031-935f-68d9000f871b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "59c006c2-7007-4b59-aae7-e4a04db7da05"}, {"Element": "<i><u><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Uncommon</span></u></i>", "ID": "aac69895-d008-436a-9ef0-952f89545e81", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "5b46d687-d445-4031-935f-68d9000f871b"}, {"Element": "<u><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Uncommon</span></u>", "ID": "91aa28f6-9358-4eee-bf6e-9a6f4c46bc14", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "aac69895-d008-436a-9ef0-952f89545e81"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Uncommon</span>", "ID": "6cdd0b6f-7966-47cc-b418-baa6563e7abd", "Styles": "font-size:10.0pt;\n   color:black", "Classes": "None", "Text": "Uncommon", "ParentId": "91aa28f6-9358-4eee-bf6e-9a6f4c46bc14"}, {"Element": "<td style=\"width:105.5pt;border:solid windowtext 1.5pt;border-left:\n   none;padding:0in 4.25pt 0in 4.25pt;height:31.65pt\" width=\"141\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><i><u><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Rare</span></u></i></b></p>\n</td>", "ID": "35b321d9-9d1f-454e-a74f-0935f46d6a31", "Styles": "width:105.5pt;border:solid windowtext 1.5pt;border-left:\n   none;padding:0in 4.25pt 0in 4.25pt;height:31.65pt", "Classes": "None", "Text": "  ", "ParentId": "649d6d6e-519c-4d67-9212-dbe66ae6a9a6"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><i><u><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Rare</span></u></i></b></p>", "ID": "f7dc202d-0690-4199-aab7-5ec0656b83ab", "Styles": "text-align:center;page-break-after:\n   avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "35b321d9-9d1f-454e-a74f-0935f46d6a31"}, {"Element": "<b><i><u><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Rare</span></u></i></b>", "ID": "0ea95f39-4741-487c-adda-6a498ea33bbd", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f7dc202d-0690-4199-aab7-5ec0656b83ab"}, {"Element": "<i><u><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Rare</span></u></i>", "ID": "192c87d9-3b2f-47cb-8659-5ae2eaaa853f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "0ea95f39-4741-487c-adda-6a498ea33bbd"}, {"Element": "<u><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Rare</span></u>", "ID": "db525e77-ad7f-497a-b7e4-78e76e69bde1", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "192c87d9-3b2f-47cb-8659-5ae2eaaa853f"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Rare</span>", "ID": "4f49d962-1ace-4bdd-b568-05b2258cf93a", "Styles": "font-size:10.0pt;\n   color:black", "Classes": "None", "Text": "Rare", "ParentId": "db525e77-ad7f-497a-b7e4-78e76e69bde1"}, {"Element": "<tr style=\"height:29.6pt\">\n<td nowrap=\"\" style=\"width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:29.6pt\" valign=\"top\" width=\"161\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Infections and infestations</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:29.6pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Nasopharyngitis</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:29.6pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Paronychia</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Upper respiratory tract\n  infection</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:29.6pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td style=\"width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:29.6pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n</tr>", "ID": "8c3a9fa9-5ede-44b0-8e6c-b5dadd232c68", "Styles": "height:29.6pt", "Classes": "None", "Text": "      ", "ParentId": "161b9621-307c-4cd5-b01e-b40713008112"}, {"Element": "<td nowrap=\"\" style=\"width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:29.6pt\" valign=\"top\" width=\"161\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Infections and infestations</span></p>\n</td>", "ID": "bb3cd4ed-9618-4360-82ca-0261f62148aa", "Styles": "width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:29.6pt", "Classes": "None", "Text": "  ", "ParentId": "8c3a9fa9-5ede-44b0-8e6c-b5dadd232c68"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Infections and infestations</span></p>", "ID": "8b6ac350-1f3b-4173-8801-4db78b51e5ea", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "bb3cd4ed-9618-4360-82ca-0261f62148aa"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Infections and infestations</span>", "ID": "6e55c0ad-d781-407c-91eb-dcf2c3b97004", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "Infections and infestations", "ParentId": "8b6ac350-1f3b-4173-8801-4db78b51e5ea"}, {"Element": "<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:29.6pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Nasopharyngitis</span></p>\n</td>", "ID": "ea3f9526-25eb-4858-a039-13ad7c1f7074", "Styles": "width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:29.6pt", "Classes": "None", "Text": "  ", "ParentId": "8c3a9fa9-5ede-44b0-8e6c-b5dadd232c68"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Nasopharyngitis</span></p>", "ID": "5402022c-fcdd-4c60-9e0a-577883dca732", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ea3f9526-25eb-4858-a039-13ad7c1f7074"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Nasopharyngitis</span>", "ID": "349271b6-3f9c-484d-be0d-0968bf0dbf42", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "Nasopharyngitis", "ParentId": "5402022c-fcdd-4c60-9e0a-577883dca732"}, {"Element": "<td nowrap=\"\" style=\"width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:29.6pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Paronychia</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Upper respiratory tract\n  infection</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>", "ID": "6717301f-c3f1-461f-994b-1b3fe7077db7", "Styles": "width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:29.6pt", "Classes": "None", "Text": "    ", "ParentId": "8c3a9fa9-5ede-44b0-8e6c-b5dadd232c68"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Paronychia</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>", "ID": "6fc76a18-4a35-4ead-8ef9-b8bd1a222c15", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "6717301f-c3f1-461f-994b-1b3fe7077db7"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Paronychia</span>", "ID": "df95f153-b740-4077-9e90-609999da25f8", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "Paronychia", "ParentId": "6fc76a18-4a35-4ead-8ef9-b8bd1a222c15"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span>", "ID": "e71212e5-2e5c-46d6-8837-fce0ab810c5b", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": " ", "ParentId": "6fc76a18-4a35-4ead-8ef9-b8bd1a222c15"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Upper respiratory tract\n  infection</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>", "ID": "e12538be-8838-45da-803c-4544d399e64e", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "6717301f-c3f1-461f-994b-1b3fe7077db7"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Upper respiratory tract\n  infection</span>", "ID": "1c7b8b8f-e066-45c2-808e-1857f8274c57", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "Upper respiratory tract   infection", "ParentId": "e12538be-8838-45da-803c-4544d399e64e"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span>", "ID": "4c3c4536-798e-421d-85aa-d35069297df4", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": " ", "ParentId": "e12538be-8838-45da-803c-4544d399e64e"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>", "ID": "42f4456b-c4a6-4ad6-9587-3f00fe6dbff9", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "6717301f-c3f1-461f-994b-1b3fe7077db7"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span>", "ID": "859b7cc4-ef39-42f2-8908-9fa303879a5f", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "42f4456b-c4a6-4ad6-9587-3f00fe6dbff9"}, {"Element": "<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:29.6pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>", "ID": "919a5b14-d4da-408e-9226-ce14e60fd313", "Styles": "width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:29.6pt", "Classes": "None", "Text": "  ", "ParentId": "8c3a9fa9-5ede-44b0-8e6c-b5dadd232c68"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>", "ID": "1ea0acf1-ca1e-4884-a473-c8d103c2f239", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "919a5b14-d4da-408e-9226-ce14e60fd313"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span>", "ID": "e94bb65b-fa47-4839-aed8-4fbc5e4f0e0f", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "1ea0acf1-ca1e-4884-a473-c8d103c2f239"}, {"Element": "<td style=\"width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:29.6pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>", "ID": "9c3f3c8d-c96c-47f6-be4c-348fe0a08272", "Styles": "width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:29.6pt", "Classes": "None", "Text": "  ", "ParentId": "8c3a9fa9-5ede-44b0-8e6c-b5dadd232c68"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>", "ID": "ac2ff3f4-d710-4c70-a5d3-d2f9b2d94906", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9c3f3c8d-c96c-47f6-be4c-348fe0a08272"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span>", "ID": "4386ee05-d066-4500-a7fe-9bf4f263faa5", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "ac2ff3f4-d710-4c70-a5d3-d2f9b2d94906"}, {"Element": "<tr style=\"height:27.05pt\">\n<td nowrap=\"\" style=\"width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:27.05pt\" valign=\"top\" width=\"161\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Blood and lymphatic system</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">disorders</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:27.05pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"IT\" style=\"font-size:10.0pt;color:black\">Febrile neutropenia*</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"IT\" style=\"font-size:10.0pt;color:black\">Neutropenia</span><span lang=\"IT\" style=\"font-size:10.0pt;color:black\"> </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"IT\" style=\"font-size:10.0pt;color:black\">Leucopenia </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"IT\" style=\"font-size:10.0pt;color:black\">Anaemia</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:27.05pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"IT\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:27.05pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"IT\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td style=\"width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:27.05pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"IT\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n</tr>", "ID": "a3ccb340-d722-4343-a838-68bbdcf4f5eb", "Styles": "height:27.05pt", "Classes": "None", "Text": "      ", "ParentId": "161b9621-307c-4cd5-b01e-b40713008112"}, {"Element": "<td nowrap=\"\" style=\"width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:27.05pt\" valign=\"top\" width=\"161\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Blood and lymphatic system</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">disorders</span></p>\n</td>", "ID": "a792d0f4-df22-4f81-9f87-085ca4370dde", "Styles": "width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:27.05pt", "Classes": "None", "Text": "   ", "ParentId": "a3ccb340-d722-4343-a838-68bbdcf4f5eb"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Blood and lymphatic system</span></p>", "ID": "9da5a5f4-052b-4ca5-a9c0-aabd554ad77f", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a792d0f4-df22-4f81-9f87-085ca4370dde"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Blood and lymphatic system</span>", "ID": "6433b1c9-792a-45d0-b7be-31b1a2860c54", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "Blood and lymphatic system", "ParentId": "9da5a5f4-052b-4ca5-a9c0-aabd554ad77f"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">disorders</span></p>", "ID": "42aa2120-00a8-4f68-a302-26101a4727d0", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a792d0f4-df22-4f81-9f87-085ca4370dde"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">disorders</span>", "ID": "086c1bae-8068-4054-8dd1-bfb9a985395b", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "disorders", "ParentId": "42aa2120-00a8-4f68-a302-26101a4727d0"}, {"Element": "<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:27.05pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"IT\" style=\"font-size:10.0pt;color:black\">Febrile neutropenia*</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"IT\" style=\"font-size:10.0pt;color:black\">Neutropenia</span><span lang=\"IT\" style=\"font-size:10.0pt;color:black\"> </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"IT\" style=\"font-size:10.0pt;color:black\">Leucopenia </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"IT\" style=\"font-size:10.0pt;color:black\">Anaemia</span></p>\n</td>", "ID": "71fe2b5f-aa31-4598-a09c-93ac16c4cb6a", "Styles": "width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:27.05pt", "Classes": "None", "Text": "     ", "ParentId": "a3ccb340-d722-4343-a838-68bbdcf4f5eb"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"IT\" style=\"font-size:10.0pt;color:black\">Febrile neutropenia*</span></p>", "ID": "d39eec13-b4ce-4377-a479-943aa9a3cf6f", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "71fe2b5f-aa31-4598-a09c-93ac16c4cb6a"}, {"Element": "<span lang=\"IT\" style=\"font-size:10.0pt;color:black\">Febrile neutropenia*</span>", "ID": "bdb82412-31e3-473a-98cd-d3f8ea4a4320", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "Febrile neutropenia*", "ParentId": "d39eec13-b4ce-4377-a479-943aa9a3cf6f"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"IT\" style=\"font-size:10.0pt;color:black\">Neutropenia</span><span lang=\"IT\" style=\"font-size:10.0pt;color:black\"> </span></p>", "ID": "5da3d609-03b8-46be-8cda-34e00c4da28d", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "71fe2b5f-aa31-4598-a09c-93ac16c4cb6a"}, {"Element": "<span lang=\"IT\" style=\"font-size:10.0pt;color:black\">Neutropenia</span>", "ID": "abed5c3d-e59f-40c3-9447-7be9c190d710", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "Neutropenia", "ParentId": "5da3d609-03b8-46be-8cda-34e00c4da28d"}, {"Element": "<span lang=\"IT\" style=\"font-size:10.0pt;color:black\"> </span>", "ID": "fb0c0913-f3df-4a2b-b2f7-b3074b26c1fa", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": " ", "ParentId": "5da3d609-03b8-46be-8cda-34e00c4da28d"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"IT\" style=\"font-size:10.0pt;color:black\">Leucopenia </span></p>", "ID": "b4db0426-0319-4f24-98ff-5e5f770a357f", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "71fe2b5f-aa31-4598-a09c-93ac16c4cb6a"}, {"Element": "<span lang=\"IT\" style=\"font-size:10.0pt;color:black\">Leucopenia </span>", "ID": "822a8b33-658a-42eb-942c-569b04b7b30a", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "Leucopenia ", "ParentId": "b4db0426-0319-4f24-98ff-5e5f770a357f"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"IT\" style=\"font-size:10.0pt;color:black\">Anaemia</span></p>", "ID": "94bb4b0b-0299-4f90-9bcc-2367f87e7869", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "71fe2b5f-aa31-4598-a09c-93ac16c4cb6a"}, {"Element": "<span lang=\"IT\" style=\"font-size:10.0pt;color:black\">Anaemia</span>", "ID": "fe24b81c-d9f6-4f56-96cb-285256de2c91", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "Anaemia", "ParentId": "94bb4b0b-0299-4f90-9bcc-2367f87e7869"}, {"Element": "<td nowrap=\"\" style=\"width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:27.05pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"IT\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>", "ID": "4470a1aa-675e-4b3e-94d6-ff664e03b071", "Styles": "width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:27.05pt", "Classes": "None", "Text": "  ", "ParentId": "a3ccb340-d722-4343-a838-68bbdcf4f5eb"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"IT\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>", "ID": "c519d522-cd4d-4f50-af81-5c4753d9e320", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4470a1aa-675e-4b3e-94d6-ff664e03b071"}, {"Element": "<span lang=\"IT\" style=\"font-size:10.0pt;color:black\">\u00a0</span>", "ID": "cd3bab4d-89e1-4c8f-91d0-8c7f9c0da0a4", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "c519d522-cd4d-4f50-af81-5c4753d9e320"}, {"Element": "<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:27.05pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"IT\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>", "ID": "088f7962-a173-4ed0-a69e-cffd5ff65f3e", "Styles": "width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:27.05pt", "Classes": "None", "Text": "  ", "ParentId": "a3ccb340-d722-4343-a838-68bbdcf4f5eb"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"IT\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>", "ID": "507249dd-06ba-498a-a5ac-2ec4795e5a2c", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "088f7962-a173-4ed0-a69e-cffd5ff65f3e"}, {"Element": "<span lang=\"IT\" style=\"font-size:10.0pt;color:black\">\u00a0</span>", "ID": "7f605842-88cd-47f7-b660-02ea1b92a917", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "507249dd-06ba-498a-a5ac-2ec4795e5a2c"}, {"Element": "<td style=\"width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:27.05pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"IT\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>", "ID": "0eb08f0e-ee48-4925-af72-32f15729b0bf", "Styles": "width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:27.05pt", "Classes": "None", "Text": "  ", "ParentId": "a3ccb340-d722-4343-a838-68bbdcf4f5eb"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"IT\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>", "ID": "c67670c9-11b3-4e7c-af12-d6a2ed076f49", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0eb08f0e-ee48-4925-af72-32f15729b0bf"}, {"Element": "<span lang=\"IT\" style=\"font-size:10.0pt;color:black\">\u00a0</span>", "ID": "4bcb00f3-1d9a-4f28-ab19-6c9d33b82d5a", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "c67670c9-11b3-4e7c-af12-d6a2ed076f49"}, {"Element": "<tr style=\"height:27.05pt\">\n<td nowrap=\"\" style=\"width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:27.05pt\" valign=\"top\" width=\"161\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Immune system disorders</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:27.05pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Infusion reaction\u00b0\u00b0, *</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:27.05pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Hypersensitivity</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00b0, *</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Drug hypersensitivity\u00b0, *</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:27.05pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Anaphylactic reaction\u00b0, *</span></p>\n</td>\n<td style=\"width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:27.05pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Cytokine release syndrome\u00b0\u00b0</span></p>\n</td>\n</tr>", "ID": "f7a28a30-5dd6-4902-a4d1-bd38ef784e0d", "Styles": "height:27.05pt", "Classes": "None", "Text": "      ", "ParentId": "161b9621-307c-4cd5-b01e-b40713008112"}, {"Element": "<td nowrap=\"\" style=\"width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:27.05pt\" valign=\"top\" width=\"161\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Immune system disorders</span></p>\n</td>", "ID": "82a849c5-5515-4f24-b031-953e2bf6954e", "Styles": "width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:27.05pt", "Classes": "None", "Text": "  ", "ParentId": "f7a28a30-5dd6-4902-a4d1-bd38ef784e0d"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Immune system disorders</span></p>", "ID": "c36ccf70-e13f-4ec7-994a-94ed316d91ba", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "82a849c5-5515-4f24-b031-953e2bf6954e"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Immune system disorders</span>", "ID": "cd8735b2-cbc7-4e5c-9f62-c3950c594d44", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "Immune system disorders", "ParentId": "c36ccf70-e13f-4ec7-994a-94ed316d91ba"}, {"Element": "<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:27.05pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Infusion reaction\u00b0\u00b0, *</span></p>\n</td>", "ID": "678623b5-aec3-4fe6-8a55-6b2359c9cecb", "Styles": "width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:27.05pt", "Classes": "None", "Text": "  ", "ParentId": "f7a28a30-5dd6-4902-a4d1-bd38ef784e0d"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Infusion reaction\u00b0\u00b0, *</span></p>", "ID": "45245dab-355b-4e37-9a44-f37774cb727f", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "678623b5-aec3-4fe6-8a55-6b2359c9cecb"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Infusion reaction\u00b0\u00b0, *</span>", "ID": "671d7cb0-3102-4525-a85e-f4891c6971a0", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "Infusion reaction\u00b0\u00b0, *", "ParentId": "45245dab-355b-4e37-9a44-f37774cb727f"}, {"Element": "<td nowrap=\"\" style=\"width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:27.05pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Hypersensitivity</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00b0, *</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Drug hypersensitivity\u00b0, *</span></p>\n</td>", "ID": "abb0bd7a-df7b-434c-a716-505aa8920ef6", "Styles": "width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:27.05pt", "Classes": "None", "Text": "   ", "ParentId": "f7a28a30-5dd6-4902-a4d1-bd38ef784e0d"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Hypersensitivity</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00b0, *</span></p>", "ID": "20f7b59b-1a85-4655-8b11-60defd37ee2e", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "abb0bd7a-df7b-434c-a716-505aa8920ef6"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Hypersensitivity</span>", "ID": "88a7ba1f-6f5f-4173-9d70-77c40d01b377", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "Hypersensitivity", "ParentId": "20f7b59b-1a85-4655-8b11-60defd37ee2e"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00b0, *</span>", "ID": "2efb6540-9f4f-41ef-9e7e-00f84fa5f445", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "\u00b0, *", "ParentId": "20f7b59b-1a85-4655-8b11-60defd37ee2e"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Drug hypersensitivity\u00b0, *</span></p>", "ID": "aeeb2618-ef9f-4e61-820c-f993461714b3", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "abb0bd7a-df7b-434c-a716-505aa8920ef6"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Drug hypersensitivity\u00b0, *</span>", "ID": "d1c9820d-7b2a-4b20-97dd-4d062b4a0625", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "Drug hypersensitivity\u00b0, *", "ParentId": "aeeb2618-ef9f-4e61-820c-f993461714b3"}, {"Element": "<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:27.05pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Anaphylactic reaction\u00b0, *</span></p>\n</td>", "ID": "f9d23841-8bcd-4c87-8955-98f6eec0eb92", "Styles": "width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:27.05pt", "Classes": "None", "Text": "  ", "ParentId": "f7a28a30-5dd6-4902-a4d1-bd38ef784e0d"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Anaphylactic reaction\u00b0, *</span></p>", "ID": "1923af2b-ebd3-40dd-8884-c370d2d3886e", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f9d23841-8bcd-4c87-8955-98f6eec0eb92"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Anaphylactic reaction\u00b0, *</span>", "ID": "d22c032f-37cc-42de-a744-facf735b80ff", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "Anaphylactic reaction\u00b0, *", "ParentId": "1923af2b-ebd3-40dd-8884-c370d2d3886e"}, {"Element": "<td style=\"width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:27.05pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Cytokine release syndrome\u00b0\u00b0</span></p>\n</td>", "ID": "498ee284-f4e2-420f-b772-5d3e6497237d", "Styles": "width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:27.05pt", "Classes": "None", "Text": "  ", "ParentId": "f7a28a30-5dd6-4902-a4d1-bd38ef784e0d"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Cytokine release syndrome\u00b0\u00b0</span></p>", "ID": "5c20bf4d-9555-41cf-b279-b15ddeb4e43a", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "498ee284-f4e2-420f-b772-5d3e6497237d"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Cytokine release syndrome\u00b0\u00b0</span>", "ID": "22739809-ddae-4454-a28d-48e8797eae85", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "Cytokine release syndrome\u00b0\u00b0", "ParentId": "5c20bf4d-9555-41cf-b279-b15ddeb4e43a"}, {"Element": "<tr style=\"height:27.05pt\">\n<td nowrap=\"\" style=\"width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:27.05pt\" valign=\"top\" width=\"161\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Metabolism and nutrition\n  disorders</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:27.05pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Decreased appetite</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:27.05pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:27.05pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td style=\"width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:27.05pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Tumour lysis syndrome\u2020</span></p>\n</td>\n</tr>", "ID": "dc1fbccc-07fd-49cf-bc3d-10b4b49ed050", "Styles": "height:27.05pt", "Classes": "None", "Text": "      ", "ParentId": "161b9621-307c-4cd5-b01e-b40713008112"}, {"Element": "<td nowrap=\"\" style=\"width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:27.05pt\" valign=\"top\" width=\"161\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Metabolism and nutrition\n  disorders</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n</td>", "ID": "5ccb39b5-26b1-408c-b418-06a008ded98b", "Styles": "width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:27.05pt", "Classes": "None", "Text": "  ", "ParentId": "dc1fbccc-07fd-49cf-bc3d-10b4b49ed050"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Metabolism and nutrition\n  disorders</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>", "ID": "9add6f0b-1371-4e98-b7d0-082cf4c8fb9f", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5ccb39b5-26b1-408c-b418-06a008ded98b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Metabolism and nutrition\n  disorders</span>", "ID": "7b19bcbb-e839-48b1-98ee-dde53fcae1b6", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "Metabolism and nutrition   disorders", "ParentId": "9add6f0b-1371-4e98-b7d0-082cf4c8fb9f"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span>", "ID": "9861891c-8c07-41a9-ae77-80be24a004dd", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": " ", "ParentId": "9add6f0b-1371-4e98-b7d0-082cf4c8fb9f"}, {"Element": "<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:27.05pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Decreased appetite</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n</td>", "ID": "b4545b43-b28b-42b7-b35a-75ae134d2e4b", "Styles": "width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:27.05pt", "Classes": "None", "Text": "  ", "ParentId": "dc1fbccc-07fd-49cf-bc3d-10b4b49ed050"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Decreased appetite</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>", "ID": "25e67831-9651-426b-b45c-475f2ee83c08", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b4545b43-b28b-42b7-b35a-75ae134d2e4b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Decreased appetite</span>", "ID": "e3bc103c-7392-4f44-90c0-661ccf973e47", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "Decreased appetite", "ParentId": "25e67831-9651-426b-b45c-475f2ee83c08"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span>", "ID": "ce3be923-33dc-4b3d-9529-9a77b78b504b", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": " ", "ParentId": "25e67831-9651-426b-b45c-475f2ee83c08"}, {"Element": "<td nowrap=\"\" style=\"width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:27.05pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>", "ID": "2fbc735e-5503-443c-b892-c0384516ab72", "Styles": "width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:27.05pt", "Classes": "None", "Text": "  ", "ParentId": "dc1fbccc-07fd-49cf-bc3d-10b4b49ed050"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>", "ID": "52759cf4-9f5d-47a5-ab3c-fb153d207b0a", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "2fbc735e-5503-443c-b892-c0384516ab72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span>", "ID": "690ba6fc-e4a6-4b48-a0a5-8034399dbe9c", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "52759cf4-9f5d-47a5-ab3c-fb153d207b0a"}, {"Element": "<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:27.05pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>", "ID": "d123cdaf-6bee-4a15-8e43-d8d3d2ec8b86", "Styles": "width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:27.05pt", "Classes": "None", "Text": "  ", "ParentId": "dc1fbccc-07fd-49cf-bc3d-10b4b49ed050"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>", "ID": "d75578eb-0366-413a-8a28-de2ffe292923", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d123cdaf-6bee-4a15-8e43-d8d3d2ec8b86"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span>", "ID": "86544c4d-4811-44e7-a2e0-af15fe90b06c", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "d75578eb-0366-413a-8a28-de2ffe292923"}, {"Element": "<td style=\"width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:27.05pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Tumour lysis syndrome\u2020</span></p>\n</td>", "ID": "7a412b1f-7c8c-4b06-aa17-0720cfd8af4d", "Styles": "width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:27.05pt", "Classes": "None", "Text": "  ", "ParentId": "dc1fbccc-07fd-49cf-bc3d-10b4b49ed050"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Tumour lysis syndrome\u2020</span></p>", "ID": "1735fe6f-5a00-4d81-960f-e3b9c345b7ef", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7a412b1f-7c8c-4b06-aa17-0720cfd8af4d"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Tumour lysis syndrome\u2020</span>", "ID": "220d0023-f7d0-4f7d-bb25-2e3eebabf4f1", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "Tumour lysis syndrome\u2020", "ParentId": "1735fe6f-5a00-4d81-960f-e3b9c345b7ef"}, {"Element": "<tr style=\"height:15.55pt\">\n<td nowrap=\"\" style=\"width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:15.55pt\" valign=\"top\" width=\"161\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Psychiatric disorders</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:15.55pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Insomnia</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:15.55pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:15.55pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td style=\"width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:15.55pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n</tr>", "ID": "b3ca5672-3e5f-40ca-9f1b-83d06893c9ca", "Styles": "height:15.55pt", "Classes": "None", "Text": "      ", "ParentId": "161b9621-307c-4cd5-b01e-b40713008112"}, {"Element": "<td nowrap=\"\" style=\"width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:15.55pt\" valign=\"top\" width=\"161\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Psychiatric disorders</span></p>\n</td>", "ID": "8443f04e-c8b2-45cf-b745-95d1b994ef8c", "Styles": "width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:15.55pt", "Classes": "None", "Text": "  ", "ParentId": "b3ca5672-3e5f-40ca-9f1b-83d06893c9ca"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Psychiatric disorders</span></p>", "ID": "a54ce26d-ed95-4dde-b02c-ea16edfb0ff8", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8443f04e-c8b2-45cf-b745-95d1b994ef8c"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Psychiatric disorders</span>", "ID": "9c8b7239-4e30-4912-a457-0cb2e4a8d068", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "Psychiatric disorders", "ParentId": "a54ce26d-ed95-4dde-b02c-ea16edfb0ff8"}, {"Element": "<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:15.55pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Insomnia</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n</td>", "ID": "a567521c-336d-465f-981b-237dcedef2d7", "Styles": "width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:15.55pt", "Classes": "None", "Text": "  ", "ParentId": "b3ca5672-3e5f-40ca-9f1b-83d06893c9ca"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Insomnia</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>", "ID": "0e999c21-3346-4e95-8105-e73d3d0a1a13", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a567521c-336d-465f-981b-237dcedef2d7"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Insomnia</span>", "ID": "992f8ca0-36d1-4d61-97f0-7a2972e241ab", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "Insomnia", "ParentId": "0e999c21-3346-4e95-8105-e73d3d0a1a13"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span>", "ID": "d31bd3f4-4636-421a-bd41-ed00de313e28", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": " ", "ParentId": "0e999c21-3346-4e95-8105-e73d3d0a1a13"}, {"Element": "<td nowrap=\"\" style=\"width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:15.55pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>", "ID": "104c1766-32c4-479d-aa10-01850d452431", "Styles": "width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:15.55pt", "Classes": "None", "Text": "  ", "ParentId": "b3ca5672-3e5f-40ca-9f1b-83d06893c9ca"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>", "ID": "0c2844f0-e125-4a06-8a6b-5be7c6a4aadc", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "104c1766-32c4-479d-aa10-01850d452431"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span>", "ID": "868fd48f-88f8-43df-9810-6e41c829fd49", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "0c2844f0-e125-4a06-8a6b-5be7c6a4aadc"}, {"Element": "<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:15.55pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>", "ID": "03425480-a327-4358-87a2-b860d9485781", "Styles": "width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:15.55pt", "Classes": "None", "Text": "  ", "ParentId": "b3ca5672-3e5f-40ca-9f1b-83d06893c9ca"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>", "ID": "fb1b3155-da85-4027-9c0a-c34d2f86ecd7", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "03425480-a327-4358-87a2-b860d9485781"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span>", "ID": "dd01eef7-6900-4ee3-a889-7205620fb0af", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "fb1b3155-da85-4027-9c0a-c34d2f86ecd7"}, {"Element": "<td style=\"width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:15.55pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>", "ID": "aa636f3b-34bc-4ed3-979a-4f3ae9cea656", "Styles": "width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:15.55pt", "Classes": "None", "Text": "  ", "ParentId": "b3ca5672-3e5f-40ca-9f1b-83d06893c9ca"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>", "ID": "cfd251da-94e7-4e45-ad74-f097f0cc0d67", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "aa636f3b-34bc-4ed3-979a-4f3ae9cea656"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span>", "ID": "c2bdc3ac-c12e-4ef6-93c2-186c4b64c8e0", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "cfd251da-94e7-4e45-ad74-f097f0cc0d67"}, {"Element": "<tr style=\"height:13.05pt\">\n<td nowrap=\"\" style=\"width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"161\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Nervous system disorders</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Neuropathy peripheral</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Headache\u00a0 </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Dysgeusia</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Peripheral sensory neuropathy</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Dizziness</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Paraesthesia</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td style=\"width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n</tr>", "ID": "0c526607-5a88-4c2a-8064-10baa1f4cf63", "Styles": "height:13.05pt", "Classes": "None", "Text": "      ", "ParentId": "161b9621-307c-4cd5-b01e-b40713008112"}, {"Element": "<td nowrap=\"\" style=\"width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"161\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Nervous system disorders</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n</td>", "ID": "e045b163-1d74-4d09-8ab5-b2cd13da3d96", "Styles": "width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:13.05pt", "Classes": "None", "Text": "  ", "ParentId": "0c526607-5a88-4c2a-8064-10baa1f4cf63"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Nervous system disorders</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>", "ID": "5bf44e0b-b4d5-4812-824f-107390830c0e", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e045b163-1d74-4d09-8ab5-b2cd13da3d96"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Nervous system disorders</span>", "ID": "fb583bfe-5420-42cf-ad4e-06e6585af197", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "Nervous system disorders", "ParentId": "5bf44e0b-b4d5-4812-824f-107390830c0e"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span>", "ID": "2cf0a3ff-8cac-4d60-8ed5-21dcb261e58d", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": " ", "ParentId": "5bf44e0b-b4d5-4812-824f-107390830c0e"}, {"Element": "<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Neuropathy peripheral</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Headache\u00a0 </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Dysgeusia</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Peripheral sensory neuropathy</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Dizziness</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Paraesthesia</span></p>\n</td>", "ID": "adf62de7-7f8a-4173-8024-eb453f09fa46", "Styles": "width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:13.05pt", "Classes": "None", "Text": "       ", "ParentId": "0c526607-5a88-4c2a-8064-10baa1f4cf63"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Neuropathy peripheral</span></p>", "ID": "2886f16c-3578-40f8-8fda-b44280c352d8", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "adf62de7-7f8a-4173-8024-eb453f09fa46"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Neuropathy peripheral</span>", "ID": "4f57a28e-e7b1-4429-be32-39b119a0b5fe", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "Neuropathy peripheral", "ParentId": "2886f16c-3578-40f8-8fda-b44280c352d8"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Headache\u00a0 </span></p>", "ID": "0d1401eb-cbef-4551-ab0f-acb9fda2c2b5", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "adf62de7-7f8a-4173-8024-eb453f09fa46"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Headache\u00a0 </span>", "ID": "6ab8b97c-184f-4224-964f-ef4be65f90bc", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "Headache\u00a0 ", "ParentId": "0d1401eb-cbef-4551-ab0f-acb9fda2c2b5"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Dysgeusia</span></p>", "ID": "079b26da-9aa7-46eb-a9e9-3fa3c72357f6", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "adf62de7-7f8a-4173-8024-eb453f09fa46"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Dysgeusia</span>", "ID": "41c4af90-81b7-4584-b893-2e3f742e11af", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "Dysgeusia", "ParentId": "079b26da-9aa7-46eb-a9e9-3fa3c72357f6"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Peripheral sensory neuropathy</span></p>", "ID": "f500c74a-e96d-45cd-99d1-1bc2618a5f3f", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "adf62de7-7f8a-4173-8024-eb453f09fa46"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Peripheral sensory neuropathy</span>", "ID": "14d63c1f-c9c7-4715-b597-c3f79b0c9266", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "Peripheral sensory neuropathy", "ParentId": "f500c74a-e96d-45cd-99d1-1bc2618a5f3f"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Dizziness</span></p>", "ID": "b4db90e3-38c4-4bfe-a7c2-1e49597c0ec9", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "adf62de7-7f8a-4173-8024-eb453f09fa46"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Dizziness</span>", "ID": "5983c607-84f3-4d25-a7f8-85b9a8ea5359", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "Dizziness", "ParentId": "b4db90e3-38c4-4bfe-a7c2-1e49597c0ec9"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Paraesthesia</span></p>", "ID": "b1f2ae0e-0448-46f7-925e-ad20bf73f930", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "adf62de7-7f8a-4173-8024-eb453f09fa46"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Paraesthesia</span>", "ID": "e8b9e43d-1fd6-446e-814e-7619f8d2de35", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "Paraesthesia", "ParentId": "b1f2ae0e-0448-46f7-925e-ad20bf73f930"}, {"Element": "<td nowrap=\"\" style=\"width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>", "ID": "6c5fca5f-b1b3-4678-a98b-b9c7c9d25e6c", "Styles": "width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:13.05pt", "Classes": "None", "Text": "  ", "ParentId": "0c526607-5a88-4c2a-8064-10baa1f4cf63"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>", "ID": "776167e8-c0f2-456c-b56e-09073327e4fc", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "6c5fca5f-b1b3-4678-a98b-b9c7c9d25e6c"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span>", "ID": "888a0b5e-bb8a-4087-ae37-647b544203b2", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "776167e8-c0f2-456c-b56e-09073327e4fc"}, {"Element": "<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>", "ID": "097ca729-8451-4f4f-981a-4397ea0b26b3", "Styles": "width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:13.05pt", "Classes": "None", "Text": "  ", "ParentId": "0c526607-5a88-4c2a-8064-10baa1f4cf63"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>", "ID": "247c13d9-5a36-47e4-b9ef-52ea0803a867", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "097ca729-8451-4f4f-981a-4397ea0b26b3"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span>", "ID": "f0231f55-d720-4560-a8bf-8b4aac996c37", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "247c13d9-5a36-47e4-b9ef-52ea0803a867"}, {"Element": "<td style=\"width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>", "ID": "0ca4c4fb-1624-4375-8b58-be9d08bfe11b", "Styles": "width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:13.05pt", "Classes": "None", "Text": "  ", "ParentId": "0c526607-5a88-4c2a-8064-10baa1f4cf63"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>", "ID": "ec22c0a4-259a-440a-b474-9649e7a504cc", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0ca4c4fb-1624-4375-8b58-be9d08bfe11b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span>", "ID": "effa00c4-9ee4-433c-8ef9-7fcd159e1ac3", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "ec22c0a4-259a-440a-b474-9649e7a504cc"}, {"Element": "<tr style=\"height:18.2pt\">\n<td nowrap=\"\" style=\"width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"161\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Eye disorders</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Lacrimation increased</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td style=\"width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n</tr>", "ID": "0e83fbf4-881c-43f2-8db8-9b25cb061ce5", "Styles": "height:18.2pt", "Classes": "None", "Text": "      ", "ParentId": "161b9621-307c-4cd5-b01e-b40713008112"}, {"Element": "<td nowrap=\"\" style=\"width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"161\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Eye disorders</span></p>\n</td>", "ID": "65f28b04-ba49-4501-8177-cdd075137598", "Styles": "width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:18.2pt", "Classes": "None", "Text": "  ", "ParentId": "0e83fbf4-881c-43f2-8db8-9b25cb061ce5"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Eye disorders</span></p>", "ID": "8f4171fa-2e48-45b3-bbc8-0381f5128b03", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "65f28b04-ba49-4501-8177-cdd075137598"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Eye disorders</span>", "ID": "e2a3bfc7-fe13-4763-946d-fc84cf9a4759", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "Eye disorders", "ParentId": "8f4171fa-2e48-45b3-bbc8-0381f5128b03"}, {"Element": "<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Lacrimation increased</span></p>\n</td>", "ID": "396f642c-29ca-447a-84e3-3a1b72a015e5", "Styles": "width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt", "Classes": "None", "Text": "  ", "ParentId": "0e83fbf4-881c-43f2-8db8-9b25cb061ce5"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Lacrimation increased</span></p>", "ID": "e5aae2fe-4748-4df8-969f-adc3d27a2027", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "396f642c-29ca-447a-84e3-3a1b72a015e5"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Lacrimation increased</span>", "ID": "98ea8e7d-e26a-493f-aaf8-f1933721c3ec", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "Lacrimation increased", "ParentId": "e5aae2fe-4748-4df8-969f-adc3d27a2027"}, {"Element": "<td nowrap=\"\" style=\"width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>", "ID": "4546aa36-eb70-40c7-a7d1-7e34768eb705", "Styles": "width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt", "Classes": "None", "Text": "  ", "ParentId": "0e83fbf4-881c-43f2-8db8-9b25cb061ce5"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>", "ID": "a0686c65-61d4-4289-8dca-e0a01af6a096", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4546aa36-eb70-40c7-a7d1-7e34768eb705"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span>", "ID": "ef548214-a6a1-427c-be8d-edee34709a96", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "a0686c65-61d4-4289-8dca-e0a01af6a096"}, {"Element": "<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>", "ID": "2606fcaf-0fea-4ce5-988b-3a9fff7237d9", "Styles": "width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt", "Classes": "None", "Text": "  ", "ParentId": "0e83fbf4-881c-43f2-8db8-9b25cb061ce5"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>", "ID": "cb37b8b4-8d7e-4d9d-8f09-793f34a4b699", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "2606fcaf-0fea-4ce5-988b-3a9fff7237d9"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span>", "ID": "5d105638-98c7-46e8-a1b3-082e2fc7e0bb", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "cb37b8b4-8d7e-4d9d-8f09-793f34a4b699"}, {"Element": "<td style=\"width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>", "ID": "20b28d80-982d-4b4c-b583-706aba8e2e53", "Styles": "width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt", "Classes": "None", "Text": "  ", "ParentId": "0e83fbf4-881c-43f2-8db8-9b25cb061ce5"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>", "ID": "78565f4f-258e-49ba-9db2-feb00db33446", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "20b28d80-982d-4b4c-b583-706aba8e2e53"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span>", "ID": "b1cd185d-0f07-46fa-bbc0-499762b149f8", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "78565f4f-258e-49ba-9db2-feb00db33446"}, {"Element": "<tr style=\"height:18.2pt\">\n<td nowrap=\"\" style=\"width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"161\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Cardiac disorders</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Left ventricular dysfunction</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">**</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Cardiac failure congestive</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">**</span></p>\n</td>\n<td style=\"width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n</tr>", "ID": "777dda90-9ba7-41e2-bc5b-e2aad8ca6571", "Styles": "height:18.2pt", "Classes": "None", "Text": "      ", "ParentId": "161b9621-307c-4cd5-b01e-b40713008112"}, {"Element": "<td nowrap=\"\" style=\"width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"161\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Cardiac disorders</span></p>\n</td>", "ID": "18347d0a-eb4d-4680-bfff-4fce07f4b9d9", "Styles": "width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:18.2pt", "Classes": "None", "Text": "  ", "ParentId": "777dda90-9ba7-41e2-bc5b-e2aad8ca6571"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Cardiac disorders</span></p>", "ID": "6097b3f6-cd28-45c0-983c-56939a5ea528", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18347d0a-eb4d-4680-bfff-4fce07f4b9d9"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Cardiac disorders</span>", "ID": "a30b9d9a-06a3-4f43-bb61-8c085e114f04", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "Cardiac disorders", "ParentId": "6097b3f6-cd28-45c0-983c-56939a5ea528"}, {"Element": "<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>", "ID": "47ff2371-13ff-4cc0-9f5f-65de760ae736", "Styles": "width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt", "Classes": "None", "Text": "  ", "ParentId": "777dda90-9ba7-41e2-bc5b-e2aad8ca6571"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>", "ID": "5e1e6cfe-7b2a-4caf-9ef3-8a681b0a4ccb", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "47ff2371-13ff-4cc0-9f5f-65de760ae736"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span>", "ID": "ba342fbc-2663-4657-9698-bb8ee0f71b36", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "5e1e6cfe-7b2a-4caf-9ef3-8a681b0a4ccb"}, {"Element": "<td nowrap=\"\" style=\"width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Left ventricular dysfunction</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">**</span></p>\n</td>", "ID": "b94a0cea-783c-40fe-8775-82894b2ab2bd", "Styles": "width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt", "Classes": "None", "Text": "  ", "ParentId": "777dda90-9ba7-41e2-bc5b-e2aad8ca6571"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Left ventricular dysfunction</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">**</span></p>", "ID": "913db1cc-ab8f-4223-a717-56de932db624", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b94a0cea-783c-40fe-8775-82894b2ab2bd"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Left ventricular dysfunction</span>", "ID": "ebaf46e6-dd9e-4d05-86ed-4897e337c076", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "Left ventricular dysfunction", "ParentId": "913db1cc-ab8f-4223-a717-56de932db624"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span>", "ID": "be179c73-0076-4060-9e58-5110ef434c6f", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": " ", "ParentId": "913db1cc-ab8f-4223-a717-56de932db624"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">**</span>", "ID": "442f58bb-f4e0-4552-83ab-db63f0001a09", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "**", "ParentId": "913db1cc-ab8f-4223-a717-56de932db624"}, {"Element": "<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Cardiac failure congestive</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">**</span></p>\n</td>", "ID": "37c3bf17-fb57-42de-96d4-6664be47577b", "Styles": "width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt", "Classes": "None", "Text": "  ", "ParentId": "777dda90-9ba7-41e2-bc5b-e2aad8ca6571"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Cardiac failure congestive</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">**</span></p>", "ID": "aa900f42-f29c-4656-b71d-adef468c46ea", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "37c3bf17-fb57-42de-96d4-6664be47577b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Cardiac failure congestive</span>", "ID": "c3f0cdaf-34fa-4bad-b64e-5bad68036075", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "Cardiac failure congestive", "ParentId": "aa900f42-f29c-4656-b71d-adef468c46ea"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">**</span>", "ID": "05460ade-4511-4690-ab80-491a48c96f15", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "**", "ParentId": "aa900f42-f29c-4656-b71d-adef468c46ea"}, {"Element": "<td style=\"width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>", "ID": "1c27a4ab-43de-494c-84e8-66da4bd64a21", "Styles": "width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt", "Classes": "None", "Text": "  ", "ParentId": "777dda90-9ba7-41e2-bc5b-e2aad8ca6571"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>", "ID": "a1db4eb0-0943-4511-ac86-da41f8d22504", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1c27a4ab-43de-494c-84e8-66da4bd64a21"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span>", "ID": "4aee9488-b713-4cf8-9354-c9d349356af3", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "a1db4eb0-0943-4511-ac86-da41f8d22504"}, {"Element": "<tr style=\"height:18.2pt\">\n<td nowrap=\"\" style=\"width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"161\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Vascular disorders</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Hot flush</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td style=\"width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n</tr>", "ID": "43e18a87-227a-487e-b12b-7ae6a224644b", "Styles": "height:18.2pt", "Classes": "None", "Text": "      ", "ParentId": "161b9621-307c-4cd5-b01e-b40713008112"}, {"Element": "<td nowrap=\"\" style=\"width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"161\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Vascular disorders</span></p>\n</td>", "ID": "71968df9-b236-4310-aeff-d279927006fe", "Styles": "width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:18.2pt", "Classes": "None", "Text": "  ", "ParentId": "43e18a87-227a-487e-b12b-7ae6a224644b"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Vascular disorders</span></p>", "ID": "8ff2a5c7-6232-429f-863c-55c2e7a7cfdb", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "71968df9-b236-4310-aeff-d279927006fe"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Vascular disorders</span>", "ID": "f4d49427-28ed-4673-a03d-86f89b89b7ed", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "Vascular disorders", "ParentId": "8ff2a5c7-6232-429f-863c-55c2e7a7cfdb"}, {"Element": "<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Hot flush</span></p>\n</td>", "ID": "0a89d855-69bb-410a-b169-6909fa51e1a0", "Styles": "width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt", "Classes": "None", "Text": "  ", "ParentId": "43e18a87-227a-487e-b12b-7ae6a224644b"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Hot flush</span></p>", "ID": "c36a0f17-15fc-4916-8d8d-b5698cf34907", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0a89d855-69bb-410a-b169-6909fa51e1a0"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Hot flush</span>", "ID": "67fd26a7-7315-4aa6-9ac0-85b463900135", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "Hot flush", "ParentId": "c36a0f17-15fc-4916-8d8d-b5698cf34907"}, {"Element": "<td nowrap=\"\" style=\"width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>", "ID": "79b76793-5d9f-49f2-9dd1-d56a1084e7c7", "Styles": "width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt", "Classes": "None", "Text": "  ", "ParentId": "43e18a87-227a-487e-b12b-7ae6a224644b"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>", "ID": "1c5bfbd1-959f-4836-9dd2-c592dd01655d", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "79b76793-5d9f-49f2-9dd1-d56a1084e7c7"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span>", "ID": "761dc9c4-a236-40f5-9e36-eb3095917e8e", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "1c5bfbd1-959f-4836-9dd2-c592dd01655d"}, {"Element": "<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>", "ID": "fe2bcd07-2b7f-4d3f-8011-e39957c1e980", "Styles": "width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt", "Classes": "None", "Text": "  ", "ParentId": "43e18a87-227a-487e-b12b-7ae6a224644b"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>", "ID": "53be1a87-fad9-4764-ad89-da27f2db6960", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "fe2bcd07-2b7f-4d3f-8011-e39957c1e980"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span>", "ID": "703dabc7-2fb1-4f0d-8ad0-f07a758a6dca", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "53be1a87-fad9-4764-ad89-da27f2db6960"}, {"Element": "<td style=\"width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>", "ID": "2934a36e-51df-4640-b71c-3e74b77afc88", "Styles": "width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt", "Classes": "None", "Text": "  ", "ParentId": "43e18a87-227a-487e-b12b-7ae6a224644b"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>", "ID": "5d96681b-afd6-48ac-a60b-9a9afd10dec2", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "2934a36e-51df-4640-b71c-3e74b77afc88"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span>", "ID": "2aea3f7a-0db4-4c1d-b1f1-630b24ef0f4a", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "5d96681b-afd6-48ac-a60b-9a9afd10dec2"}, {"Element": "<tr style=\"height:18.2pt\">\n<td nowrap=\"\" style=\"width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"161\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Respiratory, thoracic and mediastinal\n  disorders</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Cough </span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Epistaxis</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Dyspnoea</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Interstitial lung disease </span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Pleural effusion</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td style=\"width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n</tr>", "ID": "66542d08-ac0d-4a3c-8d2c-f26b9a8c9fc0", "Styles": "height:18.2pt", "Classes": "None", "Text": "      ", "ParentId": "161b9621-307c-4cd5-b01e-b40713008112"}, {"Element": "<td nowrap=\"\" style=\"width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"161\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Respiratory, thoracic and mediastinal\n  disorders</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n</td>", "ID": "78b2c66f-6901-4cb3-a442-c51a5ca905f6", "Styles": "width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:18.2pt", "Classes": "None", "Text": "  ", "ParentId": "66542d08-ac0d-4a3c-8d2c-f26b9a8c9fc0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Respiratory, thoracic and mediastinal\n  disorders</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>", "ID": "5bbc45d6-b999-4fd8-84d9-86c74debd26c", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "78b2c66f-6901-4cb3-a442-c51a5ca905f6"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Respiratory, thoracic and mediastinal\n  disorders</span>", "ID": "f1d9f70c-22f4-4b8c-991a-0431830031e6", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "Respiratory, thoracic and mediastinal   disorders", "ParentId": "5bbc45d6-b999-4fd8-84d9-86c74debd26c"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span>", "ID": "640b1607-5392-44a2-a164-0749d1473cbc", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": " ", "ParentId": "5bbc45d6-b999-4fd8-84d9-86c74debd26c"}, {"Element": "<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Cough </span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Epistaxis</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Dyspnoea</span></p>\n</td>", "ID": "ff725d3c-9efd-4c24-b4b2-5f32b8e4198d", "Styles": "width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt", "Classes": "None", "Text": "    ", "ParentId": "66542d08-ac0d-4a3c-8d2c-f26b9a8c9fc0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Cough </span></p>", "ID": "ee7f03f5-72f9-4cbc-b960-7022696221f8", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ff725d3c-9efd-4c24-b4b2-5f32b8e4198d"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Cough </span>", "ID": "dbbd7e2f-2552-4e7d-a2e5-3d04114c34a6", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "Cough ", "ParentId": "ee7f03f5-72f9-4cbc-b960-7022696221f8"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Epistaxis</span></p>", "ID": "f183a0a5-62cc-4c47-b94d-904eb732d675", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ff725d3c-9efd-4c24-b4b2-5f32b8e4198d"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">Epistaxis</span>", "ID": "583616a6-c206-4ff3-8c80-6de67cd4b8c3", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "Epistaxis", "ParentId": "f183a0a5-62cc-4c47-b94d-904eb732d675"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Dyspnoea</span></p>", "ID": "8b56f77b-d577-4aa4-80a3-87e6dc563736", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ff725d3c-9efd-4c24-b4b2-5f32b8e4198d"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">Dyspnoea</span>", "ID": "84619b8e-d66d-429b-871d-524470c88090", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "Dyspnoea", "ParentId": "8b56f77b-d577-4aa4-80a3-87e6dc563736"}, {"Element": "<td nowrap=\"\" style=\"width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>", "ID": "137870fc-0172-43ea-bc63-d6c4611ceba0", "Styles": "width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt", "Classes": "None", "Text": "  ", "ParentId": "66542d08-ac0d-4a3c-8d2c-f26b9a8c9fc0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>", "ID": "b215caa1-96b4-4352-885a-dcee2d207edb", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "137870fc-0172-43ea-bc63-d6c4611ceba0"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span>", "ID": "c10ac247-7f55-436f-895a-e97cd72d3b48", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "b215caa1-96b4-4352-885a-dcee2d207edb"}, {"Element": "<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Interstitial lung disease </span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Pleural effusion</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>", "ID": "a23025d8-28c7-40ac-a569-2613abc42469", "Styles": "width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt", "Classes": "None", "Text": "    ", "ParentId": "66542d08-ac0d-4a3c-8d2c-f26b9a8c9fc0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Interstitial lung disease </span></p>", "ID": "e8e1f53c-3a10-463f-aa53-04d976eced36", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a23025d8-28c7-40ac-a569-2613abc42469"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Interstitial lung disease </span>", "ID": "8267615e-99b4-4a96-840a-1864363d01a9", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "Interstitial lung disease ", "ParentId": "e8e1f53c-3a10-463f-aa53-04d976eced36"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Pleural effusion</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>", "ID": "84263c8d-db04-4ca3-98d5-b9b129a571e2", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a23025d8-28c7-40ac-a569-2613abc42469"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Pleural effusion</span>", "ID": "346d49fb-e2c2-48a2-a7b3-256079377693", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "Pleural effusion", "ParentId": "84263c8d-db04-4ca3-98d5-b9b129a571e2"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span>", "ID": "51720567-5481-4dd2-b32c-67e3115c9c56", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": " ", "ParentId": "84263c8d-db04-4ca3-98d5-b9b129a571e2"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>", "ID": "8d4f9d10-2d39-4ae1-906c-a569dac7ec7f", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a23025d8-28c7-40ac-a569-2613abc42469"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span>", "ID": "88f06137-535f-4cbf-b839-78edb75f9676", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "8d4f9d10-2d39-4ae1-906c-a569dac7ec7f"}, {"Element": "<td style=\"width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>", "ID": "feee3803-3a13-4228-889b-41e4242bf2ba", "Styles": "width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt", "Classes": "None", "Text": "  ", "ParentId": "66542d08-ac0d-4a3c-8d2c-f26b9a8c9fc0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>", "ID": "11d07182-5bd5-414f-bff6-399b2cce2c38", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "feee3803-3a13-4228-889b-41e4242bf2ba"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span>", "ID": "5556d363-4bd2-4382-943c-c1d96fe0aff3", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "11d07182-5bd5-414f-bff6-399b2cce2c38"}, {"Element": "<tr style=\"height:11.6pt\">\n<td nowrap=\"\" style=\"width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:11.6pt\" valign=\"top\" width=\"161\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Gastrointestinal disorders</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:11.6pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Diarrhoea</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Vomiting\u00a0 </span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Stomatitis</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Nausea </span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Constipation </span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Dyspepsia </span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Abdominal pain</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:11.6pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></b></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:11.6pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></b></p>\n</td>\n<td style=\"width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:11.6pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></b></p>\n</td>\n</tr>", "ID": "22f644ba-7107-4a5b-88dd-f1dc98c9973f", "Styles": "height:11.6pt", "Classes": "None", "Text": "      ", "ParentId": "161b9621-307c-4cd5-b01e-b40713008112"}, {"Element": "<td nowrap=\"\" style=\"width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:11.6pt\" valign=\"top\" width=\"161\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Gastrointestinal disorders</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n</td>", "ID": "5aadabbf-4ae3-4d19-903e-caed5a2cac89", "Styles": "width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:11.6pt", "Classes": "None", "Text": "  ", "ParentId": "22f644ba-7107-4a5b-88dd-f1dc98c9973f"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Gastrointestinal disorders</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>", "ID": "a224f227-6d16-40cb-be51-c9ab93538a35", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5aadabbf-4ae3-4d19-903e-caed5a2cac89"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Gastrointestinal disorders</span>", "ID": "1dd1c71e-6587-483e-b8e0-c0ea546a9504", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "Gastrointestinal disorders", "ParentId": "a224f227-6d16-40cb-be51-c9ab93538a35"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span>", "ID": "160cd379-1ab0-40a5-96db-147aa1991141", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": " ", "ParentId": "a224f227-6d16-40cb-be51-c9ab93538a35"}, {"Element": "<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:11.6pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Diarrhoea</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Vomiting\u00a0 </span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Stomatitis</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Nausea </span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Constipation </span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Dyspepsia </span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Abdominal pain</span></p>\n</td>", "ID": "22d38fa1-b0ea-4daf-ab62-c923a9c38777", "Styles": "width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:11.6pt", "Classes": "None", "Text": "        ", "ParentId": "22f644ba-7107-4a5b-88dd-f1dc98c9973f"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Diarrhoea</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>", "ID": "286c9b57-a7c0-4e33-8b8c-8420c4411954", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "22d38fa1-b0ea-4daf-ab62-c923a9c38777"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Diarrhoea</span>", "ID": "959085e0-89c6-4beb-8440-ad6179ad155a", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "Diarrhoea", "ParentId": "286c9b57-a7c0-4e33-8b8c-8420c4411954"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span>", "ID": "69a42e49-08d3-4167-988c-7644cd8cf11e", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": " ", "ParentId": "286c9b57-a7c0-4e33-8b8c-8420c4411954"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Vomiting\u00a0 </span></p>", "ID": "878ae1de-cd07-4ed2-9616-a83b3613aaab", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "22d38fa1-b0ea-4daf-ab62-c923a9c38777"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Vomiting\u00a0 </span>", "ID": "4fe64f8d-637b-468b-a5d1-062c15530dc2", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "Vomiting\u00a0 ", "ParentId": "878ae1de-cd07-4ed2-9616-a83b3613aaab"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Stomatitis</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>", "ID": "4701d24d-8713-4b33-8c78-565c922aab13", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "22d38fa1-b0ea-4daf-ab62-c923a9c38777"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Stomatitis</span>", "ID": "12503de1-d35a-4ebd-92c3-af6d7430fe97", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "Stomatitis", "ParentId": "4701d24d-8713-4b33-8c78-565c922aab13"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span>", "ID": "25aa50e4-5e8d-4531-9cab-b61bc5041697", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": " ", "ParentId": "4701d24d-8713-4b33-8c78-565c922aab13"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Nausea </span></p>", "ID": "0827083e-f167-4e68-be6e-11e9ce791f30", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "22d38fa1-b0ea-4daf-ab62-c923a9c38777"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Nausea </span>", "ID": "b813b47c-afe9-494f-ba23-5bbb2748e78c", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "Nausea ", "ParentId": "0827083e-f167-4e68-be6e-11e9ce791f30"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Constipation </span></p>", "ID": "91edd3c0-87d0-4483-9af3-f736232993e5", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "22d38fa1-b0ea-4daf-ab62-c923a9c38777"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Constipation </span>", "ID": "7b42dc16-26da-4a7c-b7cb-8284110b973f", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "Constipation ", "ParentId": "91edd3c0-87d0-4483-9af3-f736232993e5"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Dyspepsia </span></p>", "ID": "31a15d7d-950a-439e-9e10-58e18818271d", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "22d38fa1-b0ea-4daf-ab62-c923a9c38777"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Dyspepsia </span>", "ID": "d4594238-2b51-48ee-b5b6-cb48886baa32", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "Dyspepsia ", "ParentId": "31a15d7d-950a-439e-9e10-58e18818271d"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Abdominal pain</span></p>", "ID": "95bebbd6-3515-42c0-bf20-26440c7b669b", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "22d38fa1-b0ea-4daf-ab62-c923a9c38777"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Abdominal pain</span>", "ID": "4237201a-0071-4af2-a5df-2053de533a30", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "Abdominal pain", "ParentId": "95bebbd6-3515-42c0-bf20-26440c7b669b"}, {"Element": "<td nowrap=\"\" style=\"width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:11.6pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></b></p>\n</td>", "ID": "6b6afe63-9b3b-490a-bdf8-7c68f24c845e", "Styles": "width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:11.6pt", "Classes": "None", "Text": "  ", "ParentId": "22f644ba-7107-4a5b-88dd-f1dc98c9973f"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></b></p>", "ID": "029c42dc-797c-48a9-8d84-79adc8029ae4", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "6b6afe63-9b3b-490a-bdf8-7c68f24c845e"}, {"Element": "<b><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></b>", "ID": "82f398cf-bab0-4316-91f3-a2da2c81445b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "029c42dc-797c-48a9-8d84-79adc8029ae4"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span>", "ID": "dac88326-6943-4c76-80f2-bd82a9a8d2f6", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "82f398cf-bab0-4316-91f3-a2da2c81445b"}, {"Element": "<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:11.6pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></b></p>\n</td>", "ID": "a8f13adc-5efa-41af-aaf5-4d821981d457", "Styles": "width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:11.6pt", "Classes": "None", "Text": "  ", "ParentId": "22f644ba-7107-4a5b-88dd-f1dc98c9973f"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></b></p>", "ID": "eb699d68-ae44-46bc-b78f-22d9bc08e10c", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a8f13adc-5efa-41af-aaf5-4d821981d457"}, {"Element": "<b><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></b>", "ID": "354eddc2-0a5a-4c3a-b99b-f6e50e7d1f3c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "eb699d68-ae44-46bc-b78f-22d9bc08e10c"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span>", "ID": "b9d69ad0-94c7-438b-ae9e-2a9555b28a48", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "354eddc2-0a5a-4c3a-b99b-f6e50e7d1f3c"}, {"Element": "<td style=\"width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:11.6pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></b></p>\n</td>", "ID": "e57090ad-9c18-4c7a-b3bd-ee04dc07ff78", "Styles": "width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:11.6pt", "Classes": "None", "Text": "  ", "ParentId": "22f644ba-7107-4a5b-88dd-f1dc98c9973f"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></b></p>", "ID": "1828279b-e5b8-40d5-a48a-3e475ecb79a2", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e57090ad-9c18-4c7a-b3bd-ee04dc07ff78"}, {"Element": "<b><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></b>", "ID": "ac72f917-78cd-4781-8921-19c4eaddf19d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "1828279b-e5b8-40d5-a48a-3e475ecb79a2"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span>", "ID": "1143d76e-b129-47f3-a6a3-7141da60c3fe", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "ac72f917-78cd-4781-8921-19c4eaddf19d"}, {"Element": "<tr style=\"height:37.4pt\">\n<td nowrap=\"\" style=\"width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:37.4pt\" valign=\"top\" width=\"161\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Skin and subcutaneous tissue\n  disorders</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:37.4pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Alopecia</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Rash </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Nail disorder</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Pruritus</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Dry skin</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:37.4pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:37.4pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td style=\"width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:37.4pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n</tr>", "ID": "8f101120-ca43-43dc-aee1-4a1ae810eb1a", "Styles": "height:37.4pt", "Classes": "None", "Text": "      ", "ParentId": "161b9621-307c-4cd5-b01e-b40713008112"}, {"Element": "<td nowrap=\"\" style=\"width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:37.4pt\" valign=\"top\" width=\"161\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Skin and subcutaneous tissue\n  disorders</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n</td>", "ID": "2b8371c6-df66-4685-849e-c4cc271514fc", "Styles": "width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:37.4pt", "Classes": "None", "Text": "  ", "ParentId": "8f101120-ca43-43dc-aee1-4a1ae810eb1a"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Skin and subcutaneous tissue\n  disorders</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>", "ID": "34255da6-bee0-4881-975b-5b576d15f546", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "2b8371c6-df66-4685-849e-c4cc271514fc"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Skin and subcutaneous tissue\n  disorders</span>", "ID": "39fa82ef-2bae-4202-9f43-cad66f7b686d", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "Skin and subcutaneous tissue   disorders", "ParentId": "34255da6-bee0-4881-975b-5b576d15f546"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span>", "ID": "e6c477e2-80a5-4982-ae7d-82f25b3f30c2", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": " ", "ParentId": "34255da6-bee0-4881-975b-5b576d15f546"}, {"Element": "<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:37.4pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Alopecia</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Rash </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Nail disorder</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Pruritus</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Dry skin</span></p>\n</td>", "ID": "2de809af-b577-4ae4-8822-dd8331c34e21", "Styles": "width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:37.4pt", "Classes": "None", "Text": "      ", "ParentId": "8f101120-ca43-43dc-aee1-4a1ae810eb1a"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Alopecia</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>", "ID": "2f37d9ae-d829-4dff-9ed0-ad10578ba320", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "2de809af-b577-4ae4-8822-dd8331c34e21"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Alopecia</span>", "ID": "a4791ca1-ada4-4c3c-a773-822a29982bfd", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "Alopecia", "ParentId": "2f37d9ae-d829-4dff-9ed0-ad10578ba320"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span>", "ID": "faa9d420-a512-46d5-8aa1-af1a4d535ad6", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": " ", "ParentId": "2f37d9ae-d829-4dff-9ed0-ad10578ba320"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Rash </span></p>", "ID": "4b5da2c9-b0e5-41b3-b500-d0aaf3be099d", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "2de809af-b577-4ae4-8822-dd8331c34e21"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Rash </span>", "ID": "e02d3ec3-67dd-4464-aa99-f8cdc71aa342", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "Rash ", "ParentId": "4b5da2c9-b0e5-41b3-b500-d0aaf3be099d"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Nail disorder</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>", "ID": "23623752-0b0e-4cfb-bca1-14248492bc69", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "2de809af-b577-4ae4-8822-dd8331c34e21"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Nail disorder</span>", "ID": "a44e86e8-e6fe-4f86-8de0-479b618c07f8", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "Nail disorder", "ParentId": "23623752-0b0e-4cfb-bca1-14248492bc69"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span>", "ID": "5f5241f2-03fc-46b4-9f3c-b2f44a7d7ad7", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": " ", "ParentId": "23623752-0b0e-4cfb-bca1-14248492bc69"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Pruritus</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>", "ID": "83d26824-ea1d-4ac7-aca8-43d9afd733c9", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "2de809af-b577-4ae4-8822-dd8331c34e21"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Pruritus</span>", "ID": "e1a6e252-c9db-4c75-9597-ae48bec12b39", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "Pruritus", "ParentId": "83d26824-ea1d-4ac7-aca8-43d9afd733c9"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span>", "ID": "93e6f7d5-ff0c-4b5c-baee-a1c085e44438", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": " ", "ParentId": "83d26824-ea1d-4ac7-aca8-43d9afd733c9"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Dry skin</span></p>", "ID": "124d67c1-7251-4e28-a2bb-b34b9658d4f6", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "2de809af-b577-4ae4-8822-dd8331c34e21"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Dry skin</span>", "ID": "693eba08-ed28-460f-b692-2158d964d08e", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "Dry skin", "ParentId": "124d67c1-7251-4e28-a2bb-b34b9658d4f6"}, {"Element": "<td nowrap=\"\" style=\"width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:37.4pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>", "ID": "6b8c0c42-da28-4c07-a28b-b3391eab445f", "Styles": "width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:37.4pt", "Classes": "None", "Text": "  ", "ParentId": "8f101120-ca43-43dc-aee1-4a1ae810eb1a"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>", "ID": "0efc8f25-ab98-4b41-90ca-2c805f44d8b9", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "6b8c0c42-da28-4c07-a28b-b3391eab445f"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span>", "ID": "f90275d0-68ef-40ea-b93c-6097e15732da", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "0efc8f25-ab98-4b41-90ca-2c805f44d8b9"}, {"Element": "<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:37.4pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>", "ID": "05e302ab-1c5b-4697-ad90-c1ffc6acfd9f", "Styles": "width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:37.4pt", "Classes": "None", "Text": "  ", "ParentId": "8f101120-ca43-43dc-aee1-4a1ae810eb1a"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>", "ID": "5f49cf51-427b-4503-8af7-507b3384de61", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "05e302ab-1c5b-4697-ad90-c1ffc6acfd9f"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span>", "ID": "892b9603-a6b4-4cc7-8838-fe75f85200f4", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "5f49cf51-427b-4503-8af7-507b3384de61"}, {"Element": "<td style=\"width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:37.4pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>", "ID": "644cc2f9-8fad-4c34-aa8c-0aec81c8d235", "Styles": "width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:37.4pt", "Classes": "None", "Text": "  ", "ParentId": "8f101120-ca43-43dc-aee1-4a1ae810eb1a"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>", "ID": "bde393ba-42ad-4372-b373-2e9fd7171369", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "644cc2f9-8fad-4c34-aa8c-0aec81c8d235"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span>", "ID": "7804fc18-7bb8-4ba6-bef3-4abcaf77aa69", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "bde393ba-42ad-4372-b373-2e9fd7171369"}, {"Element": "<tr style=\"height:26.45pt\">\n<td nowrap=\"\" style=\"width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:26.45pt\" valign=\"top\" width=\"161\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Musculoskeletal and connective tissue disorders</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:26.45pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Myalgia</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Arthralgia</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Pain in extremity</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:26.45pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:26.45pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td style=\"width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:26.45pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n</tr>", "ID": "1a23434c-e3db-4b98-9e1a-693d758719fa", "Styles": "height:26.45pt", "Classes": "None", "Text": "      ", "ParentId": "161b9621-307c-4cd5-b01e-b40713008112"}, {"Element": "<td nowrap=\"\" style=\"width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:26.45pt\" valign=\"top\" width=\"161\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Musculoskeletal and connective tissue disorders</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n</td>", "ID": "18ca462b-8d2e-46aa-82b8-105ffac258a5", "Styles": "width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:26.45pt", "Classes": "None", "Text": "  ", "ParentId": "1a23434c-e3db-4b98-9e1a-693d758719fa"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Musculoskeletal and connective tissue disorders</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>", "ID": "25d3caa5-421d-480b-9ce6-52ab8fdfa13e", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18ca462b-8d2e-46aa-82b8-105ffac258a5"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Musculoskeletal and connective tissue disorders</span>", "ID": "f4458dfb-afd3-4718-9676-5e22736cbafd", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "Musculoskeletal and connective tissue disorders", "ParentId": "25d3caa5-421d-480b-9ce6-52ab8fdfa13e"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span>", "ID": "c9df5fcc-9732-4520-b643-3534bea77cbc", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": " ", "ParentId": "25d3caa5-421d-480b-9ce6-52ab8fdfa13e"}, {"Element": "<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:26.45pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Myalgia</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Arthralgia</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Pain in extremity</span></p>\n</td>", "ID": "96a2fba6-86d5-46b7-9402-1745c6d1bbc3", "Styles": "width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:26.45pt", "Classes": "None", "Text": "    ", "ParentId": "1a23434c-e3db-4b98-9e1a-693d758719fa"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Myalgia</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>", "ID": "d2152b76-51c7-42fd-87e1-f31baf0350a7", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "96a2fba6-86d5-46b7-9402-1745c6d1bbc3"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Myalgia</span>", "ID": "714ccf22-1346-48ce-b270-54c9ecc112ea", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "Myalgia", "ParentId": "d2152b76-51c7-42fd-87e1-f31baf0350a7"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span>", "ID": "e2375a96-b6cf-4945-a292-74f5a2b08416", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": " ", "ParentId": "d2152b76-51c7-42fd-87e1-f31baf0350a7"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Arthralgia</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span></p>", "ID": "774477cd-7ed3-42bd-9145-252b4a4a8916", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "96a2fba6-86d5-46b7-9402-1745c6d1bbc3"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Arthralgia</span>", "ID": "f1aa1b2c-d9cc-4a52-988f-b7a8ade4ed03", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "Arthralgia", "ParentId": "774477cd-7ed3-42bd-9145-252b4a4a8916"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\"> </span>", "ID": "0fded02d-f406-44e9-96db-b077c692d1aa", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": " ", "ParentId": "774477cd-7ed3-42bd-9145-252b4a4a8916"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Pain in extremity</span></p>", "ID": "1b2a6011-cfbf-47fa-920f-e0de39933763", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "96a2fba6-86d5-46b7-9402-1745c6d1bbc3"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Pain in extremity</span>", "ID": "71454238-0451-4be3-a770-e4779c0897ca", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "Pain in extremity", "ParentId": "1b2a6011-cfbf-47fa-920f-e0de39933763"}, {"Element": "<td nowrap=\"\" style=\"width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:26.45pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>", "ID": "14f6659b-3eab-4a0a-9cf8-c14ce3c9abaf", "Styles": "width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:26.45pt", "Classes": "None", "Text": "  ", "ParentId": "1a23434c-e3db-4b98-9e1a-693d758719fa"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>", "ID": "2cd26365-0198-4c5f-8be4-0dce5343708e", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "14f6659b-3eab-4a0a-9cf8-c14ce3c9abaf"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span>", "ID": "b98ad71f-6b11-4274-a96a-8b825d355026", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "2cd26365-0198-4c5f-8be4-0dce5343708e"}, {"Element": "<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:26.45pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>", "ID": "63125513-5435-4e42-a903-2ed81737e736", "Styles": "width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:26.45pt", "Classes": "None", "Text": "  ", "ParentId": "1a23434c-e3db-4b98-9e1a-693d758719fa"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>", "ID": "1db8bf43-f1fb-4c25-8a8f-1f14caca702e", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "63125513-5435-4e42-a903-2ed81737e736"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span>", "ID": "606ada9f-d8a1-433b-aa13-0428cf501b35", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "1db8bf43-f1fb-4c25-8a8f-1f14caca702e"}, {"Element": "<td style=\"width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:26.45pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>", "ID": "f2ffb6a1-ae90-4e4b-8433-75a5960a8b30", "Styles": "width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:26.45pt", "Classes": "None", "Text": "  ", "ParentId": "1a23434c-e3db-4b98-9e1a-693d758719fa"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>", "ID": "c29e8bf2-15a5-4d1b-b4d8-ff03c207d162", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f2ffb6a1-ae90-4e4b-8433-75a5960a8b30"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span>", "ID": "834dfe29-3dc4-46c7-8f2e-cb42b3701a42", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "c29e8bf2-15a5-4d1b-b4d8-ff03c207d162"}, {"Element": "<tr style=\"height:12.55pt\">\n<td nowrap=\"\" style=\"width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:12.55pt\" valign=\"top\" width=\"161\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">General disorders and\n  administration site conditions </span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:12.55pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Mucosal inflammation</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"PT-BR\" style=\"font-size:10.0pt;color:black\">Oedema peripheral</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"PT-BR\" style=\"font-size:10.0pt;color:black\">Pyrexia</span><span lang=\"PT-BR\" style=\"font-size:10.0pt;color:black\"> </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"PT-BR\" style=\"font-size:10.0pt;color:black\">Fatigue</span><span lang=\"PT-BR\" style=\"font-size:10.0pt;color:black\"> </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"PT-BR\" style=\"font-size:10.0pt;color:black\">Asthenia </span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:12.55pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Chills</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Pain</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Oedema</span></p>\n</td>\n<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:12.55pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td style=\"width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:12.55pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n</tr>", "ID": "7bc3977f-e96a-4766-9b34-4fc5b05aaa5d", "Styles": "height:12.55pt", "Classes": "None", "Text": "      ", "ParentId": "161b9621-307c-4cd5-b01e-b40713008112"}, {"Element": "<td nowrap=\"\" style=\"width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:12.55pt\" valign=\"top\" width=\"161\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">General disorders and\n  administration site conditions </span></p>\n</td>", "ID": "aa85a0b1-1db6-4f0d-a9c9-dde55f94f9f5", "Styles": "width:120.45pt;border:solid windowtext 1.5pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:12.55pt", "Classes": "None", "Text": "  ", "ParentId": "7bc3977f-e96a-4766-9b34-4fc5b05aaa5d"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">General disorders and\n  administration site conditions </span></p>", "ID": "9f65b31d-e7a5-4aa7-99ad-7edeb667bc0e", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "aa85a0b1-1db6-4f0d-a9c9-dde55f94f9f5"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">General disorders and\n  administration site conditions </span>", "ID": "f84ded9a-df65-4d9f-b6ba-06def6e369f3", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "General disorders and   administration site conditions ", "ParentId": "9f65b31d-e7a5-4aa7-99ad-7edeb667bc0e"}, {"Element": "<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:12.55pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Mucosal inflammation</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"PT-BR\" style=\"font-size:10.0pt;color:black\">Oedema peripheral</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"PT-BR\" style=\"font-size:10.0pt;color:black\">Pyrexia</span><span lang=\"PT-BR\" style=\"font-size:10.0pt;color:black\"> </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"PT-BR\" style=\"font-size:10.0pt;color:black\">Fatigue</span><span lang=\"PT-BR\" style=\"font-size:10.0pt;color:black\"> </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"PT-BR\" style=\"font-size:10.0pt;color:black\">Asthenia </span></p>\n</td>", "ID": "c1f2c469-f2bd-4c74-84e0-b426d3baa99a", "Styles": "width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:12.55pt", "Classes": "None", "Text": "      ", "ParentId": "7bc3977f-e96a-4766-9b34-4fc5b05aaa5d"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Mucosal inflammation</span></p>", "ID": "65f1e223-daf9-4f1f-956b-e181e471502d", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c1f2c469-f2bd-4c74-84e0-b426d3baa99a"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Mucosal inflammation</span>", "ID": "9a7978a9-82e0-4a3e-ae98-58e0abe77fe5", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "Mucosal inflammation", "ParentId": "65f1e223-daf9-4f1f-956b-e181e471502d"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"PT-BR\" style=\"font-size:10.0pt;color:black\">Oedema peripheral</span></p>", "ID": "5d92eaae-1a83-4457-873b-33b812c011c3", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c1f2c469-f2bd-4c74-84e0-b426d3baa99a"}, {"Element": "<span lang=\"PT-BR\" style=\"font-size:10.0pt;color:black\">Oedema peripheral</span>", "ID": "f9f931b4-6742-4d38-9ee5-c7ace2a3d56f", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "Oedema peripheral", "ParentId": "5d92eaae-1a83-4457-873b-33b812c011c3"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"PT-BR\" style=\"font-size:10.0pt;color:black\">Pyrexia</span><span lang=\"PT-BR\" style=\"font-size:10.0pt;color:black\"> </span></p>", "ID": "e41c0766-574e-479e-ad87-1443e5cf7922", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c1f2c469-f2bd-4c74-84e0-b426d3baa99a"}, {"Element": "<span lang=\"PT-BR\" style=\"font-size:10.0pt;color:black\">Pyrexia</span>", "ID": "091827bb-94d3-421b-b380-d9c5af08d794", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "Pyrexia", "ParentId": "e41c0766-574e-479e-ad87-1443e5cf7922"}, {"Element": "<span lang=\"PT-BR\" style=\"font-size:10.0pt;color:black\"> </span>", "ID": "0207df13-8ce9-4d49-8047-22fa09e0c05d", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": " ", "ParentId": "e41c0766-574e-479e-ad87-1443e5cf7922"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"PT-BR\" style=\"font-size:10.0pt;color:black\">Fatigue</span><span lang=\"PT-BR\" style=\"font-size:10.0pt;color:black\"> </span></p>", "ID": "fc5cdf95-8e5b-4e48-9fee-b4277684e086", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c1f2c469-f2bd-4c74-84e0-b426d3baa99a"}, {"Element": "<span lang=\"PT-BR\" style=\"font-size:10.0pt;color:black\">Fatigue</span>", "ID": "1a889b5f-069a-49c5-8f6e-540ab435d8fe", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "Fatigue", "ParentId": "fc5cdf95-8e5b-4e48-9fee-b4277684e086"}, {"Element": "<span lang=\"PT-BR\" style=\"font-size:10.0pt;color:black\"> </span>", "ID": "e6e11894-9973-47a5-ae37-0dbf33d53940", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": " ", "ParentId": "fc5cdf95-8e5b-4e48-9fee-b4277684e086"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"PT-BR\" style=\"font-size:10.0pt;color:black\">Asthenia </span></p>", "ID": "006606e6-8e7f-4df1-91b5-9cbf82f272d8", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c1f2c469-f2bd-4c74-84e0-b426d3baa99a"}, {"Element": "<span lang=\"PT-BR\" style=\"font-size:10.0pt;color:black\">Asthenia </span>", "ID": "9d416246-86af-4919-ba8d-7f7de5496bd7", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "Asthenia ", "ParentId": "006606e6-8e7f-4df1-91b5-9cbf82f272d8"}, {"Element": "<td nowrap=\"\" style=\"width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:12.55pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Chills</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Pain</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Oedema</span></p>\n</td>", "ID": "a10177c5-cee5-4ddf-90b5-2f2a7290ea7c", "Styles": "width:105.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:12.55pt", "Classes": "None", "Text": "    ", "ParentId": "7bc3977f-e96a-4766-9b34-4fc5b05aaa5d"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Chills</span></p>", "ID": "f3f05354-b04e-4852-b88a-ad2180674b32", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a10177c5-cee5-4ddf-90b5-2f2a7290ea7c"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Chills</span>", "ID": "bc2f0e77-e366-4521-a945-6a836d73e786", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "Chills", "ParentId": "f3f05354-b04e-4852-b88a-ad2180674b32"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Pain</span></p>", "ID": "14e26105-56e3-4b9d-895f-36257a544ccd", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a10177c5-cee5-4ddf-90b5-2f2a7290ea7c"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Pain</span>", "ID": "e36cbfc6-8861-424c-a26c-bf58abc5ef82", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "Pain", "ParentId": "14e26105-56e3-4b9d-895f-36257a544ccd"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Oedema</span></p>", "ID": "8866ba41-a480-417e-b924-e496b9c4789f", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a10177c5-cee5-4ddf-90b5-2f2a7290ea7c"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Oedema</span>", "ID": "c25830a7-0780-4911-ba93-4ad389b8adc4", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "Oedema", "ParentId": "8866ba41-a480-417e-b924-e496b9c4789f"}, {"Element": "<td nowrap=\"\" style=\"width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:12.55pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>", "ID": "4f0faf96-cb9a-46f1-8027-b570f672a6f5", "Styles": "width:105.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:12.55pt", "Classes": "None", "Text": "  ", "ParentId": "7bc3977f-e96a-4766-9b34-4fc5b05aaa5d"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>", "ID": "61d16924-b889-4972-88bd-6f673bacbee3", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4f0faf96-cb9a-46f1-8027-b570f672a6f5"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span>", "ID": "27c51a65-9b29-401d-aa72-2b3fb7b27983", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "61d16924-b889-4972-88bd-6f673bacbee3"}, {"Element": "<td style=\"width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:12.55pt\" valign=\"top\" width=\"141\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>", "ID": "89ca7126-f983-4d13-8b15-d9ba73050382", "Styles": "width:105.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;\n  padding:0in 4.25pt 0in 4.25pt;height:12.55pt", "Classes": "None", "Text": "  ", "ParentId": "7bc3977f-e96a-4766-9b34-4fc5b05aaa5d"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>", "ID": "8f8bc3f0-6f77-49dd-a4f8-ea7492b900a9", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "89ca7126-f983-4d13-8b15-d9ba73050382"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span>", "ID": "0f71b991-0372-42d4-a6d0-da658ff60cbd", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "8f8bc3f0-6f77-49dd-a4f8-ea7492b900a9"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><b><sup><span lang=\"EN-GB\" style=\"font-size:10.0pt\">^\u00a0 </span></sup></b><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Table 2 shows pooled data from the overall treatment\nperiod in CLEOPATRA (data cutoff 11 February 2014; median number of cycles of\nPerjeta was 24); and from the neoadjuvant\u00a0 treatment period in NEOSPHERE\n(median number of cycles of Perjeta was 4, across all treatment arms) and\nTRYPHAENA (median number of cycles of Perjeta was 3 \u2013 6 across treatment arms) </span><span style=\"font-size:10.0pt\">and from the treatment period of APHINITY (median\nnumber of cycles of Perjeta was 18). <sup>\u00a0</sup></span><span style=\"font-size:\n10.0pt\">\u00a0<sup>\u00a0\u00a0</sup></span></p>", "ID": "5c61fd6a-1203-49d5-ad44-7ecefd966efc", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><sup><span lang=\"EN-GB\" style=\"font-size:10.0pt\">^\u00a0 </span></sup></b>", "ID": "cdf149af-4e3f-4a48-805b-32d2aba059a0", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "5c61fd6a-1203-49d5-ad44-7ecefd966efc"}, {"Element": "<sup><span lang=\"EN-GB\" style=\"font-size:10.0pt\">^\u00a0 </span></sup>", "ID": "3e9695ea-31d3-43e8-8291-98aec01bf933", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "cdf149af-4e3f-4a48-805b-32d2aba059a0"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">^\u00a0 </span>", "ID": "4c9d0433-80ca-4af8-95aa-acadd3b3269d", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "^\u00a0 ", "ParentId": "3e9695ea-31d3-43e8-8291-98aec01bf933"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">Table 2 shows pooled data from the overall treatment\nperiod in CLEOPATRA (data cutoff 11 February 2014; median number of cycles of\nPerjeta was 24); and from the neoadjuvant\u00a0 treatment period in NEOSPHERE\n(median number of cycles of Perjeta was 4, across all treatment arms) and\nTRYPHAENA (median number of cycles of Perjeta was 3 \u2013 6 across treatment arms) </span>", "ID": "8336321d-0eff-4cf7-9ea5-0f1b9891f59b", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "Table 2 shows pooled data from the overall treatment period in CLEOPATRA (data cutoff 11 February 2014; median number of cycles of Perjeta was 24); and from the neoadjuvant\u00a0 treatment period in NEOSPHERE (median number of cycles of Perjeta was 4, across all treatment arms) and TRYPHAENA (median number of cycles of Perjeta was 3 \u2013 6 across treatment arms) ", "ParentId": "5c61fd6a-1203-49d5-ad44-7ecefd966efc"}, {"Element": "<span style=\"font-size:10.0pt\">and from the treatment period of APHINITY (median\nnumber of cycles of Perjeta was 18). <sup>\u00a0</sup></span>", "ID": "1a0e4170-820c-42cf-a9a6-463d1e699a9e", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "and from the treatment period of APHINITY (median number of cycles of Perjeta was 18). ", "ParentId": "5c61fd6a-1203-49d5-ad44-7ecefd966efc"}, {"Element": "<sup>\u00a0</sup>", "ID": "86a186e0-a49f-4f78-b98e-164afbedf709", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1a0e4170-820c-42cf-a9a6-463d1e699a9e"}, {"Element": "<span style=\"font-size:\n10.0pt\">\u00a0<sup>\u00a0\u00a0</sup></span>", "ID": "90294867-a77a-45b3-a90c-3ec8781b979b", "Styles": "font-size:\n10.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "5c61fd6a-1203-49d5-ad44-7ecefd966efc"}, {"Element": "<sup>\u00a0\u00a0</sup>", "ID": "dfba5851-3e8b-4d61-a0b1-9e5aa7121d35", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0", "ParentId": "90294867-a77a-45b3-a90c-3ec8781b979b"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>", "ID": "d8292efd-d329-4495-8d7d-f895fbca4d82", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span>", "ID": "ce5ebb95-9920-459f-acda-3d091e5308ec", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "d8292efd-d329-4495-8d7d-f895fbca4d82"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">* ADRs with a fatal outcome have been\nreported</span><span lang=\"EN-GB\" style=\"font-size:10.0pt\">.\u00a0 </span></p>", "ID": "84bb645b-d704-4253-9c48-af5911d94cca", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">* ADRs with a fatal outcome have been\nreported</span>", "ID": "b76d231d-a76e-4486-8ad7-a40e5d98997a", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "* ADRs with a fatal outcome have been reported", "ParentId": "84bb645b-d704-4253-9c48-af5911d94cca"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">.\u00a0 </span>", "ID": "74f78b7d-7a47-4f38-a549-1768f8ba18b8", "Styles": "font-size:10.0pt", "Classes": "None", "Text": ".\u00a0 ", "ParentId": "84bb645b-d704-4253-9c48-af5911d94cca"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:9.0pt;text-indent:-9.0pt;page-break-after:\navoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">** For the\noverall treatment period across the 4 studies. The incidence of left\nventricular dysfunction and cardiac failure congestive reflect the MedDRA\nPreferred Terms reported in the individual studies.</span></p>", "ID": "ce78d241-a3bc-4c74-8fe7-286dc02960a3", "Styles": "margin-left:9.0pt;text-indent:-9.0pt;page-break-after:\navoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">** For the\noverall treatment period across the 4 studies. The incidence of left\nventricular dysfunction and cardiac failure congestive reflect the MedDRA\nPreferred Terms reported in the individual studies.</span>", "ID": "ae59aa5c-696d-4a1e-99ae-dc56f300cc97", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "** For the overall treatment period across the 4 studies. The incidence of left ventricular dysfunction and cardiac failure congestive reflect the MedDRA Preferred Terms reported in the individual studies.", "ParentId": "ce78d241-a3bc-4c74-8fe7-286dc02960a3"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00b0 </span><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Hypersensitivity/anaphylactic\nreaction is based on a group of terms.</span></p>", "ID": "45e7ee93-3734-4f93-9fc7-6d899d0134bc", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00b0 </span>", "ID": "74533f21-7df8-4132-97f1-7b6a60cf3985", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00b0 ", "ParentId": "45e7ee93-3734-4f93-9fc7-6d899d0134bc"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">Hypersensitivity/anaphylactic\nreaction is based on a group of terms.</span>", "ID": "5ea0771a-7407-4107-87a2-b505e0c7d414", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "Hypersensitivity/anaphylactic reaction is based on a group of terms.", "ParentId": "45e7ee93-3734-4f93-9fc7-6d899d0134bc"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:9.0pt;text-indent:-9.0pt;page-break-after:\navoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00b0\u00b0 Infusion reaction includes\na range of different terms within a time window, see \u201cDescription of selected\nadverse reactions\u201d below. </span></p>", "ID": "bbdc0cbd-b2f1-4a5d-b46e-a5dca9333b01", "Styles": "margin-left:9.0pt;text-indent:-9.0pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00b0\u00b0 Infusion reaction includes\na range of different terms within a time window, see \u201cDescription of selected\nadverse reactions\u201d below. </span>", "ID": "1a36d2ae-30a6-4aa3-9b05-2792f5a456b4", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00b0\u00b0 Infusion reaction includes a range of different terms within a time window, see \u201cDescription of selected adverse reactions\u201d below. ", "ParentId": "bbdc0cbd-b2f1-4a5d-b46e-a5dca9333b01"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u2020 ADRs reported in the post marketing setting</span><u><span lang=\"EN-GB\">-</span></u></p>", "ID": "7115f9d1-f55d-4d3f-8108-3df10b7f5f15", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u2020 ADRs reported in the post marketing setting</span>", "ID": "0453b76f-aaf8-405d-85d4-177cb2fa8a11", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u2020 ADRs reported in the post marketing setting", "ParentId": "7115f9d1-f55d-4d3f-8108-3df10b7f5f15"}, {"Element": "<u><span lang=\"EN-GB\">-</span></u>", "ID": "229b6b55-9774-4e51-aff2-eccf9ccb17a3", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "7115f9d1-f55d-4d3f-8108-3df10b7f5f15"}, {"Element": "<span lang=\"EN-GB\">-</span>", "ID": "f177ce1d-7cdb-412f-a3ff-d9fac1da272b", "Styles": "None", "Classes": "None", "Text": "-", "ParentId": "229b6b55-9774-4e51-aff2-eccf9ccb17a3"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>", "ID": "d6f56d51-e91e-47cb-861b-c851ee1c3058", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u>", "ID": "9a729a50-f79f-4202-a620-d9531f320fc1", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d6f56d51-e91e-47cb-861b-c851ee1c3058"}, {"Element": "<span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span>", "ID": "e7e72618-e512-4fe0-9b1d-361573bfe3e5", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "9a729a50-f79f-4202-a620-d9531f320fc1"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "d0c85e1d-d785-4734-9c26-59f2ca922a9a", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "e7e72618-e512-4fe0-9b1d-361573bfe3e5"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Description\nof selected adverse reactions</span></u></p>", "ID": "9f59686b-25cc-41d2-ad8c-13e90812ad6a", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<u><span lang=\"EN-GB\">Description\nof selected adverse reactions</span></u>", "ID": "714925ad-9b85-4bdc-b117-116da4087184", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "9f59686b-25cc-41d2-ad8c-13e90812ad6a"}, {"Element": "<span lang=\"EN-GB\">Description\nof selected adverse reactions</span>", "ID": "978aef58-09e7-4182-bffc-4fb794b9126c", "Styles": "None", "Classes": "None", "Text": "Description of selected adverse reactions", "ParentId": "714925ad-9b85-4bdc-b117-116da4087184"}, {"Element": "<p class=\"MsoNormal\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>", "ID": "163ae2be-0162-49a3-9cbf-c0584e93d6c6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u>", "ID": "f75cddce-c9af-49ba-a962-8f9fc685880d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "163ae2be-0162-49a3-9cbf-c0584e93d6c6"}, {"Element": "<span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span>", "ID": "d375ece1-6e88-4a21-9362-f4c18bbc1abf", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f75cddce-c9af-49ba-a962-8f9fc685880d"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "35372ea9-240f-4d02-b8c6-03399e17e863", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "d375ece1-6e88-4a21-9362-f4c18bbc1abf"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\"><i><span lang=\"EN-GB\">Left ventricular dysfunction (LVD)</span></i></p>", "ID": "bafdda3d-d975-4ce6-93cb-dc61108a2c64", "Styles": "text-align:justify;text-justify:inter-ideograph", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<i><span lang=\"EN-GB\">Left ventricular dysfunction (LVD)</span></i>", "ID": "728139a1-c6a3-4436-9729-89f6be46ae37", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "bafdda3d-d975-4ce6-93cb-dc61108a2c64"}, {"Element": "<span lang=\"EN-GB\">Left ventricular dysfunction (LVD)</span>", "ID": "cb31eff4-67c2-4101-8cb4-f971faa46b30", "Styles": "None", "Classes": "None", "Text": "Left ventricular dysfunction (LVD)", "ParentId": "728139a1-c6a3-4436-9729-89f6be46ae37"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\"><span lang=\"EN-GB\">In the pivotal trial CLEOPATRA in metastatic breast cancer, the\nincidence of LVD during study treatment was higher in the placebo-treated group\nthan in the Perjeta-treated group (8.6% and 6.6%, respectively). The incidence\nof symptomatic LVD was also lower in the Perjeta-treated group (1.8% in the\nplacebo-treated group vs. 1.5% in the Perjeta-treated group) (see section 4.4).\n</span></p>", "ID": "fbe3cde4-ea34-4971-aa07-b0d2df4b7481", "Styles": "text-align:justify;text-justify:inter-ideograph", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">In the pivotal trial CLEOPATRA in metastatic breast cancer, the\nincidence of LVD during study treatment was higher in the placebo-treated group\nthan in the Perjeta-treated group (8.6% and 6.6%, respectively). The incidence\nof symptomatic LVD was also lower in the Perjeta-treated group (1.8% in the\nplacebo-treated group vs. 1.5% in the Perjeta-treated group) (see section 4.4).\n</span>", "ID": "6f41349e-4e18-4f95-8bfd-1737ed67fdfc", "Styles": "None", "Classes": "None", "Text": "In the pivotal trial CLEOPATRA in metastatic breast cancer, the incidence of LVD during study treatment was higher in the placebo-treated group than in the Perjeta-treated group (8.6% and 6.6%, respectively). The incidence of symptomatic LVD was also lower in the Perjeta-treated group (1.8% in the placebo-treated group vs. 1.5% in the Perjeta-treated group) (see section 4.4). ", "ParentId": "fbe3cde4-ea34-4971-aa07-b0d2df4b7481"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "23ead8fb-9766-4cb7-a676-d2b5392ec9db", "Styles": "text-align:justify;text-justify:inter-ideograph", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ee073c57-4af3-43e9-a33a-29abb0bae89f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "23ead8fb-9766-4cb7-a676-d2b5392ec9db"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\"><span lang=\"EN-GB\">In the neoadjuvant trial NEOSPHERE, in which patients received 4\ncycles of Perjeta as neoadjuvant treatment, the incidence of LVD (during the\noverall treatment period) was higher in the Perjeta, trastuzumab and\ndocetaxel-treated group (7.5%) compared to the trastuzumab and\ndocetaxel-treated group (1.9%). There was one case of symptomatic LVD in the\nPerjeta and trastuzumab-treated group. </span></p>", "ID": "06c3f737-80d8-49c7-97c5-c5fb31e7bc04", "Styles": "text-align:justify;text-justify:inter-ideograph", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">In the neoadjuvant trial NEOSPHERE, in which patients received 4\ncycles of Perjeta as neoadjuvant treatment, the incidence of LVD (during the\noverall treatment period) was higher in the Perjeta, trastuzumab and\ndocetaxel-treated group (7.5%) compared to the trastuzumab and\ndocetaxel-treated group (1.9%). There was one case of symptomatic LVD in the\nPerjeta and trastuzumab-treated group. </span>", "ID": "4c119f63-9dd5-4fa4-b532-5f4a0eb00c25", "Styles": "None", "Classes": "None", "Text": "In the neoadjuvant trial NEOSPHERE, in which patients received 4 cycles of Perjeta as neoadjuvant treatment, the incidence of LVD (during the overall treatment period) was higher in the Perjeta, trastuzumab and docetaxel-treated group (7.5%) compared to the trastuzumab and docetaxel-treated group (1.9%). There was one case of symptomatic LVD in the Perjeta and trastuzumab-treated group. ", "ParentId": "06c3f737-80d8-49c7-97c5-c5fb31e7bc04"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\"><span lang=\"EN-GB\">In the neoadjuvant trial TRYPHAENA, the incidence of LVD (during the\noverall treatment period) was 8.3% in the group treated with Perjeta plus\ntrastuzumab and FEC </span>(5-fluorouracil, epirubicin, cyclophosphamide)<span lang=\"EN-GB\"> followed by Perjeta plus trastuzumab and docetaxel; 9.3% in the\ngroup treated with Perjeta plus trastuzumab and docetaxel following FEC; and\n6.6% in the group treated with Perjeta in combination with TCH </span>(docetaxel,\ncarboplatin and trastuzumab)<span lang=\"EN-GB\">. The incidence of symptomatic LVD\n(congestive heart failure) was 1.3% in the group treated with Perjeta plus\ntrastuzumab and docetaxel following FEC (this excludes a patient who\nexperienced symptomatic LVD during FEC treatment prior to receiving Perjeta\nplus trastuzumab and docetaxel) and also 1.3% in the group treated with Perjeta\nin combination with TCH. No patients in the group treated with Perjeta plus\ntrastuzumab and FEC followed by Perjeta plus trastuzumab and docetaxel\nexperienced symptomatic LVD.</span></p>", "ID": "ed0c0c11-1bb5-45fe-8fed-6f6fca8d2bd2", "Styles": "text-align:justify;text-justify:inter-ideograph", "Classes": "['MsoNormal']", "Text": "(5-fluorouracil, epirubicin, cyclophosphamide)(docetaxel, carboplatin and trastuzumab)", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">In the neoadjuvant trial TRYPHAENA, the incidence of LVD (during the\noverall treatment period) was 8.3% in the group treated with Perjeta plus\ntrastuzumab and FEC </span>", "ID": "53c09a03-1df5-4802-b616-20d9464a7865", "Styles": "None", "Classes": "None", "Text": "In the neoadjuvant trial TRYPHAENA, the incidence of LVD (during the overall treatment period) was 8.3% in the group treated with Perjeta plus trastuzumab and FEC ", "ParentId": "ed0c0c11-1bb5-45fe-8fed-6f6fca8d2bd2"}, {"Element": "<span lang=\"EN-GB\"> followed by Perjeta plus trastuzumab and docetaxel; 9.3% in the\ngroup treated with Perjeta plus trastuzumab and docetaxel following FEC; and\n6.6% in the group treated with Perjeta in combination with TCH </span>", "ID": "410157fb-aa3c-47ec-b6a2-faf98e866841", "Styles": "None", "Classes": "None", "Text": " followed by Perjeta plus trastuzumab and docetaxel; 9.3% in the group treated with Perjeta plus trastuzumab and docetaxel following FEC; and 6.6% in the group treated with Perjeta in combination with TCH ", "ParentId": "ed0c0c11-1bb5-45fe-8fed-6f6fca8d2bd2"}, {"Element": "<span lang=\"EN-GB\">. The incidence of symptomatic LVD\n(congestive heart failure) was 1.3% in the group treated with Perjeta plus\ntrastuzumab and docetaxel following FEC (this excludes a patient who\nexperienced symptomatic LVD during FEC treatment prior to receiving Perjeta\nplus trastuzumab and docetaxel) and also 1.3% in the group treated with Perjeta\nin combination with TCH. No patients in the group treated with Perjeta plus\ntrastuzumab and FEC followed by Perjeta plus trastuzumab and docetaxel\nexperienced symptomatic LVD.</span>", "ID": "6aacc213-ae67-4172-bfe4-ba5d9995a5f3", "Styles": "None", "Classes": "None", "Text": ". The incidence of symptomatic LVD (congestive heart failure) was 1.3% in the group treated with Perjeta plus trastuzumab and docetaxel following FEC (this excludes a patient who experienced symptomatic LVD during FEC treatment prior to receiving Perjeta plus trastuzumab and docetaxel) and also 1.3% in the group treated with Perjeta in combination with TCH. No patients in the group treated with Perjeta plus trastuzumab and FEC followed by Perjeta plus trastuzumab and docetaxel experienced symptomatic LVD.", "ParentId": "ed0c0c11-1bb5-45fe-8fed-6f6fca8d2bd2"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5ebfd7c2-5a90-4990-bcd8-c4a7c64ba060", "Styles": "text-align:justify;text-justify:inter-ideograph", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f70898b3-3105-4e8e-b8fb-ae00103798be", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5ebfd7c2-5a90-4990-bcd8-c4a7c64ba060"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In the neoadjuvant period of the BERENICE\ntrial, the incidence of NYHA Class III/IV symptomatic LVD (congestive heart\nfailure</span><span lang=\"EN-CARRIBEAN\"> according to </span>NCI-CTCAE v.4<span lang=\"EN-GB\">) was 1.5% in the group treated with dose dense doxorubicin and\ncyclophosphamide (AC) followed by Perjeta plus trastuzumab and paclitaxel and none\nof the patients (0%) experienced symptomatic LVD in the group treated with FEC\nfollowed by Perjeta in combination with trastuzumab and docetaxel. The\nincidence of asymptomatic LVD (ejection fraction decrease </span><span lang=\"EN-CARRIBEAN\">according to </span>NCI-CTCAE v.4)<span lang=\"EN-GB\"> was 7% in\nthe group treated with dose dense AC followed by Perjeta plus trastuzumab and\npaclitaxel and 3.5% in the group treated with FEC followed by Perjeta plus\ntrastuzumab and docetaxel.</span></p>", "ID": "d1f75d9d-51d7-4824-b5ff-43242817cec4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "NCI-CTCAE v.4NCI-CTCAE v.4)", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">In the neoadjuvant period of the BERENICE\ntrial, the incidence of NYHA Class III/IV symptomatic LVD (congestive heart\nfailure</span>", "ID": "042aabc1-4a91-4545-b9f8-8c91bc4cf1bd", "Styles": "None", "Classes": "None", "Text": "In the neoadjuvant period of the BERENICE trial, the incidence of NYHA Class III/IV symptomatic LVD (congestive heart failure", "ParentId": "d1f75d9d-51d7-4824-b5ff-43242817cec4"}, {"Element": "<span lang=\"EN-CARRIBEAN\"> according to </span>", "ID": "675c8dd8-da95-4d5a-86e0-78836d014011", "Styles": "None", "Classes": "None", "Text": " according to ", "ParentId": "d1f75d9d-51d7-4824-b5ff-43242817cec4"}, {"Element": "<span lang=\"EN-GB\">) was 1.5% in the group treated with dose dense doxorubicin and\ncyclophosphamide (AC) followed by Perjeta plus trastuzumab and paclitaxel and none\nof the patients (0%) experienced symptomatic LVD in the group treated with FEC\nfollowed by Perjeta in combination with trastuzumab and docetaxel. The\nincidence of asymptomatic LVD (ejection fraction decrease </span>", "ID": "eb97ab7e-10ea-44e3-a293-17464d00a9f0", "Styles": "None", "Classes": "None", "Text": ") was 1.5% in the group treated with dose dense doxorubicin and cyclophosphamide (AC) followed by Perjeta plus trastuzumab and paclitaxel and none of the patients (0%) experienced symptomatic LVD in the group treated with FEC followed by Perjeta in combination with trastuzumab and docetaxel. The incidence of asymptomatic LVD (ejection fraction decrease ", "ParentId": "d1f75d9d-51d7-4824-b5ff-43242817cec4"}, {"Element": "<span lang=\"EN-CARRIBEAN\">according to </span>", "ID": "f49a857e-4b76-4031-a8ea-a3c61c5bb51a", "Styles": "None", "Classes": "None", "Text": "according to ", "ParentId": "d1f75d9d-51d7-4824-b5ff-43242817cec4"}, {"Element": "<span lang=\"EN-GB\"> was 7% in\nthe group treated with dose dense AC followed by Perjeta plus trastuzumab and\npaclitaxel and 3.5% in the group treated with FEC followed by Perjeta plus\ntrastuzumab and docetaxel.</span>", "ID": "2760423c-7e96-4a51-8c2d-9dfce112dd87", "Styles": "None", "Classes": "None", "Text": " was 7% in the group treated with dose dense AC followed by Perjeta plus trastuzumab and paclitaxel and 3.5% in the group treated with FEC followed by Perjeta plus trastuzumab and docetaxel.", "ParentId": "d1f75d9d-51d7-4824-b5ff-43242817cec4"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\">\u00a0</p>", "ID": "de942aa7-fa79-41f8-9dbf-a0bee07cba1d", "Styles": "text-align:justify;text-justify:inter-ideograph", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\">In\nAPHINITY, the incidence of symptomatic heart failure (NYHA class III or IV)\nwith a LVEF decline of at least 10% points from baseline and to &lt;50% was\n&lt;1% (0.6% of Perjeta-treated patients vs 0.3% of placebo-treated patients).\nOf the patients who experienced symptomatic heart failure, 46.7% of\nPerjeta-treated patients and 57.1% of placebo-treated patients had recovered\n(defined as 2 consecutive LVEF measurements above 50%) at the data cutoff. The\nmajority of the events were reported in anthracycline-treated patients. Asymptomatic\nor mildly symptomatic (NYHA class II) declines in LVEF of at least 10% points\nfrom baseline and to &lt;50% were reported in 2.7% of Perjeta-treated patients\nand 2.8% of placebo-treated patients, of whom 79.7% of Perjeta-treated patients\nand 80.6% of placebo-treated patients had recovered at the data cutoff. </p>", "ID": "31d7811c-2c73-480b-b2fe-4ff76e39ed4f", "Styles": "text-align:justify;text-justify:inter-ideograph", "Classes": "['MsoNormal']", "Text": "In APHINITY, the incidence of symptomatic heart failure (NYHA class III or IV) with a LVEF decline of at least 10% points from baseline and to <50% was <1% (0.6% of Perjeta-treated patients vs 0.3% of placebo-treated patients). Of the patients who experienced symptomatic heart failure, 46.7% of Perjeta-treated patients and 57.1% of placebo-treated patients had recovered (defined as 2 consecutive LVEF measurements above 50%) at the data cutoff. The majority of the events were reported in anthracycline-treated patients. Asymptomatic or mildly symptomatic (NYHA class II) declines in LVEF of at least 10% points from baseline and to <50% were reported in 2.7% of Perjeta-treated patients and 2.8% of placebo-treated patients, of whom 79.7% of Perjeta-treated patients and 80.6% of placebo-treated patients had recovered at the data cutoff. ", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">\u00a0</span></i></p>", "ID": "f9951628-f009-40c3-a864-f15ac828205a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<i><span lang=\"EN-GB\">\u00a0</span></i>", "ID": "27220f1a-8ef9-49fa-832d-917172609835", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f9951628-f009-40c3-a864-f15ac828205a"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8990006f-eeb3-45e5-8bc5-25cdf1dfd74e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "27220f1a-8ef9-49fa-832d-917172609835"}, {"Element": "<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">Infusion reactions</span></i></p>", "ID": "6b6b62ac-3bae-49f4-841b-e0604a2209cd", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<i><span lang=\"EN-GB\">Infusion reactions</span></i>", "ID": "be03df75-3d1f-428a-95dd-82258f4d8538", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "6b6b62ac-3bae-49f4-841b-e0604a2209cd"}, {"Element": "<span lang=\"EN-GB\">Infusion reactions</span>", "ID": "16b3cda3-b0b3-4440-896a-00ceecb7fb67", "Styles": "None", "Classes": "None", "Text": "Infusion reactions", "ParentId": "be03df75-3d1f-428a-95dd-82258f4d8538"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">An infusion reaction was defined in the\npivotal trials as any event reported as hypersensitivity, anaphylactic\nreaction, acute infusion reaction or cytokine release syndrome occurring during\nan infusion or on the same day as the infusion. In the pivotal trial CLEOPATRA,\nthe initial dose of Perjeta was given the day before trastuzumab and docetaxel\nto allow for the examination of Perjeta-associated reactions. On the first day\nwhen only Perjeta was administered, the overall frequency of infusion reactions\nwas 9.8% in the placebo-treated group and 13.2% in the Perjeta-treated group,\nwith the majority of infusion reactions being mild or moderate. The most common\ninfusion reactions (</span><span lang=\"EN-GB\">\u2265</span><span lang=\"EN-GB\">\u00a01.0%)\nin the Perjeta-treated group were pyrexia, chills, fatigue, headache, asthenia,\nhypersensitivity and vomiting.</span></p>", "ID": "e25cc54e-3c84-487f-902a-c1f30f4db99b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">An infusion reaction was defined in the\npivotal trials as any event reported as hypersensitivity, anaphylactic\nreaction, acute infusion reaction or cytokine release syndrome occurring during\nan infusion or on the same day as the infusion. In the pivotal trial CLEOPATRA,\nthe initial dose of Perjeta was given the day before trastuzumab and docetaxel\nto allow for the examination of Perjeta-associated reactions. On the first day\nwhen only Perjeta was administered, the overall frequency of infusion reactions\nwas 9.8% in the placebo-treated group and 13.2% in the Perjeta-treated group,\nwith the majority of infusion reactions being mild or moderate. The most common\ninfusion reactions (</span>", "ID": "af7ef77d-d323-4e89-aa44-c17a0214dbe2", "Styles": "None", "Classes": "None", "Text": "An infusion reaction was defined in the pivotal trials as any event reported as hypersensitivity, anaphylactic reaction, acute infusion reaction or cytokine release syndrome occurring during an infusion or on the same day as the infusion. In the pivotal trial CLEOPATRA, the initial dose of Perjeta was given the day before trastuzumab and docetaxel to allow for the examination of Perjeta-associated reactions. On the first day when only Perjeta was administered, the overall frequency of infusion reactions was 9.8% in the placebo-treated group and 13.2% in the Perjeta-treated group, with the majority of infusion reactions being mild or moderate. The most common infusion reactions (", "ParentId": "e25cc54e-3c84-487f-902a-c1f30f4db99b"}, {"Element": "<span lang=\"EN-GB\">\u2265</span>", "ID": "15f85e74-19a7-487f-9ef2-6f95ca436820", "Styles": "None", "Classes": "None", "Text": "\u2265", "ParentId": "e25cc54e-3c84-487f-902a-c1f30f4db99b"}, {"Element": "<span lang=\"EN-GB\">\u00a01.0%)\nin the Perjeta-treated group were pyrexia, chills, fatigue, headache, asthenia,\nhypersensitivity and vomiting.</span>", "ID": "3631a080-ecdd-4213-9648-badc7c5f19ee", "Styles": "None", "Classes": "None", "Text": "\u00a01.0%) in the Perjeta-treated group were pyrexia, chills, fatigue, headache, asthenia, hypersensitivity and vomiting.", "ParentId": "e25cc54e-3c84-487f-902a-c1f30f4db99b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4355aaad-c77f-41d0-a0d5-0210ebcfe537", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "519cd292-664e-4312-8c95-6844d7d4795b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4355aaad-c77f-41d0-a0d5-0210ebcfe537"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">During the second cycle when all medicinal\nproducts were administered on the same day, the most common infusion reactions\nin the Perjeta-treated group (</span><span lang=\"EN-GB\">\u2265</span><span lang=\"EN-GB\">\u00a01.0%) were fatigue, dysgeusia, </span><span lang=\"EN-GB\">drug </span><span lang=\"EN-GB\">hypersensitivity, myalgia and vomiting (see section 4.4).</span></p>", "ID": "a61209d0-a838-4dd8-b083-f87c418ec539", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">During the second cycle when all medicinal\nproducts were administered on the same day, the most common infusion reactions\nin the Perjeta-treated group (</span>", "ID": "3bd0946a-b16d-421f-9369-5b3bae4cec95", "Styles": "None", "Classes": "None", "Text": "During the second cycle when all medicinal products were administered on the same day, the most common infusion reactions in the Perjeta-treated group (", "ParentId": "a61209d0-a838-4dd8-b083-f87c418ec539"}, {"Element": "<span lang=\"EN-GB\">\u2265</span>", "ID": "a331d353-756c-4f3f-93b8-aaae71053dfa", "Styles": "None", "Classes": "None", "Text": "\u2265", "ParentId": "a61209d0-a838-4dd8-b083-f87c418ec539"}, {"Element": "<span lang=\"EN-GB\">\u00a01.0%) were fatigue, dysgeusia, </span>", "ID": "3e578556-1672-422d-b4b1-c79f99da34f2", "Styles": "None", "Classes": "None", "Text": "\u00a01.0%) were fatigue, dysgeusia, ", "ParentId": "a61209d0-a838-4dd8-b083-f87c418ec539"}, {"Element": "<span lang=\"EN-GB\">drug </span>", "ID": "99e0cd52-be6f-4e84-be7b-c29368638da1", "Styles": "None", "Classes": "None", "Text": "drug ", "ParentId": "a61209d0-a838-4dd8-b083-f87c418ec539"}, {"Element": "<span lang=\"EN-GB\">hypersensitivity, myalgia and vomiting (see section 4.4).</span>", "ID": "9f97ea53-efb4-4885-bcbf-3ad2c9f0b7dd", "Styles": "None", "Classes": "None", "Text": "hypersensitivity, myalgia and vomiting (see section 4.4).", "ParentId": "a61209d0-a838-4dd8-b083-f87c418ec539"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9e8a0896-8e3b-48c4-b2d2-1d003e4735ae", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5c93c4f8-ab86-45fc-9485-9192b1ab13d6", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9e8a0896-8e3b-48c4-b2d2-1d003e4735ae"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In neoadjuvant and adjuvant trials, Perjeta\nwas administered on the same day as other study treatments in all cycles.\nInfusion reactions occurred in 18.6% - 25.0% of patients on the first day of\nPerjeta administration (in combination with trastuzumab and chemotherapy). The\ntype and severity of events were consistent with those observed in CLEOPATRA at\nthe cycles when Perjeta was given on the same day as trastuzumab and docetaxel,\nwith the majority of reactions being mild or moderate in severity.</span></p>", "ID": "448b170b-7fbe-453e-a313-e9a094b25ef0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">In neoadjuvant and adjuvant trials, Perjeta\nwas administered on the same day as other study treatments in all cycles.\nInfusion reactions occurred in 18.6% - 25.0% of patients on the first day of\nPerjeta administration (in combination with trastuzumab and chemotherapy). The\ntype and severity of events were consistent with those observed in CLEOPATRA at\nthe cycles when Perjeta was given on the same day as trastuzumab and docetaxel,\nwith the majority of reactions being mild or moderate in severity.</span>", "ID": "ca88fd2b-c10a-4bf5-bc0e-ea85872fd20d", "Styles": "None", "Classes": "None", "Text": "In neoadjuvant and adjuvant trials, Perjeta was administered on the same day as other study treatments in all cycles. Infusion reactions occurred in 18.6% - 25.0% of patients on the first day of Perjeta administration (in combination with trastuzumab and chemotherapy). The type and severity of events were consistent with those observed in CLEOPATRA at the cycles when Perjeta was given on the same day as trastuzumab and docetaxel, with the majority of reactions being mild or moderate in severity.", "ParentId": "448b170b-7fbe-453e-a313-e9a094b25ef0"}, {"Element": "<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">\u00a0</span></i></p>", "ID": "b227b21d-1440-453c-9068-0504e044d237", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<i><span lang=\"EN-GB\">\u00a0</span></i>", "ID": "3dbe271e-9a6f-4ec6-b903-3a4f7cf33351", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b227b21d-1440-453c-9068-0504e044d237"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8ec65223-9de5-436b-a3c5-6998ef16bbd4", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3dbe271e-9a6f-4ec6-b903-3a4f7cf33351"}, {"Element": "<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">Hypersensitivity reactions/anaphylaxis</span></i></p>", "ID": "0e9cfe96-255d-4d2c-868c-ec8018f2ea18", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<i><span lang=\"EN-GB\">Hypersensitivity reactions/anaphylaxis</span></i>", "ID": "72bbf619-3735-4f98-bfb3-5c63143683db", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "0e9cfe96-255d-4d2c-868c-ec8018f2ea18"}, {"Element": "<span lang=\"EN-GB\">Hypersensitivity reactions/anaphylaxis</span>", "ID": "a4b5b653-485e-42b7-9afa-f5e609d5bfee", "Styles": "None", "Classes": "None", "Text": "Hypersensitivity reactions/anaphylaxis", "ParentId": "72bbf619-3735-4f98-bfb3-5c63143683db"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In the pivotal trial CLEOPATRA</span><span lang=\"EN-GB\"> in metastatic breast cancer</span><span lang=\"EN-GB\">, the overall\nfrequency of investigator reported hypersensitivity/anaphylaxis events during\nthe entire treatment period was 9.3% in the placebo-treated group and 11.3% in\nthe Perjeta-treated group, of which 2.5% and 2.0% were <br/>\nNCI-CTCAE Grade 3-4, respectively. Overall, 2 patients in the placebo-treated\ngroup and 4 patients in the Perjeta-treated group experienced </span><span lang=\"EN-GB\">events described as </span><span lang=\"EN-GB\">anaphylaxis </span><span lang=\"EN-GB\">by the investigator </span><span lang=\"EN-GB\">(see section 4.4). </span></p>", "ID": "e60b56c7-df45-417b-8a0b-e23d18020738", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">In the pivotal trial CLEOPATRA</span>", "ID": "844ce056-3a1e-43ca-899d-fd38048bcca7", "Styles": "None", "Classes": "None", "Text": "In the pivotal trial CLEOPATRA", "ParentId": "e60b56c7-df45-417b-8a0b-e23d18020738"}, {"Element": "<span lang=\"EN-GB\"> in metastatic breast cancer</span>", "ID": "8ad11b58-7a2c-4983-aed8-de8fca32ecaf", "Styles": "None", "Classes": "None", "Text": " in metastatic breast cancer", "ParentId": "e60b56c7-df45-417b-8a0b-e23d18020738"}, {"Element": "<span lang=\"EN-GB\">, the overall\nfrequency of investigator reported hypersensitivity/anaphylaxis events during\nthe entire treatment period was 9.3% in the placebo-treated group and 11.3% in\nthe Perjeta-treated group, of which 2.5% and 2.0% were <br/>\nNCI-CTCAE Grade 3-4, respectively. Overall, 2 patients in the placebo-treated\ngroup and 4 patients in the Perjeta-treated group experienced </span>", "ID": "c4589fbc-9f33-40e7-bf0e-9b8495b62d90", "Styles": "None", "Classes": "None", "Text": ", the overall frequency of investigator reported hypersensitivity/anaphylaxis events during the entire treatment period was 9.3% in the placebo-treated group and 11.3% in the Perjeta-treated group, of which 2.5% and 2.0% were  NCI-CTCAE Grade 3-4, respectively. Overall, 2 patients in the placebo-treated group and 4 patients in the Perjeta-treated group experienced ", "ParentId": "e60b56c7-df45-417b-8a0b-e23d18020738"}, {"Element": "<br/>", "ID": "18ae46b9-7c4e-426e-8b26-cb00ae380713", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c4589fbc-9f33-40e7-bf0e-9b8495b62d90"}, {"Element": "<span lang=\"EN-GB\">events described as </span>", "ID": "9033ba0c-d89b-4483-ac22-b82f3a2bbd4c", "Styles": "None", "Classes": "None", "Text": "events described as ", "ParentId": "e60b56c7-df45-417b-8a0b-e23d18020738"}, {"Element": "<span lang=\"EN-GB\">anaphylaxis </span>", "ID": "a60346f4-81e4-4ed7-bb26-fa98faefa6ee", "Styles": "None", "Classes": "None", "Text": "anaphylaxis ", "ParentId": "e60b56c7-df45-417b-8a0b-e23d18020738"}, {"Element": "<span lang=\"EN-GB\">by the investigator </span>", "ID": "de2bd74c-a06c-4b6b-92d3-227d7778ff15", "Styles": "None", "Classes": "None", "Text": "by the investigator ", "ParentId": "e60b56c7-df45-417b-8a0b-e23d18020738"}, {"Element": "<span lang=\"EN-GB\">(see section 4.4). </span>", "ID": "4d1fa9b6-06c5-4256-a97c-85b11d2d1e74", "Styles": "None", "Classes": "None", "Text": "(see section 4.4). ", "ParentId": "e60b56c7-df45-417b-8a0b-e23d18020738"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e46a21c6-5a0e-406c-aee4-92569cccbae5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "794db0a4-4566-4d8c-8498-f9cb53cae6d4", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e46a21c6-5a0e-406c-aee4-92569cccbae5"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Overall, the majority of hypersensitivity\nreactions were mild or moderate in severity and resolved upon treatment. Based\non modifications made to the study treatment, most reactions were assessed as\nsecondary to docetaxel infusions.</span></p>", "ID": "cc790577-1510-48bd-84f8-0e65967945a3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Overall, the majority of hypersensitivity\nreactions were mild or moderate in severity and resolved upon treatment. Based\non modifications made to the study treatment, most reactions were assessed as\nsecondary to docetaxel infusions.</span>", "ID": "4f6b58d6-ae6e-4bb4-bbdd-4e5923fe8d54", "Styles": "None", "Classes": "None", "Text": "Overall, the majority of hypersensitivity reactions were mild or moderate in severity and resolved upon treatment. Based on modifications made to the study treatment, most reactions were assessed as secondary to docetaxel infusions.", "ParentId": "cc790577-1510-48bd-84f8-0e65967945a3"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e98ca4d4-f39f-42a1-ba59-fcb3aad68f48", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f2925189-6a32-4f0f-b806-283dec583517", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e98ca4d4-f39f-42a1-ba59-fcb3aad68f48"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In the neoadjuvant and adjuvant trials,\nhypersensitivity/anaphylaxis events were consistent with those observed in\nCLEOPATRA. In NEOSPHERE, two patients in the Perjeta and docetaxel-treated\ngroup experienced anaphylaxis. In both the TRYPHAENA and APHINITY trials, the\noverall frequency of hypersensitivity/anaphylaxis was highest in the Perjeta\nand TCH treated group (13.2% and 7.6%, respectively), of which 2.6% and 1.3% of\nevents, respectively, were NCI-CTCAE Grade 3-4.</span></p>", "ID": "740d388b-9e2f-4384-b42b-9ba0007c8341", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">In the neoadjuvant and adjuvant trials,\nhypersensitivity/anaphylaxis events were consistent with those observed in\nCLEOPATRA. In NEOSPHERE, two patients in the Perjeta and docetaxel-treated\ngroup experienced anaphylaxis. In both the TRYPHAENA and APHINITY trials, the\noverall frequency of hypersensitivity/anaphylaxis was highest in the Perjeta\nand TCH treated group (13.2% and 7.6%, respectively), of which 2.6% and 1.3% of\nevents, respectively, were NCI-CTCAE Grade 3-4.</span>", "ID": "f52d6969-08b7-4164-97ae-17f83a495ce6", "Styles": "None", "Classes": "None", "Text": "In the neoadjuvant and adjuvant trials, hypersensitivity/anaphylaxis events were consistent with those observed in CLEOPATRA. In NEOSPHERE, two patients in the Perjeta and docetaxel-treated group experienced anaphylaxis. In both the TRYPHAENA and APHINITY trials, the overall frequency of hypersensitivity/anaphylaxis was highest in the Perjeta and TCH treated group (13.2% and 7.6%, respectively), of which 2.6% and 1.3% of events, respectively, were NCI-CTCAE Grade 3-4.", "ParentId": "740d388b-9e2f-4384-b42b-9ba0007c8341"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">\u00a0</span></i></p>", "ID": "7b7a9324-1201-41b3-b466-66454c68007e", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<i><span lang=\"EN-GB\">\u00a0</span></i>", "ID": "ce3682f5-a058-4927-bafe-7183dcd84fbe", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "7b7a9324-1201-41b3-b466-66454c68007e"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b63cbc50-10a3-4488-bf3d-358a97a4e26f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ce3682f5-a058-4927-bafe-7183dcd84fbe"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Febrile\nneutropenia</span></i></p>", "ID": "32bf7254-b210-44ff-b330-8dcabc07216b", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<i><span lang=\"EN-GB\">Febrile\nneutropenia</span></i>", "ID": "2ec99e98-aa23-4d8a-8271-3f82b4b64df7", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "32bf7254-b210-44ff-b330-8dcabc07216b"}, {"Element": "<span lang=\"EN-GB\">Febrile\nneutropenia</span>", "ID": "5bc96b82-163a-4fd0-a4b6-00b90be121af", "Styles": "None", "Classes": "None", "Text": "Febrile neutropenia", "ParentId": "2ec99e98-aa23-4d8a-8271-3f82b4b64df7"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In the pivotal trial CLEOPATRA, the\nmajority of patients in both treatment groups experienced at least one\nleucopenic event (63.0% of patients in the Perjeta-treated group and 58.3% of\npatients in the placebo-treated group), of which the majority were neutropenic\nevents (see section 4.4). Febrile neutropenia occurred in 13.7% of Perjeta-treated\npatients and 7.6% of placebo-treated patients. In both treatment groups, the\nproportion of patients experiencing febrile neutropenia was highest in the\nfirst cycle of therapy and declined steadily thereafter. An increased incidence\nof febrile neutropenia was observed </span><span lang=\"EN-GB\">among</span><span lang=\"EN-GB\"> Asian patients in both treatment groups compared with patients of\nother races and from other geographic regions. Among Asian patients, the\nincidence of febrile neutropenia was higher in the Perjeta-treated group (25.8%)\ncompared with the placebo-treated group (11.3%).</span></p>", "ID": "49b99846-63ae-42d3-b3ca-ee9e8754de91", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">In the pivotal trial CLEOPATRA, the\nmajority of patients in both treatment groups experienced at least one\nleucopenic event (63.0% of patients in the Perjeta-treated group and 58.3% of\npatients in the placebo-treated group), of which the majority were neutropenic\nevents (see section 4.4). Febrile neutropenia occurred in 13.7% of Perjeta-treated\npatients and 7.6% of placebo-treated patients. In both treatment groups, the\nproportion of patients experiencing febrile neutropenia was highest in the\nfirst cycle of therapy and declined steadily thereafter. An increased incidence\nof febrile neutropenia was observed </span>", "ID": "5368e9fb-9df2-4767-94bd-c4c509ef2726", "Styles": "None", "Classes": "None", "Text": "In the pivotal trial CLEOPATRA, the majority of patients in both treatment groups experienced at least one leucopenic event (63.0% of patients in the Perjeta-treated group and 58.3% of patients in the placebo-treated group), of which the majority were neutropenic events (see section 4.4). Febrile neutropenia occurred in 13.7% of Perjeta-treated patients and 7.6% of placebo-treated patients. In both treatment groups, the proportion of patients experiencing febrile neutropenia was highest in the first cycle of therapy and declined steadily thereafter. An increased incidence of febrile neutropenia was observed ", "ParentId": "49b99846-63ae-42d3-b3ca-ee9e8754de91"}, {"Element": "<span lang=\"EN-GB\">among</span>", "ID": "e6a09621-b98d-4671-b420-55bab135cb1d", "Styles": "None", "Classes": "None", "Text": "among", "ParentId": "49b99846-63ae-42d3-b3ca-ee9e8754de91"}, {"Element": "<span lang=\"EN-GB\"> Asian patients in both treatment groups compared with patients of\nother races and from other geographic regions. Among Asian patients, the\nincidence of febrile neutropenia was higher in the Perjeta-treated group (25.8%)\ncompared with the placebo-treated group (11.3%).</span>", "ID": "496ffd8d-4eeb-4575-a0d5-ab9b4263ffbe", "Styles": "None", "Classes": "None", "Text": " Asian patients in both treatment groups compared with patients of other races and from other geographic regions. Among Asian patients, the incidence of febrile neutropenia was higher in the Perjeta-treated group (25.8%) compared with the placebo-treated group (11.3%).", "ParentId": "49b99846-63ae-42d3-b3ca-ee9e8754de91"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6d850ace-6673-4c69-9388-a158063f4c1c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7b2d4bae-11bd-41a6-9bd6-59443805a7a0", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6d850ace-6673-4c69-9388-a158063f4c1c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In the NEOSPHERE trial, 8.4% of patients\ntreated with neoadjuvant Perjeta, trastuzumab and docetaxel experienced febrile\nneutropenia compared with 7.5% of patients treated with trastuzumab and\ndocetaxel. In the TRYPHAENA trial, febrile neutropenia occurred in 17.1% of\npatients treated with neoadjuvant Perjeta + TCH, and 9.3% of patients treated\nwith neoadjuvant Perjeta, trastuzumab and docetaxel following FEC. In TRYPHAENA,\nthe incidence of febrile neutropenia was higher in patients who received six\ncycles of Perjeta compared with patients who received three cycles of Perjeta,\nindependent of the chemotherapy given. As in the CLEOPATRA trial, a higher\nincidence of neutropenia and febrile neutropenia was observed among Asian\npatients compared with other patients in both neoadjuvant trials. In NEOSPHERE,\n8.3% of Asian patients treated with neoadjuvant Perjeta, trastuzumab and\ndocetaxel experienced febrile neutropenia compared with 4.0% of Asian patients\ntreated with neoadjuvant trastuzumab and docetaxel.</span></p>", "ID": "15499e62-d870-4b7b-a61a-245b52c9a386", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">In the NEOSPHERE trial, 8.4% of patients\ntreated with neoadjuvant Perjeta, trastuzumab and docetaxel experienced febrile\nneutropenia compared with 7.5% of patients treated with trastuzumab and\ndocetaxel. In the TRYPHAENA trial, febrile neutropenia occurred in 17.1% of\npatients treated with neoadjuvant Perjeta + TCH, and 9.3% of patients treated\nwith neoadjuvant Perjeta, trastuzumab and docetaxel following FEC. In TRYPHAENA,\nthe incidence of febrile neutropenia was higher in patients who received six\ncycles of Perjeta compared with patients who received three cycles of Perjeta,\nindependent of the chemotherapy given. As in the CLEOPATRA trial, a higher\nincidence of neutropenia and febrile neutropenia was observed among Asian\npatients compared with other patients in both neoadjuvant trials. In NEOSPHERE,\n8.3% of Asian patients treated with neoadjuvant Perjeta, trastuzumab and\ndocetaxel experienced febrile neutropenia compared with 4.0% of Asian patients\ntreated with neoadjuvant trastuzumab and docetaxel.</span>", "ID": "d1cb5169-5e65-456d-a21a-63b6824acff5", "Styles": "None", "Classes": "None", "Text": "In the NEOSPHERE trial, 8.4% of patients treated with neoadjuvant Perjeta, trastuzumab and docetaxel experienced febrile neutropenia compared with 7.5% of patients treated with trastuzumab and docetaxel. In the TRYPHAENA trial, febrile neutropenia occurred in 17.1% of patients treated with neoadjuvant Perjeta + TCH, and 9.3% of patients treated with neoadjuvant Perjeta, trastuzumab and docetaxel following FEC. In TRYPHAENA, the incidence of febrile neutropenia was higher in patients who received six cycles of Perjeta compared with patients who received three cycles of Perjeta, independent of the chemotherapy given. As in the CLEOPATRA trial, a higher incidence of neutropenia and febrile neutropenia was observed among Asian patients compared with other patients in both neoadjuvant trials. In NEOSPHERE, 8.3% of Asian patients treated with neoadjuvant Perjeta, trastuzumab and docetaxel experienced febrile neutropenia compared with 4.0% of Asian patients treated with neoadjuvant trastuzumab and docetaxel.", "ParentId": "15499e62-d870-4b7b-a61a-245b52c9a386"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "adcafe9d-9139-47ad-8f3c-5a679c09c13d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0cebd38a-5258-4359-96c4-a092133b12c5", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "adcafe9d-9139-47ad-8f3c-5a679c09c13d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In the APHINITY trial, febrile neutropenia\noccurred in 12.1% of Perjeta-treated patients and 11.1% of placebo-treated\npatients. As in the CLEOPATRA, TRYPHAENA, and NEOSPHERE trials, a higher\nincidence of febrile neutropenia was observed among Perjeta-treated Asian\npatients compared with other races in the APHINITY trial (15.9% of\nPerjeta-treated patients and 9.9% of placebo-treated patients).</span></p>", "ID": "808582f8-3038-49c6-9c7c-2ad5cfb22af5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">In the APHINITY trial, febrile neutropenia\noccurred in 12.1% of Perjeta-treated patients and 11.1% of placebo-treated\npatients. As in the CLEOPATRA, TRYPHAENA, and NEOSPHERE trials, a higher\nincidence of febrile neutropenia was observed among Perjeta-treated Asian\npatients compared with other races in the APHINITY trial (15.9% of\nPerjeta-treated patients and 9.9% of placebo-treated patients).</span>", "ID": "5a041f85-189a-4c85-be63-1f2832010383", "Styles": "None", "Classes": "None", "Text": "In the APHINITY trial, febrile neutropenia occurred in 12.1% of Perjeta-treated patients and 11.1% of placebo-treated patients. As in the CLEOPATRA, TRYPHAENA, and NEOSPHERE trials, a higher incidence of febrile neutropenia was observed among Perjeta-treated Asian patients compared with other races in the APHINITY trial (15.9% of Perjeta-treated patients and 9.9% of placebo-treated patients).", "ParentId": "808582f8-3038-49c6-9c7c-2ad5cfb22af5"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5cfe77fb-6598-4fe2-b219-ae2859293203", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "59fcb84c-f62e-4fb8-8f4d-ee5d292a5acd", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5cfe77fb-6598-4fe2-b219-ae2859293203"}, {"Element": "<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">Diarrhoea</span></i></p>", "ID": "20548f17-f6ac-4e66-aca3-725888faf187", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<i><span lang=\"EN-GB\">Diarrhoea</span></i>", "ID": "39563b18-da4b-4151-9479-10f687e9d3eb", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "20548f17-f6ac-4e66-aca3-725888faf187"}, {"Element": "<span lang=\"EN-GB\">Diarrhoea</span>", "ID": "fe3d09c7-0800-4f4a-9315-a51de0225f2c", "Styles": "None", "Classes": "None", "Text": "Diarrhoea", "ParentId": "39563b18-da4b-4151-9479-10f687e9d3eb"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In the pivotal trial CLEOPATRA</span><span lang=\"EN-GB\"> in metastatic breast cancer</span><span lang=\"EN-GB\">, diarrhoea\noccurred in 68.4% of Perjeta-treated patients and 48.7% of placebo-treated\npatients (see section 4.4). Most events were mild</span><span lang=\"EN-GB\"> to </span><span lang=\"EN-GB\">moderate in severity and occurred in the first few cycles of\ntreatment. The incidence of NCI-CTCAE Grade 3-4 diarrhoea was 9.3% in Perjeta-treated\npatients vs 5.1% in placebo-treated patients. The median duration of the longest\nepisode was 18 days in Perjeta-treated patients and 8 days in placebo-treated\npatients. Diarrhoeal events responded well to proactive management with\nanti-diarrhoeal agents.</span></p>", "ID": "c78bc8f1-8fea-499b-b763-5c70b35d5b7e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">In the pivotal trial CLEOPATRA</span>", "ID": "867a0f5d-ec09-4091-a29c-946b4406e496", "Styles": "None", "Classes": "None", "Text": "In the pivotal trial CLEOPATRA", "ParentId": "c78bc8f1-8fea-499b-b763-5c70b35d5b7e"}, {"Element": "<span lang=\"EN-GB\"> in metastatic breast cancer</span>", "ID": "9f9cc8c2-b938-44f5-bcfd-33ca7ce44db8", "Styles": "None", "Classes": "None", "Text": " in metastatic breast cancer", "ParentId": "c78bc8f1-8fea-499b-b763-5c70b35d5b7e"}, {"Element": "<span lang=\"EN-GB\">, diarrhoea\noccurred in 68.4% of Perjeta-treated patients and 48.7% of placebo-treated\npatients (see section 4.4). Most events were mild</span>", "ID": "624299e4-e6d3-4e50-8eed-1904ef80d55c", "Styles": "None", "Classes": "None", "Text": ", diarrhoea occurred in 68.4% of Perjeta-treated patients and 48.7% of placebo-treated patients (see section 4.4). Most events were mild", "ParentId": "c78bc8f1-8fea-499b-b763-5c70b35d5b7e"}, {"Element": "<span lang=\"EN-GB\"> to </span>", "ID": "185bd900-cc37-4328-a11f-9bbef4da92cf", "Styles": "None", "Classes": "None", "Text": " to ", "ParentId": "c78bc8f1-8fea-499b-b763-5c70b35d5b7e"}, {"Element": "<span lang=\"EN-GB\">moderate in severity and occurred in the first few cycles of\ntreatment. The incidence of NCI-CTCAE Grade 3-4 diarrhoea was 9.3% in Perjeta-treated\npatients vs 5.1% in placebo-treated patients. The median duration of the longest\nepisode was 18 days in Perjeta-treated patients and 8 days in placebo-treated\npatients. Diarrhoeal events responded well to proactive management with\nanti-diarrhoeal agents.</span>", "ID": "ddba0922-d833-4950-8b22-6cb27cbef199", "Styles": "None", "Classes": "None", "Text": "moderate in severity and occurred in the first few cycles of treatment. The incidence of NCI-CTCAE Grade 3-4 diarrhoea was 9.3% in Perjeta-treated patients vs 5.1% in placebo-treated patients. The median duration of the longest episode was 18 days in Perjeta-treated patients and 8 days in placebo-treated patients. Diarrhoeal events responded well to proactive management with anti-diarrhoeal agents.", "ParentId": "c78bc8f1-8fea-499b-b763-5c70b35d5b7e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "006f9742-3bd8-4c55-873f-7220b1f99bed", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "26406c4f-45ce-4b6f-afb4-d43bc392858c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "006f9742-3bd8-4c55-873f-7220b1f99bed"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In the NEOSPHERE trial, diarrhoea occurred\nin 45.8% of patients treated with neoadjuvant Perjeta, trastuzumab and\ndocetaxel compared with 33.6% of patients treated with trastuzumab and\ndocetaxel. In the TRYPHAENA trial, diarrhoea occurred in 72.3% of patients\ntreated with neoadjuvant Perjeta+TCH and 61.4% of patients treated with\nneoadjuvant Perjeta, trastuzumab and docetaxel following FEC. In both studies\nmost events were mild to moderate in severity. </span></p>", "ID": "da01d025-94f8-4491-b2c7-0ecb47f93ccc", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">In the NEOSPHERE trial, diarrhoea occurred\nin 45.8% of patients treated with neoadjuvant Perjeta, trastuzumab and\ndocetaxel compared with 33.6% of patients treated with trastuzumab and\ndocetaxel. In the TRYPHAENA trial, diarrhoea occurred in 72.3% of patients\ntreated with neoadjuvant Perjeta+TCH and 61.4% of patients treated with\nneoadjuvant Perjeta, trastuzumab and docetaxel following FEC. In both studies\nmost events were mild to moderate in severity. </span>", "ID": "1ea9b39e-397e-4c0d-bdfd-ee6492e7a8a1", "Styles": "None", "Classes": "None", "Text": "In the NEOSPHERE trial, diarrhoea occurred in 45.8% of patients treated with neoadjuvant Perjeta, trastuzumab and docetaxel compared with 33.6% of patients treated with trastuzumab and docetaxel. In the TRYPHAENA trial, diarrhoea occurred in 72.3% of patients treated with neoadjuvant Perjeta+TCH and 61.4% of patients treated with neoadjuvant Perjeta, trastuzumab and docetaxel following FEC. In both studies most events were mild to moderate in severity. ", "ParentId": "da01d025-94f8-4491-b2c7-0ecb47f93ccc"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "90ebf572-6633-4046-ae6e-c345b33aeb9e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "210f4a3c-9434-42bb-b7c7-0d470e1cdb64", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "90ebf572-6633-4046-ae6e-c345b33aeb9e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In the APHINITY trial, a higher incidence\nof diarrhoea was reported in the Perjeta-treated arm (71.2%) compared to the\nplacebo arm (45.2%).\u00a0 Grade \u2265 3 diarrhoea was reported in 9.8% of\npatients in the Perjeta arm vs. 3.7% in the placebo arm. The majority of the\nreported events were Grade 1 or 2 in severity. The highest incidence of\ndiarrhoea (all Grades) was reported during the targeted therapy+taxane\nchemotherapy period (61.4% of patients in the Perjeta arm vs. 33.8% of patients\nin the placebo arm).The incidence of diarrhoea was much lower after\nchemotherapy cessation, affecting 18.1% of patients in the Perjeta arm vs. 9.2%\nof patients in the placebo arm in the post-chemotherapy targeted therapy\nperiod.</span></p>", "ID": "271a7734-8011-4dbe-8550-64f6b3682f78", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">In the APHINITY trial, a higher incidence\nof diarrhoea was reported in the Perjeta-treated arm (71.2%) compared to the\nplacebo arm (45.2%).\u00a0 Grade \u2265 3 diarrhoea was reported in 9.8% of\npatients in the Perjeta arm vs. 3.7% in the placebo arm. The majority of the\nreported events were Grade 1 or 2 in severity. The highest incidence of\ndiarrhoea (all Grades) was reported during the targeted therapy+taxane\nchemotherapy period (61.4% of patients in the Perjeta arm vs. 33.8% of patients\nin the placebo arm).The incidence of diarrhoea was much lower after\nchemotherapy cessation, affecting 18.1% of patients in the Perjeta arm vs. 9.2%\nof patients in the placebo arm in the post-chemotherapy targeted therapy\nperiod.</span>", "ID": "b353a461-b903-4840-8681-42e734ba3770", "Styles": "None", "Classes": "None", "Text": "In the APHINITY trial, a higher incidence of diarrhoea was reported in the Perjeta-treated arm (71.2%) compared to the placebo arm (45.2%).\u00a0 Grade \u2265 3 diarrhoea was reported in 9.8% of patients in the Perjeta arm vs. 3.7% in the placebo arm. The majority of the reported events were Grade 1 or 2 in severity. The highest incidence of diarrhoea (all Grades) was reported during the targeted therapy+taxane chemotherapy period (61.4% of patients in the Perjeta arm vs. 33.8% of patients in the placebo arm).The incidence of diarrhoea was much lower after chemotherapy cessation, affecting 18.1% of patients in the Perjeta arm vs. 9.2% of patients in the placebo arm in the post-chemotherapy targeted therapy period.", "ParentId": "271a7734-8011-4dbe-8550-64f6b3682f78"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b0fe743a-788a-4f52-89a8-1bc796f1e14e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "259b85af-8091-4879-9437-15a8f4b28e86", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b0fe743a-788a-4f52-89a8-1bc796f1e14e"}, {"Element": "<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">Rash</span></i></p>", "ID": "7d4c2fb6-3187-4ee1-81b6-0a77435fb710", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<i><span lang=\"EN-GB\">Rash</span></i>", "ID": "90935e08-5998-48df-9e58-c56e8349f4d6", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "7d4c2fb6-3187-4ee1-81b6-0a77435fb710"}, {"Element": "<span lang=\"EN-GB\">Rash</span>", "ID": "1ff1b68c-873a-47a4-85dc-32a499a84f5f", "Styles": "None", "Classes": "None", "Text": "Rash", "ParentId": "90935e08-5998-48df-9e58-c56e8349f4d6"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In the pivotal trial CLEOPATRA in\nmetastatic breast cancer, r</span><span lang=\"EN-GB\">ash occurred in 51.7% of Perjeta-treated\npatients, compared with 38.9% of placebo-treated patients. Most events were\nGrade 1 or 2 in severity, occurred in the first two cycles, and responded to\nstandard therapies, such as topical or oral treatment for acne.</span></p>", "ID": "87eec7a5-9bdd-4348-9b9f-bd3e8177a30f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">In the pivotal trial CLEOPATRA in\nmetastatic breast cancer, r</span>", "ID": "911ff6a3-1ef1-4234-9473-58a3fa8b5829", "Styles": "None", "Classes": "None", "Text": "In the pivotal trial CLEOPATRA in metastatic breast cancer, r", "ParentId": "87eec7a5-9bdd-4348-9b9f-bd3e8177a30f"}, {"Element": "<span lang=\"EN-GB\">ash occurred in 51.7% of Perjeta-treated\npatients, compared with 38.9% of placebo-treated patients. Most events were\nGrade 1 or 2 in severity, occurred in the first two cycles, and responded to\nstandard therapies, such as topical or oral treatment for acne.</span>", "ID": "82304992-db28-498a-b6bb-e288c2b22ed7", "Styles": "None", "Classes": "None", "Text": "ash occurred in 51.7% of Perjeta-treated patients, compared with 38.9% of placebo-treated patients. Most events were Grade 1 or 2 in severity, occurred in the first two cycles, and responded to standard therapies, such as topical or oral treatment for acne.", "ParentId": "87eec7a5-9bdd-4348-9b9f-bd3e8177a30f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7fca5890-0ed7-40e4-874b-a58e9601a48c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "fce01bb1-c99c-4521-ab71-93c8c837d024", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7fca5890-0ed7-40e4-874b-a58e9601a48c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In the NEOSPHERE trial, rash occurred in\n40.2% of patients treated with neoadjuvant Perjeta, trastuzumab and docetaxel\ncompared with 29.0% of patients treated with trastuzumab and docetaxel. In the\nTRYPHAENA trial, rash occurred in 36.8% of patients treated with neoadjuvant\nPerjeta + TCH and 20.0% of patients treated with neoadjuvant Perjeta,\ntrastuzumab and docetaxel following FEC. The incidence of rash was higher in\npatients who received six cycles of Perjeta compared with patients who received\nthree cycles of Perjeta, independent of the chemotherapy given.</span></p>", "ID": "991654eb-98b8-4065-a9cc-51c5b1133867", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">In the NEOSPHERE trial, rash occurred in\n40.2% of patients treated with neoadjuvant Perjeta, trastuzumab and docetaxel\ncompared with 29.0% of patients treated with trastuzumab and docetaxel. In the\nTRYPHAENA trial, rash occurred in 36.8% of patients treated with neoadjuvant\nPerjeta + TCH and 20.0% of patients treated with neoadjuvant Perjeta,\ntrastuzumab and docetaxel following FEC. The incidence of rash was higher in\npatients who received six cycles of Perjeta compared with patients who received\nthree cycles of Perjeta, independent of the chemotherapy given.</span>", "ID": "42e7c680-9fd1-4ace-88d5-18fd470161c6", "Styles": "None", "Classes": "None", "Text": "In the NEOSPHERE trial, rash occurred in 40.2% of patients treated with neoadjuvant Perjeta, trastuzumab and docetaxel compared with 29.0% of patients treated with trastuzumab and docetaxel. In the TRYPHAENA trial, rash occurred in 36.8% of patients treated with neoadjuvant Perjeta + TCH and 20.0% of patients treated with neoadjuvant Perjeta, trastuzumab and docetaxel following FEC. The incidence of rash was higher in patients who received six cycles of Perjeta compared with patients who received three cycles of Perjeta, independent of the chemotherapy given.", "ParentId": "991654eb-98b8-4065-a9cc-51c5b1133867"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "22f9c86e-b993-413f-818b-7ca82ab470e8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d8dfb945-08f8-4f8e-a58a-ba84ff3f546b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "22f9c86e-b993-413f-818b-7ca82ab470e8"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In the APHINITY trial, the adverse event of\nrash occurred in 25.8% of patients in Perjeta arm vs.\u00a0 20.3% of patients in\nplacebo arm. The majority of rash events were Grade 1 or 2.</span></p>", "ID": "fc2f63a9-060f-4d6a-a53b-c62080dba1f6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">In the APHINITY trial, the adverse event of\nrash occurred in 25.8% of patients in Perjeta arm vs.\u00a0 20.3% of patients in\nplacebo arm. The majority of rash events were Grade 1 or 2.</span>", "ID": "8be8e028-629b-4895-a29b-f2204949491c", "Styles": "None", "Classes": "None", "Text": "In the APHINITY trial, the adverse event of rash occurred in 25.8% of patients in Perjeta arm vs.\u00a0 20.3% of patients in placebo arm. The majority of rash events were Grade 1 or 2.", "ParentId": "fc2f63a9-060f-4d6a-a53b-c62080dba1f6"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4f8e0f1b-dd8d-42cd-8739-4432ce21f5e1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "09cc3da2-7790-40b8-b7a0-29986b968e43", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4f8e0f1b-dd8d-42cd-8739-4432ce21f5e1"}, {"Element": "<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">Laboratory abnormalities</span></i></p>", "ID": "50293946-c7b3-4ba2-aafb-4b6110a292d0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<i><span lang=\"EN-GB\">Laboratory abnormalities</span></i>", "ID": "85a0adfd-0892-4085-9e50-17e4b971d050", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "50293946-c7b3-4ba2-aafb-4b6110a292d0"}, {"Element": "<span lang=\"EN-GB\">Laboratory abnormalities</span>", "ID": "d26e9828-a7bd-4262-805b-37a2942296c5", "Styles": "None", "Classes": "None", "Text": "Laboratory abnormalities", "ParentId": "85a0adfd-0892-4085-9e50-17e4b971d050"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In the pivotal trial CLEOPATRA in\nmetastatic breast cancer, the</span><span lang=\"EN-GB\"> incidence of NCI-CTCAE </span><span lang=\"EN-GB\">v.</span><span lang=\"EN-GB\">3 Grade 3-4 neutropenia was balanced in\nthe two treatment groups (86.3% of Perjeta-treated patients and 86.6% of\nplacebo-treated patients, including 60.7% and 64.8% Grade 4 neutropenia,\nrespectively).</span></p>", "ID": "dbd36b45-3b10-4185-a94f-5dabfa405004", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">In the pivotal trial CLEOPATRA in\nmetastatic breast cancer, the</span>", "ID": "8e0cfe47-c06b-41e5-b918-223d5fe54d33", "Styles": "None", "Classes": "None", "Text": "In the pivotal trial CLEOPATRA in metastatic breast cancer, the", "ParentId": "dbd36b45-3b10-4185-a94f-5dabfa405004"}, {"Element": "<span lang=\"EN-GB\"> incidence of NCI-CTCAE </span>", "ID": "8b19f671-1b0f-413e-91ac-9b50f61e6a2a", "Styles": "None", "Classes": "None", "Text": " incidence of NCI-CTCAE ", "ParentId": "dbd36b45-3b10-4185-a94f-5dabfa405004"}, {"Element": "<span lang=\"EN-GB\">v.</span>", "ID": "55c85e2f-6d8f-49ac-b5ad-57e8364bb552", "Styles": "None", "Classes": "None", "Text": "v.", "ParentId": "dbd36b45-3b10-4185-a94f-5dabfa405004"}, {"Element": "<span lang=\"EN-GB\">3 Grade 3-4 neutropenia was balanced in\nthe two treatment groups (86.3% of Perjeta-treated patients and 86.6% of\nplacebo-treated patients, including 60.7% and 64.8% Grade 4 neutropenia,\nrespectively).</span>", "ID": "3d4f675d-5557-43e5-8a23-a002069aebdc", "Styles": "None", "Classes": "None", "Text": "3 Grade 3-4 neutropenia was balanced in the two treatment groups (86.3% of Perjeta-treated patients and 86.6% of placebo-treated patients, including 60.7% and 64.8% Grade 4 neutropenia, respectively).", "ParentId": "dbd36b45-3b10-4185-a94f-5dabfa405004"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "881f6202-1a62-46b7-8ce2-b1a641a1a68c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "20f045b4-d9f2-4755-ba01-5ea198e07cba", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "881f6202-1a62-46b7-8ce2-b1a641a1a68c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In the NEOSPHERE trial, the incidence of\nNCI-CTCAE v.3 Grade 3-4 neutropenia was 74.5% in patients treated with\nneoadjuvant Perjeta, trastuzumab and docetaxel compared with 84.5% in patients\ntreated with trastuzumab and docetaxel, including 50.9% and 60.2% Grade 4\nneutropenia, respectively. In the TRYPHAENA trial, the incidence of NCI-CTCAE\nv.3 Grade 3-4 neutropenia was 85.3% in patients treated with neoadjuvant Perjeta\n+ TCH and 77.0% in patients treated with neoadjuvant Perjeta, trastuzumab and\ndocetaxel following FEC, including 66.7% and 59.5% Grade 4 neutropenia,\nrespectively. </span></p>", "ID": "6a98562b-edcc-4cd2-a5e1-766c4b19b61a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">In the NEOSPHERE trial, the incidence of\nNCI-CTCAE v.3 Grade 3-4 neutropenia was 74.5% in patients treated with\nneoadjuvant Perjeta, trastuzumab and docetaxel compared with 84.5% in patients\ntreated with trastuzumab and docetaxel, including 50.9% and 60.2% Grade 4\nneutropenia, respectively. In the TRYPHAENA trial, the incidence of NCI-CTCAE\nv.3 Grade 3-4 neutropenia was 85.3% in patients treated with neoadjuvant Perjeta\n+ TCH and 77.0% in patients treated with neoadjuvant Perjeta, trastuzumab and\ndocetaxel following FEC, including 66.7% and 59.5% Grade 4 neutropenia,\nrespectively. </span>", "ID": "faab72f6-27fc-45ec-8156-6d51b1de4169", "Styles": "None", "Classes": "None", "Text": "In the NEOSPHERE trial, the incidence of NCI-CTCAE v.3 Grade 3-4 neutropenia was 74.5% in patients treated with neoadjuvant Perjeta, trastuzumab and docetaxel compared with 84.5% in patients treated with trastuzumab and docetaxel, including 50.9% and 60.2% Grade 4 neutropenia, respectively. In the TRYPHAENA trial, the incidence of NCI-CTCAE v.3 Grade 3-4 neutropenia was 85.3% in patients treated with neoadjuvant Perjeta + TCH and 77.0% in patients treated with neoadjuvant Perjeta, trastuzumab and docetaxel following FEC, including 66.7% and 59.5% Grade 4 neutropenia, respectively. ", "ParentId": "6a98562b-edcc-4cd2-a5e1-766c4b19b61a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "294ba08c-8b1a-4a45-b5d7-eb45db1078b8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "583914f1-8f4a-4644-b9d7-a743826e84d8", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "294ba08c-8b1a-4a45-b5d7-eb45db1078b8"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In the APHINITY trial, the incidence of\nNCI-CTCAE v.4 Grade 3-4 neutropenia was 40.6% in patients treated with Perjeta,\ntrastuzumab and chemotherapy compared with 39.1% in patients treated with\nplacebo, trastuzumab and chemotherapy, including 28.3% and 26.5% Grade 4\nneutropenia, respectively.</span></p>", "ID": "36961de7-4981-4077-aad6-96ae59fa470b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">In the APHINITY trial, the incidence of\nNCI-CTCAE v.4 Grade 3-4 neutropenia was 40.6% in patients treated with Perjeta,\ntrastuzumab and chemotherapy compared with 39.1% in patients treated with\nplacebo, trastuzumab and chemotherapy, including 28.3% and 26.5% Grade 4\nneutropenia, respectively.</span>", "ID": "f14273e2-3ddf-45ce-9b59-c4604890c8c1", "Styles": "None", "Classes": "None", "Text": "In the APHINITY trial, the incidence of NCI-CTCAE v.4 Grade 3-4 neutropenia was 40.6% in patients treated with Perjeta, trastuzumab and chemotherapy compared with 39.1% in patients treated with placebo, trastuzumab and chemotherapy, including 28.3% and 26.5% Grade 4 neutropenia, respectively.", "ParentId": "36961de7-4981-4077-aad6-96ae59fa470b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5be37b60-05d0-4e18-aea1-06ab0cd5c4cf", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "403272cd-b608-4922-a600-2282fc561b48", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5be37b60-05d0-4e18-aea1-06ab0cd5c4cf"}, {"Element": "<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Elderly Patients</span></u></p>", "ID": "bd8b994e-e532-4969-8046-8dde6ebf57cb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<u><span lang=\"EN-GB\">Elderly Patients</span></u>", "ID": "9ad030c2-ac86-4e8d-a60e-243b031e6410", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "bd8b994e-e532-4969-8046-8dde6ebf57cb"}, {"Element": "<span lang=\"EN-GB\">Elderly Patients</span>", "ID": "ee12e933-b56c-420c-905c-39996d21887d", "Styles": "None", "Classes": "None", "Text": "Elderly Patients", "ParentId": "9ad030c2-ac86-4e8d-a60e-243b031e6410"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "099b7555-83ae-452d-8be9-f8e1a0242d2b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "588c5d53-787d-4fd9-b5dd-041631d06ba4", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "099b7555-83ae-452d-8be9-f8e1a0242d2b"}, {"Element": "<p class=\"MsoNormal\">The incidence of the following all grade adverse events was\nat least 5% higher in patients \u2265\u00a065\u00a0years of age, compared to\npatients &lt;\u00a065\u00a0years of age: decreased appetite, anaemia, weight\ndecreased, asthenia, dysgeusia, peripheral neuropathy, hypomagnesemia and\ndiarrhoea. Limited data are available in patients &gt; 75 years of age. </p>", "ID": "d680e411-33c2-4f23-ae52-7aaf23eaff51", "Styles": "None", "Classes": "['MsoNormal']", "Text": "The incidence of the following all grade adverse events was at least 5% higher in patients \u2265\u00a065\u00a0years of age, compared to patients <\u00a065\u00a0years of age: decreased appetite, anaemia, weight decreased, asthenia, dysgeusia, peripheral neuropathy, hypomagnesemia and diarrhoea. Limited data are available in patients > 75 years of age. ", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8fee628a-8f8e-470e-a777-c8a5f421ab7f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "611808ba-7a10-4556-af20-2255d096f6fb", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8fee628a-8f8e-470e-a777-c8a5f421ab7f"}, {"Element": "<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Reporting of suspected adverse reactions</span></u></p>", "ID": "d440aec6-db11-4911-8144-d471cadc3152", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<u><span lang=\"EN-GB\">Reporting of suspected adverse reactions</span></u>", "ID": "d9279ba1-5a1f-4a91-b84d-0c862935677a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d440aec6-db11-4911-8144-d471cadc3152"}, {"Element": "<span lang=\"EN-GB\">Reporting of suspected adverse reactions</span>", "ID": "6bbc0636-82fe-416b-b1c5-42fa2331ff19", "Styles": "None", "Classes": "None", "Text": "Reporting of suspected adverse reactions", "ParentId": "d9279ba1-5a1f-4a91-b84d-0c862935677a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "49eff9aa-db1b-49a6-af16-9a93648500ee", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "235a8340-94bc-47c2-880b-c6af18de9a5c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "49eff9aa-db1b-49a6-af16-9a93648500ee"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:13.0pt;text-autospace:none\"><span lang=\"EN-GB\">Reporting suspected adverse reactions after authorisation of the\nmedicinal product is important. It allows continued monitoring of the\nbenefit/risk balance of the medicinal product. Healthcare professionals are\nasked to report any suspected adverse reactions via </span><span lang=\"EN-GB\" style=\"background:lightgrey\">the national reporting system listed in </span><a href=\"https://www.ema.europa.eu/documents/template-form/appendix-v-adverse-drug-reaction-reporting-details_en.doc\"><span lang=\"EN-GB\" style=\"background:lightgrey\">Appendix V.</span></a></p>", "ID": "44dc6ab1-2ffb-4e98-b055-8225a35e30d1", "Styles": "line-height:13.0pt;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Reporting suspected adverse reactions after authorisation of the\nmedicinal product is important. It allows continued monitoring of the\nbenefit/risk balance of the medicinal product. Healthcare professionals are\nasked to report any suspected adverse reactions via </span>", "ID": "76acb6bb-8957-47c7-905d-eef92d3f20c2", "Styles": "None", "Classes": "None", "Text": "Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via ", "ParentId": "44dc6ab1-2ffb-4e98-b055-8225a35e30d1"}, {"Element": "<span lang=\"EN-GB\" style=\"background:lightgrey\">the national reporting system listed in </span>", "ID": "ed124354-71f1-4da7-9c0a-7d7c67495b35", "Styles": "background:lightgrey", "Classes": "None", "Text": "the national reporting system listed in ", "ParentId": "44dc6ab1-2ffb-4e98-b055-8225a35e30d1"}, {"Element": "<a href=\"https://www.ema.europa.eu/documents/template-form/appendix-v-adverse-drug-reaction-reporting-details_en.doc\"><span lang=\"EN-GB\" style=\"background:lightgrey\">Appendix V.</span></a>", "ID": "47c7c262-0471-4820-935d-43abdf584fca", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "44dc6ab1-2ffb-4e98-b055-8225a35e30d1"}, {"Element": "<span lang=\"EN-GB\" style=\"background:lightgrey\">Appendix V.</span>", "ID": "d0867d84-4fae-4f0d-8d3d-c84a1def26f6", "Styles": "background:lightgrey", "Classes": "None", "Text": "Appendix V.", "ParentId": "47c7c262-0471-4820-935d-43abdf584fca"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "da6a8850-ce83-4ce3-ad44-62282dfe5efe", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "75d16aaa-c79b-4d73-aa0a-cf2775e666e7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "da6a8850-ce83-4ce3-ad44-62282dfe5efe"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">4.9\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Overdose</span></b></p>", "ID": "a69be1b6-3621-45cd-a7b6-475da7d101f3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">4.9\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Overdose</span></b>", "ID": "6e0872fd-dbed-4e9f-9c19-c835ed220f97", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a69be1b6-3621-45cd-a7b6-475da7d101f3"}, {"Element": "<span lang=\"EN-GB\">4.9\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Overdose</span>", "ID": "37dab397-6077-44d5-b07b-d1242bf0f37c", "Styles": "None", "Classes": "None", "Text": "4.9\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Overdose", "ParentId": "6e0872fd-dbed-4e9f-9c19-c835ed220f97"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c21f2969-50d9-4307-b2d4-54dd15696038", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6738864d-9ffa-482f-8603-cb2900c12918", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c21f2969-50d9-4307-b2d4-54dd15696038"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The maximum tolerated dose of </span><span lang=\"EN-GB\">pertuzumab has not been determined. In clinical trials, single doses\nhigher than 25\u00a0mg/kg (1727\u00a0mg) have not been tested.</span></p>", "ID": "1604bd3b-7224-405f-b0b0-81bb2e8ab069", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">The maximum tolerated dose of </span>", "ID": "c460c7ec-22b8-48b1-9929-b5fd780bd859", "Styles": "None", "Classes": "None", "Text": "The maximum tolerated dose of ", "ParentId": "1604bd3b-7224-405f-b0b0-81bb2e8ab069"}, {"Element": "<span lang=\"EN-GB\">pertuzumab has not been determined. In clinical trials, single doses\nhigher than 25\u00a0mg/kg (1727\u00a0mg) have not been tested.</span>", "ID": "78bfbcac-d13d-4d5e-b4d5-3c8bd63bb117", "Styles": "None", "Classes": "None", "Text": "pertuzumab has not been determined. In clinical trials, single doses higher than 25\u00a0mg/kg (1727\u00a0mg) have not been tested.", "ParentId": "1604bd3b-7224-405f-b0b0-81bb2e8ab069"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "61c994e1-2e19-4ccb-8632-7e6a9b42696f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "140ae349-5e77-4294-b2f0-b2c5773c7027", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "61c994e1-2e19-4ccb-8632-7e6a9b42696f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In case of overdose, patients must be\nclosely monitored for signs or symptoms of adverse reactions and appropriate\nsymptomatic treatment instituted.</span></p>", "ID": "e1434ba1-7811-4f6d-8dcd-691036582da3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">In case of overdose, patients must be\nclosely monitored for signs or symptoms of adverse reactions and appropriate\nsymptomatic treatment instituted.</span>", "ID": "a9b1874e-156d-4e25-954f-79043d1a222e", "Styles": "None", "Classes": "None", "Text": "In case of overdose, patients must be closely monitored for signs or symptoms of adverse reactions and appropriate symptomatic treatment instituted.", "ParentId": "e1434ba1-7811-4f6d-8dcd-691036582da3"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8407b8dd-b727-47f0-8a03-bc518c257dc8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "427bbe59-65bc-4c7e-85fb-ba52cd9c5e35", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8407b8dd-b727-47f0-8a03-bc518c257dc8"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "db9199bf-19e0-4d23-b3fc-cf9a0af85eb0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9c17f529-5d76-4873-86c9-e46e5799f6d7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "db9199bf-19e0-4d23-b3fc-cf9a0af85eb0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACOLOGICAL\nPROPERTIES</span></b></p>", "ID": "1f3f8bdb-84c9-4501-ae14-9d3654bb8b34", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACOLOGICAL\nPROPERTIES</span></b>", "ID": "088e1426-0706-4e54-8557-81894d8baf93", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "1f3f8bdb-84c9-4501-ae14-9d3654bb8b34"}, {"Element": "<span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACOLOGICAL\nPROPERTIES</span>", "ID": "78cc41df-cd2a-4b45-8871-d0c9b4dd6999", "Styles": "None", "Classes": "None", "Text": "5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACOLOGICAL PROPERTIES", "ParentId": "088e1426-0706-4e54-8557-81894d8baf93"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "a4c4d492-df2a-4c38-8d7b-e74724cb78c6", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "fb05efb4-c6eb-45e5-a719-dd36582cc1de", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a4c4d492-df2a-4c38-8d7b-e74724cb78c6"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8e280de5-01ec-4ab3-a82d-5076b4d21f96", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "fb05efb4-c6eb-45e5-a719-dd36582cc1de"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">5.1\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Pharmacodynamic\nproperties</span></b></p>", "ID": "a473337b-d2a0-4b39-9095-d8cbeba1ab92", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">5.1\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Pharmacodynamic\nproperties</span></b>", "ID": "67c89168-63ff-4377-901e-8b0c039ff17f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a473337b-d2a0-4b39-9095-d8cbeba1ab92"}, {"Element": "<span lang=\"EN-GB\">5.1\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Pharmacodynamic\nproperties</span>", "ID": "69e3be94-ffdb-493a-9f0a-e5390ebbb0fb", "Styles": "None", "Classes": "None", "Text": "5.1\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Pharmacodynamic properties", "ParentId": "67c89168-63ff-4377-901e-8b0c039ff17f"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "53b31b04-f932-46b0-b0ea-767e38eadd44", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5d0ea3b2-b067-4e06-87f5-f7fdce2c9ed9", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "53b31b04-f932-46b0-b0ea-767e38eadd44"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Pharmacotherapeutic\ngroup: Antineoplastic agents, monoclonal antibodies, ATC code: L01XC13</span></p>", "ID": "5cdbf8a1-50b5-4907-9d07-9e22299a8298", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Pharmacotherapeutic\ngroup: Antineoplastic agents, monoclonal antibodies, ATC code: L01XC13</span>", "ID": "6c2d0141-4cda-41a9-b4c1-dd28370ad47b", "Styles": "None", "Classes": "None", "Text": "Pharmacotherapeutic group: Antineoplastic agents, monoclonal antibodies, ATC code: L01XC13", "ParentId": "5cdbf8a1-50b5-4907-9d07-9e22299a8298"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b6737a7a-95bb-49ae-b438-59b402ad7cbc", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "fb452f86-359d-4cbf-8a42-a8c90857f6e2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b6737a7a-95bb-49ae-b438-59b402ad7cbc"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Mechanism\nof action</span></u></p>", "ID": "a9b18884-f363-48ba-9209-5fee6a551e4e", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<u><span lang=\"EN-GB\">Mechanism\nof action</span></u>", "ID": "8f6a2701-dbef-4ddb-84a2-a5f6fb28acb7", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a9b18884-f363-48ba-9209-5fee6a551e4e"}, {"Element": "<span lang=\"EN-GB\">Mechanism\nof action</span>", "ID": "c35fb481-403f-4835-a8b8-254dcabe36fc", "Styles": "None", "Classes": "None", "Text": "Mechanism of action", "ParentId": "8f6a2701-dbef-4ddb-84a2-a5f6fb28acb7"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "dce24944-76bf-46e8-816b-3986c8e0ef16", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9daeddff-bb7a-4785-9746-3859532dd4bc", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "dce24944-76bf-46e8-816b-3986c8e0ef16"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Pertuzumab</span><span lang=\"EN-GB\"> is a\nrecombinant humanised monoclonal antibody that specifically targets the\nextracellular dimerization domain (subdomain II) of the human epidermal growth\nfactor receptor 2 protein (HER2), and thereby, blocks ligand-dependent\nheterodimerisation of HER2 with other HER family members, including EGFR, HER3\nand HER4. As a result, pertuzumab inhibits ligand\u2011initiated intracellular\nsignalling through two major signal pathways, mitogen\u2011activated protein\n(MAP) kinase and phosphoinositide\u00a03\u2011kinase (PI3K). Inhibition of\nthese signalling pathways can result in cell growth arrest and apoptosis,\nrespectively. In addition, pertuzumab mediates antibody-dependent cell-mediated\ncytotoxicity (ADCC).</span></p>", "ID": "411acfd8-405f-48d1-b046-536b3aec6d00", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Pertuzumab</span>", "ID": "5a3f44f7-383c-4de0-8aa4-eb5e4bdac2a1", "Styles": "None", "Classes": "None", "Text": "Pertuzumab", "ParentId": "411acfd8-405f-48d1-b046-536b3aec6d00"}, {"Element": "<span lang=\"EN-GB\"> is a\nrecombinant humanised monoclonal antibody that specifically targets the\nextracellular dimerization domain (subdomain II) of the human epidermal growth\nfactor receptor 2 protein (HER2), and thereby, blocks ligand-dependent\nheterodimerisation of HER2 with other HER family members, including EGFR, HER3\nand HER4. As a result, pertuzumab inhibits ligand\u2011initiated intracellular\nsignalling through two major signal pathways, mitogen\u2011activated protein\n(MAP) kinase and phosphoinositide\u00a03\u2011kinase (PI3K). Inhibition of\nthese signalling pathways can result in cell growth arrest and apoptosis,\nrespectively. In addition, pertuzumab mediates antibody-dependent cell-mediated\ncytotoxicity (ADCC).</span>", "ID": "5f89bab6-e1f7-425a-bd90-e264c56f2361", "Styles": "None", "Classes": "None", "Text": " is a recombinant humanised monoclonal antibody that specifically targets the extracellular dimerization domain (subdomain II) of the human epidermal growth factor receptor 2 protein (HER2), and thereby, blocks ligand-dependent heterodimerisation of HER2 with other HER family members, including EGFR, HER3 and HER4. As a result, pertuzumab inhibits ligand\u2011initiated intracellular signalling through two major signal pathways, mitogen\u2011activated protein (MAP) kinase and phosphoinositide\u00a03\u2011kinase (PI3K). Inhibition of these signalling pathways can result in cell growth arrest and apoptosis, respectively. In addition, pertuzumab mediates antibody-dependent cell-mediated cytotoxicity (ADCC).", "ParentId": "411acfd8-405f-48d1-b046-536b3aec6d00"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "57329bd4-ef93-425e-8896-7ff30012fd1b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "34a8f141-2b0f-4659-a573-9ffaedbad03b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "57329bd4-ef93-425e-8896-7ff30012fd1b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">While pertuzumab alone inhibited the\nproliferation of human tumour cells, the combination of pertuzumab and\ntrastuzumab significantly augmented antitumour activity in HER2-overexpressing\nxenograft models.</span></p>", "ID": "c28e6227-0489-4485-8164-e9e5770cc1fa", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">While pertuzumab alone inhibited the\nproliferation of human tumour cells, the combination of pertuzumab and\ntrastuzumab significantly augmented antitumour activity in HER2-overexpressing\nxenograft models.</span>", "ID": "52f8f0c3-7d37-4ccb-921e-c374211fc35a", "Styles": "None", "Classes": "None", "Text": "While pertuzumab alone inhibited the proliferation of human tumour cells, the combination of pertuzumab and trastuzumab significantly augmented antitumour activity in HER2-overexpressing xenograft models.", "ParentId": "c28e6227-0489-4485-8164-e9e5770cc1fa"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3d4cab24-0f7f-409b-994e-c879eb3bb29d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5ecb5d65-79c2-4663-b03d-7ef950e6b4a6", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3d4cab24-0f7f-409b-994e-c879eb3bb29d"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Clinical\nefficacy and safety</span></u></p>", "ID": "820b5064-57ee-4546-b851-44c850f2e3bc", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<u><span lang=\"EN-GB\">Clinical\nefficacy and safety</span></u>", "ID": "cffbbb41-9f4a-491d-ba4e-6cb7811c867c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "820b5064-57ee-4546-b851-44c850f2e3bc"}, {"Element": "<span lang=\"EN-GB\">Clinical\nefficacy and safety</span>", "ID": "c62f8f53-5de3-480f-9f96-f0ed635f74cc", "Styles": "None", "Classes": "None", "Text": "Clinical efficacy and safety", "ParentId": "cffbbb41-9f4a-491d-ba4e-6cb7811c867c"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>", "ID": "eed40c9c-df5b-49f8-9f60-8d28eaeee40b", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u>", "ID": "fb26bfe3-5b07-4f55-a75f-59aef62465b0", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "eed40c9c-df5b-49f8-9f60-8d28eaeee40b"}, {"Element": "<span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span>", "ID": "2e961c71-da7f-46a9-affd-1720898b0e25", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "fb26bfe3-5b07-4f55-a75f-59aef62465b0"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "8e4a3515-03d4-47b9-aa83-e31542d1be43", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "2e961c71-da7f-46a9-affd-1720898b0e25"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The efficacy of Perjeta in HER2-positive\nbreast cancer is supported by a randomised phase III trial and a single-arm\nphase II trial in metastatic breast cancer, two randomised neoadjuvant phase II\n\u00a0trials in early breast cancer (one controlled), a non-randomised neoadjuvant\nphase II trial, and a randomised phase III trial in the adjuvant setting.</span></p>", "ID": "dbd82787-d3eb-49fc-85a0-06afc3885ad2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">The efficacy of Perjeta in HER2-positive\nbreast cancer is supported by a randomised phase III trial and a single-arm\nphase II trial in metastatic breast cancer, two randomised neoadjuvant phase II\n\u00a0trials in early breast cancer (one controlled), a non-randomised neoadjuvant\nphase II trial, and a randomised phase III trial in the adjuvant setting.</span>", "ID": "f5a9cbf0-4c27-4e62-ba59-e3472c161790", "Styles": "None", "Classes": "None", "Text": "The efficacy of Perjeta in HER2-positive breast cancer is supported by a randomised phase III trial and a single-arm phase II trial in metastatic breast cancer, two randomised neoadjuvant phase II \u00a0trials in early breast cancer (one controlled), a non-randomised neoadjuvant phase II trial, and a randomised phase III trial in the adjuvant setting.", "ParentId": "dbd82787-d3eb-49fc-85a0-06afc3885ad2"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "37f9ba95-443a-4657-b712-7473a9a679be", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">HER2 overexpression was determined at a\ncentral laboratory and defined as a score of 3+ by IHC or an ISH amplification\nratio \u22652.0 in the trials outlined below.</span></p>", "ID": "93506289-5fb0-4ad8-a4ad-40384c998a92", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">HER2 overexpression was determined at a\ncentral laboratory and defined as a score of 3+ by IHC or an ISH amplification\nratio \u22652.0 in the trials outlined below.</span>", "ID": "2e035162-ed07-4053-89e9-95c3962f6caa", "Styles": "None", "Classes": "None", "Text": "HER2 overexpression was determined at a central laboratory and defined as a score of 3+ by IHC or an ISH amplification ratio \u22652.0 in the trials outlined below.", "ParentId": "93506289-5fb0-4ad8-a4ad-40384c998a92"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "80e04ff1-b937-4d1e-8e41-2b8e7770a110", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "19d8f232-a1a4-4bbd-8125-861cd92e0948", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "80e04ff1-b937-4d1e-8e41-2b8e7770a110"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Metastatic\n</span></u></i><i><u><span lang=\"EN-GB\">breast cancer </span></u></i></p>", "ID": "42898a43-3b26-4e39-a53d-c4cce0b47c1e", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<i><u><span lang=\"EN-GB\">Metastatic\n</span></u></i>", "ID": "fe6a01e7-c28b-4ade-bbd6-3cfa576fdfa9", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "42898a43-3b26-4e39-a53d-c4cce0b47c1e"}, {"Element": "<u><span lang=\"EN-GB\">Metastatic\n</span></u>", "ID": "2d5fbfea-c7b2-4a36-834d-48a6e4668fdb", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "fe6a01e7-c28b-4ade-bbd6-3cfa576fdfa9"}, {"Element": "<span lang=\"EN-GB\">Metastatic\n</span>", "ID": "4a846ae9-5e43-4d9f-9895-004a4a23cddb", "Styles": "None", "Classes": "None", "Text": "Metastatic ", "ParentId": "2d5fbfea-c7b2-4a36-834d-48a6e4668fdb"}, {"Element": "<i><u><span lang=\"EN-GB\">breast cancer </span></u></i>", "ID": "5751dba5-b59d-4e51-8052-72225c72bff0", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "42898a43-3b26-4e39-a53d-c4cce0b47c1e"}, {"Element": "<u><span lang=\"EN-GB\">breast cancer </span></u>", "ID": "8dfde2c9-870a-477c-bb92-3cc0f9018421", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "5751dba5-b59d-4e51-8052-72225c72bff0"}, {"Element": "<span lang=\"EN-GB\">breast cancer </span>", "ID": "0b5698f6-0d16-418a-99ca-52157491086b", "Styles": "None", "Classes": "None", "Text": "breast cancer ", "ParentId": "8dfde2c9-870a-477c-bb92-3cc0f9018421"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2b03c48b-af55-4102-b97a-ccf4b9b7a421", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "109488b4-20fd-4763-91d0-c7848e70000f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2b03c48b-af55-4102-b97a-ccf4b9b7a421"}, {"Element": "<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">Perjeta in combination with trastuzumab\nand docetaxel</span></i></p>", "ID": "b0b6e65f-eb53-4d04-a175-25b4f3ed219e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<i><span lang=\"EN-GB\">Perjeta in combination with trastuzumab\nand docetaxel</span></i>", "ID": "9d065a47-38ec-44fe-b232-a06fa54479a2", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b0b6e65f-eb53-4d04-a175-25b4f3ed219e"}, {"Element": "<span lang=\"EN-GB\">Perjeta in combination with trastuzumab\nand docetaxel</span>", "ID": "68e3605c-dfa1-429e-a66b-4a92541211a3", "Styles": "None", "Classes": "None", "Text": "Perjeta in combination with trastuzumab and docetaxel", "ParentId": "9d065a47-38ec-44fe-b232-a06fa54479a2"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">CLEOPATRA</span><span lang=\"EN-GB\"> (WO20698)</span><span lang=\"EN-GB\"> is a multicentre, randomised, double-blind, placebo-controlled\nphase III clinical trial conducted in 808 patients with HER2-positive\nmetastatic or locally recurrent unresectable breast cancer. Patients with clinically\nimportant cardiac risk factors were not included (see section 4.4). Due to the\nexclusion of patients with brain metastases no data are available on Perjeta\nactivity on brain metastases. There is very limited data available in patients\nwith unresectable locally recurrent disease. Patients were randomised 1:1 to\nreceive placebo + trastuzumab + docetaxel or Perjeta + trastuzumab + docetaxel.\n</span></p>", "ID": "6aa4b79f-1e34-4ade-bb7a-213669fead83", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">CLEOPATRA</span>", "ID": "ae425545-b4e9-478d-bd6a-98b2805a7bbf", "Styles": "None", "Classes": "None", "Text": "CLEOPATRA", "ParentId": "6aa4b79f-1e34-4ade-bb7a-213669fead83"}, {"Element": "<span lang=\"EN-GB\"> (WO20698)</span>", "ID": "c9bffd3b-e901-4a50-be23-6e0eb59cfd90", "Styles": "None", "Classes": "None", "Text": " (WO20698)", "ParentId": "6aa4b79f-1e34-4ade-bb7a-213669fead83"}, {"Element": "<span lang=\"EN-GB\"> is a multicentre, randomised, double-blind, placebo-controlled\nphase III clinical trial conducted in 808 patients with HER2-positive\nmetastatic or locally recurrent unresectable breast cancer. Patients with clinically\nimportant cardiac risk factors were not included (see section 4.4). Due to the\nexclusion of patients with brain metastases no data are available on Perjeta\nactivity on brain metastases. There is very limited data available in patients\nwith unresectable locally recurrent disease. Patients were randomised 1:1 to\nreceive placebo + trastuzumab + docetaxel or Perjeta + trastuzumab + docetaxel.\n</span>", "ID": "6f0e0619-abb6-49ee-9aa2-d94b76743430", "Styles": "None", "Classes": "None", "Text": " is a multicentre, randomised, double-blind, placebo-controlled phase III clinical trial conducted in 808 patients with HER2-positive metastatic or locally recurrent unresectable breast cancer. Patients with clinically important cardiac risk factors were not included (see section 4.4). Due to the exclusion of patients with brain metastases no data are available on Perjeta activity on brain metastases. There is very limited data available in patients with unresectable locally recurrent disease. Patients were randomised 1:1 to receive placebo + trastuzumab + docetaxel or Perjeta + trastuzumab + docetaxel. ", "ParentId": "6aa4b79f-1e34-4ade-bb7a-213669fead83"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c5ce341b-4010-4ece-9c45-351d712e3b02", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f98def17-92cf-4c47-ae8d-5db4566c438f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c5ce341b-4010-4ece-9c45-351d712e3b02"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Perjeta and trastuzumab were given at\nstandard doses in a 3-weekly regimen. Patients were treated with Perjeta and trastuzumab\nuntil disease progression, withdrawal of consent or unmanageable toxicity.\nDocetaxel was given as an initial dose of 75\u00a0mg/m<sup>2</sup> as an\nintravenous infusion every three weeks for at least 6 cycles. The dose of\ndocetaxel could be escalated to 100\u00a0mg/m<sup>2</sup> at the investigator\u2019s\ndiscretion if the initial dose was well tolerated. </span></p>", "ID": "c5a50485-79ea-4543-8c5c-309abc9a06e2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Perjeta and trastuzumab were given at\nstandard doses in a 3-weekly regimen. Patients were treated with Perjeta and trastuzumab\nuntil disease progression, withdrawal of consent or unmanageable toxicity.\nDocetaxel was given as an initial dose of 75\u00a0mg/m<sup>2</sup> as an\nintravenous infusion every three weeks for at least 6 cycles. The dose of\ndocetaxel could be escalated to 100\u00a0mg/m<sup>2</sup> at the investigator\u2019s\ndiscretion if the initial dose was well tolerated. </span>", "ID": "304dd636-14fa-469f-b79a-0b118a720a47", "Styles": "None", "Classes": "None", "Text": "Perjeta and trastuzumab were given at standard doses in a 3-weekly regimen. Patients were treated with Perjeta and trastuzumab until disease progression, withdrawal of consent or unmanageable toxicity. Docetaxel was given as an initial dose of 75\u00a0mg/m as an intravenous infusion every three weeks for at least 6 cycles. The dose of docetaxel could be escalated to 100\u00a0mg/m at the investigator\u2019s discretion if the initial dose was well tolerated. ", "ParentId": "c5a50485-79ea-4543-8c5c-309abc9a06e2"}, {"Element": "<sup>2</sup>", "ID": "a25f0813-0139-4d4b-b041-c381f8e52ada", "Styles": "None", "Classes": "None", "Text": "2", "ParentId": "304dd636-14fa-469f-b79a-0b118a720a47"}, {"Element": "<sup>2</sup>", "ID": "4bb15203-bdf0-4dc0-80ce-6d901ebf79cc", "Styles": "None", "Classes": "None", "Text": "2", "ParentId": "304dd636-14fa-469f-b79a-0b118a720a47"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3a1821c6-adde-4987-a14b-976e31d183b8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e371542d-b661-4580-b52d-02a4974fb212", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3a1821c6-adde-4987-a14b-976e31d183b8"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The primary endpoint of the study was\nprogression-free survival (PFS) as assessed by an independent review facility\n(IRF) and defined as the time from the date of randomisation to the date of\ndisease progression or death (from any cause) if the death occurred within 18\nweeks of the last tumour assessment. </span><span lang=\"EN-GB\">Secondary efficacy\nendpoints were overall survival (OS), PFS (investigator-assessed), objective\nresponse rate (ORR), duration of response, and time to symptom progression\naccording to the FACT B Quality of Life questionnaire.</span></p>", "ID": "31dc87ab-9952-4d19-81ea-0ffbbbfa92fe", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">The primary endpoint of the study was\nprogression-free survival (PFS) as assessed by an independent review facility\n(IRF) and defined as the time from the date of randomisation to the date of\ndisease progression or death (from any cause) if the death occurred within 18\nweeks of the last tumour assessment. </span>", "ID": "0ae062aa-b5ed-41ac-9643-4b02e877c2fe", "Styles": "None", "Classes": "None", "Text": "The primary endpoint of the study was progression-free survival (PFS) as assessed by an independent review facility (IRF) and defined as the time from the date of randomisation to the date of disease progression or death (from any cause) if the death occurred within 18 weeks of the last tumour assessment. ", "ParentId": "31dc87ab-9952-4d19-81ea-0ffbbbfa92fe"}, {"Element": "<span lang=\"EN-GB\">Secondary efficacy\nendpoints were overall survival (OS), PFS (investigator-assessed), objective\nresponse rate (ORR), duration of response, and time to symptom progression\naccording to the FACT B Quality of Life questionnaire.</span>", "ID": "c5dd0e8a-1c05-44aa-b4ef-104d5288e1ac", "Styles": "None", "Classes": "None", "Text": "Secondary efficacy endpoints were overall survival (OS), PFS (investigator-assessed), objective response rate (ORR), duration of response, and time to symptom progression according to the FACT B Quality of Life questionnaire.", "ParentId": "31dc87ab-9952-4d19-81ea-0ffbbbfa92fe"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0da1b937-9a45-4063-a0a0-62fda3893232", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6d7af21f-34fa-48f9-8a25-46846338bc92", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0da1b937-9a45-4063-a0a0-62fda3893232"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Approximately half the patients in each\ntreatment group had hormone receptor-positive disease (defined as o</span><span lang=\"EN-GB\">estrogen</span><span lang=\"EN-GB\"> receptor</span><span lang=\"EN-GB\">\n(ER) </span><span lang=\"EN-GB\">positive and/or progesterone receptor</span><span lang=\"EN-GB\"> (PgR) </span><span lang=\"EN-GB\">positive) and approximately half of\nthe patients in each treatment group had received prior adjuvant or neoadjuvant\ntherapy. Most of these patients had received prior anthracycline therapy and 11%\nof all patients had received prior trastuzumab. A total of 43% of patients in\nboth treatment groups had previously received radiotherapy. Patients\u2019 median LVEF\nat baseline was 65.0% (range 50% \u2013 88%) in both groups. </span></p>", "ID": "bb4442d7-4069-4618-a2a3-cc4053e46c01", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Approximately half the patients in each\ntreatment group had hormone receptor-positive disease (defined as o</span>", "ID": "4942a945-7b83-40d6-bc29-387a916beba9", "Styles": "None", "Classes": "None", "Text": "Approximately half the patients in each treatment group had hormone receptor-positive disease (defined as o", "ParentId": "bb4442d7-4069-4618-a2a3-cc4053e46c01"}, {"Element": "<span lang=\"EN-GB\">estrogen</span>", "ID": "d917e52d-0f0d-4eb1-8ae3-2318e51ea7b5", "Styles": "None", "Classes": "None", "Text": "estrogen", "ParentId": "bb4442d7-4069-4618-a2a3-cc4053e46c01"}, {"Element": "<span lang=\"EN-GB\"> receptor</span>", "ID": "58f590d5-f17a-4c7e-ab8f-ccefa6f11d9c", "Styles": "None", "Classes": "None", "Text": " receptor", "ParentId": "bb4442d7-4069-4618-a2a3-cc4053e46c01"}, {"Element": "<span lang=\"EN-GB\">\n(ER) </span>", "ID": "c5fabfe5-7375-439b-97c4-7fb529ca1684", "Styles": "None", "Classes": "None", "Text": " (ER) ", "ParentId": "bb4442d7-4069-4618-a2a3-cc4053e46c01"}, {"Element": "<span lang=\"EN-GB\">positive and/or progesterone receptor</span>", "ID": "13fa15fb-1d94-4068-a185-4d31252c551b", "Styles": "None", "Classes": "None", "Text": "positive and/or progesterone receptor", "ParentId": "bb4442d7-4069-4618-a2a3-cc4053e46c01"}, {"Element": "<span lang=\"EN-GB\"> (PgR) </span>", "ID": "41293855-82ac-4bce-8385-c6df69a5d3e6", "Styles": "None", "Classes": "None", "Text": " (PgR) ", "ParentId": "bb4442d7-4069-4618-a2a3-cc4053e46c01"}, {"Element": "<span lang=\"EN-GB\">positive) and approximately half of\nthe patients in each treatment group had received prior adjuvant or neoadjuvant\ntherapy. Most of these patients had received prior anthracycline therapy and 11%\nof all patients had received prior trastuzumab. A total of 43% of patients in\nboth treatment groups had previously received radiotherapy. Patients\u2019 median LVEF\nat baseline was 65.0% (range 50% \u2013 88%) in both groups. </span>", "ID": "9c85853f-1c0b-4d92-a1e8-8188ca7dd887", "Styles": "None", "Classes": "None", "Text": "positive) and approximately half of the patients in each treatment group had received prior adjuvant or neoadjuvant therapy. Most of these patients had received prior anthracycline therapy and 11% of all patients had received prior trastuzumab. A total of 43% of patients in both treatment groups had previously received radiotherapy. Patients\u2019 median LVEF at baseline was 65.0% (range 50% \u2013 88%) in both groups. ", "ParentId": "bb4442d7-4069-4618-a2a3-cc4053e46c01"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "52a5a8d7-9afd-4976-8ca6-c6fd9a89389f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "dca7cac8-f309-4a3b-a7f3-0f5931366319", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "52a5a8d7-9afd-4976-8ca6-c6fd9a89389f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The efficacy results from the CLEOPATRA\nstudy are summarised in Table 3. </span><span lang=\"EN-GB\">A statistically\nsignificant improvement in IRF-assessed PFS was demonstrated in the Perjeta-treated\ngroup compared with the placebo-treated group. The results for investigator-assessed\nPFS were similar to those observed for IRF-assessed PFS. </span></p>", "ID": "cab87d1f-6e88-437e-a0b7-8758f1868860", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">The efficacy results from the CLEOPATRA\nstudy are summarised in Table 3. </span>", "ID": "abef5cf7-c10c-418c-87ce-f8958afe1ed4", "Styles": "None", "Classes": "None", "Text": "The efficacy results from the CLEOPATRA study are summarised in Table 3. ", "ParentId": "cab87d1f-6e88-437e-a0b7-8758f1868860"}, {"Element": "<span lang=\"EN-GB\">A statistically\nsignificant improvement in IRF-assessed PFS was demonstrated in the Perjeta-treated\ngroup compared with the placebo-treated group. The results for investigator-assessed\nPFS were similar to those observed for IRF-assessed PFS. </span>", "ID": "e8fd07dc-8a0d-4771-aea2-e09ae4ecd629", "Styles": "None", "Classes": "None", "Text": "A statistically significant improvement in IRF-assessed PFS was demonstrated in the Perjeta-treated group compared with the placebo-treated group. The results for investigator-assessed PFS were similar to those observed for IRF-assessed PFS. ", "ParentId": "cab87d1f-6e88-437e-a0b7-8758f1868860"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "38ad0e95-6440-4e3b-9a07-26196d1b638d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f5d8b0f6-5919-490e-a3cf-bf3631f8522a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "38ad0e95-6440-4e3b-9a07-26196d1b638d"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Table 3  Summary\nof efficacy from CLEOPATRA study</span></b></p>", "ID": "f653145a-aa4b-4c7f-ba9c-a3d1f29862f0", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">Table 3  Summary\nof efficacy from CLEOPATRA study</span></b>", "ID": "450d95fc-f186-4ec3-a76a-cfffa4c1ee20", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f653145a-aa4b-4c7f-ba9c-a3d1f29862f0"}, {"Element": "<span lang=\"EN-GB\">Table 3  Summary\nof efficacy from CLEOPATRA study</span>", "ID": "7591579f-b50d-4ada-a882-e8d7bbdd09b1", "Styles": "None", "Classes": "None", "Text": "Table 3  Summary of efficacy from CLEOPATRA study", "ParentId": "450d95fc-f186-4ec3-a76a-cfffa4c1ee20"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>", "ID": "be522867-79a5-43e5-8fc2-da1b3d06459f", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">\u00a0</span>", "ID": "972b02ed-b1f5-4a56-ab8e-bae7b2504e02", "Styles": "color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "be522867-79a5-43e5-8fc2-da1b3d06459f"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"margin-left:5.4pt;border-collapse:collapse;border:none\">\n<thead>\n<tr>\n<td style=\"width:163.05pt;border:solid windowtext 1.0pt;\n   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"217\">\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\n   page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">Parameter </span></b></p>\n</td>\n<td style=\"width:70.85pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"94\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">Placebo+ </span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">trastuzumab</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">+ docetaxel</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">n=406</span></b></p>\n</td>\n<td style=\"width:70.9pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"95\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">Perjeta+ </span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">trastuzumab</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">+ docetaxel</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">n=402</span></b></p>\n</td>\n<td style=\"width:63.75pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">HR</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">(95% CI)</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n<td style=\"width:70.9pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"95\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">p-value</span></b></p>\n</td>\n</tr>\n</thead>\n<tr>\n<td style=\"width:163.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"217\">\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\n  page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">Progression-Free\n  Survival </span></b></p>\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\n  page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">(independent\n  review) \u2013 primary endpoint*</span></b></p>\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\n  page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\n  page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">no. of patients\n  with an event</span></p>\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\n  page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Median months</span></p>\n</td>\n<td style=\"width:70.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"94\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">242 (59%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">12.4</span></p>\n</td>\n<td style=\"width:70.9pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"95\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">191 (47.5%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">18.5</span></p>\n</td>\n<td style=\"width:63.75pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">0.62</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">[0.51;0.75]</span></p>\n</td>\n<td style=\"width:70.9pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"95\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">&lt;0.0001</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:163.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"217\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">Overall Survival - secondary endpoint**</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">no. of patients with an event</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Median months</span></p>\n</td>\n<td style=\"width:70.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"94\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><s><span lang=\"EN-GB\"><span style=\"text-decoration:\n   none\">\u00a0</span></span></s></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><s><span lang=\"EN-GB\"><span style=\"text-decoration:\n   none\">\u00a0</span></span></s></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><s><span lang=\"EN-GB\"><span style=\"text-decoration:\n   none\">\u00a0</span></span></s></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">221 (54.4%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">40.8</span></p>\n</td>\n<td style=\"width:70.9pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"95\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><s><span lang=\"EN-GB\"><span style=\"text-decoration:\n   none\">\u00a0</span></span></s></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><s><span lang=\"EN-GB\"><span style=\"text-decoration:\n   none\">\u00a0</span></span></s></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><s><span lang=\"EN-GB\"><span style=\"text-decoration:\n   none\">\u00a0</span></span></s></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">168 (41.8%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">56.5</span></p>\n</td>\n<td style=\"width:63.75pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><s><span lang=\"EN-GB\"><span style=\"text-decoration:\n   none\">\u00a0</span></span></s></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">0.68</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">[0.56;0.84]</span></p>\n</td>\n<td style=\"width:70.9pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"95\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><s><span lang=\"EN-GB\"><span style=\"text-decoration:\n   none\">\u00a0</span></span></s></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><s><span lang=\"EN-GB\"><span style=\"text-decoration:\n   none\">\u00a0</span></span></s></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><s><span lang=\"EN-GB\"><span style=\"text-decoration:\n   none\">\u00a0</span></span></s></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">0.0002</span></p>\n</td>\n</tr>\n<tr style=\"height:21.0pt\">\n<td style=\"width:163.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:21.0pt\" valign=\"top\" width=\"217\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">Objective Response Rate (ORR)^ - secondary endpoint</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">no. of patients with measurable disease</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Responders***\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n  </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">95% CI for\n  ORR\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Complete\n  response (CR)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Partial\n  Response (PR)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Stable\n  disease (SD)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Progressive\n  disease (PD)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span></p>\n</td>\n<td style=\"width:70.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:21.0pt\" valign=\"top\" width=\"94\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">336</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">233 (69.3%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">[64.1; 74.2]</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">14 (4.2%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">219 (65.2%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">70 (20.8%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">28 (8.3%)</span></p>\n</td>\n<td style=\"width:70.9pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:21.0pt\" valign=\"top\" width=\"95\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">343</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">275 (80.2%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">[75.6; 84.3]</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">19 (5.5%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">256 (74.6%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">50 (14.6%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">13 (3.8 %)</span></p>\n</td>\n<td style=\"width:63.75pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:21.0pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">Difference in ORR:</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">10.8%</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">[4.2,17.5]</span></p>\n</td>\n<td style=\"width:70.9pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:21.0pt\" valign=\"top\" width=\"95\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">0.0011</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:163.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"217\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><b><span lang=\"EN-GB\">Duration\n  of Response </span></b><span lang=\"EN-GB\">\u2020<b>^</b></span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">n=</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Median weeks </span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">95% CI for\n  Median</span></p>\n</td>\n<td style=\"width:70.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"94\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-autospace:none\"><span lang=\"EN-GB\">233</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-autospace:none\"><span lang=\"EN-GB\">54.1</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-autospace:none\"><span lang=\"EN-GB\">[46;64]</span></p>\n</td>\n<td style=\"width:70.9pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"95\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-autospace:none\"><span lang=\"EN-GB\">275</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-autospace:none\"><span lang=\"EN-GB\">87.6</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-autospace:none\"><span lang=\"EN-GB\">[71;106]</span></p>\n</td>\n<td style=\"width:63.75pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:70.9pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"95\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n</table>", "ID": "05ef5c17-13d4-4d27-8fc0-92ab9f46a654", "Styles": "margin-left:5.4pt;border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Text": "      ", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<thead>\n<tr>\n<td style=\"width:163.05pt;border:solid windowtext 1.0pt;\n   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"217\">\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\n   page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">Parameter </span></b></p>\n</td>\n<td style=\"width:70.85pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"94\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">Placebo+ </span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">trastuzumab</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">+ docetaxel</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">n=406</span></b></p>\n</td>\n<td style=\"width:70.9pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"95\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">Perjeta+ </span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">trastuzumab</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">+ docetaxel</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">n=402</span></b></p>\n</td>\n<td style=\"width:63.75pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">HR</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">(95% CI)</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n<td style=\"width:70.9pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"95\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">p-value</span></b></p>\n</td>\n</tr>\n</thead>", "ID": "36dbdcc7-b97c-49e8-9ff4-911d83635f59", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "05ef5c17-13d4-4d27-8fc0-92ab9f46a654"}, {"Element": "<tr>\n<td style=\"width:163.05pt;border:solid windowtext 1.0pt;\n   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"217\">\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\n   page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">Parameter </span></b></p>\n</td>\n<td style=\"width:70.85pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"94\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">Placebo+ </span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">trastuzumab</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">+ docetaxel</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">n=406</span></b></p>\n</td>\n<td style=\"width:70.9pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"95\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">Perjeta+ </span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">trastuzumab</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">+ docetaxel</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">n=402</span></b></p>\n</td>\n<td style=\"width:63.75pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">HR</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">(95% CI)</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n<td style=\"width:70.9pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"95\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">p-value</span></b></p>\n</td>\n</tr>", "ID": "84d1122c-9d4a-4fba-9b38-6d556c60e865", "Styles": "None", "Classes": "None", "Text": "      ", "ParentId": "36dbdcc7-b97c-49e8-9ff4-911d83635f59"}, {"Element": "<td style=\"width:163.05pt;border:solid windowtext 1.0pt;\n   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"217\">\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\n   page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">Parameter </span></b></p>\n</td>", "ID": "8cd099fd-b487-4c28-9e7e-a77c2c2b3178", "Styles": "width:163.05pt;border:solid windowtext 1.0pt;\n   padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "84d1122c-9d4a-4fba-9b38-6d556c60e865"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\n   page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">Parameter </span></b></p>", "ID": "19a7f175-d3fb-4bb9-891e-33fad2ced4cd", "Styles": "text-align:justify;text-justify:inter-ideograph;\n   page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8cd099fd-b487-4c28-9e7e-a77c2c2b3178"}, {"Element": "<b><span lang=\"EN-GB\">Parameter </span></b>", "ID": "c01ddc74-ff19-47b3-8cd0-26ef8197273d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "19a7f175-d3fb-4bb9-891e-33fad2ced4cd"}, {"Element": "<span lang=\"EN-GB\">Parameter </span>", "ID": "80338d3d-05b1-4039-8a2e-6edcac925f34", "Styles": "None", "Classes": "None", "Text": "Parameter ", "ParentId": "c01ddc74-ff19-47b3-8cd0-26ef8197273d"}, {"Element": "<td style=\"width:70.85pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"94\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">Placebo+ </span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">trastuzumab</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">+ docetaxel</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">n=406</span></b></p>\n</td>", "ID": "e7dd4a06-95f0-466e-85b2-3b47f69b50a3", "Styles": "width:70.85pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "84d1122c-9d4a-4fba-9b38-6d556c60e865"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">Placebo+ </span></b></p>", "ID": "678eaf09-efe9-406a-93c6-7f75299d9632", "Styles": "text-align:center;page-break-after:\n   avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e7dd4a06-95f0-466e-85b2-3b47f69b50a3"}, {"Element": "<b><span lang=\"EN-GB\">Placebo+ </span></b>", "ID": "9023384a-dff0-4b0b-85fd-15ba9488742f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "678eaf09-efe9-406a-93c6-7f75299d9632"}, {"Element": "<span lang=\"EN-GB\">Placebo+ </span>", "ID": "043eca26-a754-4f80-9d80-dba4fcb533c4", "Styles": "None", "Classes": "None", "Text": "Placebo+ ", "ParentId": "9023384a-dff0-4b0b-85fd-15ba9488742f"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">trastuzumab</span></b></p>", "ID": "883e11a1-71fb-4fe7-8776-d8996d5655c0", "Styles": "text-align:center;page-break-after:\n   avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e7dd4a06-95f0-466e-85b2-3b47f69b50a3"}, {"Element": "<b><span lang=\"EN-GB\">trastuzumab</span></b>", "ID": "af052566-313b-4582-afc3-5d88d33b767b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "883e11a1-71fb-4fe7-8776-d8996d5655c0"}, {"Element": "<span lang=\"EN-GB\">trastuzumab</span>", "ID": "daa60245-5e5b-4545-9edc-e2786cb12dc6", "Styles": "None", "Classes": "None", "Text": "trastuzumab", "ParentId": "af052566-313b-4582-afc3-5d88d33b767b"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">+ docetaxel</span></b></p>", "ID": "743fc10a-b336-4730-aca2-7fd35839b45c", "Styles": "text-align:center;page-break-after:\n   avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e7dd4a06-95f0-466e-85b2-3b47f69b50a3"}, {"Element": "<b><span lang=\"EN-GB\">+ docetaxel</span></b>", "ID": "5a613ec1-77d8-42b9-8d74-d0119663a21e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "743fc10a-b336-4730-aca2-7fd35839b45c"}, {"Element": "<span lang=\"EN-GB\">+ docetaxel</span>", "ID": "c9873928-875e-4cdd-aba5-a19ca862fe33", "Styles": "None", "Classes": "None", "Text": "+ docetaxel", "ParentId": "5a613ec1-77d8-42b9-8d74-d0119663a21e"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">n=406</span></b></p>", "ID": "4a2e19da-9966-4341-ae43-9380eb00c501", "Styles": "text-align:center;page-break-after:\n   avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e7dd4a06-95f0-466e-85b2-3b47f69b50a3"}, {"Element": "<b><span lang=\"EN-GB\">n=406</span></b>", "ID": "dc1a12cf-c41f-4a05-bb94-a2d12c2c3c61", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4a2e19da-9966-4341-ae43-9380eb00c501"}, {"Element": "<span lang=\"EN-GB\">n=406</span>", "ID": "4a066d20-481b-468b-a969-355ba049f07c", "Styles": "None", "Classes": "None", "Text": "n=406", "ParentId": "dc1a12cf-c41f-4a05-bb94-a2d12c2c3c61"}, {"Element": "<td style=\"width:70.9pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"95\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">Perjeta+ </span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">trastuzumab</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">+ docetaxel</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">n=402</span></b></p>\n</td>", "ID": "e0a7bb8a-8f14-4560-8328-d764314c20ed", "Styles": "width:70.9pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "84d1122c-9d4a-4fba-9b38-6d556c60e865"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">Perjeta+ </span></b></p>", "ID": "98214d7e-700a-4c66-8977-afcf035061a3", "Styles": "text-align:center;page-break-after:\n   avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e0a7bb8a-8f14-4560-8328-d764314c20ed"}, {"Element": "<b><span lang=\"EN-GB\">Perjeta+ </span></b>", "ID": "be1ea85f-d85f-4a41-bc0d-9e80049c73bb", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "98214d7e-700a-4c66-8977-afcf035061a3"}, {"Element": "<span lang=\"EN-GB\">Perjeta+ </span>", "ID": "bf449e38-bc5c-4481-92b7-ee01f608a374", "Styles": "None", "Classes": "None", "Text": "Perjeta+ ", "ParentId": "be1ea85f-d85f-4a41-bc0d-9e80049c73bb"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">trastuzumab</span></b></p>", "ID": "0fd1b8b4-342e-47b5-b7d1-6be9f9bb8afe", "Styles": "text-align:center;page-break-after:\n   avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e0a7bb8a-8f14-4560-8328-d764314c20ed"}, {"Element": "<b><span lang=\"EN-GB\">trastuzumab</span></b>", "ID": "cbf60842-5732-47e8-a07a-d95e63a89bb4", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "0fd1b8b4-342e-47b5-b7d1-6be9f9bb8afe"}, {"Element": "<span lang=\"EN-GB\">trastuzumab</span>", "ID": "2cdc9876-0eec-4c88-9331-c4a99a66566a", "Styles": "None", "Classes": "None", "Text": "trastuzumab", "ParentId": "cbf60842-5732-47e8-a07a-d95e63a89bb4"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">+ docetaxel</span></b></p>", "ID": "065aab48-46b2-4af0-99ce-19d02cf83998", "Styles": "text-align:center;page-break-after:\n   avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e0a7bb8a-8f14-4560-8328-d764314c20ed"}, {"Element": "<b><span lang=\"EN-GB\">+ docetaxel</span></b>", "ID": "138446c5-7dc6-41b8-a6fc-faf8059df440", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "065aab48-46b2-4af0-99ce-19d02cf83998"}, {"Element": "<span lang=\"EN-GB\">+ docetaxel</span>", "ID": "913dcb4b-6110-42bb-a93b-30f05f8c0e93", "Styles": "None", "Classes": "None", "Text": "+ docetaxel", "ParentId": "138446c5-7dc6-41b8-a6fc-faf8059df440"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">n=402</span></b></p>", "ID": "27c6adb0-7c3a-449d-89d7-12f0ba92f895", "Styles": "text-align:center;page-break-after:\n   avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e0a7bb8a-8f14-4560-8328-d764314c20ed"}, {"Element": "<b><span lang=\"EN-GB\">n=402</span></b>", "ID": "0d8244a8-5916-4e14-8b8e-c4ffe6c36246", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "27c6adb0-7c3a-449d-89d7-12f0ba92f895"}, {"Element": "<span lang=\"EN-GB\">n=402</span>", "ID": "9df5af2a-9eaf-4f7a-b9c4-c395a3ab98d4", "Styles": "None", "Classes": "None", "Text": "n=402", "ParentId": "0d8244a8-5916-4e14-8b8e-c4ffe6c36246"}, {"Element": "<td style=\"width:63.75pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">HR</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">(95% CI)</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>", "ID": "928dcc39-d989-4719-87cb-2e6f9ad85f26", "Styles": "width:63.75pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "    ", "ParentId": "84d1122c-9d4a-4fba-9b38-6d556c60e865"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">HR</span></b></p>", "ID": "330b8902-bc53-4344-ab74-b869803f57b2", "Styles": "text-align:center;page-break-after:\n   avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "928dcc39-d989-4719-87cb-2e6f9ad85f26"}, {"Element": "<b><span lang=\"EN-GB\">HR</span></b>", "ID": "0af35035-3751-4f8a-a8b9-80ae60073b76", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "330b8902-bc53-4344-ab74-b869803f57b2"}, {"Element": "<span lang=\"EN-GB\">HR</span>", "ID": "1026d599-e29f-48dd-baf2-d17578f46575", "Styles": "None", "Classes": "None", "Text": "HR", "ParentId": "0af35035-3751-4f8a-a8b9-80ae60073b76"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">(95% CI)</span></b></p>", "ID": "242098c6-6d84-495e-a4bc-40afdbf15710", "Styles": "text-align:center;page-break-after:\n   avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "928dcc39-d989-4719-87cb-2e6f9ad85f26"}, {"Element": "<b><span lang=\"EN-GB\">(95% CI)</span></b>", "ID": "a698ac27-fdc0-4c89-8d53-45b51f19ee15", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "242098c6-6d84-495e-a4bc-40afdbf15710"}, {"Element": "<span lang=\"EN-GB\">(95% CI)</span>", "ID": "3cbeef62-aad7-4150-b683-14dc8e37f164", "Styles": "None", "Classes": "None", "Text": "(95% CI)", "ParentId": "a698ac27-fdc0-4c89-8d53-45b51f19ee15"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "e95cc2e6-eac3-44a9-9b96-811894dfe5ee", "Styles": "text-align:center;page-break-after:\n   avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "928dcc39-d989-4719-87cb-2e6f9ad85f26"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "fdd5ba1f-ca2d-433f-a984-64aaa634ff2b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e95cc2e6-eac3-44a9-9b96-811894dfe5ee"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d0e8532d-3f45-4eaf-8e29-fd3aa51d097b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "fdd5ba1f-ca2d-433f-a984-64aaa634ff2b"}, {"Element": "<td style=\"width:70.9pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"95\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">p-value</span></b></p>\n</td>", "ID": "4d026d11-c830-4185-8dce-25cb9113c98c", "Styles": "width:70.9pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "84d1122c-9d4a-4fba-9b38-6d556c60e865"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">p-value</span></b></p>", "ID": "f4054426-1029-4ec5-b35e-59371c01788e", "Styles": "text-align:center;page-break-after:\n   avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4d026d11-c830-4185-8dce-25cb9113c98c"}, {"Element": "<b><span lang=\"EN-GB\">p-value</span></b>", "ID": "fac23d8e-8072-476b-8032-486649721173", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f4054426-1029-4ec5-b35e-59371c01788e"}, {"Element": "<span lang=\"EN-GB\">p-value</span>", "ID": "50eb164e-abd1-4972-8e00-ee2766211718", "Styles": "None", "Classes": "None", "Text": "p-value", "ParentId": "fac23d8e-8072-476b-8032-486649721173"}, {"Element": "<tr>\n<td style=\"width:163.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"217\">\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\n  page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">Progression-Free\n  Survival </span></b></p>\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\n  page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">(independent\n  review) \u2013 primary endpoint*</span></b></p>\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\n  page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\n  page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">no. of patients\n  with an event</span></p>\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\n  page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Median months</span></p>\n</td>\n<td style=\"width:70.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"94\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">242 (59%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">12.4</span></p>\n</td>\n<td style=\"width:70.9pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"95\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">191 (47.5%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">18.5</span></p>\n</td>\n<td style=\"width:63.75pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">0.62</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">[0.51;0.75]</span></p>\n</td>\n<td style=\"width:70.9pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"95\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">&lt;0.0001</span></p>\n</td>\n</tr>", "ID": "2b9dc3c3-d6a3-4897-82dc-dad08ea064f2", "Styles": "None", "Classes": "None", "Text": "      ", "ParentId": "05ef5c17-13d4-4d27-8fc0-92ab9f46a654"}, {"Element": "<td style=\"width:163.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"217\">\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\n  page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">Progression-Free\n  Survival </span></b></p>\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\n  page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">(independent\n  review) \u2013 primary endpoint*</span></b></p>\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\n  page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\n  page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">no. of patients\n  with an event</span></p>\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\n  page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Median months</span></p>\n</td>", "ID": "f50ace65-480f-47ae-a635-0a01210b60f2", "Styles": "width:163.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "      ", "ParentId": "2b9dc3c3-d6a3-4897-82dc-dad08ea064f2"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\n  page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">Progression-Free\n  Survival </span></b></p>", "ID": "ffe7cb42-666b-4797-909b-3eb8c2d95195", "Styles": "text-align:justify;text-justify:inter-ideograph;\n  page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f50ace65-480f-47ae-a635-0a01210b60f2"}, {"Element": "<b><span lang=\"EN-GB\">Progression-Free\n  Survival </span></b>", "ID": "9a6c3e4b-ea55-46ec-90ed-6a69e2fb2fa3", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ffe7cb42-666b-4797-909b-3eb8c2d95195"}, {"Element": "<span lang=\"EN-GB\">Progression-Free\n  Survival </span>", "ID": "f37cdf5e-5cfd-42f9-bca4-4f28cd26a18f", "Styles": "None", "Classes": "None", "Text": "Progression-Free   Survival ", "ParentId": "9a6c3e4b-ea55-46ec-90ed-6a69e2fb2fa3"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\n  page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">(independent\n  review) \u2013 primary endpoint*</span></b></p>", "ID": "0cca1a14-51fd-4a60-af8f-89dc0a7bb16f", "Styles": "text-align:justify;text-justify:inter-ideograph;\n  page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f50ace65-480f-47ae-a635-0a01210b60f2"}, {"Element": "<b><span lang=\"EN-GB\">(independent\n  review) \u2013 primary endpoint*</span></b>", "ID": "43417b07-1254-4aeb-89bf-e1bddca8d6bb", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "0cca1a14-51fd-4a60-af8f-89dc0a7bb16f"}, {"Element": "<span lang=\"EN-GB\">(independent\n  review) \u2013 primary endpoint*</span>", "ID": "63062124-fb7a-4173-a4d4-12fa146a25e4", "Styles": "None", "Classes": "None", "Text": "(independent   review) \u2013 primary endpoint*", "ParentId": "43417b07-1254-4aeb-89bf-e1bddca8d6bb"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\n  page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "a1103c50-ac54-4a68-9559-206b38d36ec6", "Styles": "text-align:justify;text-justify:inter-ideograph;\n  page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f50ace65-480f-47ae-a635-0a01210b60f2"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "2007478c-df45-4b60-93b3-cb5f685e0986", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a1103c50-ac54-4a68-9559-206b38d36ec6"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "04215982-2a01-4317-a992-aee89510823c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2007478c-df45-4b60-93b3-cb5f685e0986"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\n  page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">no. of patients\n  with an event</span></p>", "ID": "04032c70-4f16-4b03-b81a-08fc2f669ae4", "Styles": "text-align:justify;text-justify:inter-ideograph;\n  page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f50ace65-480f-47ae-a635-0a01210b60f2"}, {"Element": "<span lang=\"EN-GB\">no. of patients\n  with an event</span>", "ID": "fd02cf0d-09f1-457e-af61-2f71e5aa43ea", "Styles": "None", "Classes": "None", "Text": "no. of patients   with an event", "ParentId": "04032c70-4f16-4b03-b81a-08fc2f669ae4"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\n  page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Median months</span></p>", "ID": "3378b567-f526-4d70-aa7f-d7fda78adf3a", "Styles": "text-align:justify;text-justify:inter-ideograph;\n  page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f50ace65-480f-47ae-a635-0a01210b60f2"}, {"Element": "<span lang=\"EN-GB\">Median months</span>", "ID": "fb6539af-489d-454d-b210-02e04e3b9dc8", "Styles": "None", "Classes": "None", "Text": "Median months", "ParentId": "3378b567-f526-4d70-aa7f-d7fda78adf3a"}, {"Element": "<td style=\"width:70.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"94\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">242 (59%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">12.4</span></p>\n</td>", "ID": "9e571f38-92fb-4c83-8b56-20c2f8356d43", "Styles": "width:70.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "       ", "ParentId": "2b9dc3c3-d6a3-4897-82dc-dad08ea064f2"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "be942f23-82c2-4910-9cae-5217b60e7ad4", "Styles": "text-align:center;page-break-after:\n  avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9e571f38-92fb-4c83-8b56-20c2f8356d43"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9501e1ed-cf3a-4e9b-93c4-90ed31ce8990", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "be942f23-82c2-4910-9cae-5217b60e7ad4"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e9b79394-c7f0-4e58-be51-a179d75b879f", "Styles": "text-align:center;page-break-after:\n  avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9e571f38-92fb-4c83-8b56-20c2f8356d43"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4493a48a-72fb-4937-8ee2-6d8f8f860c17", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e9b79394-c7f0-4e58-be51-a179d75b879f"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d5506517-5900-4e0d-9543-d9633eb250c2", "Styles": "text-align:center;page-break-after:\n  avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9e571f38-92fb-4c83-8b56-20c2f8356d43"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "eeb24c5e-f8a3-477f-a44d-c3c595f5db7b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d5506517-5900-4e0d-9543-d9633eb250c2"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c5e9ac77-a01b-4a4a-b60d-0244acc84a0d", "Styles": "text-align:center;page-break-after:\n  avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9e571f38-92fb-4c83-8b56-20c2f8356d43"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "42aec2b5-ff02-494e-8cb0-a320ab1704f8", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c5e9ac77-a01b-4a4a-b60d-0244acc84a0d"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">242 (59%)</span></p>", "ID": "bda46bd5-40ed-46a8-a46a-82824ebebb8f", "Styles": "text-align:center;page-break-after:\n  avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9e571f38-92fb-4c83-8b56-20c2f8356d43"}, {"Element": "<span lang=\"EN-GB\">242 (59%)</span>", "ID": "220688f1-4668-4e9e-a070-0e7bc047ed7f", "Styles": "None", "Classes": "None", "Text": "242 (59%)", "ParentId": "bda46bd5-40ed-46a8-a46a-82824ebebb8f"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">12.4</span></p>", "ID": "88fac325-2ada-4903-93a1-f7b116ab882a", "Styles": "text-align:center;page-break-after:\n  avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9e571f38-92fb-4c83-8b56-20c2f8356d43"}, {"Element": "<span lang=\"EN-GB\">12.4</span>", "ID": "f3c17c34-bd32-4eec-a874-20bb60de4484", "Styles": "None", "Classes": "None", "Text": "12.4", "ParentId": "88fac325-2ada-4903-93a1-f7b116ab882a"}, {"Element": "<td style=\"width:70.9pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"95\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">191 (47.5%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">18.5</span></p>\n</td>", "ID": "7b9e30bb-d79d-42de-8a12-fa230a8dabd1", "Styles": "width:70.9pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "       ", "ParentId": "2b9dc3c3-d6a3-4897-82dc-dad08ea064f2"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8788dd32-fcbb-4868-b1c3-60099de080d1", "Styles": "text-align:center;page-break-after:\n  avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7b9e30bb-d79d-42de-8a12-fa230a8dabd1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f719f6e4-8264-4b5e-8beb-aed54e46aad5", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8788dd32-fcbb-4868-b1c3-60099de080d1"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6cd7737e-6fca-4959-a497-0ad0ce2a12c1", "Styles": "text-align:center;page-break-after:\n  avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7b9e30bb-d79d-42de-8a12-fa230a8dabd1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "32e1b009-2131-482f-bc22-626eb0cdb0a0", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6cd7737e-6fca-4959-a497-0ad0ce2a12c1"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "03d5832d-8bfd-4390-a948-07b20f4505e3", "Styles": "text-align:center;page-break-after:\n  avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7b9e30bb-d79d-42de-8a12-fa230a8dabd1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9d645cd6-926d-4d60-a060-5329562580dd", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "03d5832d-8bfd-4390-a948-07b20f4505e3"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4edc57a2-74ef-4c71-9854-aede72ae6f08", "Styles": "text-align:center;page-break-after:\n  avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7b9e30bb-d79d-42de-8a12-fa230a8dabd1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b6e4990e-d59c-4334-bc32-bc105259fd01", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4edc57a2-74ef-4c71-9854-aede72ae6f08"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">191 (47.5%)</span></p>", "ID": "61deabe1-8deb-491c-8148-8450b1a378b3", "Styles": "text-align:center;page-break-after:\n  avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7b9e30bb-d79d-42de-8a12-fa230a8dabd1"}, {"Element": "<span lang=\"EN-GB\">191 (47.5%)</span>", "ID": "82ba0a23-b127-4c4d-9213-1bcae1747e41", "Styles": "None", "Classes": "None", "Text": "191 (47.5%)", "ParentId": "61deabe1-8deb-491c-8148-8450b1a378b3"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">18.5</span></p>", "ID": "8dc5e94f-cdf4-4627-b420-dc6ad139a465", "Styles": "text-align:center;page-break-after:\n  avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7b9e30bb-d79d-42de-8a12-fa230a8dabd1"}, {"Element": "<span lang=\"EN-GB\">18.5</span>", "ID": "5a40acf8-a219-4530-80dd-e452f16d89d4", "Styles": "None", "Classes": "None", "Text": "18.5", "ParentId": "8dc5e94f-cdf4-4627-b420-dc6ad139a465"}, {"Element": "<td style=\"width:63.75pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">0.62</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">[0.51;0.75]</span></p>\n</td>", "ID": "c24a5baf-3fcc-4721-98d1-3cde1408649a", "Styles": "width:63.75pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "       ", "ParentId": "2b9dc3c3-d6a3-4897-82dc-dad08ea064f2"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "667208f2-bba7-4af4-a531-6f98b277f1ea", "Styles": "text-align:center;page-break-after:\n  avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c24a5baf-3fcc-4721-98d1-3cde1408649a"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9e584550-2302-45ac-8062-b91b2acb1a58", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "667208f2-bba7-4af4-a531-6f98b277f1ea"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "72fb25c5-2176-4431-87ba-7f2a36e023ef", "Styles": "text-align:center;page-break-after:\n  avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c24a5baf-3fcc-4721-98d1-3cde1408649a"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "27333c54-8988-4677-a44f-e6b499310440", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "72fb25c5-2176-4431-87ba-7f2a36e023ef"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "59934701-7455-4c1b-a509-e004cd0c246b", "Styles": "text-align:center;page-break-after:\n  avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c24a5baf-3fcc-4721-98d1-3cde1408649a"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5ca0a7f7-cb76-4d31-8803-e1c3cb7aa42e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "59934701-7455-4c1b-a509-e004cd0c246b"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "89b6faf6-8ea7-4634-ae1d-7f7c008451fd", "Styles": "text-align:center;page-break-after:\n  avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c24a5baf-3fcc-4721-98d1-3cde1408649a"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0ce1a538-1da3-4296-930e-c020d8461a72", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "89b6faf6-8ea7-4634-ae1d-7f7c008451fd"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">0.62</span></p>", "ID": "5c782f94-0969-4de9-bd83-a2dc00643386", "Styles": "text-align:center;page-break-after:\n  avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c24a5baf-3fcc-4721-98d1-3cde1408649a"}, {"Element": "<span lang=\"EN-GB\">0.62</span>", "ID": "0a483a4b-6860-4a52-9479-8a542a25d221", "Styles": "None", "Classes": "None", "Text": "0.62", "ParentId": "5c782f94-0969-4de9-bd83-a2dc00643386"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">[0.51;0.75]</span></p>", "ID": "cc21005b-b650-46ff-8681-77926e99e453", "Styles": "text-align:center;page-break-after:\n  avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c24a5baf-3fcc-4721-98d1-3cde1408649a"}, {"Element": "<span lang=\"EN-GB\">[0.51;0.75]</span>", "ID": "7f6534e6-42af-4df8-9d6b-5e7b781a4eef", "Styles": "None", "Classes": "None", "Text": "[0.51;0.75]", "ParentId": "cc21005b-b650-46ff-8681-77926e99e453"}, {"Element": "<td style=\"width:70.9pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"95\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">&lt;0.0001</span></p>\n</td>", "ID": "d01abddf-e812-462a-8752-8306797e8745", "Styles": "width:70.9pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "      ", "ParentId": "2b9dc3c3-d6a3-4897-82dc-dad08ea064f2"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d30e759c-d1eb-4988-82e9-b801a7475f35", "Styles": "text-align:center;page-break-after:\n  avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d01abddf-e812-462a-8752-8306797e8745"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5e079a2c-c519-4d42-9ff0-0e42876ab9f8", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d30e759c-d1eb-4988-82e9-b801a7475f35"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2e0a4c41-d035-4eb6-9eee-3a70ffd821a5", "Styles": "text-align:center;page-break-after:\n  avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d01abddf-e812-462a-8752-8306797e8745"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "56602739-ddb0-44d3-88d3-262abaf7dc3b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2e0a4c41-d035-4eb6-9eee-3a70ffd821a5"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2105a483-3289-4e1b-84bc-63ddb7af885f", "Styles": "text-align:center;page-break-after:\n  avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d01abddf-e812-462a-8752-8306797e8745"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ebf4e066-4ca1-481f-96e3-976747be21f6", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2105a483-3289-4e1b-84bc-63ddb7af885f"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0c6daa40-7080-452b-87b3-8b52bed396f7", "Styles": "text-align:center;page-break-after:\n  avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d01abddf-e812-462a-8752-8306797e8745"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8c02effa-ea44-4d81-aea3-8d25d5ddd9df", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0c6daa40-7080-452b-87b3-8b52bed396f7"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">&lt;0.0001</span></p>", "ID": "6068f9cc-fd9d-4630-9b17-05f3b932d1bd", "Styles": "text-align:center;page-break-after:\n  avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d01abddf-e812-462a-8752-8306797e8745"}, {"Element": "<span lang=\"EN-GB\">&lt;0.0001</span>", "ID": "c55b6008-f24e-48f2-8ce2-358b43be62d2", "Styles": "None", "Classes": "None", "Text": "<0.0001", "ParentId": "6068f9cc-fd9d-4630-9b17-05f3b932d1bd"}, {"Element": "<tr>\n<td style=\"width:163.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"217\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">Overall Survival - secondary endpoint**</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">no. of patients with an event</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Median months</span></p>\n</td>\n<td style=\"width:70.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"94\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><s><span lang=\"EN-GB\"><span style=\"text-decoration:\n   none\">\u00a0</span></span></s></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><s><span lang=\"EN-GB\"><span style=\"text-decoration:\n   none\">\u00a0</span></span></s></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><s><span lang=\"EN-GB\"><span style=\"text-decoration:\n   none\">\u00a0</span></span></s></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">221 (54.4%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">40.8</span></p>\n</td>\n<td style=\"width:70.9pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"95\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><s><span lang=\"EN-GB\"><span style=\"text-decoration:\n   none\">\u00a0</span></span></s></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><s><span lang=\"EN-GB\"><span style=\"text-decoration:\n   none\">\u00a0</span></span></s></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><s><span lang=\"EN-GB\"><span style=\"text-decoration:\n   none\">\u00a0</span></span></s></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">168 (41.8%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">56.5</span></p>\n</td>\n<td style=\"width:63.75pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><s><span lang=\"EN-GB\"><span style=\"text-decoration:\n   none\">\u00a0</span></span></s></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">0.68</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">[0.56;0.84]</span></p>\n</td>\n<td style=\"width:70.9pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"95\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><s><span lang=\"EN-GB\"><span style=\"text-decoration:\n   none\">\u00a0</span></span></s></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><s><span lang=\"EN-GB\"><span style=\"text-decoration:\n   none\">\u00a0</span></span></s></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><s><span lang=\"EN-GB\"><span style=\"text-decoration:\n   none\">\u00a0</span></span></s></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">0.0002</span></p>\n</td>\n</tr>", "ID": "17489535-8aa3-483a-b5cb-2736adcc75d7", "Styles": "None", "Classes": "None", "Text": "      ", "ParentId": "05ef5c17-13d4-4d27-8fc0-92ab9f46a654"}, {"Element": "<td style=\"width:163.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"217\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">Overall Survival - secondary endpoint**</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">no. of patients with an event</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Median months</span></p>\n</td>", "ID": "b81d3ca2-1a89-44d8-a8f9-91cd46c93a30", "Styles": "width:163.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "17489535-8aa3-483a-b5cb-2736adcc75d7"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">Overall Survival - secondary endpoint**</span></b></p>", "ID": "96c28bb4-da84-41f8-bf77-17de9670dc74", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b81d3ca2-1a89-44d8-a8f9-91cd46c93a30"}, {"Element": "<b><span lang=\"EN-GB\">Overall Survival - secondary endpoint**</span></b>", "ID": "b174ca1a-9c05-4552-af01-06b72274fe05", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "96c28bb4-da84-41f8-bf77-17de9670dc74"}, {"Element": "<span lang=\"EN-GB\">Overall Survival - secondary endpoint**</span>", "ID": "1c0285e7-406a-4b98-83cf-f0ed7c8f5416", "Styles": "None", "Classes": "None", "Text": "Overall Survival - secondary endpoint**", "ParentId": "b174ca1a-9c05-4552-af01-06b72274fe05"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "a5527e4c-9a88-4a8f-94c8-aec4fc780aa2", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b81d3ca2-1a89-44d8-a8f9-91cd46c93a30"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "69245ceb-813c-4cde-b334-68db43f7ff76", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a5527e4c-9a88-4a8f-94c8-aec4fc780aa2"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "017e4a34-a79d-4743-b333-791859964279", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "69245ceb-813c-4cde-b334-68db43f7ff76"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">no. of patients with an event</span></p>", "ID": "0144aeb6-0640-4b4d-9412-8148e2d5e816", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b81d3ca2-1a89-44d8-a8f9-91cd46c93a30"}, {"Element": "<span lang=\"EN-GB\">no. of patients with an event</span>", "ID": "d977a0ab-c6d5-44fe-bd6a-555e97cca37c", "Styles": "None", "Classes": "None", "Text": "no. of patients with an event", "ParentId": "0144aeb6-0640-4b4d-9412-8148e2d5e816"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Median months</span></p>", "ID": "33afd30a-2cde-4f05-8176-d3fd5048abd6", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b81d3ca2-1a89-44d8-a8f9-91cd46c93a30"}, {"Element": "<span lang=\"EN-GB\">Median months</span>", "ID": "4372d787-4ecf-402f-9db4-6c77c889980e", "Styles": "None", "Classes": "None", "Text": "Median months", "ParentId": "33afd30a-2cde-4f05-8176-d3fd5048abd6"}, {"Element": "<td style=\"width:70.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"94\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><s><span lang=\"EN-GB\"><span style=\"text-decoration:\n   none\">\u00a0</span></span></s></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><s><span lang=\"EN-GB\"><span style=\"text-decoration:\n   none\">\u00a0</span></span></s></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><s><span lang=\"EN-GB\"><span style=\"text-decoration:\n   none\">\u00a0</span></span></s></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">221 (54.4%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">40.8</span></p>\n</td>", "ID": "aabb027b-1c56-4fd7-885b-26f5a5d62ae6", "Styles": "width:70.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "      ", "ParentId": "17489535-8aa3-483a-b5cb-2736adcc75d7"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><s><span lang=\"EN-GB\"><span style=\"text-decoration:\n   none\">\u00a0</span></span></s></p>", "ID": "d7aed846-3dab-40c5-86fd-e3b8b25eb11f", "Styles": "text-align:center;page-break-after:\n  avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "aabb027b-1c56-4fd7-885b-26f5a5d62ae6"}, {"Element": "<s><span lang=\"EN-GB\"><span style=\"text-decoration:\n   none\">\u00a0</span></span></s>", "ID": "8a47c92d-d05c-4ae8-853a-6cd6444968bb", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d7aed846-3dab-40c5-86fd-e3b8b25eb11f"}, {"Element": "<span lang=\"EN-GB\"><span style=\"text-decoration:\n   none\">\u00a0</span></span>", "ID": "2bb488d2-cad9-4622-87ba-78ff7fd20f4f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8a47c92d-d05c-4ae8-853a-6cd6444968bb"}, {"Element": "<span style=\"text-decoration:\n   none\">\u00a0</span>", "ID": "feacc2d4-63af-471c-9b35-7be66b0d85c6", "Styles": "text-decoration:\n   none", "Classes": "None", "Text": "\u00a0", "ParentId": "2bb488d2-cad9-4622-87ba-78ff7fd20f4f"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><s><span lang=\"EN-GB\"><span style=\"text-decoration:\n   none\">\u00a0</span></span></s></p>", "ID": "83bc82cf-bb7f-41ca-992d-a09eed659dcf", "Styles": "text-align:center;page-break-after:\n  avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "aabb027b-1c56-4fd7-885b-26f5a5d62ae6"}, {"Element": "<s><span lang=\"EN-GB\"><span style=\"text-decoration:\n   none\">\u00a0</span></span></s>", "ID": "a7b64431-6209-4345-ac22-c62501b9f4df", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "83bc82cf-bb7f-41ca-992d-a09eed659dcf"}, {"Element": "<span lang=\"EN-GB\"><span style=\"text-decoration:\n   none\">\u00a0</span></span>", "ID": "f0eba66d-421a-442c-bc87-2b8dc9ef44a3", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a7b64431-6209-4345-ac22-c62501b9f4df"}, {"Element": "<span style=\"text-decoration:\n   none\">\u00a0</span>", "ID": "96ee2c8f-77c3-4c70-9b68-a85f518e9611", "Styles": "text-decoration:\n   none", "Classes": "None", "Text": "\u00a0", "ParentId": "f0eba66d-421a-442c-bc87-2b8dc9ef44a3"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><s><span lang=\"EN-GB\"><span style=\"text-decoration:\n   none\">\u00a0</span></span></s></p>", "ID": "a7d4e7ad-4442-4299-a4d8-ff71220d7a19", "Styles": "text-align:center;page-break-after:\n  avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "aabb027b-1c56-4fd7-885b-26f5a5d62ae6"}, {"Element": "<s><span lang=\"EN-GB\"><span style=\"text-decoration:\n   none\">\u00a0</span></span></s>", "ID": "434dc1ba-2ff0-4e9b-9cad-af6578ebb523", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a7d4e7ad-4442-4299-a4d8-ff71220d7a19"}, {"Element": "<span lang=\"EN-GB\"><span style=\"text-decoration:\n   none\">\u00a0</span></span>", "ID": "4d67a821-0de2-46a6-b5c2-0aa1fae2c1e1", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "434dc1ba-2ff0-4e9b-9cad-af6578ebb523"}, {"Element": "<span style=\"text-decoration:\n   none\">\u00a0</span>", "ID": "618973d1-aab1-488d-bbea-1f0d7e4992e8", "Styles": "text-decoration:\n   none", "Classes": "None", "Text": "\u00a0", "ParentId": "4d67a821-0de2-46a6-b5c2-0aa1fae2c1e1"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">221 (54.4%)</span></p>", "ID": "60107dc1-5d82-45e6-8d53-643dfd0e0aed", "Styles": "text-align:center;page-break-after:\n  avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "aabb027b-1c56-4fd7-885b-26f5a5d62ae6"}, {"Element": "<span lang=\"EN-GB\">221 (54.4%)</span>", "ID": "44bc54ac-4982-4ac4-bd14-63fd99e98b51", "Styles": "None", "Classes": "None", "Text": "221 (54.4%)", "ParentId": "60107dc1-5d82-45e6-8d53-643dfd0e0aed"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">40.8</span></p>", "ID": "5cafd59b-e3ff-4f14-904a-097628787af3", "Styles": "text-align:center;page-break-after:\n  avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "aabb027b-1c56-4fd7-885b-26f5a5d62ae6"}, {"Element": "<span lang=\"EN-GB\">40.8</span>", "ID": "02e2980f-8417-4e72-ba75-c37978b8ac88", "Styles": "None", "Classes": "None", "Text": "40.8", "ParentId": "5cafd59b-e3ff-4f14-904a-097628787af3"}, {"Element": "<td style=\"width:70.9pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"95\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><s><span lang=\"EN-GB\"><span style=\"text-decoration:\n   none\">\u00a0</span></span></s></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><s><span lang=\"EN-GB\"><span style=\"text-decoration:\n   none\">\u00a0</span></span></s></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><s><span lang=\"EN-GB\"><span style=\"text-decoration:\n   none\">\u00a0</span></span></s></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">168 (41.8%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">56.5</span></p>\n</td>", "ID": "dae033dc-2179-42d7-91de-6a87c71b1880", "Styles": "width:70.9pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "      ", "ParentId": "17489535-8aa3-483a-b5cb-2736adcc75d7"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><s><span lang=\"EN-GB\"><span style=\"text-decoration:\n   none\">\u00a0</span></span></s></p>", "ID": "91dc0bca-09ef-4fe8-bee9-187f9b8e120d", "Styles": "text-align:center;page-break-after:\n  avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "dae033dc-2179-42d7-91de-6a87c71b1880"}, {"Element": "<s><span lang=\"EN-GB\"><span style=\"text-decoration:\n   none\">\u00a0</span></span></s>", "ID": "bac6e0c2-335c-472d-bd56-9d3d62094349", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "91dc0bca-09ef-4fe8-bee9-187f9b8e120d"}, {"Element": "<span lang=\"EN-GB\"><span style=\"text-decoration:\n   none\">\u00a0</span></span>", "ID": "866bfa25-920c-4f82-8fe0-37c530bf2538", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "bac6e0c2-335c-472d-bd56-9d3d62094349"}, {"Element": "<span style=\"text-decoration:\n   none\">\u00a0</span>", "ID": "6b980310-8a8e-4780-8437-26b7e22d097e", "Styles": "text-decoration:\n   none", "Classes": "None", "Text": "\u00a0", "ParentId": "866bfa25-920c-4f82-8fe0-37c530bf2538"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><s><span lang=\"EN-GB\"><span style=\"text-decoration:\n   none\">\u00a0</span></span></s></p>", "ID": "49235821-3a31-4e29-bd23-5187bc8b8763", "Styles": "text-align:center;page-break-after:\n  avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "dae033dc-2179-42d7-91de-6a87c71b1880"}, {"Element": "<s><span lang=\"EN-GB\"><span style=\"text-decoration:\n   none\">\u00a0</span></span></s>", "ID": "0a28794c-30ce-4916-bf2a-8597b6121e51", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "49235821-3a31-4e29-bd23-5187bc8b8763"}, {"Element": "<span lang=\"EN-GB\"><span style=\"text-decoration:\n   none\">\u00a0</span></span>", "ID": "d8dc1f93-2d37-478f-960e-53b45dd7c071", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "0a28794c-30ce-4916-bf2a-8597b6121e51"}, {"Element": "<span style=\"text-decoration:\n   none\">\u00a0</span>", "ID": "801d41f0-0e65-47fe-bb7f-3979dbc20f77", "Styles": "text-decoration:\n   none", "Classes": "None", "Text": "\u00a0", "ParentId": "d8dc1f93-2d37-478f-960e-53b45dd7c071"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><s><span lang=\"EN-GB\"><span style=\"text-decoration:\n   none\">\u00a0</span></span></s></p>", "ID": "06203dd2-8ca6-4a5f-8f23-47f92d3b45d4", "Styles": "text-align:center;page-break-after:\n  avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "dae033dc-2179-42d7-91de-6a87c71b1880"}, {"Element": "<s><span lang=\"EN-GB\"><span style=\"text-decoration:\n   none\">\u00a0</span></span></s>", "ID": "a1adfadb-80e4-4cbb-b844-dc27c414c832", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "06203dd2-8ca6-4a5f-8f23-47f92d3b45d4"}, {"Element": "<span lang=\"EN-GB\"><span style=\"text-decoration:\n   none\">\u00a0</span></span>", "ID": "d7ecf114-860f-491e-ade2-f5d0b22ffae1", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a1adfadb-80e4-4cbb-b844-dc27c414c832"}, {"Element": "<span style=\"text-decoration:\n   none\">\u00a0</span>", "ID": "cba3356a-1f31-44a2-942f-4286b3d34d17", "Styles": "text-decoration:\n   none", "Classes": "None", "Text": "\u00a0", "ParentId": "d7ecf114-860f-491e-ade2-f5d0b22ffae1"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">168 (41.8%)</span></p>", "ID": "572e7526-95e5-4389-ac3f-db9348e715cb", "Styles": "text-align:center;page-break-after:\n  avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "dae033dc-2179-42d7-91de-6a87c71b1880"}, {"Element": "<span lang=\"EN-GB\">168 (41.8%)</span>", "ID": "16680eb0-3ec1-4245-8ef7-6f255a4d79f7", "Styles": "None", "Classes": "None", "Text": "168 (41.8%)", "ParentId": "572e7526-95e5-4389-ac3f-db9348e715cb"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">56.5</span></p>", "ID": "660e8b12-0125-4095-85ec-f0f3ede34e3f", "Styles": "text-align:center;page-break-after:\n  avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "dae033dc-2179-42d7-91de-6a87c71b1880"}, {"Element": "<span lang=\"EN-GB\">56.5</span>", "ID": "d7d02f28-4ab9-4aa9-81b9-91a6e703621d", "Styles": "None", "Classes": "None", "Text": "56.5", "ParentId": "660e8b12-0125-4095-85ec-f0f3ede34e3f"}, {"Element": "<td style=\"width:63.75pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><s><span lang=\"EN-GB\"><span style=\"text-decoration:\n   none\">\u00a0</span></span></s></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">0.68</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">[0.56;0.84]</span></p>\n</td>", "ID": "8944af73-1850-42a7-86ba-dc36bf393172", "Styles": "width:63.75pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "      ", "ParentId": "17489535-8aa3-483a-b5cb-2736adcc75d7"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><s><span lang=\"EN-GB\"><span style=\"text-decoration:\n   none\">\u00a0</span></span></s></p>", "ID": "05ffc125-13a8-42f4-80da-abddd66e6465", "Styles": "text-align:center;page-break-after:\n  avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8944af73-1850-42a7-86ba-dc36bf393172"}, {"Element": "<s><span lang=\"EN-GB\"><span style=\"text-decoration:\n   none\">\u00a0</span></span></s>", "ID": "0dc88ed2-4dce-49ed-8f4f-5c6e0fd6cdd4", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "05ffc125-13a8-42f4-80da-abddd66e6465"}, {"Element": "<span lang=\"EN-GB\"><span style=\"text-decoration:\n   none\">\u00a0</span></span>", "ID": "bb65a0ff-bc91-4d9e-a936-3a152c388d0e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "0dc88ed2-4dce-49ed-8f4f-5c6e0fd6cdd4"}, {"Element": "<span style=\"text-decoration:\n   none\">\u00a0</span>", "ID": "5416b109-cc1a-4ba8-8e02-d746805d5145", "Styles": "text-decoration:\n   none", "Classes": "None", "Text": "\u00a0", "ParentId": "bb65a0ff-bc91-4d9e-a936-3a152c388d0e"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3a2fecc4-6257-4432-8d3f-73a065ba2fee", "Styles": "text-align:center;page-break-after:\n  avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8944af73-1850-42a7-86ba-dc36bf393172"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a2a0dca5-99b7-4938-bdf6-7e807bc10d01", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3a2fecc4-6257-4432-8d3f-73a065ba2fee"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f302b0bf-e7c0-4ea4-8e55-a70c67bd26b5", "Styles": "text-align:center;page-break-after:\n  avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8944af73-1850-42a7-86ba-dc36bf393172"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ee35b3eb-87d9-432b-a4c3-226f6a25e12d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f302b0bf-e7c0-4ea4-8e55-a70c67bd26b5"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">0.68</span></p>", "ID": "4299a7e8-8271-4074-b3fb-11ede9f94e5b", "Styles": "text-align:center;page-break-after:\n  avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8944af73-1850-42a7-86ba-dc36bf393172"}, {"Element": "<span lang=\"EN-GB\">0.68</span>", "ID": "1ad53b29-28d8-45e2-aef2-9e4e7acf80bd", "Styles": "None", "Classes": "None", "Text": "0.68", "ParentId": "4299a7e8-8271-4074-b3fb-11ede9f94e5b"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">[0.56;0.84]</span></p>", "ID": "270abe17-06e4-4407-86d3-2e0398e1fa86", "Styles": "text-align:center;page-break-after:\n  avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8944af73-1850-42a7-86ba-dc36bf393172"}, {"Element": "<span lang=\"EN-GB\">[0.56;0.84]</span>", "ID": "51edaa76-a6db-48cd-92e1-395d27b7b9a9", "Styles": "None", "Classes": "None", "Text": "[0.56;0.84]", "ParentId": "270abe17-06e4-4407-86d3-2e0398e1fa86"}, {"Element": "<td style=\"width:70.9pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"95\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><s><span lang=\"EN-GB\"><span style=\"text-decoration:\n   none\">\u00a0</span></span></s></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><s><span lang=\"EN-GB\"><span style=\"text-decoration:\n   none\">\u00a0</span></span></s></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><s><span lang=\"EN-GB\"><span style=\"text-decoration:\n   none\">\u00a0</span></span></s></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">0.0002</span></p>\n</td>", "ID": "7c7c3b36-26b4-4cd4-a8c7-a0ab5f2828ab", "Styles": "width:70.9pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "17489535-8aa3-483a-b5cb-2736adcc75d7"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><s><span lang=\"EN-GB\"><span style=\"text-decoration:\n   none\">\u00a0</span></span></s></p>", "ID": "3298db57-d527-45fc-9496-a3a04ddc95e7", "Styles": "text-align:center;page-break-after:\n  avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7c7c3b36-26b4-4cd4-a8c7-a0ab5f2828ab"}, {"Element": "<s><span lang=\"EN-GB\"><span style=\"text-decoration:\n   none\">\u00a0</span></span></s>", "ID": "884d8bfb-caba-4b1c-9181-04891aa438df", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3298db57-d527-45fc-9496-a3a04ddc95e7"}, {"Element": "<span lang=\"EN-GB\"><span style=\"text-decoration:\n   none\">\u00a0</span></span>", "ID": "6ac0c60d-e1f1-42ea-bdd3-6cee4bd7fbf1", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "884d8bfb-caba-4b1c-9181-04891aa438df"}, {"Element": "<span style=\"text-decoration:\n   none\">\u00a0</span>", "ID": "3c9bd3e5-0f6c-4aa4-9cdd-674b68625d90", "Styles": "text-decoration:\n   none", "Classes": "None", "Text": "\u00a0", "ParentId": "6ac0c60d-e1f1-42ea-bdd3-6cee4bd7fbf1"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><s><span lang=\"EN-GB\"><span style=\"text-decoration:\n   none\">\u00a0</span></span></s></p>", "ID": "348bad05-0508-4a7e-95ba-a43eba7012ee", "Styles": "text-align:center;page-break-after:\n  avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7c7c3b36-26b4-4cd4-a8c7-a0ab5f2828ab"}, {"Element": "<s><span lang=\"EN-GB\"><span style=\"text-decoration:\n   none\">\u00a0</span></span></s>", "ID": "bbcecb1d-ce1e-4448-9885-3fd65dd84121", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "348bad05-0508-4a7e-95ba-a43eba7012ee"}, {"Element": "<span lang=\"EN-GB\"><span style=\"text-decoration:\n   none\">\u00a0</span></span>", "ID": "747bcb76-abdd-4830-a88b-2f449ebf1562", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "bbcecb1d-ce1e-4448-9885-3fd65dd84121"}, {"Element": "<span style=\"text-decoration:\n   none\">\u00a0</span>", "ID": "5eba45e1-0703-4405-a313-2dba0b8cd803", "Styles": "text-decoration:\n   none", "Classes": "None", "Text": "\u00a0", "ParentId": "747bcb76-abdd-4830-a88b-2f449ebf1562"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><s><span lang=\"EN-GB\"><span style=\"text-decoration:\n   none\">\u00a0</span></span></s></p>", "ID": "efad1f75-9dc6-49ee-9efe-8d68f66250dd", "Styles": "text-align:center;page-break-after:\n  avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7c7c3b36-26b4-4cd4-a8c7-a0ab5f2828ab"}, {"Element": "<s><span lang=\"EN-GB\"><span style=\"text-decoration:\n   none\">\u00a0</span></span></s>", "ID": "bac03282-5e78-47fe-a38f-dac09263a75d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "efad1f75-9dc6-49ee-9efe-8d68f66250dd"}, {"Element": "<span lang=\"EN-GB\"><span style=\"text-decoration:\n   none\">\u00a0</span></span>", "ID": "6f71dafb-4bed-408e-8783-65db5d1401fc", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "bac03282-5e78-47fe-a38f-dac09263a75d"}, {"Element": "<span style=\"text-decoration:\n   none\">\u00a0</span>", "ID": "d09534a0-31d6-47b9-94e9-dee069a6b406", "Styles": "text-decoration:\n   none", "Classes": "None", "Text": "\u00a0", "ParentId": "6f71dafb-4bed-408e-8783-65db5d1401fc"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">0.0002</span></p>", "ID": "fc220668-c28d-4c1e-8f38-1790c4cf46bc", "Styles": "text-align:center;page-break-after:\n  avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7c7c3b36-26b4-4cd4-a8c7-a0ab5f2828ab"}, {"Element": "<span lang=\"EN-GB\">0.0002</span>", "ID": "357a0a5e-34f3-48ad-9528-c4b223f115fc", "Styles": "None", "Classes": "None", "Text": "0.0002", "ParentId": "fc220668-c28d-4c1e-8f38-1790c4cf46bc"}, {"Element": "<tr style=\"height:21.0pt\">\n<td style=\"width:163.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:21.0pt\" valign=\"top\" width=\"217\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">Objective Response Rate (ORR)^ - secondary endpoint</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">no. of patients with measurable disease</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Responders***\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n  </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">95% CI for\n  ORR\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Complete\n  response (CR)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Partial\n  Response (PR)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Stable\n  disease (SD)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Progressive\n  disease (PD)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span></p>\n</td>\n<td style=\"width:70.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:21.0pt\" valign=\"top\" width=\"94\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">336</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">233 (69.3%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">[64.1; 74.2]</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">14 (4.2%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">219 (65.2%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">70 (20.8%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">28 (8.3%)</span></p>\n</td>\n<td style=\"width:70.9pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:21.0pt\" valign=\"top\" width=\"95\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">343</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">275 (80.2%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">[75.6; 84.3]</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">19 (5.5%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">256 (74.6%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">50 (14.6%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">13 (3.8 %)</span></p>\n</td>\n<td style=\"width:63.75pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:21.0pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">Difference in ORR:</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">10.8%</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">[4.2,17.5]</span></p>\n</td>\n<td style=\"width:70.9pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:21.0pt\" valign=\"top\" width=\"95\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">0.0011</span></p>\n</td>\n</tr>", "ID": "30a22ca1-2e83-495e-93c3-820b5557e3d7", "Styles": "height:21.0pt", "Classes": "None", "Text": "      ", "ParentId": "05ef5c17-13d4-4d27-8fc0-92ab9f46a654"}, {"Element": "<td style=\"width:163.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:21.0pt\" valign=\"top\" width=\"217\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">Objective Response Rate (ORR)^ - secondary endpoint</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">no. of patients with measurable disease</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Responders***\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n  </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">95% CI for\n  ORR\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Complete\n  response (CR)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Partial\n  Response (PR)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Stable\n  disease (SD)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Progressive\n  disease (PD)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span></p>\n</td>", "ID": "89e52c80-d153-4a7d-ad7b-1cfffdd97f0b", "Styles": "width:163.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:21.0pt", "Classes": "None", "Text": "         ", "ParentId": "30a22ca1-2e83-495e-93c3-820b5557e3d7"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">Objective Response Rate (ORR)^ - secondary endpoint</span></b></p>", "ID": "5522b038-a160-4ff8-ad87-8abd5d132067", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "89e52c80-d153-4a7d-ad7b-1cfffdd97f0b"}, {"Element": "<b><span lang=\"EN-GB\">Objective Response Rate (ORR)^ - secondary endpoint</span></b>", "ID": "c028e968-903a-4743-be39-5af4070b7b54", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "5522b038-a160-4ff8-ad87-8abd5d132067"}, {"Element": "<span lang=\"EN-GB\">Objective Response Rate (ORR)^ - secondary endpoint</span>", "ID": "a1163f4a-f310-46c3-a94b-b107bf9792af", "Styles": "None", "Classes": "None", "Text": "Objective Response Rate (ORR)^ - secondary endpoint", "ParentId": "c028e968-903a-4743-be39-5af4070b7b54"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">no. of patients with measurable disease</span></p>", "ID": "dc2c99d6-bb03-442d-9936-fceaf1f27f53", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "89e52c80-d153-4a7d-ad7b-1cfffdd97f0b"}, {"Element": "<span lang=\"EN-GB\">no. of patients with measurable disease</span>", "ID": "38c65df0-3aee-42ae-b624-20448809e661", "Styles": "None", "Classes": "None", "Text": "no. of patients with measurable disease", "ParentId": "dc2c99d6-bb03-442d-9936-fceaf1f27f53"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Responders***\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n  </span></p>", "ID": "48cdf4b4-f4d5-4700-b173-8844f64da393", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "89e52c80-d153-4a7d-ad7b-1cfffdd97f0b"}, {"Element": "<span lang=\"EN-GB\">Responders***\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n  </span>", "ID": "08c5dacd-33db-49c6-9da4-81235c74d2bc", "Styles": "None", "Classes": "None", "Text": "Responders***\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0   ", "ParentId": "48cdf4b4-f4d5-4700-b173-8844f64da393"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">95% CI for\n  ORR\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span></p>", "ID": "f9307c80-b3ff-475a-8fca-a7610276fdcc", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "89e52c80-d153-4a7d-ad7b-1cfffdd97f0b"}, {"Element": "<span lang=\"EN-GB\">95% CI for\n  ORR\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span>", "ID": "7c60f88e-3ae3-4751-aef1-f80cd951fe1a", "Styles": "None", "Classes": "None", "Text": "95% CI for   ORR\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "f9307c80-b3ff-475a-8fca-a7610276fdcc"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Complete\n  response (CR)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span></p>", "ID": "fff89dec-15bb-4aa3-8fd3-aa51d76e06c1", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "89e52c80-d153-4a7d-ad7b-1cfffdd97f0b"}, {"Element": "<span lang=\"EN-GB\">Complete\n  response (CR)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span>", "ID": "14b62113-b7d5-4b9e-9940-90624f433aae", "Styles": "None", "Classes": "None", "Text": "Complete   response (CR)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "fff89dec-15bb-4aa3-8fd3-aa51d76e06c1"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Partial\n  Response (PR)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span></p>", "ID": "baba0d8d-a5d8-4ab9-b762-c01c77de4cd7", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "89e52c80-d153-4a7d-ad7b-1cfffdd97f0b"}, {"Element": "<span lang=\"EN-GB\">Partial\n  Response (PR)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span>", "ID": "be4da297-5e64-4742-a2f1-d67ddc1aa98b", "Styles": "None", "Classes": "None", "Text": "Partial   Response (PR)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "baba0d8d-a5d8-4ab9-b762-c01c77de4cd7"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Stable\n  disease (SD)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span></p>", "ID": "8453e59d-4349-48aa-ac7d-6e94d90bb50a", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "89e52c80-d153-4a7d-ad7b-1cfffdd97f0b"}, {"Element": "<span lang=\"EN-GB\">Stable\n  disease (SD)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span>", "ID": "6a6d0775-c96f-4606-acea-5f5bdff4cd08", "Styles": "None", "Classes": "None", "Text": "Stable   disease (SD)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "8453e59d-4349-48aa-ac7d-6e94d90bb50a"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Progressive\n  disease (PD)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span></p>", "ID": "5e182da0-57b3-4655-877e-b1f5e7a0ed89", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "89e52c80-d153-4a7d-ad7b-1cfffdd97f0b"}, {"Element": "<span lang=\"EN-GB\">Progressive\n  disease (PD)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>", "ID": "a2c33ba4-bad9-4935-b454-11078ce17671", "Styles": "None", "Classes": "None", "Text": "Progressive   disease (PD)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0", "ParentId": "5e182da0-57b3-4655-877e-b1f5e7a0ed89"}, {"Element": "<td style=\"width:70.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:21.0pt\" valign=\"top\" width=\"94\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">336</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">233 (69.3%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">[64.1; 74.2]</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">14 (4.2%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">219 (65.2%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">70 (20.8%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">28 (8.3%)</span></p>\n</td>", "ID": "a04bfaf4-9aed-4411-9735-0348a4f19de7", "Styles": "width:70.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:21.0pt", "Classes": "None", "Text": "           ", "ParentId": "30a22ca1-2e83-495e-93c3-820b5557e3d7"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a36af11a-3645-478e-ad83-ae97f446823e", "Styles": "text-align:center;page-break-after:\n  avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a04bfaf4-9aed-4411-9735-0348a4f19de7"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9bb76b4f-c15a-4d8a-9af9-0dbac0e33265", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a36af11a-3645-478e-ad83-ae97f446823e"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "88924313-125e-4522-a16f-e37a42f44ca3", "Styles": "text-align:center;page-break-after:\n  avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a04bfaf4-9aed-4411-9735-0348a4f19de7"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0aef81b7-66e9-435f-8f0f-d60f2fdd6cb8", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "88924313-125e-4522-a16f-e37a42f44ca3"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "76977c91-e21a-4f2a-8a71-e64cb2619193", "Styles": "text-align:center;page-break-after:\n  avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a04bfaf4-9aed-4411-9735-0348a4f19de7"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "fbe508e9-3871-4eb1-8fcc-cb1c871d7b78", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "76977c91-e21a-4f2a-8a71-e64cb2619193"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">336</span></p>", "ID": "6fa6b376-23ba-465a-8de4-01a2609191d1", "Styles": "text-align:center;page-break-after:\n  avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a04bfaf4-9aed-4411-9735-0348a4f19de7"}, {"Element": "<span lang=\"EN-GB\">336</span>", "ID": "465227c1-3dc8-4429-9d5c-04665785654f", "Styles": "None", "Classes": "None", "Text": "336", "ParentId": "6fa6b376-23ba-465a-8de4-01a2609191d1"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">233 (69.3%)</span></p>", "ID": "677eec58-13e7-43a1-a669-bfd0df56735d", "Styles": "text-align:center;page-break-after:\n  avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a04bfaf4-9aed-4411-9735-0348a4f19de7"}, {"Element": "<span lang=\"EN-GB\">233 (69.3%)</span>", "ID": "c23a367a-6ce1-4d51-9c58-40b61f4d088e", "Styles": "None", "Classes": "None", "Text": "233 (69.3%)", "ParentId": "677eec58-13e7-43a1-a669-bfd0df56735d"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">[64.1; 74.2]</span></p>", "ID": "e217e78d-1de8-430b-8554-34844ecd9be8", "Styles": "text-align:center;page-break-after:\n  avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a04bfaf4-9aed-4411-9735-0348a4f19de7"}, {"Element": "<span lang=\"EN-GB\">[64.1; 74.2]</span>", "ID": "f6a029b6-b95a-4716-a7b0-fae56bd3d212", "Styles": "None", "Classes": "None", "Text": "[64.1; 74.2]", "ParentId": "e217e78d-1de8-430b-8554-34844ecd9be8"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">14 (4.2%)</span></p>", "ID": "95aeea8a-2aa2-4f1b-ac4c-3ae2b991dd2c", "Styles": "text-align:center;page-break-after:\n  avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a04bfaf4-9aed-4411-9735-0348a4f19de7"}, {"Element": "<span lang=\"EN-GB\">14 (4.2%)</span>", "ID": "60bbbf0c-b40f-4327-b14f-66d04b2499a4", "Styles": "None", "Classes": "None", "Text": "14 (4.2%)", "ParentId": "95aeea8a-2aa2-4f1b-ac4c-3ae2b991dd2c"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">219 (65.2%)</span></p>", "ID": "e449546e-3b40-4dee-9c41-d4d4d72b29df", "Styles": "text-align:center;page-break-after:\n  avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a04bfaf4-9aed-4411-9735-0348a4f19de7"}, {"Element": "<span lang=\"EN-GB\">219 (65.2%)</span>", "ID": "3811980b-4e01-43af-9e92-9c6f74e0468d", "Styles": "None", "Classes": "None", "Text": "219 (65.2%)", "ParentId": "e449546e-3b40-4dee-9c41-d4d4d72b29df"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">70 (20.8%)</span></p>", "ID": "0229a53a-c30e-416b-9d95-be0365432a25", "Styles": "text-align:center;page-break-after:\n  avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a04bfaf4-9aed-4411-9735-0348a4f19de7"}, {"Element": "<span lang=\"EN-GB\">70 (20.8%)</span>", "ID": "ce0353e9-fe68-4fde-a9de-cf908197c89d", "Styles": "None", "Classes": "None", "Text": "70 (20.8%)", "ParentId": "0229a53a-c30e-416b-9d95-be0365432a25"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">28 (8.3%)</span></p>", "ID": "b7c30ca6-8312-48c7-bfaa-c40304d57f61", "Styles": "text-align:center;page-break-after:\n  avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a04bfaf4-9aed-4411-9735-0348a4f19de7"}, {"Element": "<span lang=\"EN-GB\">28 (8.3%)</span>", "ID": "64c3739e-0e85-4e32-be1e-774657f3dacc", "Styles": "None", "Classes": "None", "Text": "28 (8.3%)", "ParentId": "b7c30ca6-8312-48c7-bfaa-c40304d57f61"}, {"Element": "<td style=\"width:70.9pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:21.0pt\" valign=\"top\" width=\"95\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">343</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">275 (80.2%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">[75.6; 84.3]</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">19 (5.5%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">256 (74.6%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">50 (14.6%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">13 (3.8 %)</span></p>\n</td>", "ID": "0633cc4d-bc11-403f-8230-582fe2d8408e", "Styles": "width:70.9pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:21.0pt", "Classes": "None", "Text": "           ", "ParentId": "30a22ca1-2e83-495e-93c3-820b5557e3d7"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b2d6dec0-0788-4f6b-b717-829de4f7f692", "Styles": "text-align:center;page-break-after:\n  avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0633cc4d-bc11-403f-8230-582fe2d8408e"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e87141b9-f1e3-435c-aaec-c96d3092defe", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b2d6dec0-0788-4f6b-b717-829de4f7f692"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f702cfd7-489f-4f72-b285-0c2aa937b9b7", "Styles": "text-align:center;page-break-after:\n  avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0633cc4d-bc11-403f-8230-582fe2d8408e"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "fb5b9261-3b62-449a-99cc-87818064b680", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f702cfd7-489f-4f72-b285-0c2aa937b9b7"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4a7427d7-a2b5-4020-8ea2-e0df819991d4", "Styles": "text-align:center;page-break-after:\n  avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0633cc4d-bc11-403f-8230-582fe2d8408e"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "de2a0043-8459-451e-86d3-85df2f111a4c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4a7427d7-a2b5-4020-8ea2-e0df819991d4"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">343</span></p>", "ID": "529f47c6-1e13-47ac-8e1e-2c0f5ef6b645", "Styles": "text-align:center;page-break-after:\n  avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0633cc4d-bc11-403f-8230-582fe2d8408e"}, {"Element": "<span lang=\"EN-GB\">343</span>", "ID": "50d3272a-1c4c-4680-b23d-deefed7a03a0", "Styles": "None", "Classes": "None", "Text": "343", "ParentId": "529f47c6-1e13-47ac-8e1e-2c0f5ef6b645"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">275 (80.2%)</span></p>", "ID": "673806bb-0b6e-4bef-8a0c-6f9ad42d4571", "Styles": "text-align:center;page-break-after:\n  avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0633cc4d-bc11-403f-8230-582fe2d8408e"}, {"Element": "<span lang=\"EN-GB\">275 (80.2%)</span>", "ID": "6c1959f8-96ec-4bf9-b643-134608e61fa4", "Styles": "None", "Classes": "None", "Text": "275 (80.2%)", "ParentId": "673806bb-0b6e-4bef-8a0c-6f9ad42d4571"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">[75.6; 84.3]</span></p>", "ID": "8f3acc9c-a921-4e44-be02-5a148baf3e6e", "Styles": "text-align:center;page-break-after:\n  avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0633cc4d-bc11-403f-8230-582fe2d8408e"}, {"Element": "<span lang=\"EN-GB\">[75.6; 84.3]</span>", "ID": "ab9904ad-6f78-4d70-a92e-4c10c083b166", "Styles": "None", "Classes": "None", "Text": "[75.6; 84.3]", "ParentId": "8f3acc9c-a921-4e44-be02-5a148baf3e6e"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">19 (5.5%)</span></p>", "ID": "835a95dc-8589-44e4-b7b3-76850b92b370", "Styles": "text-align:center;page-break-after:\n  avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0633cc4d-bc11-403f-8230-582fe2d8408e"}, {"Element": "<span lang=\"EN-GB\">19 (5.5%)</span>", "ID": "a91c80af-c909-41eb-8973-aa324146abc9", "Styles": "None", "Classes": "None", "Text": "19 (5.5%)", "ParentId": "835a95dc-8589-44e4-b7b3-76850b92b370"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">256 (74.6%)</span></p>", "ID": "d9c69127-8627-4bcb-9336-370943ec3cce", "Styles": "text-align:center;page-break-after:\n  avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0633cc4d-bc11-403f-8230-582fe2d8408e"}, {"Element": "<span lang=\"EN-GB\">256 (74.6%)</span>", "ID": "aedf7fad-ca16-4428-8a06-932dffe6da0a", "Styles": "None", "Classes": "None", "Text": "256 (74.6%)", "ParentId": "d9c69127-8627-4bcb-9336-370943ec3cce"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">50 (14.6%)</span></p>", "ID": "9530a76e-d5cc-4a57-a418-3a60392b4b4e", "Styles": "text-align:center;page-break-after:\n  avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0633cc4d-bc11-403f-8230-582fe2d8408e"}, {"Element": "<span lang=\"EN-GB\">50 (14.6%)</span>", "ID": "7fe3d3de-37ba-44ce-9e49-6e724d84c310", "Styles": "None", "Classes": "None", "Text": "50 (14.6%)", "ParentId": "9530a76e-d5cc-4a57-a418-3a60392b4b4e"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">13 (3.8 %)</span></p>", "ID": "e3b13289-7933-457e-b6e0-35525f007f1c", "Styles": "text-align:center;page-break-after:\n  avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0633cc4d-bc11-403f-8230-582fe2d8408e"}, {"Element": "<span lang=\"EN-GB\">13 (3.8 %)</span>", "ID": "53c8453c-010b-44d8-88d2-9a6e91466c5b", "Styles": "None", "Classes": "None", "Text": "13 (3.8 %)", "ParentId": "e3b13289-7933-457e-b6e0-35525f007f1c"}, {"Element": "<td style=\"width:63.75pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:21.0pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">Difference in ORR:</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">10.8%</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">[4.2,17.5]</span></p>\n</td>", "ID": "66d9f093-7153-483f-8f65-aa8a971a86e0", "Styles": "width:63.75pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:21.0pt", "Classes": "None", "Text": "       ", "ParentId": "30a22ca1-2e83-495e-93c3-820b5557e3d7"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d6d30e69-87d8-40c9-a4ef-a2388cecae75", "Styles": "text-align:center;page-break-after:\n  avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "66d9f093-7153-483f-8f65-aa8a971a86e0"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "182ae952-c01a-4bfc-a372-0a8e58a4709c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d6d30e69-87d8-40c9-a4ef-a2388cecae75"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "971be390-95a9-4467-b887-fadcbdf46f33", "Styles": "text-align:center;page-break-after:\n  avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "66d9f093-7153-483f-8f65-aa8a971a86e0"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2a154828-cf4c-42af-bd73-4b6555d1a56a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "971be390-95a9-4467-b887-fadcbdf46f33"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2bcfaadb-db6b-48ca-a828-09f947cacd73", "Styles": "text-align:center;page-break-after:\n  avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "66d9f093-7153-483f-8f65-aa8a971a86e0"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "13557fca-2a74-4177-b0d0-a6575dc51ce0", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2bcfaadb-db6b-48ca-a828-09f947cacd73"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">Difference in ORR:</span></p>", "ID": "cde91818-9d8e-4323-ad58-bad1edb4d2b0", "Styles": "text-align:center;page-break-after:\n  avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "66d9f093-7153-483f-8f65-aa8a971a86e0"}, {"Element": "<span lang=\"EN-GB\">Difference in ORR:</span>", "ID": "8b387813-34d4-4105-9fd9-e7487d00e59d", "Styles": "None", "Classes": "None", "Text": "Difference in ORR:", "ParentId": "cde91818-9d8e-4323-ad58-bad1edb4d2b0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">10.8%</span></p>", "ID": "f77e0b2b-911b-4edc-b5ee-498f357537cd", "Styles": "text-align:center;page-break-after:\n  avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "66d9f093-7153-483f-8f65-aa8a971a86e0"}, {"Element": "<span lang=\"EN-GB\">10.8%</span>", "ID": "53b94eed-a61c-46e8-bcae-29a176dccbbc", "Styles": "None", "Classes": "None", "Text": "10.8%", "ParentId": "f77e0b2b-911b-4edc-b5ee-498f357537cd"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">[4.2,17.5]</span></p>", "ID": "47b4627b-9a46-49c0-9054-e129d8cd0515", "Styles": "text-align:center;page-break-after:\n  avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "66d9f093-7153-483f-8f65-aa8a971a86e0"}, {"Element": "<span lang=\"EN-GB\">[4.2,17.5]</span>", "ID": "593e2ea2-b88a-4599-9c01-541a027a3f68", "Styles": "None", "Classes": "None", "Text": "[4.2,17.5]", "ParentId": "47b4627b-9a46-49c0-9054-e129d8cd0515"}, {"Element": "<td style=\"width:70.9pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:21.0pt\" valign=\"top\" width=\"95\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">0.0011</span></p>\n</td>", "ID": "2b3e1e6a-2b8d-4b59-acd7-1c5e249936fb", "Styles": "width:70.9pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:21.0pt", "Classes": "None", "Text": "     ", "ParentId": "30a22ca1-2e83-495e-93c3-820b5557e3d7"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7b71ff08-8504-4b3b-8799-9b098ef3397e", "Styles": "text-align:center;page-break-after:\n  avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "2b3e1e6a-2b8d-4b59-acd7-1c5e249936fb"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c27e1ac2-e352-4002-9d1e-0b9d42a105ff", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7b71ff08-8504-4b3b-8799-9b098ef3397e"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2a49af6c-4841-4970-a458-55379d7c39d5", "Styles": "text-align:center;page-break-after:\n  avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "2b3e1e6a-2b8d-4b59-acd7-1c5e249936fb"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "57ede209-2ad7-429d-815f-b51573459ab3", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2a49af6c-4841-4970-a458-55379d7c39d5"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "00cc4dec-79b8-4f28-8520-51fd49daf229", "Styles": "text-align:center;page-break-after:\n  avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "2b3e1e6a-2b8d-4b59-acd7-1c5e249936fb"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "72c3b864-e404-4b61-a55b-8de72a130928", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "00cc4dec-79b8-4f28-8520-51fd49daf229"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid;text-autospace:none\"><span lang=\"EN-GB\">0.0011</span></p>", "ID": "1031ad7e-2450-4621-ab62-9f96a1ce480c", "Styles": "text-align:center;page-break-after:\n  avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "2b3e1e6a-2b8d-4b59-acd7-1c5e249936fb"}, {"Element": "<span lang=\"EN-GB\">0.0011</span>", "ID": "6cae2012-6f71-47c7-aa04-33842542776b", "Styles": "None", "Classes": "None", "Text": "0.0011", "ParentId": "1031ad7e-2450-4621-ab62-9f96a1ce480c"}, {"Element": "<tr>\n<td style=\"width:163.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"217\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><b><span lang=\"EN-GB\">Duration\n  of Response </span></b><span lang=\"EN-GB\">\u2020<b>^</b></span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">n=</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Median weeks </span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">95% CI for\n  Median</span></p>\n</td>\n<td style=\"width:70.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"94\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-autospace:none\"><span lang=\"EN-GB\">233</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-autospace:none\"><span lang=\"EN-GB\">54.1</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-autospace:none\"><span lang=\"EN-GB\">[46;64]</span></p>\n</td>\n<td style=\"width:70.9pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"95\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-autospace:none\"><span lang=\"EN-GB\">275</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-autospace:none\"><span lang=\"EN-GB\">87.6</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-autospace:none\"><span lang=\"EN-GB\">[71;106]</span></p>\n</td>\n<td style=\"width:63.75pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:70.9pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"95\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "c19a5e88-2970-4b3d-bf1b-80f8d11ce294", "Styles": "None", "Classes": "None", "Text": "      ", "ParentId": "05ef5c17-13d4-4d27-8fc0-92ab9f46a654"}, {"Element": "<td style=\"width:163.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"217\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><b><span lang=\"EN-GB\">Duration\n  of Response </span></b><span lang=\"EN-GB\">\u2020<b>^</b></span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">n=</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Median weeks </span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">95% CI for\n  Median</span></p>\n</td>", "ID": "fdbdbe50-e0ba-4c3d-94e0-1f4780453468", "Styles": "width:163.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "c19a5e88-2970-4b3d-bf1b-80f8d11ce294"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><b><span lang=\"EN-GB\">Duration\n  of Response </span></b><span lang=\"EN-GB\">\u2020<b>^</b></span></p>", "ID": "706635ba-6b89-4bc8-a031-cfdd06f1aa93", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "fdbdbe50-e0ba-4c3d-94e0-1f4780453468"}, {"Element": "<b><span lang=\"EN-GB\">Duration\n  of Response </span></b>", "ID": "4d082353-3615-4ff6-abca-c524f2f0179e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "706635ba-6b89-4bc8-a031-cfdd06f1aa93"}, {"Element": "<span lang=\"EN-GB\">Duration\n  of Response </span>", "ID": "324a09ac-236d-4f77-a4c2-b6a3d0044ae9", "Styles": "None", "Classes": "None", "Text": "Duration   of Response ", "ParentId": "4d082353-3615-4ff6-abca-c524f2f0179e"}, {"Element": "<span lang=\"EN-GB\">\u2020<b>^</b></span>", "ID": "7846a984-64cc-4bdb-943e-2e4c2f2d3040", "Styles": "None", "Classes": "None", "Text": "\u2020", "ParentId": "706635ba-6b89-4bc8-a031-cfdd06f1aa93"}, {"Element": "<b>^</b>", "ID": "ed09a740-7f83-4558-8d8b-1f8261103e86", "Styles": "None", "Classes": "None", "Text": "^", "ParentId": "7846a984-64cc-4bdb-943e-2e4c2f2d3040"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">n=</span></p>", "ID": "4f0023bc-6f73-4c3f-bac3-d7e2f373eb24", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "fdbdbe50-e0ba-4c3d-94e0-1f4780453468"}, {"Element": "<span lang=\"EN-GB\">n=</span>", "ID": "e0f9c7cf-063f-455b-b2f4-d63d9a295ecf", "Styles": "None", "Classes": "None", "Text": "n=", "ParentId": "4f0023bc-6f73-4c3f-bac3-d7e2f373eb24"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Median weeks </span></p>", "ID": "38374e66-d333-40df-ba5a-0cb5e76d169c", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "fdbdbe50-e0ba-4c3d-94e0-1f4780453468"}, {"Element": "<span lang=\"EN-GB\">Median weeks </span>", "ID": "1599fd57-6dae-423b-8420-ae696817c881", "Styles": "None", "Classes": "None", "Text": "Median weeks ", "ParentId": "38374e66-d333-40df-ba5a-0cb5e76d169c"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">95% CI for\n  Median</span></p>", "ID": "f330faeb-2489-42d1-97c3-804e72e5e512", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "fdbdbe50-e0ba-4c3d-94e0-1f4780453468"}, {"Element": "<span lang=\"EN-GB\">95% CI for\n  Median</span>", "ID": "d9a8c822-b6d1-434e-a950-e689cfb900d6", "Styles": "None", "Classes": "None", "Text": "95% CI for   Median", "ParentId": "f330faeb-2489-42d1-97c3-804e72e5e512"}, {"Element": "<td style=\"width:70.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"94\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-autospace:none\"><span lang=\"EN-GB\">233</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-autospace:none\"><span lang=\"EN-GB\">54.1</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-autospace:none\"><span lang=\"EN-GB\">[46;64]</span></p>\n</td>", "ID": "4314541e-4637-4767-b88c-58033d6837a2", "Styles": "width:70.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "c19a5e88-2970-4b3d-bf1b-80f8d11ce294"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "28abdad0-11ec-436a-84ae-2a777a124b19", "Styles": "text-align:center;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4314541e-4637-4767-b88c-58033d6837a2"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3f0ab9c0-b193-4227-83fb-1efe2afbab91", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "28abdad0-11ec-436a-84ae-2a777a124b19"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-autospace:none\"><span lang=\"EN-GB\">233</span></p>", "ID": "dff0bcd2-e8ba-4764-b1be-2172e2a3231c", "Styles": "text-align:center;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4314541e-4637-4767-b88c-58033d6837a2"}, {"Element": "<span lang=\"EN-GB\">233</span>", "ID": "1b3e9a39-29f1-470a-b491-d6aafff3d21a", "Styles": "None", "Classes": "None", "Text": "233", "ParentId": "dff0bcd2-e8ba-4764-b1be-2172e2a3231c"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-autospace:none\"><span lang=\"EN-GB\">54.1</span></p>", "ID": "4574cb88-1226-4aec-ab25-e5cc17da6066", "Styles": "text-align:center;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4314541e-4637-4767-b88c-58033d6837a2"}, {"Element": "<span lang=\"EN-GB\">54.1</span>", "ID": "0a829ffa-6d2f-4005-ac1a-7e79a41ff9a1", "Styles": "None", "Classes": "None", "Text": "54.1", "ParentId": "4574cb88-1226-4aec-ab25-e5cc17da6066"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-autospace:none\"><span lang=\"EN-GB\">[46;64]</span></p>", "ID": "5d3c822d-209b-4117-a8cb-7f18fd1f957b", "Styles": "text-align:center;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4314541e-4637-4767-b88c-58033d6837a2"}, {"Element": "<span lang=\"EN-GB\">[46;64]</span>", "ID": "ac64ad9e-a781-45b4-8dc8-65f68ce7126e", "Styles": "None", "Classes": "None", "Text": "[46;64]", "ParentId": "5d3c822d-209b-4117-a8cb-7f18fd1f957b"}, {"Element": "<td style=\"width:70.9pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"95\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-autospace:none\"><span lang=\"EN-GB\">275</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-autospace:none\"><span lang=\"EN-GB\">87.6</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-autospace:none\"><span lang=\"EN-GB\">[71;106]</span></p>\n</td>", "ID": "ab36f262-254d-46a0-9ff7-ffc36353831c", "Styles": "width:70.9pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "c19a5e88-2970-4b3d-bf1b-80f8d11ce294"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e53d9a96-3b1e-40be-9892-b8d4706e447a", "Styles": "text-align:center;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ab36f262-254d-46a0-9ff7-ffc36353831c"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d3ce9adc-f334-4de4-ab31-aff87b6ae485", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e53d9a96-3b1e-40be-9892-b8d4706e447a"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-autospace:none\"><span lang=\"EN-GB\">275</span></p>", "ID": "71f7d120-5c47-4a79-aabd-03487867f879", "Styles": "text-align:center;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ab36f262-254d-46a0-9ff7-ffc36353831c"}, {"Element": "<span lang=\"EN-GB\">275</span>", "ID": "518b66a1-88cb-4a9a-bc32-e8219999714c", "Styles": "None", "Classes": "None", "Text": "275", "ParentId": "71f7d120-5c47-4a79-aabd-03487867f879"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-autospace:none\"><span lang=\"EN-GB\">87.6</span></p>", "ID": "44fb8626-e62b-4480-a8b7-41b4c602e66f", "Styles": "text-align:center;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ab36f262-254d-46a0-9ff7-ffc36353831c"}, {"Element": "<span lang=\"EN-GB\">87.6</span>", "ID": "d6fefe84-6603-4dff-9861-3ae8515f6a8d", "Styles": "None", "Classes": "None", "Text": "87.6", "ParentId": "44fb8626-e62b-4480-a8b7-41b4c602e66f"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-autospace:none\"><span lang=\"EN-GB\">[71;106]</span></p>", "ID": "7e1f91a5-c7c5-4ef2-b92c-bbfeff6906b7", "Styles": "text-align:center;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ab36f262-254d-46a0-9ff7-ffc36353831c"}, {"Element": "<span lang=\"EN-GB\">[71;106]</span>", "ID": "3a09da1b-faa8-4c84-b12a-9711b59202fc", "Styles": "None", "Classes": "None", "Text": "[71;106]", "ParentId": "7e1f91a5-c7c5-4ef2-b92c-bbfeff6906b7"}, {"Element": "<td style=\"width:63.75pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "68d659e2-f3b5-48dc-8061-e68e80687202", "Styles": "width:63.75pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "c19a5e88-2970-4b3d-bf1b-80f8d11ce294"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a53cc4ee-e187-4f22-948b-35d5d7d5d015", "Styles": "text-align:center;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "68d659e2-f3b5-48dc-8061-e68e80687202"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "70f8d52c-bf8e-40bb-ab49-8b7cf75706e8", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a53cc4ee-e187-4f22-948b-35d5d7d5d015"}, {"Element": "<td style=\"width:70.9pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"95\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "6fe8088c-2e7a-4ed9-a64e-17ae6e2b33b2", "Styles": "width:70.9pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "c19a5e88-2970-4b3d-bf1b-80f8d11ce294"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ab02c1bc-d14c-49e1-98d0-f396728bea22", "Styles": "text-align:center;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "6fe8088c-2e7a-4ed9-a64e-17ae6e2b33b2"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "054415c5-f41f-4ceb-9e8e-cacc19263d2e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ab02c1bc-d14c-49e1-98d0-f396728bea22"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:9.0pt;text-indent:-9.0pt\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">* Primary progression-free survival\nanalysis, cutoff date 13<sup>th</sup> May 2011.</span></p>", "ID": "b3f484b2-3f64-4baa-8663-fe4c55117da7", "Styles": "margin-left:9.0pt;text-indent:-9.0pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">* Primary progression-free survival\nanalysis, cutoff date 13<sup>th</sup> May 2011.</span>", "ID": "c7896131-4178-40b9-b0a2-54b62786c250", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "* Primary progression-free survival analysis, cutoff date 13 May 2011.", "ParentId": "b3f484b2-3f64-4baa-8663-fe4c55117da7"}, {"Element": "<sup>th</sup>", "ID": "f7d7871e-ca2f-444a-8e14-d40e81bab1a3", "Styles": "None", "Classes": "None", "Text": "th", "ParentId": "c7896131-4178-40b9-b0a2-54b62786c250"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:9.0pt;text-indent:-9.0pt\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">**</span><span lang=\"EN-GB\" style=\"font-size:\n10.0pt\"> Event-driven final overall survival analysis, cutoff date 11<sup>th</sup>\nFebruary 2014.</span></p>", "ID": "8f182088-5288-4463-8f56-f7147797ad70", "Styles": "margin-left:9.0pt;text-indent:-9.0pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">**</span>", "ID": "b6f444ca-1587-4611-acd8-c5391130f9f8", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "**", "ParentId": "8f182088-5288-4463-8f56-f7147797ad70"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:\n10.0pt\"> Event-driven final overall survival analysis, cutoff date 11<sup>th</sup>\nFebruary 2014.</span>", "ID": "8dbbbe5a-68cc-4930-bc23-cb5ea8a925a0", "Styles": "font-size:\n10.0pt", "Classes": "None", "Text": " Event-driven final overall survival analysis, cutoff date 11 February 2014.", "ParentId": "8f182088-5288-4463-8f56-f7147797ad70"}, {"Element": "<sup>th</sup>", "ID": "1317c8ce-c9b8-4c75-b441-a4a1c299e187", "Styles": "None", "Classes": "None", "Text": "th", "ParentId": "8dbbbe5a-68cc-4930-bc23-cb5ea8a925a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">*** Patients with\nbest overall response of confirmed CR or PR by RECIST.</span></p>", "ID": "9b85ae18-417f-45e8-9bf3-123186918617", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">*** Patients with\nbest overall response of confirmed CR or PR by RECIST.</span>", "ID": "f2a15919-38a4-499c-9263-5aef4805bea1", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "*** Patients with best overall response of confirmed CR or PR by RECIST.", "ParentId": "9b85ae18-417f-45e8-9bf3-123186918617"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u2020 Evaluated in\npatients with Best Overall Response of CR or PR</span><span lang=\"EN-GB\" style=\"font-size:10.0pt\">.</span></p>", "ID": "0264a734-d1d4-41f7-9919-c78abc62988a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u2020 Evaluated in\npatients with Best Overall Response of CR or PR</span>", "ID": "cb90ed05-a2da-4d82-a7ca-c59f7f94bd5a", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u2020 Evaluated in patients with Best Overall Response of CR or PR", "ParentId": "0264a734-d1d4-41f7-9919-c78abc62988a"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">.</span>", "ID": "b8414501-47ab-4acb-8641-2debebf65ecc", "Styles": "font-size:10.0pt", "Classes": "None", "Text": ".", "ParentId": "0264a734-d1d4-41f7-9919-c78abc62988a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">^ Objective\nresponse rate and duration of response are based on IRF-assessed tumour\nassessments</span><span lang=\"EN-GB\" style=\"font-size:10.0pt\">.</span></p>", "ID": "105c96a9-c51b-401b-b10a-296bb0813fd4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">^ Objective\nresponse rate and duration of response are based on IRF-assessed tumour\nassessments</span>", "ID": "b52068fe-4422-4d79-a5f0-08b1f253a676", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "^ Objective response rate and duration of response are based on IRF-assessed tumour assessments", "ParentId": "105c96a9-c51b-401b-b10a-296bb0813fd4"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">.</span>", "ID": "168a64c9-1c86-4772-9280-964d0f1bfa34", "Styles": "font-size:10.0pt", "Classes": "None", "Text": ".", "ParentId": "105c96a9-c51b-401b-b10a-296bb0813fd4"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "77ebf463-c427-49ab-ae56-b148fc696a32", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "52fa5571-9334-404c-a3d2-c782baceae82", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "77ebf463-c427-49ab-ae56-b148fc696a32"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Consistent results were observed across\npre-specified patient subgroups including the subgroups based on stratification\nfactors of geographic region and prior adjuvant/neoadjuvant therapy or de novo\nmetastatic breast cancer (see Figure 1). A post hoc exploratory analysis\nrevealed that for patients who had received prior trastuzumab (n = 88), the\nhazard ratio for IRF-assessed PFS was 0.62 (95% CI 0.35, 1.07), compared with\n0.60 (95% CI 0.43, 0.83) for patients who had received prior therapy which did\nnot include trastuzumab (n = 288).</span></p>", "ID": "4449598b-f619-4fdf-ab95-7f5a6065b5d2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Consistent results were observed across\npre-specified patient subgroups including the subgroups based on stratification\nfactors of geographic region and prior adjuvant/neoadjuvant therapy or de novo\nmetastatic breast cancer (see Figure 1). A post hoc exploratory analysis\nrevealed that for patients who had received prior trastuzumab (n = 88), the\nhazard ratio for IRF-assessed PFS was 0.62 (95% CI 0.35, 1.07), compared with\n0.60 (95% CI 0.43, 0.83) for patients who had received prior therapy which did\nnot include trastuzumab (n = 288).</span>", "ID": "dbb531ac-c0bf-4c3b-981e-f5ed8e9aee77", "Styles": "None", "Classes": "None", "Text": "Consistent results were observed across pre-specified patient subgroups including the subgroups based on stratification factors of geographic region and prior adjuvant/neoadjuvant therapy or de novo metastatic breast cancer (see Figure 1). A post hoc exploratory analysis revealed that for patients who had received prior trastuzumab (n = 88), the hazard ratio for IRF-assessed PFS was 0.62 (95% CI 0.35, 1.07), compared with 0.60 (95% CI 0.43, 0.83) for patients who had received prior therapy which did not include trastuzumab (n = 288).", "ParentId": "4449598b-f619-4fdf-ab95-7f5a6065b5d2"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "dd93ee98-9017-42ae-b4bc-eec05aafcf8f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0b37b33a-1f09-4342-a028-1b815d87221e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "dd93ee98-9017-42ae-b4bc-eec05aafcf8f"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.75in;text-indent:-.75in;page-break-after:\navoid\"><b><span lang=\"EN-GB\">Figure 1\u00a0\u00a0\u00a0\u00a0 IRF-assessed PFS by patient subgroup</span></b></p>", "ID": "2c65cb28-cc12-4cc4-b708-07140f3f603c", "Styles": "margin-left:.75in;text-indent:-.75in;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">Figure 1\u00a0\u00a0\u00a0\u00a0 IRF-assessed PFS by patient subgroup</span></b>", "ID": "8be0c8fd-c6d0-432d-ba52-f3d8c9c47fbd", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "2c65cb28-cc12-4cc4-b708-07140f3f603c"}, {"Element": "<span lang=\"EN-GB\">Figure 1\u00a0\u00a0\u00a0\u00a0 IRF-assessed PFS by patient subgroup</span>", "ID": "ca440676-a2ae-443a-bc35-7e72fcfdcd88", "Styles": "None", "Classes": "None", "Text": "Figure 1\u00a0\u00a0\u00a0\u00a0 IRF-assessed PFS by patient subgroup", "ParentId": "8be0c8fd-c6d0-432d-ba52-f3d8c9c47fbd"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3490ca15-067d-49ab-a262-1a24ec8eda58", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2194d7a8-c886-4998-97a9-cf4546930553", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3490ca15-067d-49ab-a262-1a24ec8eda58"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-bottom:6.0pt;line-height:12.0pt;page-break-after:\navoid\"><img alt=\"picutre-01\" border=\"0\" height=\"385\" id=\"Picture 2\" src=\"Perjeta-II-48%20EN%20PI%20clean_files/image002.jpg\" width=\"651\"/></p>", "ID": "b6b4f496-19fd-455a-8443-9c210021fce2", "Styles": "margin-bottom:6.0pt;line-height:12.0pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<img alt=\"picutre-01\" border=\"0\" height=\"385\" id=\"Picture 2\" src=\"Perjeta-II-48%20EN%20PI%20clean_files/image002.jpg\" width=\"651\"/>", "ID": "119297e0-8fbe-421c-8a34-174f55c6df3e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b6b4f496-19fd-455a-8443-9c210021fce2"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-bottom:6.0pt;line-height:12.0pt;page-break-after:\navoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d5b53fc0-fa72-4438-8477-2273965aaf41", "Styles": "margin-bottom:6.0pt;line-height:12.0pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "79eb7b06-03d2-4952-8721-1d97e5cdb61b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d5b53fc0-fa72-4438-8477-2273965aaf41"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The event-driven final analysis of OS was\nperformed when 389 patients had died (221 in the placebo-treated group and 168\nin the Perjeta-treated group). The statistically significant OS benefit in favour\nof the Perjeta-treated group, </span><span style=\"color:#222222;background:\nwhite\">previously observed at an interim analysis of OS (performed one year\nafter the primary analysis),\u00a0</span><span lang=\"EN-GB\">was maintained (HR\n0.68, p = 0.0002 log-rank test). The median time to death was 40.8 months in\nthe placebo-treated group and 56.5 months in the Perjeta-treated group </span><span lang=\"EN-GB\">(see Table 3, Figure\u00a02).</span></p>", "ID": "a3bb64b0-0e2e-4d79-92bd-ee7161a6a983", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">The event-driven final analysis of OS was\nperformed when 389 patients had died (221 in the placebo-treated group and 168\nin the Perjeta-treated group). The statistically significant OS benefit in favour\nof the Perjeta-treated group, </span>", "ID": "120f4646-989e-4bc7-bd2c-e4dc07ed8f0d", "Styles": "None", "Classes": "None", "Text": "The event-driven final analysis of OS was performed when 389 patients had died (221 in the placebo-treated group and 168 in the Perjeta-treated group). The statistically significant OS benefit in favour of the Perjeta-treated group, ", "ParentId": "a3bb64b0-0e2e-4d79-92bd-ee7161a6a983"}, {"Element": "<span style=\"color:#222222;background:\nwhite\">previously observed at an interim analysis of OS (performed one year\nafter the primary analysis),\u00a0</span>", "ID": "41dfb11f-6ee4-49cd-ba01-a371752264ab", "Styles": "color:#222222;background:\nwhite", "Classes": "None", "Text": "previously observed at an interim analysis of OS (performed one year after the primary analysis),\u00a0", "ParentId": "a3bb64b0-0e2e-4d79-92bd-ee7161a6a983"}, {"Element": "<span lang=\"EN-GB\">was maintained (HR\n0.68, p = 0.0002 log-rank test). The median time to death was 40.8 months in\nthe placebo-treated group and 56.5 months in the Perjeta-treated group </span>", "ID": "28c04264-501b-4983-9de9-0eacc59a2400", "Styles": "None", "Classes": "None", "Text": "was maintained (HR 0.68, p = 0.0002 log-rank test). The median time to death was 40.8 months in the placebo-treated group and 56.5 months in the Perjeta-treated group ", "ParentId": "a3bb64b0-0e2e-4d79-92bd-ee7161a6a983"}, {"Element": "<span lang=\"EN-GB\">(see Table 3, Figure\u00a02).</span>", "ID": "2ff8de34-83d8-4b77-864f-0ce3b3ea870e", "Styles": "None", "Classes": "None", "Text": "(see Table 3, Figure\u00a02).", "ParentId": "a3bb64b0-0e2e-4d79-92bd-ee7161a6a983"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4dd024f2-1e49-4abd-9b7a-0570c2c49727", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "25037e70-87f2-4a36-bba0-438879cad5c4", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4dd024f2-1e49-4abd-9b7a-0570c2c49727"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">A descriptive analysis of OS performed at\nthe end of the study when 515 patients had died (280 in the placebo-treated\ngroup and 235 in the Perjeta-treated group) showed that the statistically\nsignificant OS benefit in favour of the Perjeta-treated group was maintained over\ntime after a median follow-up of 99 months (HR 0.69, p &lt; 0.0001 log-rank\ntest; median time to death 40.8 months [placebo-treated group] versus 57.1\nmonths [Perjeta-treated group]). Landmark survival estimates at 8 years were\n37% in the Perjeta-treated group and 23% in the placebo-treated group.</span></p>", "ID": "b7aa77c6-5880-44af-a3c7-4aca5d11565c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">A descriptive analysis of OS performed at\nthe end of the study when 515 patients had died (280 in the placebo-treated\ngroup and 235 in the Perjeta-treated group) showed that the statistically\nsignificant OS benefit in favour of the Perjeta-treated group was maintained over\ntime after a median follow-up of 99 months (HR 0.69, p &lt; 0.0001 log-rank\ntest; median time to death 40.8 months [placebo-treated group] versus 57.1\nmonths [Perjeta-treated group]). Landmark survival estimates at 8 years were\n37% in the Perjeta-treated group and 23% in the placebo-treated group.</span>", "ID": "826b5468-e754-4446-958d-c74c86763533", "Styles": "None", "Classes": "None", "Text": "A descriptive analysis of OS performed at the end of the study when 515 patients had died (280 in the placebo-treated group and 235 in the Perjeta-treated group) showed that the statistically significant OS benefit in favour of the Perjeta-treated group was maintained over time after a median follow-up of 99 months (HR 0.69, p < 0.0001 log-rank test; median time to death 40.8 months [placebo-treated group] versus 57.1 months [Perjeta-treated group]). Landmark survival estimates at 8 years were 37% in the Perjeta-treated group and 23% in the placebo-treated group.", "ParentId": "b7aa77c6-5880-44af-a3c7-4aca5d11565c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ed29fff0-6a61-4188-8127-1d6114ce4e6a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d6f89e9f-d82b-45b4-884e-1aa44969ff91", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ed29fff0-6a61-4188-8127-1d6114ce4e6a"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:62.95pt;text-indent:-62.95pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">Figure 2\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Kaplan-Meier Curve of Event\u2011Driven\nOverall Survival</span></b></p>", "ID": "0f67c795-b205-4c9a-a3ba-3581278367f6", "Styles": "margin-left:62.95pt;text-indent:-62.95pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">Figure 2\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Kaplan-Meier Curve of Event\u2011Driven\nOverall Survival</span></b>", "ID": "48154fce-3e1d-457a-8314-932d43f3682a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "0f67c795-b205-4c9a-a3ba-3581278367f6"}, {"Element": "<span lang=\"EN-GB\">Figure 2\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Kaplan-Meier Curve of Event\u2011Driven\nOverall Survival</span>", "ID": "c93b643e-d4b7-479b-98f0-ee992a3717c7", "Styles": "None", "Classes": "None", "Text": "Figure 2\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Kaplan-Meier Curve of Event\u2011Driven Overall Survival", "ParentId": "48154fce-3e1d-457a-8314-932d43f3682a"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "414c27ad-c233-4763-bfbf-a0c8b486dfa0", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "391893f0-05b3-415f-b3fa-38d3fe08aa28", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "414c27ad-c233-4763-bfbf-a0c8b486dfa0"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "98fdfaf2-eae5-467a-a80a-54c2dfacc075", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "391893f0-05b3-415f-b3fa-38d3fe08aa28"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:10.0pt;text-align:center;\nline-height:115%;page-break-after:avoid\"><img border=\"0\" height=\"354\" id=\"Picture 1\" src=\"Perjeta-II-48%20EN%20PI%20clean_files/image003.jpg\" width=\"580\"/></p>", "ID": "630a0d05-dc6f-482d-8262-c84dd36a83cf", "Styles": "margin-bottom:10.0pt;text-align:center;\nline-height:115%;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<img border=\"0\" height=\"354\" id=\"Picture 1\" src=\"Perjeta-II-48%20EN%20PI%20clean_files/image003.jpg\" width=\"580\"/>", "ID": "8799cc51-c293-48bc-beaf-c206869e570d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "630a0d05-dc6f-482d-8262-c84dd36a83cf"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:10.0pt;text-align:center;\nline-height:115%\"><span lang=\"EN-GB\" style=\"font-size:8.0pt;line-height:115%\">HR=\nhazard ratio; CI= confidence interval; Pla= placebo; Ptz= pertuzumab (Perjeta);\nT= trastuzumab (Herceptin); D= docetaxel</span><span lang=\"EN-GB\" style=\"font-size:8.0pt;line-height:115%\">.</span></p>", "ID": "e78fec17-db02-4e60-b46e-4cee63593bee", "Styles": "margin-bottom:10.0pt;text-align:center;\nline-height:115%", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:8.0pt;line-height:115%\">HR=\nhazard ratio; CI= confidence interval; Pla= placebo; Ptz= pertuzumab (Perjeta);\nT= trastuzumab (Herceptin); D= docetaxel</span>", "ID": "3ac989e5-4db1-4cf7-9948-4c49c20120b6", "Styles": "font-size:8.0pt;line-height:115%", "Classes": "None", "Text": "HR= hazard ratio; CI= confidence interval; Pla= placebo; Ptz= pertuzumab (Perjeta); T= trastuzumab (Herceptin); D= docetaxel", "ParentId": "e78fec17-db02-4e60-b46e-4cee63593bee"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:8.0pt;line-height:115%\">.</span>", "ID": "6958a99c-84d2-491b-aca0-3ff9c88424d0", "Styles": "font-size:8.0pt;line-height:115%", "Classes": "None", "Text": ".", "ParentId": "e78fec17-db02-4e60-b46e-4cee63593bee"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "63b48b69-a003-4351-a80e-1fdc0b29f343", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "da99c789-c24a-4c56-a1ca-4549c9a26d1b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "63b48b69-a003-4351-a80e-1fdc0b29f343"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">No statistically significant differences\nwere found between the two treatment groups in Health Related Quality of Life\nas assessed by FACT-B TOI-PFB scores. </span></p>", "ID": "7be251cf-6586-4274-a005-2bdb962f9a4f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">No statistically significant differences\nwere found between the two treatment groups in Health Related Quality of Life\nas assessed by FACT-B TOI-PFB scores. </span>", "ID": "76593876-4f2c-43ac-a1b8-693cd96f4379", "Styles": "None", "Classes": "None", "Text": "No statistically significant differences were found between the two treatment groups in Health Related Quality of Life as assessed by FACT-B TOI-PFB scores. ", "ParentId": "7be251cf-6586-4274-a005-2bdb962f9a4f"}, {"Element": "<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">\u00a0</span></i></p>", "ID": "3ba8b6f0-a3eb-4576-be88-840bde688840", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<i><span lang=\"EN-GB\">\u00a0</span></i>", "ID": "bd618202-e44f-49c0-9b8a-582146d49f79", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3ba8b6f0-a3eb-4576-be88-840bde688840"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "96e2cc99-e8af-4625-9e6a-72819efc3795", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "bd618202-e44f-49c0-9b8a-582146d49f79"}, {"Element": "<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">Additional </span></i><i><span lang=\"EN-GB\">supportive clinical trial</span></i><i><span lang=\"EN-GB\"> information</span></i></p>", "ID": "5b660477-926e-4bce-9e96-2eb8bfababfb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<i><span lang=\"EN-GB\">Additional </span></i>", "ID": "978a0ba1-1b6d-4e50-a5e5-e479b2c78163", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "5b660477-926e-4bce-9e96-2eb8bfababfb"}, {"Element": "<span lang=\"EN-GB\">Additional </span>", "ID": "5d0f9a93-feee-42fb-82af-83e065c4bf23", "Styles": "None", "Classes": "None", "Text": "Additional ", "ParentId": "978a0ba1-1b6d-4e50-a5e5-e479b2c78163"}, {"Element": "<i><span lang=\"EN-GB\">supportive clinical trial</span></i>", "ID": "b3fc4534-c283-4652-acef-67554b0feb4e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "5b660477-926e-4bce-9e96-2eb8bfababfb"}, {"Element": "<span lang=\"EN-GB\">supportive clinical trial</span>", "ID": "91009390-2a71-4baf-9848-469e215256cc", "Styles": "None", "Classes": "None", "Text": "supportive clinical trial", "ParentId": "b3fc4534-c283-4652-acef-67554b0feb4e"}, {"Element": "<i><span lang=\"EN-GB\"> information</span></i>", "ID": "4e793a8f-f26f-4d13-88a2-ceb6a3611674", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "5b660477-926e-4bce-9e96-2eb8bfababfb"}, {"Element": "<span lang=\"EN-GB\"> information</span>", "ID": "94686a73-45db-4c60-8171-db84eec44276", "Styles": "None", "Classes": "None", "Text": " information", "ParentId": "4e793a8f-f26f-4d13-88a2-ceb6a3611674"}, {"Element": "<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">\u00a0</span></i></p>", "ID": "2cac82a1-a268-42a5-808f-5db17ed0beac", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<i><span lang=\"EN-GB\">\u00a0</span></i>", "ID": "2c072294-2ee4-4cdd-bf7b-5ebf168af8fb", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "2cac82a1-a268-42a5-808f-5db17ed0beac"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0464988f-baf7-46c6-bd26-744ae462d54f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2c072294-2ee4-4cdd-bf7b-5ebf168af8fb"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">BO17929</span></b><span lang=\"EN-GB\"> -<b>\n</b>single-arm trial in metastatic breast cancer</span></p>", "ID": "42475c43-91a2-49e6-9964-b980b11132bd", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">BO17929</span></b>", "ID": "068886a3-20c6-4a41-bf77-5d406b969970", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "42475c43-91a2-49e6-9964-b980b11132bd"}, {"Element": "<span lang=\"EN-GB\">BO17929</span>", "ID": "e610e948-9e05-45c9-99c2-73f9eeda6165", "Styles": "None", "Classes": "None", "Text": "BO17929", "ParentId": "068886a3-20c6-4a41-bf77-5d406b969970"}, {"Element": "<span lang=\"EN-GB\"> -<b>\n</b>single-arm trial in metastatic breast cancer</span>", "ID": "97e24aa7-efc3-47ce-8f0f-6496b9ecbe8b", "Styles": "None", "Classes": "None", "Text": " -single-arm trial in metastatic breast cancer", "ParentId": "42475c43-91a2-49e6-9964-b980b11132bd"}, {"Element": "<b>\n</b>", "ID": "62b6e390-d76d-45d6-840b-bd188260dc3e", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "97e24aa7-efc3-47ce-8f0f-6496b9ecbe8b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ac5e0720-b290-4e4e-84dd-ec19168797b0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "be59cf0c-acb5-4098-a6db-ba9db092657d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ac5e0720-b290-4e4e-84dd-ec19168797b0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">BO17929 was a phase II, non-randomised study\nin patients with metastatic breast cancer whose tumours had progressed during\ntreatment with trastuzumab. Treatment with Perjeta and trastuzumab resulted in\na response rate of 24.2%, with a further 25.8% of patients experiencing\nstabilisation of disease lasting at least 6 months, indicating that Perjeta is\nactive </span><span lang=\"EN-GB\">following</span><span lang=\"EN-GB\"> progression on\n</span><span lang=\"EN-GB\">trastuzumab.</span>\u00a0 </p>", "ID": "a9c289a5-3e6a-4673-ab0f-e421f0dc2234", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0 ", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">BO17929 was a phase II, non-randomised study\nin patients with metastatic breast cancer whose tumours had progressed during\ntreatment with trastuzumab. Treatment with Perjeta and trastuzumab resulted in\na response rate of 24.2%, with a further 25.8% of patients experiencing\nstabilisation of disease lasting at least 6 months, indicating that Perjeta is\nactive </span>", "ID": "4da263f9-6557-412a-aadf-996c4ea341ba", "Styles": "None", "Classes": "None", "Text": "BO17929 was a phase II, non-randomised study in patients with metastatic breast cancer whose tumours had progressed during treatment with trastuzumab. Treatment with Perjeta and trastuzumab resulted in a response rate of 24.2%, with a further 25.8% of patients experiencing stabilisation of disease lasting at least 6 months, indicating that Perjeta is active ", "ParentId": "a9c289a5-3e6a-4673-ab0f-e421f0dc2234"}, {"Element": "<span lang=\"EN-GB\">following</span>", "ID": "9277a4bb-67f6-43d0-8a6c-56f40c6793c2", "Styles": "None", "Classes": "None", "Text": "following", "ParentId": "a9c289a5-3e6a-4673-ab0f-e421f0dc2234"}, {"Element": "<span lang=\"EN-GB\"> progression on\n</span>", "ID": "9a274555-3bb9-4d7c-8ffd-d537e64d906c", "Styles": "None", "Classes": "None", "Text": " progression on ", "ParentId": "a9c289a5-3e6a-4673-ab0f-e421f0dc2234"}, {"Element": "<span lang=\"EN-GB\">trastuzumab.</span>", "ID": "92789a1d-53ed-45d7-908e-c21062da26fa", "Styles": "None", "Classes": "None", "Text": "trastuzumab.", "ParentId": "a9c289a5-3e6a-4673-ab0f-e421f0dc2234"}, {"Element": "<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">\u00a0</span></i></p>", "ID": "bec1264e-83d8-46ba-a099-4c619b44ad08", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<i><span lang=\"EN-GB\">\u00a0</span></i>", "ID": "fb496624-fa09-48c3-bf78-058c27edb554", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "bec1264e-83d8-46ba-a099-4c619b44ad08"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b59bdb5e-8cdb-4199-84b7-2b0a75348b44", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "fb496624-fa09-48c3-bf78-058c27edb554"}, {"Element": "<p class=\"MsoNormal\"><i><span lang=\"EN-GB\" style=\"color:black\">Early Breast Cancer</span></i></p>", "ID": "92c73677-eca2-4567-8fff-93c67ac0511f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<i><span lang=\"EN-GB\" style=\"color:black\">Early Breast Cancer</span></i>", "ID": "3064b6dd-4fd0-4dc2-aadf-52ed3ed1e7f7", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "92c73677-eca2-4567-8fff-93c67ac0511f"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Early Breast Cancer</span>", "ID": "91e1272a-9cac-4d42-997f-10098d6d0832", "Styles": "color:black", "Classes": "None", "Text": "Early Breast Cancer", "ParentId": "3064b6dd-4fd0-4dc2-aadf-52ed3ed1e7f7"}, {"Element": "<p class=\"MsoNormal\"><i><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></i></p>", "ID": "a14d9a74-5f3a-4686-83d9-8a0efd505ba4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<i><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></i>", "ID": "b0b9c0a5-c718-42ce-ae73-c91ce7a78c9b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a14d9a74-5f3a-4686-83d9-8a0efd505ba4"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">\u00a0</span>", "ID": "5a780921-ac6b-49e8-8aa6-fda8a2e07de4", "Styles": "color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "b0b9c0a5-c718-42ce-ae73-c91ce7a78c9b"}, {"Element": "<p class=\"MsoNormal\"><i><span lang=\"EN-GB\" style=\"color:black\">Neoadjuvant\nTreatment</span></i></p>", "ID": "dac03d1c-70dc-4ee9-93d6-1458b1f6e6bf", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<i><span lang=\"EN-GB\" style=\"color:black\">Neoadjuvant\nTreatment</span></i>", "ID": "78127df7-3ce3-4960-a70d-8d0c134075df", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "dac03d1c-70dc-4ee9-93d6-1458b1f6e6bf"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Neoadjuvant\nTreatment</span>", "ID": "052978a8-2c68-43eb-8042-b4fa6ae3a48e", "Styles": "color:black", "Classes": "None", "Text": "Neoadjuvant Treatment", "ParentId": "78127df7-3ce3-4960-a70d-8d0c134075df"}, {"Element": "<p class=\"MsoNormal\"><i><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></i></p>", "ID": "2cc95377-2933-4335-a6db-9d5b4a4314a7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<i><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></i>", "ID": "3e104cf9-ed36-4aba-823a-945c09744d52", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "2cc95377-2933-4335-a6db-9d5b4a4314a7"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">\u00a0</span>", "ID": "4658ad33-e141-4b73-a7d4-5a82807b68c4", "Styles": "color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "3e104cf9-ed36-4aba-823a-945c09744d52"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">In the neoadjuvant\nsetting, locally advanced and inflammatory breast cancers are considered as\nhigh-risk irrespective of hormone receptor status. In early stage breast cancer,\ntumor size, grade, hormone receptor status and lymph node metastases should be\ntaken into account in the risk assessment.</span></p>", "ID": "271d83ab-9351-4296-9702-e00ff5709aff", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">In the neoadjuvant\nsetting, locally advanced and inflammatory breast cancers are considered as\nhigh-risk irrespective of hormone receptor status. In early stage breast cancer,\ntumor size, grade, hormone receptor status and lymph node metastases should be\ntaken into account in the risk assessment.</span>", "ID": "87a5b548-e656-4f28-a677-51f16f281fcc", "Styles": "color:black", "Classes": "None", "Text": "In the neoadjuvant setting, locally advanced and inflammatory breast cancers are considered as high-risk irrespective of hormone receptor status. In early stage breast cancer, tumor size, grade, hormone receptor status and lymph node metastases should be taken into account in the risk assessment.", "ParentId": "271d83ab-9351-4296-9702-e00ff5709aff"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>", "ID": "3c3b814b-01e5-402a-8970-ec7b172ec4c1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">\u00a0</span>", "ID": "208d034c-d93c-43c1-bddd-27c9432b4310", "Styles": "color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "3c3b814b-01e5-402a-8970-ec7b172ec4c1"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">The indication in the\nneoadjuvant treatment of breast cancer is based on demonstration of an\nimprovement in pathological complete response rate,</span><span lang=\"EN-GB\"> </span><span lang=\"EN-GB\" style=\"color:black\">and trends to improvement in disease-free\nsurvival that nevertheless do not establish or precisely measure a benefit with\nregard to long-term outcomes, such as overall survival or disease-free\nsurvival. </span></p>", "ID": "b26111cf-4e25-4ba9-93eb-e0c01f71f90b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">The indication in the\nneoadjuvant treatment of breast cancer is based on demonstration of an\nimprovement in pathological complete response rate,</span>", "ID": "a11c14d9-8b1b-44d7-b032-d1464ee2c869", "Styles": "color:black", "Classes": "None", "Text": "The indication in the neoadjuvant treatment of breast cancer is based on demonstration of an improvement in pathological complete response rate,", "ParentId": "b26111cf-4e25-4ba9-93eb-e0c01f71f90b"}, {"Element": "<span lang=\"EN-GB\"> </span>", "ID": "9481b6a4-7f47-43e3-b398-6f9ade3da8e6", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "b26111cf-4e25-4ba9-93eb-e0c01f71f90b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">and trends to improvement in disease-free\nsurvival that nevertheless do not establish or precisely measure a benefit with\nregard to long-term outcomes, such as overall survival or disease-free\nsurvival. </span>", "ID": "42754fac-d3f1-4c9a-89d8-4c03139672a3", "Styles": "color:black", "Classes": "None", "Text": "and trends to improvement in disease-free survival that nevertheless do not establish or precisely measure a benefit with regard to long-term outcomes, such as overall survival or disease-free survival. ", "ParentId": "b26111cf-4e25-4ba9-93eb-e0c01f71f90b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>", "ID": "640b2b95-3850-4fb1-b999-545d9c7f44e6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">\u00a0</span>", "ID": "a0a824c0-4390-40e2-9258-69de6656e88e", "Styles": "color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "640b2b95-3850-4fb1-b999-545d9c7f44e6"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"color:black\">NEOSPHERE (WO20697)</span></b><span lang=\"EN-GB\" style=\"color:black\"> </span></p>", "ID": "c3db8244-bf9c-426e-8233-824a0b4a78a0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\" style=\"color:black\">NEOSPHERE (WO20697)</span></b>", "ID": "4f23e2ff-9794-4681-b023-8ed220476f54", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c3db8244-bf9c-426e-8233-824a0b4a78a0"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">NEOSPHERE (WO20697)</span>", "ID": "ba2fed0e-5c7c-4f29-8b72-8eab3c08cb31", "Styles": "color:black", "Classes": "None", "Text": "NEOSPHERE (WO20697)", "ParentId": "4f23e2ff-9794-4681-b023-8ed220476f54"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\"> </span>", "ID": "0d54991d-88f3-44dc-9495-11c7f4a3222b", "Styles": "color:black", "Classes": "None", "Text": " ", "ParentId": "c3db8244-bf9c-426e-8233-824a0b4a78a0"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></b></p>", "ID": "023fac49-78da-43ee-a2d6-7d4a21492747", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></b>", "ID": "5cdbd2d5-ddc1-417f-b1b1-5586173fa00a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "023fac49-78da-43ee-a2d6-7d4a21492747"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">\u00a0</span>", "ID": "118ca3c0-4fe9-4f2d-a6f5-2bc08353997f", "Styles": "color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "5cdbd2d5-ddc1-417f-b1b1-5586173fa00a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">NEOSPHERE is a phase\nII, multicentre, multinational randomised controlled trial with Perjeta and was\nconducted in 417 adult female patients</span><span lang=\"EN-GB\"> </span><span lang=\"EN-GB\" style=\"color:black\">with newly diagnosed, early, inflammatory or\nlocally advanced HER2-positive breast cancer (T2-4d</span>; <span lang=\"EN-GB\" style=\"color:black\">primary tumour &gt; 2cm in diameter) who had not received\nprior trastuzumab, chemotherapy or radiotherapy. Patients with metastases,\nbilateral breast cancer, clinically important cardiac risk factors (see section\n4.4) or LVEF &lt; 55% were not included. The majority of</span><span lang=\"EN-GB\" style=\"color:black\"> patients were </span><span lang=\"EN-GB\" style=\"color:black\">less than 65 years old. </span></p>", "ID": "438b6b3d-66a1-4c9d-80fd-a6c83e614f59", "Styles": "None", "Classes": "['MsoNormal']", "Text": "; ", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">NEOSPHERE is a phase\nII, multicentre, multinational randomised controlled trial with Perjeta and was\nconducted in 417 adult female patients</span>", "ID": "b312d2cd-c6b1-4027-b91d-af0c1ed21f65", "Styles": "color:black", "Classes": "None", "Text": "NEOSPHERE is a phase II, multicentre, multinational randomised controlled trial with Perjeta and was conducted in 417 adult female patients", "ParentId": "438b6b3d-66a1-4c9d-80fd-a6c83e614f59"}, {"Element": "<span lang=\"EN-GB\"> </span>", "ID": "52c25af8-7f23-4a61-9b67-8b6a21b0d3c6", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "438b6b3d-66a1-4c9d-80fd-a6c83e614f59"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">with newly diagnosed, early, inflammatory or\nlocally advanced HER2-positive breast cancer (T2-4d</span>", "ID": "f4b1e5fe-bec7-4adc-b351-b6d6c4cf8f54", "Styles": "color:black", "Classes": "None", "Text": "with newly diagnosed, early, inflammatory or locally advanced HER2-positive breast cancer (T2-4d", "ParentId": "438b6b3d-66a1-4c9d-80fd-a6c83e614f59"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">primary tumour &gt; 2cm in diameter) who had not received\nprior trastuzumab, chemotherapy or radiotherapy. Patients with metastases,\nbilateral breast cancer, clinically important cardiac risk factors (see section\n4.4) or LVEF &lt; 55% were not included. The majority of</span>", "ID": "d6085793-d076-42bd-8aef-84c436847042", "Styles": "color:black", "Classes": "None", "Text": "primary tumour > 2cm in diameter) who had not received prior trastuzumab, chemotherapy or radiotherapy. Patients with metastases, bilateral breast cancer, clinically important cardiac risk factors (see section 4.4) or LVEF < 55% were not included. The majority of", "ParentId": "438b6b3d-66a1-4c9d-80fd-a6c83e614f59"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\"> patients were </span>", "ID": "5599d27e-867e-468d-af7d-108500c148c0", "Styles": "color:black", "Classes": "None", "Text": " patients were ", "ParentId": "438b6b3d-66a1-4c9d-80fd-a6c83e614f59"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">less than 65 years old. </span>", "ID": "ae094fd1-3aa2-4c40-871c-5bc13a5d01aa", "Styles": "color:black", "Classes": "None", "Text": "less than 65 years old. ", "ParentId": "438b6b3d-66a1-4c9d-80fd-a6c83e614f59"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>", "ID": "767bc636-638d-4750-ba08-2383fd34fbdb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">\u00a0</span>", "ID": "2be9470a-1074-4aeb-9ba3-750b3ac4cf8b", "Styles": "color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "767bc636-638d-4750-ba08-2383fd34fbdb"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Patients were </span><span lang=\"EN-GB\" style=\"color:black\">randomised\n</span><span lang=\"EN-GB\" style=\"color:black\">to receive</span><span lang=\"EN-GB\" style=\"color:black\"> one of </span><span lang=\"EN-GB\" style=\"color:black\">the\nfollowing neoadjuvant regimens for 4 cycles prior to surgery: </span></p>", "ID": "480445a9-f3d2-4ffd-8e52-5fec443dc3d5", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Patients were </span>", "ID": "4ebcd586-8b5f-40b1-b250-e48dc0739874", "Styles": "color:black", "Classes": "None", "Text": "Patients were ", "ParentId": "480445a9-f3d2-4ffd-8e52-5fec443dc3d5"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">randomised\n</span>", "ID": "e43fc330-b798-419b-a3ec-941eea85efeb", "Styles": "color:black", "Classes": "None", "Text": "randomised ", "ParentId": "480445a9-f3d2-4ffd-8e52-5fec443dc3d5"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">to receive</span>", "ID": "45f3b244-e1a2-4405-b370-7fa0400b4ed6", "Styles": "color:black", "Classes": "None", "Text": "to receive", "ParentId": "480445a9-f3d2-4ffd-8e52-5fec443dc3d5"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\"> one of </span>", "ID": "50fec972-e87b-4409-91dd-e395e017e01c", "Styles": "color:black", "Classes": "None", "Text": " one of ", "ParentId": "480445a9-f3d2-4ffd-8e52-5fec443dc3d5"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">the\nfollowing neoadjuvant regimens for 4 cycles prior to surgery: </span>", "ID": "9332767e-c3cf-4ebd-8ea1-5b0427165ddd", "Styles": "color:black", "Classes": "None", "Text": "the following neoadjuvant regimens for 4 cycles prior to surgery: ", "ParentId": "480445a9-f3d2-4ffd-8e52-5fec443dc3d5"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>", "ID": "11bef9f0-7273-426a-ab5e-e2bb649d8641", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">\u00a0</span>", "ID": "5d00a8a5-c170-4f93-af40-4b2f1d211a56", "Styles": "color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "11bef9f0-7273-426a-ab5e-e2bb649d8641"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.25in;page-break-after:avoid\"><span style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0 <span style=\"color:\nblack\">Trastuzumab plus docetaxel </span></span></p>", "ID": "7bfb9adb-f867-48d6-a2c9-a029ca5bfe00", "Styles": "margin-left:.25in;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span style=\"font-family:Symbol\">\u00b7</span>", "ID": "dc26d609-e35c-4c97-9b93-320b9260ed75", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "7bfb9adb-f867-48d6-a2c9-a029ca5bfe00"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0 <span style=\"color:\nblack\">Trastuzumab plus docetaxel </span></span>", "ID": "5f1a872c-fb88-4be1-8148-ea5a398e1500", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "7bfb9adb-f867-48d6-a2c9-a029ca5bfe00"}, {"Element": "<span style=\"color:\nblack\">Trastuzumab plus docetaxel </span>", "ID": "e9137eb5-39a8-47bf-a926-bae78696c4e2", "Styles": "color:\nblack", "Classes": "None", "Text": "Trastuzumab plus docetaxel ", "ParentId": "5f1a872c-fb88-4be1-8148-ea5a398e1500"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.25in;page-break-after:avoid\"><span style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0 <span style=\"color:\nblack\">Perjeta plus trastuzumab and docetaxel</span></span></p>", "ID": "adb2614f-2908-450e-b97d-31f9ccf986a5", "Styles": "margin-left:.25in;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span style=\"font-family:Symbol\">\u00b7</span>", "ID": "78849b07-b5c9-407c-b332-eeabd41e77b9", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "adb2614f-2908-450e-b97d-31f9ccf986a5"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0 <span style=\"color:\nblack\">Perjeta plus trastuzumab and docetaxel</span></span>", "ID": "959ef3b7-668e-4357-b4f2-5767ac8ee1be", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "adb2614f-2908-450e-b97d-31f9ccf986a5"}, {"Element": "<span style=\"color:\nblack\">Perjeta plus trastuzumab and docetaxel</span>", "ID": "2a4d2858-b6d2-45c8-b824-dcb399433884", "Styles": "color:\nblack", "Classes": "None", "Text": "Perjeta plus trastuzumab and docetaxel", "ParentId": "959ef3b7-668e-4357-b4f2-5767ac8ee1be"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.25in\"><span style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 <span style=\"color:black\">Perjeta plus trastuzumab</span></p>", "ID": "4970ac6a-1665-49ac-a9c3-53466b8982bd", "Styles": "margin-left:.25in", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span style=\"font-family:Symbol\">\u00b7</span>", "ID": "77306b8d-ee4f-44fa-a7a0-4260c1d9f625", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "4970ac6a-1665-49ac-a9c3-53466b8982bd"}, {"Element": "<span style=\"color:black\">Perjeta plus trastuzumab</span>", "ID": "40008205-9905-4149-93e6-eb65824412f5", "Styles": "color:black", "Classes": "None", "Text": "Perjeta plus trastuzumab", "ParentId": "4970ac6a-1665-49ac-a9c3-53466b8982bd"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.25in\"><span style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 <span style=\"color:black\">Perjeta plus docetaxel. </span></p>", "ID": "c6fb34a6-e757-42da-ac42-a4468a6d2ec9", "Styles": "margin-left:.25in", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span style=\"font-family:Symbol\">\u00b7</span>", "ID": "958c0bce-9ecb-4aae-b708-797bddd3880d", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "c6fb34a6-e757-42da-ac42-a4468a6d2ec9"}, {"Element": "<span style=\"color:black\">Perjeta plus docetaxel. </span>", "ID": "dac37384-a1b3-4af2-a5e3-0672bdbbbbac", "Styles": "color:black", "Classes": "None", "Text": "Perjeta plus docetaxel. ", "ParentId": "c6fb34a6-e757-42da-ac42-a4468a6d2ec9"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.5in\"><span style=\"color:black\">\u00a0</span></p>", "ID": "5ae9c7c4-00ec-4ded-97ec-5e94494f951f", "Styles": "margin-left:.5in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span style=\"color:black\">\u00a0</span>", "ID": "c5d86e15-79fc-44b7-9bab-2bba948a466a", "Styles": "color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "5ae9c7c4-00ec-4ded-97ec-5e94494f951f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Randomisation was\nstratified by breast cancer type (operable, locally advanced, or inflammatory)\nand ER or PgR positivity.</span></p>", "ID": "3c9b3e13-bbff-484c-8bea-d2708a6101c0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Randomisation was\nstratified by breast cancer type (operable, locally advanced, or inflammatory)\nand ER or PgR positivity.</span>", "ID": "34782864-72c2-4f63-9ae3-ceabf1976ab9", "Styles": "color:black", "Classes": "None", "Text": "Randomisation was stratified by breast cancer type (operable, locally advanced, or inflammatory) and ER or PgR positivity.", "ParentId": "3c9b3e13-bbff-484c-8bea-d2708a6101c0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0 </span></p>", "ID": "58a63362-9a3d-4fc0-ae49-3b179c36bfba", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">\u00a0 </span>", "ID": "0ca04a31-5e67-43ad-bc05-90b4d11a49ed", "Styles": "color:black", "Classes": "None", "Text": "\u00a0 ", "ParentId": "58a63362-9a3d-4fc0-ae49-3b179c36bfba"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Pertuzumab was given\nintravenously at an initial dose of 840 mg, followed by 420 mg every three\nweeks. Trastuzumab was given intravenously at an initial dose of 8 mg/kg,\nfollowed by 6 mg/kg every three weeks. Docetaxel was given intravenously at an\ninitial dose of 75 mg/ m<sup>2</sup> followed by 75 mg/ m<sup>2</sup> or 100\nmg/ m<sup>2</sup> (if tolerated) every 3 weeks. Following surgery all patients\nreceived 3 cycles of 5-fluorouracil (600\u00a0mg/m<sup>2</sup>), epirubicin\n(90\u00a0mg/m<sup>2</sup>), cyclophosphamide (600\u00a0mg/m<sup>2</sup>) (FEC)\ngiven intravenously every three weeks, and trastuzumab administered\nintravenously every three weeks to complete one year of therapy. Patients who\nonly received Perjeta plus trastuzumab prior to surgery subsequently received\nboth FEC and docetaxel post surgery.</span></p>", "ID": "d992df03-a75f-40e4-879b-6a73971d720f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Pertuzumab was given\nintravenously at an initial dose of 840 mg, followed by 420 mg every three\nweeks. Trastuzumab was given intravenously at an initial dose of 8 mg/kg,\nfollowed by 6 mg/kg every three weeks. Docetaxel was given intravenously at an\ninitial dose of 75 mg/ m<sup>2</sup> followed by 75 mg/ m<sup>2</sup> or 100\nmg/ m<sup>2</sup> (if tolerated) every 3 weeks. Following surgery all patients\nreceived 3 cycles of 5-fluorouracil (600\u00a0mg/m<sup>2</sup>), epirubicin\n(90\u00a0mg/m<sup>2</sup>), cyclophosphamide (600\u00a0mg/m<sup>2</sup>) (FEC)\ngiven intravenously every three weeks, and trastuzumab administered\nintravenously every three weeks to complete one year of therapy. Patients who\nonly received Perjeta plus trastuzumab prior to surgery subsequently received\nboth FEC and docetaxel post surgery.</span>", "ID": "af39f452-cc8a-4150-8d22-e820e00690a1", "Styles": "color:black", "Classes": "None", "Text": "Pertuzumab was given intravenously at an initial dose of 840 mg, followed by 420 mg every three weeks. Trastuzumab was given intravenously at an initial dose of 8 mg/kg, followed by 6 mg/kg every three weeks. Docetaxel was given intravenously at an initial dose of 75 mg/ m followed by 75 mg/ m or 100 mg/ m (if tolerated) every 3 weeks. Following surgery all patients received 3 cycles of 5-fluorouracil (600\u00a0mg/m), epirubicin (90\u00a0mg/m), cyclophosphamide (600\u00a0mg/m) (FEC) given intravenously every three weeks, and trastuzumab administered intravenously every three weeks to complete one year of therapy. Patients who only received Perjeta plus trastuzumab prior to surgery subsequently received both FEC and docetaxel post surgery.", "ParentId": "d992df03-a75f-40e4-879b-6a73971d720f"}, {"Element": "<sup>2</sup>", "ID": "e0b4ca00-9d06-4801-9605-fd4de95e3454", "Styles": "None", "Classes": "None", "Text": "2", "ParentId": "af39f452-cc8a-4150-8d22-e820e00690a1"}, {"Element": "<sup>2</sup>", "ID": "8cff7801-e95c-489b-8957-2c5058357306", "Styles": "None", "Classes": "None", "Text": "2", "ParentId": "af39f452-cc8a-4150-8d22-e820e00690a1"}, {"Element": "<sup>2</sup>", "ID": "31c54d81-68c1-455d-87ec-d8094cf78a31", "Styles": "None", "Classes": "None", "Text": "2", "ParentId": "af39f452-cc8a-4150-8d22-e820e00690a1"}, {"Element": "<sup>2</sup>", "ID": "fdbde084-c553-4d47-bd27-3a2dcda4fe0e", "Styles": "None", "Classes": "None", "Text": "2", "ParentId": "af39f452-cc8a-4150-8d22-e820e00690a1"}, {"Element": "<sup>2</sup>", "ID": "bf6c5ff8-7db5-451a-ae5a-459f3acaa43c", "Styles": "None", "Classes": "None", "Text": "2", "ParentId": "af39f452-cc8a-4150-8d22-e820e00690a1"}, {"Element": "<sup>2</sup>", "ID": "2b8c0905-868b-4aed-a5be-757b1e4720a7", "Styles": "None", "Classes": "None", "Text": "2", "ParentId": "af39f452-cc8a-4150-8d22-e820e00690a1"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>", "ID": "365ae5c5-b6ad-4895-baf3-b906c30c8a16", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">\u00a0</span>", "ID": "51e31506-3250-41ff-82cc-953012463236", "Styles": "color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "365ae5c5-b6ad-4895-baf3-b906c30c8a16"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">The primary endpoint of\nthe study was pathological complete response (pCR) rate in the breast\n(ypT0/is).\u00a0 Secondary efficacy endpoints were clinical response rate, breast\nconserving surgery rate (T2-3 tumours only), disease-free survival (DFS), and\nPFS. Additional exploratory pCR rates included nodal status (ypT0/isN0 and\nypT0N0).</span></p>", "ID": "5e80f438-c343-4bf9-877c-8a7edd545734", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">The primary endpoint of\nthe study was pathological complete response (pCR) rate in the breast\n(ypT0/is).\u00a0 Secondary efficacy endpoints were clinical response rate, breast\nconserving surgery rate (T2-3 tumours only), disease-free survival (DFS), and\nPFS. Additional exploratory pCR rates included nodal status (ypT0/isN0 and\nypT0N0).</span>", "ID": "fbd30638-bfca-4b92-bb70-9d84110db82d", "Styles": "color:black", "Classes": "None", "Text": "The primary endpoint of the study was pathological complete response (pCR) rate in the breast (ypT0/is).\u00a0 Secondary efficacy endpoints were clinical response rate, breast conserving surgery rate (T2-3 tumours only), disease-free survival (DFS), and PFS. Additional exploratory pCR rates included nodal status (ypT0/isN0 and ypT0N0).", "ParentId": "5e80f438-c343-4bf9-877c-8a7edd545734"}, {"Element": "<p class=\"MsoNormal\"><u><span lang=\"EN-GB\" style=\"color:black\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>", "ID": "3e3b2745-075a-49b7-a71f-93f87e3ffa64", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<u><span lang=\"EN-GB\" style=\"color:black\"><span style=\"text-decoration:none\">\u00a0</span></span></u>", "ID": "cf9a943c-fd24-4a7a-ad04-c40a505157e3", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3e3b2745-075a-49b7-a71f-93f87e3ffa64"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\"><span style=\"text-decoration:none\">\u00a0</span></span>", "ID": "2009a6a6-742d-440d-924a-a64c00160664", "Styles": "color:black", "Classes": "None", "Text": "", "ParentId": "cf9a943c-fd24-4a7a-ad04-c40a505157e3"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "1795f0fe-a341-4902-b0b6-5a72452e58fe", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "2009a6a6-742d-440d-924a-a64c00160664"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Demographics were well\nbalanced (median age was 49-50 years, the majority were caucasian (71%)) and\nall patients were female. Overall 7% of patients had inflammatory breast\ncancer, 32% had locally advanced breast cancer and 61% had operable breast\ncancer.\u00a0 Approximately half the patients in each treatment group had hormone\nreceptor-positive disease (defined as ER positive and/or PgR positive). </span></p>", "ID": "7f21fb84-4b1d-4357-a817-e056346a5636", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Demographics were well\nbalanced (median age was 49-50 years, the majority were caucasian (71%)) and\nall patients were female. Overall 7% of patients had inflammatory breast\ncancer, 32% had locally advanced breast cancer and 61% had operable breast\ncancer.\u00a0 Approximately half the patients in each treatment group had hormone\nreceptor-positive disease (defined as ER positive and/or PgR positive). </span>", "ID": "a770de6c-490e-42ed-8dda-bafe0f8cc151", "Styles": "color:black", "Classes": "None", "Text": "Demographics were well balanced (median age was 49-50 years, the majority were caucasian (71%)) and all patients were female. Overall 7% of patients had inflammatory breast cancer, 32% had locally advanced breast cancer and 61% had operable breast cancer.\u00a0 Approximately half the patients in each treatment group had hormone receptor-positive disease (defined as ER positive and/or PgR positive). ", "ParentId": "7f21fb84-4b1d-4357-a817-e056346a5636"}, {"Element": "<p class=\"MsoNormal\"><u><span lang=\"EN-GB\" style=\"color:black\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>", "ID": "3e943b9f-dac9-4b36-9a04-b82ccdcb95a5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<u><span lang=\"EN-GB\" style=\"color:black\"><span style=\"text-decoration:none\">\u00a0</span></span></u>", "ID": "78171bd7-df08-4934-b900-6b1e71f2c785", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3e943b9f-dac9-4b36-9a04-b82ccdcb95a5"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\"><span style=\"text-decoration:none\">\u00a0</span></span>", "ID": "3597e5c8-3222-4123-b24d-26c6dff62754", "Styles": "color:black", "Classes": "None", "Text": "", "ParentId": "78171bd7-df08-4934-b900-6b1e71f2c785"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "01a9c7a0-3a4a-4219-8525-244eb4a1282f", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "3597e5c8-3222-4123-b24d-26c6dff62754"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The efficacy results are presented in Table\n4. A statistically significant\u00a0 improvement in pCR rate (ypT0/is) was observed\nin patients receiving Perjeta plus trastuzumab and docetaxel compared to\npatients receiving trastuzumab and docetaxel (45.8% vs 29.0%, p value = </span><span lang=\"EN-GB\">0.0141</span><span lang=\"EN-GB\">). A consistent pattern of results was\nobserved regardless of pCR definition. The difference in pCR rate is considered\nlikely to translate into a clinically meaningful difference in long term\noutcomes and is supported by positive trends in PFS (HR 0.69, 95% CI 0.34, 1.40)\nand DFS (HR 0.60, 95% CI 0.28, 1.27).<u> </u></span></p>", "ID": "88f0e9d5-b981-4e70-a13a-4fc7b40c2edc", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">The efficacy results are presented in Table\n4. A statistically significant\u00a0 improvement in pCR rate (ypT0/is) was observed\nin patients receiving Perjeta plus trastuzumab and docetaxel compared to\npatients receiving trastuzumab and docetaxel (45.8% vs 29.0%, p value = </span>", "ID": "5a4790f7-e9aa-4795-869d-98b424a7c341", "Styles": "None", "Classes": "None", "Text": "The efficacy results are presented in Table 4. A statistically significant\u00a0 improvement in pCR rate (ypT0/is) was observed in patients receiving Perjeta plus trastuzumab and docetaxel compared to patients receiving trastuzumab and docetaxel (45.8% vs 29.0%, p value = ", "ParentId": "88f0e9d5-b981-4e70-a13a-4fc7b40c2edc"}, {"Element": "<span lang=\"EN-GB\">0.0141</span>", "ID": "cb83db83-b1f1-421d-9324-02e0a8afefcb", "Styles": "None", "Classes": "None", "Text": "0.0141", "ParentId": "88f0e9d5-b981-4e70-a13a-4fc7b40c2edc"}, {"Element": "<span lang=\"EN-GB\">). A consistent pattern of results was\nobserved regardless of pCR definition. The difference in pCR rate is considered\nlikely to translate into a clinically meaningful difference in long term\noutcomes and is supported by positive trends in PFS (HR 0.69, 95% CI 0.34, 1.40)\nand DFS (HR 0.60, 95% CI 0.28, 1.27).<u> </u></span>", "ID": "ce0637a2-433e-4e67-86a7-3c4f93912178", "Styles": "None", "Classes": "None", "Text": "). A consistent pattern of results was observed regardless of pCR definition. The difference in pCR rate is considered likely to translate into a clinically meaningful difference in long term outcomes and is supported by positive trends in PFS (HR 0.69, 95% CI 0.34, 1.40) and DFS (HR 0.60, 95% CI 0.28, 1.27).", "ParentId": "88f0e9d5-b981-4e70-a13a-4fc7b40c2edc"}, {"Element": "<u> </u>", "ID": "1fc0693f-a221-4223-ace1-47f69116efd5", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "ce0637a2-433e-4e67-86a7-3c4f93912178"}, {"Element": "<p class=\"MsoNormal\"><u><span lang=\"EN-GB\" style=\"color:black\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>", "ID": "b6430f67-7ff0-4139-9d11-bfea7471a212", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<u><span lang=\"EN-GB\" style=\"color:black\"><span style=\"text-decoration:none\">\u00a0</span></span></u>", "ID": "95494fe8-2a53-485c-86bd-edfabffde6b8", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b6430f67-7ff0-4139-9d11-bfea7471a212"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\"><span style=\"text-decoration:none\">\u00a0</span></span>", "ID": "bf17e28b-629a-471c-a83b-0fa5399c847f", "Styles": "color:black", "Classes": "None", "Text": "", "ParentId": "95494fe8-2a53-485c-86bd-edfabffde6b8"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "04874a63-5933-4488-8649-cb6896e72ad7", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "bf17e28b-629a-471c-a83b-0fa5399c847f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The pCR rates as well as the magnitude of\nbenefit with Perjeta (Perjeta plus trastuzumab and docetaxel compared to\npatients receiving trastuzumab and docetaxel) were lower in the subgroup of\npatients with hormone receptor-positive tumours (difference of 6% in pCR in the\nbreast) than in patients with hormone receptor-negative tumours (difference of\n26.4% in pCR in the breast).</span><span lang=\"EN-GB\"> </span></p>", "ID": "57bef2be-d2dd-43b1-aae0-06e4d4bd5fe9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">The pCR rates as well as the magnitude of\nbenefit with Perjeta (Perjeta plus trastuzumab and docetaxel compared to\npatients receiving trastuzumab and docetaxel) were lower in the subgroup of\npatients with hormone receptor-positive tumours (difference of 6% in pCR in the\nbreast) than in patients with hormone receptor-negative tumours (difference of\n26.4% in pCR in the breast).</span>", "ID": "b762a43e-728a-45db-ab84-6792f7a1e5cc", "Styles": "None", "Classes": "None", "Text": "The pCR rates as well as the magnitude of benefit with Perjeta (Perjeta plus trastuzumab and docetaxel compared to patients receiving trastuzumab and docetaxel) were lower in the subgroup of patients with hormone receptor-positive tumours (difference of 6% in pCR in the breast) than in patients with hormone receptor-negative tumours (difference of 26.4% in pCR in the breast).", "ParentId": "57bef2be-d2dd-43b1-aae0-06e4d4bd5fe9"}, {"Element": "<span lang=\"EN-GB\"> </span>", "ID": "117839ff-3130-4938-9c43-d6aff7bf35fe", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "57bef2be-d2dd-43b1-aae0-06e4d4bd5fe9"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">pCR rates were similar in patients with operable\nversus locally advanced disease. There were too few patients with inflammatory\nbreast cancer to draw any firm conclusions but the pCR rate was higher in\npatients who received Perjeta plus trastuzumab and docetaxel.</span></p>", "ID": "1b8e0627-3333-43ac-806b-783628eff517", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">pCR rates were similar in patients with operable\nversus locally advanced disease. There were too few patients with inflammatory\nbreast cancer to draw any firm conclusions but the pCR rate was higher in\npatients who received Perjeta plus trastuzumab and docetaxel.</span>", "ID": "e50864b1-a425-4c2d-864d-e44c5ca92d50", "Styles": "None", "Classes": "None", "Text": "pCR rates were similar in patients with operable versus locally advanced disease. There were too few patients with inflammatory breast cancer to draw any firm conclusions but the pCR rate was higher in patients who received Perjeta plus trastuzumab and docetaxel.", "ParentId": "1b8e0627-3333-43ac-806b-783628eff517"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5edc1ae6-9c71-4dcc-86d8-16f1103c5d1f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "16754f4e-08a1-4cd3-87a5-8261f9d1b12b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5edc1ae6-9c71-4dcc-86d8-16f1103c5d1f"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">TRYPHAENA\n(BO22280)</span></b></p>", "ID": "1d55c45a-15e3-4f95-8d64-de3506887e82", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">TRYPHAENA\n(BO22280)</span></b>", "ID": "9b199bf3-ac72-42b1-a3cf-1e90c45b3e7b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "1d55c45a-15e3-4f95-8d64-de3506887e82"}, {"Element": "<span lang=\"EN-GB\">TRYPHAENA\n(BO22280)</span>", "ID": "ade550aa-0510-40b6-bff8-25d037e36ee3", "Styles": "None", "Classes": "None", "Text": "TRYPHAENA (BO22280)", "ParentId": "9b199bf3-ac72-42b1-a3cf-1e90c45b3e7b"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "b621ce52-f32d-4820-a9ab-6feb4d514d40", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "1a69b29e-838f-4b67-b456-cedc2f509962", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b621ce52-f32d-4820-a9ab-6feb4d514d40"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5faf701b-67ef-43e7-962c-5c788bd276b9", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1a69b29e-838f-4b67-b456-cedc2f509962"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">TRYPHAENA is\na multicentre, randomised phase II clinical trial conducted in 225 adult female\npatients with HER2-positive locally advanced, operable, or inflammatory breast\ncancer (T2-4d; primary tumour\u00a0 &gt; 2cm in diameter) who had not received prior\ntrastuzumab, chemotherapy or radiotherapy.\u00a0 Patients with metastases, bilateral\nbreast cancer, clinically important cardiac risk factors (see section 4.4) or\nLVEF\u00a0 &lt;\u00a0 55% were not included. The majority of patients were less than 65\nyears old. Patients were randomised to receive one of three neoadjuvant\nregimens prior to surgery as follows: </span></p>", "ID": "7ee75500-191f-446a-8b52-c11dcc38e2c0", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">TRYPHAENA is\na multicentre, randomised phase II clinical trial conducted in 225 adult female\npatients with HER2-positive locally advanced, operable, or inflammatory breast\ncancer (T2-4d; primary tumour\u00a0 &gt; 2cm in diameter) who had not received prior\ntrastuzumab, chemotherapy or radiotherapy.\u00a0 Patients with metastases, bilateral\nbreast cancer, clinically important cardiac risk factors (see section 4.4) or\nLVEF\u00a0 &lt;\u00a0 55% were not included. The majority of patients were less than 65\nyears old. Patients were randomised to receive one of three neoadjuvant\nregimens prior to surgery as follows: </span>", "ID": "5630e026-8682-4b1a-bb6a-b0d68be95793", "Styles": "None", "Classes": "None", "Text": "TRYPHAENA is a multicentre, randomised phase II clinical trial conducted in 225 adult female patients with HER2-positive locally advanced, operable, or inflammatory breast cancer (T2-4d; primary tumour\u00a0 > 2cm in diameter) who had not received prior trastuzumab, chemotherapy or radiotherapy.\u00a0 Patients with metastases, bilateral breast cancer, clinically important cardiac risk factors (see section 4.4) or LVEF\u00a0 <\u00a0 55% were not included. The majority of patients were less than 65 years old. Patients were randomised to receive one of three neoadjuvant regimens prior to surgery as follows: ", "ParentId": "7ee75500-191f-446a-8b52-c11dcc38e2c0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "750d1edd-824f-4f9f-9824-8be854fabda3", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0631ed0a-aeda-4605-8749-7c89256798cf", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "750d1edd-824f-4f9f-9824-8be854fabda3"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:35.7pt;text-indent:-17.85pt\"><span style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 <span lang=\"EN-GB\" style=\"color:black\">3\ncycles of FEC followed by 3 cycles of docetaxel, all given concurrently with\nPerjeta and trastuzumab</span></p>", "ID": "3e36acf6-2433-44de-841d-804986a93715", "Styles": "margin-left:35.7pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span style=\"font-family:Symbol\">\u00b7</span>", "ID": "5a8667f0-152e-45aa-9b66-8706d73a2bf0", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "3e36acf6-2433-44de-841d-804986a93715"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">3\ncycles of FEC followed by 3 cycles of docetaxel, all given concurrently with\nPerjeta and trastuzumab</span>", "ID": "d3c0ce0a-b8a1-4db9-94f9-34cd7ed9b411", "Styles": "color:black", "Classes": "None", "Text": "3 cycles of FEC followed by 3 cycles of docetaxel, all given concurrently with Perjeta and trastuzumab", "ParentId": "3e36acf6-2433-44de-841d-804986a93715"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:35.7pt;text-indent:-17.85pt\"><span style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 <span lang=\"EN-GB\" style=\"color:black\">3\ncycles of FEC alone followed by 3 cycles of docetaxel, with trastuzumab and\nPerjeta given concurrently</span></p>", "ID": "a7163967-d118-471b-962b-d9da1f1c2542", "Styles": "margin-left:35.7pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span style=\"font-family:Symbol\">\u00b7</span>", "ID": "f577e769-34ad-466c-a8ca-10597202b86c", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "a7163967-d118-471b-962b-d9da1f1c2542"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">3\ncycles of FEC alone followed by 3 cycles of docetaxel, with trastuzumab and\nPerjeta given concurrently</span>", "ID": "0628c298-fb3a-4836-884e-19a3c5bd62f6", "Styles": "color:black", "Classes": "None", "Text": "3 cycles of FEC alone followed by 3 cycles of docetaxel, with trastuzumab and Perjeta given concurrently", "ParentId": "a7163967-d118-471b-962b-d9da1f1c2542"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:35.7pt;text-indent:-17.85pt\"><span style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 <span lang=\"EN-GB\" style=\"color:black\">6\ncycles of TCH in combination with Perjeta. </span></p>", "ID": "ba909283-f36d-4b23-9124-aaf8a01c36cd", "Styles": "margin-left:35.7pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span style=\"font-family:Symbol\">\u00b7</span>", "ID": "69103419-d03b-405a-b4bb-b39ba94a610d", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "ba909283-f36d-4b23-9124-aaf8a01c36cd"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">6\ncycles of TCH in combination with Perjeta. </span>", "ID": "6dbf4e4b-d2e5-4641-85c5-d8baa357edb5", "Styles": "color:black", "Classes": "None", "Text": "6 cycles of TCH in combination with Perjeta. ", "ParentId": "ba909283-f36d-4b23-9124-aaf8a01c36cd"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:35.7pt;text-indent:-17.85pt\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>", "ID": "6e4038bc-ae6a-4b44-ba8a-6a55b1491a20", "Styles": "margin-left:35.7pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">\u00a0</span>", "ID": "e0b44220-e8dc-461e-81ef-7c54c9a8721f", "Styles": "color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "6e4038bc-ae6a-4b44-ba8a-6a55b1491a20"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Randomisation was stratified by breast\ncancer type (operable, locally advanced, or inflammatory) and ER and /or PgR\npositivity. </span></p>", "ID": "5da80187-ab06-44a5-bbcc-2bd3d83ca1af", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Randomisation was stratified by breast\ncancer type (operable, locally advanced, or inflammatory) and ER and /or PgR\npositivity. </span>", "ID": "d0e40065-f127-48a9-afa3-09de6b96c74f", "Styles": "None", "Classes": "None", "Text": "Randomisation was stratified by breast cancer type (operable, locally advanced, or inflammatory) and ER and /or PgR positivity. ", "ParentId": "5da80187-ab06-44a5-bbcc-2bd3d83ca1af"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "182ad40b-fbad-49e3-88b0-ba6926c893ca", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e5ef4e4a-ec48-4b38-bbdb-cb5f4baab7b8", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "182ad40b-fbad-49e3-88b0-ba6926c893ca"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Pertuzumab was given intravenously at an\ninitial dose of 840 mg, followed by 420 mg every three weeks.\u00a0 Trastuzumab was\ngiven intravenously at an initial dose of 8 mg/kg, followed by 6 mg/kg every\nthree weeks.\u00a0 FEC (5-fluorouracil [500\u00a0mg/m<sup>2</sup>], epirubicin [100\nmg/m2], cyclophosphamide [600 mg/m2]) were given intravenously every three\nweeks for 3 cycles.\u00a0 Docetaxel was given as an initial dose of 75\u00a0mg/m<sup>2</sup>\nIV infusion every three weeks with the option to escalate to 100 mg/m<sup>2</sup>\nat the investigator\u2019s discretion if the initial dose was well tolerated.\u00a0\nHowever, in the group treated with Perjeta in combination with TCH, docetaxel\nwas given intravenously at 75\u00a0mg/m<sup>2</sup> (no escalation was\npermitted) and carboplatin (AUC 6) was given intravenously every three weeks.\nFollowing surgery all patients received trastuzumab</span><span lang=\"EN-GB\"> to\ncomplete </span><span lang=\"EN-GB\">one year of therapy</span><span lang=\"EN-GB\">.</span></p>", "ID": "e7ee5c8d-b937-4efa-998a-33f993cf2f70", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Pertuzumab was given intravenously at an\ninitial dose of 840 mg, followed by 420 mg every three weeks.\u00a0 Trastuzumab was\ngiven intravenously at an initial dose of 8 mg/kg, followed by 6 mg/kg every\nthree weeks.\u00a0 FEC (5-fluorouracil [500\u00a0mg/m<sup>2</sup>], epirubicin [100\nmg/m2], cyclophosphamide [600 mg/m2]) were given intravenously every three\nweeks for 3 cycles.\u00a0 Docetaxel was given as an initial dose of 75\u00a0mg/m<sup>2</sup>\nIV infusion every three weeks with the option to escalate to 100 mg/m<sup>2</sup>\nat the investigator\u2019s discretion if the initial dose was well tolerated.\u00a0\nHowever, in the group treated with Perjeta in combination with TCH, docetaxel\nwas given intravenously at 75\u00a0mg/m<sup>2</sup> (no escalation was\npermitted) and carboplatin (AUC 6) was given intravenously every three weeks.\nFollowing surgery all patients received trastuzumab</span>", "ID": "4c91c05d-db9c-4b1a-ad7a-f5a2ea864b5f", "Styles": "None", "Classes": "None", "Text": "Pertuzumab was given intravenously at an initial dose of 840 mg, followed by 420 mg every three weeks.\u00a0 Trastuzumab was given intravenously at an initial dose of 8 mg/kg, followed by 6 mg/kg every three weeks.\u00a0 FEC (5-fluorouracil [500\u00a0mg/m], epirubicin [100 mg/m2], cyclophosphamide [600 mg/m2]) were given intravenously every three weeks for 3 cycles.\u00a0 Docetaxel was given as an initial dose of 75\u00a0mg/m IV infusion every three weeks with the option to escalate to 100 mg/m at the investigator\u2019s discretion if the initial dose was well tolerated.\u00a0 However, in the group treated with Perjeta in combination with TCH, docetaxel was given intravenously at 75\u00a0mg/m (no escalation was permitted) and carboplatin (AUC 6) was given intravenously every three weeks. Following surgery all patients received trastuzumab", "ParentId": "e7ee5c8d-b937-4efa-998a-33f993cf2f70"}, {"Element": "<sup>2</sup>", "ID": "bd14c5b4-e6f8-4b42-b351-834d1ceff329", "Styles": "None", "Classes": "None", "Text": "2", "ParentId": "4c91c05d-db9c-4b1a-ad7a-f5a2ea864b5f"}, {"Element": "<sup>2</sup>", "ID": "e2b74e2f-7145-4493-aec0-d9efc75bada7", "Styles": "None", "Classes": "None", "Text": "2", "ParentId": "4c91c05d-db9c-4b1a-ad7a-f5a2ea864b5f"}, {"Element": "<sup>2</sup>", "ID": "0fe067c3-79d8-4233-b40e-7ac1a82dbab8", "Styles": "None", "Classes": "None", "Text": "2", "ParentId": "4c91c05d-db9c-4b1a-ad7a-f5a2ea864b5f"}, {"Element": "<sup>2</sup>", "ID": "b4086945-3b26-4d39-b229-6d644012b9c7", "Styles": "None", "Classes": "None", "Text": "2", "ParentId": "4c91c05d-db9c-4b1a-ad7a-f5a2ea864b5f"}, {"Element": "<span lang=\"EN-GB\"> to\ncomplete </span>", "ID": "3d033340-1e72-42be-b354-41be6a2c268b", "Styles": "None", "Classes": "None", "Text": " to complete ", "ParentId": "e7ee5c8d-b937-4efa-998a-33f993cf2f70"}, {"Element": "<span lang=\"EN-GB\">one year of therapy</span>", "ID": "512e5fe9-9fd0-481b-ba66-85a8c6d70ee6", "Styles": "None", "Classes": "None", "Text": "one year of therapy", "ParentId": "e7ee5c8d-b937-4efa-998a-33f993cf2f70"}, {"Element": "<span lang=\"EN-GB\">.</span>", "ID": "6dee2d60-2c29-465f-9fbf-75c417e98913", "Styles": "None", "Classes": "None", "Text": ".", "ParentId": "e7ee5c8d-b937-4efa-998a-33f993cf2f70"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4967afaa-7a85-487d-890c-2d492d9179eb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "fc34499b-a3b7-4763-9003-20ea130ea630", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4967afaa-7a85-487d-890c-2d492d9179eb"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The primary endpoint of this study was\ncardiac safety during the neoadjuvant treatment period of the study.\u00a0 Secondary\nefficacy endpoints were pCR rate in the breast (ypT0/is), DFS, PFS and OS. </span></p>", "ID": "ba0c43d0-8993-4817-841f-1bdb9cce1cb0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">The primary endpoint of this study was\ncardiac safety during the neoadjuvant treatment period of the study.\u00a0 Secondary\nefficacy endpoints were pCR rate in the breast (ypT0/is), DFS, PFS and OS. </span>", "ID": "f3a0764b-1e68-483c-a1bc-279df6bec982", "Styles": "None", "Classes": "None", "Text": "The primary endpoint of this study was cardiac safety during the neoadjuvant treatment period of the study.\u00a0 Secondary efficacy endpoints were pCR rate in the breast (ypT0/is), DFS, PFS and OS. ", "ParentId": "ba0c43d0-8993-4817-841f-1bdb9cce1cb0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f991bb7d-929c-4046-bb42-c5ced3236e97", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6017d3b5-4e7e-4b2b-9663-c7aec97d06ec", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f991bb7d-929c-4046-bb42-c5ced3236e97"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Demographics were well balanced between\narms (median age was 49-50 years, the majority were Caucasian [77%]) and all\npatients were female. Overall 6% of patients had inflammatory breast cancer,\n25% had locally advanced breast cancer and 69% had operable breast cancer.\nApproximately half the patients in each treatment group had ER-positive and/or PgR-positive\ndisease.</span></p>", "ID": "38d2c95f-0821-4bec-bacb-cfc94ad51a3b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Demographics were well balanced between\narms (median age was 49-50 years, the majority were Caucasian [77%]) and all\npatients were female. Overall 6% of patients had inflammatory breast cancer,\n25% had locally advanced breast cancer and 69% had operable breast cancer.\nApproximately half the patients in each treatment group had ER-positive and/or PgR-positive\ndisease.</span>", "ID": "6a520eb4-f305-48c4-b253-e0d470bad4c2", "Styles": "None", "Classes": "None", "Text": "Demographics were well balanced between arms (median age was 49-50 years, the majority were Caucasian [77%]) and all patients were female. Overall 6% of patients had inflammatory breast cancer, 25% had locally advanced breast cancer and 69% had operable breast cancer. Approximately half the patients in each treatment group had ER-positive and/or PgR-positive disease.", "ParentId": "38d2c95f-0821-4bec-bacb-cfc94ad51a3b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "db7d9ccc-15f3-4507-b28e-1e22d50d1a67", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0b2db694-a347-484d-af00-5432cd291002", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "db7d9ccc-15f3-4507-b28e-1e22d50d1a67"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Compared with published data for similar\nregimens without pertuzumab, high pCR rates were observed in all 3 treatment arms\n(see Table 4). A consistent pattern of results was observed regardless of pCR\ndefinition used. The pCR rates were lower in the subgroup of patients with\nhormone receptor-positive tumours (range 46.2% to 50.0%) than in patients with\nhormone receptor-negative tumours (range 65.0% to 83.8%).</span></p>", "ID": "1b987258-bf53-41b2-a9d5-7eb9116cce35", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Compared with published data for similar\nregimens without pertuzumab, high pCR rates were observed in all 3 treatment arms\n(see Table 4). A consistent pattern of results was observed regardless of pCR\ndefinition used. The pCR rates were lower in the subgroup of patients with\nhormone receptor-positive tumours (range 46.2% to 50.0%) than in patients with\nhormone receptor-negative tumours (range 65.0% to 83.8%).</span>", "ID": "f1373521-101f-4352-acf0-dfb10d3d1a40", "Styles": "None", "Classes": "None", "Text": "Compared with published data for similar regimens without pertuzumab, high pCR rates were observed in all 3 treatment arms (see Table 4). A consistent pattern of results was observed regardless of pCR definition used. The pCR rates were lower in the subgroup of patients with hormone receptor-positive tumours (range 46.2% to 50.0%) than in patients with hormone receptor-negative tumours (range 65.0% to 83.8%).", "ParentId": "1b987258-bf53-41b2-a9d5-7eb9116cce35"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2b4708b1-d263-4ed9-a34c-065b6556b9af", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7c735808-0308-425c-b109-f1ccae2086f4", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2b4708b1-d263-4ed9-a34c-065b6556b9af"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">pCR rates were similar in patients with\noperable and locally advanced disease. There were too few patients with\ninflammatory breast cancer to draw any firm conclusions. </span></p>", "ID": "7dec3e54-bcc3-4e1e-ac8b-b3b9b3c615f6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">pCR rates were similar in patients with\noperable and locally advanced disease. There were too few patients with\ninflammatory breast cancer to draw any firm conclusions. </span>", "ID": "3d1590ce-1778-4e19-9d0f-b37b8db92bab", "Styles": "None", "Classes": "None", "Text": "pCR rates were similar in patients with operable and locally advanced disease. There were too few patients with inflammatory breast cancer to draw any firm conclusions. ", "ParentId": "7dec3e54-bcc3-4e1e-ac8b-b3b9b3c615f6"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "bb7681e8-4880-4062-8d36-1f4256ce6c38", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.75in;text-indent:-.75in;page-break-after:\navoid\"><b><span lang=\"EN-GB\" style=\"color:black\">Table 4\u00a0\u00a0\u00a0\u00a0\u00a0 NEOSPHERE (WO20697)\nand TRYPHAENA (BO22280): Overview of efficacy (Intent to Treat Population) </span></b></p>", "ID": "312951a6-479f-45f4-bac4-fe1f4b56741a", "Styles": "margin-left:.75in;text-indent:-.75in;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\" style=\"color:black\">Table 4\u00a0\u00a0\u00a0\u00a0\u00a0 NEOSPHERE (WO20697)\nand TRYPHAENA (BO22280): Overview of efficacy (Intent to Treat Population) </span></b>", "ID": "23855751-0e46-47ad-89c3-20886bf8830c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "312951a6-479f-45f4-bac4-fe1f4b56741a"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Table 4\u00a0\u00a0\u00a0\u00a0\u00a0 NEOSPHERE (WO20697)\nand TRYPHAENA (BO22280): Overview of efficacy (Intent to Treat Population) </span>", "ID": "18c694bf-c736-4997-86f5-ea2391ac0913", "Styles": "color:black", "Classes": "None", "Text": "Table 4\u00a0\u00a0\u00a0\u00a0\u00a0 NEOSPHERE (WO20697) and TRYPHAENA (BO22280): Overview of efficacy (Intent to Treat Population) ", "ParentId": "23855751-0e46-47ad-89c3-20886bf8830c"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "86c657aa-ec97-4735-98eb-e3e34ce4f484", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "be2950f0-2f8f-44c9-bf99-9e975ecb99e0", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "86c657aa-ec97-4735-98eb-e3e34ce4f484"}, {"Element": "<div align=\"center\">\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\" width=\"108%\">\n<thead>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:10.6%;border:solid windowtext 1.0pt;padding:\n   0in 2.85pt 0in 2.85pt\" width=\"10%\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n   2.5pt;margin-left:0in;line-height:12.0pt;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></b></p>\n</td>\n<td colspan=\"4\" style=\"width:47.48%;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 2.85pt 0in 2.85pt\" width=\"47%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">NEOSPHERE (WO20697)</span></b></p>\n</td>\n<td colspan=\"3\" style=\"width:41.92%;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 2.85pt 0in 2.85pt\" width=\"41%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">TRYPHAENA (BO22280)</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:10.6%;border:solid windowtext 1.0pt;border-top:\n   none;padding:0in 2.85pt 0in 2.85pt\" width=\"10%\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n   2.5pt;margin-left:0in;line-height:12.0pt;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Parameter</span></b></p>\n</td>\n<td style=\"width:11.44%;border-top:none;border-left:none;\n   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n   padding:0in 2.85pt 0in 2.85pt\" width=\"11%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Trastuzumab +Docetaxel</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">N=107</span></b></p>\n</td>\n<td style=\"width:12.1%;border-top:none;border-left:none;\n   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n   padding:0in 2.85pt 0in 2.85pt\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Perjeta+</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Trastuzumab+</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Docetaxel</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">N=107</span></b></p>\n</td>\n<td style=\"width:12.12%;border-top:none;border-left:none;\n   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n   padding:0in 2.85pt 0in 2.85pt\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Perjeta+</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Trastuzumab</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">N=107</span></b></p>\n</td>\n<td style=\"width:11.82%;border-top:none;border-left:none;\n   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n   padding:0in 2.85pt 0in 2.85pt\" width=\"11%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Perjeta</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">+Docetaxel</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">N=96</span></b></p>\n</td>\n<td style=\"width:13.72%;border-top:none;border-left:none;\n   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n   padding:0in 2.85pt 0in 2.85pt\" width=\"13%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:-1.45pt;\n   margin-bottom:2.5pt;margin-left:-1.2pt;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"ES\" style=\"font-size:10.0pt;color:black\">Perjeta+</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:-1.45pt;\n   margin-bottom:2.5pt;margin-left:-1.2pt;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"ES\" style=\"font-size:10.0pt;color:black\">Trastuzumab+</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:-1.45pt;\n   margin-bottom:2.5pt;margin-left:-1.2pt;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"ES\" style=\"font-size:10.0pt;color:black\">FEC</span></b><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Wingdings;color:black\">\u00e0</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"ES\" style=\"font-size:10.0pt;color:black\">Perjeta+</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"ES\" style=\"font-size:10.0pt;color:black\">Trastuzumab+</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Docetaxel</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">N=73</span></b></p>\n</td>\n<td style=\"width:13.44%;border-top:none;border-left:none;\n   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n   padding:0in 2.85pt 0in 2.85pt\" width=\"13%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"ES\" style=\"font-size:10.0pt;color:black\">FEC</span></b><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Wingdings;color:black\">\u00e0</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"ES\" style=\"font-size:10.0pt;color:black\">Perjeta+</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"ES\" style=\"font-size:10.0pt;color:black\">Trastuzumab+</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"ES\" style=\"font-size:10.0pt;color:black\">Docetaxel</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"ES\" style=\"font-size:10.0pt;color:black\">N=75</span></b></p>\n</td>\n<td style=\"width:14.76%;border-top:none;border-left:none;\n   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n   padding:0in 2.85pt 0in 2.85pt\" width=\"14%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Perjeta</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">+TCH</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">N=77</span></b></p>\n</td>\n</tr>\n</thead>\n<tr style=\"page-break-inside:avoid;height:48.2pt\">\n<td style=\"width:10.6%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt;height:48.2pt\" valign=\"top\" width=\"10%\">\n<p class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;margin-bottom:\n  1.0pt;margin-left:0in;line-height:14.0pt;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">pCR rate in the breast\n  (ypT0/is)</span></p>\n<p class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;margin-bottom:\n  1.0pt;margin-left:0in;line-height:14.0pt;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">n (%)</span></p>\n<p class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;margin-bottom:\n  1.0pt;margin-left:0in;line-height:14.0pt;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[95% CI]<sup>1</sup></span></p>\n</td>\n<td style=\"width:11.44%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:48.2pt\" width=\"11%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">31\n  (29.0%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[20.6;\n  38.5]</span></p>\n</td>\n<td style=\"width:12.1%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:48.2pt\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">49\n  (45.8%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[36.1;\n  55.7]</span></p>\n</td>\n<td style=\"width:12.12%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:48.2pt\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">18\n  (16.8%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[10.3;\n  25.3]</span></p>\n</td>\n<td style=\"width:11.82%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:48.2pt\" width=\"11%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">23\n  (24.0%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[15.8;\n  33.7]</span></p>\n</td>\n<td style=\"width:13.72%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:48.2pt\" width=\"13%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">45\n  (61.6%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[49.5;\n  72.8]</span></p>\n</td>\n<td style=\"width:13.44%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:48.2pt\" width=\"13%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">43\n  (57.3%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[45.4;\n  68.7]</span></p>\n</td>\n<td style=\"width:14.76%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:48.2pt\" width=\"14%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">51\n  (66.2%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[54.6;\n  76.6]</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:10.6%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"top\" width=\"10%\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Difference in pCR rates<sup>2</sup></span></p>\n<p class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;margin-bottom:\n  1.0pt;margin-left:0in;line-height:14.0pt;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[95% CI]<sup>3</sup></span></p>\n</td>\n<td style=\"width:11.44%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"11%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td style=\"width:12.1%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">+16.8 %</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[3.5; 30.1]</span></p>\n</td>\n<td style=\"width:12.12%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">-12.2 %</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:-4.05pt;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;text-indent:-4.1pt;\n  line-height:14.0pt;page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[-23.8; -0.5]</span></p>\n</td>\n<td style=\"width:11.82%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"11%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">-21.8 %</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:-2.8pt;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;text-indent:-1.65pt;\n  line-height:14.0pt;page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[-35.1; -8.5]</span></p>\n</td>\n<td style=\"width:13.72%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"13%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">NA</span></p>\n</td>\n<td style=\"width:13.44%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"13%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">NA</span></p>\n</td>\n<td style=\"width:14.76%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"14%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">NA</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:10.6%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"top\" width=\"10%\">\n<p class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;margin-bottom:\n  1.0pt;margin-left:0in;line-height:14.0pt;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">p-value (with Simes corr. for\n  CMH test)<sup>4</sup></span></p>\n</td>\n<td style=\"width:11.44%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"11%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td style=\"width:12.1%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">0.0141</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">(vs.\n  Trastuzumab+Docetaxel)</span></p>\n</td>\n<td style=\"width:12.12%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">0.0198</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">(vs.\n  Trastuzumab+Docetaxel)</span></p>\n</td>\n<td style=\"width:11.82%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"11%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">0.0030</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:-4.45pt;\n  margin-bottom:1.0pt;margin-left:-2.8pt;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">(vs\n  Perjeta+</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:-4.45pt;\n  margin-bottom:1.0pt;margin-left:-2.8pt;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Trastuzumab+Docetaxel)</span></p>\n</td>\n<td style=\"width:13.72%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"13%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">NA</span></p>\n</td>\n<td style=\"width:13.44%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"13%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">NA</span></p>\n</td>\n<td style=\"width:14.76%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"14%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">NA</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:10.6%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"top\" width=\"10%\">\n<p class=\"MsoNormal\" style=\"line-height:14.0pt;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">pCR rate in the breast and\n  lymph node (ypT0/is N0)</span></p>\n<p class=\"MsoNormal\" style=\"margin-bottom:1.0pt;line-height:14.0pt;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">n (%)</span></p>\n<p class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;margin-bottom:\n  1.0pt;margin-left:0in;line-height:14.0pt;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[95% CI]</span></p>\n</td>\n<td style=\"width:11.44%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"11%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">23\n  (21.5%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[14.1;\n  30.5]</span></p>\n</td>\n<td style=\"width:12.1%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">42\n  (39.3%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[30.3;\n  49.2]</span></p>\n</td>\n<td style=\"width:12.12%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">12\n  (11.2%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[5.9;\n  18.8]</span></p>\n</td>\n<td style=\"width:11.82%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"11%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">17\n  (17.7%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[10.7;\n  26.8]</span></p>\n</td>\n<td style=\"width:13.72%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"13%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">41\n  (56.2%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[44.1;\n  67.8]</span></p>\n</td>\n<td style=\"width:13.44%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"13%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">41\n  (54.7%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[42.7;\n  66.2]</span></p>\n</td>\n<td style=\"width:14.76%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"14%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">49\n  (63.6%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[51.9;\n  74.3]</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:10.6%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"top\" width=\"10%\">\n<p class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;margin-bottom:\n  1.0pt;margin-left:0in;line-height:14.0pt;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">ypT0 N0 </span></p>\n<p class=\"MsoNormal\" style=\"margin-bottom:1.0pt;line-height:14.0pt;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">n (%)</span></p>\n<p class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;margin-bottom:\n  1.0pt;margin-left:0in;line-height:14.0pt;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[95% CI]</span></p>\n</td>\n<td style=\"width:11.44%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"11%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">13\n  (12.1%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[6.6;\n  19.9]</span></p>\n</td>\n<td style=\"width:12.1%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">35\n  (32.7%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[24.0;\n  42.5]</span></p>\n</td>\n<td style=\"width:12.12%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">6\n  (5.6%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[2.1;\n  11.8]</span></p>\n</td>\n<td style=\"width:11.82%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"11%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">13\n  (13.2%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[7.4;\n  22.0]</span></p>\n</td>\n<td style=\"width:13.72%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"13%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">37\n  (50.7%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[38.7;\n  62.6]</span></p>\n</td>\n<td style=\"width:13.44%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"13%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">34\n  (45.3%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[33.8;\n  57.3]</span></p>\n</td>\n<td style=\"width:14.76%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"14%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">40\n  (51.9%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[40.3;\n  63.5]</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:10.6%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"top\" width=\"10%\">\n<p class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;margin-bottom:\n  1.0pt;margin-left:0in;line-height:14.0pt;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Clinical Response<sup>5</sup></span></p>\n</td>\n<td style=\"width:11.44%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"11%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">79\n  (79.8%)</span></p>\n</td>\n<td style=\"width:12.1%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">89\n  (88.1%)</span></p>\n</td>\n<td style=\"width:12.12%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">69\n  (67.6%)</span></p>\n</td>\n<td style=\"width:11.82%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"11%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">65\n  (71.4%)</span></p>\n</td>\n<td style=\"width:13.72%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"13%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">67\n  (91.8%)</span></p>\n</td>\n<td style=\"width:13.44%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"13%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">71\n  (94.7%)</span></p>\n</td>\n<td style=\"width:14.76%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"14%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">69\n  (89.6%)</span></p>\n</td>\n</tr>\n</table>\n</div>", "ID": "15b40999-cd5a-40a5-9b4f-2088191ecc9f", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\" width=\"108%\">\n<thead>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:10.6%;border:solid windowtext 1.0pt;padding:\n   0in 2.85pt 0in 2.85pt\" width=\"10%\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n   2.5pt;margin-left:0in;line-height:12.0pt;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></b></p>\n</td>\n<td colspan=\"4\" style=\"width:47.48%;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 2.85pt 0in 2.85pt\" width=\"47%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">NEOSPHERE (WO20697)</span></b></p>\n</td>\n<td colspan=\"3\" style=\"width:41.92%;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 2.85pt 0in 2.85pt\" width=\"41%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">TRYPHAENA (BO22280)</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:10.6%;border:solid windowtext 1.0pt;border-top:\n   none;padding:0in 2.85pt 0in 2.85pt\" width=\"10%\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n   2.5pt;margin-left:0in;line-height:12.0pt;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Parameter</span></b></p>\n</td>\n<td style=\"width:11.44%;border-top:none;border-left:none;\n   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n   padding:0in 2.85pt 0in 2.85pt\" width=\"11%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Trastuzumab +Docetaxel</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">N=107</span></b></p>\n</td>\n<td style=\"width:12.1%;border-top:none;border-left:none;\n   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n   padding:0in 2.85pt 0in 2.85pt\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Perjeta+</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Trastuzumab+</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Docetaxel</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">N=107</span></b></p>\n</td>\n<td style=\"width:12.12%;border-top:none;border-left:none;\n   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n   padding:0in 2.85pt 0in 2.85pt\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Perjeta+</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Trastuzumab</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">N=107</span></b></p>\n</td>\n<td style=\"width:11.82%;border-top:none;border-left:none;\n   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n   padding:0in 2.85pt 0in 2.85pt\" width=\"11%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Perjeta</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">+Docetaxel</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">N=96</span></b></p>\n</td>\n<td style=\"width:13.72%;border-top:none;border-left:none;\n   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n   padding:0in 2.85pt 0in 2.85pt\" width=\"13%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:-1.45pt;\n   margin-bottom:2.5pt;margin-left:-1.2pt;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"ES\" style=\"font-size:10.0pt;color:black\">Perjeta+</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:-1.45pt;\n   margin-bottom:2.5pt;margin-left:-1.2pt;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"ES\" style=\"font-size:10.0pt;color:black\">Trastuzumab+</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:-1.45pt;\n   margin-bottom:2.5pt;margin-left:-1.2pt;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"ES\" style=\"font-size:10.0pt;color:black\">FEC</span></b><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Wingdings;color:black\">\u00e0</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"ES\" style=\"font-size:10.0pt;color:black\">Perjeta+</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"ES\" style=\"font-size:10.0pt;color:black\">Trastuzumab+</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Docetaxel</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">N=73</span></b></p>\n</td>\n<td style=\"width:13.44%;border-top:none;border-left:none;\n   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n   padding:0in 2.85pt 0in 2.85pt\" width=\"13%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"ES\" style=\"font-size:10.0pt;color:black\">FEC</span></b><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Wingdings;color:black\">\u00e0</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"ES\" style=\"font-size:10.0pt;color:black\">Perjeta+</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"ES\" style=\"font-size:10.0pt;color:black\">Trastuzumab+</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"ES\" style=\"font-size:10.0pt;color:black\">Docetaxel</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"ES\" style=\"font-size:10.0pt;color:black\">N=75</span></b></p>\n</td>\n<td style=\"width:14.76%;border-top:none;border-left:none;\n   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n   padding:0in 2.85pt 0in 2.85pt\" width=\"14%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Perjeta</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">+TCH</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">N=77</span></b></p>\n</td>\n</tr>\n</thead>\n<tr style=\"page-break-inside:avoid;height:48.2pt\">\n<td style=\"width:10.6%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt;height:48.2pt\" valign=\"top\" width=\"10%\">\n<p class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;margin-bottom:\n  1.0pt;margin-left:0in;line-height:14.0pt;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">pCR rate in the breast\n  (ypT0/is)</span></p>\n<p class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;margin-bottom:\n  1.0pt;margin-left:0in;line-height:14.0pt;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">n (%)</span></p>\n<p class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;margin-bottom:\n  1.0pt;margin-left:0in;line-height:14.0pt;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[95% CI]<sup>1</sup></span></p>\n</td>\n<td style=\"width:11.44%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:48.2pt\" width=\"11%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">31\n  (29.0%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[20.6;\n  38.5]</span></p>\n</td>\n<td style=\"width:12.1%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:48.2pt\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">49\n  (45.8%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[36.1;\n  55.7]</span></p>\n</td>\n<td style=\"width:12.12%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:48.2pt\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">18\n  (16.8%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[10.3;\n  25.3]</span></p>\n</td>\n<td style=\"width:11.82%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:48.2pt\" width=\"11%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">23\n  (24.0%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[15.8;\n  33.7]</span></p>\n</td>\n<td style=\"width:13.72%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:48.2pt\" width=\"13%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">45\n  (61.6%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[49.5;\n  72.8]</span></p>\n</td>\n<td style=\"width:13.44%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:48.2pt\" width=\"13%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">43\n  (57.3%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[45.4;\n  68.7]</span></p>\n</td>\n<td style=\"width:14.76%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:48.2pt\" width=\"14%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">51\n  (66.2%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[54.6;\n  76.6]</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:10.6%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"top\" width=\"10%\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Difference in pCR rates<sup>2</sup></span></p>\n<p class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;margin-bottom:\n  1.0pt;margin-left:0in;line-height:14.0pt;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[95% CI]<sup>3</sup></span></p>\n</td>\n<td style=\"width:11.44%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"11%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td style=\"width:12.1%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">+16.8 %</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[3.5; 30.1]</span></p>\n</td>\n<td style=\"width:12.12%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">-12.2 %</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:-4.05pt;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;text-indent:-4.1pt;\n  line-height:14.0pt;page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[-23.8; -0.5]</span></p>\n</td>\n<td style=\"width:11.82%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"11%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">-21.8 %</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:-2.8pt;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;text-indent:-1.65pt;\n  line-height:14.0pt;page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[-35.1; -8.5]</span></p>\n</td>\n<td style=\"width:13.72%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"13%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">NA</span></p>\n</td>\n<td style=\"width:13.44%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"13%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">NA</span></p>\n</td>\n<td style=\"width:14.76%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"14%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">NA</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:10.6%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"top\" width=\"10%\">\n<p class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;margin-bottom:\n  1.0pt;margin-left:0in;line-height:14.0pt;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">p-value (with Simes corr. for\n  CMH test)<sup>4</sup></span></p>\n</td>\n<td style=\"width:11.44%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"11%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td style=\"width:12.1%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">0.0141</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">(vs.\n  Trastuzumab+Docetaxel)</span></p>\n</td>\n<td style=\"width:12.12%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">0.0198</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">(vs.\n  Trastuzumab+Docetaxel)</span></p>\n</td>\n<td style=\"width:11.82%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"11%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">0.0030</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:-4.45pt;\n  margin-bottom:1.0pt;margin-left:-2.8pt;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">(vs\n  Perjeta+</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:-4.45pt;\n  margin-bottom:1.0pt;margin-left:-2.8pt;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Trastuzumab+Docetaxel)</span></p>\n</td>\n<td style=\"width:13.72%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"13%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">NA</span></p>\n</td>\n<td style=\"width:13.44%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"13%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">NA</span></p>\n</td>\n<td style=\"width:14.76%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"14%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">NA</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:10.6%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"top\" width=\"10%\">\n<p class=\"MsoNormal\" style=\"line-height:14.0pt;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">pCR rate in the breast and\n  lymph node (ypT0/is N0)</span></p>\n<p class=\"MsoNormal\" style=\"margin-bottom:1.0pt;line-height:14.0pt;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">n (%)</span></p>\n<p class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;margin-bottom:\n  1.0pt;margin-left:0in;line-height:14.0pt;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[95% CI]</span></p>\n</td>\n<td style=\"width:11.44%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"11%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">23\n  (21.5%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[14.1;\n  30.5]</span></p>\n</td>\n<td style=\"width:12.1%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">42\n  (39.3%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[30.3;\n  49.2]</span></p>\n</td>\n<td style=\"width:12.12%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">12\n  (11.2%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[5.9;\n  18.8]</span></p>\n</td>\n<td style=\"width:11.82%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"11%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">17\n  (17.7%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[10.7;\n  26.8]</span></p>\n</td>\n<td style=\"width:13.72%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"13%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">41\n  (56.2%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[44.1;\n  67.8]</span></p>\n</td>\n<td style=\"width:13.44%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"13%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">41\n  (54.7%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[42.7;\n  66.2]</span></p>\n</td>\n<td style=\"width:14.76%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"14%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">49\n  (63.6%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[51.9;\n  74.3]</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:10.6%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"top\" width=\"10%\">\n<p class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;margin-bottom:\n  1.0pt;margin-left:0in;line-height:14.0pt;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">ypT0 N0 </span></p>\n<p class=\"MsoNormal\" style=\"margin-bottom:1.0pt;line-height:14.0pt;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">n (%)</span></p>\n<p class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;margin-bottom:\n  1.0pt;margin-left:0in;line-height:14.0pt;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[95% CI]</span></p>\n</td>\n<td style=\"width:11.44%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"11%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">13\n  (12.1%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[6.6;\n  19.9]</span></p>\n</td>\n<td style=\"width:12.1%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">35\n  (32.7%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[24.0;\n  42.5]</span></p>\n</td>\n<td style=\"width:12.12%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">6\n  (5.6%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[2.1;\n  11.8]</span></p>\n</td>\n<td style=\"width:11.82%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"11%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">13\n  (13.2%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[7.4;\n  22.0]</span></p>\n</td>\n<td style=\"width:13.72%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"13%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">37\n  (50.7%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[38.7;\n  62.6]</span></p>\n</td>\n<td style=\"width:13.44%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"13%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">34\n  (45.3%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[33.8;\n  57.3]</span></p>\n</td>\n<td style=\"width:14.76%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"14%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">40\n  (51.9%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[40.3;\n  63.5]</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:10.6%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"top\" width=\"10%\">\n<p class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;margin-bottom:\n  1.0pt;margin-left:0in;line-height:14.0pt;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Clinical Response<sup>5</sup></span></p>\n</td>\n<td style=\"width:11.44%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"11%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">79\n  (79.8%)</span></p>\n</td>\n<td style=\"width:12.1%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">89\n  (88.1%)</span></p>\n</td>\n<td style=\"width:12.12%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">69\n  (67.6%)</span></p>\n</td>\n<td style=\"width:11.82%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"11%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">65\n  (71.4%)</span></p>\n</td>\n<td style=\"width:13.72%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"13%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">67\n  (91.8%)</span></p>\n</td>\n<td style=\"width:13.44%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"13%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">71\n  (94.7%)</span></p>\n</td>\n<td style=\"width:14.76%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"14%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">69\n  (89.6%)</span></p>\n</td>\n</tr>\n</table>", "ID": "3f853db6-990e-4e05-a5db-63e5deba97c8", "Styles": "border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Text": "        ", "ParentId": "15b40999-cd5a-40a5-9b4f-2088191ecc9f"}, {"Element": "<thead>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:10.6%;border:solid windowtext 1.0pt;padding:\n   0in 2.85pt 0in 2.85pt\" width=\"10%\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n   2.5pt;margin-left:0in;line-height:12.0pt;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></b></p>\n</td>\n<td colspan=\"4\" style=\"width:47.48%;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 2.85pt 0in 2.85pt\" width=\"47%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">NEOSPHERE (WO20697)</span></b></p>\n</td>\n<td colspan=\"3\" style=\"width:41.92%;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 2.85pt 0in 2.85pt\" width=\"41%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">TRYPHAENA (BO22280)</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:10.6%;border:solid windowtext 1.0pt;border-top:\n   none;padding:0in 2.85pt 0in 2.85pt\" width=\"10%\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n   2.5pt;margin-left:0in;line-height:12.0pt;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Parameter</span></b></p>\n</td>\n<td style=\"width:11.44%;border-top:none;border-left:none;\n   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n   padding:0in 2.85pt 0in 2.85pt\" width=\"11%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Trastuzumab +Docetaxel</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">N=107</span></b></p>\n</td>\n<td style=\"width:12.1%;border-top:none;border-left:none;\n   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n   padding:0in 2.85pt 0in 2.85pt\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Perjeta+</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Trastuzumab+</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Docetaxel</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">N=107</span></b></p>\n</td>\n<td style=\"width:12.12%;border-top:none;border-left:none;\n   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n   padding:0in 2.85pt 0in 2.85pt\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Perjeta+</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Trastuzumab</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">N=107</span></b></p>\n</td>\n<td style=\"width:11.82%;border-top:none;border-left:none;\n   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n   padding:0in 2.85pt 0in 2.85pt\" width=\"11%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Perjeta</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">+Docetaxel</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">N=96</span></b></p>\n</td>\n<td style=\"width:13.72%;border-top:none;border-left:none;\n   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n   padding:0in 2.85pt 0in 2.85pt\" width=\"13%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:-1.45pt;\n   margin-bottom:2.5pt;margin-left:-1.2pt;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"ES\" style=\"font-size:10.0pt;color:black\">Perjeta+</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:-1.45pt;\n   margin-bottom:2.5pt;margin-left:-1.2pt;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"ES\" style=\"font-size:10.0pt;color:black\">Trastuzumab+</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:-1.45pt;\n   margin-bottom:2.5pt;margin-left:-1.2pt;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"ES\" style=\"font-size:10.0pt;color:black\">FEC</span></b><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Wingdings;color:black\">\u00e0</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"ES\" style=\"font-size:10.0pt;color:black\">Perjeta+</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"ES\" style=\"font-size:10.0pt;color:black\">Trastuzumab+</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Docetaxel</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">N=73</span></b></p>\n</td>\n<td style=\"width:13.44%;border-top:none;border-left:none;\n   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n   padding:0in 2.85pt 0in 2.85pt\" width=\"13%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"ES\" style=\"font-size:10.0pt;color:black\">FEC</span></b><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Wingdings;color:black\">\u00e0</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"ES\" style=\"font-size:10.0pt;color:black\">Perjeta+</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"ES\" style=\"font-size:10.0pt;color:black\">Trastuzumab+</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"ES\" style=\"font-size:10.0pt;color:black\">Docetaxel</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"ES\" style=\"font-size:10.0pt;color:black\">N=75</span></b></p>\n</td>\n<td style=\"width:14.76%;border-top:none;border-left:none;\n   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n   padding:0in 2.85pt 0in 2.85pt\" width=\"14%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Perjeta</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">+TCH</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">N=77</span></b></p>\n</td>\n</tr>\n</thead>", "ID": "395d0472-c119-477f-9dfa-57e1f7e1b659", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "3f853db6-990e-4e05-a5db-63e5deba97c8"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:10.6%;border:solid windowtext 1.0pt;padding:\n   0in 2.85pt 0in 2.85pt\" width=\"10%\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n   2.5pt;margin-left:0in;line-height:12.0pt;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></b></p>\n</td>\n<td colspan=\"4\" style=\"width:47.48%;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 2.85pt 0in 2.85pt\" width=\"47%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">NEOSPHERE (WO20697)</span></b></p>\n</td>\n<td colspan=\"3\" style=\"width:41.92%;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 2.85pt 0in 2.85pt\" width=\"41%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">TRYPHAENA (BO22280)</span></b></p>\n</td>\n</tr>", "ID": "236d9908-c61f-4e19-a503-c6243fb8c9c4", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "    ", "ParentId": "395d0472-c119-477f-9dfa-57e1f7e1b659"}, {"Element": "<td style=\"width:10.6%;border:solid windowtext 1.0pt;padding:\n   0in 2.85pt 0in 2.85pt\" width=\"10%\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n   2.5pt;margin-left:0in;line-height:12.0pt;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></b></p>\n</td>", "ID": "9b14bc44-0bf0-4a55-8456-b0ab4ff1a4a3", "Styles": "width:10.6%;border:solid windowtext 1.0pt;padding:\n   0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "236d9908-c61f-4e19-a503-c6243fb8c9c4"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n   2.5pt;margin-left:0in;line-height:12.0pt;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></b></p>", "ID": "8cc6ac2d-29aa-43fa-be2f-527a2eda1d03", "Styles": "margin-top:2.5pt;margin-right:0in;margin-bottom:\n   2.5pt;margin-left:0in;line-height:12.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9b14bc44-0bf0-4a55-8456-b0ab4ff1a4a3"}, {"Element": "<b><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></b>", "ID": "b55ecc14-4d26-4f6d-97b9-56a69051851d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8cc6ac2d-29aa-43fa-be2f-527a2eda1d03"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span>", "ID": "d6a8888e-b407-4a54-b111-ac73e21d5bc1", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "b55ecc14-4d26-4f6d-97b9-56a69051851d"}, {"Element": "<td colspan=\"4\" style=\"width:47.48%;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 2.85pt 0in 2.85pt\" width=\"47%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">NEOSPHERE (WO20697)</span></b></p>\n</td>", "ID": "ae61ca88-dcb6-420e-a19c-39312e22f64b", "Styles": "width:47.48%;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "236d9908-c61f-4e19-a503-c6243fb8c9c4"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">NEOSPHERE (WO20697)</span></b></p>", "ID": "0aca3ec6-33d9-4f79-b1ed-acb86c24b8ee", "Styles": "margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ae61ca88-dcb6-420e-a19c-39312e22f64b"}, {"Element": "<b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">NEOSPHERE (WO20697)</span></b>", "ID": "c2c57744-2b91-4dcf-809f-872bc93c4e44", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "0aca3ec6-33d9-4f79-b1ed-acb86c24b8ee"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">NEOSPHERE (WO20697)</span>", "ID": "8840781b-3eb6-4f87-afa8-57e944abc426", "Styles": "font-size:10.0pt;\n   color:black", "Classes": "None", "Text": "NEOSPHERE (WO20697)", "ParentId": "c2c57744-2b91-4dcf-809f-872bc93c4e44"}, {"Element": "<td colspan=\"3\" style=\"width:41.92%;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 2.85pt 0in 2.85pt\" width=\"41%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">TRYPHAENA (BO22280)</span></b></p>\n</td>", "ID": "6c770c92-c91e-4019-9d57-4438abd0b34b", "Styles": "width:41.92%;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "236d9908-c61f-4e19-a503-c6243fb8c9c4"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">TRYPHAENA (BO22280)</span></b></p>", "ID": "9d6d52bb-c487-4272-a83a-d4b67e3deb04", "Styles": "margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "6c770c92-c91e-4019-9d57-4438abd0b34b"}, {"Element": "<b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">TRYPHAENA (BO22280)</span></b>", "ID": "d5746021-4508-4efc-8cd9-04e6912a74fa", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "9d6d52bb-c487-4272-a83a-d4b67e3deb04"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">TRYPHAENA (BO22280)</span>", "ID": "8d139602-d468-4323-8283-f40f8c703844", "Styles": "font-size:10.0pt;\n   color:black", "Classes": "None", "Text": "TRYPHAENA (BO22280)", "ParentId": "d5746021-4508-4efc-8cd9-04e6912a74fa"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:10.6%;border:solid windowtext 1.0pt;border-top:\n   none;padding:0in 2.85pt 0in 2.85pt\" width=\"10%\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n   2.5pt;margin-left:0in;line-height:12.0pt;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Parameter</span></b></p>\n</td>\n<td style=\"width:11.44%;border-top:none;border-left:none;\n   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n   padding:0in 2.85pt 0in 2.85pt\" width=\"11%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Trastuzumab +Docetaxel</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">N=107</span></b></p>\n</td>\n<td style=\"width:12.1%;border-top:none;border-left:none;\n   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n   padding:0in 2.85pt 0in 2.85pt\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Perjeta+</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Trastuzumab+</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Docetaxel</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">N=107</span></b></p>\n</td>\n<td style=\"width:12.12%;border-top:none;border-left:none;\n   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n   padding:0in 2.85pt 0in 2.85pt\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Perjeta+</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Trastuzumab</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">N=107</span></b></p>\n</td>\n<td style=\"width:11.82%;border-top:none;border-left:none;\n   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n   padding:0in 2.85pt 0in 2.85pt\" width=\"11%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Perjeta</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">+Docetaxel</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">N=96</span></b></p>\n</td>\n<td style=\"width:13.72%;border-top:none;border-left:none;\n   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n   padding:0in 2.85pt 0in 2.85pt\" width=\"13%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:-1.45pt;\n   margin-bottom:2.5pt;margin-left:-1.2pt;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"ES\" style=\"font-size:10.0pt;color:black\">Perjeta+</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:-1.45pt;\n   margin-bottom:2.5pt;margin-left:-1.2pt;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"ES\" style=\"font-size:10.0pt;color:black\">Trastuzumab+</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:-1.45pt;\n   margin-bottom:2.5pt;margin-left:-1.2pt;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"ES\" style=\"font-size:10.0pt;color:black\">FEC</span></b><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Wingdings;color:black\">\u00e0</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"ES\" style=\"font-size:10.0pt;color:black\">Perjeta+</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"ES\" style=\"font-size:10.0pt;color:black\">Trastuzumab+</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Docetaxel</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">N=73</span></b></p>\n</td>\n<td style=\"width:13.44%;border-top:none;border-left:none;\n   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n   padding:0in 2.85pt 0in 2.85pt\" width=\"13%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"ES\" style=\"font-size:10.0pt;color:black\">FEC</span></b><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Wingdings;color:black\">\u00e0</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"ES\" style=\"font-size:10.0pt;color:black\">Perjeta+</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"ES\" style=\"font-size:10.0pt;color:black\">Trastuzumab+</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"ES\" style=\"font-size:10.0pt;color:black\">Docetaxel</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"ES\" style=\"font-size:10.0pt;color:black\">N=75</span></b></p>\n</td>\n<td style=\"width:14.76%;border-top:none;border-left:none;\n   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n   padding:0in 2.85pt 0in 2.85pt\" width=\"14%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Perjeta</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">+TCH</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">N=77</span></b></p>\n</td>\n</tr>", "ID": "1c5495d5-84fc-4edf-989c-63356c86e6be", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "         ", "ParentId": "395d0472-c119-477f-9dfa-57e1f7e1b659"}, {"Element": "<td style=\"width:10.6%;border:solid windowtext 1.0pt;border-top:\n   none;padding:0in 2.85pt 0in 2.85pt\" width=\"10%\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n   2.5pt;margin-left:0in;line-height:12.0pt;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Parameter</span></b></p>\n</td>", "ID": "fdf7dba5-19be-4260-8b17-d3b810e1e0ac", "Styles": "width:10.6%;border:solid windowtext 1.0pt;border-top:\n   none;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "1c5495d5-84fc-4edf-989c-63356c86e6be"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n   2.5pt;margin-left:0in;line-height:12.0pt;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Parameter</span></b></p>", "ID": "51e6a2d7-5144-414d-9543-abebb93dd3ea", "Styles": "margin-top:2.5pt;margin-right:0in;margin-bottom:\n   2.5pt;margin-left:0in;line-height:12.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "fdf7dba5-19be-4260-8b17-d3b810e1e0ac"}, {"Element": "<b><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Parameter</span></b>", "ID": "121d03d9-3bd2-4684-9328-963c64bd85f4", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "51e6a2d7-5144-414d-9543-abebb93dd3ea"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Parameter</span>", "ID": "63b6ff6d-ff20-42c2-9e97-a4ced9f4c4a7", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "Parameter", "ParentId": "121d03d9-3bd2-4684-9328-963c64bd85f4"}, {"Element": "<td style=\"width:11.44%;border-top:none;border-left:none;\n   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n   padding:0in 2.85pt 0in 2.85pt\" width=\"11%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Trastuzumab +Docetaxel</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">N=107</span></b></p>\n</td>", "ID": "97107359-0656-4039-b765-776210589357", "Styles": "width:11.44%;border-top:none;border-left:none;\n   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n   padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "   ", "ParentId": "1c5495d5-84fc-4edf-989c-63356c86e6be"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Trastuzumab +Docetaxel</span></b></p>", "ID": "2b2b1470-e173-47a3-a1dc-d610a63dd36e", "Styles": "margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "97107359-0656-4039-b765-776210589357"}, {"Element": "<b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Trastuzumab +Docetaxel</span></b>", "ID": "6575ce52-6752-4799-8be7-0e60a9e4c7ee", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "2b2b1470-e173-47a3-a1dc-d610a63dd36e"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Trastuzumab +Docetaxel</span>", "ID": "0e2bac68-2826-40d0-9edb-4d707f52e320", "Styles": "font-size:10.0pt;\n   color:black", "Classes": "None", "Text": "Trastuzumab +Docetaxel", "ParentId": "6575ce52-6752-4799-8be7-0e60a9e4c7ee"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">N=107</span></b></p>", "ID": "e2dcdb4d-eb87-4142-b277-18a6a2ebd93e", "Styles": "margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "97107359-0656-4039-b765-776210589357"}, {"Element": "<b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">N=107</span></b>", "ID": "af9bbaa8-daf1-4995-84d9-304123afbf14", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e2dcdb4d-eb87-4142-b277-18a6a2ebd93e"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">N=107</span>", "ID": "a3480213-60fe-463d-9aa9-9de81d07c616", "Styles": "font-size:10.0pt;\n   color:black", "Classes": "None", "Text": "N=107", "ParentId": "af9bbaa8-daf1-4995-84d9-304123afbf14"}, {"Element": "<td style=\"width:12.1%;border-top:none;border-left:none;\n   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n   padding:0in 2.85pt 0in 2.85pt\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Perjeta+</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Trastuzumab+</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Docetaxel</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">N=107</span></b></p>\n</td>", "ID": "a01466c9-081b-4037-9dbe-8ef38397a298", "Styles": "width:12.1%;border-top:none;border-left:none;\n   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n   padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "     ", "ParentId": "1c5495d5-84fc-4edf-989c-63356c86e6be"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Perjeta+</span></b></p>", "ID": "f60b7934-ff9f-42d0-8c38-8e10546f5dc0", "Styles": "margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a01466c9-081b-4037-9dbe-8ef38397a298"}, {"Element": "<b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Perjeta+</span></b>", "ID": "9e2929ea-d6e2-4955-93c7-d718eadf561b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f60b7934-ff9f-42d0-8c38-8e10546f5dc0"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Perjeta+</span>", "ID": "e6c10c35-fbb4-4d82-8166-98746c94867e", "Styles": "font-size:10.0pt;\n   color:black", "Classes": "None", "Text": "Perjeta+", "ParentId": "9e2929ea-d6e2-4955-93c7-d718eadf561b"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Trastuzumab+</span></b></p>", "ID": "8a5ac106-6776-4952-acd9-7d058f452d53", "Styles": "margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a01466c9-081b-4037-9dbe-8ef38397a298"}, {"Element": "<b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Trastuzumab+</span></b>", "ID": "81f00e98-15e7-442b-8aec-639d9ade9dae", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8a5ac106-6776-4952-acd9-7d058f452d53"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Trastuzumab+</span>", "ID": "1649f44a-d756-418b-9051-0abf2a47bf90", "Styles": "font-size:10.0pt;\n   color:black", "Classes": "None", "Text": "Trastuzumab+", "ParentId": "81f00e98-15e7-442b-8aec-639d9ade9dae"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Docetaxel</span></b></p>", "ID": "f6d653d5-1747-491c-b720-ce7fb54052e4", "Styles": "margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a01466c9-081b-4037-9dbe-8ef38397a298"}, {"Element": "<b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Docetaxel</span></b>", "ID": "a2bd6747-f5b9-4370-a8d5-a4f512d97c5e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f6d653d5-1747-491c-b720-ce7fb54052e4"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Docetaxel</span>", "ID": "d7401015-b031-413f-a753-0631ad77dec2", "Styles": "font-size:10.0pt;\n   color:black", "Classes": "None", "Text": "Docetaxel", "ParentId": "a2bd6747-f5b9-4370-a8d5-a4f512d97c5e"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">N=107</span></b></p>", "ID": "38751313-eb53-4c55-bd7e-e7667d59572d", "Styles": "margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a01466c9-081b-4037-9dbe-8ef38397a298"}, {"Element": "<b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">N=107</span></b>", "ID": "efed5da6-85de-4e93-acd9-a672d3fcd57e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "38751313-eb53-4c55-bd7e-e7667d59572d"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">N=107</span>", "ID": "a0142f50-7dbf-4708-8866-f2fc29d0e158", "Styles": "font-size:10.0pt;\n   color:black", "Classes": "None", "Text": "N=107", "ParentId": "efed5da6-85de-4e93-acd9-a672d3fcd57e"}, {"Element": "<td style=\"width:12.12%;border-top:none;border-left:none;\n   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n   padding:0in 2.85pt 0in 2.85pt\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Perjeta+</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Trastuzumab</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">N=107</span></b></p>\n</td>", "ID": "78a6fa23-a943-4ad7-b199-fb26b06bcd6f", "Styles": "width:12.12%;border-top:none;border-left:none;\n   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n   padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "    ", "ParentId": "1c5495d5-84fc-4edf-989c-63356c86e6be"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Perjeta+</span></b></p>", "ID": "26072c9b-bf4f-41c9-ae09-437a026621e9", "Styles": "margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "78a6fa23-a943-4ad7-b199-fb26b06bcd6f"}, {"Element": "<b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Perjeta+</span></b>", "ID": "cd6698ff-2055-41c0-9c06-77acda77aa9e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "26072c9b-bf4f-41c9-ae09-437a026621e9"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Perjeta+</span>", "ID": "17beaf62-d25f-4fff-b98f-6e6d61c0ff30", "Styles": "font-size:10.0pt;\n   color:black", "Classes": "None", "Text": "Perjeta+", "ParentId": "cd6698ff-2055-41c0-9c06-77acda77aa9e"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Trastuzumab</span></b></p>", "ID": "946b59b3-4697-4ce7-bdff-55eeb815f767", "Styles": "margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "78a6fa23-a943-4ad7-b199-fb26b06bcd6f"}, {"Element": "<b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Trastuzumab</span></b>", "ID": "27879391-deb1-4fdd-bbdf-88d1d68409aa", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "946b59b3-4697-4ce7-bdff-55eeb815f767"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Trastuzumab</span>", "ID": "c8802f4d-229a-4e07-99eb-a1f28e04d6e3", "Styles": "font-size:10.0pt;\n   color:black", "Classes": "None", "Text": "Trastuzumab", "ParentId": "27879391-deb1-4fdd-bbdf-88d1d68409aa"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">N=107</span></b></p>", "ID": "0e22ff2b-c303-4589-b66c-ffd2713c55e7", "Styles": "margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "78a6fa23-a943-4ad7-b199-fb26b06bcd6f"}, {"Element": "<b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">N=107</span></b>", "ID": "d1e3d9ac-d08d-4e49-91ec-fb00b542981c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "0e22ff2b-c303-4589-b66c-ffd2713c55e7"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">N=107</span>", "ID": "8b8a7ffd-af9f-4d28-a2a2-8c7e12ae2f5e", "Styles": "font-size:10.0pt;\n   color:black", "Classes": "None", "Text": "N=107", "ParentId": "d1e3d9ac-d08d-4e49-91ec-fb00b542981c"}, {"Element": "<td style=\"width:11.82%;border-top:none;border-left:none;\n   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n   padding:0in 2.85pt 0in 2.85pt\" width=\"11%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Perjeta</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">+Docetaxel</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">N=96</span></b></p>\n</td>", "ID": "1fa4837e-45c1-4b07-a28d-34645d92741e", "Styles": "width:11.82%;border-top:none;border-left:none;\n   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n   padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "    ", "ParentId": "1c5495d5-84fc-4edf-989c-63356c86e6be"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Perjeta</span></b></p>", "ID": "113600b5-6287-4346-a584-1fc19eda34b9", "Styles": "margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1fa4837e-45c1-4b07-a28d-34645d92741e"}, {"Element": "<b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Perjeta</span></b>", "ID": "2c09cdc4-ebca-400e-8510-ab37f3fc4061", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "113600b5-6287-4346-a584-1fc19eda34b9"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Perjeta</span>", "ID": "1889fc8a-a233-48a1-b084-075e3f074008", "Styles": "font-size:10.0pt;\n   color:black", "Classes": "None", "Text": "Perjeta", "ParentId": "2c09cdc4-ebca-400e-8510-ab37f3fc4061"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">+Docetaxel</span></b></p>", "ID": "d1ad68df-1e92-4fa4-8bc7-165969471ee1", "Styles": "margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1fa4837e-45c1-4b07-a28d-34645d92741e"}, {"Element": "<b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">+Docetaxel</span></b>", "ID": "96c027a1-e866-464d-bf2d-f0b8ddbeeb9f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d1ad68df-1e92-4fa4-8bc7-165969471ee1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">+Docetaxel</span>", "ID": "c16081a3-1921-453d-9843-8c55c9a297f5", "Styles": "font-size:10.0pt;\n   color:black", "Classes": "None", "Text": "+Docetaxel", "ParentId": "96c027a1-e866-464d-bf2d-f0b8ddbeeb9f"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">N=96</span></b></p>", "ID": "a6d88377-26da-4106-af81-bdb4957df8d1", "Styles": "margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1fa4837e-45c1-4b07-a28d-34645d92741e"}, {"Element": "<b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">N=96</span></b>", "ID": "acebb2b9-de16-4c26-ba7b-d3edcbc113fc", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a6d88377-26da-4106-af81-bdb4957df8d1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">N=96</span>", "ID": "7da4962b-21e1-4fee-b0b7-d458b08c8200", "Styles": "font-size:10.0pt;\n   color:black", "Classes": "None", "Text": "N=96", "ParentId": "acebb2b9-de16-4c26-ba7b-d3edcbc113fc"}, {"Element": "<td style=\"width:13.72%;border-top:none;border-left:none;\n   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n   padding:0in 2.85pt 0in 2.85pt\" width=\"13%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:-1.45pt;\n   margin-bottom:2.5pt;margin-left:-1.2pt;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"ES\" style=\"font-size:10.0pt;color:black\">Perjeta+</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:-1.45pt;\n   margin-bottom:2.5pt;margin-left:-1.2pt;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"ES\" style=\"font-size:10.0pt;color:black\">Trastuzumab+</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:-1.45pt;\n   margin-bottom:2.5pt;margin-left:-1.2pt;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"ES\" style=\"font-size:10.0pt;color:black\">FEC</span></b><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Wingdings;color:black\">\u00e0</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"ES\" style=\"font-size:10.0pt;color:black\">Perjeta+</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"ES\" style=\"font-size:10.0pt;color:black\">Trastuzumab+</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Docetaxel</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">N=73</span></b></p>\n</td>", "ID": "384b4ec0-6a1b-48fe-b452-4db6b6c7a797", "Styles": "width:13.72%;border-top:none;border-left:none;\n   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n   padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "        ", "ParentId": "1c5495d5-84fc-4edf-989c-63356c86e6be"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:-1.45pt;\n   margin-bottom:2.5pt;margin-left:-1.2pt;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"ES\" style=\"font-size:10.0pt;color:black\">Perjeta+</span></b></p>", "ID": "0920160b-cc95-4491-8c67-7f50d213fce1", "Styles": "margin-top:2.5pt;margin-right:-1.45pt;\n   margin-bottom:2.5pt;margin-left:-1.2pt;text-align:center;line-height:12.0pt;\n   page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "384b4ec0-6a1b-48fe-b452-4db6b6c7a797"}, {"Element": "<b><span lang=\"ES\" style=\"font-size:10.0pt;color:black\">Perjeta+</span></b>", "ID": "cf569ab3-7ce0-49b9-99ac-10bc911e26ae", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "0920160b-cc95-4491-8c67-7f50d213fce1"}, {"Element": "<span lang=\"ES\" style=\"font-size:10.0pt;color:black\">Perjeta+</span>", "ID": "12624a86-44ee-4fb3-8101-a8082eeee95c", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "Perjeta+", "ParentId": "cf569ab3-7ce0-49b9-99ac-10bc911e26ae"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:-1.45pt;\n   margin-bottom:2.5pt;margin-left:-1.2pt;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"ES\" style=\"font-size:10.0pt;color:black\">Trastuzumab+</span></b></p>", "ID": "90153873-0575-4840-9f24-95b009c7355c", "Styles": "margin-top:2.5pt;margin-right:-1.45pt;\n   margin-bottom:2.5pt;margin-left:-1.2pt;text-align:center;line-height:12.0pt;\n   page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "384b4ec0-6a1b-48fe-b452-4db6b6c7a797"}, {"Element": "<b><span lang=\"ES\" style=\"font-size:10.0pt;color:black\">Trastuzumab+</span></b>", "ID": "0a591815-8646-46dd-8381-0cae7701bbd2", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "90153873-0575-4840-9f24-95b009c7355c"}, {"Element": "<span lang=\"ES\" style=\"font-size:10.0pt;color:black\">Trastuzumab+</span>", "ID": "6fa8e231-7138-471b-9b4e-993773b9f705", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "Trastuzumab+", "ParentId": "0a591815-8646-46dd-8381-0cae7701bbd2"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:-1.45pt;\n   margin-bottom:2.5pt;margin-left:-1.2pt;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"ES\" style=\"font-size:10.0pt;color:black\">FEC</span></b><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Wingdings;color:black\">\u00e0</span></b></p>", "ID": "be086e60-b51e-434b-928b-c5abefff8ad3", "Styles": "margin-top:2.5pt;margin-right:-1.45pt;\n   margin-bottom:2.5pt;margin-left:-1.2pt;text-align:center;line-height:12.0pt;\n   page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "384b4ec0-6a1b-48fe-b452-4db6b6c7a797"}, {"Element": "<b><span lang=\"ES\" style=\"font-size:10.0pt;color:black\">FEC</span></b>", "ID": "8f975d3d-eb4a-47ea-9b6f-9d36089f5ce5", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "be086e60-b51e-434b-928b-c5abefff8ad3"}, {"Element": "<span lang=\"ES\" style=\"font-size:10.0pt;color:black\">FEC</span>", "ID": "18ccc840-b71c-41f9-81a7-cb2ba7f96a51", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "FEC", "ParentId": "8f975d3d-eb4a-47ea-9b6f-9d36089f5ce5"}, {"Element": "<b><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Wingdings;color:black\">\u00e0</span></b>", "ID": "7bf3754c-c2d5-4695-b911-ff3ef7cde583", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "be086e60-b51e-434b-928b-c5abefff8ad3"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Wingdings;color:black\">\u00e0</span>", "ID": "73cdbeca-eb82-42bf-9b72-97b902239ae6", "Styles": "font-size:10.0pt;font-family:Wingdings;color:black", "Classes": "None", "Text": "\u00e0", "ParentId": "7bf3754c-c2d5-4695-b911-ff3ef7cde583"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"ES\" style=\"font-size:10.0pt;color:black\">Perjeta+</span></b></p>", "ID": "f58f2124-92a4-47f0-bd6a-3438c9582334", "Styles": "margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "384b4ec0-6a1b-48fe-b452-4db6b6c7a797"}, {"Element": "<b><span lang=\"ES\" style=\"font-size:10.0pt;color:black\">Perjeta+</span></b>", "ID": "56280ba8-61f8-4aa8-bf2a-7c2c578dde45", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f58f2124-92a4-47f0-bd6a-3438c9582334"}, {"Element": "<span lang=\"ES\" style=\"font-size:10.0pt;color:black\">Perjeta+</span>", "ID": "c55847c6-c3b3-4a6f-a5ec-a0247980fa43", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "Perjeta+", "ParentId": "56280ba8-61f8-4aa8-bf2a-7c2c578dde45"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"ES\" style=\"font-size:10.0pt;color:black\">Trastuzumab+</span></b></p>", "ID": "f69c7fc4-5db0-4aac-8980-a60f5c75387e", "Styles": "margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "384b4ec0-6a1b-48fe-b452-4db6b6c7a797"}, {"Element": "<b><span lang=\"ES\" style=\"font-size:10.0pt;color:black\">Trastuzumab+</span></b>", "ID": "539452e5-6058-4056-b11b-138870704e86", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f69c7fc4-5db0-4aac-8980-a60f5c75387e"}, {"Element": "<span lang=\"ES\" style=\"font-size:10.0pt;color:black\">Trastuzumab+</span>", "ID": "403b255e-4d41-48a6-bbae-00dd21ce90ff", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "Trastuzumab+", "ParentId": "539452e5-6058-4056-b11b-138870704e86"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Docetaxel</span></b></p>", "ID": "48f75566-df67-475f-b009-4d07da3aa5fa", "Styles": "margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "384b4ec0-6a1b-48fe-b452-4db6b6c7a797"}, {"Element": "<b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Docetaxel</span></b>", "ID": "18a6672e-1be7-4df9-8fdc-f53e1afa1467", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "48f75566-df67-475f-b009-4d07da3aa5fa"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Docetaxel</span>", "ID": "6ced7591-57ab-4cf6-8839-143e5858cf6b", "Styles": "font-size:10.0pt;\n   color:black", "Classes": "None", "Text": "Docetaxel", "ParentId": "18a6672e-1be7-4df9-8fdc-f53e1afa1467"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">N=73</span></b></p>", "ID": "f6fa487e-e400-40b6-b982-e180104d0af5", "Styles": "margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "384b4ec0-6a1b-48fe-b452-4db6b6c7a797"}, {"Element": "<b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">N=73</span></b>", "ID": "df9c2da8-341a-4a29-bc0f-825139ace390", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f6fa487e-e400-40b6-b982-e180104d0af5"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">N=73</span>", "ID": "10978bc9-f365-48ff-9fa0-fcc5b49f45c2", "Styles": "font-size:10.0pt;\n   color:black", "Classes": "None", "Text": "N=73", "ParentId": "df9c2da8-341a-4a29-bc0f-825139ace390"}, {"Element": "<td style=\"width:13.44%;border-top:none;border-left:none;\n   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n   padding:0in 2.85pt 0in 2.85pt\" width=\"13%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"ES\" style=\"font-size:10.0pt;color:black\">FEC</span></b><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Wingdings;color:black\">\u00e0</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"ES\" style=\"font-size:10.0pt;color:black\">Perjeta+</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"ES\" style=\"font-size:10.0pt;color:black\">Trastuzumab+</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"ES\" style=\"font-size:10.0pt;color:black\">Docetaxel</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"ES\" style=\"font-size:10.0pt;color:black\">N=75</span></b></p>\n</td>", "ID": "b27948df-f714-4be9-982f-58e6ca7a8d1e", "Styles": "width:13.44%;border-top:none;border-left:none;\n   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n   padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "      ", "ParentId": "1c5495d5-84fc-4edf-989c-63356c86e6be"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"ES\" style=\"font-size:10.0pt;color:black\">FEC</span></b><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Wingdings;color:black\">\u00e0</span></b></p>", "ID": "25baf67e-2cbf-4f58-a5e8-28609043fc49", "Styles": "margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b27948df-f714-4be9-982f-58e6ca7a8d1e"}, {"Element": "<b><span lang=\"ES\" style=\"font-size:10.0pt;color:black\">FEC</span></b>", "ID": "17bd91a7-8406-4ec3-b569-5af8c81c4ad9", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "25baf67e-2cbf-4f58-a5e8-28609043fc49"}, {"Element": "<span lang=\"ES\" style=\"font-size:10.0pt;color:black\">FEC</span>", "ID": "76838c87-7822-40d2-9a27-ebd94690ede8", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "FEC", "ParentId": "17bd91a7-8406-4ec3-b569-5af8c81c4ad9"}, {"Element": "<b><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Wingdings;color:black\">\u00e0</span></b>", "ID": "5e57f22b-1975-4b99-b03a-5b33777b6301", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "25baf67e-2cbf-4f58-a5e8-28609043fc49"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Wingdings;color:black\">\u00e0</span>", "ID": "c6152fe0-a151-43f1-ae16-75a0278e1107", "Styles": "font-size:10.0pt;font-family:Wingdings;color:black", "Classes": "None", "Text": "\u00e0", "ParentId": "5e57f22b-1975-4b99-b03a-5b33777b6301"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"ES\" style=\"font-size:10.0pt;color:black\">Perjeta+</span></b></p>", "ID": "c8858bbe-4c6d-4de6-ac6e-c45ced5b3c1d", "Styles": "margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b27948df-f714-4be9-982f-58e6ca7a8d1e"}, {"Element": "<b><span lang=\"ES\" style=\"font-size:10.0pt;color:black\">Perjeta+</span></b>", "ID": "a6b87fc3-4794-4ff4-90a6-7672391bb98e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c8858bbe-4c6d-4de6-ac6e-c45ced5b3c1d"}, {"Element": "<span lang=\"ES\" style=\"font-size:10.0pt;color:black\">Perjeta+</span>", "ID": "75fa1f25-5de8-4079-89a8-cd02c4648f86", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "Perjeta+", "ParentId": "a6b87fc3-4794-4ff4-90a6-7672391bb98e"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"ES\" style=\"font-size:10.0pt;color:black\">Trastuzumab+</span></b></p>", "ID": "5c491e25-2d29-4682-8814-69ff53b3294d", "Styles": "margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b27948df-f714-4be9-982f-58e6ca7a8d1e"}, {"Element": "<b><span lang=\"ES\" style=\"font-size:10.0pt;color:black\">Trastuzumab+</span></b>", "ID": "4e752b9f-0fdf-4210-aaec-77b588fccec8", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "5c491e25-2d29-4682-8814-69ff53b3294d"}, {"Element": "<span lang=\"ES\" style=\"font-size:10.0pt;color:black\">Trastuzumab+</span>", "ID": "d06ef162-7e76-4b65-ba0a-c539106e3808", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "Trastuzumab+", "ParentId": "4e752b9f-0fdf-4210-aaec-77b588fccec8"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"ES\" style=\"font-size:10.0pt;color:black\">Docetaxel</span></b></p>", "ID": "38a5cced-98d3-41e2-a58d-f5fe7ee867e3", "Styles": "margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b27948df-f714-4be9-982f-58e6ca7a8d1e"}, {"Element": "<b><span lang=\"ES\" style=\"font-size:10.0pt;color:black\">Docetaxel</span></b>", "ID": "154f5b5c-8031-46f7-a3fd-92ac8d582658", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "38a5cced-98d3-41e2-a58d-f5fe7ee867e3"}, {"Element": "<span lang=\"ES\" style=\"font-size:10.0pt;color:black\">Docetaxel</span>", "ID": "a33f9e19-21e9-4fee-a790-bee41be4a1ba", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "Docetaxel", "ParentId": "154f5b5c-8031-46f7-a3fd-92ac8d582658"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"ES\" style=\"font-size:10.0pt;color:black\">N=75</span></b></p>", "ID": "f5d45c2f-de88-4593-9509-d0eb5f1f87c2", "Styles": "margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b27948df-f714-4be9-982f-58e6ca7a8d1e"}, {"Element": "<b><span lang=\"ES\" style=\"font-size:10.0pt;color:black\">N=75</span></b>", "ID": "b2770c6b-f818-430c-ba40-eaaede4e281b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f5d45c2f-de88-4593-9509-d0eb5f1f87c2"}, {"Element": "<span lang=\"ES\" style=\"font-size:10.0pt;color:black\">N=75</span>", "ID": "32e5b289-7550-4673-99fe-8faa97ce9862", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "N=75", "ParentId": "b2770c6b-f818-430c-ba40-eaaede4e281b"}, {"Element": "<td style=\"width:14.76%;border-top:none;border-left:none;\n   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n   padding:0in 2.85pt 0in 2.85pt\" width=\"14%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Perjeta</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">+TCH</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">N=77</span></b></p>\n</td>", "ID": "1be10864-62a0-409a-81f9-baabdd945971", "Styles": "width:14.76%;border-top:none;border-left:none;\n   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n   padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "    ", "ParentId": "1c5495d5-84fc-4edf-989c-63356c86e6be"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Perjeta</span></b></p>", "ID": "0f9d50de-e812-465c-a60c-81b56a325b2c", "Styles": "margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1be10864-62a0-409a-81f9-baabdd945971"}, {"Element": "<b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Perjeta</span></b>", "ID": "cf1c8aa4-b944-467a-922c-b2e531265423", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "0f9d50de-e812-465c-a60c-81b56a325b2c"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">Perjeta</span>", "ID": "aeaf2f42-e49f-40b5-b0af-a70f3e9d5218", "Styles": "font-size:10.0pt;\n   color:black", "Classes": "None", "Text": "Perjeta", "ParentId": "cf1c8aa4-b944-467a-922c-b2e531265423"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">+TCH</span></b></p>", "ID": "a1a2bc46-6690-41d7-8927-9a93cd8de53a", "Styles": "margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1be10864-62a0-409a-81f9-baabdd945971"}, {"Element": "<b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">+TCH</span></b>", "ID": "3f83f09e-0198-4fbb-a96b-42f45782b1c5", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a1a2bc46-6690-41d7-8927-9a93cd8de53a"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">+TCH</span>", "ID": "0bbb56e5-d925-47fe-804b-76f4cc1b99cd", "Styles": "font-size:10.0pt;\n   color:black", "Classes": "None", "Text": "+TCH", "ParentId": "3f83f09e-0198-4fbb-a96b-42f45782b1c5"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">N=77</span></b></p>", "ID": "25bf9a24-49af-4f36-a77c-d0e7c29a7098", "Styles": "margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1be10864-62a0-409a-81f9-baabdd945971"}, {"Element": "<b><span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">N=77</span></b>", "ID": "3a8708e0-1c78-4b0a-ae27-72709ae2786d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "25bf9a24-49af-4f36-a77c-d0e7c29a7098"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;\n   color:black\">N=77</span>", "ID": "92c749e9-b28e-42fc-af90-8ae2bb5af5dd", "Styles": "font-size:10.0pt;\n   color:black", "Classes": "None", "Text": "N=77", "ParentId": "3a8708e0-1c78-4b0a-ae27-72709ae2786d"}, {"Element": "<tr style=\"page-break-inside:avoid;height:48.2pt\">\n<td style=\"width:10.6%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt;height:48.2pt\" valign=\"top\" width=\"10%\">\n<p class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;margin-bottom:\n  1.0pt;margin-left:0in;line-height:14.0pt;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">pCR rate in the breast\n  (ypT0/is)</span></p>\n<p class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;margin-bottom:\n  1.0pt;margin-left:0in;line-height:14.0pt;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">n (%)</span></p>\n<p class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;margin-bottom:\n  1.0pt;margin-left:0in;line-height:14.0pt;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[95% CI]<sup>1</sup></span></p>\n</td>\n<td style=\"width:11.44%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:48.2pt\" width=\"11%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">31\n  (29.0%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[20.6;\n  38.5]</span></p>\n</td>\n<td style=\"width:12.1%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:48.2pt\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">49\n  (45.8%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[36.1;\n  55.7]</span></p>\n</td>\n<td style=\"width:12.12%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:48.2pt\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">18\n  (16.8%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[10.3;\n  25.3]</span></p>\n</td>\n<td style=\"width:11.82%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:48.2pt\" width=\"11%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">23\n  (24.0%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[15.8;\n  33.7]</span></p>\n</td>\n<td style=\"width:13.72%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:48.2pt\" width=\"13%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">45\n  (61.6%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[49.5;\n  72.8]</span></p>\n</td>\n<td style=\"width:13.44%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:48.2pt\" width=\"13%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">43\n  (57.3%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[45.4;\n  68.7]</span></p>\n</td>\n<td style=\"width:14.76%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:48.2pt\" width=\"14%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">51\n  (66.2%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[54.6;\n  76.6]</span></p>\n</td>\n</tr>", "ID": "84704cfd-d9b8-4058-ac3b-a5c72f42f8ec", "Styles": "page-break-inside:avoid;height:48.2pt", "Classes": "None", "Text": "         ", "ParentId": "3f853db6-990e-4e05-a5db-63e5deba97c8"}, {"Element": "<td style=\"width:10.6%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt;height:48.2pt\" valign=\"top\" width=\"10%\">\n<p class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;margin-bottom:\n  1.0pt;margin-left:0in;line-height:14.0pt;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">pCR rate in the breast\n  (ypT0/is)</span></p>\n<p class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;margin-bottom:\n  1.0pt;margin-left:0in;line-height:14.0pt;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">n (%)</span></p>\n<p class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;margin-bottom:\n  1.0pt;margin-left:0in;line-height:14.0pt;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[95% CI]<sup>1</sup></span></p>\n</td>", "ID": "2dd0e56b-09e8-4184-8577-875fefda3cb7", "Styles": "width:10.6%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt;height:48.2pt", "Classes": "None", "Text": "    ", "ParentId": "84704cfd-d9b8-4058-ac3b-a5c72f42f8ec"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;margin-bottom:\n  1.0pt;margin-left:0in;line-height:14.0pt;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">pCR rate in the breast\n  (ypT0/is)</span></p>", "ID": "693cbd34-b4b1-4d6d-8fd1-4681f81e2319", "Styles": "margin-top:1.0pt;margin-right:0in;margin-bottom:\n  1.0pt;margin-left:0in;line-height:14.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "2dd0e56b-09e8-4184-8577-875fefda3cb7"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">pCR rate in the breast\n  (ypT0/is)</span>", "ID": "9a194b1d-6328-44a4-980d-6fca8a5054f2", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "pCR rate in the breast   (ypT0/is)", "ParentId": "693cbd34-b4b1-4d6d-8fd1-4681f81e2319"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;margin-bottom:\n  1.0pt;margin-left:0in;line-height:14.0pt;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">n (%)</span></p>", "ID": "15d9e52c-e2fc-41c7-abdd-5456a32c2990", "Styles": "margin-top:1.0pt;margin-right:0in;margin-bottom:\n  1.0pt;margin-left:0in;line-height:14.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "2dd0e56b-09e8-4184-8577-875fefda3cb7"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">n (%)</span>", "ID": "8e15ebef-7965-44a8-9627-e1b70b46cf5d", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "n (%)", "ParentId": "15d9e52c-e2fc-41c7-abdd-5456a32c2990"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;margin-bottom:\n  1.0pt;margin-left:0in;line-height:14.0pt;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[95% CI]<sup>1</sup></span></p>", "ID": "0d21e2a5-a67a-4e2b-904a-3960e1c4edd9", "Styles": "margin-top:1.0pt;margin-right:0in;margin-bottom:\n  1.0pt;margin-left:0in;line-height:14.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "2dd0e56b-09e8-4184-8577-875fefda3cb7"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[95% CI]<sup>1</sup></span>", "ID": "855af8f9-8046-437d-b6c5-0317a63b2fd5", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "[95% CI]", "ParentId": "0d21e2a5-a67a-4e2b-904a-3960e1c4edd9"}, {"Element": "<sup>1</sup>", "ID": "2107022b-98ad-44ac-9f2a-8847fd976546", "Styles": "None", "Classes": "None", "Text": "1", "ParentId": "855af8f9-8046-437d-b6c5-0317a63b2fd5"}, {"Element": "<td style=\"width:11.44%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:48.2pt\" width=\"11%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">31\n  (29.0%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[20.6;\n  38.5]</span></p>\n</td>", "ID": "b85da9d6-ef3a-4e4b-a5f9-e3cb85fe4b5f", "Styles": "width:11.44%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:48.2pt", "Classes": "None", "Text": "   ", "ParentId": "84704cfd-d9b8-4058-ac3b-a5c72f42f8ec"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">31\n  (29.0%)</span></p>", "ID": "3bf2818f-5900-46e0-a554-5f007d3f1e5f", "Styles": "margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b85da9d6-ef3a-4e4b-a5f9-e3cb85fe4b5f"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">31\n  (29.0%)</span>", "ID": "5572087a-e25e-47e8-bcec-d146c66d93b1", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "31   (29.0%)", "ParentId": "3bf2818f-5900-46e0-a554-5f007d3f1e5f"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[20.6;\n  38.5]</span></p>", "ID": "85df78db-0f06-44c9-b522-17abd8221a52", "Styles": "margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b85da9d6-ef3a-4e4b-a5f9-e3cb85fe4b5f"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[20.6;\n  38.5]</span>", "ID": "e4879215-15a3-4a7d-9c10-51c8447c446e", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "[20.6;   38.5]", "ParentId": "85df78db-0f06-44c9-b522-17abd8221a52"}, {"Element": "<td style=\"width:12.1%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:48.2pt\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">49\n  (45.8%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[36.1;\n  55.7]</span></p>\n</td>", "ID": "bd593dbf-5070-4e12-b23a-991604277ba8", "Styles": "width:12.1%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:48.2pt", "Classes": "None", "Text": "   ", "ParentId": "84704cfd-d9b8-4058-ac3b-a5c72f42f8ec"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">49\n  (45.8%)</span></p>", "ID": "32905b79-63fe-4d06-9639-6e83ecc7c629", "Styles": "margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "bd593dbf-5070-4e12-b23a-991604277ba8"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">49\n  (45.8%)</span>", "ID": "6d824434-e281-46b5-8c78-bf66b8a05eb6", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "49   (45.8%)", "ParentId": "32905b79-63fe-4d06-9639-6e83ecc7c629"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[36.1;\n  55.7]</span></p>", "ID": "dae7e3be-1ea3-492d-b341-7e1d14a2cbd8", "Styles": "margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "bd593dbf-5070-4e12-b23a-991604277ba8"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[36.1;\n  55.7]</span>", "ID": "e370f1bf-7d5c-4ad6-a916-656b913faed6", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "[36.1;   55.7]", "ParentId": "dae7e3be-1ea3-492d-b341-7e1d14a2cbd8"}, {"Element": "<td style=\"width:12.12%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:48.2pt\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">18\n  (16.8%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[10.3;\n  25.3]</span></p>\n</td>", "ID": "11844313-e60e-4bbc-b2ec-4daaa7da2678", "Styles": "width:12.12%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:48.2pt", "Classes": "None", "Text": "   ", "ParentId": "84704cfd-d9b8-4058-ac3b-a5c72f42f8ec"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">18\n  (16.8%)</span></p>", "ID": "affa0594-61a6-4b97-8a96-86bd02d32b3f", "Styles": "margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "11844313-e60e-4bbc-b2ec-4daaa7da2678"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">18\n  (16.8%)</span>", "ID": "52732272-63b4-4b7b-aee0-9a17003f8f84", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "18   (16.8%)", "ParentId": "affa0594-61a6-4b97-8a96-86bd02d32b3f"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[10.3;\n  25.3]</span></p>", "ID": "86abbbc8-574e-4e7f-b320-4c8b508b78f6", "Styles": "margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "11844313-e60e-4bbc-b2ec-4daaa7da2678"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[10.3;\n  25.3]</span>", "ID": "a5e15c60-4157-4b1f-880b-ab7c7891b0bf", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "[10.3;   25.3]", "ParentId": "86abbbc8-574e-4e7f-b320-4c8b508b78f6"}, {"Element": "<td style=\"width:11.82%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:48.2pt\" width=\"11%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">23\n  (24.0%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[15.8;\n  33.7]</span></p>\n</td>", "ID": "296a7750-8067-432d-95af-09ef3bec9f2a", "Styles": "width:11.82%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:48.2pt", "Classes": "None", "Text": "   ", "ParentId": "84704cfd-d9b8-4058-ac3b-a5c72f42f8ec"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">23\n  (24.0%)</span></p>", "ID": "a154d58a-a662-4af9-8b87-02520dda091f", "Styles": "margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "296a7750-8067-432d-95af-09ef3bec9f2a"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">23\n  (24.0%)</span>", "ID": "f9ed7172-5af9-4aaf-aa9e-5360d67a9875", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "23   (24.0%)", "ParentId": "a154d58a-a662-4af9-8b87-02520dda091f"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[15.8;\n  33.7]</span></p>", "ID": "f96015e8-e73a-4a0e-9315-1a1c3bbd676c", "Styles": "margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "296a7750-8067-432d-95af-09ef3bec9f2a"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[15.8;\n  33.7]</span>", "ID": "91facf8f-6e5c-4409-b3d1-47e1b9856256", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "[15.8;   33.7]", "ParentId": "f96015e8-e73a-4a0e-9315-1a1c3bbd676c"}, {"Element": "<td style=\"width:13.72%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:48.2pt\" width=\"13%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">45\n  (61.6%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[49.5;\n  72.8]</span></p>\n</td>", "ID": "2f6456b6-716d-4450-abd3-55eee978036d", "Styles": "width:13.72%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:48.2pt", "Classes": "None", "Text": "   ", "ParentId": "84704cfd-d9b8-4058-ac3b-a5c72f42f8ec"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">45\n  (61.6%)</span></p>", "ID": "32dc5fee-2749-424c-b86b-f3b0744f2266", "Styles": "margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "2f6456b6-716d-4450-abd3-55eee978036d"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">45\n  (61.6%)</span>", "ID": "06b599e8-e34c-47c6-8b9c-3ed54179b34a", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "45   (61.6%)", "ParentId": "32dc5fee-2749-424c-b86b-f3b0744f2266"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[49.5;\n  72.8]</span></p>", "ID": "2a644d4b-5660-4256-b9d8-2ca621429114", "Styles": "margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "2f6456b6-716d-4450-abd3-55eee978036d"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[49.5;\n  72.8]</span>", "ID": "afe762e4-36c1-4fa4-88d5-fad0d745d60f", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "[49.5;   72.8]", "ParentId": "2a644d4b-5660-4256-b9d8-2ca621429114"}, {"Element": "<td style=\"width:13.44%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:48.2pt\" width=\"13%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">43\n  (57.3%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[45.4;\n  68.7]</span></p>\n</td>", "ID": "04230d74-1675-4dba-873a-643a2dd0c30b", "Styles": "width:13.44%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:48.2pt", "Classes": "None", "Text": "   ", "ParentId": "84704cfd-d9b8-4058-ac3b-a5c72f42f8ec"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">43\n  (57.3%)</span></p>", "ID": "71d4d6f8-0d66-463c-b365-e038cec0a99b", "Styles": "margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "04230d74-1675-4dba-873a-643a2dd0c30b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">43\n  (57.3%)</span>", "ID": "a79224b0-71e5-42b5-afb2-21fcf4d3c073", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "43   (57.3%)", "ParentId": "71d4d6f8-0d66-463c-b365-e038cec0a99b"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[45.4;\n  68.7]</span></p>", "ID": "134bc875-0eee-4489-a691-c9544dccd747", "Styles": "margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "04230d74-1675-4dba-873a-643a2dd0c30b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[45.4;\n  68.7]</span>", "ID": "42d405a2-bfb8-4d00-b203-624100c2f674", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "[45.4;   68.7]", "ParentId": "134bc875-0eee-4489-a691-c9544dccd747"}, {"Element": "<td style=\"width:14.76%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:48.2pt\" width=\"14%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">51\n  (66.2%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[54.6;\n  76.6]</span></p>\n</td>", "ID": "63680a07-ac0e-46b6-864c-52c318fba4bc", "Styles": "width:14.76%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:48.2pt", "Classes": "None", "Text": "   ", "ParentId": "84704cfd-d9b8-4058-ac3b-a5c72f42f8ec"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">51\n  (66.2%)</span></p>", "ID": "16bdfa34-6a7f-4e0a-ae40-5ff962e0d6db", "Styles": "margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "63680a07-ac0e-46b6-864c-52c318fba4bc"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">51\n  (66.2%)</span>", "ID": "e339cb73-595a-469a-bfd9-5890f33fde3e", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "51   (66.2%)", "ParentId": "16bdfa34-6a7f-4e0a-ae40-5ff962e0d6db"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[54.6;\n  76.6]</span></p>", "ID": "9e2d84a4-308c-4753-8df5-15f59476ca50", "Styles": "margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "63680a07-ac0e-46b6-864c-52c318fba4bc"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[54.6;\n  76.6]</span>", "ID": "f48a8ce0-dae1-4d49-9503-ddf0f7e746d4", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "[54.6;   76.6]", "ParentId": "9e2d84a4-308c-4753-8df5-15f59476ca50"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:10.6%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"top\" width=\"10%\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Difference in pCR rates<sup>2</sup></span></p>\n<p class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;margin-bottom:\n  1.0pt;margin-left:0in;line-height:14.0pt;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[95% CI]<sup>3</sup></span></p>\n</td>\n<td style=\"width:11.44%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"11%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td style=\"width:12.1%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">+16.8 %</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[3.5; 30.1]</span></p>\n</td>\n<td style=\"width:12.12%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">-12.2 %</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:-4.05pt;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;text-indent:-4.1pt;\n  line-height:14.0pt;page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[-23.8; -0.5]</span></p>\n</td>\n<td style=\"width:11.82%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"11%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">-21.8 %</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:-2.8pt;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;text-indent:-1.65pt;\n  line-height:14.0pt;page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[-35.1; -8.5]</span></p>\n</td>\n<td style=\"width:13.72%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"13%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">NA</span></p>\n</td>\n<td style=\"width:13.44%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"13%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">NA</span></p>\n</td>\n<td style=\"width:14.76%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"14%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">NA</span></p>\n</td>\n</tr>", "ID": "3b06ad32-6422-4506-9926-76a561be34ff", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "         ", "ParentId": "3f853db6-990e-4e05-a5db-63e5deba97c8"}, {"Element": "<td style=\"width:10.6%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"top\" width=\"10%\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Difference in pCR rates<sup>2</sup></span></p>\n<p class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;margin-bottom:\n  1.0pt;margin-left:0in;line-height:14.0pt;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[95% CI]<sup>3</sup></span></p>\n</td>", "ID": "4d3f2cd6-dc89-4c01-bf28-6d8487a8d0ea", "Styles": "width:10.6%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "   ", "ParentId": "3b06ad32-6422-4506-9926-76a561be34ff"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Difference in pCR rates<sup>2</sup></span></p>", "ID": "610bfd85-a4eb-4ad1-9a3c-c111e84ef261", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4d3f2cd6-dc89-4c01-bf28-6d8487a8d0ea"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Difference in pCR rates<sup>2</sup></span>", "ID": "3e144eb5-1774-42b6-b4be-cc5cd9cf83cd", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "Difference in pCR rates", "ParentId": "610bfd85-a4eb-4ad1-9a3c-c111e84ef261"}, {"Element": "<sup>2</sup>", "ID": "99b6b121-9721-4bd0-a295-78ab456e2f99", "Styles": "None", "Classes": "None", "Text": "2", "ParentId": "3e144eb5-1774-42b6-b4be-cc5cd9cf83cd"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;margin-bottom:\n  1.0pt;margin-left:0in;line-height:14.0pt;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[95% CI]<sup>3</sup></span></p>", "ID": "8bfbeca4-594a-4554-b876-2c9a5dfa3d1c", "Styles": "margin-top:1.0pt;margin-right:0in;margin-bottom:\n  1.0pt;margin-left:0in;line-height:14.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4d3f2cd6-dc89-4c01-bf28-6d8487a8d0ea"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[95% CI]<sup>3</sup></span>", "ID": "c6f8a285-d2cc-4736-be15-548149d3d708", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "[95% CI]", "ParentId": "8bfbeca4-594a-4554-b876-2c9a5dfa3d1c"}, {"Element": "<sup>3</sup>", "ID": "e69df363-adac-4b06-ad1d-284f05e6fc94", "Styles": "None", "Classes": "None", "Text": "3", "ParentId": "c6f8a285-d2cc-4736-be15-548149d3d708"}, {"Element": "<td style=\"width:11.44%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"11%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>", "ID": "e465e949-386c-475a-9210-2fff6e484089", "Styles": "width:11.44%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "3b06ad32-6422-4506-9926-76a561be34ff"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>", "ID": "303db816-66ac-4905-bf65-8220b5e0ee9e", "Styles": "margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e465e949-386c-475a-9210-2fff6e484089"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span>", "ID": "0aecb961-a990-4338-a7cc-db481d035723", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "303db816-66ac-4905-bf65-8220b5e0ee9e"}, {"Element": "<td style=\"width:12.1%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">+16.8 %</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[3.5; 30.1]</span></p>\n</td>", "ID": "4dff85a9-792e-4990-bce5-ed84ea4a79c5", "Styles": "width:12.1%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "   ", "ParentId": "3b06ad32-6422-4506-9926-76a561be34ff"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">+16.8 %</span></p>", "ID": "5615ef86-fa69-496a-ad60-326ee4aa41b8", "Styles": "margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4dff85a9-792e-4990-bce5-ed84ea4a79c5"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">+16.8 %</span>", "ID": "8bcb1fa0-bf9d-4cc4-a086-df02fce0b155", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "+16.8 %", "ParentId": "5615ef86-fa69-496a-ad60-326ee4aa41b8"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[3.5; 30.1]</span></p>", "ID": "e085fa93-6751-4b42-9db9-bf16576a8d97", "Styles": "margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4dff85a9-792e-4990-bce5-ed84ea4a79c5"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[3.5; 30.1]</span>", "ID": "4fb3bd2f-3473-48d1-98cd-d6065033b70a", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "[3.5; 30.1]", "ParentId": "e085fa93-6751-4b42-9db9-bf16576a8d97"}, {"Element": "<td style=\"width:12.12%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">-12.2 %</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:-4.05pt;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;text-indent:-4.1pt;\n  line-height:14.0pt;page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[-23.8; -0.5]</span></p>\n</td>", "ID": "76796af5-e7ff-4fd9-a72c-49793aaf76d8", "Styles": "width:12.12%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "   ", "ParentId": "3b06ad32-6422-4506-9926-76a561be34ff"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">-12.2 %</span></p>", "ID": "f9a5af0c-132a-4a33-ad26-c79001620c55", "Styles": "margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "76796af5-e7ff-4fd9-a72c-49793aaf76d8"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">-12.2 %</span>", "ID": "966c2ace-48b5-498b-adcc-d8f61c4dbc7a", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "-12.2 %", "ParentId": "f9a5af0c-132a-4a33-ad26-c79001620c55"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:-4.05pt;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;text-indent:-4.1pt;\n  line-height:14.0pt;page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[-23.8; -0.5]</span></p>", "ID": "9bf8d454-7b8c-4a7c-87c7-8d48f071521f", "Styles": "margin-top:1.0pt;margin-right:-4.05pt;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;text-indent:-4.1pt;\n  line-height:14.0pt;page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "76796af5-e7ff-4fd9-a72c-49793aaf76d8"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[-23.8; -0.5]</span>", "ID": "bf35707c-4e5c-47fc-b6d9-ea336ba2cf1f", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "[-23.8; -0.5]", "ParentId": "9bf8d454-7b8c-4a7c-87c7-8d48f071521f"}, {"Element": "<td style=\"width:11.82%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"11%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">-21.8 %</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:-2.8pt;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;text-indent:-1.65pt;\n  line-height:14.0pt;page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[-35.1; -8.5]</span></p>\n</td>", "ID": "797cc342-f66e-48a5-be9d-082b977fe711", "Styles": "width:11.82%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "   ", "ParentId": "3b06ad32-6422-4506-9926-76a561be34ff"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">-21.8 %</span></p>", "ID": "d45396e8-1a07-4ea2-9783-08bef975d7f7", "Styles": "margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "797cc342-f66e-48a5-be9d-082b977fe711"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">-21.8 %</span>", "ID": "97912a00-e09b-40cc-93f2-5dc1b8f61a35", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "-21.8 %", "ParentId": "d45396e8-1a07-4ea2-9783-08bef975d7f7"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:-2.8pt;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;text-indent:-1.65pt;\n  line-height:14.0pt;page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[-35.1; -8.5]</span></p>", "ID": "cfcf9d83-db8e-4b65-a338-3f98ceb6ee94", "Styles": "margin-top:1.0pt;margin-right:-2.8pt;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;text-indent:-1.65pt;\n  line-height:14.0pt;page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "797cc342-f66e-48a5-be9d-082b977fe711"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[-35.1; -8.5]</span>", "ID": "44de3d13-804c-4f77-9e97-94480411c5ab", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "[-35.1; -8.5]", "ParentId": "cfcf9d83-db8e-4b65-a338-3f98ceb6ee94"}, {"Element": "<td style=\"width:13.72%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"13%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">NA</span></p>\n</td>", "ID": "a932ce52-9878-46b8-9361-7b0e2b5d5b5a", "Styles": "width:13.72%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "3b06ad32-6422-4506-9926-76a561be34ff"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">NA</span></p>", "ID": "1d43acb4-15bd-4d1b-958b-ec3605af496d", "Styles": "margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a932ce52-9878-46b8-9361-7b0e2b5d5b5a"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">NA</span>", "ID": "4547ff2a-3f31-41ae-96cd-7cefc620d3cf", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "NA", "ParentId": "1d43acb4-15bd-4d1b-958b-ec3605af496d"}, {"Element": "<td style=\"width:13.44%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"13%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">NA</span></p>\n</td>", "ID": "d5af7c0d-64f5-4e29-ac7b-f1f77750e49e", "Styles": "width:13.44%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "3b06ad32-6422-4506-9926-76a561be34ff"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">NA</span></p>", "ID": "ba4b97a6-162e-4a4b-88ec-54651927ab7e", "Styles": "margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d5af7c0d-64f5-4e29-ac7b-f1f77750e49e"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">NA</span>", "ID": "f2f2407d-05fc-4e0f-8253-0998029651f4", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "NA", "ParentId": "ba4b97a6-162e-4a4b-88ec-54651927ab7e"}, {"Element": "<td style=\"width:14.76%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"14%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">NA</span></p>\n</td>", "ID": "8ef40bd6-3261-4880-8d1d-43eb73b38ae7", "Styles": "width:14.76%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "3b06ad32-6422-4506-9926-76a561be34ff"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">NA</span></p>", "ID": "8fe4bb91-f24d-4a17-87ae-e60fceb5e6e3", "Styles": "margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8ef40bd6-3261-4880-8d1d-43eb73b38ae7"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">NA</span>", "ID": "a0ef7056-e700-4b36-aaf1-61d47f63f3c3", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "NA", "ParentId": "8fe4bb91-f24d-4a17-87ae-e60fceb5e6e3"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:10.6%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"top\" width=\"10%\">\n<p class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;margin-bottom:\n  1.0pt;margin-left:0in;line-height:14.0pt;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">p-value (with Simes corr. for\n  CMH test)<sup>4</sup></span></p>\n</td>\n<td style=\"width:11.44%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"11%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>\n<td style=\"width:12.1%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">0.0141</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">(vs.\n  Trastuzumab+Docetaxel)</span></p>\n</td>\n<td style=\"width:12.12%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">0.0198</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">(vs.\n  Trastuzumab+Docetaxel)</span></p>\n</td>\n<td style=\"width:11.82%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"11%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">0.0030</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:-4.45pt;\n  margin-bottom:1.0pt;margin-left:-2.8pt;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">(vs\n  Perjeta+</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:-4.45pt;\n  margin-bottom:1.0pt;margin-left:-2.8pt;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Trastuzumab+Docetaxel)</span></p>\n</td>\n<td style=\"width:13.72%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"13%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">NA</span></p>\n</td>\n<td style=\"width:13.44%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"13%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">NA</span></p>\n</td>\n<td style=\"width:14.76%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"14%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">NA</span></p>\n</td>\n</tr>", "ID": "89586c5d-334e-4665-b7d5-34e7d96a9f37", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "         ", "ParentId": "3f853db6-990e-4e05-a5db-63e5deba97c8"}, {"Element": "<td style=\"width:10.6%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"top\" width=\"10%\">\n<p class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;margin-bottom:\n  1.0pt;margin-left:0in;line-height:14.0pt;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">p-value (with Simes corr. for\n  CMH test)<sup>4</sup></span></p>\n</td>", "ID": "76fe032d-dbdf-44f8-b5d6-6ec7dc2088ba", "Styles": "width:10.6%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "89586c5d-334e-4665-b7d5-34e7d96a9f37"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;margin-bottom:\n  1.0pt;margin-left:0in;line-height:14.0pt;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">p-value (with Simes corr. for\n  CMH test)<sup>4</sup></span></p>", "ID": "5ea967ec-a9db-4050-b968-7cd509518014", "Styles": "margin-top:1.0pt;margin-right:0in;margin-bottom:\n  1.0pt;margin-left:0in;line-height:14.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "76fe032d-dbdf-44f8-b5d6-6ec7dc2088ba"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">p-value (with Simes corr. for\n  CMH test)<sup>4</sup></span>", "ID": "79a066d8-98a5-427c-b54c-a2ffd7464560", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "p-value (with Simes corr. for   CMH test)", "ParentId": "5ea967ec-a9db-4050-b968-7cd509518014"}, {"Element": "<sup>4</sup>", "ID": "3e476c93-a787-461a-98eb-cc8db04325f4", "Styles": "None", "Classes": "None", "Text": "4", "ParentId": "79a066d8-98a5-427c-b54c-a2ffd7464560"}, {"Element": "<td style=\"width:11.44%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"11%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>\n</td>", "ID": "dae16442-0943-46c6-85d6-f7dffe5adc44", "Styles": "width:11.44%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "89586c5d-334e-4665-b7d5-34e7d96a9f37"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span></p>", "ID": "a375ed05-51d3-440b-9c52-941f5bd58bfa", "Styles": "margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "dae16442-0943-46c6-85d6-f7dffe5adc44"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">\u00a0</span>", "ID": "8d7457dc-4fd6-4f50-8a90-b30dad7f4f09", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "a375ed05-51d3-440b-9c52-941f5bd58bfa"}, {"Element": "<td style=\"width:12.1%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">0.0141</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">(vs.\n  Trastuzumab+Docetaxel)</span></p>\n</td>", "ID": "20de3941-f3c8-404c-a627-9bdb4bed1d93", "Styles": "width:12.1%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "   ", "ParentId": "89586c5d-334e-4665-b7d5-34e7d96a9f37"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">0.0141</span></p>", "ID": "b5e63e1c-e494-4996-9877-1e052d97d5d9", "Styles": "margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "20de3941-f3c8-404c-a627-9bdb4bed1d93"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">0.0141</span>", "ID": "f0160850-1ce4-4db3-bfc6-d9abd6e69f5e", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "0.0141", "ParentId": "b5e63e1c-e494-4996-9877-1e052d97d5d9"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">(vs.\n  Trastuzumab+Docetaxel)</span></p>", "ID": "082944fa-67bd-4a9c-a670-e647c70ce5aa", "Styles": "margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "20de3941-f3c8-404c-a627-9bdb4bed1d93"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">(vs.\n  Trastuzumab+Docetaxel)</span>", "ID": "99632569-3872-4915-ac37-d74737335ac1", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "(vs.   Trastuzumab+Docetaxel)", "ParentId": "082944fa-67bd-4a9c-a670-e647c70ce5aa"}, {"Element": "<td style=\"width:12.12%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">0.0198</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">(vs.\n  Trastuzumab+Docetaxel)</span></p>\n</td>", "ID": "529091ed-13ca-4ed9-94e9-2e2a4cdccf6c", "Styles": "width:12.12%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "   ", "ParentId": "89586c5d-334e-4665-b7d5-34e7d96a9f37"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">0.0198</span></p>", "ID": "deb37ee0-2ac9-4286-8466-08d351a7b64a", "Styles": "margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "529091ed-13ca-4ed9-94e9-2e2a4cdccf6c"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">0.0198</span>", "ID": "0b567c34-2175-40c3-bfb0-911b88527bbc", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "0.0198", "ParentId": "deb37ee0-2ac9-4286-8466-08d351a7b64a"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">(vs.\n  Trastuzumab+Docetaxel)</span></p>", "ID": "8b2e3208-08fd-4a17-a73d-5efb898fd3ec", "Styles": "margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "529091ed-13ca-4ed9-94e9-2e2a4cdccf6c"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">(vs.\n  Trastuzumab+Docetaxel)</span>", "ID": "37a03e30-570c-4848-afa3-f0da683a461a", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "(vs.   Trastuzumab+Docetaxel)", "ParentId": "8b2e3208-08fd-4a17-a73d-5efb898fd3ec"}, {"Element": "<td style=\"width:11.82%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"11%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">0.0030</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:-4.45pt;\n  margin-bottom:1.0pt;margin-left:-2.8pt;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">(vs\n  Perjeta+</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:-4.45pt;\n  margin-bottom:1.0pt;margin-left:-2.8pt;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Trastuzumab+Docetaxel)</span></p>\n</td>", "ID": "b9c771db-6f37-4223-b68a-b4c1700308c9", "Styles": "width:11.82%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "    ", "ParentId": "89586c5d-334e-4665-b7d5-34e7d96a9f37"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">0.0030</span></p>", "ID": "137db029-5f42-4b76-93cf-5caf44e70ed7", "Styles": "margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b9c771db-6f37-4223-b68a-b4c1700308c9"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">0.0030</span>", "ID": "171e76db-e8a4-4803-a0f6-e9ff6cb6f10d", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "0.0030", "ParentId": "137db029-5f42-4b76-93cf-5caf44e70ed7"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:-4.45pt;\n  margin-bottom:1.0pt;margin-left:-2.8pt;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">(vs\n  Perjeta+</span></p>", "ID": "e4e756ca-8f0e-4337-a47b-90a2e038f046", "Styles": "margin-top:1.0pt;margin-right:-4.45pt;\n  margin-bottom:1.0pt;margin-left:-2.8pt;text-align:center;line-height:14.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b9c771db-6f37-4223-b68a-b4c1700308c9"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">(vs\n  Perjeta+</span>", "ID": "b2509ea0-4418-458a-a76e-1b97db394bea", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "(vs   Perjeta+", "ParentId": "e4e756ca-8f0e-4337-a47b-90a2e038f046"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:-4.45pt;\n  margin-bottom:1.0pt;margin-left:-2.8pt;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Trastuzumab+Docetaxel)</span></p>", "ID": "7a5384ce-bf52-473e-99d6-97ffd462a2ac", "Styles": "margin-top:1.0pt;margin-right:-4.45pt;\n  margin-bottom:1.0pt;margin-left:-2.8pt;text-align:center;line-height:14.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b9c771db-6f37-4223-b68a-b4c1700308c9"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Trastuzumab+Docetaxel)</span>", "ID": "7df21140-e3e5-4a4c-8ca3-fdb652c84c03", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "Trastuzumab+Docetaxel)", "ParentId": "7a5384ce-bf52-473e-99d6-97ffd462a2ac"}, {"Element": "<td style=\"width:13.72%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"13%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">NA</span></p>\n</td>", "ID": "d05f8d18-194a-4d30-b97c-731d00e993bc", "Styles": "width:13.72%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "89586c5d-334e-4665-b7d5-34e7d96a9f37"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">NA</span></p>", "ID": "3992f3cd-c211-4b31-bea6-62c3b95c656f", "Styles": "margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d05f8d18-194a-4d30-b97c-731d00e993bc"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">NA</span>", "ID": "d448c55a-90c6-49c6-b139-da5b7b0f97c1", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "NA", "ParentId": "3992f3cd-c211-4b31-bea6-62c3b95c656f"}, {"Element": "<td style=\"width:13.44%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"13%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">NA</span></p>\n</td>", "ID": "48177e4d-9233-415b-a5c0-36e8c68d0d61", "Styles": "width:13.44%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "89586c5d-334e-4665-b7d5-34e7d96a9f37"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">NA</span></p>", "ID": "c3dd475b-e042-4109-a335-b4f5a59cc4ce", "Styles": "margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "48177e4d-9233-415b-a5c0-36e8c68d0d61"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">NA</span>", "ID": "7f43828c-53dc-4603-a727-2da4771838e1", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "NA", "ParentId": "c3dd475b-e042-4109-a335-b4f5a59cc4ce"}, {"Element": "<td style=\"width:14.76%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"14%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">NA</span></p>\n</td>", "ID": "3b75f26e-cdcf-47ee-98a3-291a20f6fbf4", "Styles": "width:14.76%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "89586c5d-334e-4665-b7d5-34e7d96a9f37"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">NA</span></p>", "ID": "abf43721-a992-4055-9f0c-910ddffa4000", "Styles": "margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "3b75f26e-cdcf-47ee-98a3-291a20f6fbf4"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">NA</span>", "ID": "253a6ddd-ea1a-4f8c-b4ef-cc176f898918", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "NA", "ParentId": "abf43721-a992-4055-9f0c-910ddffa4000"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:10.6%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"top\" width=\"10%\">\n<p class=\"MsoNormal\" style=\"line-height:14.0pt;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">pCR rate in the breast and\n  lymph node (ypT0/is N0)</span></p>\n<p class=\"MsoNormal\" style=\"margin-bottom:1.0pt;line-height:14.0pt;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">n (%)</span></p>\n<p class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;margin-bottom:\n  1.0pt;margin-left:0in;line-height:14.0pt;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[95% CI]</span></p>\n</td>\n<td style=\"width:11.44%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"11%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">23\n  (21.5%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[14.1;\n  30.5]</span></p>\n</td>\n<td style=\"width:12.1%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">42\n  (39.3%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[30.3;\n  49.2]</span></p>\n</td>\n<td style=\"width:12.12%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">12\n  (11.2%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[5.9;\n  18.8]</span></p>\n</td>\n<td style=\"width:11.82%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"11%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">17\n  (17.7%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[10.7;\n  26.8]</span></p>\n</td>\n<td style=\"width:13.72%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"13%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">41\n  (56.2%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[44.1;\n  67.8]</span></p>\n</td>\n<td style=\"width:13.44%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"13%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">41\n  (54.7%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[42.7;\n  66.2]</span></p>\n</td>\n<td style=\"width:14.76%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"14%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">49\n  (63.6%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[51.9;\n  74.3]</span></p>\n</td>\n</tr>", "ID": "23f11d97-dbf7-44cd-b576-de6d7e552491", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "         ", "ParentId": "3f853db6-990e-4e05-a5db-63e5deba97c8"}, {"Element": "<td style=\"width:10.6%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"top\" width=\"10%\">\n<p class=\"MsoNormal\" style=\"line-height:14.0pt;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">pCR rate in the breast and\n  lymph node (ypT0/is N0)</span></p>\n<p class=\"MsoNormal\" style=\"margin-bottom:1.0pt;line-height:14.0pt;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">n (%)</span></p>\n<p class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;margin-bottom:\n  1.0pt;margin-left:0in;line-height:14.0pt;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[95% CI]</span></p>\n</td>", "ID": "9ca8fd60-36a2-49e1-9920-9f0b37aa6df5", "Styles": "width:10.6%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "    ", "ParentId": "23f11d97-dbf7-44cd-b576-de6d7e552491"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:14.0pt;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">pCR rate in the breast and\n  lymph node (ypT0/is N0)</span></p>", "ID": "4b4ddd64-8043-4713-8d1e-99e9d96bc3b4", "Styles": "line-height:14.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9ca8fd60-36a2-49e1-9920-9f0b37aa6df5"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">pCR rate in the breast and\n  lymph node (ypT0/is N0)</span>", "ID": "2364d48f-b91c-4491-9ace-157ee92976db", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "pCR rate in the breast and   lymph node (ypT0/is N0)", "ParentId": "4b4ddd64-8043-4713-8d1e-99e9d96bc3b4"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-bottom:1.0pt;line-height:14.0pt;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">n (%)</span></p>", "ID": "66ad2d25-036d-4753-ad26-25965a9eeb6e", "Styles": "margin-bottom:1.0pt;line-height:14.0pt;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9ca8fd60-36a2-49e1-9920-9f0b37aa6df5"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">n (%)</span>", "ID": "752bc900-61c6-4ded-8194-83df4534b49a", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "n (%)", "ParentId": "66ad2d25-036d-4753-ad26-25965a9eeb6e"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;margin-bottom:\n  1.0pt;margin-left:0in;line-height:14.0pt;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[95% CI]</span></p>", "ID": "8a93d591-906e-4de6-9163-8f4f1c2cbe8d", "Styles": "margin-top:1.0pt;margin-right:0in;margin-bottom:\n  1.0pt;margin-left:0in;line-height:14.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9ca8fd60-36a2-49e1-9920-9f0b37aa6df5"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[95% CI]</span>", "ID": "f0874ff4-c572-42bf-b73e-3c298c4618c5", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "[95% CI]", "ParentId": "8a93d591-906e-4de6-9163-8f4f1c2cbe8d"}, {"Element": "<td style=\"width:11.44%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"11%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">23\n  (21.5%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[14.1;\n  30.5]</span></p>\n</td>", "ID": "a7cca3c2-faaa-4c58-9e3d-c6f7eebdd153", "Styles": "width:11.44%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "   ", "ParentId": "23f11d97-dbf7-44cd-b576-de6d7e552491"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">23\n  (21.5%)</span></p>", "ID": "bbb22b19-9595-433f-b058-dd864a4982c7", "Styles": "margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a7cca3c2-faaa-4c58-9e3d-c6f7eebdd153"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">23\n  (21.5%)</span>", "ID": "e0791b69-dd73-4ee1-a27a-318db126f668", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "23   (21.5%)", "ParentId": "bbb22b19-9595-433f-b058-dd864a4982c7"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[14.1;\n  30.5]</span></p>", "ID": "3f3adb7b-7a07-47c0-b310-6ad5356e9c77", "Styles": "margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a7cca3c2-faaa-4c58-9e3d-c6f7eebdd153"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[14.1;\n  30.5]</span>", "ID": "6522770f-f3b6-4891-b3a9-df51917c2413", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "[14.1;   30.5]", "ParentId": "3f3adb7b-7a07-47c0-b310-6ad5356e9c77"}, {"Element": "<td style=\"width:12.1%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">42\n  (39.3%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[30.3;\n  49.2]</span></p>\n</td>", "ID": "735c9896-ceef-4fd3-97bb-b928434d993c", "Styles": "width:12.1%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "   ", "ParentId": "23f11d97-dbf7-44cd-b576-de6d7e552491"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">42\n  (39.3%)</span></p>", "ID": "ef8e8ae8-678f-4550-aa9a-e146df14fb76", "Styles": "margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "735c9896-ceef-4fd3-97bb-b928434d993c"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">42\n  (39.3%)</span>", "ID": "46c831cd-09f7-4d7a-b892-598993d476fd", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "42   (39.3%)", "ParentId": "ef8e8ae8-678f-4550-aa9a-e146df14fb76"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[30.3;\n  49.2]</span></p>", "ID": "325b91d9-5ee1-4347-8935-610386a05ba3", "Styles": "margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "735c9896-ceef-4fd3-97bb-b928434d993c"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[30.3;\n  49.2]</span>", "ID": "be8dbcd4-d139-4f37-979f-e2f41aa51537", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "[30.3;   49.2]", "ParentId": "325b91d9-5ee1-4347-8935-610386a05ba3"}, {"Element": "<td style=\"width:12.12%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">12\n  (11.2%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[5.9;\n  18.8]</span></p>\n</td>", "ID": "b80c4924-101f-4458-9d8f-dddde3556d29", "Styles": "width:12.12%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "   ", "ParentId": "23f11d97-dbf7-44cd-b576-de6d7e552491"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">12\n  (11.2%)</span></p>", "ID": "dd93db37-c927-44cc-821e-2180c023b875", "Styles": "margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b80c4924-101f-4458-9d8f-dddde3556d29"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">12\n  (11.2%)</span>", "ID": "95287267-101d-4f64-b9e4-a890d8be5fb9", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "12   (11.2%)", "ParentId": "dd93db37-c927-44cc-821e-2180c023b875"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[5.9;\n  18.8]</span></p>", "ID": "d8509413-0846-4fc2-9862-3575469e34af", "Styles": "margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b80c4924-101f-4458-9d8f-dddde3556d29"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[5.9;\n  18.8]</span>", "ID": "de050d60-a819-4581-800b-21001f723389", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "[5.9;   18.8]", "ParentId": "d8509413-0846-4fc2-9862-3575469e34af"}, {"Element": "<td style=\"width:11.82%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"11%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">17\n  (17.7%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[10.7;\n  26.8]</span></p>\n</td>", "ID": "82dc469a-9430-4ec3-a7b1-f9c944cfbc21", "Styles": "width:11.82%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "   ", "ParentId": "23f11d97-dbf7-44cd-b576-de6d7e552491"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">17\n  (17.7%)</span></p>", "ID": "9d98ebc6-4897-4e3f-ad4e-0c3e502e542c", "Styles": "margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "82dc469a-9430-4ec3-a7b1-f9c944cfbc21"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">17\n  (17.7%)</span>", "ID": "24904e46-2bef-403a-b358-6cfa9d365541", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "17   (17.7%)", "ParentId": "9d98ebc6-4897-4e3f-ad4e-0c3e502e542c"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[10.7;\n  26.8]</span></p>", "ID": "4ebcd7f0-9bbf-474f-98d7-e505faf7a8ca", "Styles": "margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "82dc469a-9430-4ec3-a7b1-f9c944cfbc21"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[10.7;\n  26.8]</span>", "ID": "65ef03fc-f3b1-4f33-8225-8e60aa253995", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "[10.7;   26.8]", "ParentId": "4ebcd7f0-9bbf-474f-98d7-e505faf7a8ca"}, {"Element": "<td style=\"width:13.72%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"13%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">41\n  (56.2%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[44.1;\n  67.8]</span></p>\n</td>", "ID": "922b2fd7-131f-422c-b096-e980c89e4bd7", "Styles": "width:13.72%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "   ", "ParentId": "23f11d97-dbf7-44cd-b576-de6d7e552491"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">41\n  (56.2%)</span></p>", "ID": "63405470-103b-44cd-b3ca-3396c7e2e5d1", "Styles": "margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "922b2fd7-131f-422c-b096-e980c89e4bd7"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">41\n  (56.2%)</span>", "ID": "f5ab446d-1b79-4c02-90df-daa8818d37f2", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "41   (56.2%)", "ParentId": "63405470-103b-44cd-b3ca-3396c7e2e5d1"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[44.1;\n  67.8]</span></p>", "ID": "7495fe65-b862-4828-8874-688bcf8a219b", "Styles": "margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "922b2fd7-131f-422c-b096-e980c89e4bd7"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[44.1;\n  67.8]</span>", "ID": "b4e7b630-9cc9-4ade-bdf2-e97917f795aa", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "[44.1;   67.8]", "ParentId": "7495fe65-b862-4828-8874-688bcf8a219b"}, {"Element": "<td style=\"width:13.44%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"13%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">41\n  (54.7%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[42.7;\n  66.2]</span></p>\n</td>", "ID": "58f7518d-c354-4fab-b12e-15b32665c68f", "Styles": "width:13.44%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "   ", "ParentId": "23f11d97-dbf7-44cd-b576-de6d7e552491"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">41\n  (54.7%)</span></p>", "ID": "8f8b367e-335b-40ba-bd30-cfd57af5554b", "Styles": "margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "58f7518d-c354-4fab-b12e-15b32665c68f"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">41\n  (54.7%)</span>", "ID": "cd62eb2c-0201-4779-9a39-ea5b0d55b532", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "41   (54.7%)", "ParentId": "8f8b367e-335b-40ba-bd30-cfd57af5554b"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[42.7;\n  66.2]</span></p>", "ID": "81fc6816-99c3-4570-b332-8632456b5507", "Styles": "margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "58f7518d-c354-4fab-b12e-15b32665c68f"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[42.7;\n  66.2]</span>", "ID": "c936f059-1060-4fd3-9fa0-25c068b3228f", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "[42.7;   66.2]", "ParentId": "81fc6816-99c3-4570-b332-8632456b5507"}, {"Element": "<td style=\"width:14.76%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"14%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">49\n  (63.6%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[51.9;\n  74.3]</span></p>\n</td>", "ID": "1a51c899-0115-47f2-9aa7-bfad740fc4b8", "Styles": "width:14.76%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "   ", "ParentId": "23f11d97-dbf7-44cd-b576-de6d7e552491"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">49\n  (63.6%)</span></p>", "ID": "832c4896-db48-423e-bf62-095257c9ab2e", "Styles": "margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1a51c899-0115-47f2-9aa7-bfad740fc4b8"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">49\n  (63.6%)</span>", "ID": "c3e561b4-f45c-460b-b459-1af667e23409", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "49   (63.6%)", "ParentId": "832c4896-db48-423e-bf62-095257c9ab2e"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[51.9;\n  74.3]</span></p>", "ID": "49133f55-1503-4677-9bac-8a389c2e8614", "Styles": "margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1a51c899-0115-47f2-9aa7-bfad740fc4b8"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[51.9;\n  74.3]</span>", "ID": "4e117a4a-12d3-4fed-9dac-874fa008b073", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "[51.9;   74.3]", "ParentId": "49133f55-1503-4677-9bac-8a389c2e8614"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:10.6%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"top\" width=\"10%\">\n<p class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;margin-bottom:\n  1.0pt;margin-left:0in;line-height:14.0pt;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">ypT0 N0 </span></p>\n<p class=\"MsoNormal\" style=\"margin-bottom:1.0pt;line-height:14.0pt;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">n (%)</span></p>\n<p class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;margin-bottom:\n  1.0pt;margin-left:0in;line-height:14.0pt;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[95% CI]</span></p>\n</td>\n<td style=\"width:11.44%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"11%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">13\n  (12.1%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[6.6;\n  19.9]</span></p>\n</td>\n<td style=\"width:12.1%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">35\n  (32.7%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[24.0;\n  42.5]</span></p>\n</td>\n<td style=\"width:12.12%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">6\n  (5.6%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[2.1;\n  11.8]</span></p>\n</td>\n<td style=\"width:11.82%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"11%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">13\n  (13.2%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[7.4;\n  22.0]</span></p>\n</td>\n<td style=\"width:13.72%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"13%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">37\n  (50.7%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[38.7;\n  62.6]</span></p>\n</td>\n<td style=\"width:13.44%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"13%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">34\n  (45.3%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[33.8;\n  57.3]</span></p>\n</td>\n<td style=\"width:14.76%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"14%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">40\n  (51.9%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[40.3;\n  63.5]</span></p>\n</td>\n</tr>", "ID": "ebd47328-8571-4e5d-9f12-79f89bc29921", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "         ", "ParentId": "3f853db6-990e-4e05-a5db-63e5deba97c8"}, {"Element": "<td style=\"width:10.6%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"top\" width=\"10%\">\n<p class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;margin-bottom:\n  1.0pt;margin-left:0in;line-height:14.0pt;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">ypT0 N0 </span></p>\n<p class=\"MsoNormal\" style=\"margin-bottom:1.0pt;line-height:14.0pt;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">n (%)</span></p>\n<p class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;margin-bottom:\n  1.0pt;margin-left:0in;line-height:14.0pt;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[95% CI]</span></p>\n</td>", "ID": "95e89c80-cafa-4631-95f6-d42c9d4c82e5", "Styles": "width:10.6%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "    ", "ParentId": "ebd47328-8571-4e5d-9f12-79f89bc29921"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;margin-bottom:\n  1.0pt;margin-left:0in;line-height:14.0pt;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">ypT0 N0 </span></p>", "ID": "e317d24c-3ae9-4403-9c4b-5d56cd0f7c46", "Styles": "margin-top:1.0pt;margin-right:0in;margin-bottom:\n  1.0pt;margin-left:0in;line-height:14.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "95e89c80-cafa-4631-95f6-d42c9d4c82e5"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">ypT0 N0 </span>", "ID": "e70fedc6-f561-4d0c-badb-06e362bebaf6", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "ypT0 N0 ", "ParentId": "e317d24c-3ae9-4403-9c4b-5d56cd0f7c46"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-bottom:1.0pt;line-height:14.0pt;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">n (%)</span></p>", "ID": "db145f06-837f-41e1-89ce-408d6dfa22a7", "Styles": "margin-bottom:1.0pt;line-height:14.0pt;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "95e89c80-cafa-4631-95f6-d42c9d4c82e5"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">n (%)</span>", "ID": "f04cfc30-3599-476e-b668-f0f97f25df03", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "n (%)", "ParentId": "db145f06-837f-41e1-89ce-408d6dfa22a7"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;margin-bottom:\n  1.0pt;margin-left:0in;line-height:14.0pt;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[95% CI]</span></p>", "ID": "5218fcb4-641b-45de-9431-1b110781cd15", "Styles": "margin-top:1.0pt;margin-right:0in;margin-bottom:\n  1.0pt;margin-left:0in;line-height:14.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "95e89c80-cafa-4631-95f6-d42c9d4c82e5"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[95% CI]</span>", "ID": "15be7881-614f-4114-979f-33b0698baf74", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "[95% CI]", "ParentId": "5218fcb4-641b-45de-9431-1b110781cd15"}, {"Element": "<td style=\"width:11.44%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"11%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">13\n  (12.1%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[6.6;\n  19.9]</span></p>\n</td>", "ID": "4d5f8cf1-d738-4743-8221-6e7d9ff93539", "Styles": "width:11.44%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "   ", "ParentId": "ebd47328-8571-4e5d-9f12-79f89bc29921"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">13\n  (12.1%)</span></p>", "ID": "df4a8041-5bcb-49f3-b7fc-e276074c708e", "Styles": "margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4d5f8cf1-d738-4743-8221-6e7d9ff93539"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">13\n  (12.1%)</span>", "ID": "6543af26-a4b2-46e0-a726-a7ed1858be1e", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "13   (12.1%)", "ParentId": "df4a8041-5bcb-49f3-b7fc-e276074c708e"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[6.6;\n  19.9]</span></p>", "ID": "9355fae4-f1da-4732-9ac5-7d6ebf3e00b2", "Styles": "margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4d5f8cf1-d738-4743-8221-6e7d9ff93539"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[6.6;\n  19.9]</span>", "ID": "5ea0c463-e835-4b82-9a70-9c8e1a2e997a", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "[6.6;   19.9]", "ParentId": "9355fae4-f1da-4732-9ac5-7d6ebf3e00b2"}, {"Element": "<td style=\"width:12.1%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">35\n  (32.7%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[24.0;\n  42.5]</span></p>\n</td>", "ID": "74d755d6-a051-46be-9be0-57e91ec8368e", "Styles": "width:12.1%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "   ", "ParentId": "ebd47328-8571-4e5d-9f12-79f89bc29921"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">35\n  (32.7%)</span></p>", "ID": "0810983b-0cbd-47a6-9fb8-f12a89af0620", "Styles": "margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "74d755d6-a051-46be-9be0-57e91ec8368e"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">35\n  (32.7%)</span>", "ID": "1314a179-3f74-4788-9292-9701465c645e", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "35   (32.7%)", "ParentId": "0810983b-0cbd-47a6-9fb8-f12a89af0620"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[24.0;\n  42.5]</span></p>", "ID": "01140622-56e9-4e97-931a-237ef9a9a056", "Styles": "margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "74d755d6-a051-46be-9be0-57e91ec8368e"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[24.0;\n  42.5]</span>", "ID": "383a53c6-b0df-460e-b666-44ce75158255", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "[24.0;   42.5]", "ParentId": "01140622-56e9-4e97-931a-237ef9a9a056"}, {"Element": "<td style=\"width:12.12%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">6\n  (5.6%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[2.1;\n  11.8]</span></p>\n</td>", "ID": "7f69fcac-789f-449c-b430-3705e5ec84b5", "Styles": "width:12.12%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "   ", "ParentId": "ebd47328-8571-4e5d-9f12-79f89bc29921"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">6\n  (5.6%)</span></p>", "ID": "5e78b33c-4022-4bb6-9923-a85d52e4e9d1", "Styles": "margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7f69fcac-789f-449c-b430-3705e5ec84b5"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">6\n  (5.6%)</span>", "ID": "24b6e2c9-05c4-47fc-8613-2ec8896eb98e", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "6   (5.6%)", "ParentId": "5e78b33c-4022-4bb6-9923-a85d52e4e9d1"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[2.1;\n  11.8]</span></p>", "ID": "39237a20-515f-4f23-94c9-d91677bdcbe4", "Styles": "margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7f69fcac-789f-449c-b430-3705e5ec84b5"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[2.1;\n  11.8]</span>", "ID": "a2053a6f-15ba-4002-bfb3-26e0105a63a4", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "[2.1;   11.8]", "ParentId": "39237a20-515f-4f23-94c9-d91677bdcbe4"}, {"Element": "<td style=\"width:11.82%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"11%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">13\n  (13.2%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[7.4;\n  22.0]</span></p>\n</td>", "ID": "d3d6bf74-9c80-4b61-a769-75f4fea9ca8e", "Styles": "width:11.82%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "   ", "ParentId": "ebd47328-8571-4e5d-9f12-79f89bc29921"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">13\n  (13.2%)</span></p>", "ID": "ccf59415-84f0-4682-8dc8-d526ad211a55", "Styles": "margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d3d6bf74-9c80-4b61-a769-75f4fea9ca8e"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">13\n  (13.2%)</span>", "ID": "691047b3-570b-4150-b8f0-55eafd414fee", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "13   (13.2%)", "ParentId": "ccf59415-84f0-4682-8dc8-d526ad211a55"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[7.4;\n  22.0]</span></p>", "ID": "8510b137-0188-43b9-9953-c86f4a8543f7", "Styles": "margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d3d6bf74-9c80-4b61-a769-75f4fea9ca8e"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[7.4;\n  22.0]</span>", "ID": "06f37dee-b618-4e51-be88-9386abeb6a70", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "[7.4;   22.0]", "ParentId": "8510b137-0188-43b9-9953-c86f4a8543f7"}, {"Element": "<td style=\"width:13.72%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"13%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">37\n  (50.7%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[38.7;\n  62.6]</span></p>\n</td>", "ID": "7b820c38-dac3-43e4-bd78-db7ad9439e62", "Styles": "width:13.72%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "   ", "ParentId": "ebd47328-8571-4e5d-9f12-79f89bc29921"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">37\n  (50.7%)</span></p>", "ID": "26455837-6886-44f1-bb9f-fdcd21640ce3", "Styles": "margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7b820c38-dac3-43e4-bd78-db7ad9439e62"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">37\n  (50.7%)</span>", "ID": "a25cb957-3a9a-4188-bc05-3feaea08196a", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "37   (50.7%)", "ParentId": "26455837-6886-44f1-bb9f-fdcd21640ce3"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[38.7;\n  62.6]</span></p>", "ID": "e55b2a38-c776-42c5-872f-e196014fab19", "Styles": "margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7b820c38-dac3-43e4-bd78-db7ad9439e62"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[38.7;\n  62.6]</span>", "ID": "e0e07e83-ea81-493c-9da6-855f809ccfe5", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "[38.7;   62.6]", "ParentId": "e55b2a38-c776-42c5-872f-e196014fab19"}, {"Element": "<td style=\"width:13.44%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"13%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">34\n  (45.3%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[33.8;\n  57.3]</span></p>\n</td>", "ID": "04faafa5-28f0-4434-88b9-d3bd2e4021cf", "Styles": "width:13.44%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "   ", "ParentId": "ebd47328-8571-4e5d-9f12-79f89bc29921"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">34\n  (45.3%)</span></p>", "ID": "2dc4dfe0-0f33-4f15-b066-4006d9b520cd", "Styles": "margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "04faafa5-28f0-4434-88b9-d3bd2e4021cf"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">34\n  (45.3%)</span>", "ID": "fe63838a-6201-473c-a4af-0b203e603851", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "34   (45.3%)", "ParentId": "2dc4dfe0-0f33-4f15-b066-4006d9b520cd"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[33.8;\n  57.3]</span></p>", "ID": "2ee0300f-6617-4345-a51b-163dce2f98c3", "Styles": "margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "04faafa5-28f0-4434-88b9-d3bd2e4021cf"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[33.8;\n  57.3]</span>", "ID": "cc809db6-5867-44c8-af91-0e5ee5f97c2f", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "[33.8;   57.3]", "ParentId": "2ee0300f-6617-4345-a51b-163dce2f98c3"}, {"Element": "<td style=\"width:14.76%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"14%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">40\n  (51.9%)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[40.3;\n  63.5]</span></p>\n</td>", "ID": "89fdf88c-bc6c-4a4b-865f-6f003d9a4ab1", "Styles": "width:14.76%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "   ", "ParentId": "ebd47328-8571-4e5d-9f12-79f89bc29921"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">40\n  (51.9%)</span></p>", "ID": "f18e92de-1a37-464d-8ceb-b085dfdccc7c", "Styles": "margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "89fdf88c-bc6c-4a4b-865f-6f003d9a4ab1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">40\n  (51.9%)</span>", "ID": "0383cb6e-637d-4abf-a7ce-8af6c89c103f", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "40   (51.9%)", "ParentId": "f18e92de-1a37-464d-8ceb-b085dfdccc7c"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[40.3;\n  63.5]</span></p>", "ID": "c38fceb9-2dee-4275-9411-2aba4cd83c25", "Styles": "margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "89fdf88c-bc6c-4a4b-865f-6f003d9a4ab1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">[40.3;\n  63.5]</span>", "ID": "f5bf5dd5-f324-438e-9404-a2d6833a0942", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "[40.3;   63.5]", "ParentId": "c38fceb9-2dee-4275-9411-2aba4cd83c25"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:10.6%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"top\" width=\"10%\">\n<p class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;margin-bottom:\n  1.0pt;margin-left:0in;line-height:14.0pt;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Clinical Response<sup>5</sup></span></p>\n</td>\n<td style=\"width:11.44%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"11%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">79\n  (79.8%)</span></p>\n</td>\n<td style=\"width:12.1%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">89\n  (88.1%)</span></p>\n</td>\n<td style=\"width:12.12%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">69\n  (67.6%)</span></p>\n</td>\n<td style=\"width:11.82%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"11%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">65\n  (71.4%)</span></p>\n</td>\n<td style=\"width:13.72%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"13%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">67\n  (91.8%)</span></p>\n</td>\n<td style=\"width:13.44%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"13%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">71\n  (94.7%)</span></p>\n</td>\n<td style=\"width:14.76%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"14%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">69\n  (89.6%)</span></p>\n</td>\n</tr>", "ID": "6c477e2d-5fb2-477f-88a2-381afbba91c9", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "         ", "ParentId": "3f853db6-990e-4e05-a5db-63e5deba97c8"}, {"Element": "<td style=\"width:10.6%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"top\" width=\"10%\">\n<p class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;margin-bottom:\n  1.0pt;margin-left:0in;line-height:14.0pt;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Clinical Response<sup>5</sup></span></p>\n</td>", "ID": "ca3c8325-df75-4541-a024-2468f1cda5d9", "Styles": "width:10.6%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "6c477e2d-5fb2-477f-88a2-381afbba91c9"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;margin-bottom:\n  1.0pt;margin-left:0in;line-height:14.0pt;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Clinical Response<sup>5</sup></span></p>", "ID": "ea500cd6-367c-44b6-b8bc-90e0a3803f58", "Styles": "margin-top:1.0pt;margin-right:0in;margin-bottom:\n  1.0pt;margin-left:0in;line-height:14.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ca3c8325-df75-4541-a024-2468f1cda5d9"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">Clinical Response<sup>5</sup></span>", "ID": "8e6f0fd8-3bbb-40ea-b2ee-43ff98950a94", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "Clinical Response", "ParentId": "ea500cd6-367c-44b6-b8bc-90e0a3803f58"}, {"Element": "<sup>5</sup>", "ID": "83959cb1-2c34-4773-8c13-31edecc40777", "Styles": "None", "Classes": "None", "Text": "5", "ParentId": "8e6f0fd8-3bbb-40ea-b2ee-43ff98950a94"}, {"Element": "<td style=\"width:11.44%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"11%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">79\n  (79.8%)</span></p>\n</td>", "ID": "edea7918-248e-4dd8-a3be-c136cdf85a54", "Styles": "width:11.44%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "6c477e2d-5fb2-477f-88a2-381afbba91c9"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">79\n  (79.8%)</span></p>", "ID": "69af1167-0a47-47ab-8f98-c9476d8df488", "Styles": "margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "edea7918-248e-4dd8-a3be-c136cdf85a54"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">79\n  (79.8%)</span>", "ID": "4e12e2ca-06a6-4061-bd09-463f13f7f4f0", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "79   (79.8%)", "ParentId": "69af1167-0a47-47ab-8f98-c9476d8df488"}, {"Element": "<td style=\"width:12.1%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">89\n  (88.1%)</span></p>\n</td>", "ID": "0f0e0654-5634-46e4-ae77-0c60df926d4c", "Styles": "width:12.1%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "6c477e2d-5fb2-477f-88a2-381afbba91c9"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">89\n  (88.1%)</span></p>", "ID": "1a3ecc52-2b76-4e97-9381-c9b63490d372", "Styles": "margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0f0e0654-5634-46e4-ae77-0c60df926d4c"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">89\n  (88.1%)</span>", "ID": "d63de4bb-40c8-4cf5-b69e-5fee9e310878", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "89   (88.1%)", "ParentId": "1a3ecc52-2b76-4e97-9381-c9b63490d372"}, {"Element": "<td style=\"width:12.12%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">69\n  (67.6%)</span></p>\n</td>", "ID": "4871b5d7-8ce8-4e0b-b533-68870fb0ca5a", "Styles": "width:12.12%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "6c477e2d-5fb2-477f-88a2-381afbba91c9"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">69\n  (67.6%)</span></p>", "ID": "d2e06e96-605c-4824-956d-393481e085b4", "Styles": "margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4871b5d7-8ce8-4e0b-b533-68870fb0ca5a"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">69\n  (67.6%)</span>", "ID": "92a3d610-f7f7-4933-bd0e-bf01613094f0", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "69   (67.6%)", "ParentId": "d2e06e96-605c-4824-956d-393481e085b4"}, {"Element": "<td style=\"width:11.82%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"11%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">65\n  (71.4%)</span></p>\n</td>", "ID": "6be8101d-3354-4a0e-9e0c-6a0527fc2dce", "Styles": "width:11.82%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "6c477e2d-5fb2-477f-88a2-381afbba91c9"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">65\n  (71.4%)</span></p>", "ID": "915b904e-311d-4b03-b325-19aad1e8d23e", "Styles": "margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "6be8101d-3354-4a0e-9e0c-6a0527fc2dce"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">65\n  (71.4%)</span>", "ID": "c6806f2b-a0a9-4468-aae6-45a9caaf9b4a", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "65   (71.4%)", "ParentId": "915b904e-311d-4b03-b325-19aad1e8d23e"}, {"Element": "<td style=\"width:13.72%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"13%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">67\n  (91.8%)</span></p>\n</td>", "ID": "21cb4cdf-4e7b-46ca-aa50-17dc725ecdce", "Styles": "width:13.72%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "6c477e2d-5fb2-477f-88a2-381afbba91c9"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">67\n  (91.8%)</span></p>", "ID": "5e0189f9-76cb-4d57-9772-28b81b1102a2", "Styles": "margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "21cb4cdf-4e7b-46ca-aa50-17dc725ecdce"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">67\n  (91.8%)</span>", "ID": "c00f0faf-cf38-406c-9a29-66436b8ec90b", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "67   (91.8%)", "ParentId": "5e0189f9-76cb-4d57-9772-28b81b1102a2"}, {"Element": "<td style=\"width:13.44%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"13%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">71\n  (94.7%)</span></p>\n</td>", "ID": "c80a76d9-737b-47b4-b760-eb454512dfce", "Styles": "width:13.44%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "6c477e2d-5fb2-477f-88a2-381afbba91c9"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">71\n  (94.7%)</span></p>", "ID": "52db8e96-7a74-412e-b1c8-2361208e0d46", "Styles": "margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c80a76d9-737b-47b4-b760-eb454512dfce"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">71\n  (94.7%)</span>", "ID": "969702b9-c664-4a28-abbb-6e0da4786ef7", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "71   (94.7%)", "ParentId": "52db8e96-7a74-412e-b1c8-2361208e0d46"}, {"Element": "<td style=\"width:14.76%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" width=\"14%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">69\n  (89.6%)</span></p>\n</td>", "ID": "75ad9de9-36dd-4612-a686-ae302670c9b8", "Styles": "width:14.76%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "6c477e2d-5fb2-477f-88a2-381afbba91c9"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">69\n  (89.6%)</span></p>", "ID": "b5da8600-b142-4d88-a261-d890d3440967", "Styles": "margin-top:1.0pt;margin-right:0in;\n  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "75ad9de9-36dd-4612-a686-ae302670c9b8"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">69\n  (89.6%)</span>", "ID": "b9fc7219-1940-4828-bc76-05cc9efde7b8", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "69   (89.6%)", "ParentId": "b5da8600-b142-4d88-a261-d890d3440967"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">FEC: 5-fluorouracil,\nepirubicin, cyclophosphamide; TCH: docetaxel, carboplatin and trastuzumab, CMH:\nCochran\u2013Mantel\u2013Haenszel</span></p>", "ID": "87b4fc31-ff0c-4574-8714-3311a281daa3", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">FEC: 5-fluorouracil,\nepirubicin, cyclophosphamide; TCH: docetaxel, carboplatin and trastuzumab, CMH:\nCochran\u2013Mantel\u2013Haenszel</span>", "ID": "4f98ab77-f527-4986-a32d-fc096d216ad6", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "FEC: 5-fluorouracil, epirubicin, cyclophosphamide; TCH: docetaxel, carboplatin and trastuzumab, CMH: Cochran\u2013Mantel\u2013Haenszel", "ParentId": "87b4fc31-ff0c-4574-8714-3311a281daa3"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">1. 95% CI for one sample\nbinomial using Pearson-Clopper method.</span></p>", "ID": "da7414b3-8e43-45a0-96c1-3a4537a65b48", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">1. 95% CI for one sample\nbinomial using Pearson-Clopper method.</span>", "ID": "0192809c-c882-4499-ae38-8489e3b9ef5c", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "1. 95% CI for one sample binomial using Pearson-Clopper method.", "ParentId": "da7414b3-8e43-45a0-96c1-3a4537a65b48"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">2. Treatment Perjeta+Trastuzumab+Docetaxel\nand Perjeta+Trastuzumab are compared to Trastuzumab+ Docetaxel while\nPerjeta+Docetaxel\u00a0 is compared to Perjeta+Trastuzumab+Docetaxel.</span></p>", "ID": "5107880e-164d-4426-8961-0e2a87765b68", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">2. Treatment Perjeta+Trastuzumab+Docetaxel\nand Perjeta+Trastuzumab are compared to Trastuzumab+ Docetaxel while\nPerjeta+Docetaxel\u00a0 is compared to Perjeta+Trastuzumab+Docetaxel.</span>", "ID": "5c1f3794-8905-4095-8624-7cab1bdd6aed", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "2. Treatment Perjeta+Trastuzumab+Docetaxel and Perjeta+Trastuzumab are compared to Trastuzumab+ Docetaxel while Perjeta+Docetaxel\u00a0 is compared to Perjeta+Trastuzumab+Docetaxel.", "ParentId": "5107880e-164d-4426-8961-0e2a87765b68"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">3. Approximate 95% CI for\ndifference of two response rates using Hauck-Anderson method.</span></p>", "ID": "0c5e5ebd-eb5a-45f7-8160-b12b3d33df80", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">3. Approximate 95% CI for\ndifference of two response rates using Hauck-Anderson method.</span>", "ID": "05fbb969-db9d-4c48-bb41-ee1daf6f976a", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "3. Approximate 95% CI for difference of two response rates using Hauck-Anderson method.", "ParentId": "0c5e5ebd-eb5a-45f7-8160-b12b3d33df80"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">4. p-value from Cochran-Mantel-Haenszel\u00a0\ntest, with Simes multiplicity adjustment.</span></p>", "ID": "891cacc5-0513-4faa-ac49-5790a3971c74", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">4. p-value from Cochran-Mantel-Haenszel\u00a0\ntest, with Simes multiplicity adjustment.</span>", "ID": "fe1a2e9c-d229-4bdd-a360-e508c5dd5cbe", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "4. p-value from Cochran-Mantel-Haenszel\u00a0 test, with Simes multiplicity adjustment.", "ParentId": "891cacc5-0513-4faa-ac49-5790a3971c74"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">5.\nClinical response represents patients with a best overall response of CR or PR\nduring the neoadjuvant period (in the primary breast lesion).</span></p>", "ID": "dc27d0cf-8b3a-46f4-ae41-725ea6d040c9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">5.\nClinical response represents patients with a best overall response of CR or PR\nduring the neoadjuvant period (in the primary breast lesion).</span>", "ID": "611eefc1-7a1a-472e-9b95-c01ff99ea198", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "5. Clinical response represents patients with a best overall response of CR or PR during the neoadjuvant period (in the primary breast lesion).", "ParentId": "dc27d0cf-8b3a-46f4-ae41-725ea6d040c9"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:9.0pt;text-indent:-9.0pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>", "ID": "9c6fd947-e6c6-4d2c-84e8-72f85cc4fbab", "Styles": "margin-left:9.0pt;text-indent:-9.0pt;text-autospace:\nnone", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span>", "ID": "6f23a1b7-9b14-4191-a64f-0cc9368e9d07", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "9c6fd947-e6c6-4d2c-84e8-72f85cc4fbab"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">BERENICE\n(WO29217)</span></b></p>", "ID": "886fb1d0-49e2-474a-b3b0-d8adcd7fcfd1", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">BERENICE\n(WO29217)</span></b>", "ID": "add6494e-fdbc-42da-bc3b-de87d612ff9e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "886fb1d0-49e2-474a-b3b0-d8adcd7fcfd1"}, {"Element": "<span lang=\"EN-GB\">BERENICE\n(WO29217)</span>", "ID": "2e0db756-ad04-4866-8496-dfb886982e2a", "Styles": "None", "Classes": "None", "Text": "BERENICE (WO29217)", "ParentId": "add6494e-fdbc-42da-bc3b-de87d612ff9e"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "f1a3d906-2446-4417-9a6d-f6752f1d5684", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "99770a98-93e2-4ffe-a829-89bdea258092", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f1a3d906-2446-4417-9a6d-f6752f1d5684"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "79ff8a60-d81d-432f-8d16-13a2bdf524db", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "99770a98-93e2-4ffe-a829-89bdea258092"}, {"Element": "<p class=\"MsoNormal\">BERENICE is a non-randomized, open-label, multicentre,\nmultinational, Phase II trial conducted in 401 patients with HER2-positive\nlocally advanced, inflammatory, or early-stage breast cancer (with primary\ntumours <span style=\"font-family:Symbol\">&gt;</span>\u00a02cm in diameter or\nnode\u2011positive disease).</p>", "ID": "6e713786-5009-48cd-ada6-44d55a431a38", "Styles": "None", "Classes": "['MsoNormal']", "Text": "BERENICE is a non-randomized, open-label, multicentre, multinational, Phase II trial conducted in 401 patients with HER2-positive locally advanced, inflammatory, or early-stage breast cancer (with primary tumours \u00a02cm in diameter or node\u2011positive disease).", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span style=\"font-family:Symbol\">&gt;</span>", "ID": "d6a9614b-62ca-480a-b9da-59591af569d5", "Styles": "font-family:Symbol", "Classes": "None", "Text": ">", "ParentId": "6e713786-5009-48cd-ada6-44d55a431a38"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "74a133a2-653c-4c3d-84e5-c51004213b36", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<p class=\"MsoNormal\">The BERENICE study included two parallel groups of patients.\nPatients considered suitable for neoadjuvant treatment with trastuzumab plus\nanthracycline/taxane-based chemotherapy were allocated to receive one of the\ntwo following regimens prior to surgery as follows: </p>", "ID": "f4548167-c298-41cf-810f-19ccd779a2a4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "The BERENICE study included two parallel groups of patients. Patients considered suitable for neoadjuvant treatment with trastuzumab plus anthracycline/taxane-based chemotherapy were allocated to receive one of the two following regimens prior to surgery as follows: ", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "5358eda8-b841-4e9c-863a-500eacd7eb93", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:35.7pt;text-indent:-17.85pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0 </span>Cohort\nA - 4 cycles of two weekly dose-dense doxorubicin and cyclophosphamide followed\nby 4 cycles of Perjeta in combination with trastuzumab and paclitaxel.</p>", "ID": "d055911c-638d-43c0-88e9-680886802ca7", "Styles": "margin-left:35.7pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "Cohort A - 4 cycles of two weekly dose-dense doxorubicin and cyclophosphamide followed by 4 cycles of Perjeta in combination with trastuzumab and paclitaxel.", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "bb3d4acc-de6d-4708-8505-90f4a93fc623", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "d055911c-638d-43c0-88e9-680886802ca7"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0 </span>", "ID": "6b4849de-ee09-4f83-ab8a-710973ca38a8", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "d055911c-638d-43c0-88e9-680886802ca7"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:35.7pt;text-indent:-17.85pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0 </span>Cohort\nB - 4 cycles of FEC followed by 4 cycles of Perjeta in combination with trastuzumab\nand docetaxel. </p>", "ID": "5d15de54-ab19-41a2-ab05-543db77b97af", "Styles": "margin-left:35.7pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "Cohort B - 4 cycles of FEC followed by 4 cycles of Perjeta in combination with trastuzumab and docetaxel. ", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "9c1b3bf8-154e-4e31-b2f5-3b2eecefa7d8", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "5d15de54-ab19-41a2-ab05-543db77b97af"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0 </span>", "ID": "21edf9ce-930a-44c9-9bb9-7103f345b23e", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "5d15de54-ab19-41a2-ab05-543db77b97af"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "cb8127bf-4ece-4dc4-8a22-42584ae105e5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<p class=\"MsoNormal\">Following surgery all patients received Perjeta and\ntrastuzumab intravenously every 3 weeks to complete 1 year of therapy.</p>", "ID": "ef457da1-a4be-4be7-8eba-5de3670bdfcc", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Following surgery all patients received Perjeta and trastuzumab intravenously every 3 weeks to complete 1 year of therapy.", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "1a74fa71-6ac3-4725-8a3e-3ed93606ac1b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<p class=\"MsoNormal\">The primary endpoint of the BERENICE trial is cardiac safety\nin the neoadjuvant period of the trial. The primary endpoint of cardiac safety,\ni.e. the incidence of NYHA Class III/IV LVD and LVEF declines, was consistent\nwith previous data in the neoadjuvant setting (see section 4.4. and 4.8).</p>", "ID": "7fd0c4ae-4705-4060-8532-ae16151ff12d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "The primary endpoint of the BERENICE trial is cardiac safety in the neoadjuvant period of the trial. The primary endpoint of cardiac safety, i.e. the incidence of NYHA Class III/IV LVD and LVEF declines, was consistent with previous data in the neoadjuvant setting (see section 4.4. and 4.8).", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "bb6d9cca-aefc-4de4-bcf3-9484aaf21a3f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<p class=\"MsoNormal\"><i>Adjuvant Treatment</i></p>", "ID": "cab934a6-c747-43cf-9c28-9aedf29200b9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<i>Adjuvant Treatment</i>", "ID": "4471978d-f71b-4375-8da1-ea05ecdae696", "Styles": "None", "Classes": "None", "Text": "Adjuvant Treatment", "ParentId": "cab934a6-c747-43cf-9c28-9aedf29200b9"}, {"Element": "<p class=\"MsoNormal\"><i>\u00a0</i></p>", "ID": "eecb61ad-5164-4049-9135-90951a1f1355", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<i>\u00a0</i>", "ID": "49b9e1dc-a87b-4017-95fc-d4d097e9cf31", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "eecb61ad-5164-4049-9135-90951a1f1355"}, {"Element": "<p class=\"MsoNormal\">In the adjuvant setting, based on data from the APHINITY\nstudy, HER2-positive early breast cancer patients at high risk of recurrence\nare defined as those with lymph node-positive or hormone receptor-negative\ndisease.</p>", "ID": "39c4ccb3-e03f-42b4-941b-e8cbecb58fa5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "In the adjuvant setting, based on data from the APHINITY study, HER2-positive early breast cancer patients at high risk of recurrence are defined as those with lymph node-positive or hormone receptor-negative disease.", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<p class=\"MsoNormal\"><b>\u00a0</b></p>", "ID": "f63e8c9e-2510-4ee2-81c3-be48b0329263", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b>\u00a0</b>", "ID": "40e6efef-cdbd-43d7-9017-a13df204f01e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f63e8c9e-2510-4ee2-81c3-be48b0329263"}, {"Element": "<p class=\"MsoNormal\"><b>APHINITY (BO25126) </b></p>", "ID": "7c24630e-a8a3-47c5-b8f3-9b5fef3af8e8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b>APHINITY (BO25126) </b>", "ID": "1b3e38db-f2b6-4d78-904b-5e5a39a172c9", "Styles": "None", "Classes": "None", "Text": "APHINITY (BO25126) ", "ParentId": "7c24630e-a8a3-47c5-b8f3-9b5fef3af8e8"}, {"Element": "<p class=\"MsoNormal\"><b>\u00a0</b></p>", "ID": "1b4dad1d-6790-4a26-9d35-16489632b41d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b>\u00a0</b>", "ID": "bb8152a9-7e8f-412e-a976-27d9a1699a1d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1b4dad1d-6790-4a26-9d35-16489632b41d"}, {"Element": "<p class=\"MsoNormal\">APHINITY is a multicentre, randomised, double-blind,\nplacebo-controlled Phase III trial conducted in 4804 patients with\nHER2-positive early breast cancer who had their primary tumour excised prior to\nrandomisation. Patients were then randomised to receive Perjeta or placebo, in\ncombination with adjuvant trastuzumab and chemotherapy. Investigators selected\none of the following anthracycline-based or non-anthracycline-based\nchemotherapy regimens for individual patients:</p>", "ID": "6000b8d0-128f-4628-b08c-ebadc712d17f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "APHINITY is a multicentre, randomised, double-blind, placebo-controlled Phase III trial conducted in 4804 patients with HER2-positive early breast cancer who had their primary tumour excised prior to randomisation. Patients were then randomised to receive Perjeta or placebo, in combination with adjuvant trastuzumab and chemotherapy. Investigators selected one of the following anthracycline-based or non-anthracycline-based chemotherapy regimens for individual patients:", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "36fa58d4-1cf3-4b56-800e-49eacecc86e6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:35.7pt;text-indent:-17.85pt\"><span style=\"font-family:Symbol;color:black\">\u00b7</span><span lang=\"BG\" style=\"color:black\">\u00a0\u00a0\u00a0 </span>3\nor 4 cycles of FEC or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC),\nfollowed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel</p>", "ID": "c6aef419-ea93-40cb-8289-fa05d9529ec4", "Styles": "margin-left:35.7pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "3 or 4 cycles of FEC or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span style=\"font-family:Symbol;color:black\">\u00b7</span>", "ID": "d5e71607-c737-4ddc-839a-ed8e18ef534e", "Styles": "font-family:Symbol;color:black", "Classes": "None", "Text": "\u00b7", "ParentId": "c6aef419-ea93-40cb-8289-fa05d9529ec4"}, {"Element": "<span lang=\"BG\" style=\"color:black\">\u00a0\u00a0\u00a0 </span>", "ID": "8622cf19-9b3f-49a8-af6b-35271c0700e4", "Styles": "color:black", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "c6aef419-ea93-40cb-8289-fa05d9529ec4"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:35.7pt;text-indent:-17.85pt\"><span style=\"font-family:Symbol;color:black\">\u00b7</span><span lang=\"BG\" style=\"color:black\">\u00a0\u00a0\u00a0 </span>4\ncycles of AC or epirubicin and cyclophosphamide (EC), followed by 3 or 4 cycles\nof docetaxel or 12 cycles of weekly paclitaxel </p>", "ID": "f7ea0433-7177-4e56-8714-0735099d37f8", "Styles": "margin-left:35.7pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "4 cycles of AC or epirubicin and cyclophosphamide (EC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel ", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span style=\"font-family:Symbol;color:black\">\u00b7</span>", "ID": "e756cd1a-1fcc-41da-bf78-86f5202d2c98", "Styles": "font-family:Symbol;color:black", "Classes": "None", "Text": "\u00b7", "ParentId": "f7ea0433-7177-4e56-8714-0735099d37f8"}, {"Element": "<span lang=\"BG\" style=\"color:black\">\u00a0\u00a0\u00a0 </span>", "ID": "6ab34866-ce67-4102-add5-c5cf0c85eb31", "Styles": "color:black", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "f7ea0433-7177-4e56-8714-0735099d37f8"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:35.7pt;text-indent:-17.85pt\"><span style=\"font-family:Symbol;color:black\">\u00b7</span><span lang=\"BG\" style=\"color:black\">\u00a0\u00a0\u00a0 </span>6\ncycles of docetaxel in combination with carboplatin\u00a0 </p>", "ID": "854fab03-a404-4e3a-8b09-bdb4c7cfae70", "Styles": "margin-left:35.7pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "6 cycles of docetaxel in combination with carboplatin\u00a0 ", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span style=\"font-family:Symbol;color:black\">\u00b7</span>", "ID": "24509db7-ea6b-4e30-b0a1-9810eb19c8ef", "Styles": "font-family:Symbol;color:black", "Classes": "None", "Text": "\u00b7", "ParentId": "854fab03-a404-4e3a-8b09-bdb4c7cfae70"}, {"Element": "<span lang=\"BG\" style=\"color:black\">\u00a0\u00a0\u00a0 </span>", "ID": "a7c3645b-4f2d-46e7-97b2-1f52eb604dde", "Styles": "color:black", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "854fab03-a404-4e3a-8b09-bdb4c7cfae70"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.5in\">\u00a0</p>", "ID": "505ecf2c-8ff9-4e49-bf83-eb44ba9828b3", "Styles": "margin-left:.5in", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<p class=\"MsoNormal\">Pertuzumab and trastuzumab were administered intravenously\n(see section 4.2) every 3 weeks starting<i> </i>on Day 1 of the first\ntaxane-containing cycle, for a total of 52 weeks (up to 18 cycles) or until\nrecurrence, withdrawal of consent or unmanageable toxicity. Standard doses of\n5-fluorouracil, epirubicin, doxorubicin, cyclophosphamide, docetaxel,\npaclitaxel and carboplatin were administered. After completion of chemotherapy,\npatients received radiotherapy and/or hormone therapy as per local clinical\nstandard.</p>", "ID": "fd131867-0b79-4070-b837-937ec5abeb77", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Pertuzumab and trastuzumab were administered intravenously (see section 4.2) every 3 weeks startingon Day 1 of the first taxane-containing cycle, for a total of 52 weeks (up to 18 cycles) or until recurrence, withdrawal of consent or unmanageable toxicity. Standard doses of 5-fluorouracil, epirubicin, doxorubicin, cyclophosphamide, docetaxel, paclitaxel and carboplatin were administered. After completion of chemotherapy, patients received radiotherapy and/or hormone therapy as per local clinical standard.", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<i> </i>", "ID": "3beb551e-3dcc-417d-b842-e58f455ee845", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "fd131867-0b79-4070-b837-937ec5abeb77"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "10fd2f7a-4d66-4f3d-bd04-616e21764c30", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<p class=\"MsoNormal\">The primary endpoint of the study was invasive disease-free\nsurvival (IDFS), defined as the time from randomisation to first occurrence of\nipsilateral local or regional invasive breast cancer recurrence, distant\nrecurrence, contralateral invasive breast cancer, or death from any cause.\nSecondary efficacy endpoints were IDFS including second primary non-breast\ncancer, overall survival (OS), disease-free survival (DFS), recurrence-free interval\n(RFI) and distant recurrence-free interval (DRFI).</p>", "ID": "3e3543ff-10cf-4836-a0bc-7a93dffd0469", "Styles": "None", "Classes": "['MsoNormal']", "Text": "The primary endpoint of the study was invasive disease-free survival (IDFS), defined as the time from randomisation to first occurrence of ipsilateral local or regional invasive breast cancer recurrence, distant recurrence, contralateral invasive breast cancer, or death from any cause. Secondary efficacy endpoints were IDFS including second primary non-breast cancer, overall survival (OS), disease-free survival (DFS), recurrence-free interval (RFI) and distant recurrence-free interval (DRFI).", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "58f87e68-f121-4e6b-8f3d-344bbe544378", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Demographics were well\nbalanced between the two treatment arms. The median age was 51 years, and over\n99% of patients were female. The majority of patients had node-positive (63%)\nand/or hormone receptor-positive disease (64%), and were Caucasian (71%).</p>", "ID": "236fa95c-a310-4068-bbb7-e738a7255e6f", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "Demographics were well balanced between the two treatment arms. The median age was 51 years, and over 99% of patients were female. The majority of patients had node-positive (63%) and/or hormone receptor-positive disease (64%), and were Caucasian (71%).", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "d1d16c83-ab39-4139-9e5f-f10606fda87b", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">After a median follow-up of\n45.4 months, the APHINITY study showed a 19% (hazard ratio [HR] = 0.81; 95% CI\n0.66, 1.00 p-value 0.0446) reduction in risk of recurrence or death in patients\nrandomised to receive Perjeta compared with patients randomised to receive\nplacebo.</p>", "ID": "f647eb34-c231-4c62-a38f-0dbf9d27a2ed", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "After a median follow-up of 45.4 months, the APHINITY study showed a 19% (hazard ratio [HR] = 0.81; 95% CI 0.66, 1.00 p-value 0.0446) reduction in risk of recurrence or death in patients randomised to receive Perjeta compared with patients randomised to receive placebo.", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "88435c63-762a-4dd1-9ef6-2e3972068e75", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">The efficacy results from the\nAPHINITY trial are summarised in Table 5 and in Figure 3.</p>", "ID": "7d89fbda-acce-4593-9e55-9644256d389f", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "The efficacy results from the APHINITY trial are summarised in Table 5 and in Figure 3.", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<p class=\"MsoNormal\"><u><span style=\"text-decoration:none\">\u00a0</span></u></p>", "ID": "324eec5d-fc44-4d1a-bf5f-aa1617fc8bad", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<u><span style=\"text-decoration:none\">\u00a0</span></u>", "ID": "09fc58d1-3812-45de-97a3-7902fc7ddb60", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "324eec5d-fc44-4d1a-bf5f-aa1617fc8bad"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "f7fe8f30-1cb8-46ba-9e88-b3ac8270b62b", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "09fc58d1-3812-45de-97a3-7902fc7ddb60"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.75in;text-indent:-.75in;page-break-after:\navoid\"><b>Table 5 \u00a0\u00a0\u00a0\u00a0 Overall Efficacy: ITT Population</b></p>", "ID": "10123351-dea9-4188-bd8b-5e093d877250", "Styles": "margin-left:.75in;text-indent:-.75in;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b>Table 5 \u00a0\u00a0\u00a0\u00a0 Overall Efficacy: ITT Population</b>", "ID": "053e312d-0d1d-4740-840e-093fe14da92c", "Styles": "None", "Classes": "None", "Text": "Table 5 \u00a0\u00a0\u00a0\u00a0 Overall Efficacy: ITT Population", "ParentId": "10123351-dea9-4188-bd8b-5e093d877250"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.75in;text-indent:-.75in;page-break-after:\navoid\"><b>\u00a0</b></p>", "ID": "eea20bda-5cac-4f85-aa6b-0e9392a9095d", "Styles": "margin-left:.75in;text-indent:-.75in;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b>\u00a0</b>", "ID": "a5d68cf9-21fb-41ef-be0e-384719946e13", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "eea20bda-5cac-4f85-aa6b-0e9392a9095d"}, {"Element": "<div align=\"right\">\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:457.35pt;border-collapse:collapse;border:none\" width=\"610\">\n<thead>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:238.5pt;border:solid windowtext 1.0pt;\n   padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:112.5pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"150\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Perjeta\n   + trastuzumab + Chemotherapy</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">N=2400</span></b></p>\n</td>\n<td style=\"width:106.35pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"142\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Placebo\n   + trastuzumab + Chemotherapy</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">N=2404</span></b></p>\n</td>\n</tr>\n</thead>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:238.5pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Primary\n  Endpoint</span></i></b></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">\u00a0</span></i></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Invasive\n  Disease Free Survival (IDFS)<sup> </sup></span></b></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Number (%)\n  of patients with event </span></p>\n</td>\n<td style=\"width:112.5pt;border:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"150\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">171 (7.1%)</span></p>\n</td>\n<td style=\"width:106.35pt;border:none;border-right:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"142\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\">210 (8.7%)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">HR [95%\n  CI]</span></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0.81 [0.66, 1.00]</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">p-value\n  (Log-Rank test, stratified<sup>1</sup>)</span></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0.0446</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:238.5pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">3 year\n  event-free rate<sup>2</sup> [95% CI] </span></p>\n</td>\n<td style=\"width:112.5pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"150\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">94.1\n  [93.1, 95.0]</span></p>\n</td>\n<td style=\"width:106.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"142\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\">93.2 [92.2, 94.3]</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:238.5pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Secondary\n  Endpoints<sup>1</sup></span></i></b></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">\u00a0</span></i></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">IDFS</span></b><span lang=\"EN-GB\"> </span><b><span lang=\"EN-GB\">including second primary non-breast\n  cancer</span></b></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Number (%)\n  of patients with event </span></p>\n</td>\n<td style=\"width:112.5pt;border:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"150\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">189 (7.9%)</span></p>\n</td>\n<td style=\"width:106.35pt;border:none;border-right:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"142\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\">230 (9.6%)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"top\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">HR [95%\n  CI]</span></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"top\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0.82 [0.68, 0.99]</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">p-value\n  (Log-Rank test, stratified<sup>1</sup>)</span></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0.0430</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:238.5pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">3 year\n  event-free rate<sup>2</sup> [95% CI] </span></p>\n</td>\n<td style=\"width:112.5pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"150\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">93.5\n  [92.5, 94.5]</span></p>\n</td>\n<td style=\"width:106.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"142\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\">92.5 [91.4, 93.6]</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Disease\n  Free Survival (DFS) </span></b></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Number (%)\n  of patients with event</span></p>\n</td>\n<td style=\"width:112.5pt;border:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"150\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">192 (8.0%)</span></p>\n</td>\n<td style=\"width:106.35pt;border:none;border-right:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"142\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\">236 (9.8%)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">HR [95%\n  CI]</span></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0.81 [0.67, 0.98]</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">p-value (Log-Rank\n  test, stratified<sup>1</sup>)</span></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0.0327</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:238.5pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">3 year\n  event-free rate<sup>2</sup> [95% CI]</span></p>\n</td>\n<td style=\"width:112.5pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"150\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">93.4\n  [92.4, 94.4]</span></p>\n</td>\n<td style=\"width:106.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"142\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\">92.3 [91.2, 93.4]</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid;height:6.1pt\">\n<td style=\"width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:6.1pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Overall\n  Survival (OS)<sup>3</sup></span></b></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt;height:\n  6.1pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid;height:10.9pt\">\n<td style=\"width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:10.9pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Number (%)\n  of patients with event</span></p>\n</td>\n<td style=\"width:112.5pt;border:none;padding:0in 2.85pt 0in 2.85pt;\n  height:10.9pt\" valign=\"bottom\" width=\"150\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">80 (3.3%)</span></p>\n</td>\n<td style=\"width:106.35pt;border:none;border-right:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt;height:10.9pt\" valign=\"bottom\" width=\"142\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\">89 (3.7%)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid;height:10.9pt\">\n<td style=\"width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:10.9pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">HR [95%\n  CI]</span></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt;height:\n  10.9pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0.89 [0.66, 1.21]</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid;height:10.9pt\">\n<td style=\"width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:10.9pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">p-value\n  (Log-Rank test, stratified<sup>1</sup>)</span></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt;height:\n  10.9pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0.4673</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid;height:10.9pt\">\n<td style=\"width:238.5pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt;height:10.9pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">3 year\n  event-free rate<sup>2</sup> [95% CI]</span></p>\n</td>\n<td style=\"width:112.5pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt;height:10.9pt\" valign=\"bottom\" width=\"150\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">97.7\n  [97.0, 98.3]</span></p>\n</td>\n<td style=\"width:106.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:10.9pt\" valign=\"bottom\" width=\"142\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\">97.7 [97.1, 98.3]</span></p>\n</td>\n</tr>\n</table>\n</div>", "ID": "19485b85-683a-4216-bc81-0c4879c47f32", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:457.35pt;border-collapse:collapse;border:none\" width=\"610\">\n<thead>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:238.5pt;border:solid windowtext 1.0pt;\n   padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:112.5pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"150\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Perjeta\n   + trastuzumab + Chemotherapy</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">N=2400</span></b></p>\n</td>\n<td style=\"width:106.35pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"142\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Placebo\n   + trastuzumab + Chemotherapy</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">N=2404</span></b></p>\n</td>\n</tr>\n</thead>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:238.5pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Primary\n  Endpoint</span></i></b></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">\u00a0</span></i></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Invasive\n  Disease Free Survival (IDFS)<sup> </sup></span></b></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Number (%)\n  of patients with event </span></p>\n</td>\n<td style=\"width:112.5pt;border:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"150\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">171 (7.1%)</span></p>\n</td>\n<td style=\"width:106.35pt;border:none;border-right:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"142\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\">210 (8.7%)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">HR [95%\n  CI]</span></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0.81 [0.66, 1.00]</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">p-value\n  (Log-Rank test, stratified<sup>1</sup>)</span></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0.0446</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:238.5pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">3 year\n  event-free rate<sup>2</sup> [95% CI] </span></p>\n</td>\n<td style=\"width:112.5pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"150\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">94.1\n  [93.1, 95.0]</span></p>\n</td>\n<td style=\"width:106.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"142\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\">93.2 [92.2, 94.3]</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:238.5pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Secondary\n  Endpoints<sup>1</sup></span></i></b></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">\u00a0</span></i></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">IDFS</span></b><span lang=\"EN-GB\"> </span><b><span lang=\"EN-GB\">including second primary non-breast\n  cancer</span></b></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Number (%)\n  of patients with event </span></p>\n</td>\n<td style=\"width:112.5pt;border:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"150\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">189 (7.9%)</span></p>\n</td>\n<td style=\"width:106.35pt;border:none;border-right:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"142\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\">230 (9.6%)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"top\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">HR [95%\n  CI]</span></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"top\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0.82 [0.68, 0.99]</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">p-value\n  (Log-Rank test, stratified<sup>1</sup>)</span></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0.0430</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:238.5pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">3 year\n  event-free rate<sup>2</sup> [95% CI] </span></p>\n</td>\n<td style=\"width:112.5pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"150\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">93.5\n  [92.5, 94.5]</span></p>\n</td>\n<td style=\"width:106.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"142\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\">92.5 [91.4, 93.6]</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Disease\n  Free Survival (DFS) </span></b></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Number (%)\n  of patients with event</span></p>\n</td>\n<td style=\"width:112.5pt;border:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"150\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">192 (8.0%)</span></p>\n</td>\n<td style=\"width:106.35pt;border:none;border-right:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"142\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\">236 (9.8%)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">HR [95%\n  CI]</span></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0.81 [0.67, 0.98]</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">p-value (Log-Rank\n  test, stratified<sup>1</sup>)</span></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0.0327</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:238.5pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">3 year\n  event-free rate<sup>2</sup> [95% CI]</span></p>\n</td>\n<td style=\"width:112.5pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"150\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">93.4\n  [92.4, 94.4]</span></p>\n</td>\n<td style=\"width:106.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"142\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\">92.3 [91.2, 93.4]</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid;height:6.1pt\">\n<td style=\"width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:6.1pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Overall\n  Survival (OS)<sup>3</sup></span></b></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt;height:\n  6.1pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid;height:10.9pt\">\n<td style=\"width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:10.9pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Number (%)\n  of patients with event</span></p>\n</td>\n<td style=\"width:112.5pt;border:none;padding:0in 2.85pt 0in 2.85pt;\n  height:10.9pt\" valign=\"bottom\" width=\"150\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">80 (3.3%)</span></p>\n</td>\n<td style=\"width:106.35pt;border:none;border-right:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt;height:10.9pt\" valign=\"bottom\" width=\"142\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\">89 (3.7%)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid;height:10.9pt\">\n<td style=\"width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:10.9pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">HR [95%\n  CI]</span></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt;height:\n  10.9pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0.89 [0.66, 1.21]</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid;height:10.9pt\">\n<td style=\"width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:10.9pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">p-value\n  (Log-Rank test, stratified<sup>1</sup>)</span></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt;height:\n  10.9pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0.4673</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid;height:10.9pt\">\n<td style=\"width:238.5pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt;height:10.9pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">3 year\n  event-free rate<sup>2</sup> [95% CI]</span></p>\n</td>\n<td style=\"width:112.5pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt;height:10.9pt\" valign=\"bottom\" width=\"150\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">97.7\n  [97.0, 98.3]</span></p>\n</td>\n<td style=\"width:106.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:10.9pt\" valign=\"bottom\" width=\"142\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\">97.7 [97.1, 98.3]</span></p>\n</td>\n</tr>\n</table>", "ID": "c3380690-4437-494c-b76a-e1a236283af6", "Styles": "width:457.35pt;border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Text": "                        ", "ParentId": "19485b85-683a-4216-bc81-0c4879c47f32"}, {"Element": "<thead>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:238.5pt;border:solid windowtext 1.0pt;\n   padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:112.5pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"150\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Perjeta\n   + trastuzumab + Chemotherapy</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">N=2400</span></b></p>\n</td>\n<td style=\"width:106.35pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"142\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Placebo\n   + trastuzumab + Chemotherapy</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">N=2404</span></b></p>\n</td>\n</tr>\n</thead>", "ID": "e9ba7112-de9e-44f9-bd16-70c2c08acfd6", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "c3380690-4437-494c-b76a-e1a236283af6"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:238.5pt;border:solid windowtext 1.0pt;\n   padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:112.5pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"150\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Perjeta\n   + trastuzumab + Chemotherapy</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">N=2400</span></b></p>\n</td>\n<td style=\"width:106.35pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"142\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Placebo\n   + trastuzumab + Chemotherapy</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">N=2404</span></b></p>\n</td>\n</tr>", "ID": "8aa5cd49-7fc8-455b-9b34-7d533a1c6a54", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "    ", "ParentId": "e9ba7112-de9e-44f9-bd16-70c2c08acfd6"}, {"Element": "<td style=\"width:238.5pt;border:solid windowtext 1.0pt;\n   padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "e63e2dd7-336f-4a62-95f3-2d939b33f6d5", "Styles": "width:238.5pt;border:solid windowtext 1.0pt;\n   padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "8aa5cd49-7fc8-455b-9b34-7d533a1c6a54"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0e6b81bf-f088-42c2-9cd8-e162f1d932b3", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e63e2dd7-336f-4a62-95f3-2d939b33f6d5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d16d322c-2c84-4141-8e6e-ed424a9ce538", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0e6b81bf-f088-42c2-9cd8-e162f1d932b3"}, {"Element": "<td style=\"width:112.5pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"150\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Perjeta\n   + trastuzumab + Chemotherapy</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">N=2400</span></b></p>\n</td>", "ID": "2e4ebc8a-c6e5-4ed1-af1f-b5b7ee86ce3c", "Styles": "width:112.5pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "   ", "ParentId": "8aa5cd49-7fc8-455b-9b34-7d533a1c6a54"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Perjeta\n   + trastuzumab + Chemotherapy</span></b></p>", "ID": "acdfa9a4-1109-4c8d-93c9-1758a1a5544a", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "2e4ebc8a-c6e5-4ed1-af1f-b5b7ee86ce3c"}, {"Element": "<b><span lang=\"EN-GB\">Perjeta\n   + trastuzumab + Chemotherapy</span></b>", "ID": "a2927cf3-80f4-4888-be63-38ee2e3bf8b9", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "acdfa9a4-1109-4c8d-93c9-1758a1a5544a"}, {"Element": "<span lang=\"EN-GB\">Perjeta\n   + trastuzumab + Chemotherapy</span>", "ID": "d853726b-8859-4052-bb88-7348e9f76aa8", "Styles": "None", "Classes": "None", "Text": "Perjeta    + trastuzumab + Chemotherapy", "ParentId": "a2927cf3-80f4-4888-be63-38ee2e3bf8b9"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">N=2400</span></b></p>", "ID": "7c4df324-f358-480d-b1e1-269cd4714023", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "2e4ebc8a-c6e5-4ed1-af1f-b5b7ee86ce3c"}, {"Element": "<b><span lang=\"EN-GB\">N=2400</span></b>", "ID": "7e030308-0ef5-4e18-9dab-884bb96d4f95", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "7c4df324-f358-480d-b1e1-269cd4714023"}, {"Element": "<span lang=\"EN-GB\">N=2400</span>", "ID": "b3e4f2fb-794e-4538-9dfa-03a2b8bb8405", "Styles": "None", "Classes": "None", "Text": "N=2400", "ParentId": "7e030308-0ef5-4e18-9dab-884bb96d4f95"}, {"Element": "<td style=\"width:106.35pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"142\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Placebo\n   + trastuzumab + Chemotherapy</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">N=2404</span></b></p>\n</td>", "ID": "1eda1c6f-9984-4b9a-b8d2-0ca68b33e7d0", "Styles": "width:106.35pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "   ", "ParentId": "8aa5cd49-7fc8-455b-9b34-7d533a1c6a54"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Placebo\n   + trastuzumab + Chemotherapy</span></b></p>", "ID": "2a3ba066-23b9-4cc8-b28f-f5558583d0b6", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1eda1c6f-9984-4b9a-b8d2-0ca68b33e7d0"}, {"Element": "<b><span lang=\"EN-GB\">Placebo\n   + trastuzumab + Chemotherapy</span></b>", "ID": "1462554e-d67d-406a-b69b-3f15a925aac3", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "2a3ba066-23b9-4cc8-b28f-f5558583d0b6"}, {"Element": "<span lang=\"EN-GB\">Placebo\n   + trastuzumab + Chemotherapy</span>", "ID": "4b652980-1f60-4f49-ac31-3b906794e4da", "Styles": "None", "Classes": "None", "Text": "Placebo    + trastuzumab + Chemotherapy", "ParentId": "1462554e-d67d-406a-b69b-3f15a925aac3"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">N=2404</span></b></p>", "ID": "d7a51248-fc3c-4bc2-90ea-1c5979dae112", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1eda1c6f-9984-4b9a-b8d2-0ca68b33e7d0"}, {"Element": "<b><span lang=\"EN-GB\">N=2404</span></b>", "ID": "98b3e87a-1a18-49d1-b4cb-82d3bfd0af83", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d7a51248-fc3c-4bc2-90ea-1c5979dae112"}, {"Element": "<span lang=\"EN-GB\">N=2404</span>", "ID": "83bc7539-84af-4a3d-a152-1e3ab6a73912", "Styles": "None", "Classes": "None", "Text": "N=2404", "ParentId": "98b3e87a-1a18-49d1-b4cb-82d3bfd0af83"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:238.5pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Primary\n  Endpoint</span></i></b></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">\u00a0</span></i></b></p>\n</td>\n</tr>", "ID": "b6613ff4-bf6f-4c50-8a91-4dd1a866bb20", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "c3380690-4437-494c-b76a-e1a236283af6"}, {"Element": "<td style=\"width:238.5pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Primary\n  Endpoint</span></i></b></p>\n</td>", "ID": "75df29dd-1c21-4b00-8901-cbf7386839b7", "Styles": "width:238.5pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "b6613ff4-bf6f-4c50-8a91-4dd1a866bb20"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Primary\n  Endpoint</span></i></b></p>", "ID": "8bd37939-218c-4926-8803-8ae16befe5c6", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "75df29dd-1c21-4b00-8901-cbf7386839b7"}, {"Element": "<b><i><span lang=\"EN-GB\">Primary\n  Endpoint</span></i></b>", "ID": "e7987198-cb35-4916-bcc4-05a55ecd0f9e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8bd37939-218c-4926-8803-8ae16befe5c6"}, {"Element": "<i><span lang=\"EN-GB\">Primary\n  Endpoint</span></i>", "ID": "a277b745-b7e7-4de6-a0d5-508666a4d439", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e7987198-cb35-4916-bcc4-05a55ecd0f9e"}, {"Element": "<span lang=\"EN-GB\">Primary\n  Endpoint</span>", "ID": "a9528b1a-d456-4eeb-be99-1b6d87d2dbb6", "Styles": "None", "Classes": "None", "Text": "Primary   Endpoint", "ParentId": "a277b745-b7e7-4de6-a0d5-508666a4d439"}, {"Element": "<td colspan=\"2\" style=\"width:218.85pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">\u00a0</span></i></b></p>\n</td>", "ID": "8137fc68-467b-44ae-87d2-55a792364398", "Styles": "width:218.85pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "b6613ff4-bf6f-4c50-8a91-4dd1a866bb20"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">\u00a0</span></i></b></p>", "ID": "a456c0af-b31d-4f17-a01e-6536960464b3", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8137fc68-467b-44ae-87d2-55a792364398"}, {"Element": "<b><i><span lang=\"EN-GB\">\u00a0</span></i></b>", "ID": "51b3e23d-b24f-4757-af6f-0fe830bd34de", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a456c0af-b31d-4f17-a01e-6536960464b3"}, {"Element": "<i><span lang=\"EN-GB\">\u00a0</span></i>", "ID": "2d7ab501-6c21-4686-94cb-e5b953f3970a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "51b3e23d-b24f-4757-af6f-0fe830bd34de"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a43e8998-c6d1-4df1-b422-a7aee828a6db", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2d7ab501-6c21-4686-94cb-e5b953f3970a"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Invasive\n  Disease Free Survival (IDFS)<sup> </sup></span></b></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n</tr>", "ID": "14c8c46f-e046-47d0-af59-1da9bb88c32e", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "c3380690-4437-494c-b76a-e1a236283af6"}, {"Element": "<td style=\"width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Invasive\n  Disease Free Survival (IDFS)<sup> </sup></span></b></p>\n</td>", "ID": "14e3c04e-d1e1-4730-81f7-db8fbd7a349a", "Styles": "width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "14c8c46f-e046-47d0-af59-1da9bb88c32e"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Invasive\n  Disease Free Survival (IDFS)<sup> </sup></span></b></p>", "ID": "de290e18-c36e-485b-92a8-f14873c21611", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "14e3c04e-d1e1-4730-81f7-db8fbd7a349a"}, {"Element": "<b><span lang=\"EN-GB\">Invasive\n  Disease Free Survival (IDFS)<sup> </sup></span></b>", "ID": "1e298e66-e9e1-495e-8d57-c0d1cab96c9b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "de290e18-c36e-485b-92a8-f14873c21611"}, {"Element": "<span lang=\"EN-GB\">Invasive\n  Disease Free Survival (IDFS)<sup> </sup></span>", "ID": "3255121f-d8fb-44c6-bd2b-cfb849a97a6e", "Styles": "None", "Classes": "None", "Text": "Invasive   Disease Free Survival (IDFS)", "ParentId": "1e298e66-e9e1-495e-8d57-c0d1cab96c9b"}, {"Element": "<sup> </sup>", "ID": "c7027e69-12a2-4af8-879e-2a30b8e4de7d", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "3255121f-d8fb-44c6-bd2b-cfb849a97a6e"}, {"Element": "<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>", "ID": "1a40bfff-2f78-412b-8d5d-a5470030f068", "Styles": "width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "14c8c46f-e046-47d0-af59-1da9bb88c32e"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "c3a91530-4dc3-4939-a653-4eb4fedbaaa8", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "1a40bfff-2f78-412b-8d5d-a5470030f068"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Number (%)\n  of patients with event </span></p>\n</td>\n<td style=\"width:112.5pt;border:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"150\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">171 (7.1%)</span></p>\n</td>\n<td style=\"width:106.35pt;border:none;border-right:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"142\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\">210 (8.7%)</span></p>\n</td>\n</tr>", "ID": "b7d0c6ab-45ee-4d79-a68d-f417449f7f00", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "    ", "ParentId": "c3380690-4437-494c-b76a-e1a236283af6"}, {"Element": "<td style=\"width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Number (%)\n  of patients with event </span></p>\n</td>", "ID": "fe32e176-79ea-4c93-99c3-c2dc5da3cb9b", "Styles": "width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "b7d0c6ab-45ee-4d79-a68d-f417449f7f00"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Number (%)\n  of patients with event </span></p>", "ID": "69b38b1f-361c-4ab3-be2c-3385a57e07bb", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "fe32e176-79ea-4c93-99c3-c2dc5da3cb9b"}, {"Element": "<span lang=\"EN-GB\">Number (%)\n  of patients with event </span>", "ID": "273560fb-184d-4759-9c89-58368e392913", "Styles": "None", "Classes": "None", "Text": "Number (%)   of patients with event ", "ParentId": "69b38b1f-361c-4ab3-be2c-3385a57e07bb"}, {"Element": "<td style=\"width:112.5pt;border:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"150\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">171 (7.1%)</span></p>\n</td>", "ID": "cc9287fe-3e29-4e5c-8054-5b2011b9f5b9", "Styles": "width:112.5pt;border:none;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "b7d0c6ab-45ee-4d79-a68d-f417449f7f00"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">171 (7.1%)</span></p>", "ID": "71d30886-bc3a-4658-8588-5de0d7908aed", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "cc9287fe-3e29-4e5c-8054-5b2011b9f5b9"}, {"Element": "<span lang=\"EN-GB\">171 (7.1%)</span>", "ID": "ce0087a0-b8a1-441b-a932-16ad0fc51b6b", "Styles": "None", "Classes": "None", "Text": "171 (7.1%)", "ParentId": "71d30886-bc3a-4658-8588-5de0d7908aed"}, {"Element": "<td style=\"width:106.35pt;border:none;border-right:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"142\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\">210 (8.7%)</span></p>\n</td>", "ID": "5ccd8efc-af56-479a-8897-1733ae240b26", "Styles": "width:106.35pt;border:none;border-right:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "b7d0c6ab-45ee-4d79-a68d-f417449f7f00"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\">210 (8.7%)</span></p>", "ID": "16aa2515-e204-4ba3-9239-e3e9deacebae", "Styles": "text-align:right;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5ccd8efc-af56-479a-8897-1733ae240b26"}, {"Element": "<span lang=\"EN-GB\">210 (8.7%)</span>", "ID": "17c4db96-4811-4f0d-b93c-463e3b374c71", "Styles": "None", "Classes": "None", "Text": "210 (8.7%)", "ParentId": "16aa2515-e204-4ba3-9239-e3e9deacebae"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">HR [95%\n  CI]</span></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0.81 [0.66, 1.00]</span></p>\n</td>\n</tr>", "ID": "6e419399-bc94-40f0-83fa-7220697290e9", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "c3380690-4437-494c-b76a-e1a236283af6"}, {"Element": "<td style=\"width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">HR [95%\n  CI]</span></p>\n</td>", "ID": "4ad52db9-3a16-4dab-9ff0-7ac153d4e4f9", "Styles": "width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "6e419399-bc94-40f0-83fa-7220697290e9"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">HR [95%\n  CI]</span></p>", "ID": "811df181-079c-4cc2-8b2c-85731bf46b06", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4ad52db9-3a16-4dab-9ff0-7ac153d4e4f9"}, {"Element": "<span lang=\"EN-GB\">HR [95%\n  CI]</span>", "ID": "ed29477f-087a-436f-8ab8-6bff5351035b", "Styles": "None", "Classes": "None", "Text": "HR [95%   CI]", "ParentId": "811df181-079c-4cc2-8b2c-85731bf46b06"}, {"Element": "<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0.81 [0.66, 1.00]</span></p>\n</td>", "ID": "a20a72f9-dcb2-423d-80d8-dfd9bc440410", "Styles": "width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "6e419399-bc94-40f0-83fa-7220697290e9"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0.81 [0.66, 1.00]</span></p>", "ID": "aad5defd-6d90-446b-9656-ec6850e56bf3", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a20a72f9-dcb2-423d-80d8-dfd9bc440410"}, {"Element": "<span lang=\"EN-GB\">0.81 [0.66, 1.00]</span>", "ID": "a77a160a-6874-49b5-8eea-2699c4e2736d", "Styles": "None", "Classes": "None", "Text": "0.81 [0.66, 1.00]", "ParentId": "aad5defd-6d90-446b-9656-ec6850e56bf3"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">p-value\n  (Log-Rank test, stratified<sup>1</sup>)</span></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0.0446</span></p>\n</td>\n</tr>", "ID": "98bcb79b-b98b-4afe-aaa2-51879f0b0958", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "c3380690-4437-494c-b76a-e1a236283af6"}, {"Element": "<td style=\"width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">p-value\n  (Log-Rank test, stratified<sup>1</sup>)</span></p>\n</td>", "ID": "a6dc4cf0-b4ad-4fcf-829c-e90828492ae4", "Styles": "width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "98bcb79b-b98b-4afe-aaa2-51879f0b0958"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">p-value\n  (Log-Rank test, stratified<sup>1</sup>)</span></p>", "ID": "186b473b-1ee6-4a86-ab07-bd87a920d9b9", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a6dc4cf0-b4ad-4fcf-829c-e90828492ae4"}, {"Element": "<span lang=\"EN-GB\">p-value\n  (Log-Rank test, stratified<sup>1</sup>)</span>", "ID": "c9777b92-6201-4539-ae4c-2c48f07703d9", "Styles": "None", "Classes": "None", "Text": "p-value   (Log-Rank test, stratified)", "ParentId": "186b473b-1ee6-4a86-ab07-bd87a920d9b9"}, {"Element": "<sup>1</sup>", "ID": "f06da31d-d17c-4a5c-9f8f-6b79b8be54bc", "Styles": "None", "Classes": "None", "Text": "1", "ParentId": "c9777b92-6201-4539-ae4c-2c48f07703d9"}, {"Element": "<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0.0446</span></p>\n</td>", "ID": "8882bdfb-3707-4060-a750-332714202dc8", "Styles": "width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "98bcb79b-b98b-4afe-aaa2-51879f0b0958"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0.0446</span></p>", "ID": "b275cb5c-34eb-43e4-8b1a-d535194f617d", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8882bdfb-3707-4060-a750-332714202dc8"}, {"Element": "<span lang=\"EN-GB\">0.0446</span>", "ID": "7d6aa9c1-23e5-46bd-ac80-0ff0f0b58dda", "Styles": "None", "Classes": "None", "Text": "0.0446", "ParentId": "b275cb5c-34eb-43e4-8b1a-d535194f617d"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:238.5pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">3 year\n  event-free rate<sup>2</sup> [95% CI] </span></p>\n</td>\n<td style=\"width:112.5pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"150\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">94.1\n  [93.1, 95.0]</span></p>\n</td>\n<td style=\"width:106.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"142\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\">93.2 [92.2, 94.3]</span></p>\n</td>\n</tr>", "ID": "5803cd69-3516-44b7-80d9-73c77d48a093", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "    ", "ParentId": "c3380690-4437-494c-b76a-e1a236283af6"}, {"Element": "<td style=\"width:238.5pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">3 year\n  event-free rate<sup>2</sup> [95% CI] </span></p>\n</td>", "ID": "28912978-2d0d-4db8-9189-b0d07d7d769d", "Styles": "width:238.5pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "5803cd69-3516-44b7-80d9-73c77d48a093"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">3 year\n  event-free rate<sup>2</sup> [95% CI] </span></p>", "ID": "f1e9da05-c334-46cc-bf54-ec98c6e57075", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "28912978-2d0d-4db8-9189-b0d07d7d769d"}, {"Element": "<span lang=\"EN-GB\">3 year\n  event-free rate<sup>2</sup> [95% CI] </span>", "ID": "deadbb75-8471-4bf6-928e-1705c7941b42", "Styles": "None", "Classes": "None", "Text": "3 year   event-free rate [95% CI] ", "ParentId": "f1e9da05-c334-46cc-bf54-ec98c6e57075"}, {"Element": "<sup>2</sup>", "ID": "6bd945ea-cae4-4a50-a4ad-078638dd88d1", "Styles": "None", "Classes": "None", "Text": "2", "ParentId": "deadbb75-8471-4bf6-928e-1705c7941b42"}, {"Element": "<td style=\"width:112.5pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"150\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">94.1\n  [93.1, 95.0]</span></p>\n</td>", "ID": "2bf867f3-4285-4990-b773-c38afad355da", "Styles": "width:112.5pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "5803cd69-3516-44b7-80d9-73c77d48a093"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">94.1\n  [93.1, 95.0]</span></p>", "ID": "5b88f17a-1c7d-4176-8a8b-1f3d561376f5", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "2bf867f3-4285-4990-b773-c38afad355da"}, {"Element": "<span lang=\"EN-GB\">94.1\n  [93.1, 95.0]</span>", "ID": "956148e2-ea90-4283-a5c0-02a88e72b953", "Styles": "None", "Classes": "None", "Text": "94.1   [93.1, 95.0]", "ParentId": "5b88f17a-1c7d-4176-8a8b-1f3d561376f5"}, {"Element": "<td style=\"width:106.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"142\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\">93.2 [92.2, 94.3]</span></p>\n</td>", "ID": "b5da2048-88a7-423f-a062-ca47e129cc73", "Styles": "width:106.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "5803cd69-3516-44b7-80d9-73c77d48a093"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\">93.2 [92.2, 94.3]</span></p>", "ID": "b4b2d68a-0b1b-4b9e-a1a1-caeb8ffa2514", "Styles": "text-align:right;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b5da2048-88a7-423f-a062-ca47e129cc73"}, {"Element": "<span lang=\"EN-GB\">93.2 [92.2, 94.3]</span>", "ID": "941a7fa2-5ccf-4e4d-81a3-bfaefb20d3c2", "Styles": "None", "Classes": "None", "Text": "93.2 [92.2, 94.3]", "ParentId": "b4b2d68a-0b1b-4b9e-a1a1-caeb8ffa2514"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:238.5pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Secondary\n  Endpoints<sup>1</sup></span></i></b></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">\u00a0</span></i></b></p>\n</td>\n</tr>", "ID": "d5cb3990-842b-41bb-ac9c-91d6664ad409", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "c3380690-4437-494c-b76a-e1a236283af6"}, {"Element": "<td style=\"width:238.5pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Secondary\n  Endpoints<sup>1</sup></span></i></b></p>\n</td>", "ID": "f126823d-ee7f-4a7a-8191-775e9f80f0cd", "Styles": "width:238.5pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "d5cb3990-842b-41bb-ac9c-91d6664ad409"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Secondary\n  Endpoints<sup>1</sup></span></i></b></p>", "ID": "5c20ae61-bd2d-4ae7-be66-5d82396421c4", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f126823d-ee7f-4a7a-8191-775e9f80f0cd"}, {"Element": "<b><i><span lang=\"EN-GB\">Secondary\n  Endpoints<sup>1</sup></span></i></b>", "ID": "7f667fd8-855f-4999-952d-ff5b556cff34", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "5c20ae61-bd2d-4ae7-be66-5d82396421c4"}, {"Element": "<i><span lang=\"EN-GB\">Secondary\n  Endpoints<sup>1</sup></span></i>", "ID": "f27887a8-0df2-47f2-b7af-2d94ea33ce01", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "7f667fd8-855f-4999-952d-ff5b556cff34"}, {"Element": "<span lang=\"EN-GB\">Secondary\n  Endpoints<sup>1</sup></span>", "ID": "0bb1858d-9174-4736-866c-309d7b65c627", "Styles": "None", "Classes": "None", "Text": "Secondary   Endpoints", "ParentId": "f27887a8-0df2-47f2-b7af-2d94ea33ce01"}, {"Element": "<sup>1</sup>", "ID": "7e9e1cea-141f-4c97-b3db-5561bcaaa4d1", "Styles": "None", "Classes": "None", "Text": "1", "ParentId": "0bb1858d-9174-4736-866c-309d7b65c627"}, {"Element": "<td colspan=\"2\" style=\"width:218.85pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">\u00a0</span></i></b></p>\n</td>", "ID": "a99d3ad9-235c-4773-93f9-48774731b5e6", "Styles": "width:218.85pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "d5cb3990-842b-41bb-ac9c-91d6664ad409"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">\u00a0</span></i></b></p>", "ID": "630df47c-fc95-44a2-b23c-a9d0ce737bae", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a99d3ad9-235c-4773-93f9-48774731b5e6"}, {"Element": "<b><i><span lang=\"EN-GB\">\u00a0</span></i></b>", "ID": "e180e0ee-e31d-4f18-838e-2736ebbe00b9", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "630df47c-fc95-44a2-b23c-a9d0ce737bae"}, {"Element": "<i><span lang=\"EN-GB\">\u00a0</span></i>", "ID": "cf0a0ee5-84d7-455f-b165-df9171e931d6", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e180e0ee-e31d-4f18-838e-2736ebbe00b9"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8248bc00-9406-4368-b67b-5f49588e73b4", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "cf0a0ee5-84d7-455f-b165-df9171e931d6"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">IDFS</span></b><span lang=\"EN-GB\"> </span><b><span lang=\"EN-GB\">including second primary non-breast\n  cancer</span></b></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n</tr>", "ID": "f25b607e-2684-450c-9f00-77ebc09fbefb", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "c3380690-4437-494c-b76a-e1a236283af6"}, {"Element": "<td style=\"width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">IDFS</span></b><span lang=\"EN-GB\"> </span><b><span lang=\"EN-GB\">including second primary non-breast\n  cancer</span></b></p>\n</td>", "ID": "d1e92693-435b-40e6-876a-71d7f98ca544", "Styles": "width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "f25b607e-2684-450c-9f00-77ebc09fbefb"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">IDFS</span></b><span lang=\"EN-GB\"> </span><b><span lang=\"EN-GB\">including second primary non-breast\n  cancer</span></b></p>", "ID": "356f9e00-f742-4659-951c-a6ec35ef1c1d", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d1e92693-435b-40e6-876a-71d7f98ca544"}, {"Element": "<b><span lang=\"EN-GB\">IDFS</span></b>", "ID": "0ba23a49-aaee-4fa0-9862-2a887f58ae16", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "356f9e00-f742-4659-951c-a6ec35ef1c1d"}, {"Element": "<span lang=\"EN-GB\">IDFS</span>", "ID": "95f30c7a-ffc2-423f-87c9-c93dc357538d", "Styles": "None", "Classes": "None", "Text": "IDFS", "ParentId": "0ba23a49-aaee-4fa0-9862-2a887f58ae16"}, {"Element": "<span lang=\"EN-GB\"> </span>", "ID": "f8e42da3-a113-442a-ba19-6e4c82606540", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "356f9e00-f742-4659-951c-a6ec35ef1c1d"}, {"Element": "<b><span lang=\"EN-GB\">including second primary non-breast\n  cancer</span></b>", "ID": "ae5a76c8-aa2e-4537-ad77-c6e8d75b6c72", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "356f9e00-f742-4659-951c-a6ec35ef1c1d"}, {"Element": "<span lang=\"EN-GB\">including second primary non-breast\n  cancer</span>", "ID": "690899b2-e2e4-4a08-a2d9-1213bae8fdb0", "Styles": "None", "Classes": "None", "Text": "including second primary non-breast   cancer", "ParentId": "ae5a76c8-aa2e-4537-ad77-c6e8d75b6c72"}, {"Element": "<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>", "ID": "d0156dee-8c0a-491f-b5f6-e625301fb6ce", "Styles": "width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "f25b607e-2684-450c-9f00-77ebc09fbefb"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "592f0d4a-059e-4d27-b4c9-8e57963ccc26", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d0156dee-8c0a-491f-b5f6-e625301fb6ce"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Number (%)\n  of patients with event </span></p>\n</td>\n<td style=\"width:112.5pt;border:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"150\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">189 (7.9%)</span></p>\n</td>\n<td style=\"width:106.35pt;border:none;border-right:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"142\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\">230 (9.6%)</span></p>\n</td>\n</tr>", "ID": "fe105da5-9b76-448f-846e-693ccd7ee38a", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "    ", "ParentId": "c3380690-4437-494c-b76a-e1a236283af6"}, {"Element": "<td style=\"width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Number (%)\n  of patients with event </span></p>\n</td>", "ID": "4318c78b-1bc1-4c4c-aca4-e4794c0bc3ee", "Styles": "width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "fe105da5-9b76-448f-846e-693ccd7ee38a"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Number (%)\n  of patients with event </span></p>", "ID": "db6d2b0f-3d0f-4650-ae30-779258b6756b", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4318c78b-1bc1-4c4c-aca4-e4794c0bc3ee"}, {"Element": "<span lang=\"EN-GB\">Number (%)\n  of patients with event </span>", "ID": "18798bf2-2064-447d-9a41-bd7904169aff", "Styles": "None", "Classes": "None", "Text": "Number (%)   of patients with event ", "ParentId": "db6d2b0f-3d0f-4650-ae30-779258b6756b"}, {"Element": "<td style=\"width:112.5pt;border:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"150\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">189 (7.9%)</span></p>\n</td>", "ID": "5c6888c7-6070-47ad-bfc0-a42d14569622", "Styles": "width:112.5pt;border:none;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "fe105da5-9b76-448f-846e-693ccd7ee38a"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">189 (7.9%)</span></p>", "ID": "23b8ac29-0f4b-4922-b194-50d6e7d63ea2", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5c6888c7-6070-47ad-bfc0-a42d14569622"}, {"Element": "<span lang=\"EN-GB\">189 (7.9%)</span>", "ID": "3bece2ba-0b74-47bf-a6f2-84ecf294cf8c", "Styles": "None", "Classes": "None", "Text": "189 (7.9%)", "ParentId": "23b8ac29-0f4b-4922-b194-50d6e7d63ea2"}, {"Element": "<td style=\"width:106.35pt;border:none;border-right:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"142\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\">230 (9.6%)</span></p>\n</td>", "ID": "3d9b72e5-3cbf-4cd0-9603-8dc61a60b05f", "Styles": "width:106.35pt;border:none;border-right:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "fe105da5-9b76-448f-846e-693ccd7ee38a"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\">230 (9.6%)</span></p>", "ID": "05cb3d5e-ee6a-4c9e-a007-696c9e956af3", "Styles": "text-align:right;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "3d9b72e5-3cbf-4cd0-9603-8dc61a60b05f"}, {"Element": "<span lang=\"EN-GB\">230 (9.6%)</span>", "ID": "d421468f-dc2a-4c63-a97b-f3a34b1a9770", "Styles": "None", "Classes": "None", "Text": "230 (9.6%)", "ParentId": "05cb3d5e-ee6a-4c9e-a007-696c9e956af3"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"top\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">HR [95%\n  CI]</span></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"top\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0.82 [0.68, 0.99]</span></p>\n</td>\n</tr>", "ID": "bd76559d-acb2-4fc8-b579-766f2ac658de", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "c3380690-4437-494c-b76a-e1a236283af6"}, {"Element": "<td style=\"width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"top\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">HR [95%\n  CI]</span></p>\n</td>", "ID": "f90a91f0-cef1-4479-917e-be444620d898", "Styles": "width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "bd76559d-acb2-4fc8-b579-766f2ac658de"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">HR [95%\n  CI]</span></p>", "ID": "9f078394-f9ea-4ff2-9dbf-d3fcefecbf6c", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f90a91f0-cef1-4479-917e-be444620d898"}, {"Element": "<span lang=\"EN-GB\">HR [95%\n  CI]</span>", "ID": "807c9e72-0132-43f7-bd39-96696b188097", "Styles": "None", "Classes": "None", "Text": "HR [95%   CI]", "ParentId": "9f078394-f9ea-4ff2-9dbf-d3fcefecbf6c"}, {"Element": "<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"top\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0.82 [0.68, 0.99]</span></p>\n</td>", "ID": "32388dda-f07a-45e3-8748-f31f27bfca19", "Styles": "width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "bd76559d-acb2-4fc8-b579-766f2ac658de"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0.82 [0.68, 0.99]</span></p>", "ID": "4c64d054-a17f-47fb-a969-835100068946", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "32388dda-f07a-45e3-8748-f31f27bfca19"}, {"Element": "<span lang=\"EN-GB\">0.82 [0.68, 0.99]</span>", "ID": "5ea4ccba-a4c2-4053-aa4b-77c172006288", "Styles": "None", "Classes": "None", "Text": "0.82 [0.68, 0.99]", "ParentId": "4c64d054-a17f-47fb-a969-835100068946"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">p-value\n  (Log-Rank test, stratified<sup>1</sup>)</span></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0.0430</span></p>\n</td>\n</tr>", "ID": "93483c2a-9f19-4d37-90b9-f2788655a482", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "c3380690-4437-494c-b76a-e1a236283af6"}, {"Element": "<td style=\"width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">p-value\n  (Log-Rank test, stratified<sup>1</sup>)</span></p>\n</td>", "ID": "56d490ca-5141-47bb-94dd-036ec8c993e6", "Styles": "width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "93483c2a-9f19-4d37-90b9-f2788655a482"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">p-value\n  (Log-Rank test, stratified<sup>1</sup>)</span></p>", "ID": "7b47b9a3-35e6-4256-9b6d-f5249dd57a73", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "56d490ca-5141-47bb-94dd-036ec8c993e6"}, {"Element": "<span lang=\"EN-GB\">p-value\n  (Log-Rank test, stratified<sup>1</sup>)</span>", "ID": "a10bb0a9-5b5c-402c-a549-f1d0ac99616a", "Styles": "None", "Classes": "None", "Text": "p-value   (Log-Rank test, stratified)", "ParentId": "7b47b9a3-35e6-4256-9b6d-f5249dd57a73"}, {"Element": "<sup>1</sup>", "ID": "bcb0d2ef-1525-4f17-b55d-b391038fbc23", "Styles": "None", "Classes": "None", "Text": "1", "ParentId": "a10bb0a9-5b5c-402c-a549-f1d0ac99616a"}, {"Element": "<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0.0430</span></p>\n</td>", "ID": "f767901f-f677-42b4-82cf-9a06c91e26a5", "Styles": "width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "93483c2a-9f19-4d37-90b9-f2788655a482"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0.0430</span></p>", "ID": "c50fc6b1-37ce-4216-aaee-ea8a155f31c5", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f767901f-f677-42b4-82cf-9a06c91e26a5"}, {"Element": "<span lang=\"EN-GB\">0.0430</span>", "ID": "981d74a4-94f7-4d43-aea6-f6afded3da72", "Styles": "None", "Classes": "None", "Text": "0.0430", "ParentId": "c50fc6b1-37ce-4216-aaee-ea8a155f31c5"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:238.5pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">3 year\n  event-free rate<sup>2</sup> [95% CI] </span></p>\n</td>\n<td style=\"width:112.5pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"150\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">93.5\n  [92.5, 94.5]</span></p>\n</td>\n<td style=\"width:106.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"142\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\">92.5 [91.4, 93.6]</span></p>\n</td>\n</tr>", "ID": "72c2830f-2b8d-4174-aa34-420e3a449ecd", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "    ", "ParentId": "c3380690-4437-494c-b76a-e1a236283af6"}, {"Element": "<td style=\"width:238.5pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">3 year\n  event-free rate<sup>2</sup> [95% CI] </span></p>\n</td>", "ID": "12468a52-264d-4f16-9b2d-686bf6ef665c", "Styles": "width:238.5pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "72c2830f-2b8d-4174-aa34-420e3a449ecd"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">3 year\n  event-free rate<sup>2</sup> [95% CI] </span></p>", "ID": "f4b7be83-f072-4163-a568-eac3e03493a7", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "12468a52-264d-4f16-9b2d-686bf6ef665c"}, {"Element": "<span lang=\"EN-GB\">3 year\n  event-free rate<sup>2</sup> [95% CI] </span>", "ID": "82cf1ec4-57e7-47b6-a7a0-bfba7847e661", "Styles": "None", "Classes": "None", "Text": "3 year   event-free rate [95% CI] ", "ParentId": "f4b7be83-f072-4163-a568-eac3e03493a7"}, {"Element": "<sup>2</sup>", "ID": "4f339482-366b-40c9-97d2-97e60741edb4", "Styles": "None", "Classes": "None", "Text": "2", "ParentId": "82cf1ec4-57e7-47b6-a7a0-bfba7847e661"}, {"Element": "<td style=\"width:112.5pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"150\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">93.5\n  [92.5, 94.5]</span></p>\n</td>", "ID": "251884f6-0e3b-43dc-9bc0-839f2ef68099", "Styles": "width:112.5pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "72c2830f-2b8d-4174-aa34-420e3a449ecd"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">93.5\n  [92.5, 94.5]</span></p>", "ID": "2b202795-7ee4-4d7c-a283-c4c89863888f", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "251884f6-0e3b-43dc-9bc0-839f2ef68099"}, {"Element": "<span lang=\"EN-GB\">93.5\n  [92.5, 94.5]</span>", "ID": "7f7273c1-fd41-41a4-8ec1-bbede81d7b72", "Styles": "None", "Classes": "None", "Text": "93.5   [92.5, 94.5]", "ParentId": "2b202795-7ee4-4d7c-a283-c4c89863888f"}, {"Element": "<td style=\"width:106.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"142\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\">92.5 [91.4, 93.6]</span></p>\n</td>", "ID": "d9813315-5122-4128-bffd-dabbe35048b5", "Styles": "width:106.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "72c2830f-2b8d-4174-aa34-420e3a449ecd"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\">92.5 [91.4, 93.6]</span></p>", "ID": "f7c29235-c100-4c4e-8258-124eeed20cbd", "Styles": "text-align:right;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d9813315-5122-4128-bffd-dabbe35048b5"}, {"Element": "<span lang=\"EN-GB\">92.5 [91.4, 93.6]</span>", "ID": "5aba7a32-ce13-453a-8c94-00f98f361bd2", "Styles": "None", "Classes": "None", "Text": "92.5 [91.4, 93.6]", "ParentId": "f7c29235-c100-4c4e-8258-124eeed20cbd"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Disease\n  Free Survival (DFS) </span></b></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n</tr>", "ID": "363245b9-04f7-4dc7-a6e5-aa50ff3f5b7d", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "c3380690-4437-494c-b76a-e1a236283af6"}, {"Element": "<td style=\"width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Disease\n  Free Survival (DFS) </span></b></p>\n</td>", "ID": "74e45930-ea50-42b9-ac16-733f5b6d744f", "Styles": "width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "363245b9-04f7-4dc7-a6e5-aa50ff3f5b7d"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Disease\n  Free Survival (DFS) </span></b></p>", "ID": "db680350-b576-4259-a9b3-8e389f9295aa", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "74e45930-ea50-42b9-ac16-733f5b6d744f"}, {"Element": "<b><span lang=\"EN-GB\">Disease\n  Free Survival (DFS) </span></b>", "ID": "5342aa87-fd53-4b19-8c3d-cff2e99d8d39", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "db680350-b576-4259-a9b3-8e389f9295aa"}, {"Element": "<span lang=\"EN-GB\">Disease\n  Free Survival (DFS) </span>", "ID": "d2518bd2-2c9e-4ffd-a8c2-0d6ed26aac95", "Styles": "None", "Classes": "None", "Text": "Disease   Free Survival (DFS) ", "ParentId": "5342aa87-fd53-4b19-8c3d-cff2e99d8d39"}, {"Element": "<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>", "ID": "c87d4a31-9bed-45a7-8179-610feadb259e", "Styles": "width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "363245b9-04f7-4dc7-a6e5-aa50ff3f5b7d"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "dd2b5855-27cc-4f6d-b109-8123f52320b3", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c87d4a31-9bed-45a7-8179-610feadb259e"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "778987e3-5cf5-4301-be2d-362da89616be", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "dd2b5855-27cc-4f6d-b109-8123f52320b3"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "944f7b5d-c210-4f76-8034-dc4bacc85ec0", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "778987e3-5cf5-4301-be2d-362da89616be"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Number (%)\n  of patients with event</span></p>\n</td>\n<td style=\"width:112.5pt;border:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"150\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">192 (8.0%)</span></p>\n</td>\n<td style=\"width:106.35pt;border:none;border-right:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"142\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\">236 (9.8%)</span></p>\n</td>\n</tr>", "ID": "52c79d18-8d91-4a3d-bd77-fce8663a14da", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "    ", "ParentId": "c3380690-4437-494c-b76a-e1a236283af6"}, {"Element": "<td style=\"width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Number (%)\n  of patients with event</span></p>\n</td>", "ID": "1e085107-96b9-4614-9f37-bb3c236ddce3", "Styles": "width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "52c79d18-8d91-4a3d-bd77-fce8663a14da"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Number (%)\n  of patients with event</span></p>", "ID": "e9598b99-68fe-4bf1-b226-c32b131d9120", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1e085107-96b9-4614-9f37-bb3c236ddce3"}, {"Element": "<span lang=\"EN-GB\">Number (%)\n  of patients with event</span>", "ID": "47166f70-2118-4c8e-b80f-273128b97797", "Styles": "None", "Classes": "None", "Text": "Number (%)   of patients with event", "ParentId": "e9598b99-68fe-4bf1-b226-c32b131d9120"}, {"Element": "<td style=\"width:112.5pt;border:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"150\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">192 (8.0%)</span></p>\n</td>", "ID": "f3a7f239-d5c6-4679-aae5-5fa0078fc3e3", "Styles": "width:112.5pt;border:none;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "52c79d18-8d91-4a3d-bd77-fce8663a14da"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">192 (8.0%)</span></p>", "ID": "322c25c5-68e3-4ce4-8c0d-48a3bf3f93b8", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f3a7f239-d5c6-4679-aae5-5fa0078fc3e3"}, {"Element": "<span lang=\"EN-GB\">192 (8.0%)</span>", "ID": "646808bf-ee80-49bc-8842-0722f8929ee4", "Styles": "None", "Classes": "None", "Text": "192 (8.0%)", "ParentId": "322c25c5-68e3-4ce4-8c0d-48a3bf3f93b8"}, {"Element": "<td style=\"width:106.35pt;border:none;border-right:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"142\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\">236 (9.8%)</span></p>\n</td>", "ID": "bd37399d-299a-42b4-b17f-8cc5696e3f3c", "Styles": "width:106.35pt;border:none;border-right:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "52c79d18-8d91-4a3d-bd77-fce8663a14da"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\">236 (9.8%)</span></p>", "ID": "820c5cb0-5101-4195-87fe-0c130f16ed3e", "Styles": "text-align:right;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "bd37399d-299a-42b4-b17f-8cc5696e3f3c"}, {"Element": "<span lang=\"EN-GB\">236 (9.8%)</span>", "ID": "67b42700-eaa9-47b6-97ba-ce19273e84a6", "Styles": "None", "Classes": "None", "Text": "236 (9.8%)", "ParentId": "820c5cb0-5101-4195-87fe-0c130f16ed3e"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">HR [95%\n  CI]</span></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0.81 [0.67, 0.98]</span></p>\n</td>\n</tr>", "ID": "a3242ff3-8c4f-4cf3-8fb8-3b2c62017f05", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "c3380690-4437-494c-b76a-e1a236283af6"}, {"Element": "<td style=\"width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">HR [95%\n  CI]</span></p>\n</td>", "ID": "98338941-e9c5-422a-81ff-c10cd8c22a02", "Styles": "width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "a3242ff3-8c4f-4cf3-8fb8-3b2c62017f05"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">HR [95%\n  CI]</span></p>", "ID": "3424dc6a-38a1-4cbd-9c51-aa0c6d8fba9b", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "98338941-e9c5-422a-81ff-c10cd8c22a02"}, {"Element": "<span lang=\"EN-GB\">HR [95%\n  CI]</span>", "ID": "6f16aa0d-bdf3-4a34-a7dd-56724c36322e", "Styles": "None", "Classes": "None", "Text": "HR [95%   CI]", "ParentId": "3424dc6a-38a1-4cbd-9c51-aa0c6d8fba9b"}, {"Element": "<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0.81 [0.67, 0.98]</span></p>\n</td>", "ID": "86ba3e57-c696-4f10-a0b3-064448800d95", "Styles": "width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "a3242ff3-8c4f-4cf3-8fb8-3b2c62017f05"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0.81 [0.67, 0.98]</span></p>", "ID": "442ddcfa-d4d0-4fae-9d64-6b270e8abd6a", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "86ba3e57-c696-4f10-a0b3-064448800d95"}, {"Element": "<span lang=\"EN-GB\">0.81 [0.67, 0.98]</span>", "ID": "eddc360c-d4bf-474e-8877-a096f76d7925", "Styles": "None", "Classes": "None", "Text": "0.81 [0.67, 0.98]", "ParentId": "442ddcfa-d4d0-4fae-9d64-6b270e8abd6a"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">p-value (Log-Rank\n  test, stratified<sup>1</sup>)</span></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0.0327</span></p>\n</td>\n</tr>", "ID": "edd9d79d-03e6-47ba-a9cf-f28e1c8a7064", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "c3380690-4437-494c-b76a-e1a236283af6"}, {"Element": "<td style=\"width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">p-value (Log-Rank\n  test, stratified<sup>1</sup>)</span></p>\n</td>", "ID": "3cd0ebf2-2de3-4b43-ac15-9b35801f97c2", "Styles": "width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "edd9d79d-03e6-47ba-a9cf-f28e1c8a7064"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">p-value (Log-Rank\n  test, stratified<sup>1</sup>)</span></p>", "ID": "5c1b1f7d-74c2-4866-a346-943549660a79", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "3cd0ebf2-2de3-4b43-ac15-9b35801f97c2"}, {"Element": "<span lang=\"EN-GB\">p-value (Log-Rank\n  test, stratified<sup>1</sup>)</span>", "ID": "ca60e8f3-7a99-40a1-a7a0-963161f35a36", "Styles": "None", "Classes": "None", "Text": "p-value (Log-Rank   test, stratified)", "ParentId": "5c1b1f7d-74c2-4866-a346-943549660a79"}, {"Element": "<sup>1</sup>", "ID": "cb0a9922-d0fd-4e1d-8131-08cce4661b45", "Styles": "None", "Classes": "None", "Text": "1", "ParentId": "ca60e8f3-7a99-40a1-a7a0-963161f35a36"}, {"Element": "<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0.0327</span></p>\n</td>", "ID": "6543e231-7dee-4338-ab98-d5af78c2ef50", "Styles": "width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "edd9d79d-03e6-47ba-a9cf-f28e1c8a7064"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0.0327</span></p>", "ID": "e535b7bc-e1a1-40b7-bc20-15fe07c23237", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "6543e231-7dee-4338-ab98-d5af78c2ef50"}, {"Element": "<span lang=\"EN-GB\">0.0327</span>", "ID": "e7e00c06-24af-4471-81e2-8501a074624e", "Styles": "None", "Classes": "None", "Text": "0.0327", "ParentId": "e535b7bc-e1a1-40b7-bc20-15fe07c23237"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:238.5pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">3 year\n  event-free rate<sup>2</sup> [95% CI]</span></p>\n</td>\n<td style=\"width:112.5pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"150\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">93.4\n  [92.4, 94.4]</span></p>\n</td>\n<td style=\"width:106.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"142\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\">92.3 [91.2, 93.4]</span></p>\n</td>\n</tr>", "ID": "93e56c4e-4102-4192-8dc3-dad2bf5eaec0", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "    ", "ParentId": "c3380690-4437-494c-b76a-e1a236283af6"}, {"Element": "<td style=\"width:238.5pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">3 year\n  event-free rate<sup>2</sup> [95% CI]</span></p>\n</td>", "ID": "637c0ab5-e4a9-4d76-9e6b-6532eb2e8ad8", "Styles": "width:238.5pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "93e56c4e-4102-4192-8dc3-dad2bf5eaec0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">3 year\n  event-free rate<sup>2</sup> [95% CI]</span></p>", "ID": "0e94a81f-619c-4085-bb90-920b664a1765", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "637c0ab5-e4a9-4d76-9e6b-6532eb2e8ad8"}, {"Element": "<span lang=\"EN-GB\">3 year\n  event-free rate<sup>2</sup> [95% CI]</span>", "ID": "75a7c9f4-210b-445f-99f5-a6c913291eef", "Styles": "None", "Classes": "None", "Text": "3 year   event-free rate [95% CI]", "ParentId": "0e94a81f-619c-4085-bb90-920b664a1765"}, {"Element": "<sup>2</sup>", "ID": "9339eb82-c46a-4a64-a8e6-72f3b8204bc1", "Styles": "None", "Classes": "None", "Text": "2", "ParentId": "75a7c9f4-210b-445f-99f5-a6c913291eef"}, {"Element": "<td style=\"width:112.5pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"150\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">93.4\n  [92.4, 94.4]</span></p>\n</td>", "ID": "11584f3d-e05d-422d-b71d-a6f5c8a181dc", "Styles": "width:112.5pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "93e56c4e-4102-4192-8dc3-dad2bf5eaec0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">93.4\n  [92.4, 94.4]</span></p>", "ID": "22878b99-a012-4ca0-9589-0ee90166436b", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "11584f3d-e05d-422d-b71d-a6f5c8a181dc"}, {"Element": "<span lang=\"EN-GB\">93.4\n  [92.4, 94.4]</span>", "ID": "1aad6b9b-e74d-4e35-a990-2d7b21ac66d2", "Styles": "None", "Classes": "None", "Text": "93.4   [92.4, 94.4]", "ParentId": "22878b99-a012-4ca0-9589-0ee90166436b"}, {"Element": "<td style=\"width:106.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"142\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\">92.3 [91.2, 93.4]</span></p>\n</td>", "ID": "ec10a0e9-9537-4cf4-b8af-ca6d6f2f18b6", "Styles": "width:106.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "93e56c4e-4102-4192-8dc3-dad2bf5eaec0"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\">92.3 [91.2, 93.4]</span></p>", "ID": "dc68c1ae-dd8e-4ef6-8e55-f0390ba332d0", "Styles": "text-align:right;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ec10a0e9-9537-4cf4-b8af-ca6d6f2f18b6"}, {"Element": "<span lang=\"EN-GB\">92.3 [91.2, 93.4]</span>", "ID": "ea0c31a5-c527-4c39-950c-d0ea894167b2", "Styles": "None", "Classes": "None", "Text": "92.3 [91.2, 93.4]", "ParentId": "dc68c1ae-dd8e-4ef6-8e55-f0390ba332d0"}, {"Element": "<tr style=\"page-break-inside:avoid;height:6.1pt\">\n<td style=\"width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:6.1pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Overall\n  Survival (OS)<sup>3</sup></span></b></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt;height:\n  6.1pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n</tr>", "ID": "a3fb37c1-8cbc-4f74-9ef0-6e1e9f6a6777", "Styles": "page-break-inside:avoid;height:6.1pt", "Classes": "None", "Text": "   ", "ParentId": "c3380690-4437-494c-b76a-e1a236283af6"}, {"Element": "<td style=\"width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:6.1pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Overall\n  Survival (OS)<sup>3</sup></span></b></p>\n</td>", "ID": "17de2c98-9c28-41c1-9121-592c36a3615d", "Styles": "width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:6.1pt", "Classes": "None", "Text": "  ", "ParentId": "a3fb37c1-8cbc-4f74-9ef0-6e1e9f6a6777"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Overall\n  Survival (OS)<sup>3</sup></span></b></p>", "ID": "981f60f1-d3b2-44fc-a4f5-6296d90e3ea3", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "17de2c98-9c28-41c1-9121-592c36a3615d"}, {"Element": "<b><span lang=\"EN-GB\">Overall\n  Survival (OS)<sup>3</sup></span></b>", "ID": "c5089f02-9c07-4f2d-86c9-b066ad930202", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "981f60f1-d3b2-44fc-a4f5-6296d90e3ea3"}, {"Element": "<span lang=\"EN-GB\">Overall\n  Survival (OS)<sup>3</sup></span>", "ID": "072f7a6a-dbb6-4c11-a76f-c76a8d60721b", "Styles": "None", "Classes": "None", "Text": "Overall   Survival (OS)", "ParentId": "c5089f02-9c07-4f2d-86c9-b066ad930202"}, {"Element": "<sup>3</sup>", "ID": "af732d6a-fe3b-44d5-9d6f-bebf47e09614", "Styles": "None", "Classes": "None", "Text": "3", "ParentId": "072f7a6a-dbb6-4c11-a76f-c76a8d60721b"}, {"Element": "<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt;height:\n  6.1pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>", "ID": "21801575-4f31-4958-81f8-2500fe9b9481", "Styles": "width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt;height:\n  6.1pt", "Classes": "None", "Text": "  ", "ParentId": "a3fb37c1-8cbc-4f74-9ef0-6e1e9f6a6777"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "1720a570-2dc8-4c45-88b5-ba944171b864", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "21801575-4f31-4958-81f8-2500fe9b9481"}, {"Element": "<tr style=\"page-break-inside:avoid;height:10.9pt\">\n<td style=\"width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:10.9pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Number (%)\n  of patients with event</span></p>\n</td>\n<td style=\"width:112.5pt;border:none;padding:0in 2.85pt 0in 2.85pt;\n  height:10.9pt\" valign=\"bottom\" width=\"150\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">80 (3.3%)</span></p>\n</td>\n<td style=\"width:106.35pt;border:none;border-right:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt;height:10.9pt\" valign=\"bottom\" width=\"142\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\">89 (3.7%)</span></p>\n</td>\n</tr>", "ID": "6cc566ba-a18b-4922-9857-c7a3980a61c3", "Styles": "page-break-inside:avoid;height:10.9pt", "Classes": "None", "Text": "    ", "ParentId": "c3380690-4437-494c-b76a-e1a236283af6"}, {"Element": "<td style=\"width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:10.9pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Number (%)\n  of patients with event</span></p>\n</td>", "ID": "e5591bbb-065d-489d-ad05-d1ae2a91ce34", "Styles": "width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:10.9pt", "Classes": "None", "Text": "  ", "ParentId": "6cc566ba-a18b-4922-9857-c7a3980a61c3"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Number (%)\n  of patients with event</span></p>", "ID": "6c429277-030f-422b-bb2e-a3d93d385035", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e5591bbb-065d-489d-ad05-d1ae2a91ce34"}, {"Element": "<span lang=\"EN-GB\">Number (%)\n  of patients with event</span>", "ID": "cbd414ab-3c06-4f3b-8800-3909ef44ca75", "Styles": "None", "Classes": "None", "Text": "Number (%)   of patients with event", "ParentId": "6c429277-030f-422b-bb2e-a3d93d385035"}, {"Element": "<td style=\"width:112.5pt;border:none;padding:0in 2.85pt 0in 2.85pt;\n  height:10.9pt\" valign=\"bottom\" width=\"150\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">80 (3.3%)</span></p>\n</td>", "ID": "a491e70f-ee16-41ea-8052-a3a44bd5f8b1", "Styles": "width:112.5pt;border:none;padding:0in 2.85pt 0in 2.85pt;\n  height:10.9pt", "Classes": "None", "Text": "  ", "ParentId": "6cc566ba-a18b-4922-9857-c7a3980a61c3"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">80 (3.3%)</span></p>", "ID": "fa7fae43-0b2b-4e52-8feb-fd0b620e552a", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a491e70f-ee16-41ea-8052-a3a44bd5f8b1"}, {"Element": "<span lang=\"EN-GB\">80 (3.3%)</span>", "ID": "4e569aa3-0364-422e-a82b-a81c055601c6", "Styles": "None", "Classes": "None", "Text": "80 (3.3%)", "ParentId": "fa7fae43-0b2b-4e52-8feb-fd0b620e552a"}, {"Element": "<td style=\"width:106.35pt;border:none;border-right:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt;height:10.9pt\" valign=\"bottom\" width=\"142\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\">89 (3.7%)</span></p>\n</td>", "ID": "3f780269-7ea0-4314-a969-160ffca60740", "Styles": "width:106.35pt;border:none;border-right:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt;height:10.9pt", "Classes": "None", "Text": "  ", "ParentId": "6cc566ba-a18b-4922-9857-c7a3980a61c3"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\">89 (3.7%)</span></p>", "ID": "ade3073d-2bc3-4e43-ab8f-cd21e832b124", "Styles": "text-align:right;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "3f780269-7ea0-4314-a969-160ffca60740"}, {"Element": "<span lang=\"EN-GB\">89 (3.7%)</span>", "ID": "5f72030f-e68d-4bed-b681-d3c566532cb7", "Styles": "None", "Classes": "None", "Text": "89 (3.7%)", "ParentId": "ade3073d-2bc3-4e43-ab8f-cd21e832b124"}, {"Element": "<tr style=\"page-break-inside:avoid;height:10.9pt\">\n<td style=\"width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:10.9pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">HR [95%\n  CI]</span></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt;height:\n  10.9pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0.89 [0.66, 1.21]</span></p>\n</td>\n</tr>", "ID": "82c13f8f-e50c-4145-b5fb-0a3514e62dee", "Styles": "page-break-inside:avoid;height:10.9pt", "Classes": "None", "Text": "   ", "ParentId": "c3380690-4437-494c-b76a-e1a236283af6"}, {"Element": "<td style=\"width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:10.9pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">HR [95%\n  CI]</span></p>\n</td>", "ID": "68297e7f-dc42-42d6-8df3-89096ede61f4", "Styles": "width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:10.9pt", "Classes": "None", "Text": "  ", "ParentId": "82c13f8f-e50c-4145-b5fb-0a3514e62dee"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">HR [95%\n  CI]</span></p>", "ID": "9c812fc1-fadf-41c3-ad6a-816899e8f30f", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "68297e7f-dc42-42d6-8df3-89096ede61f4"}, {"Element": "<span lang=\"EN-GB\">HR [95%\n  CI]</span>", "ID": "e0733b05-9c41-4b40-a3b1-6eac9b801d03", "Styles": "None", "Classes": "None", "Text": "HR [95%   CI]", "ParentId": "9c812fc1-fadf-41c3-ad6a-816899e8f30f"}, {"Element": "<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt;height:\n  10.9pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0.89 [0.66, 1.21]</span></p>\n</td>", "ID": "ce2af260-1f22-4964-9965-e1b7e0244ba5", "Styles": "width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt;height:\n  10.9pt", "Classes": "None", "Text": "  ", "ParentId": "82c13f8f-e50c-4145-b5fb-0a3514e62dee"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0.89 [0.66, 1.21]</span></p>", "ID": "5a60d148-65fa-440f-b20c-65031f118bb9", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ce2af260-1f22-4964-9965-e1b7e0244ba5"}, {"Element": "<span lang=\"EN-GB\">0.89 [0.66, 1.21]</span>", "ID": "ff64b14b-3b77-4491-9841-77fb696f4e2d", "Styles": "None", "Classes": "None", "Text": "0.89 [0.66, 1.21]", "ParentId": "5a60d148-65fa-440f-b20c-65031f118bb9"}, {"Element": "<tr style=\"page-break-inside:avoid;height:10.9pt\">\n<td style=\"width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:10.9pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">p-value\n  (Log-Rank test, stratified<sup>1</sup>)</span></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt;height:\n  10.9pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0.4673</span></p>\n</td>\n</tr>", "ID": "c443ae34-404e-46ad-b8b0-6aba9da5b2d6", "Styles": "page-break-inside:avoid;height:10.9pt", "Classes": "None", "Text": "   ", "ParentId": "c3380690-4437-494c-b76a-e1a236283af6"}, {"Element": "<td style=\"width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:10.9pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">p-value\n  (Log-Rank test, stratified<sup>1</sup>)</span></p>\n</td>", "ID": "fd6f575f-34c8-47dc-8617-8368e0d8c087", "Styles": "width:238.5pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:10.9pt", "Classes": "None", "Text": "  ", "ParentId": "c443ae34-404e-46ad-b8b0-6aba9da5b2d6"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">p-value\n  (Log-Rank test, stratified<sup>1</sup>)</span></p>", "ID": "d52ce156-fa16-47cf-9c81-05ef228ac631", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "fd6f575f-34c8-47dc-8617-8368e0d8c087"}, {"Element": "<span lang=\"EN-GB\">p-value\n  (Log-Rank test, stratified<sup>1</sup>)</span>", "ID": "87be12f8-50f1-45ae-a7f9-cb5de2241dcb", "Styles": "None", "Classes": "None", "Text": "p-value   (Log-Rank test, stratified)", "ParentId": "d52ce156-fa16-47cf-9c81-05ef228ac631"}, {"Element": "<sup>1</sup>", "ID": "2fc5cf22-5746-4daa-b7a5-e44c4acd10e0", "Styles": "None", "Classes": "None", "Text": "1", "ParentId": "87be12f8-50f1-45ae-a7f9-cb5de2241dcb"}, {"Element": "<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt;height:\n  10.9pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0.4673</span></p>\n</td>", "ID": "1046802a-7abc-41bc-96d5-b5511a9f4223", "Styles": "width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt;height:\n  10.9pt", "Classes": "None", "Text": "  ", "ParentId": "c443ae34-404e-46ad-b8b0-6aba9da5b2d6"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0.4673</span></p>", "ID": "e426a576-642b-434f-ab86-857f34789298", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1046802a-7abc-41bc-96d5-b5511a9f4223"}, {"Element": "<span lang=\"EN-GB\">0.4673</span>", "ID": "e0200327-0e02-49e6-81a1-7dcdafb511a7", "Styles": "None", "Classes": "None", "Text": "0.4673", "ParentId": "e426a576-642b-434f-ab86-857f34789298"}, {"Element": "<tr style=\"page-break-inside:avoid;height:10.9pt\">\n<td style=\"width:238.5pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt;height:10.9pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">3 year\n  event-free rate<sup>2</sup> [95% CI]</span></p>\n</td>\n<td style=\"width:112.5pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt;height:10.9pt\" valign=\"bottom\" width=\"150\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">97.7\n  [97.0, 98.3]</span></p>\n</td>\n<td style=\"width:106.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:10.9pt\" valign=\"bottom\" width=\"142\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\">97.7 [97.1, 98.3]</span></p>\n</td>\n</tr>", "ID": "7e343594-ae2d-4729-b240-7f4e0c4d9b5a", "Styles": "page-break-inside:avoid;height:10.9pt", "Classes": "None", "Text": "    ", "ParentId": "c3380690-4437-494c-b76a-e1a236283af6"}, {"Element": "<td style=\"width:238.5pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt;height:10.9pt\" valign=\"bottom\" width=\"318\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">3 year\n  event-free rate<sup>2</sup> [95% CI]</span></p>\n</td>", "ID": "db2db22b-1bba-48c2-b508-762f12a49b20", "Styles": "width:238.5pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt;height:10.9pt", "Classes": "None", "Text": "  ", "ParentId": "7e343594-ae2d-4729-b240-7f4e0c4d9b5a"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">3 year\n  event-free rate<sup>2</sup> [95% CI]</span></p>", "ID": "8c52923f-4398-4185-aa88-501132e1d4b0", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "db2db22b-1bba-48c2-b508-762f12a49b20"}, {"Element": "<span lang=\"EN-GB\">3 year\n  event-free rate<sup>2</sup> [95% CI]</span>", "ID": "75729aba-cf74-4ffc-ac1b-02ac701e31b4", "Styles": "None", "Classes": "None", "Text": "3 year   event-free rate [95% CI]", "ParentId": "8c52923f-4398-4185-aa88-501132e1d4b0"}, {"Element": "<sup>2</sup>", "ID": "d1fbe2bc-3cd5-4793-a241-9c3794845493", "Styles": "None", "Classes": "None", "Text": "2", "ParentId": "75729aba-cf74-4ffc-ac1b-02ac701e31b4"}, {"Element": "<td style=\"width:112.5pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt;height:10.9pt\" valign=\"bottom\" width=\"150\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">97.7\n  [97.0, 98.3]</span></p>\n</td>", "ID": "739393be-2de0-47f7-9eef-07d030c0e432", "Styles": "width:112.5pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt;height:10.9pt", "Classes": "None", "Text": "  ", "ParentId": "7e343594-ae2d-4729-b240-7f4e0c4d9b5a"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">97.7\n  [97.0, 98.3]</span></p>", "ID": "7ccc257d-0a93-4a56-8778-a785908efde9", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "739393be-2de0-47f7-9eef-07d030c0e432"}, {"Element": "<span lang=\"EN-GB\">97.7\n  [97.0, 98.3]</span>", "ID": "90628406-dfb2-4997-84a8-73d8ccf7a597", "Styles": "None", "Classes": "None", "Text": "97.7   [97.0, 98.3]", "ParentId": "7ccc257d-0a93-4a56-8778-a785908efde9"}, {"Element": "<td style=\"width:106.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:10.9pt\" valign=\"bottom\" width=\"142\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\">97.7 [97.1, 98.3]</span></p>\n</td>", "ID": "cab84f82-c046-4334-9e6f-44d43996f05e", "Styles": "width:106.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:10.9pt", "Classes": "None", "Text": "  ", "ParentId": "7e343594-ae2d-4729-b240-7f4e0c4d9b5a"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\">97.7 [97.1, 98.3]</span></p>", "ID": "b8da5f15-31d8-4a37-8c18-7f171560b848", "Styles": "text-align:right;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "cab84f82-c046-4334-9e6f-44d43996f05e"}, {"Element": "<span lang=\"EN-GB\">97.7 [97.1, 98.3]</span>", "ID": "7f2ceddd-8adf-4e36-8523-5b3d75b2de5f", "Styles": "None", "Classes": "None", "Text": "97.7 [97.1, 98.3]", "ParentId": "b8da5f15-31d8-4a37-8c18-7f171560b848"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span style=\"font-size:\n10.0pt\">Key to abbreviations (Table 5): </span></b><span lang=\"EN-GB\" style=\"font-size:10.0pt\">HR: Hazard Ratio; CI: Confidence Interval </span></p>", "ID": "ed771f02-b513-4cef-976c-464ed6465f10", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span style=\"font-size:\n10.0pt\">Key to abbreviations (Table 5): </span></b>", "ID": "62b012d0-98e6-484e-916c-a92a98b091ae", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ed771f02-b513-4cef-976c-464ed6465f10"}, {"Element": "<span style=\"font-size:\n10.0pt\">Key to abbreviations (Table 5): </span>", "ID": "de7ef6a3-e2b3-4f1b-a06f-695c2453fc82", "Styles": "font-size:\n10.0pt", "Classes": "None", "Text": "Key to abbreviations (Table 5): ", "ParentId": "62b012d0-98e6-484e-916c-a92a98b091ae"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">HR: Hazard Ratio; CI: Confidence Interval </span>", "ID": "92936677-4760-403d-87d9-98239ed203db", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "HR: Hazard Ratio; CI: Confidence Interval ", "ParentId": "ed771f02-b513-4cef-976c-464ed6465f10"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span style=\"font-size:10.0pt\">1.\nAll analyses stratified by nodal status, protocol version, central hormone\nreceptor status, and adjuvant chemotherapy\nregimen.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span></p>", "ID": "04ea187a-52f5-4fee-8a83-699762f4a494", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span style=\"font-size:10.0pt\">1.\nAll analyses stratified by nodal status, protocol version, central hormone\nreceptor status, and adjuvant chemotherapy\nregimen.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span>", "ID": "e4a38e30-f48d-4165-af6f-79bd2d64627b", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "1. All analyses stratified by nodal status, protocol version, central hormone receptor status, and adjuvant chemotherapy regimen.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "04ea187a-52f5-4fee-8a83-699762f4a494"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span style=\"font-size:10.0pt\">2.\n3-year event-free rate derived from Kaplan-Meier estimates.</span></p>", "ID": "918d8d24-ff50-482e-9b0e-8b30db06e2f6", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span style=\"font-size:10.0pt\">2.\n3-year event-free rate derived from Kaplan-Meier estimates.</span>", "ID": "c968ec92-fde5-41c6-bb3e-5336831e779c", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "2. 3-year event-free rate derived from Kaplan-Meier estimates.", "ParentId": "918d8d24-ff50-482e-9b0e-8b30db06e2f6"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.75in;text-indent:-.75in;page-break-after:\navoid\"><span style=\"font-size:10.0pt\">3. Data from first interim analysis. </span></p>", "ID": "a88cf76a-0c99-447c-a72d-4abd78975d11", "Styles": "margin-left:.75in;text-indent:-.75in;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span style=\"font-size:10.0pt\">3. Data from first interim analysis. </span>", "ID": "d0c6342c-3f39-4f18-b60c-9aecacd8b3da", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "3. Data from first interim analysis. ", "ParentId": "a88cf76a-0c99-447c-a72d-4abd78975d11"}, {"Element": "<p class=\"MsoNormal\"><b>\u00a0</b></p>", "ID": "b0a0cc58-2a85-4fd7-812c-e2eb75cbae33", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b>\u00a0</b>", "ID": "69469b6d-3007-4846-8b84-0a6dee41d3cc", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b0a0cc58-2a85-4fd7-812c-e2eb75cbae33"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.75in;text-indent:-.75in;page-break-after:\navoid\"><b>Figure 3\u00a0\u00a0\u00a0\u00a0 Kaplan-Meier Curve of Invasive Disease Free Survival </b></p>", "ID": "2beecd14-d43d-4f45-a76a-179105042cd1", "Styles": "margin-left:.75in;text-indent:-.75in;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b>Figure 3\u00a0\u00a0\u00a0\u00a0 Kaplan-Meier Curve of Invasive Disease Free Survival </b>", "ID": "b84446cb-5727-4e52-8af7-064142927acb", "Styles": "None", "Classes": "None", "Text": "Figure 3\u00a0\u00a0\u00a0\u00a0 Kaplan-Meier Curve of Invasive Disease Free Survival ", "ParentId": "2beecd14-d43d-4f45-a76a-179105042cd1"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.75in;text-indent:-.75in;page-break-after:\navoid\"><b>\u00a0</b></p>", "ID": "cb0de46a-83b9-4a86-8592-ac012d88c110", "Styles": "margin-left:.75in;text-indent:-.75in;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b>\u00a0</b>", "ID": "deaf5c00-bfd5-46e7-a3db-05f600e2a548", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "cb0de46a-83b9-4a86-8592-ac012d88c110"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span style=\"font-size:8.0pt\"><img border=\"0\" height=\"385\" id=\"Picture 8\" src=\"Perjeta-II-48%20EN%20PI%20clean_files/image004.png\" width=\"604\"/></span></p>", "ID": "5ba5011c-cb97-41b7-9829-59533def0f9a", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span style=\"font-size:8.0pt\"><img border=\"0\" height=\"385\" id=\"Picture 8\" src=\"Perjeta-II-48%20EN%20PI%20clean_files/image004.png\" width=\"604\"/></span>", "ID": "ae9b2f7f-b41d-4650-8cd3-24e9b4564fdf", "Styles": "font-size:8.0pt", "Classes": "None", "Text": "", "ParentId": "5ba5011c-cb97-41b7-9829-59533def0f9a"}, {"Element": "<img border=\"0\" height=\"385\" id=\"Picture 8\" src=\"Perjeta-II-48%20EN%20PI%20clean_files/image004.png\" width=\"604\"/>", "ID": "cd20f8be-ba32-4263-9780-70193b2b7bcd", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ae9b2f7f-b41d-4650-8cd3-24e9b4564fdf"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span style=\"font-size:8.0pt\">IDFS=\ninvasive disease free survival; CI= confidence interval; Pla= placebo; Ptz=\npertuzumab (Perjeta); T= trastuzumab.</span></p>", "ID": "c715bf5a-5fe1-43c4-a710-8c491b33326a", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span style=\"font-size:8.0pt\">IDFS=\ninvasive disease free survival; CI= confidence interval; Pla= placebo; Ptz=\npertuzumab (Perjeta); T= trastuzumab.</span>", "ID": "48c294a0-4b7e-4f71-a779-48b0b5e7066b", "Styles": "font-size:8.0pt", "Classes": "None", "Text": "IDFS= invasive disease free survival; CI= confidence interval; Pla= placebo; Ptz= pertuzumab (Perjeta); T= trastuzumab.", "ParentId": "c715bf5a-5fe1-43c4-a710-8c491b33326a"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-bottom:10.0pt;line-height:115%\"><span style=\"line-height:115%\">\u00a0</span></p>", "ID": "aff01cfb-ee9d-49d2-a580-dba4e0128da0", "Styles": "margin-bottom:10.0pt;line-height:115%", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span style=\"line-height:115%\">\u00a0</span>", "ID": "0f443b42-16eb-4337-a0d1-0de92598a795", "Styles": "line-height:115%", "Classes": "None", "Text": "\u00a0", "ParentId": "aff01cfb-ee9d-49d2-a580-dba4e0128da0"}, {"Element": "<p class=\"MsoNormal\">The estimate of IDFS at 4-years was 92.3% in the\nPerjeta-treated group versus 90.6% in the placebo-treated group. At the time of\nthe estimate the median follow-up was 45.4 months.</p>", "ID": "4ff402b8-8c0b-4d99-b375-0a32820032b6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "The estimate of IDFS at 4-years was 92.3% in the Perjeta-treated group versus 90.6% in the placebo-treated group. At the time of the estimate the median follow-up was 45.4 months.", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<p class=\"MsoNormal\"><u><span style=\"text-decoration:none\">\u00a0</span></u></p>", "ID": "81918c32-08ac-45a9-905b-bd79087c8d69", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<u><span style=\"text-decoration:none\">\u00a0</span></u>", "ID": "92fb6391-3e6e-4ab8-bf71-b0fa18b625ee", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "81918c32-08ac-45a9-905b-bd79087c8d69"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "7558eff0-3abc-41ba-b707-7a84dd22f23f", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "92fb6391-3e6e-4ab8-bf71-b0fa18b625ee"}, {"Element": "<p class=\"MsoNormal\"><u>Results of Subgroup Analysis </u></p>", "ID": "acb55431-008e-4ad7-8979-588bdf14468b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<u>Results of Subgroup Analysis </u>", "ID": "f6460454-2665-4432-8708-91ff2a5e89f3", "Styles": "None", "Classes": "None", "Text": "Results of Subgroup Analysis ", "ParentId": "acb55431-008e-4ad7-8979-588bdf14468b"}, {"Element": "<p class=\"MsoNormal\"><u><span style=\"text-decoration:none\">\u00a0</span></u></p>", "ID": "e1fdf214-aa23-4eff-84b8-f3ba85e73157", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<u><span style=\"text-decoration:none\">\u00a0</span></u>", "ID": "1adc6cc8-795d-452e-97d3-05e78fc7cbae", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e1fdf214-aa23-4eff-84b8-f3ba85e73157"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "29d0b868-9a9c-44ef-a566-cd527cd8b35e", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "1adc6cc8-795d-452e-97d3-05e78fc7cbae"}, {"Element": "<p class=\"MsoNormal\">At the time of the primary analysis, the benefits of Perjeta\nwere more apparent in subgroups of patients a high risk of recurrence: patients\nwith node-positive or hormone receptor-negative disease (see table 6).</p>", "ID": "6a4ba972-4ea4-4448-899c-9ecd37c98148", "Styles": "None", "Classes": "['MsoNormal']", "Text": "At the time of the primary analysis, the benefits of Perjeta were more apparent in subgroups of patients a high risk of recurrence: patients with node-positive or hormone receptor-negative disease (see table 6).", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "4a27f5f6-84a0-4e89-a8b5-4bd137815965", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><u>Table\u00a06\u00a0 Efficacy\nresults in subgroups by nodal status and hormone receptor status<sup>1</sup></u></b></p>", "ID": "53619995-8011-4e47-8040-924acde175f8", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><u>Table\u00a06\u00a0 Efficacy\nresults in subgroups by nodal status and hormone receptor status<sup>1</sup></u></b>", "ID": "319cf657-50c3-4da7-8e00-30a36c7114e3", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "53619995-8011-4e47-8040-924acde175f8"}, {"Element": "<u>Table\u00a06\u00a0 Efficacy\nresults in subgroups by nodal status and hormone receptor status<sup>1</sup></u>", "ID": "d664dacc-4466-48d4-a27b-1e8e18338e5e", "Styles": "None", "Classes": "None", "Text": "Table\u00a06\u00a0 Efficacy results in subgroups by nodal status and hormone receptor status", "ParentId": "319cf657-50c3-4da7-8e00-30a36c7114e3"}, {"Element": "<sup>1</sup>", "ID": "f87d5d8f-d31f-444b-85d1-17e63c92426e", "Styles": "None", "Classes": "None", "Text": "1", "ParentId": "d664dacc-4466-48d4-a27b-1e8e18338e5e"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><u><span style=\"text-decoration:\n none\">\u00a0</span></u></b></p>", "ID": "ba09b801-a37b-47bb-8ec8-27a6f7787abc", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><u><span style=\"text-decoration:\n none\">\u00a0</span></u></b>", "ID": "2e353dbf-21e2-495d-8b72-6a62be5fba46", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ba09b801-a37b-47bb-8ec8-27a6f7787abc"}, {"Element": "<u><span style=\"text-decoration:\n none\">\u00a0</span></u>", "ID": "480a0a88-ea3e-4779-aff0-8bf7ae2f6c8f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "2e353dbf-21e2-495d-8b72-6a62be5fba46"}, {"Element": "<span style=\"text-decoration:\n none\">\u00a0</span>", "ID": "b087541d-1c0b-4110-90c8-0029d993edee", "Styles": "text-decoration:\n none", "Classes": "None", "Text": "\u00a0", "ParentId": "480a0a88-ea3e-4779-aff0-8bf7ae2f6c8f"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:460.25pt;border-collapse:collapse;border:none\" width=\"614\">\n<tr style=\"height:11.1pt\">\n<td rowspan=\"2\" style=\"width:126.9pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:11.1pt\" valign=\"top\" width=\"169\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Population</span></b></p>\n</td>\n<td colspan=\"2\" style=\"width:232.9pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:11.1pt\" valign=\"top\" width=\"311\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Number\n  of IDFS events/Total N (%)</span></b></p>\n</td>\n<td rowspan=\"2\" style=\"width:100.45pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:11.1pt\" valign=\"top\" width=\"134\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Unstratified\n  HR (95% CI)</span></b></p>\n</td>\n</tr>\n<tr style=\"height:44.95pt\">\n<td style=\"width:113.6pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:44.95pt\" valign=\"top\" width=\"151\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Perjeta + trastuzumab + chemotherapy</span></b></p>\n</td>\n<td style=\"width:119.3pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:44.95pt\" valign=\"top\" width=\"159\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Placebo + <br/>\n  trastuzumab + chemotherapy</span></b></p>\n</td>\n</tr>\n<tr style=\"height:11.65pt\">\n<td colspan=\"4\" style=\"width:460.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:11.65pt\" valign=\"top\" width=\"614\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Nodal\n  status</span></b></p>\n</td>\n</tr>\n<tr style=\"height:26.75pt\">\n<td style=\"width:126.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:26.75pt\" valign=\"top\" width=\"169\">\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\n  page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0\u00a0 Positive</span></p>\n</td>\n<td style=\"width:113.6pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:26.75pt\" valign=\"top\" width=\"151\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">139/1503</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(9.2%)</span></p>\n</td>\n<td style=\"width:119.3pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:26.75pt\" valign=\"top\" width=\"159\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">181/1502</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(12.1%)</span></p>\n</td>\n<td style=\"width:100.45pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:26.75pt\" valign=\"top\" width=\"134\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0.77</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(0.62, 0.96)</span></p>\n</td>\n</tr>\n<tr style=\"height:23.3pt\">\n<td style=\"width:126.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:23.3pt\" valign=\"top\" width=\"169\">\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\n  page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0\u00a0 Negative </span></p>\n</td>\n<td style=\"width:113.6pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:23.3pt\" valign=\"top\" width=\"151\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">32/897</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(3.6%)</span></p>\n</td>\n<td style=\"width:119.3pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:23.3pt\" valign=\"top\" width=\"159\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">29/902</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(3.2%)</span></p>\n</td>\n<td style=\"width:100.45pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:23.3pt\" valign=\"top\" width=\"134\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">1.13</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(0.68, 1.86)</span></p>\n</td>\n</tr>\n<tr style=\"height:11.25pt\">\n<td style=\"width:126.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:11.25pt\" valign=\"top\" width=\"169\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Hormone\n  receptor status</span></b></p>\n</td>\n<td style=\"width:113.6pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:11.25pt\" valign=\"top\" width=\"151\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:119.3pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:11.25pt\" valign=\"top\" width=\"159\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:100.45pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:11.25pt\" valign=\"top\" width=\"134\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"height:26.75pt\">\n<td style=\"width:126.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:26.75pt\" valign=\"top\" width=\"169\">\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\n  page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0\u00a0 Negative</span></p>\n</td>\n<td style=\"width:113.6pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:26.75pt\" valign=\"top\" width=\"151\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">71/864</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(8.2%)</span></p>\n</td>\n<td style=\"width:119.3pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:26.75pt\" valign=\"top\" width=\"159\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">91/858</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(10.6%)</span></p>\n</td>\n<td style=\"width:100.45pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:26.75pt\" valign=\"top\" width=\"134\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0.76</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(0.56, 1.04)</span></p>\n</td>\n</tr>\n<tr style=\"height:26.75pt\">\n<td style=\"width:126.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:26.75pt\" valign=\"top\" width=\"169\">\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\n  page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0\u00a0 Positive</span></p>\n</td>\n<td style=\"width:113.6pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:26.75pt\" valign=\"top\" width=\"151\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">100/1536</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(6.5%)</span></p>\n</td>\n<td style=\"width:119.3pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:26.75pt\" valign=\"top\" width=\"159\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">119/1546</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(7.7%)</span></p>\n</td>\n<td style=\"width:100.45pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:26.75pt\" valign=\"top\" width=\"134\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0.86</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(0.66, 1.13)</span></p>\n</td>\n</tr>\n</table>", "ID": "0148a950-a6c0-4edd-8b66-a72bd74ea20a", "Styles": "width:460.25pt;border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Text": "         ", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<tr style=\"height:11.1pt\">\n<td rowspan=\"2\" style=\"width:126.9pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:11.1pt\" valign=\"top\" width=\"169\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Population</span></b></p>\n</td>\n<td colspan=\"2\" style=\"width:232.9pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:11.1pt\" valign=\"top\" width=\"311\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Number\n  of IDFS events/Total N (%)</span></b></p>\n</td>\n<td rowspan=\"2\" style=\"width:100.45pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:11.1pt\" valign=\"top\" width=\"134\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Unstratified\n  HR (95% CI)</span></b></p>\n</td>\n</tr>", "ID": "6523b37c-bee8-4358-877c-885dbf581cda", "Styles": "height:11.1pt", "Classes": "None", "Text": "    ", "ParentId": "0148a950-a6c0-4edd-8b66-a72bd74ea20a"}, {"Element": "<td rowspan=\"2\" style=\"width:126.9pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:11.1pt\" valign=\"top\" width=\"169\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Population</span></b></p>\n</td>", "ID": "4be40af4-0306-4548-947f-9ad42df5e2fc", "Styles": "width:126.9pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:11.1pt", "Classes": "None", "Text": "    ", "ParentId": "6523b37c-bee8-4358-877c-885dbf581cda"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "8eeed0dc-9a0f-400d-b03a-ca3a5310c100", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4be40af4-0306-4548-947f-9ad42df5e2fc"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "72355741-d2c0-402e-b214-8fc7e731d26a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8eeed0dc-9a0f-400d-b03a-ca3a5310c100"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4fcecadb-c9ff-4103-b824-748bc7d950c2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "72355741-d2c0-402e-b214-8fc7e731d26a"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "e615b490-2a8e-479f-bf25-466437badda7", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4be40af4-0306-4548-947f-9ad42df5e2fc"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "2f7cfbed-b0a0-4563-8617-2d163546fafd", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e615b490-2a8e-479f-bf25-466437badda7"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "72820127-3afc-4cda-b876-e1529e02b2e1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2f7cfbed-b0a0-4563-8617-2d163546fafd"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Population</span></b></p>", "ID": "625eb906-8f0f-45f0-ba74-15a5a0a89822", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4be40af4-0306-4548-947f-9ad42df5e2fc"}, {"Element": "<b><span lang=\"EN-GB\">Population</span></b>", "ID": "b5de199a-5e19-42b1-a824-04266f283f4e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "625eb906-8f0f-45f0-ba74-15a5a0a89822"}, {"Element": "<span lang=\"EN-GB\">Population</span>", "ID": "d316ffda-5eda-4aec-ace0-f31e030c1325", "Styles": "None", "Classes": "None", "Text": "Population", "ParentId": "b5de199a-5e19-42b1-a824-04266f283f4e"}, {"Element": "<td colspan=\"2\" style=\"width:232.9pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:11.1pt\" valign=\"top\" width=\"311\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Number\n  of IDFS events/Total N (%)</span></b></p>\n</td>", "ID": "517aea9a-73bc-4a10-b73e-5084dfa75e42", "Styles": "width:232.9pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:11.1pt", "Classes": "None", "Text": "  ", "ParentId": "6523b37c-bee8-4358-877c-885dbf581cda"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Number\n  of IDFS events/Total N (%)</span></b></p>", "ID": "ea98537e-9675-45df-90d4-5b3770ec1941", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "517aea9a-73bc-4a10-b73e-5084dfa75e42"}, {"Element": "<b><span lang=\"EN-GB\">Number\n  of IDFS events/Total N (%)</span></b>", "ID": "e538ef04-4ffd-4019-ba29-1b8443145385", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ea98537e-9675-45df-90d4-5b3770ec1941"}, {"Element": "<span lang=\"EN-GB\">Number\n  of IDFS events/Total N (%)</span>", "ID": "693912e1-a149-4630-a605-0bcbdec1504d", "Styles": "None", "Classes": "None", "Text": "Number   of IDFS events/Total N (%)", "ParentId": "e538ef04-4ffd-4019-ba29-1b8443145385"}, {"Element": "<td rowspan=\"2\" style=\"width:100.45pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:11.1pt\" valign=\"top\" width=\"134\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Unstratified\n  HR (95% CI)</span></b></p>\n</td>", "ID": "91d583bb-0f8c-41ad-be0a-cf892c86bbec", "Styles": "width:100.45pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:11.1pt", "Classes": "None", "Text": "  ", "ParentId": "6523b37c-bee8-4358-877c-885dbf581cda"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Unstratified\n  HR (95% CI)</span></b></p>", "ID": "dc16aec7-9a69-47cb-a433-5e88afa23f71", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "91d583bb-0f8c-41ad-be0a-cf892c86bbec"}, {"Element": "<b><span lang=\"EN-GB\">Unstratified\n  HR (95% CI)</span></b>", "ID": "53f5d744-66f3-44e3-901c-5687cfa53903", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "dc16aec7-9a69-47cb-a433-5e88afa23f71"}, {"Element": "<span lang=\"EN-GB\">Unstratified\n  HR (95% CI)</span>", "ID": "c5d16458-37a2-4ca9-ae58-0ecb28290e3a", "Styles": "None", "Classes": "None", "Text": "Unstratified   HR (95% CI)", "ParentId": "53f5d744-66f3-44e3-901c-5687cfa53903"}, {"Element": "<tr style=\"height:44.95pt\">\n<td style=\"width:113.6pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:44.95pt\" valign=\"top\" width=\"151\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Perjeta + trastuzumab + chemotherapy</span></b></p>\n</td>\n<td style=\"width:119.3pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:44.95pt\" valign=\"top\" width=\"159\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Placebo + <br/>\n  trastuzumab + chemotherapy</span></b></p>\n</td>\n</tr>", "ID": "505bd012-e78e-45c9-8036-c4f6c2137b5c", "Styles": "height:44.95pt", "Classes": "None", "Text": "   ", "ParentId": "0148a950-a6c0-4edd-8b66-a72bd74ea20a"}, {"Element": "<td style=\"width:113.6pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:44.95pt\" valign=\"top\" width=\"151\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Perjeta + trastuzumab + chemotherapy</span></b></p>\n</td>", "ID": "254161e5-78c6-4b79-8942-a36bf2955ae3", "Styles": "width:113.6pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:44.95pt", "Classes": "None", "Text": "  ", "ParentId": "505bd012-e78e-45c9-8036-c4f6c2137b5c"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Perjeta + trastuzumab + chemotherapy</span></b></p>", "ID": "ad7c6caa-78d5-4884-bd39-9a44dcc56e41", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "254161e5-78c6-4b79-8942-a36bf2955ae3"}, {"Element": "<b><span lang=\"EN-GB\">Perjeta + trastuzumab + chemotherapy</span></b>", "ID": "2e6008c1-395f-4225-b0b1-1a53df8392f4", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ad7c6caa-78d5-4884-bd39-9a44dcc56e41"}, {"Element": "<span lang=\"EN-GB\">Perjeta + trastuzumab + chemotherapy</span>", "ID": "2a4e4d3c-5ace-4d5a-b866-2edb2b839797", "Styles": "None", "Classes": "None", "Text": "Perjeta + trastuzumab + chemotherapy", "ParentId": "2e6008c1-395f-4225-b0b1-1a53df8392f4"}, {"Element": "<td style=\"width:119.3pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:44.95pt\" valign=\"top\" width=\"159\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Placebo + <br/>\n  trastuzumab + chemotherapy</span></b></p>\n</td>", "ID": "246f9038-6bb8-4d7d-bead-6c2b5dd04f24", "Styles": "width:119.3pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:44.95pt", "Classes": "None", "Text": "  ", "ParentId": "505bd012-e78e-45c9-8036-c4f6c2137b5c"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Placebo + <br/>\n  trastuzumab + chemotherapy</span></b></p>", "ID": "071126c7-8813-4a7e-8951-504aeecac4d2", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "246f9038-6bb8-4d7d-bead-6c2b5dd04f24"}, {"Element": "<b><span lang=\"EN-GB\">Placebo + <br/>\n  trastuzumab + chemotherapy</span></b>", "ID": "31ec20b8-1d2a-4235-bb21-eaa7f38e6c5e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "071126c7-8813-4a7e-8951-504aeecac4d2"}, {"Element": "<span lang=\"EN-GB\">Placebo + <br/>\n  trastuzumab + chemotherapy</span>", "ID": "a024c7a7-6fa8-4242-b1e0-d7c4ff39ba5d", "Styles": "None", "Classes": "None", "Text": "Placebo +    trastuzumab + chemotherapy", "ParentId": "31ec20b8-1d2a-4235-bb21-eaa7f38e6c5e"}, {"Element": "<br/>", "ID": "8861ac64-0d64-4684-98da-bc52f8ba3c45", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a024c7a7-6fa8-4242-b1e0-d7c4ff39ba5d"}, {"Element": "<tr style=\"height:11.65pt\">\n<td colspan=\"4\" style=\"width:460.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:11.65pt\" valign=\"top\" width=\"614\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Nodal\n  status</span></b></p>\n</td>\n</tr>", "ID": "c00f137f-2b78-43c3-8c83-f6fc654918d1", "Styles": "height:11.65pt", "Classes": "None", "Text": "  ", "ParentId": "0148a950-a6c0-4edd-8b66-a72bd74ea20a"}, {"Element": "<td colspan=\"4\" style=\"width:460.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:11.65pt\" valign=\"top\" width=\"614\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Nodal\n  status</span></b></p>\n</td>", "ID": "1df4e96b-76f5-4d2d-bcab-e44cf678e8f0", "Styles": "width:460.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:11.65pt", "Classes": "None", "Text": "  ", "ParentId": "c00f137f-2b78-43c3-8c83-f6fc654918d1"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Nodal\n  status</span></b></p>", "ID": "a2fb3268-9b4e-4345-bfce-497d5216f86c", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1df4e96b-76f5-4d2d-bcab-e44cf678e8f0"}, {"Element": "<b><span lang=\"EN-GB\">Nodal\n  status</span></b>", "ID": "f96d15ff-880e-4dd2-b489-451e0fd83439", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a2fb3268-9b4e-4345-bfce-497d5216f86c"}, {"Element": "<span lang=\"EN-GB\">Nodal\n  status</span>", "ID": "572c9769-3b34-4f37-b4e6-b3a46845ea24", "Styles": "None", "Classes": "None", "Text": "Nodal   status", "ParentId": "f96d15ff-880e-4dd2-b489-451e0fd83439"}, {"Element": "<tr style=\"height:26.75pt\">\n<td style=\"width:126.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:26.75pt\" valign=\"top\" width=\"169\">\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\n  page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0\u00a0 Positive</span></p>\n</td>\n<td style=\"width:113.6pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:26.75pt\" valign=\"top\" width=\"151\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">139/1503</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(9.2%)</span></p>\n</td>\n<td style=\"width:119.3pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:26.75pt\" valign=\"top\" width=\"159\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">181/1502</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(12.1%)</span></p>\n</td>\n<td style=\"width:100.45pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:26.75pt\" valign=\"top\" width=\"134\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0.77</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(0.62, 0.96)</span></p>\n</td>\n</tr>", "ID": "07f48260-a566-45bf-98b4-1aaa636a531d", "Styles": "height:26.75pt", "Classes": "None", "Text": "     ", "ParentId": "0148a950-a6c0-4edd-8b66-a72bd74ea20a"}, {"Element": "<td style=\"width:126.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:26.75pt\" valign=\"top\" width=\"169\">\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\n  page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0\u00a0 Positive</span></p>\n</td>", "ID": "8270f765-850e-4c9b-86b0-60e5df18bda1", "Styles": "width:126.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:26.75pt", "Classes": "None", "Text": "  ", "ParentId": "07f48260-a566-45bf-98b4-1aaa636a531d"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\n  page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0\u00a0 Positive</span></p>", "ID": "b3c7c291-9fd5-4563-8b3d-5c0842eaf94f", "Styles": "text-align:justify;text-justify:inter-ideograph;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8270f765-850e-4c9b-86b0-60e5df18bda1"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0 Positive</span>", "ID": "437dc403-b4a1-480e-ab70-3f23a64f36c5", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0 Positive", "ParentId": "b3c7c291-9fd5-4563-8b3d-5c0842eaf94f"}, {"Element": "<td style=\"width:113.6pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:26.75pt\" valign=\"top\" width=\"151\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">139/1503</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(9.2%)</span></p>\n</td>", "ID": "225f3514-6929-4c6f-b133-66a7aa8335dd", "Styles": "width:113.6pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:26.75pt", "Classes": "None", "Text": "   ", "ParentId": "07f48260-a566-45bf-98b4-1aaa636a531d"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">139/1503</span></p>", "ID": "84238be5-5214-41ec-9e31-3b76d0e55bfd", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "225f3514-6929-4c6f-b133-66a7aa8335dd"}, {"Element": "<span lang=\"EN-GB\">139/1503</span>", "ID": "2ede62af-2700-44d2-a0a1-2a82c20cbc2b", "Styles": "None", "Classes": "None", "Text": "139/1503", "ParentId": "84238be5-5214-41ec-9e31-3b76d0e55bfd"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(9.2%)</span></p>", "ID": "1c4a2a8b-b53b-44c2-a101-1bf21d09a29f", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "225f3514-6929-4c6f-b133-66a7aa8335dd"}, {"Element": "<span lang=\"EN-GB\">(9.2%)</span>", "ID": "5c193f91-6d8b-47e0-8cce-7b5905f9a704", "Styles": "None", "Classes": "None", "Text": "(9.2%)", "ParentId": "1c4a2a8b-b53b-44c2-a101-1bf21d09a29f"}, {"Element": "<td style=\"width:119.3pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:26.75pt\" valign=\"top\" width=\"159\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">181/1502</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(12.1%)</span></p>\n</td>", "ID": "5af149d9-9dac-4ae4-be7c-03a9008d187c", "Styles": "width:119.3pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:26.75pt", "Classes": "None", "Text": "   ", "ParentId": "07f48260-a566-45bf-98b4-1aaa636a531d"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">181/1502</span></p>", "ID": "8adc8768-289a-440c-bc06-dfaafe224fea", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5af149d9-9dac-4ae4-be7c-03a9008d187c"}, {"Element": "<span lang=\"EN-GB\">181/1502</span>", "ID": "361c61e8-5870-49d3-b5fe-6bce7ae41e63", "Styles": "None", "Classes": "None", "Text": "181/1502", "ParentId": "8adc8768-289a-440c-bc06-dfaafe224fea"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(12.1%)</span></p>", "ID": "ff0fb919-3324-45b6-8715-d0ccae3e04f4", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5af149d9-9dac-4ae4-be7c-03a9008d187c"}, {"Element": "<span lang=\"EN-GB\">(12.1%)</span>", "ID": "4e2dc438-9969-43fa-bcfd-2decae9acfa0", "Styles": "None", "Classes": "None", "Text": "(12.1%)", "ParentId": "ff0fb919-3324-45b6-8715-d0ccae3e04f4"}, {"Element": "<td style=\"width:100.45pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:26.75pt\" valign=\"top\" width=\"134\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0.77</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(0.62, 0.96)</span></p>\n</td>", "ID": "aeef8142-12c4-43b9-ac85-b489b434e94b", "Styles": "width:100.45pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:26.75pt", "Classes": "None", "Text": "   ", "ParentId": "07f48260-a566-45bf-98b4-1aaa636a531d"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0.77</span></p>", "ID": "1bcf3828-3e8b-44d4-9ef8-21f3304ef3b3", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "aeef8142-12c4-43b9-ac85-b489b434e94b"}, {"Element": "<span lang=\"EN-GB\">0.77</span>", "ID": "7460d948-4b21-4854-af5f-27af9a7db2bd", "Styles": "None", "Classes": "None", "Text": "0.77", "ParentId": "1bcf3828-3e8b-44d4-9ef8-21f3304ef3b3"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(0.62, 0.96)</span></p>", "ID": "524cad29-8afd-45e3-afbf-3269a17187fb", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "aeef8142-12c4-43b9-ac85-b489b434e94b"}, {"Element": "<span lang=\"EN-GB\">(0.62, 0.96)</span>", "ID": "b7ae9adc-cdeb-4d10-8307-d282bcd52665", "Styles": "None", "Classes": "None", "Text": "(0.62, 0.96)", "ParentId": "524cad29-8afd-45e3-afbf-3269a17187fb"}, {"Element": "<tr style=\"height:23.3pt\">\n<td style=\"width:126.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:23.3pt\" valign=\"top\" width=\"169\">\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\n  page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0\u00a0 Negative </span></p>\n</td>\n<td style=\"width:113.6pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:23.3pt\" valign=\"top\" width=\"151\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">32/897</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(3.6%)</span></p>\n</td>\n<td style=\"width:119.3pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:23.3pt\" valign=\"top\" width=\"159\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">29/902</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(3.2%)</span></p>\n</td>\n<td style=\"width:100.45pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:23.3pt\" valign=\"top\" width=\"134\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">1.13</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(0.68, 1.86)</span></p>\n</td>\n</tr>", "ID": "60cfbd3c-d15e-4761-82f6-4cafc3a4517c", "Styles": "height:23.3pt", "Classes": "None", "Text": "     ", "ParentId": "0148a950-a6c0-4edd-8b66-a72bd74ea20a"}, {"Element": "<td style=\"width:126.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:23.3pt\" valign=\"top\" width=\"169\">\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\n  page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0\u00a0 Negative </span></p>\n</td>", "ID": "109959e5-b6e1-461b-ab43-68c4fa32d908", "Styles": "width:126.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:23.3pt", "Classes": "None", "Text": "  ", "ParentId": "60cfbd3c-d15e-4761-82f6-4cafc3a4517c"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\n  page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0\u00a0 Negative </span></p>", "ID": "42070e6c-2c4e-40ee-924e-d9daae95a69b", "Styles": "text-align:justify;text-justify:inter-ideograph;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "109959e5-b6e1-461b-ab43-68c4fa32d908"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0 Negative </span>", "ID": "cc9e575f-09b3-41f8-b12c-8fa08257bcea", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0 Negative ", "ParentId": "42070e6c-2c4e-40ee-924e-d9daae95a69b"}, {"Element": "<td style=\"width:113.6pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:23.3pt\" valign=\"top\" width=\"151\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">32/897</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(3.6%)</span></p>\n</td>", "ID": "45f54060-d213-4c60-baf2-f279d536ce94", "Styles": "width:113.6pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:23.3pt", "Classes": "None", "Text": "   ", "ParentId": "60cfbd3c-d15e-4761-82f6-4cafc3a4517c"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">32/897</span></p>", "ID": "6f583d27-b45f-4da7-bdba-6d656dca2de9", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "45f54060-d213-4c60-baf2-f279d536ce94"}, {"Element": "<span lang=\"EN-GB\">32/897</span>", "ID": "8837579d-8c95-4006-974c-4f2ace893a42", "Styles": "None", "Classes": "None", "Text": "32/897", "ParentId": "6f583d27-b45f-4da7-bdba-6d656dca2de9"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(3.6%)</span></p>", "ID": "936d0b46-bdab-499a-b385-d4ba232766e6", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "45f54060-d213-4c60-baf2-f279d536ce94"}, {"Element": "<span lang=\"EN-GB\">(3.6%)</span>", "ID": "3c68c061-b969-49a8-84ea-1ce4d8355731", "Styles": "None", "Classes": "None", "Text": "(3.6%)", "ParentId": "936d0b46-bdab-499a-b385-d4ba232766e6"}, {"Element": "<td style=\"width:119.3pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:23.3pt\" valign=\"top\" width=\"159\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">29/902</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(3.2%)</span></p>\n</td>", "ID": "41f5e1b7-8bd2-489e-8968-d457382b0846", "Styles": "width:119.3pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:23.3pt", "Classes": "None", "Text": "   ", "ParentId": "60cfbd3c-d15e-4761-82f6-4cafc3a4517c"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">29/902</span></p>", "ID": "e6d20f8a-e05c-4ccc-b909-b7a6c85dca2c", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "41f5e1b7-8bd2-489e-8968-d457382b0846"}, {"Element": "<span lang=\"EN-GB\">29/902</span>", "ID": "d2fb43a3-939b-4829-b786-f102a59d78fb", "Styles": "None", "Classes": "None", "Text": "29/902", "ParentId": "e6d20f8a-e05c-4ccc-b909-b7a6c85dca2c"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(3.2%)</span></p>", "ID": "30aef6ff-7a6c-41ea-b5e7-c415aa2ef1f4", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "41f5e1b7-8bd2-489e-8968-d457382b0846"}, {"Element": "<span lang=\"EN-GB\">(3.2%)</span>", "ID": "c9f6a4aa-6988-497c-80d9-45e4d0c072d3", "Styles": "None", "Classes": "None", "Text": "(3.2%)", "ParentId": "30aef6ff-7a6c-41ea-b5e7-c415aa2ef1f4"}, {"Element": "<td style=\"width:100.45pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:23.3pt\" valign=\"top\" width=\"134\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">1.13</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(0.68, 1.86)</span></p>\n</td>", "ID": "77c448b4-cc3a-40e6-b75c-35f8b0e956a7", "Styles": "width:100.45pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:23.3pt", "Classes": "None", "Text": "   ", "ParentId": "60cfbd3c-d15e-4761-82f6-4cafc3a4517c"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">1.13</span></p>", "ID": "ba4c21f1-c2ed-4935-b11f-4c740aebd5c5", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "77c448b4-cc3a-40e6-b75c-35f8b0e956a7"}, {"Element": "<span lang=\"EN-GB\">1.13</span>", "ID": "fc09919d-974f-4c71-bbbe-0bf4c5dc163e", "Styles": "None", "Classes": "None", "Text": "1.13", "ParentId": "ba4c21f1-c2ed-4935-b11f-4c740aebd5c5"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(0.68, 1.86)</span></p>", "ID": "c3d28dbb-ffaa-4b33-8770-b4e9da0aa453", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "77c448b4-cc3a-40e6-b75c-35f8b0e956a7"}, {"Element": "<span lang=\"EN-GB\">(0.68, 1.86)</span>", "ID": "6b2851a4-02f2-45a0-a023-5f48c1ba3e5d", "Styles": "None", "Classes": "None", "Text": "(0.68, 1.86)", "ParentId": "c3d28dbb-ffaa-4b33-8770-b4e9da0aa453"}, {"Element": "<tr style=\"height:11.25pt\">\n<td style=\"width:126.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:11.25pt\" valign=\"top\" width=\"169\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Hormone\n  receptor status</span></b></p>\n</td>\n<td style=\"width:113.6pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:11.25pt\" valign=\"top\" width=\"151\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:119.3pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:11.25pt\" valign=\"top\" width=\"159\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:100.45pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:11.25pt\" valign=\"top\" width=\"134\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "1a296dd5-63bf-46ba-9e96-db6889aa2f7c", "Styles": "height:11.25pt", "Classes": "None", "Text": "     ", "ParentId": "0148a950-a6c0-4edd-8b66-a72bd74ea20a"}, {"Element": "<td style=\"width:126.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:11.25pt\" valign=\"top\" width=\"169\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Hormone\n  receptor status</span></b></p>\n</td>", "ID": "4d5baaa5-980e-4862-8e32-683e4bd257bc", "Styles": "width:126.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:11.25pt", "Classes": "None", "Text": "  ", "ParentId": "1a296dd5-63bf-46ba-9e96-db6889aa2f7c"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Hormone\n  receptor status</span></b></p>", "ID": "5453882e-592b-4520-97da-8cecc6238044", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4d5baaa5-980e-4862-8e32-683e4bd257bc"}, {"Element": "<b><span lang=\"EN-GB\">Hormone\n  receptor status</span></b>", "ID": "4cc10d36-a49f-4132-94ec-258ef34a1ef5", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "5453882e-592b-4520-97da-8cecc6238044"}, {"Element": "<span lang=\"EN-GB\">Hormone\n  receptor status</span>", "ID": "1f60a4df-dda0-41ae-8844-1241e35e43a4", "Styles": "None", "Classes": "None", "Text": "Hormone   receptor status", "ParentId": "4cc10d36-a49f-4132-94ec-258ef34a1ef5"}, {"Element": "<td style=\"width:113.6pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:11.25pt\" valign=\"top\" width=\"151\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "a286759c-295b-404b-8319-403f5eb0c27e", "Styles": "width:113.6pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:11.25pt", "Classes": "None", "Text": "  ", "ParentId": "1a296dd5-63bf-46ba-9e96-db6889aa2f7c"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2e11b83b-8941-43cb-98b3-f6867bd69bb1", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a286759c-295b-404b-8319-403f5eb0c27e"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "16e93172-70c7-450a-ae0f-ccd1a7cd6463", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2e11b83b-8941-43cb-98b3-f6867bd69bb1"}, {"Element": "<td style=\"width:119.3pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:11.25pt\" valign=\"top\" width=\"159\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "cc038b0f-2941-423b-92f4-9881ed6ce49a", "Styles": "width:119.3pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:11.25pt", "Classes": "None", "Text": "  ", "ParentId": "1a296dd5-63bf-46ba-9e96-db6889aa2f7c"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e2c00210-9068-4c0d-9382-53cd665bd08c", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "cc038b0f-2941-423b-92f4-9881ed6ce49a"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3ef7fc24-814b-494e-b4a1-aed667a904bf", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e2c00210-9068-4c0d-9382-53cd665bd08c"}, {"Element": "<td style=\"width:100.45pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:11.25pt\" valign=\"top\" width=\"134\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "e2f8701a-2a1f-462d-b80d-de47a4d114f2", "Styles": "width:100.45pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:11.25pt", "Classes": "None", "Text": "  ", "ParentId": "1a296dd5-63bf-46ba-9e96-db6889aa2f7c"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b662bdfc-9f6d-4066-b897-e59b8481a0ba", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e2f8701a-2a1f-462d-b80d-de47a4d114f2"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "73b8585b-a284-42ec-b662-826f4190e145", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b662bdfc-9f6d-4066-b897-e59b8481a0ba"}, {"Element": "<tr style=\"height:26.75pt\">\n<td style=\"width:126.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:26.75pt\" valign=\"top\" width=\"169\">\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\n  page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0\u00a0 Negative</span></p>\n</td>\n<td style=\"width:113.6pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:26.75pt\" valign=\"top\" width=\"151\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">71/864</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(8.2%)</span></p>\n</td>\n<td style=\"width:119.3pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:26.75pt\" valign=\"top\" width=\"159\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">91/858</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(10.6%)</span></p>\n</td>\n<td style=\"width:100.45pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:26.75pt\" valign=\"top\" width=\"134\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0.76</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(0.56, 1.04)</span></p>\n</td>\n</tr>", "ID": "57148cd8-3fd6-4c6c-91f5-adaa3d86783b", "Styles": "height:26.75pt", "Classes": "None", "Text": "     ", "ParentId": "0148a950-a6c0-4edd-8b66-a72bd74ea20a"}, {"Element": "<td style=\"width:126.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:26.75pt\" valign=\"top\" width=\"169\">\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\n  page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0\u00a0 Negative</span></p>\n</td>", "ID": "09dcb12b-5ffe-4e21-aef9-0aef7e694cc4", "Styles": "width:126.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:26.75pt", "Classes": "None", "Text": "  ", "ParentId": "57148cd8-3fd6-4c6c-91f5-adaa3d86783b"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\n  page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0\u00a0 Negative</span></p>", "ID": "22fa864a-7ba8-4bd4-a512-0ade268c509a", "Styles": "text-align:justify;text-justify:inter-ideograph;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "09dcb12b-5ffe-4e21-aef9-0aef7e694cc4"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0 Negative</span>", "ID": "e6e9ab85-9c5d-4628-b0bd-024d68266d69", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0 Negative", "ParentId": "22fa864a-7ba8-4bd4-a512-0ade268c509a"}, {"Element": "<td style=\"width:113.6pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:26.75pt\" valign=\"top\" width=\"151\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">71/864</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(8.2%)</span></p>\n</td>", "ID": "a7153e12-1feb-4706-9a71-a0395bcacc6a", "Styles": "width:113.6pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:26.75pt", "Classes": "None", "Text": "   ", "ParentId": "57148cd8-3fd6-4c6c-91f5-adaa3d86783b"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">71/864</span></p>", "ID": "3bb0df32-8e6d-4fba-b33d-93a2b28703aa", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a7153e12-1feb-4706-9a71-a0395bcacc6a"}, {"Element": "<span lang=\"EN-GB\">71/864</span>", "ID": "8035d7b1-b987-45e1-8f63-c38bb63eb92c", "Styles": "None", "Classes": "None", "Text": "71/864", "ParentId": "3bb0df32-8e6d-4fba-b33d-93a2b28703aa"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(8.2%)</span></p>", "ID": "1cb200f6-e9d7-43b2-8102-46c7a10ffbf4", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a7153e12-1feb-4706-9a71-a0395bcacc6a"}, {"Element": "<span lang=\"EN-GB\">(8.2%)</span>", "ID": "80a82ac6-2024-4405-a50e-c92fb3055cf3", "Styles": "None", "Classes": "None", "Text": "(8.2%)", "ParentId": "1cb200f6-e9d7-43b2-8102-46c7a10ffbf4"}, {"Element": "<td style=\"width:119.3pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:26.75pt\" valign=\"top\" width=\"159\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">91/858</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(10.6%)</span></p>\n</td>", "ID": "44371e74-38da-485a-94f5-a4bfcfb81c8c", "Styles": "width:119.3pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:26.75pt", "Classes": "None", "Text": "   ", "ParentId": "57148cd8-3fd6-4c6c-91f5-adaa3d86783b"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">91/858</span></p>", "ID": "c5cf241b-45ca-4e97-8cae-0512312a53ea", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "44371e74-38da-485a-94f5-a4bfcfb81c8c"}, {"Element": "<span lang=\"EN-GB\">91/858</span>", "ID": "851c5415-0a5b-45ef-9255-1371caf70f0c", "Styles": "None", "Classes": "None", "Text": "91/858", "ParentId": "c5cf241b-45ca-4e97-8cae-0512312a53ea"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(10.6%)</span></p>", "ID": "346ca04a-073e-47dd-befd-3847533f4c79", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "44371e74-38da-485a-94f5-a4bfcfb81c8c"}, {"Element": "<span lang=\"EN-GB\">(10.6%)</span>", "ID": "3363df01-789c-4c61-a504-322ca6c351af", "Styles": "None", "Classes": "None", "Text": "(10.6%)", "ParentId": "346ca04a-073e-47dd-befd-3847533f4c79"}, {"Element": "<td style=\"width:100.45pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:26.75pt\" valign=\"top\" width=\"134\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0.76</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(0.56, 1.04)</span></p>\n</td>", "ID": "50d0412f-28da-4858-87a8-164f76a404ce", "Styles": "width:100.45pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:26.75pt", "Classes": "None", "Text": "   ", "ParentId": "57148cd8-3fd6-4c6c-91f5-adaa3d86783b"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0.76</span></p>", "ID": "9f7ca7d4-c8b0-4c71-888e-49dc5ab7668d", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "50d0412f-28da-4858-87a8-164f76a404ce"}, {"Element": "<span lang=\"EN-GB\">0.76</span>", "ID": "67ea8ce9-fc61-4b22-9857-1a86f9304c76", "Styles": "None", "Classes": "None", "Text": "0.76", "ParentId": "9f7ca7d4-c8b0-4c71-888e-49dc5ab7668d"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(0.56, 1.04)</span></p>", "ID": "6bb39f54-4e41-461f-9437-9ea6a608a6d8", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "50d0412f-28da-4858-87a8-164f76a404ce"}, {"Element": "<span lang=\"EN-GB\">(0.56, 1.04)</span>", "ID": "f4e439a1-9251-4ca5-960a-3cd9dcc7288f", "Styles": "None", "Classes": "None", "Text": "(0.56, 1.04)", "ParentId": "6bb39f54-4e41-461f-9437-9ea6a608a6d8"}, {"Element": "<tr style=\"height:26.75pt\">\n<td style=\"width:126.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:26.75pt\" valign=\"top\" width=\"169\">\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\n  page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0\u00a0 Positive</span></p>\n</td>\n<td style=\"width:113.6pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:26.75pt\" valign=\"top\" width=\"151\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">100/1536</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(6.5%)</span></p>\n</td>\n<td style=\"width:119.3pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:26.75pt\" valign=\"top\" width=\"159\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">119/1546</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(7.7%)</span></p>\n</td>\n<td style=\"width:100.45pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:26.75pt\" valign=\"top\" width=\"134\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0.86</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(0.66, 1.13)</span></p>\n</td>\n</tr>", "ID": "36dafe9a-3e37-4246-9daf-cc206447003b", "Styles": "height:26.75pt", "Classes": "None", "Text": "     ", "ParentId": "0148a950-a6c0-4edd-8b66-a72bd74ea20a"}, {"Element": "<td style=\"width:126.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:26.75pt\" valign=\"top\" width=\"169\">\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\n  page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0\u00a0 Positive</span></p>\n</td>", "ID": "0a0ace6a-d918-470b-b36a-db0bd38f8538", "Styles": "width:126.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:26.75pt", "Classes": "None", "Text": "  ", "ParentId": "36dafe9a-3e37-4246-9daf-cc206447003b"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\n  page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0\u00a0 Positive</span></p>", "ID": "a7cd9934-43e8-475c-b88c-e5d5a80f9706", "Styles": "text-align:justify;text-justify:inter-ideograph;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0a0ace6a-d918-470b-b36a-db0bd38f8538"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0 Positive</span>", "ID": "27935c35-ff9d-430b-a46f-c94d8047e228", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0 Positive", "ParentId": "a7cd9934-43e8-475c-b88c-e5d5a80f9706"}, {"Element": "<td style=\"width:113.6pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:26.75pt\" valign=\"top\" width=\"151\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">100/1536</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(6.5%)</span></p>\n</td>", "ID": "55aa0e77-795c-4432-bb80-24f054dc0ea4", "Styles": "width:113.6pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:26.75pt", "Classes": "None", "Text": "   ", "ParentId": "36dafe9a-3e37-4246-9daf-cc206447003b"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">100/1536</span></p>", "ID": "a191bbac-b435-414f-977b-fec76974015e", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "55aa0e77-795c-4432-bb80-24f054dc0ea4"}, {"Element": "<span lang=\"EN-GB\">100/1536</span>", "ID": "72cd9dbd-cd68-4a45-b02a-8ece8925b0a2", "Styles": "None", "Classes": "None", "Text": "100/1536", "ParentId": "a191bbac-b435-414f-977b-fec76974015e"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(6.5%)</span></p>", "ID": "c5e94837-e3c1-4833-8c45-c2cc05e8d69e", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "55aa0e77-795c-4432-bb80-24f054dc0ea4"}, {"Element": "<span lang=\"EN-GB\">(6.5%)</span>", "ID": "c6222608-7161-4cb0-92fb-cba40333e937", "Styles": "None", "Classes": "None", "Text": "(6.5%)", "ParentId": "c5e94837-e3c1-4833-8c45-c2cc05e8d69e"}, {"Element": "<td style=\"width:119.3pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:26.75pt\" valign=\"top\" width=\"159\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">119/1546</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(7.7%)</span></p>\n</td>", "ID": "0c6d474e-6ce8-431f-a2a7-4406faf25911", "Styles": "width:119.3pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:26.75pt", "Classes": "None", "Text": "   ", "ParentId": "36dafe9a-3e37-4246-9daf-cc206447003b"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">119/1546</span></p>", "ID": "f50f9991-4dec-48a9-ad2d-b9193c1c5d8a", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0c6d474e-6ce8-431f-a2a7-4406faf25911"}, {"Element": "<span lang=\"EN-GB\">119/1546</span>", "ID": "fe9bb439-735c-4627-818e-f6a878ae835a", "Styles": "None", "Classes": "None", "Text": "119/1546", "ParentId": "f50f9991-4dec-48a9-ad2d-b9193c1c5d8a"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(7.7%)</span></p>", "ID": "5c3a6c1c-69c0-41fb-b412-88b8d122e25f", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0c6d474e-6ce8-431f-a2a7-4406faf25911"}, {"Element": "<span lang=\"EN-GB\">(7.7%)</span>", "ID": "5c9751fd-1bae-4a81-8008-7c0e51835a2b", "Styles": "None", "Classes": "None", "Text": "(7.7%)", "ParentId": "5c3a6c1c-69c0-41fb-b412-88b8d122e25f"}, {"Element": "<td style=\"width:100.45pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:26.75pt\" valign=\"top\" width=\"134\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0.86</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(0.66, 1.13)</span></p>\n</td>", "ID": "9e534705-4f0a-4bca-a95a-314038e477c4", "Styles": "width:100.45pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:26.75pt", "Classes": "None", "Text": "   ", "ParentId": "36dafe9a-3e37-4246-9daf-cc206447003b"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0.86</span></p>", "ID": "492bb7cc-24ce-44c8-8c4b-e38004eaf95b", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9e534705-4f0a-4bca-a95a-314038e477c4"}, {"Element": "<span lang=\"EN-GB\">0.86</span>", "ID": "5e1564ed-6b3c-4b33-b0a3-02b84dddd1d5", "Styles": "None", "Classes": "None", "Text": "0.86", "ParentId": "492bb7cc-24ce-44c8-8c4b-e38004eaf95b"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(0.66, 1.13)</span></p>", "ID": "c3f23a02-7df3-48e0-9240-37d648f178a5", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9e534705-4f0a-4bca-a95a-314038e477c4"}, {"Element": "<span lang=\"EN-GB\">(0.66, 1.13)</span>", "ID": "53f8e0e1-5685-4d0b-b2bf-dccf2c85733c", "Styles": "None", "Classes": "None", "Text": "(0.66, 1.13)", "ParentId": "c3f23a02-7df3-48e0-9240-37d648f178a5"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><sup><span style=\"font-size:\n10.0pt\">1</span></sup><span style=\"font-size:10.0pt\"> Prespecified subgroup\nanalyses without adjusting for multiple comparisons, therefore, results are\nconsidered descriptive.</span></p>", "ID": "27cdc08d-140c-4f56-99a3-9bde0020dead", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<sup><span style=\"font-size:\n10.0pt\">1</span></sup>", "ID": "1623f733-7cf4-479b-8274-bf13e593c788", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "27cdc08d-140c-4f56-99a3-9bde0020dead"}, {"Element": "<span style=\"font-size:\n10.0pt\">1</span>", "ID": "1c096bb1-e4ef-4d98-934b-b6eefe0b98ea", "Styles": "font-size:\n10.0pt", "Classes": "None", "Text": "1", "ParentId": "1623f733-7cf4-479b-8274-bf13e593c788"}, {"Element": "<span style=\"font-size:10.0pt\"> Prespecified subgroup\nanalyses without adjusting for multiple comparisons, therefore, results are\nconsidered descriptive.</span>", "ID": "49e79eef-4c25-47a3-869a-9ce4b0b97332", "Styles": "font-size:10.0pt", "Classes": "None", "Text": " Prespecified subgroup analyses without adjusting for multiple comparisons, therefore, results are considered descriptive.", "ParentId": "27cdc08d-140c-4f56-99a3-9bde0020dead"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "1d2785c9-5760-4148-a702-c5a414c19ccb", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Estimates of IDFS rates in\nthe lymph node- positive subgroup were 92.0% versus 90.2% at 3\u00a0years and\n89.9% vs. 86.7% at 4 years in Perjeta-treated patients versus placebo-treated\npatients, respectively. In the lymph node- negative subgroup, estimates of IDFS\nrates were 97.5% versus 98.4% at 3\u00a0years and 96.2% versus 96.7% at 4 years\nin Perjeta-treated patients versus placebo-treated patients, respectively. In\nthe hormone receptor-negative subgroup, estimates of IDFS rates were 92.8%\nversus 91.2% at 3 years and 91.0% versus 88.7% at 4 years in Perjeta-treated\npatients versus placebo-treated patients, respectively. In the hormone\nreceptor-positive subgroup estimates of IDFS rates were 94.8% versus 94.4% at 3\nyears and 93.0% versus 91.6% at 4 years in Perjeta-treated patients versus\nplacebo-treated patients, respectively. </p>", "ID": "d4c10c7a-f797-40f3-a782-206545cf70a1", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "Estimates of IDFS rates in the lymph node- positive subgroup were 92.0% versus 90.2% at 3\u00a0years and 89.9% vs. 86.7% at 4 years in Perjeta-treated patients versus placebo-treated patients, respectively. In the lymph node- negative subgroup, estimates of IDFS rates were 97.5% versus 98.4% at 3\u00a0years and 96.2% versus 96.7% at 4 years in Perjeta-treated patients versus placebo-treated patients, respectively. In the hormone receptor-negative subgroup, estimates of IDFS rates were 92.8% versus 91.2% at 3 years and 91.0% versus 88.7% at 4 years in Perjeta-treated patients versus placebo-treated patients, respectively. In the hormone receptor-positive subgroup estimates of IDFS rates were 94.8% versus 94.4% at 3 years and 93.0% versus 91.6% at 4 years in Perjeta-treated patients versus placebo-treated patients, respectively. ", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><u><span style=\"text-decoration:\n none\">\u00a0</span></u></b></p>", "ID": "86fc53b7-4a63-4686-a9fd-5adc6ca477ca", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><u><span style=\"text-decoration:\n none\">\u00a0</span></u></b>", "ID": "7ef94d1c-18e5-404a-92a6-baaf18e8af45", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "86fc53b7-4a63-4686-a9fd-5adc6ca477ca"}, {"Element": "<u><span style=\"text-decoration:\n none\">\u00a0</span></u>", "ID": "4981049c-e99f-4fe9-935a-7b7d24e27704", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "7ef94d1c-18e5-404a-92a6-baaf18e8af45"}, {"Element": "<span style=\"text-decoration:\n none\">\u00a0</span>", "ID": "5108da64-2398-41ac-9c14-c40f3a46fd12", "Styles": "text-decoration:\n none", "Classes": "None", "Text": "\u00a0", "ParentId": "4981049c-e99f-4fe9-935a-7b7d24e27704"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Patient\nReported Outcomes (PRO)</span></u></p>", "ID": "9372b5f8-d0a2-4c31-84c0-4a7ff416192b", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<u><span lang=\"EN-GB\">Patient\nReported Outcomes (PRO)</span></u>", "ID": "5300568c-86e7-40f0-9e0b-c45da6bdd4c1", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "9372b5f8-d0a2-4c31-84c0-4a7ff416192b"}, {"Element": "<span lang=\"EN-GB\">Patient\nReported Outcomes (PRO)</span>", "ID": "6bca7360-0996-4bcf-880e-768c1f810975", "Styles": "None", "Classes": "None", "Text": "Patient Reported Outcomes (PRO)", "ParentId": "5300568c-86e7-40f0-9e0b-c45da6bdd4c1"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>", "ID": "9ccab5bd-900b-441d-8623-a2df66feceee", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u>", "ID": "624f909a-11ac-4c13-9052-ce6afe879131", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "9ccab5bd-900b-441d-8623-a2df66feceee"}, {"Element": "<span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span>", "ID": "119db2de-cc7c-4c23-918b-f6788ff6d8f7", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "624f909a-11ac-4c13-9052-ce6afe879131"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "c2602ab2-67de-46cc-9a2c-4e868fde63ad", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "119db2de-cc7c-4c23-918b-f6788ff6d8f7"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Secondary\nendpoints included the assessment of patient-reported global health status,\nrole and physical function, and treatment symptoms using the EORTC QLQ-C30 and\nEORTC QLQ-BR23 questionnaires. In the analyses of patient-reported outcomes, a\n10-point difference was considered clinically meaningful. </span></p>", "ID": "ff1bae8c-d2c2-486c-add8-6796d3e55c43", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Secondary\nendpoints included the assessment of patient-reported global health status,\nrole and physical function, and treatment symptoms using the EORTC QLQ-C30 and\nEORTC QLQ-BR23 questionnaires. In the analyses of patient-reported outcomes, a\n10-point difference was considered clinically meaningful. </span>", "ID": "1e56e5f3-4796-4af1-a411-ef0a17246a1d", "Styles": "None", "Classes": "None", "Text": "Secondary endpoints included the assessment of patient-reported global health status, role and physical function, and treatment symptoms using the EORTC QLQ-C30 and EORTC QLQ-BR23 questionnaires. In the analyses of patient-reported outcomes, a 10-point difference was considered clinically meaningful. ", "ParentId": "ff1bae8c-d2c2-486c-add8-6796d3e55c43"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "de49be28-5333-45d6-b0ea-172eef85cd99", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "af855558-31c9-4b17-ad4a-6e0085cb9923", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "de49be28-5333-45d6-b0ea-172eef85cd99"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Patients\u2019\nphysical function, global health status and diarrhoea scores showed a\nclinically meaningful change during chemotherapy in both treatment arms. The\nmean decrease from baseline at that time for physical function was -10.7 (95%\nCI-11.4, -10.0) in the Perjeta arm and -10.6 (95% CI -11.4, -9.9) in the\nplacebo arm; global health status was -11.2 (95% CI -12.2, -10.2) in the\nPerjeta arm and -10.2 (95% CI -11.1,-9.2) in the placebo arm. Change in\ndiarrhoea symptoms increased to +22.3 (95% CI 21.0, 23.6) in the Perjeta arm\nversus +9.2 (95% CI 8.2, 10.2) in the placebo arm. </span></p>", "ID": "31bde9c7-7052-4fa4-aa30-6a52319b822d", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Patients\u2019\nphysical function, global health status and diarrhoea scores showed a\nclinically meaningful change during chemotherapy in both treatment arms. The\nmean decrease from baseline at that time for physical function was -10.7 (95%\nCI-11.4, -10.0) in the Perjeta arm and -10.6 (95% CI -11.4, -9.9) in the\nplacebo arm; global health status was -11.2 (95% CI -12.2, -10.2) in the\nPerjeta arm and -10.2 (95% CI -11.1,-9.2) in the placebo arm. Change in\ndiarrhoea symptoms increased to +22.3 (95% CI 21.0, 23.6) in the Perjeta arm\nversus +9.2 (95% CI 8.2, 10.2) in the placebo arm. </span>", "ID": "61e9481a-1c63-46bd-92e2-107eee479d34", "Styles": "None", "Classes": "None", "Text": "Patients\u2019 physical function, global health status and diarrhoea scores showed a clinically meaningful change during chemotherapy in both treatment arms. The mean decrease from baseline at that time for physical function was -10.7 (95% CI-11.4, -10.0) in the Perjeta arm and -10.6 (95% CI -11.4, -9.9) in the placebo arm; global health status was -11.2 (95% CI -12.2, -10.2) in the Perjeta arm and -10.2 (95% CI -11.1,-9.2) in the placebo arm. Change in diarrhoea symptoms increased to +22.3 (95% CI 21.0, 23.6) in the Perjeta arm versus +9.2 (95% CI 8.2, 10.2) in the placebo arm. ", "ParentId": "31bde9c7-7052-4fa4-aa30-6a52319b822d"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4dc38497-73c3-4f84-9d6b-dac384c197b4", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2b02792c-0358-4562-b3c5-7f44cc606add", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4dc38497-73c3-4f84-9d6b-dac384c197b4"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Thereafter\nin both arms physical function and global health status scores returned to\nbaseline levels during targeted treatment. Diarrhoea symptoms returned to\nbaseline after HER2 therapy in the Perjeta-arm. The addition of Perjeta to\ntrastuzumab plus chemotherapy did not affect patients\u2019 overall role function\nover the course of the study. </span></p>", "ID": "3342c2cd-cfec-4f9b-b996-7242cc1c0d35", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Thereafter\nin both arms physical function and global health status scores returned to\nbaseline levels during targeted treatment. Diarrhoea symptoms returned to\nbaseline after HER2 therapy in the Perjeta-arm. The addition of Perjeta to\ntrastuzumab plus chemotherapy did not affect patients\u2019 overall role function\nover the course of the study. </span>", "ID": "32c40bed-a5b4-49f9-ad09-fea84cb22768", "Styles": "None", "Classes": "None", "Text": "Thereafter in both arms physical function and global health status scores returned to baseline levels during targeted treatment. Diarrhoea symptoms returned to baseline after HER2 therapy in the Perjeta-arm. The addition of Perjeta to trastuzumab plus chemotherapy did not affect patients\u2019 overall role function over the course of the study. ", "ParentId": "3342c2cd-cfec-4f9b-b996-7242cc1c0d35"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:9.0pt;text-indent:-9.0pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>", "ID": "3ac58142-54fb-44ca-9402-7c0fc6c16ca4", "Styles": "margin-left:9.0pt;text-indent:-9.0pt;text-autospace:\nnone", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span>", "ID": "4359dc24-ce0b-42ae-91ec-b3f8a07ed758", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "3ac58142-54fb-44ca-9402-7c0fc6c16ca4"}, {"Element": "<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Immunogenicity</span></u></p>", "ID": "598173b8-8383-4267-9ad6-05e302e8005d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<u><span lang=\"EN-GB\">Immunogenicity</span></u>", "ID": "3b2b7c45-2129-4e76-b782-0ff84d0fe3d4", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "598173b8-8383-4267-9ad6-05e302e8005d"}, {"Element": "<span lang=\"EN-GB\">Immunogenicity</span>", "ID": "089acad0-e905-46e3-b25e-4add17a4ec4d", "Styles": "None", "Classes": "None", "Text": "Immunogenicity", "ParentId": "3b2b7c45-2129-4e76-b782-0ff84d0fe3d4"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "1db4e16a-1f07-45aa-8dbd-4c874256b0f9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b5e7af56-293a-49f5-b475-e3817bca5115", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1db4e16a-1f07-45aa-8dbd-4c874256b0f9"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Patients in the pivotal trial CLEOPATRA\nwere tested at multiple time-points for </span><span lang=\"EN-GB\">anti-drug antibodies\n(ADA</span><span lang=\"EN-GB\">) to </span><span lang=\"EN-GB\">Perjeta. </span><span lang=\"EN-GB\">3.3% (13/389 patients) of Perjeta-treated patients and 6.7% (25/372\npatients) of placebo-treated patients tested positive for ADA. </span>In BERENICE,\n4.1% (16/392) of the patients treated with Perjeta tested positive for ADA.\u00a0 <span lang=\"EN-GB\">None of these patients experienced anaphylactic/hypersensitivity\nreactions that were clearly related to ADA.</span></p>", "ID": "835b2a32-5d15-4484-bf26-4befb0cb1a94", "Styles": "None", "Classes": "['MsoNormal']", "Text": "In BERENICE, 4.1% (16/392) of the patients treated with Perjeta tested positive for ADA.\u00a0 ", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Patients in the pivotal trial CLEOPATRA\nwere tested at multiple time-points for </span>", "ID": "8ae2ba8b-7553-46d3-854e-b2343555785f", "Styles": "None", "Classes": "None", "Text": "Patients in the pivotal trial CLEOPATRA were tested at multiple time-points for ", "ParentId": "835b2a32-5d15-4484-bf26-4befb0cb1a94"}, {"Element": "<span lang=\"EN-GB\">anti-drug antibodies\n(ADA</span>", "ID": "cd0a9f1f-bb06-4ecb-902e-b75fc4eb3122", "Styles": "None", "Classes": "None", "Text": "anti-drug antibodies (ADA", "ParentId": "835b2a32-5d15-4484-bf26-4befb0cb1a94"}, {"Element": "<span lang=\"EN-GB\">) to </span>", "ID": "c41591fb-a32d-49cb-b555-0cda8474cb13", "Styles": "None", "Classes": "None", "Text": ") to ", "ParentId": "835b2a32-5d15-4484-bf26-4befb0cb1a94"}, {"Element": "<span lang=\"EN-GB\">Perjeta. </span>", "ID": "2bea4d09-38cb-4e66-b386-f86228f143e3", "Styles": "None", "Classes": "None", "Text": "Perjeta. ", "ParentId": "835b2a32-5d15-4484-bf26-4befb0cb1a94"}, {"Element": "<span lang=\"EN-GB\">3.3% (13/389 patients) of Perjeta-treated patients and 6.7% (25/372\npatients) of placebo-treated patients tested positive for ADA. </span>", "ID": "3c5ffe72-731d-4501-9c46-ec91bce08ef4", "Styles": "None", "Classes": "None", "Text": "3.3% (13/389 patients) of Perjeta-treated patients and 6.7% (25/372 patients) of placebo-treated patients tested positive for ADA. ", "ParentId": "835b2a32-5d15-4484-bf26-4befb0cb1a94"}, {"Element": "<span lang=\"EN-GB\">None of these patients experienced anaphylactic/hypersensitivity\nreactions that were clearly related to ADA.</span>", "ID": "a5c02e31-df36-46b0-9b5c-5a689f1107ad", "Styles": "None", "Classes": "None", "Text": "None of these patients experienced anaphylactic/hypersensitivity reactions that were clearly related to ADA.", "ParentId": "835b2a32-5d15-4484-bf26-4befb0cb1a94"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "fada6378-c6c9-42ff-b3c9-9faa7b0ee598", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0d73c731-8eef-4ee0-bdbf-3ce28f79ae8c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "fada6378-c6c9-42ff-b3c9-9faa7b0ee598"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Paediatric\npopulation</span></u></p>", "ID": "47587283-2eeb-45a9-b84f-9ab02a76ef42", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<u><span lang=\"EN-GB\">Paediatric\npopulation</span></u>", "ID": "233215ef-13a4-4d94-aaa5-dddedf9dddd6", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "47587283-2eeb-45a9-b84f-9ab02a76ef42"}, {"Element": "<span lang=\"EN-GB\">Paediatric\npopulation</span>", "ID": "78a2f3a1-5e15-47f9-b74c-4fa83580fec6", "Styles": "None", "Classes": "None", "Text": "Paediatric population", "ParentId": "233215ef-13a4-4d94-aaa5-dddedf9dddd6"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "485e18dc-62ea-4d8f-99f4-dad8e160473d", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "fb54764c-6221-4d52-884c-bbf085b6e094", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "485e18dc-62ea-4d8f-99f4-dad8e160473d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The European Medicines Agency has waived\nthe obligation to submit the results of studies with </span><span lang=\"EN-GB\">Perjeta\n</span><span lang=\"EN-GB\">in all subsets of the paediatric population in </span><span lang=\"EN-GB\">breast cancer</span><span lang=\"EN-GB\"> (see section 4.2 for\ninformation on paediatric use).</span></p>", "ID": "b585a752-04da-44c5-a55d-45700bc17f5e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">The European Medicines Agency has waived\nthe obligation to submit the results of studies with </span>", "ID": "a27bb53e-8749-44d1-9754-59aede0daa43", "Styles": "None", "Classes": "None", "Text": "The European Medicines Agency has waived the obligation to submit the results of studies with ", "ParentId": "b585a752-04da-44c5-a55d-45700bc17f5e"}, {"Element": "<span lang=\"EN-GB\">Perjeta\n</span>", "ID": "2591019e-b8ed-4a27-ada8-fc8ab2e180ff", "Styles": "None", "Classes": "None", "Text": "Perjeta ", "ParentId": "b585a752-04da-44c5-a55d-45700bc17f5e"}, {"Element": "<span lang=\"EN-GB\">in all subsets of the paediatric population in </span>", "ID": "1b0d5e26-0560-4aba-988c-4d99c546017d", "Styles": "None", "Classes": "None", "Text": "in all subsets of the paediatric population in ", "ParentId": "b585a752-04da-44c5-a55d-45700bc17f5e"}, {"Element": "<span lang=\"EN-GB\">breast cancer</span>", "ID": "e6f26238-05d5-4059-b8ab-497ff516cea8", "Styles": "None", "Classes": "None", "Text": "breast cancer", "ParentId": "b585a752-04da-44c5-a55d-45700bc17f5e"}, {"Element": "<span lang=\"EN-GB\"> (see section 4.2 for\ninformation on paediatric use).</span>", "ID": "00cad098-12d4-423f-821a-b31a161b53dc", "Styles": "None", "Classes": "None", "Text": " (see section 4.2 for information on paediatric use).", "ParentId": "b585a752-04da-44c5-a55d-45700bc17f5e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e28e610c-7b8f-43b8-931d-492460ae0727", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6f5bac6f-1c14-469d-b63c-c087e8d6783f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e28e610c-7b8f-43b8-931d-492460ae0727"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">5.2\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Pharmacokinetic properties</span></b></p>", "ID": "cb80e479-1176-4bda-86fb-11c4281a3ad7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">5.2\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Pharmacokinetic properties</span></b>", "ID": "60f129ad-292e-49e0-8796-f4734daaed87", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "cb80e479-1176-4bda-86fb-11c4281a3ad7"}, {"Element": "<span lang=\"EN-GB\">5.2\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Pharmacokinetic properties</span>", "ID": "b62e3146-739e-4df8-8855-fa49426adf0a", "Styles": "None", "Classes": "None", "Text": "5.2\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Pharmacokinetic properties", "ParentId": "60f129ad-292e-49e0-8796-f4734daaed87"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "a49d79f5-416d-41d6-8fbb-03a407c93dec", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "a47c9f5c-4cb1-4055-a86a-1d44eef6166e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a49d79f5-416d-41d6-8fbb-03a407c93dec"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "30c90245-6b73-46b4-9a9b-ee0256379836", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a47c9f5c-4cb1-4055-a86a-1d44eef6166e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">A population pharmacokinetic analysis was\nperformed with data from 481 patients across different clinical trials (phase\nI, II and III) with various types of advanced malignancies who had received Perjeta\nas a single agent or in combination at pertuzumab doses ranging from 2 to 25\u00a0mg/kg\nadministered every 3 weeks as a 30-60 minutes intravenous infusion.</span></p>", "ID": "a6cd7d06-5918-40b8-813b-01e8d15d557c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">A population pharmacokinetic analysis was\nperformed with data from 481 patients across different clinical trials (phase\nI, II and III) with various types of advanced malignancies who had received Perjeta\nas a single agent or in combination at pertuzumab doses ranging from 2 to 25\u00a0mg/kg\nadministered every 3 weeks as a 30-60 minutes intravenous infusion.</span>", "ID": "0ec194bd-7efc-42cb-9348-d524bf004ce9", "Styles": "None", "Classes": "None", "Text": "A population pharmacokinetic analysis was performed with data from 481 patients across different clinical trials (phase I, II and III) with various types of advanced malignancies who had received Perjeta as a single agent or in combination at pertuzumab doses ranging from 2 to 25\u00a0mg/kg administered every 3 weeks as a 30-60 minutes intravenous infusion.", "ParentId": "a6cd7d06-5918-40b8-813b-01e8d15d557c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "11f43deb-cfa9-4336-a450-9092e67234c9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "bb221b1b-32b3-4d7f-b7e7-8726fb00e7ba", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "11f43deb-cfa9-4336-a450-9092e67234c9"}, {"Element": "<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Absorption</span></u></p>", "ID": "0e28d7df-707a-43da-97d8-a764bf04d051", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<u><span lang=\"EN-GB\">Absorption</span></u>", "ID": "1d793ca6-0106-4e3c-af78-dc234779037b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "0e28d7df-707a-43da-97d8-a764bf04d051"}, {"Element": "<span lang=\"EN-GB\">Absorption</span>", "ID": "be0017ac-4728-4380-8a85-3deafdd362e0", "Styles": "None", "Classes": "None", "Text": "Absorption", "ParentId": "1d793ca6-0106-4e3c-af78-dc234779037b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a7947c6d-e692-4d74-90a7-76bfa36f681d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "915aaf50-e7ae-4f23-82d0-a054491ab1af", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a7947c6d-e692-4d74-90a7-76bfa36f681d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Perjeta is administered as an intravenous\ninfusion. </span></p>", "ID": "2a25275e-1408-46a4-956a-12a97f4d7645", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Perjeta is administered as an intravenous\ninfusion. </span>", "ID": "f400a1cc-e956-4804-b5ea-dd286f060d51", "Styles": "None", "Classes": "None", "Text": "Perjeta is administered as an intravenous infusion. ", "ParentId": "2a25275e-1408-46a4-956a-12a97f4d7645"}, {"Element": "<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">\u00a0</span></i></p>", "ID": "f9c4f405-b416-48ff-a531-63dbae5db34e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<i><span lang=\"EN-GB\">\u00a0</span></i>", "ID": "cba3e38e-dd5c-47bd-8886-ae09586c824b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f9c4f405-b416-48ff-a531-63dbae5db34e"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a94853b2-6aaf-45f0-811f-96cbc7b4075e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "cba3e38e-dd5c-47bd-8886-ae09586c824b"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Distribution</span></u></p>", "ID": "ac28b97f-542a-44eb-b0fa-ccce9e0f49ac", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<u><span lang=\"EN-GB\">Distribution</span></u>", "ID": "8aa834e3-cf6a-4928-87c1-643c9a623ffb", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ac28b97f-542a-44eb-b0fa-ccce9e0f49ac"}, {"Element": "<span lang=\"EN-GB\">Distribution</span>", "ID": "87fcbb66-0c20-42bb-9692-ed66e063e13d", "Styles": "None", "Classes": "None", "Text": "Distribution", "ParentId": "8aa834e3-cf6a-4928-87c1-643c9a623ffb"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "697feb89-1d04-46b2-804f-55419450a46c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "246296da-9400-44d8-97dc-c841d2143169", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "697feb89-1d04-46b2-804f-55419450a46c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Across all clinical studies, the volume of\ndistribution of the central (Vc) and the peripheral (Vp) compartment in the\ntypical patient, was 3.11\u00a0litres and 2.46\u00a0litres, respectively.</span></p>", "ID": "4010dec0-c2dd-4f37-97ea-31e9f6285bdc", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Across all clinical studies, the volume of\ndistribution of the central (Vc) and the peripheral (Vp) compartment in the\ntypical patient, was 3.11\u00a0litres and 2.46\u00a0litres, respectively.</span>", "ID": "1c89ecd6-49bf-480f-b3da-6528d9050eb8", "Styles": "None", "Classes": "None", "Text": "Across all clinical studies, the volume of distribution of the central (Vc) and the peripheral (Vp) compartment in the typical patient, was 3.11\u00a0litres and 2.46\u00a0litres, respectively.", "ParentId": "4010dec0-c2dd-4f37-97ea-31e9f6285bdc"}, {"Element": "<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">\u00a0</span></i></p>", "ID": "0f2e8019-24df-4d2d-96bb-f7db637d90ad", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<i><span lang=\"EN-GB\">\u00a0</span></i>", "ID": "51169b6e-3aa0-476d-b1f3-7f0699a7edd7", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "0f2e8019-24df-4d2d-96bb-f7db637d90ad"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e5f2554f-7102-4c7b-bf08-ba891479dfcb", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "51169b6e-3aa0-476d-b1f3-7f0699a7edd7"}, {"Element": "<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Biotransformation</span></u></p>", "ID": "ffcebca4-814d-4b3c-a5cb-86493f23327f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<u><span lang=\"EN-GB\">Biotransformation</span></u>", "ID": "557c96f3-6f46-4007-9362-071b3100e56e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ffcebca4-814d-4b3c-a5cb-86493f23327f"}, {"Element": "<span lang=\"EN-GB\">Biotransformation</span>", "ID": "a4bb3393-85a2-413e-b997-5f9982e45ea1", "Styles": "None", "Classes": "None", "Text": "Biotransformation", "ParentId": "557c96f3-6f46-4007-9362-071b3100e56e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d69fda4a-2123-41a7-bc2c-9d62615e25a6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e6915942-6d39-490a-804c-f2557e6d2f68", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d69fda4a-2123-41a7-bc2c-9d62615e25a6"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The metabolism of pertuzumab has not been directly\nstudied. Antibodies are cleared principally by catabolism.</span></p>", "ID": "fcef6017-b7d2-4ba6-9c1b-b1d1f8c262fb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">The metabolism of pertuzumab has not been directly\nstudied. Antibodies are cleared principally by catabolism.</span>", "ID": "60aa6f30-c07a-4c42-a0ff-0b93b54a7bcf", "Styles": "None", "Classes": "None", "Text": "The metabolism of pertuzumab has not been directly studied. Antibodies are cleared principally by catabolism.", "ParentId": "fcef6017-b7d2-4ba6-9c1b-b1d1f8c262fb"}, {"Element": "<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">\u00a0</span></i></p>", "ID": "6e8486fa-1efb-4b29-8eec-b91492133995", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<i><span lang=\"EN-GB\">\u00a0</span></i>", "ID": "41d490cd-6191-43f3-838e-435a3909c2d8", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "6e8486fa-1efb-4b29-8eec-b91492133995"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "72a3da7f-cad0-4721-95ff-aa7bebce0032", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "41d490cd-6191-43f3-838e-435a3909c2d8"}, {"Element": "<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Elimination</span></u></p>", "ID": "e7280c4e-73a1-484c-9dc8-7427ef460cd5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<u><span lang=\"EN-GB\">Elimination</span></u>", "ID": "307efed3-a036-440a-9c3b-4482ca7fbb0a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e7280c4e-73a1-484c-9dc8-7427ef460cd5"}, {"Element": "<span lang=\"EN-GB\">Elimination</span>", "ID": "95843845-86a2-4913-bbfa-8d76f1468ffa", "Styles": "None", "Classes": "None", "Text": "Elimination", "ParentId": "307efed3-a036-440a-9c3b-4482ca7fbb0a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c7d9ce3b-5ca6-40b5-a7be-2ad32ef5dfba", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c893d0d6-0f8a-40a8-8356-82c098554845", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c7d9ce3b-5ca6-40b5-a7be-2ad32ef5dfba"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The median clearance (CL) of pertuzumab was\n0.235\u00a0litres/day and the median half-life was 18 days.</span></p>", "ID": "448f36da-3cce-453e-824d-1abbed7cac33", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">The median clearance (CL) of pertuzumab was\n0.235\u00a0litres/day and the median half-life was 18 days.</span>", "ID": "f7f7fc09-fd28-4acd-add4-d8daebf1e204", "Styles": "None", "Classes": "None", "Text": "The median clearance (CL) of pertuzumab was 0.235\u00a0litres/day and the median half-life was 18 days.", "ParentId": "448f36da-3cce-453e-824d-1abbed7cac33"}, {"Element": "<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">\u00a0</span></i></p>", "ID": "85f29718-7dc6-446a-a114-ec394e96d425", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<i><span lang=\"EN-GB\">\u00a0</span></i>", "ID": "52647ba8-b0b5-490e-8681-c21caee6c31d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "85f29718-7dc6-446a-a114-ec394e96d425"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "359f3f87-69c9-475d-81f1-a600df8603da", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "52647ba8-b0b5-490e-8681-c21caee6c31d"}, {"Element": "<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Linearity/non-linearity</span></u></p>", "ID": "2ce7ac5c-18db-46a8-a1b3-d0f8fa29dd0d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<u><span lang=\"EN-GB\">Linearity/non-linearity</span></u>", "ID": "bae2320e-2256-4d48-ae8e-2e5af6f7c61b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "2ce7ac5c-18db-46a8-a1b3-d0f8fa29dd0d"}, {"Element": "<span lang=\"EN-GB\">Linearity/non-linearity</span>", "ID": "078ed530-598e-424c-a2bc-bfde5d40a0bc", "Styles": "None", "Classes": "None", "Text": "Linearity/non-linearity", "ParentId": "bae2320e-2256-4d48-ae8e-2e5af6f7c61b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ee449fc4-c2cc-4954-ad32-4e60a50d70be", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c5c36eb5-85ba-4e37-9c98-faaa6e682427", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ee449fc4-c2cc-4954-ad32-4e60a50d70be"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Pertuzumab displayed linear\npharmacokinetics within the recommended dose range.</span></p>", "ID": "f426b635-c1df-4e3f-945a-1c89a3bfa151", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Pertuzumab displayed linear\npharmacokinetics within the recommended dose range.</span>", "ID": "692038f9-d677-456e-861c-25de611de730", "Styles": "None", "Classes": "None", "Text": "Pertuzumab displayed linear pharmacokinetics within the recommended dose range.", "ParentId": "f426b635-c1df-4e3f-945a-1c89a3bfa151"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "92a3d1c4-6e10-4510-90b8-96eb0630e397", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9bc6f0f9-3006-4fc5-b88b-e4a5b9cb2ceb", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "92a3d1c4-6e10-4510-90b8-96eb0630e397"}, {"Element": "<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Elderly patients</span></u></p>", "ID": "a46e721c-856d-4169-85da-f1286bceadfb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<u><span lang=\"EN-GB\">Elderly patients</span></u>", "ID": "f6d6a3ca-f103-4ea6-b158-22450814908e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a46e721c-856d-4169-85da-f1286bceadfb"}, {"Element": "<span lang=\"EN-GB\">Elderly patients</span>", "ID": "c9fdfe1e-f162-440a-a6dc-3e0d41211198", "Styles": "None", "Classes": "None", "Text": "Elderly patients", "ParentId": "f6d6a3ca-f103-4ea6-b158-22450814908e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>", "ID": "7bb639b4-2cd7-4f63-aae3-4f6b7087b125", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">\u00a0</span>", "ID": "ee8de724-71e7-49d3-9bde-0588134cc09e", "Styles": "color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "7bb639b4-2cd7-4f63-aae3-4f6b7087b125"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Based on the population\npharmacokinetic analysis, no significant difference was observed in the\npharmacokinetics of pertuzumab between patients &lt;\u00a065 years (n=306) and\npatients \u2265\u00a065 years (n=175).</span></p>", "ID": "ee31f783-f01b-4361-867f-ec93825189c1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Based on the population\npharmacokinetic analysis, no significant difference was observed in the\npharmacokinetics of pertuzumab between patients &lt;\u00a065 years (n=306) and\npatients \u2265\u00a065 years (n=175).</span>", "ID": "f95bd3e5-851b-43f1-882a-03088921182f", "Styles": "color:black", "Classes": "None", "Text": "Based on the population pharmacokinetic analysis, no significant difference was observed in the pharmacokinetics of pertuzumab between patients <\u00a065 years (n=306) and patients \u2265\u00a065 years (n=175).", "ParentId": "ee31f783-f01b-4361-867f-ec93825189c1"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f662aeda-1975-48cc-bc05-919279a532a4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2ef51dbc-8337-472e-91ec-b1d51e0033d8", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f662aeda-1975-48cc-bc05-919279a532a4"}, {"Element": "<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Renal impairment </span></u></p>", "ID": "3d097158-1b00-4b99-b2ae-e45b65909e51", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<u><span lang=\"EN-GB\">Renal impairment </span></u>", "ID": "946d99a6-4e16-410a-a76b-3466557913a8", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3d097158-1b00-4b99-b2ae-e45b65909e51"}, {"Element": "<span lang=\"EN-GB\">Renal impairment </span>", "ID": "26325146-9c90-43ff-9a07-84229d792aa5", "Styles": "None", "Classes": "None", "Text": "Renal impairment ", "ParentId": "946d99a6-4e16-410a-a76b-3466557913a8"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "38c4fa57-1dd3-45db-875f-53a30f58056a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3d8aae5c-d2fe-47e3-a05c-8d98ba595263", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "38c4fa57-1dd3-45db-875f-53a30f58056a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">No dedicated renal impairment trial for Perjeta\nhas been conducted. Based on the results of the population pharmacokinetic\nanalysis, pertuzumab exposure in patients with mild (creatinine clearance\n[CLcr] 60 to 90\u00a0ml/min, N=200) and moderate renal impairment (CLcr 30 to\n60\u00a0ml/min, N=71) was similar to that in patients with normal renal\nfunction (CLcr greater than 90\u00a0ml/min, N=200). No relationship between\nCLcr and pertuzumab exposure was observed over the range of CLcr (27 to 244\u00a0ml/min).</span></p>", "ID": "cb31b39f-c180-49d0-aac0-a0a01c7a29a8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">No dedicated renal impairment trial for Perjeta\nhas been conducted. Based on the results of the population pharmacokinetic\nanalysis, pertuzumab exposure in patients with mild (creatinine clearance\n[CLcr] 60 to 90\u00a0ml/min, N=200) and moderate renal impairment (CLcr 30 to\n60\u00a0ml/min, N=71) was similar to that in patients with normal renal\nfunction (CLcr greater than 90\u00a0ml/min, N=200). No relationship between\nCLcr and pertuzumab exposure was observed over the range of CLcr (27 to 244\u00a0ml/min).</span>", "ID": "f1eba2de-bc7b-448c-bbc4-1cf0443dabef", "Styles": "None", "Classes": "None", "Text": "No dedicated renal impairment trial for Perjeta has been conducted. Based on the results of the population pharmacokinetic analysis, pertuzumab exposure in patients with mild (creatinine clearance [CLcr] 60 to 90\u00a0ml/min, N=200) and moderate renal impairment (CLcr 30 to 60\u00a0ml/min, N=71) was similar to that in patients with normal renal function (CLcr greater than 90\u00a0ml/min, N=200). No relationship between CLcr and pertuzumab exposure was observed over the range of CLcr (27 to 244\u00a0ml/min).", "ParentId": "cb31b39f-c180-49d0-aac0-a0a01c7a29a8"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ea9e8b78-d6c6-4d3f-b45b-b752a84c0763", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "951366ca-4529-457e-954d-c0f8388889c1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ea9e8b78-d6c6-4d3f-b45b-b752a84c0763"}, {"Element": "<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Other special populations</span></u></p>", "ID": "83bef39c-5f8e-4dcc-bf82-a2fa29f15a97", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<u><span lang=\"EN-GB\">Other special populations</span></u>", "ID": "82e6a925-4eaf-46ed-b74f-b084c3988d2d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "83bef39c-5f8e-4dcc-bf82-a2fa29f15a97"}, {"Element": "<span lang=\"EN-GB\">Other special populations</span>", "ID": "b2a75370-462a-4394-b01b-969d45270c15", "Styles": "None", "Classes": "None", "Text": "Other special populations", "ParentId": "82e6a925-4eaf-46ed-b74f-b084c3988d2d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "64d6aab6-9659-4c89-b2fc-3fde252e62df", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "27c4b160-699f-4f24-995a-5a2ed479da7a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "64d6aab6-9659-4c89-b2fc-3fde252e62df"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The population PK analysis suggested no PK\ndifferences based on age, gender and ethnicity (Japanese versus non-Japanese).\nBaseline albumin and lean body weight were the most significant covariates\ninfluencing CL. CL decreased in patients with higher baseline albumin\nconcentrations and increased in patients with greater lean body weight. However\nsensitivity analyses performed at the recommended dose and schedule of Perjeta\nshowed that at the extreme values of these two covariates, there was no\nsignificant impact on the ability to achieve target steady-state concentrations\nidentified in preclinical tumour xenograft models. Therefore, there is no need\nto adjust the dosage of pertuzumab based on these covariates.</span></p>", "ID": "3f7f1b10-e4c8-4eef-931c-fbea78069948", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">The population PK analysis suggested no PK\ndifferences based on age, gender and ethnicity (Japanese versus non-Japanese).\nBaseline albumin and lean body weight were the most significant covariates\ninfluencing CL. CL decreased in patients with higher baseline albumin\nconcentrations and increased in patients with greater lean body weight. However\nsensitivity analyses performed at the recommended dose and schedule of Perjeta\nshowed that at the extreme values of these two covariates, there was no\nsignificant impact on the ability to achieve target steady-state concentrations\nidentified in preclinical tumour xenograft models. Therefore, there is no need\nto adjust the dosage of pertuzumab based on these covariates.</span>", "ID": "56d8c5c2-2eab-44cf-94e3-6ced54db719a", "Styles": "None", "Classes": "None", "Text": "The population PK analysis suggested no PK differences based on age, gender and ethnicity (Japanese versus non-Japanese). Baseline albumin and lean body weight were the most significant covariates influencing CL. CL decreased in patients with higher baseline albumin concentrations and increased in patients with greater lean body weight. However sensitivity analyses performed at the recommended dose and schedule of Perjeta showed that at the extreme values of these two covariates, there was no significant impact on the ability to achieve target steady-state concentrations identified in preclinical tumour xenograft models. Therefore, there is no need to adjust the dosage of pertuzumab based on these covariates.", "ParentId": "3f7f1b10-e4c8-4eef-931c-fbea78069948"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e4d8ab86-0ac6-414f-bed1-036d41d4d8ac", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "91588b58-525c-4348-a535-ef735b69656f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e4d8ab86-0ac6-414f-bed1-036d41d4d8ac"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The PK results of pertuzumab in the\nNEOSPHERE and APHINITY studies were consistent with the predictions from the\nprevious population PK model. </span>No differences in pertuzumab PK were\nobserved in patients with early breast cancer compared to patients with\nmetastatic breast cancer.</p>", "ID": "a5f85e01-3f94-4f01-9bdc-aa0608e26cfe", "Styles": "None", "Classes": "['MsoNormal']", "Text": "No differences in pertuzumab PK were observed in patients with early breast cancer compared to patients with metastatic breast cancer.", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">The PK results of pertuzumab in the\nNEOSPHERE and APHINITY studies were consistent with the predictions from the\nprevious population PK model. </span>", "ID": "ea552a4e-605e-4cd6-bcbb-4b6d88fb71ce", "Styles": "None", "Classes": "None", "Text": "The PK results of pertuzumab in the NEOSPHERE and APHINITY studies were consistent with the predictions from the previous population PK model. ", "ParentId": "a5f85e01-3f94-4f01-9bdc-aa0608e26cfe"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ac0d1073-cc9e-4cc2-9885-6074a7d69326", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0b411ebf-f301-4462-b25c-29cc4f717bc3", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ac0d1073-cc9e-4cc2-9885-6074a7d69326"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><b><span lang=\"EN-GB\">5.3\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Preclinical safety data</span></b></p>", "ID": "efbd96ef-bad7-4d2d-8186-d86d3eeb148e", "Styles": "margin-left:.5in;text-indent:-.5in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">5.3\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Preclinical safety data</span></b>", "ID": "12c55714-ae2f-43e4-a7cf-94e87f2475d5", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "efbd96ef-bad7-4d2d-8186-d86d3eeb148e"}, {"Element": "<span lang=\"EN-GB\">5.3\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Preclinical safety data</span>", "ID": "3fb7c15f-f924-4766-b428-b147d4d5d2a5", "Styles": "None", "Classes": "None", "Text": "5.3\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Preclinical safety data", "ParentId": "12c55714-ae2f-43e4-a7cf-94e87f2475d5"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0436ee09-92fa-47f4-b295-e5c9f7d32611", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2a14aad6-fc9d-429d-92cf-8520be1f97bb", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0436ee09-92fa-47f4-b295-e5c9f7d32611"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">No specific fertility studies in animals\nhave been performed to evaluate the effect of pertuzumab. No definitive\nconclusion on adverse effects can be drawn on the male reproductive organs in\ncynomolgus monkey repeated dose toxicity study.</span></p>", "ID": "c87c796d-d197-4837-8c86-ecb5f608700e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">No specific fertility studies in animals\nhave been performed to evaluate the effect of pertuzumab. No definitive\nconclusion on adverse effects can be drawn on the male reproductive organs in\ncynomolgus monkey repeated dose toxicity study.</span>", "ID": "3ec016f4-2ca5-4ddf-9bbb-6be839680bf3", "Styles": "None", "Classes": "None", "Text": "No specific fertility studies in animals have been performed to evaluate the effect of pertuzumab. No definitive conclusion on adverse effects can be drawn on the male reproductive organs in cynomolgus monkey repeated dose toxicity study.", "ParentId": "c87c796d-d197-4837-8c86-ecb5f608700e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "1b8433b1-ee75-4218-9bcc-17b2ddac4c3d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7631d9f3-8f3f-4c6d-86fa-4ae14568d1c8", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1b8433b1-ee75-4218-9bcc-17b2ddac4c3d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Reproductive toxicology studies have been\nconducted in pregnant cynomolgus monkeys (Gestational Day (GD) 19 through to GD\n50) at initial doses of 30 to 150\u00a0mg/kg followed by bi\u2011weekly doses\nof 10\u00a0to\u00a0100\u00a0mg/kg. These dose levels resulted in clinically\nrelevant exposures of 2.5\u00a0to\u00a020-fold greater than the recommended\nhuman dose, based on C<sub>max</sub>. Intravenous administration of pertuzumab from\nGD19 through GD50 (period of organogenesis) was embryotoxic, with\ndose-dependent increases in embryo-foetal death between GD25\u00a0to\u00a0GD70.\nThe incidences of embryo-foetal loss were 33, 50, and 85% for pregnant female\nmonkeys treated with bi\u2011weekly pertuzumab doses of 10, 30, and\n100\u00a0mg/kg, respectively (2.5\u00a0to\u00a020-fold greater than the\nrecommended human dose, based on C<sub>max</sub>). At Caesarean section on\nGD100, oligohydramnios, decreased relative lung and kidney weights and\nmicroscopic evidence of renal hypoplasia consistent with delayed renal\ndevelopment were identified in all pertuzumab dose groups. In addition,\nconsistent with foetal growth restrictions, secondary to oligohydramnios, lung\nhypoplasia (1 of 6 in 30\u00a0mg/kg and 1 of 2 in100\u00a0mg/kg groups),\nventricular septal defects (1 of 6 in 30\u00a0mg/kg group), thin ventricular\nwall (1 of 2 in 100\u00a0mg/kg group) and minor skeletal defects (external - 3\nof 6 in 30\u00a0mg/kg group) were also noted.\u00a0 Pertuzumab exposure was reported\nin offspring from all treated groups, at levels of 29% to 40% of maternal serum\nlevels at GD100. </span></p>", "ID": "44034418-1d4f-46a9-a4e9-3f422b4b95ce", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Reproductive toxicology studies have been\nconducted in pregnant cynomolgus monkeys (Gestational Day (GD) 19 through to GD\n50) at initial doses of 30 to 150\u00a0mg/kg followed by bi\u2011weekly doses\nof 10\u00a0to\u00a0100\u00a0mg/kg. These dose levels resulted in clinically\nrelevant exposures of 2.5\u00a0to\u00a020-fold greater than the recommended\nhuman dose, based on C<sub>max</sub>. Intravenous administration of pertuzumab from\nGD19 through GD50 (period of organogenesis) was embryotoxic, with\ndose-dependent increases in embryo-foetal death between GD25\u00a0to\u00a0GD70.\nThe incidences of embryo-foetal loss were 33, 50, and 85% for pregnant female\nmonkeys treated with bi\u2011weekly pertuzumab doses of 10, 30, and\n100\u00a0mg/kg, respectively (2.5\u00a0to\u00a020-fold greater than the\nrecommended human dose, based on C<sub>max</sub>). At Caesarean section on\nGD100, oligohydramnios, decreased relative lung and kidney weights and\nmicroscopic evidence of renal hypoplasia consistent with delayed renal\ndevelopment were identified in all pertuzumab dose groups. In addition,\nconsistent with foetal growth restrictions, secondary to oligohydramnios, lung\nhypoplasia (1 of 6 in 30\u00a0mg/kg and 1 of 2 in100\u00a0mg/kg groups),\nventricular septal defects (1 of 6 in 30\u00a0mg/kg group), thin ventricular\nwall (1 of 2 in 100\u00a0mg/kg group) and minor skeletal defects (external - 3\nof 6 in 30\u00a0mg/kg group) were also noted.\u00a0 Pertuzumab exposure was reported\nin offspring from all treated groups, at levels of 29% to 40% of maternal serum\nlevels at GD100. </span>", "ID": "fb89c501-a124-4ec3-b895-9ad037d606db", "Styles": "None", "Classes": "None", "Text": "Reproductive toxicology studies have been conducted in pregnant cynomolgus monkeys (Gestational Day (GD) 19 through to GD 50) at initial doses of 30 to 150\u00a0mg/kg followed by bi\u2011weekly doses of 10\u00a0to\u00a0100\u00a0mg/kg. These dose levels resulted in clinically relevant exposures of 2.5\u00a0to\u00a020-fold greater than the recommended human dose, based on C. Intravenous administration of pertuzumab from GD19 through GD50 (period of organogenesis) was embryotoxic, with dose-dependent increases in embryo-foetal death between GD25\u00a0to\u00a0GD70. The incidences of embryo-foetal loss were 33, 50, and 85% for pregnant female monkeys treated with bi\u2011weekly pertuzumab doses of 10, 30, and 100\u00a0mg/kg, respectively (2.5\u00a0to\u00a020-fold greater than the recommended human dose, based on C). At Caesarean section on GD100, oligohydramnios, decreased relative lung and kidney weights and microscopic evidence of renal hypoplasia consistent with delayed renal development were identified in all pertuzumab dose groups. In addition, consistent with foetal growth restrictions, secondary to oligohydramnios, lung hypoplasia (1 of 6 in 30\u00a0mg/kg and 1 of 2 in100\u00a0mg/kg groups), ventricular septal defects (1 of 6 in 30\u00a0mg/kg group), thin ventricular wall (1 of 2 in 100\u00a0mg/kg group) and minor skeletal defects (external - 3 of 6 in 30\u00a0mg/kg group) were also noted.\u00a0 Pertuzumab exposure was reported in offspring from all treated groups, at levels of 29% to 40% of maternal serum levels at GD100. ", "ParentId": "44034418-1d4f-46a9-a4e9-3f422b4b95ce"}, {"Element": "<sub>max</sub>", "ID": "c8008136-d7fd-49e7-8319-9f5088507846", "Styles": "None", "Classes": "None", "Text": "max", "ParentId": "fb89c501-a124-4ec3-b895-9ad037d606db"}, {"Element": "<sub>max</sub>", "ID": "18c48ecd-f3c6-4261-8a0d-18749febdce6", "Styles": "None", "Classes": "None", "Text": "max", "ParentId": "fb89c501-a124-4ec3-b895-9ad037d606db"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2a9fa83e-f3e7-4dd6-a61c-1b308cac21b4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b76b2ecc-90e7-45b4-b644-d9ebcd68c22d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2a9fa83e-f3e7-4dd6-a61c-1b308cac21b4"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In cynomolgus monkeys, weekly intravenous\nadministration of </span><span lang=\"EN-GB\">pertuzumab </span><span lang=\"EN-GB\">at\ndoses up to 150\u00a0mg/kg/dose was generally well tolerated. With doses of\n15\u00a0mg/kg and higher, intermittent mild treatment-associated diarrhoea was\nnoted. In a subset of monkeys, chronic dosing (7 to 26 weekly doses) resulted in\nepisodes of severe secretory diarrhoea. The diarrhoea was managed (with the\nexception of euthanasia of one animal, 50\u00a0mg/kg/dose) with supportive care\nincluding intravenous fluid replacement therapy.</span></p>", "ID": "52ca2ef8-9ef8-4511-905d-e7a025ded030", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">In cynomolgus monkeys, weekly intravenous\nadministration of </span>", "ID": "a777af4e-ba3c-4409-84e3-8d64ff11d757", "Styles": "None", "Classes": "None", "Text": "In cynomolgus monkeys, weekly intravenous administration of ", "ParentId": "52ca2ef8-9ef8-4511-905d-e7a025ded030"}, {"Element": "<span lang=\"EN-GB\">pertuzumab </span>", "ID": "946a2066-9ad3-43b5-bb3c-d5bf1b044278", "Styles": "None", "Classes": "None", "Text": "pertuzumab ", "ParentId": "52ca2ef8-9ef8-4511-905d-e7a025ded030"}, {"Element": "<span lang=\"EN-GB\">at\ndoses up to 150\u00a0mg/kg/dose was generally well tolerated. With doses of\n15\u00a0mg/kg and higher, intermittent mild treatment-associated diarrhoea was\nnoted. In a subset of monkeys, chronic dosing (7 to 26 weekly doses) resulted in\nepisodes of severe secretory diarrhoea. The diarrhoea was managed (with the\nexception of euthanasia of one animal, 50\u00a0mg/kg/dose) with supportive care\nincluding intravenous fluid replacement therapy.</span>", "ID": "2e1d50ad-b623-495b-9bce-6d804a1cf98e", "Styles": "None", "Classes": "None", "Text": "at doses up to 150\u00a0mg/kg/dose was generally well tolerated. With doses of 15\u00a0mg/kg and higher, intermittent mild treatment-associated diarrhoea was noted. In a subset of monkeys, chronic dosing (7 to 26 weekly doses) resulted in episodes of severe secretory diarrhoea. The diarrhoea was managed (with the exception of euthanasia of one animal, 50\u00a0mg/kg/dose) with supportive care including intravenous fluid replacement therapy.", "ParentId": "52ca2ef8-9ef8-4511-905d-e7a025ded030"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "eb3f9fde-fadd-4ce4-9bde-1e0f28ea5219", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "57fe75ba-5508-47ed-b7da-455587d82296", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "eb3f9fde-fadd-4ce4-9bde-1e0f28ea5219"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "05c828ae-d594-49cf-9098-0c812c02b3b8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "68861fb7-f56e-4a1b-ac84-732bc3c70540", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "05c828ae-d594-49cf-9098-0c812c02b3b8"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "86b612f0-971a-4f48-b995-43b7b98d91c6", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "68861fb7-f56e-4a1b-ac84-732bc3c70540"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL PARTICULARS</span></b></p>", "ID": "b5e51d4f-39ac-4c8c-b2d5-124692235d62", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL PARTICULARS</span></b>", "ID": "70e81501-14f1-48ba-8859-9c66ef716586", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b5e51d4f-39ac-4c8c-b2d5-124692235d62"}, {"Element": "<span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL PARTICULARS</span>", "ID": "011e1cfc-f110-4399-9043-c11444cd1cd6", "Styles": "None", "Classes": "None", "Text": "6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL PARTICULARS", "ParentId": "70e81501-14f1-48ba-8859-9c66ef716586"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "25c36e23-5949-472a-83ca-c7671823ed4f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "49d80f95-2377-4193-bdb5-fda1c74c24e0", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "25c36e23-5949-472a-83ca-c7671823ed4f"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">6.1\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 List of excipients</span></b></p>", "ID": "0092b348-4d0e-4348-88c3-1822ab98d2fd", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">6.1\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 List of excipients</span></b>", "ID": "4daf30b4-6fab-41da-a9d6-ad0c70f52c41", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "0092b348-4d0e-4348-88c3-1822ab98d2fd"}, {"Element": "<span lang=\"EN-GB\">6.1\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 List of excipients</span>", "ID": "ec4f7201-a8d6-45c1-a3f5-edd4b5cabd0d", "Styles": "None", "Classes": "None", "Text": "6.1\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 List of excipients", "ParentId": "4daf30b4-6fab-41da-a9d6-ad0c70f52c41"}, {"Element": "<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">\u00a0</span></i></p>", "ID": "ef46aefd-faab-4502-bef0-30e2571d9f72", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<i><span lang=\"EN-GB\">\u00a0</span></i>", "ID": "2c020ab9-2633-4eee-ac59-3291d4430fd2", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ef46aefd-faab-4502-bef0-30e2571d9f72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "39d7ad6e-b3fe-4ce8-974a-47198e020641", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2c020ab9-2633-4eee-ac59-3291d4430fd2"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Glacial acetic acid</span></p>", "ID": "474aeb38-8f35-42eb-b21e-a63fccda159e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Glacial acetic acid</span>", "ID": "9919582e-e367-4244-ac68-249c5ba208db", "Styles": "None", "Classes": "None", "Text": "Glacial acetic acid", "ParentId": "474aeb38-8f35-42eb-b21e-a63fccda159e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">L-Histidine</span></p>", "ID": "69731dcb-9f8b-41ca-ad5f-a69ddbc88975", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">L-Histidine</span>", "ID": "63d0ef2d-5d6f-4c28-9d18-ad2439de3a39", "Styles": "None", "Classes": "None", "Text": "L-Histidine", "ParentId": "69731dcb-9f8b-41ca-ad5f-a69ddbc88975"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Sucrose</span></p>", "ID": "4b523b83-ef4f-4817-9e65-1f56edbbc4b1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Sucrose</span>", "ID": "12cae73d-cdf0-4cac-bfa7-3fb4c5cdbb41", "Styles": "None", "Classes": "None", "Text": "Sucrose", "ParentId": "4b523b83-ef4f-4817-9e65-1f56edbbc4b1"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Polysorbate 20</span></p>", "ID": "cc14b36b-6a95-41e6-8645-ea35fc99681c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Polysorbate 20</span>", "ID": "fcf792ce-d235-49cb-8417-c695d288a96b", "Styles": "None", "Classes": "None", "Text": "Polysorbate 20", "ParentId": "cc14b36b-6a95-41e6-8645-ea35fc99681c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Water for injections</span></p>", "ID": "204954ba-3c00-461e-815d-3192bfe97700", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Water for injections</span>", "ID": "29691da7-2bac-4de1-a547-af862d4a308f", "Styles": "None", "Classes": "None", "Text": "Water for injections", "ParentId": "204954ba-3c00-461e-815d-3192bfe97700"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0ac2f5aa-0410-433c-8b23-357dac845f96", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "526c2b0d-7d78-4ce7-b2bc-de3039c378eb", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0ac2f5aa-0410-433c-8b23-357dac845f96"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">6.2\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Incompatibilities</span></b></p>", "ID": "2025013a-bd88-44e9-a8c1-4113f5877c3d", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">6.2\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Incompatibilities</span></b>", "ID": "39539bce-fad1-49d2-a8ea-9e30eee94aed", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "2025013a-bd88-44e9-a8c1-4113f5877c3d"}, {"Element": "<span lang=\"EN-GB\">6.2\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Incompatibilities</span>", "ID": "aa31f4d3-1f72-4c6e-ac1f-fc492e35377b", "Styles": "None", "Classes": "None", "Text": "6.2\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Incompatibilities", "ParentId": "39539bce-fad1-49d2-a8ea-9e30eee94aed"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "df4b643d-1644-4fcc-98a5-3e7c2378c411", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2dde0918-fd38-4caf-a006-04b5d9cf0bc7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "df4b643d-1644-4fcc-98a5-3e7c2378c411"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Glucose (5%)\nsolution should not be used to dilute Perjeta since it is chemically and\nphysically unstable in such solutions.</span></p>", "ID": "f9ed5be0-dc1d-4004-ac83-2782ac87bfb0", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Glucose (5%)\nsolution should not be used to dilute Perjeta since it is chemically and\nphysically unstable in such solutions.</span>", "ID": "e30c4d37-20a6-4ce5-865a-e293310efee1", "Styles": "None", "Classes": "None", "Text": "Glucose (5%) solution should not be used to dilute Perjeta since it is chemically and physically unstable in such solutions.", "ParentId": "f9ed5be0-dc1d-4004-ac83-2782ac87bfb0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "fece646e-3485-4994-b315-908655f73ffd", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e0c37ce2-52a6-4bb2-b64b-2142237be562", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "fece646e-3485-4994-b315-908655f73ffd"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">This medicinal product must not be mixed\nwith other medicinal products except those mentioned in section 6.6.</span></p>", "ID": "5f0a160c-3604-48ba-bcdd-3ed2cc296e12", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">This medicinal product must not be mixed\nwith other medicinal products except those mentioned in section 6.6.</span>", "ID": "6c6b884b-2978-453b-ac59-0079e6af9da9", "Styles": "None", "Classes": "None", "Text": "This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.", "ParentId": "5f0a160c-3604-48ba-bcdd-3ed2cc296e12"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ae42283c-4131-4764-8aa2-89a92445285b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "682a8308-fa8e-473a-83cd-075615f3fd9c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ae42283c-4131-4764-8aa2-89a92445285b"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">6.3\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Shelf life</span></b></p>", "ID": "cd8def59-4275-4bb3-97f3-665133699825", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">6.3\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Shelf life</span></b>", "ID": "cae09882-3413-4698-bf19-e130d6f5034f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "cd8def59-4275-4bb3-97f3-665133699825"}, {"Element": "<span lang=\"EN-GB\">6.3\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Shelf life</span>", "ID": "aa65bb37-361c-47a2-9cc4-546c7ac52f6d", "Styles": "None", "Classes": "None", "Text": "6.3\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Shelf life", "ParentId": "cae09882-3413-4698-bf19-e130d6f5034f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "854a2045-c7e0-427f-8461-d244fdf004bc", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "26b04df5-6f6f-4cb2-91f7-3065431aa688", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "854a2045-c7e0-427f-8461-d244fdf004bc"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><u><span lang=\"EN-GB\" style=\"color:black\">Unopened vial</span></u><span lang=\"EN-GB\" style=\"color:black\">\n</span></p>", "ID": "26a99c96-3404-4202-ac59-32aeefc01de6", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<u><span lang=\"EN-GB\" style=\"color:black\">Unopened vial</span></u>", "ID": "c97b9015-c74c-4ae1-8fd0-db7e2f1ad68a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "26a99c96-3404-4202-ac59-32aeefc01de6"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Unopened vial</span>", "ID": "d24a4a70-9fd1-4b09-ba2b-53e1917e96f9", "Styles": "color:black", "Classes": "None", "Text": "Unopened vial", "ParentId": "c97b9015-c74c-4ae1-8fd0-db7e2f1ad68a"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">\n</span>", "ID": "772682bf-5465-4944-a073-2031edbe54ed", "Styles": "color:black", "Classes": "None", "Text": " ", "ParentId": "26a99c96-3404-4202-ac59-32aeefc01de6"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>", "ID": "42262969-48e5-4538-9738-6d81d8ef4f47", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">\u00a0</span>", "ID": "905291e0-9ff9-4eef-ab11-5815888258ac", "Styles": "color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "42262969-48e5-4538-9738-6d81d8ef4f47"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">2 years</span><span lang=\"EN-GB\" style=\"color:black\">. </span></p>", "ID": "d8445abd-2b13-484f-9125-a06b8bf3b08e", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">2 years</span>", "ID": "e5ae1a2e-ccdf-4c20-8cda-1992157587c0", "Styles": "color:black", "Classes": "None", "Text": "2 years", "ParentId": "d8445abd-2b13-484f-9125-a06b8bf3b08e"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">. </span>", "ID": "f0743494-64f2-44b8-90ab-f25cc4ffe756", "Styles": "color:black", "Classes": "None", "Text": ". ", "ParentId": "d8445abd-2b13-484f-9125-a06b8bf3b08e"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>", "ID": "7a63d171-c429-41f3-a58d-b597c1b2eed1", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">\u00a0</span>", "ID": "2c5bb685-a00e-4fc4-a59e-81ce9816f8b2", "Styles": "color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "7a63d171-c429-41f3-a58d-b597c1b2eed1"}, {"Element": "<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Diluted solution</span></u></p>", "ID": "7c16338b-020a-4d8b-8592-e6ff27ad62f6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<u><span lang=\"EN-GB\">Diluted solution</span></u>", "ID": "2ec8e3c5-6b09-4229-a194-cb4d147edd8e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "7c16338b-020a-4d8b-8592-e6ff27ad62f6"}, {"Element": "<span lang=\"EN-GB\">Diluted solution</span>", "ID": "4055a9e1-0c41-4c48-ad1d-68b0fc0b3b6e", "Styles": "None", "Classes": "None", "Text": "Diluted solution", "ParentId": "2ec8e3c5-6b09-4229-a194-cb4d147edd8e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "851caaca-7e8e-414c-8ceb-3e639df39a84", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d4b9ac19-a391-4f74-bdd7-d4a5eb7ace0c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "851caaca-7e8e-414c-8ceb-3e639df39a84"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Chemical and physical in-use stability has\nbeen demonstrated for 24 hours at 30\u00b0C. </span></p>", "ID": "09b8c188-28fc-4a02-938d-02d3689a01ec", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Chemical and physical in-use stability has\nbeen demonstrated for 24 hours at 30\u00b0C. </span>", "ID": "445e5667-7425-4116-8073-cde2ea97472f", "Styles": "None", "Classes": "None", "Text": "Chemical and physical in-use stability has been demonstrated for 24 hours at 30\u00b0C. ", "ParentId": "09b8c188-28fc-4a02-938d-02d3689a01ec"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">From a microbiological point of view, the\nproduct should be used immediately. If not used immediately, in-use storage\ntimes and conditions prior to use are the responsibility of the user and would\nnormally not be longer than 24 hours at 2\u00b0C to 8\u00b0C, unless dilution has taken\nplace in controlled and validated aseptic conditions.</span><span lang=\"EN-GB\"> </span></p>", "ID": "27af3aab-258c-42ea-b4fe-447e24dc1ad4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">From a microbiological point of view, the\nproduct should be used immediately. If not used immediately, in-use storage\ntimes and conditions prior to use are the responsibility of the user and would\nnormally not be longer than 24 hours at 2\u00b0C to 8\u00b0C, unless dilution has taken\nplace in controlled and validated aseptic conditions.</span>", "ID": "7636045f-f3ba-4073-b6c2-0af0ae462be1", "Styles": "None", "Classes": "None", "Text": "From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2\u00b0C to 8\u00b0C, unless dilution has taken place in controlled and validated aseptic conditions.", "ParentId": "27af3aab-258c-42ea-b4fe-447e24dc1ad4"}, {"Element": "<span lang=\"EN-GB\"> </span>", "ID": "5d25868e-edbf-4c7e-836e-ecdbc15ff0f5", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "27af3aab-258c-42ea-b4fe-447e24dc1ad4"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "10b4fb51-15be-4517-bd08-bb779fd7004e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "793d63c7-a30d-41ef-bb7d-bc60bbb5724f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "10b4fb51-15be-4517-bd08-bb779fd7004e"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">6.4\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Special precautions for\nstorage</span></b></p>", "ID": "d0ebb7f5-327f-4602-812a-fed1edb9e185", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">6.4\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Special precautions for\nstorage</span></b>", "ID": "687a4d1d-3173-420f-b4df-be27bc30a8e9", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d0ebb7f5-327f-4602-812a-fed1edb9e185"}, {"Element": "<span lang=\"EN-GB\">6.4\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Special precautions for\nstorage</span>", "ID": "8e424831-1f3d-4e1f-a4c5-fe50e33a2c26", "Styles": "None", "Classes": "None", "Text": "6.4\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Special precautions for storage", "ParentId": "687a4d1d-3173-420f-b4df-be27bc30a8e9"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2255714c-7993-493d-b0db-b270afc13ca3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "57d8505a-c287-4857-928c-1bfb2edbf89e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2255714c-7993-493d-b0db-b270afc13ca3"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Store in a refrigerator (2\u00b0C-8\u00b0C).</span></p>", "ID": "d1959655-ecf7-43b4-8b33-1b6817a276bc", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Store in a refrigerator (2\u00b0C-8\u00b0C).</span>", "ID": "e28bb98c-1f4f-4191-bc9c-1fd1a6bece3b", "Styles": "None", "Classes": "None", "Text": "Store in a refrigerator (2\u00b0C-8\u00b0C).", "ParentId": "d1959655-ecf7-43b4-8b33-1b6817a276bc"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9b3a54fa-d113-40d0-bd74-108469c33fed", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b023b018-c3fe-49a1-ae00-adec5c192175", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9b3a54fa-d113-40d0-bd74-108469c33fed"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Do not freeze. </span></p>", "ID": "6af7092b-6175-41b9-88a3-2f6ce2aa6d80", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Do not freeze. </span>", "ID": "9722d92d-5a95-4b40-bf44-4759e99cad7f", "Styles": "None", "Classes": "None", "Text": "Do not freeze. ", "ParentId": "6af7092b-6175-41b9-88a3-2f6ce2aa6d80"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "1b903bba-1b35-4f74-917d-83b23f2f4551", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "436fac80-d356-4a50-b174-cc44aef88249", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1b903bba-1b35-4f74-917d-83b23f2f4551"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Keep the vial in the outer carton in order\nto protect from light.</span></p>", "ID": "9c31e50d-37f4-42d1-b917-50a7b333719e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Keep the vial in the outer carton in order\nto protect from light.</span>", "ID": "9d41fa21-61f1-4e25-b5a5-ec8591aea606", "Styles": "None", "Classes": "None", "Text": "Keep the vial in the outer carton in order to protect from light.", "ParentId": "9c31e50d-37f4-42d1-b917-50a7b333719e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9ea51399-f478-4983-8a53-6a06d6b54555", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c55f0e3d-b684-4f44-be73-d19bc4403e13", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9ea51399-f478-4983-8a53-6a06d6b54555"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">For storage conditions after dilution of\nthe medicinal product, see section 6.3.</span></p>", "ID": "7736c732-35e5-44e7-b58b-6e26edf4b87d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">For storage conditions after dilution of\nthe medicinal product, see section 6.3.</span>", "ID": "496f0396-9ccd-481b-a9df-fc5ab2f0fca0", "Styles": "None", "Classes": "None", "Text": "For storage conditions after dilution of the medicinal product, see section 6.3.", "ParentId": "7736c732-35e5-44e7-b58b-6e26edf4b87d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b40a9ad2-058a-42a5-81a9-5be4c728922b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8976aa4f-3d7e-4bee-87de-036b4efb8b78", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b40a9ad2-058a-42a5-81a9-5be4c728922b"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">6.5\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Nature and contents of\ncontainer</span></b></p>", "ID": "2e8fca84-14e8-456e-96bb-c40b238d64df", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">6.5\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Nature and contents of\ncontainer</span></b>", "ID": "12b4c885-cc6c-40af-a5d3-66de57fdfc2a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "2e8fca84-14e8-456e-96bb-c40b238d64df"}, {"Element": "<span lang=\"EN-GB\">6.5\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Nature and contents of\ncontainer</span>", "ID": "b5e59312-2835-476f-a2f1-bbc0b1855872", "Styles": "None", "Classes": "None", "Text": "6.5\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Nature and contents of container", "ParentId": "12b4c885-cc6c-40af-a5d3-66de57fdfc2a"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "24e8b68a-fe17-43c6-afe1-84f5d24bb633", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "c65be890-f3fe-489f-8a14-e7a5fc27a882", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "24e8b68a-fe17-43c6-afe1-84f5d24bb633"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8db89692-40f1-4d0e-b88a-92cae20a5415", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c65be890-f3fe-489f-8a14-e7a5fc27a882"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Vial (Type I glass) with a stopper (butyl\nrubber) containing 14\u00a0ml of solution. </span></p>", "ID": "5d7c3f20-6a42-403c-b60b-71f14c1016c2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Vial (Type I glass) with a stopper (butyl\nrubber) containing 14\u00a0ml of solution. </span>", "ID": "44625b9c-787c-4896-bda3-5d599d6a4910", "Styles": "None", "Classes": "None", "Text": "Vial (Type I glass) with a stopper (butyl rubber) containing 14\u00a0ml of solution. ", "ParentId": "5d7c3f20-6a42-403c-b60b-71f14c1016c2"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8b566336-f8cc-437c-8697-ac91e2b36c0e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4bc19722-3bb2-4e41-a8c2-3c9837bef079", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8b566336-f8cc-437c-8697-ac91e2b36c0e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Pack of 1 vial.</span></p>", "ID": "3d627786-caef-45cb-83c4-90066d6c16ca", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Pack of 1 vial.</span>", "ID": "c06910da-2cb6-43b2-b47a-971fe92705d5", "Styles": "None", "Classes": "None", "Text": "Pack of 1 vial.", "ParentId": "3d627786-caef-45cb-83c4-90066d6c16ca"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "1c7f34e4-537f-4876-b826-4c20969f66d0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "96d46485-841d-4049-a801-4863b0fabe6a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1c7f34e4-537f-4876-b826-4c20969f66d0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><a name=\"OLE_LINK1\"><b><span lang=\"EN-GB\">6.6\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Special precautions for disposal and other handling</span></b></a></p>", "ID": "d079d002-bb0f-4bcb-b1ae-95c992b60db6", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<a name=\"OLE_LINK1\"><b><span lang=\"EN-GB\">6.6\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Special precautions for disposal and other handling</span></b></a>", "ID": "ec39e301-dde0-46d4-9226-45058319b16f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d079d002-bb0f-4bcb-b1ae-95c992b60db6"}, {"Element": "<b><span lang=\"EN-GB\">6.6\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Special precautions for disposal and other handling</span></b>", "ID": "8e14b68c-aef0-4dba-9a15-a8c40627ed1e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ec39e301-dde0-46d4-9226-45058319b16f"}, {"Element": "<span lang=\"EN-GB\">6.6\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Special precautions for disposal and other handling</span>", "ID": "0df87cd7-fa9a-4793-9330-b526332cd70c", "Styles": "None", "Classes": "None", "Text": "6.6\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Special precautions for disposal and other handling", "ParentId": "8e14b68c-aef0-4dba-9a15-a8c40627ed1e"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "741ca96d-cd3f-4427-b975-63f75a732a6f", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "816d8f6b-4b48-4549-a2da-35b213ec5328", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "741ca96d-cd3f-4427-b975-63f75a732a6f"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Perjeta does\nnot contain any antimicrobial preservative. Therefore, care must be taken to\nensure the sterility of the prepared solution for infusion and should be\nprepared by a healthcare professional. </span></p>", "ID": "90c55b15-ae97-41e4-ac34-c4d710144243", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Perjeta does\nnot contain any antimicrobial preservative. Therefore, care must be taken to\nensure the sterility of the prepared solution for infusion and should be\nprepared by a healthcare professional. </span>", "ID": "57784aa5-98c7-48c1-ba86-49bf2bcbc5a2", "Styles": "None", "Classes": "None", "Text": "Perjeta does not contain any antimicrobial preservative. Therefore, care must be taken to ensure the sterility of the prepared solution for infusion and should be prepared by a healthcare professional. ", "ParentId": "90c55b15-ae97-41e4-ac34-c4d710144243"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9be83fd1-788d-4be9-b46d-43a9ed9e5925", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2c73497f-4474-4289-b31b-742cd9c4c1de", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9be83fd1-788d-4be9-b46d-43a9ed9e5925"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Perjeta is\nfor single use only.</span></p>", "ID": "6af914a6-729a-4f52-88a2-09c56b8a3862", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Perjeta is\nfor single use only.</span>", "ID": "26f1a471-6391-4b4c-af89-12555ee6fdd3", "Styles": "None", "Classes": "None", "Text": "Perjeta is for single use only.", "ParentId": "6af914a6-729a-4f52-88a2-09c56b8a3862"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "fdf9c7c0-db4f-4d9c-b832-b5a177290dc5", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "516b8743-5c78-4bdb-94bc-731960d2c28d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "fdf9c7c0-db4f-4d9c-b832-b5a177290dc5"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">The vial\nmust not be shaken. 14 ml of Perjeta concentrate should be withdrawn from the\nvial and diluted into a 250\u00a0ml PVC or non-PVC polyolefin infusion bag of\nsodium chloride 9\u00a0mg/ml (0.9%) solution for infusion. After dilution, one\nml of solution should contain approximately </span><span lang=\"EN-GB\">3.02\u00a0mg\nof pertuzumab (840\u00a0mg/278\u00a0ml) for the initial dose where two vials\nare required and approximately 1.59\u00a0mg of pertuzumab (420\u00a0mg/264 \u00a0ml)\nfor the maintenance dose where one vial is required. </span></p>", "ID": "0c126301-5897-47d2-b4c9-40b6842dd96c", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">The vial\nmust not be shaken. 14 ml of Perjeta concentrate should be withdrawn from the\nvial and diluted into a 250\u00a0ml PVC or non-PVC polyolefin infusion bag of\nsodium chloride 9\u00a0mg/ml (0.9%) solution for infusion. After dilution, one\nml of solution should contain approximately </span>", "ID": "cce83b06-6bf7-40ce-a88a-ed3a78acc9d8", "Styles": "None", "Classes": "None", "Text": "The vial must not be shaken. 14 ml of Perjeta concentrate should be withdrawn from the vial and diluted into a 250\u00a0ml PVC or non-PVC polyolefin infusion bag of sodium chloride 9\u00a0mg/ml (0.9%) solution for infusion. After dilution, one ml of solution should contain approximately ", "ParentId": "0c126301-5897-47d2-b4c9-40b6842dd96c"}, {"Element": "<span lang=\"EN-GB\">3.02\u00a0mg\nof pertuzumab (840\u00a0mg/278\u00a0ml) for the initial dose where two vials\nare required and approximately 1.59\u00a0mg of pertuzumab (420\u00a0mg/264 \u00a0ml)\nfor the maintenance dose where one vial is required. </span>", "ID": "b2800865-c7da-4e69-bede-fc84dcf93189", "Styles": "None", "Classes": "None", "Text": "3.02\u00a0mg of pertuzumab (840\u00a0mg/278\u00a0ml) for the initial dose where two vials are required and approximately 1.59\u00a0mg of pertuzumab (420\u00a0mg/264 \u00a0ml) for the maintenance dose where one vial is required. ", "ParentId": "0c126301-5897-47d2-b4c9-40b6842dd96c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The bag should be gently inverted to mix\nthe solution in order to avoid foaming.</span></p>", "ID": "0eca25cb-c22f-4058-9e7a-1e18a5434153", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">The bag should be gently inverted to mix\nthe solution in order to avoid foaming.</span>", "ID": "29abeaa7-c6a9-4153-9c7e-34bc69673929", "Styles": "None", "Classes": "None", "Text": "The bag should be gently inverted to mix the solution in order to avoid foaming.", "ParentId": "0eca25cb-c22f-4058-9e7a-1e18a5434153"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e3506b99-b56a-4c77-9b25-6083eb6cc6b2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "df67f441-23c8-481c-ae88-0932be55f832", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e3506b99-b56a-4c77-9b25-6083eb6cc6b2"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Parenteral medicinal products should be\ninspected visually for particulates and discolouration prior to administration.\nIf particulates or discoloration are observed, the solution should not be used.\nOnce the infusion is prepared it should be administered immediately (see\nsection 6.3). </span></p>", "ID": "f467cc3a-8352-48f7-8bd0-c790d586f05a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Parenteral medicinal products should be\ninspected visually for particulates and discolouration prior to administration.\nIf particulates or discoloration are observed, the solution should not be used.\nOnce the infusion is prepared it should be administered immediately (see\nsection 6.3). </span>", "ID": "e9618b6d-e573-4ea9-bbaa-946103d6fbb4", "Styles": "None", "Classes": "None", "Text": "Parenteral medicinal products should be inspected visually for particulates and discolouration prior to administration. If particulates or discoloration are observed, the solution should not be used. Once the infusion is prepared it should be administered immediately (see section 6.3). ", "ParentId": "f467cc3a-8352-48f7-8bd0-c790d586f05a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6102181c-695f-4e04-b87f-f1af332d6d59", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d3fb538b-4fd4-4ec5-95fd-2c0dd8ea8074", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6102181c-695f-4e04-b87f-f1af332d6d59"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Any unused medicinal product or waste\nmaterial should be disposed of in accordance with local requirements.</span></p>", "ID": "3dc47f68-ecdf-4b5e-aa71-af7c28fed0fe", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Any unused medicinal product or waste\nmaterial should be disposed of in accordance with local requirements.</span>", "ID": "0b9c2814-9729-4d38-924d-b5e06175e3b8", "Styles": "None", "Classes": "None", "Text": "Any unused medicinal product or waste material should be disposed of in accordance with local requirements.", "ParentId": "3dc47f68-ecdf-4b5e-aa71-af7c28fed0fe"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "489f40ab-3096-4fe0-b87f-b3457ca4b4bc", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "94767630-253f-4b70-9471-f67076952e06", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "489f40ab-3096-4fe0-b87f-b3457ca4b4bc"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Perjeta is compatible with\npolyvinylchloride (PVC) or non-PVC polyolefin bags including polyethylene.</span></p>", "ID": "0e06bc44-690c-43b3-9ffd-09a4af622e31", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Perjeta is compatible with\npolyvinylchloride (PVC) or non-PVC polyolefin bags including polyethylene.</span>", "ID": "5a20cd2e-ee08-44aa-add2-1a1fbf890d9d", "Styles": "None", "Classes": "None", "Text": "Perjeta is compatible with polyvinylchloride (PVC) or non-PVC polyolefin bags including polyethylene.", "ParentId": "0e06bc44-690c-43b3-9ffd-09a4af622e31"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f68a9198-9f79-4833-bc77-2058cb3dcccb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "56cdecb0-a175-4efd-a40a-48d0bddea336", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f68a9198-9f79-4833-bc77-2058cb3dcccb"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a5a1a892-1f47-40be-a4a0-a4ef4c58b04f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1f275114-8cf7-4e97-aa39-ad00e4b5b239", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a5a1a892-1f47-40be-a4a0-a4ef4c58b04f"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">7.</span></b><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <b>MARKETING AUTHORISATION HOLDER</b></span></p>", "ID": "de56977a-e920-43ac-b19d-587c0f0dc37b", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">7.</span></b>", "ID": "1f965ecd-ca8f-46c4-ac5b-3744b06d66da", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "de56977a-e920-43ac-b19d-587c0f0dc37b"}, {"Element": "<span lang=\"EN-GB\">7.</span>", "ID": "e5218136-c8f5-4988-977a-a4747a6426f7", "Styles": "None", "Classes": "None", "Text": "7.", "ParentId": "1f965ecd-ca8f-46c4-ac5b-3744b06d66da"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <b>MARKETING AUTHORISATION HOLDER</b></span>", "ID": "64bf3ba1-1df7-42fa-bd87-dc55751352b8", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "de56977a-e920-43ac-b19d-587c0f0dc37b"}, {"Element": "<b>MARKETING AUTHORISATION HOLDER</b>", "ID": "94416cc6-812c-4ea9-8737-15c354107b82", "Styles": "None", "Classes": "None", "Text": "MARKETING AUTHORISATION HOLDER", "ParentId": "64bf3ba1-1df7-42fa-bd87-dc55751352b8"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "844caa96-f94e-4cdf-ae53-751236e84d13", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5d8815d2-597d-438e-84c0-7eed3b16f27a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "844caa96-f94e-4cdf-ae53-751236e84d13"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Roche Registration GmbH </span></p>", "ID": "e56adfd7-65b6-4f8b-aacd-19b26f03cd96", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Roche Registration GmbH </span>", "ID": "19ba2058-8754-47ba-89c1-a8e7b5b6630a", "Styles": "None", "Classes": "None", "Text": "Roche Registration GmbH ", "ParentId": "e56adfd7-65b6-4f8b-aacd-19b26f03cd96"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Emil-Barell-Strasse 1</span></p>", "ID": "6ddf773f-86c5-4381-9c1c-6d404c527095", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Emil-Barell-Strasse 1</span>", "ID": "aa0333a4-6b93-45cf-b495-418fe7eb236b", "Styles": "None", "Classes": "None", "Text": "Emil-Barell-Strasse 1", "ParentId": "6ddf773f-86c5-4381-9c1c-6d404c527095"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">79639 Grenzach-Wyhlen</span></p>", "ID": "cf0afe4b-63ba-4fa5-a486-0c46bf3ad956", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">79639 Grenzach-Wyhlen</span>", "ID": "0543e49f-d953-4d27-9522-ed31d5e3d81e", "Styles": "None", "Classes": "None", "Text": "79639 Grenzach-Wyhlen", "ParentId": "cf0afe4b-63ba-4fa5-a486-0c46bf3ad956"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Germany</span></p>", "ID": "f2bba28a-17fe-4eb9-b70f-4bc834d2369b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Germany</span>", "ID": "5644536d-2e28-44a2-a3e7-be3d745785d2", "Styles": "None", "Classes": "None", "Text": "Germany", "ParentId": "f2bba28a-17fe-4eb9-b70f-4bc834d2369b"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e3f613f1-0b84-4dd9-b0f2-b6ca0023d350", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "78df5906-2039-4a5f-9baf-430d765a0c6e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e3f613f1-0b84-4dd9-b0f2-b6ca0023d350"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "63718803-a486-4754-ad2d-90192e39cfd3", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "086af46c-3468-46f5-a63d-78993c456bf2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "63718803-a486-4754-ad2d-90192e39cfd3"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 MARKETING\nAUTHORISATION NUMBER(S) </span></b></p>", "ID": "2daafa67-b1b0-475d-ab10-47d6808c905e", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 MARKETING\nAUTHORISATION NUMBER(S) </span></b>", "ID": "14a0d36d-cdf4-439c-8fa9-51134db31983", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "2daafa67-b1b0-475d-ab10-47d6808c905e"}, {"Element": "<span lang=\"EN-GB\">8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 MARKETING\nAUTHORISATION NUMBER(S) </span>", "ID": "33fe8518-9b95-4124-aa8c-4323ce0ae665", "Styles": "None", "Classes": "None", "Text": "8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 MARKETING AUTHORISATION NUMBER(S) ", "ParentId": "14a0d36d-cdf4-439c-8fa9-51134db31983"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "716432d7-1ea2-478d-999c-9f5af7891588", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "bc0e2afe-3fa7-4f80-8723-d0e22ecd5999", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "716432d7-1ea2-478d-999c-9f5af7891588"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">EU/1/13/813/001</span></p>", "ID": "76ebf327-fcfd-4269-a7a0-deb3631eee5f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">EU/1/13/813/001</span>", "ID": "f9e55ef3-9f77-463c-be9c-2ad069fd17ea", "Styles": "None", "Classes": "None", "Text": "EU/1/13/813/001", "ParentId": "76ebf327-fcfd-4269-a7a0-deb3631eee5f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "22dd4dda-8f94-41a6-ba7c-61606118bed7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9f460fae-fc94-4a04-9276-7097676362dc", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "22dd4dda-8f94-41a6-ba7c-61606118bed7"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8643edd4-b162-4668-9f3a-1c5f8b507a81", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "babb0a93-42d0-433a-aee3-978d2b94b663", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8643edd4-b162-4668-9f3a-1c5f8b507a81"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 DATE OF FIRST\nAUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p>", "ID": "d8b981f6-740f-473b-95c5-5db10240b3c3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 DATE OF FIRST\nAUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b>", "ID": "6af34a60-3c73-4367-96bf-a310a869a356", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d8b981f6-740f-473b-95c5-5db10240b3c3"}, {"Element": "<span lang=\"EN-GB\">9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 DATE OF FIRST\nAUTHORISATION/RENEWAL OF THE AUTHORISATION</span>", "ID": "255a68bb-5cca-44f4-b70c-c11734af64cd", "Styles": "None", "Classes": "None", "Text": "9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION", "ParentId": "6af34a60-3c73-4367-96bf-a310a869a356"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5a1fd1ea-bc9d-47ba-a826-bea969c029a4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "666ca3d5-5417-400a-83d8-ffdf2dc640eb", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5a1fd1ea-bc9d-47ba-a826-bea969c029a4"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Date of first authorisation: 4<sup>th</sup>\nMarch 2013</span></p>", "ID": "0f359fcb-a207-477d-bf53-2d4aa65b2275", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Date of first authorisation: 4<sup>th</sup>\nMarch 2013</span>", "ID": "d4626f4d-5037-4ea1-8f37-322ec4ffd030", "Styles": "None", "Classes": "None", "Text": "Date of first authorisation: 4 March 2013", "ParentId": "0f359fcb-a207-477d-bf53-2d4aa65b2275"}, {"Element": "<sup>th</sup>", "ID": "cd16cd80-ffb8-4b7a-b419-56008814471d", "Styles": "None", "Classes": "None", "Text": "th", "ParentId": "d4626f4d-5037-4ea1-8f37-322ec4ffd030"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Date of latest renewal: 8<sup>th</sup>\nDecember 2017</span></p>", "ID": "a1ca3657-d8e4-4420-ae59-b19c0c887427", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Date of latest renewal: 8<sup>th</sup>\nDecember 2017</span>", "ID": "874c8b10-99bf-4b8a-9d1f-9861a1c8099b", "Styles": "None", "Classes": "None", "Text": "Date of latest renewal: 8 December 2017", "ParentId": "a1ca3657-d8e4-4420-ae59-b19c0c887427"}, {"Element": "<sup>th</sup>", "ID": "21d367ea-90de-4e6b-bdae-cdf882ab6a72", "Styles": "None", "Classes": "None", "Text": "th", "ParentId": "874c8b10-99bf-4b8a-9d1f-9861a1c8099b"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "de4162a8-487c-428f-9594-94989ead3ba5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "2d025fe5-343f-4045-ad6b-3da10d4b1b38", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "de4162a8-487c-428f-9594-94989ead3ba5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "25a416f4-c0f9-4bb3-beff-de6327b60129", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2d025fe5-343f-4045-ad6b-3da10d4b1b38"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "cbf83cf3-f364-442f-b815-d01c5abb1793", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "c34e6c10-6ec8-4bb1-a0fc-ec0418460e5a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "cbf83cf3-f364-442f-b815-d01c5abb1793"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3e14b683-0146-4849-8600-b44c33990c1f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c34e6c10-6ec8-4bb1-a0fc-ec0418460e5a"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">10.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 DATE\nOF REVISION OF THE TEXT</span></b></p>", "ID": "480812be-02cf-4e66-af3a-281513422cc8", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">10.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 DATE\nOF REVISION OF THE TEXT</span></b>", "ID": "41b54087-5558-4262-980d-7d38cdc32648", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "480812be-02cf-4e66-af3a-281513422cc8"}, {"Element": "<span lang=\"EN-GB\">10.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 DATE\nOF REVISION OF THE TEXT</span>", "ID": "b59aef01-a69b-44fd-a446-ad84f610c873", "Styles": "None", "Classes": "None", "Text": "10.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 DATE OF REVISION OF THE TEXT", "ParentId": "41b54087-5558-4262-980d-7d38cdc32648"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "dcf4080f-6c45-4a48-aad1-a97702efc467", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b9a320a4-5290-4f43-a555-4d4e762e1c45", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "dcf4080f-6c45-4a48-aad1-a97702efc467"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Detailed\ninformation on this medicinal product </span><span lang=\"EN-GB\">is available on\nthe website of the European Medicines Agency </span><a href=\"http://www.ema.europa.eu\"><span lang=\"EN-GB\">http://www.ema.europa.eu</span></a><span lang=\"EN-GB\" style=\"color:blue\">.</span></p>", "ID": "9480ddb4-f230-4819-b34b-272d82012326", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Detailed\ninformation on this medicinal product </span>", "ID": "1d046494-b9da-40a2-93c2-d3d7df4e220b", "Styles": "None", "Classes": "None", "Text": "Detailed information on this medicinal product ", "ParentId": "9480ddb4-f230-4819-b34b-272d82012326"}, {"Element": "<span lang=\"EN-GB\">is available on\nthe website of the European Medicines Agency </span>", "ID": "7e3a67cd-a2c7-4227-841d-f55d5e9dffe6", "Styles": "None", "Classes": "None", "Text": "is available on the website of the European Medicines Agency ", "ParentId": "9480ddb4-f230-4819-b34b-272d82012326"}, {"Element": "<a href=\"http://www.ema.europa.eu\"><span lang=\"EN-GB\">http://www.ema.europa.eu</span></a>", "ID": "7a4fb879-999d-4694-8c55-9fc21499055d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "9480ddb4-f230-4819-b34b-272d82012326"}, {"Element": "<span lang=\"EN-GB\">http://www.ema.europa.eu</span>", "ID": "c6f5cc8f-18a2-44dd-8113-82523f86c3c2", "Styles": "None", "Classes": "None", "Text": "http://www.ema.europa.eu", "ParentId": "7a4fb879-999d-4694-8c55-9fc21499055d"}, {"Element": "<span lang=\"EN-GB\" style=\"color:blue\">.</span>", "ID": "309299fc-ce81-40c4-bc65-104032e52455", "Styles": "color:blue", "Classes": "None", "Text": ".", "ParentId": "9480ddb4-f230-4819-b34b-272d82012326"}, {"Element": "<b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span></b>", "ID": "460f6efb-3b82-48b6-9722-f813bda196c1", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>", "ID": "e60c2de0-b781-4515-b871-a67e54993b21", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": " ", "ParentId": "460f6efb-3b82-48b6-9722-f813bda196c1"}, {"Element": "<br clear=\"all\" style=\"page-break-before:always\"/>", "ID": "4761f9d9-58b4-4d64-86e6-89342da1b9d4", "Styles": "page-break-before:always", "Classes": "None", "Text": "", "ParentId": "e60c2de0-b781-4515-b871-a67e54993b21"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "dec6d788-a072-46b5-9c51-5fcbccde613f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c91084c2-6d4a-4cc5-8b44-ae5dc6babf1b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "dec6d788-a072-46b5-9c51-5fcbccde613f"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8cf069ce-7f61-4493-87be-1e065812aba2", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "540d51e1-96a7-4935-941b-34c146909f9f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8cf069ce-7f61-4493-87be-1e065812aba2"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "18e387e2-3357-44af-8f47-3fe1fe6babc1", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c7b8a14c-b410-4d29-89a0-0041edb1b760", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "18e387e2-3357-44af-8f47-3fe1fe6babc1"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "cae6d726-82b8-40a7-9301-7b7344c249c3", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "fa1d7207-b495-4421-bb61-b82b32e06039", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "cae6d726-82b8-40a7-9301-7b7344c249c3"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d1f3c50a-9813-439b-aad9-e5a9a57f2512", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8d08e438-2b93-4938-9bed-3356cc7ca865", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d1f3c50a-9813-439b-aad9-e5a9a57f2512"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "65f2e4f3-ce9a-4074-9df1-11fcc53a40a9", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5acee4b3-da85-4ce1-9d3b-e2b2757acd6d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "65f2e4f3-ce9a-4074-9df1-11fcc53a40a9"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "33667a96-24dd-409f-8753-1129f0de730f", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "50d2c560-e13a-46c2-bb3e-2834495958c2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "33667a96-24dd-409f-8753-1129f0de730f"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "368064a5-55bf-497b-81a9-d41e9adb0568", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5ef2fcab-3513-4439-b4ca-a7c63400eeeb", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "368064a5-55bf-497b-81a9-d41e9adb0568"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5238059d-23ef-4ad6-9958-cbfa02a9cd1a", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d4f4fc09-1655-4d0f-9b07-d43538909329", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5238059d-23ef-4ad6-9958-cbfa02a9cd1a"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "be1e8711-dde6-406f-84b7-ca362519a1c3", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ef2ca4c0-4966-4711-8ba4-317f50faba75", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "be1e8711-dde6-406f-84b7-ca362519a1c3"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a667980d-4dbe-4c1d-b805-f865ee524194", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5cb45933-9abf-4166-b858-78b8820ad2f8", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a667980d-4dbe-4c1d-b805-f865ee524194"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "94f08435-b70b-47b9-b417-7a4820e06ef3", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "558798ed-e385-4898-80a1-823c37e3f7f4", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "94f08435-b70b-47b9-b417-7a4820e06ef3"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "03ec547b-4a47-440c-a4f3-6ede5dffe337", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "398c3371-8e55-4034-ba18-63c36b74ef67", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "03ec547b-4a47-440c-a4f3-6ede5dffe337"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d91a2e98-da9a-4d1a-b701-8a5d5370cc6f", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "08a1de9e-39cd-4715-873c-2d2fe868d9ba", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d91a2e98-da9a-4d1a-b701-8a5d5370cc6f"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f4dc3e07-9084-4b1a-bdf6-a9e09ae05757", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "396107f7-bd6b-4729-990f-1d9155329ea2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f4dc3e07-9084-4b1a-bdf6-a9e09ae05757"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "665603ba-066e-452c-9665-076c31b38e5d", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c08e8b1c-678b-41a9-91a3-9a09362bfdb4", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "665603ba-066e-452c-9665-076c31b38e5d"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2d52a117-c0fa-473a-bfc1-0823e1237926", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "212867fc-d958-498b-94b8-ce9c2cb1a27a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2d52a117-c0fa-473a-bfc1-0823e1237926"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ecceb46c-acdd-4650-9392-ac277ca4fe19", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a52c48a5-cd88-4ca3-b9c4-4d02c23f3b8e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ecceb46c-acdd-4650-9392-ac277ca4fe19"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "94c4db14-2186-4de2-ba06-3f15086f2a55", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3347323a-56d1-4f90-900a-ab73192531e5", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "94c4db14-2186-4de2-ba06-3f15086f2a55"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "72b0f888-55cd-401a-9ef2-e3d5d9d5dc6d", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e9af26df-ac1a-4147-866c-42a49d11f7c1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "72b0f888-55cd-401a-9ef2-e3d5d9d5dc6d"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7c4b5a05-5de4-4ee0-93ee-d8f192c69b4f", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "63949b0d-fe33-48ae-a5b8-bc72cf2245ce", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7c4b5a05-5de4-4ee0-93ee-d8f192c69b4f"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e9e87d27-e406-4d70-802e-32f17a9ebab3", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c6157bb2-773c-4f44-8ab6-98188cd42b63", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e9e87d27-e406-4d70-802e-32f17a9ebab3"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "71cde182-6f1d-4117-a0e5-0f68fd75d725", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "159bbfe1-4b95-4b65-8c6b-7a9cab72945f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "71cde182-6f1d-4117-a0e5-0f68fd75d725"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "29d7a07e-ddda-426f-aa24-4609ebe7d493", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "e81600d3-8a07-4af9-9760-191535ea25fa", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "29d7a07e-ddda-426f-aa24-4609ebe7d493"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c38394c6-72f0-452f-a6c7-d7030b329eb1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e81600d3-8a07-4af9-9760-191535ea25fa"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">ANNEX</span></b><b><span lang=\"EN-GB\"> II</span></b></p>", "ID": "93f70a58-b882-4378-bc29-aafb05947bf4", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">ANNEX</span></b>", "ID": "e6bcc801-2448-4890-b842-138c92f5bb60", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "93f70a58-b882-4378-bc29-aafb05947bf4"}, {"Element": "<span lang=\"EN-GB\">ANNEX</span>", "ID": "0de04d4b-f316-415c-9e1c-48682d82e772", "Styles": "None", "Classes": "None", "Text": "ANNEX", "ParentId": "e6bcc801-2448-4890-b842-138c92f5bb60"}, {"Element": "<b><span lang=\"EN-GB\"> II</span></b>", "ID": "e0ffc8d9-aad2-47ce-aa81-ba7b071be1ad", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "93f70a58-b882-4378-bc29-aafb05947bf4"}, {"Element": "<span lang=\"EN-GB\"> II</span>", "ID": "f5c6dafb-7434-4b8b-a303-c683641ba80b", "Styles": "None", "Classes": "None", "Text": " II", "ParentId": "e0ffc8d9-aad2-47ce-aa81-ba7b071be1ad"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "dbe8410c-1887-4cda-b5b7-55b97f0906d2", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ec436f42-1021-45ff-940c-88de3f1a4269", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "dbe8410c-1887-4cda-b5b7-55b97f0906d2"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:70.9pt;margin-bottom:\n0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">A.\u00a0\u00a0\u00a0\u00a0\u00a0 MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND\nMANUFACTURER RESPONSIBLE FOR BATCH RELEASE </span></b></p>", "ID": "f6f2134f-bb37-408a-a2d6-02093a8f0b5e", "Styles": "margin-top:0in;margin-right:70.9pt;margin-bottom:\n0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">A.\u00a0\u00a0\u00a0\u00a0\u00a0 MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND\nMANUFACTURER RESPONSIBLE FOR BATCH RELEASE </span></b>", "ID": "73780cdf-0490-4b90-a632-5f3681bf6bf2", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f6f2134f-bb37-408a-a2d6-02093a8f0b5e"}, {"Element": "<span lang=\"EN-GB\">A.\u00a0\u00a0\u00a0\u00a0\u00a0 MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND\nMANUFACTURER RESPONSIBLE FOR BATCH RELEASE </span>", "ID": "1fbe7c27-9643-45ff-af02-fece5542c30a", "Styles": "None", "Classes": "None", "Text": "A.\u00a0\u00a0\u00a0\u00a0\u00a0 MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE ", "ParentId": "73780cdf-0490-4b90-a632-5f3681bf6bf2"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:70.9pt;margin-bottom:\n0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "5867fa09-31b5-45e3-8a6a-e01c9ae3a999", "Styles": "margin-top:0in;margin-right:70.9pt;margin-bottom:\n0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "db570644-6f6e-426d-ba38-75a002ed8391", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "5867fa09-31b5-45e3-8a6a-e01c9ae3a999"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ce2cc1f9-d3ff-4ad9-b49c-a3ab67f7148b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "db570644-6f6e-426d-ba38-75a002ed8391"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:70.9pt;margin-bottom:\n0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">B.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE</span></b></p>", "ID": "eae0ef10-ec02-4108-8032-8b2a3a8085b1", "Styles": "margin-top:0in;margin-right:70.9pt;margin-bottom:\n0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">B.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE</span></b>", "ID": "ba7abbff-58b3-40e6-8dbd-fea708ad1902", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "eae0ef10-ec02-4108-8032-8b2a3a8085b1"}, {"Element": "<span lang=\"EN-GB\">B.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE</span>", "ID": "46d4d32b-16ba-4556-a968-5e2e23e82e31", "Styles": "None", "Classes": "None", "Text": "B.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE", "ParentId": "ba7abbff-58b3-40e6-8dbd-fea708ad1902"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:70.9pt;margin-bottom:\n0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "45848c8c-5efa-4623-8375-c0c480590cd6", "Styles": "margin-top:0in;margin-right:70.9pt;margin-bottom:\n0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "beeaeaba-d5d7-4ecb-8ee7-17946a85490d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "45848c8c-5efa-4623-8375-c0c480590cd6"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "36e6b95f-5d4f-408c-8c9b-0b91321f3415", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "beeaeaba-d5d7-4ecb-8ee7-17946a85490d"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:70.9pt;margin-bottom:\n0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">C.\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING\nAUTHORISATION</span></b></p>", "ID": "18c2fab7-9213-4fba-b748-5d44738a610c", "Styles": "margin-top:0in;margin-right:70.9pt;margin-bottom:\n0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">C.\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING\nAUTHORISATION</span></b>", "ID": "4da2584f-f463-4603-bf58-231b080e7146", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "18c2fab7-9213-4fba-b748-5d44738a610c"}, {"Element": "<span lang=\"EN-GB\">C.\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING\nAUTHORISATION</span>", "ID": "4cca97c7-764e-461c-ad9b-85f2381c2399", "Styles": "None", "Classes": "None", "Text": "C.\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION", "ParentId": "4da2584f-f463-4603-bf58-231b080e7146"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:70.9pt;margin-bottom:\n0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "a7481e01-fe3d-4297-8476-fd628c9f4b33", "Styles": "margin-top:0in;margin-right:70.9pt;margin-bottom:\n0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "ebb5bdd1-a9a5-4138-b78f-affb93a1ae7a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a7481e01-fe3d-4297-8476-fd628c9f4b33"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a95f93bb-6a18-47bc-bc57-35e2f78effc4", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ebb5bdd1-a9a5-4138-b78f-affb93a1ae7a"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:70.9pt;margin-bottom:\n0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">D.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND\nEFFECTIVE USE OF THE MEDICINAL PRODUCT</span></b></p>", "ID": "7c90c051-cf34-4b72-9cfc-9a2e9f018d37", "Styles": "margin-top:0in;margin-right:70.9pt;margin-bottom:\n0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">D.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND\nEFFECTIVE USE OF THE MEDICINAL PRODUCT</span></b>", "ID": "ab7744ef-7ee6-4fbb-bf54-449c8508c941", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "7c90c051-cf34-4b72-9cfc-9a2e9f018d37"}, {"Element": "<span lang=\"EN-GB\">D.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND\nEFFECTIVE USE OF THE MEDICINAL PRODUCT</span>", "ID": "cf954efa-436d-4e56-a4b3-a1e2c8831b50", "Styles": "None", "Classes": "None", "Text": "D.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT", "ParentId": "ab7744ef-7ee6-4fbb-bf54-449c8508c941"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "baa0fc48-ed90-482f-8346-0c4de1add7fb", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8476d858-d4b5-4f46-8f54-488a7afe21f7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "baa0fc48-ed90-482f-8346-0c4de1add7fb"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "77895760-bb0a-4ac9-b7b0-37116ac13cd3", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4a7aa58a-8bd6-4a70-83a2-c7407826b611", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "77895760-bb0a-4ac9-b7b0-37116ac13cd3"}, {"Element": "<b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span></b>", "ID": "7c74a556-91d6-427a-b037-3d36e95574ea", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>", "ID": "3bf22def-c253-4108-b911-3d198c0b62f2", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": " ", "ParentId": "7c74a556-91d6-427a-b037-3d36e95574ea"}, {"Element": "<br clear=\"all\" style=\"page-break-before:always\"/>", "ID": "f90eaf94-64be-408d-9ae6-2ea99e1153a0", "Styles": "page-break-before:always", "Classes": "None", "Text": "", "ParentId": "3bf22def-c253-4108-b911-3d198c0b62f2"}, {"Element": "<p class=\"AnnexHeading\"><span lang=\"EN-GB\">A.\u00a0\u00a0\u00a0\u00a0\u00a0 </span><span lang=\"EN-GB\">MANUFACTURER\nOF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH\nRELEASE</span></p>", "ID": "3f6cf3f4-2f00-48bb-bc10-3b096939946c", "Styles": "None", "Classes": "['AnnexHeading']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">A.\u00a0\u00a0\u00a0\u00a0\u00a0 </span>", "ID": "4b07fb7d-6e6f-47f9-95d5-ad19f6402ca8", "Styles": "None", "Classes": "None", "Text": "A.\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "3f6cf3f4-2f00-48bb-bc10-3b096939946c"}, {"Element": "<span lang=\"EN-GB\">MANUFACTURER\nOF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH\nRELEASE</span>", "ID": "842ca22f-abe6-4dd7-b54c-e3a681c480d1", "Styles": "None", "Classes": "None", "Text": "MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE", "ParentId": "3f6cf3f4-2f00-48bb-bc10-3b096939946c"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:10.0pt\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "a359b3b6-885d-43c7-b506-c10b0d8d208a", "Styles": "margin-left:.5in;text-indent:-.5in;line-height:10.0pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "e0d658f2-be33-42b8-ac0c-4ce612a2518f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a359b3b6-885d-43c7-b506-c10b0d8d208a"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "442d849c-e670-4176-b247-ac0ea600ea3b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e0d658f2-be33-42b8-ac0c-4ce612a2518f"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><u><span lang=\"EN-GB\">Name and address of the manufacturer of the biological active\nsubstance(s) </span></u></p>", "ID": "17ee2110-4013-49a7-953a-ae6f9d5ad780", "Styles": "margin-left:.5in;text-indent:-.5in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<u><span lang=\"EN-GB\">Name and address of the manufacturer of the biological active\nsubstance(s) </span></u>", "ID": "5094b4c9-d81a-46d7-817c-ad11d27fa319", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "17ee2110-4013-49a7-953a-ae6f9d5ad780"}, {"Element": "<span lang=\"EN-GB\">Name and address of the manufacturer of the biological active\nsubstance(s) </span>", "ID": "736fbe89-6eb5-4554-9ec5-b6eb38464066", "Styles": "None", "Classes": "None", "Text": "Name and address of the manufacturer of the biological active substance(s) ", "ParentId": "5094b4c9-d81a-46d7-817c-ad11d27fa319"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Genentech, Inc.</span></p>", "ID": "692eedba-46e0-448f-90e3-5912cde65f46", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Genentech, Inc.</span>", "ID": "874bffde-1a3a-45ef-bffc-305f9e816c12", "Styles": "None", "Classes": "None", "Text": "Genentech, Inc.", "ParentId": "692eedba-46e0-448f-90e3-5912cde65f46"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">1000 New Horizons Way</span></p>", "ID": "c05dc1f9-a92c-41b9-b25f-cd468f486fc0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">1000 New Horizons Way</span>", "ID": "5a54466b-8251-4522-9c92-5ee80c1bbd86", "Styles": "None", "Classes": "None", "Text": "1000 New Horizons Way", "ParentId": "c05dc1f9-a92c-41b9-b25f-cd468f486fc0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Vacaville, CA 95688-9431</span></p>", "ID": "4044136c-b0a1-470e-8584-c6c522e6221f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Vacaville, CA 95688-9431</span>", "ID": "5f217805-6c65-4db2-a84a-2e3c78f8f9e4", "Styles": "None", "Classes": "None", "Text": "Vacaville, CA 95688-9431", "ParentId": "4044136c-b0a1-470e-8584-c6c522e6221f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">USA</span></p>", "ID": "b8799273-713a-4bc9-a4f8-58058c699504", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">USA</span>", "ID": "25aa049b-bfd4-4f8e-8d54-0794d03e20f9", "Styles": "None", "Classes": "None", "Text": "USA", "ParentId": "b8799273-713a-4bc9-a4f8-58058c699504"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "731c9534-be32-4612-bc29-a8e20616ea29", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "cbfeabb3-ade9-4854-b276-35646a5eb109", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "731c9534-be32-4612-bc29-a8e20616ea29"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><u><span lang=\"EN-GB\">Name and address of the manufacturer responsible for batch release</span></u></p>", "ID": "e5073a0d-a146-4de8-99b7-866cd6017dff", "Styles": "margin-left:.5in;text-indent:-.5in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<u><span lang=\"EN-GB\">Name and address of the manufacturer responsible for batch release</span></u>", "ID": "0fa305bb-4b23-4160-90e6-616e9cb8ab5c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e5073a0d-a146-4de8-99b7-866cd6017dff"}, {"Element": "<span lang=\"EN-GB\">Name and address of the manufacturer responsible for batch release</span>", "ID": "dc3f69ed-3483-4dbc-91b1-8e1248b4a341", "Styles": "None", "Classes": "None", "Text": "Name and address of the manufacturer responsible for batch release", "ParentId": "0fa305bb-4b23-4160-90e6-616e9cb8ab5c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche Pharma AG</span></p>", "ID": "e80c8cbd-6a09-4651-9152-38faedc43ad6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"DE-CH\">Roche Pharma AG</span>", "ID": "c32dcd02-3d00-42dd-8b9c-ba54dea4c22e", "Styles": "None", "Classes": "None", "Text": "Roche Pharma AG", "ParentId": "e80c8cbd-6a09-4651-9152-38faedc43ad6"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE-CH\">Emil-Barell-Strasse 1</span></p>", "ID": "f36d75d5-5eff-437f-b407-c792c1de20ba", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"DE-CH\">Emil-Barell-Strasse 1</span>", "ID": "af0c91f1-f5ff-42a0-a6da-f22f44e4d197", "Styles": "None", "Classes": "None", "Text": "Emil-Barell-Strasse 1", "ParentId": "f36d75d5-5eff-437f-b407-c792c1de20ba"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">D-79639 Grenzach-Whylen</span></p>", "ID": "ec62b41a-9e24-4f6f-95da-4a099555298a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">D-79639 Grenzach-Whylen</span>", "ID": "7d170c26-da1c-4a0b-b93e-7ba8d98e4c80", "Styles": "None", "Classes": "None", "Text": "D-79639 Grenzach-Whylen", "ParentId": "ec62b41a-9e24-4f6f-95da-4a099555298a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Germany</span></p>", "ID": "feb9f383-ea9a-4880-be8a-7111f443b205", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Germany</span>", "ID": "dfb5d6e2-b822-42ea-a2a4-f8b2677e3382", "Styles": "None", "Classes": "None", "Text": "Germany", "ParentId": "feb9f383-ea9a-4880-be8a-7111f443b205"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:10.0pt\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d2b98f17-405c-47f2-9fbb-c24f115f8da0", "Styles": "line-height:10.0pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6daa66ab-9823-49b1-8f78-818ea7b073f2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d2b98f17-405c-47f2-9fbb-c24f115f8da0"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:10.0pt\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0807c334-8fa4-4f03-a855-49fa3758b65d", "Styles": "line-height:10.0pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9e87d29e-e14f-4076-a046-ac4bf066fad9", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0807c334-8fa4-4f03-a855-49fa3758b65d"}, {"Element": "<p class=\"AnnexHeading\"><span lang=\"EN-GB\">B.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR RESTRICTIONS\nREGARDING SUPPLY AND USE</span></p>", "ID": "c2f2f3d7-a8d2-4816-837d-b558bb4b6209", "Styles": "None", "Classes": "['AnnexHeading']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">B.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR RESTRICTIONS\nREGARDING SUPPLY AND USE</span>", "ID": "fc9957bc-4313-40d7-b8f9-492d09963196", "Styles": "None", "Classes": "None", "Text": "B.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE", "ParentId": "c2f2f3d7-a8d2-4816-837d-b558bb4b6209"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a5ba8176-219e-4349-8516-51d401649c23", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "29b64c71-23f8-4ac9-bd7c-edbc6a66f967", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a5ba8176-219e-4349-8516-51d401649c23"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Medicinal product subject to restricted\nmedical prescription (see Annex I: Summary of Product Characteristics, section\n4.2).</span></p>", "ID": "a7b9d617-316e-44ce-a724-441929fb3d0e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Medicinal product subject to restricted\nmedical prescription (see Annex I: Summary of Product Characteristics, section\n4.2).</span>", "ID": "df15c4f3-cac1-4533-bb96-39a9d7377bf2", "Styles": "None", "Classes": "None", "Text": "Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).", "ParentId": "a7b9d617-316e-44ce-a724-441929fb3d0e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "79010370-1637-459b-8ae8-c03af94113ef", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a1d339c3-84ae-476b-81d9-7f24c6ae1fe7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "79010370-1637-459b-8ae8-c03af94113ef"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:10.0pt\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9f2a9407-4eff-44e0-8a11-e00b982d180d", "Styles": "line-height:10.0pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3d4eb2e5-7c80-437f-b77f-2765da7171de", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9f2a9407-4eff-44e0-8a11-e00b982d180d"}, {"Element": "<p class=\"AnnexHeading\"><span lang=\"EN-GB\">C. \u00a0\u00a0\u00a0\u00a0 OTHER CONDITIONS AND\nREQUIREMENTS OF THE MARKETING AUTHORISATION </span></p>", "ID": "f5d1c76f-64bc-4ff4-af17-a023a3399be7", "Styles": "None", "Classes": "['AnnexHeading']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">C. \u00a0\u00a0\u00a0\u00a0 OTHER CONDITIONS AND\nREQUIREMENTS OF THE MARKETING AUTHORISATION </span>", "ID": "afbd044c-de82-4785-99a5-ef087e453e73", "Styles": "None", "Classes": "None", "Text": "C. \u00a0\u00a0\u00a0\u00a0 OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION ", "ParentId": "f5d1c76f-64bc-4ff4-af17-a023a3399be7"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:10.0pt\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8ed2996b-cfb9-40d4-b9c0-727a66dea4ab", "Styles": "line-height:10.0pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "eeac77b6-a14f-485e-8cb6-e182b7ea188a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8ed2996b-cfb9-40d4-b9c0-727a66dea4ab"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.05pt;line-height:13.0pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span><b><span lang=\"EN-GB\">Periodic safety update reports </span></b></p>", "ID": "09e77dc3-8637-47ae-98fe-6873dd28cc74", "Styles": "margin-right:-.05pt;line-height:13.0pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "2d06b280-a39c-4f00-8c1c-5e4b633e05a5", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "09e77dc3-8637-47ae-98fe-6873dd28cc74"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span>", "ID": "2670bb50-aa06-41ae-94d9-b336f2a096fc", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "09e77dc3-8637-47ae-98fe-6873dd28cc74"}, {"Element": "<b><span lang=\"EN-GB\">Periodic safety update reports </span></b>", "ID": "34389d1e-65cd-406b-801d-68a0813f1482", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "09e77dc3-8637-47ae-98fe-6873dd28cc74"}, {"Element": "<span lang=\"EN-GB\">Periodic safety update reports </span>", "ID": "051ea833-c8b5-420e-b11e-43e788a05695", "Styles": "None", "Classes": "None", "Text": "Periodic safety update reports ", "ParentId": "34389d1e-65cd-406b-801d-68a0813f1482"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:28.35pt;line-height:13.0pt\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5b3f33ec-d461-4de9-ad19-7205f37719b7", "Styles": "margin-right:28.35pt;line-height:13.0pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2b7c71a9-7064-4997-a85f-0d197193ac51", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5b3f33ec-d461-4de9-ad19-7205f37719b7"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:14.0pt\">The requirements for submission\nof periodic safety update reports for this medicinal product are <span lang=\"EN-GB\">set out in the list of Union reference dates (EURD list) provided\nfor under Article 107c(7) of Directive 2001/83/EC and any subsquent updates published\non the European medicines web-portal.</span></p>", "ID": "5a211845-4da2-4df6-96fd-88558b0ab424", "Styles": "line-height:14.0pt", "Classes": "['MsoNormal']", "Text": "The requirements for submission of periodic safety update reports for this medicinal product are ", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">set out in the list of Union reference dates (EURD list) provided\nfor under Article 107c(7) of Directive 2001/83/EC and any subsquent updates published\non the European medicines web-portal.</span>", "ID": "0f5aad77-75b6-4710-8de8-341dcfc9b832", "Styles": "None", "Classes": "None", "Text": "set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsquent updates published on the European medicines web-portal.", "ParentId": "5a211845-4da2-4df6-96fd-88558b0ab424"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:28.35pt;line-height:13.0pt\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "dd730eb9-e218-4bdb-a55f-2c094ddd0fe9", "Styles": "margin-right:28.35pt;line-height:13.0pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "54813e69-21ec-452f-bcab-ea131f307af1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "dd730eb9-e218-4bdb-a55f-2c094ddd0fe9"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:28.35pt;line-height:13.0pt\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c8eba283-a8f1-44cf-8d04-8dd789340d65", "Styles": "margin-right:28.35pt;line-height:13.0pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "375a6f83-eb63-4551-92fc-fea9abb66272", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c8eba283-a8f1-44cf-8d04-8dd789340d65"}, {"Element": "<p class=\"AnnexHeading\"><span lang=\"EN-GB\">D.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR RESTRICTIONS WITH\nREGARD TO THE SAFE AND EFFECTIVE\u00a0 USE OF THE MEDICINAL PRODUCT</span></p>", "ID": "4849652e-58e6-414a-ad24-34e85fe62163", "Styles": "None", "Classes": "['AnnexHeading']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">D.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR RESTRICTIONS WITH\nREGARD TO THE SAFE AND EFFECTIVE\u00a0 USE OF THE MEDICINAL PRODUCT</span>", "ID": "1a7e7bb8-ef14-4a84-b089-500719e2a360", "Styles": "None", "Classes": "None", "Text": "D.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE\u00a0 USE OF THE MEDICINAL PRODUCT", "ParentId": "4849652e-58e6-414a-ad24-34e85fe62163"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:28.35pt;line-height:11.0pt\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3199be7d-31c4-4b93-a35c-eb225666e43a", "Styles": "margin-right:28.35pt;line-height:11.0pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7e258e9b-6764-4468-a2e3-840cdeaf1464", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3199be7d-31c4-4b93-a35c-eb225666e43a"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.05pt;line-height:13.0pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span><b><span lang=\"EN-GB\">Risk Management Plan (RMP)</span></b></p>", "ID": "2911aefa-526a-4f64-be1e-28b21998925f", "Styles": "margin-right:-.05pt;line-height:13.0pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "8da51997-e46c-4f63-91f8-80d16d6f3da0", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "2911aefa-526a-4f64-be1e-28b21998925f"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span>", "ID": "9f1c5e2b-6431-45a4-b0cd-128361f48f1c", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "2911aefa-526a-4f64-be1e-28b21998925f"}, {"Element": "<b><span lang=\"EN-GB\">Risk Management Plan (RMP)</span></b>", "ID": "93fc8bfc-ed75-4889-b707-84816e65d296", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "2911aefa-526a-4f64-be1e-28b21998925f"}, {"Element": "<span lang=\"EN-GB\">Risk Management Plan (RMP)</span>", "ID": "98257980-cf8b-45db-bb12-0b96eaef0cf5", "Styles": "None", "Classes": "None", "Text": "Risk Management Plan (RMP)", "ParentId": "93fc8bfc-ed75-4889-b707-84816e65d296"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.05pt;margin-bottom:\n0in;margin-left:.5in;margin-bottom:.0001pt;line-height:13.0pt\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "2da2d2d6-7ef9-4230-b490-5390fbad3600", "Styles": "margin-top:0in;margin-right:-.05pt;margin-bottom:\n0in;margin-left:.5in;margin-bottom:.0001pt;line-height:13.0pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "c3c8058e-1fae-4f7c-9a08-31850af680a4", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "2da2d2d6-7ef9-4230-b490-5390fbad3600"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "dca2b435-df1f-413c-9cda-5ebcda36554b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c3c8058e-1fae-4f7c-9a08-31850af680a4"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:28.35pt;line-height:13.0pt\"><span lang=\"EN-GB\">The MAH shall perform the required\u00a0 pharmacovigilance activities and\ninterventions detailed in the\u00a0 agreed RMP presented in Module 1.8.2 of the\nMarketing Authorisation and any agreeed\u00a0 subsequent updates of the RMP.</span></p>", "ID": "762d281b-b31f-4d5a-b650-7bd53fd76651", "Styles": "margin-right:28.35pt;line-height:13.0pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">The MAH shall perform the required\u00a0 pharmacovigilance activities and\ninterventions detailed in the\u00a0 agreed RMP presented in Module 1.8.2 of the\nMarketing Authorisation and any agreeed\u00a0 subsequent updates of the RMP.</span>", "ID": "375dff66-d56e-4931-9b5d-a97b44258a47", "Styles": "None", "Classes": "None", "Text": "The MAH shall perform the required\u00a0 pharmacovigilance activities and interventions detailed in the\u00a0 agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreeed\u00a0 subsequent updates of the RMP.", "ParentId": "762d281b-b31f-4d5a-b650-7bd53fd76651"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.05pt;line-height:13.0pt\"><span lang=\"EN-GB\">An updated RMP should be submitted:</span></p>", "ID": "730d865f-5d8b-48d2-a81a-3c0bc1651410", "Styles": "margin-right:-.05pt;line-height:13.0pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">An updated RMP should be submitted:</span>", "ID": "7f341f91-3d89-4e53-b4e4-c163d8505b7b", "Styles": "None", "Classes": "None", "Text": "An updated RMP should be submitted:", "ParentId": "730d865f-5d8b-48d2-a81a-3c0bc1651410"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.05pt;margin-bottom:\n0in;margin-left:14.2pt;margin-bottom:.0001pt;line-height:13.0pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0 </span><span lang=\"EN-GB\">At the request of the European Medicines Agency;</span></p>", "ID": "6ce56bad-fd91-4d9c-86bd-219e0432cf15", "Styles": "margin-top:0in;margin-right:-.05pt;margin-bottom:\n0in;margin-left:14.2pt;margin-bottom:.0001pt;line-height:13.0pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "202ca573-e326-4890-b2f1-b972bfacd6fe", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "6ce56bad-fd91-4d9c-86bd-219e0432cf15"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0 </span>", "ID": "b5d803b2-ae2d-476b-9344-ae2e305fb66a", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0 ", "ParentId": "6ce56bad-fd91-4d9c-86bd-219e0432cf15"}, {"Element": "<span lang=\"EN-GB\">At the request of the European Medicines Agency;</span>", "ID": "7a6d45e8-df7e-47a5-a826-db5621a44908", "Styles": "None", "Classes": "None", "Text": "At the request of the European Medicines Agency;", "ParentId": "6ce56bad-fd91-4d9c-86bd-219e0432cf15"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-12.8pt;line-height:\n13.0pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0 Whenever\nthe risk management system is modified, especially as the result of new\ninformation being received that may lead to a significant change to the\nbenefit/risk profile or as the result of an important (pharmacovigilance or\nrisk minimisation) milestone being reached. </span></p>", "ID": "bc11167e-ac92-4d25-a478-0b5da1041f1e", "Styles": "margin-left:27.0pt;text-indent:-12.8pt;line-height:\n13.0pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "668f3178-c9f8-4aef-9679-3e62956aaed1", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "bc11167e-ac92-4d25-a478-0b5da1041f1e"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0 Whenever\nthe risk management system is modified, especially as the result of new\ninformation being received that may lead to a significant change to the\nbenefit/risk profile or as the result of an important (pharmacovigilance or\nrisk minimisation) milestone being reached. </span>", "ID": "aba50e12-63fc-4c38-9f0b-47d7fbab51b6", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0 Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached. ", "ParentId": "bc11167e-ac92-4d25-a478-0b5da1041f1e"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:28.35pt;line-height:13.0pt\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c0bccb2e-e8a8-45d2-b2df-be47ce6f6b70", "Styles": "margin-right:28.35pt;line-height:13.0pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ecc0c64c-2279-4149-b175-ad542416ccc5", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c0bccb2e-e8a8-45d2-b2df-be47ce6f6b70"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.05pt;line-height:13.0pt;page-break-after:\navoid\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span><b><span lang=\"EN-GB\">Obligation to conduct post-authorisation measures</span></b></p>", "ID": "5053a40f-1db7-467b-a8cf-26eb3dd55740", "Styles": "margin-right:-.05pt;line-height:13.0pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "ef2da175-9d89-4b78-9aae-4588412f47aa", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "5053a40f-1db7-467b-a8cf-26eb3dd55740"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span>", "ID": "84f2c262-f371-4306-b0eb-9c19950e328b", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "5053a40f-1db7-467b-a8cf-26eb3dd55740"}, {"Element": "<b><span lang=\"EN-GB\">Obligation to conduct post-authorisation measures</span></b>", "ID": "b883f1d0-bd85-49b1-a6bd-1901075b1311", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "5053a40f-1db7-467b-a8cf-26eb3dd55740"}, {"Element": "<span lang=\"EN-GB\">Obligation to conduct post-authorisation measures</span>", "ID": "447a28fb-6a18-4e12-a43c-e6eb25925964", "Styles": "None", "Classes": "None", "Text": "Obligation to conduct post-authorisation measures", "ParentId": "b883f1d0-bd85-49b1-a6bd-1901075b1311"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.05pt;line-height:13.0pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "521453aa-4948-4f18-b702-1953199fb7d7", "Styles": "margin-right:-.05pt;line-height:13.0pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "4189fe53-0622-4b7f-9b47-80fc8034fa1a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "521453aa-4948-4f18-b702-1953199fb7d7"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9334da52-f5a7-4320-9d21-954b089ac9ef", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4189fe53-0622-4b7f-9b47-80fc8034fa1a"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:28.35pt;line-height:13.0pt;page-break-after:\navoid\"><span lang=\"EN-GB\">The MAH shall complete, within the stated timeframe,\nthe following measures:</span></p>", "ID": "0bc77311-9c3c-486f-abdb-f2750335c14b", "Styles": "margin-right:28.35pt;line-height:13.0pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">The MAH shall complete, within the stated timeframe,\nthe following measures:</span>", "ID": "82769b2c-1875-4c86-8311-a1c248acaf1f", "Styles": "None", "Classes": "None", "Text": "The MAH shall complete, within the stated timeframe, the following measures:", "ParentId": "0bc77311-9c3c-486f-abdb-f2750335c14b"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:28.35pt;line-height:13.0pt;page-break-after:\navoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4fc0c566-c8f3-4f61-a9d9-5b28fd9740c1", "Styles": "margin-right:28.35pt;line-height:13.0pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8e9a8c6a-4e8b-43bc-baeb-215ce8567c10", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4fc0c566-c8f3-4f61-a9d9-5b28fd9740c1"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:98.0%;border-collapse:collapse;border:none\" width=\"98%\">\n<tr>\n<td style=\"width:83.62%;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"83%\">\n<p class=\"MsoNormal\" style=\"margin-right:-.05pt\"><b><span lang=\"EN-GB\">Description</span></b></p>\n</td>\n<td style=\"width:16.38%;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16%\">\n<p class=\"MsoBodyText\"><b><span lang=\"EN-GB\" style=\"color:windowtext;font-style:\n  normal\">Due date</span></b></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:83.62%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"83%\">\n<p class=\"MsoNormal\" style=\"line-height:14.0pt\"><span lang=\"EN-GB\">MO28047\n  (PERUSE) </span></p>\n<p class=\"MsoNormal\" style=\"line-height:14.0pt\"><span lang=\"EN-GB\">A multicenter,\n  open-label, single-arm study of pertuzumab in combination with trastuzumab\n  and a taxane in first line treatment of patients with HER2- positive advanced\n  (metastatic or locally recurrent) breast cancer</span></p>\n<p class=\"MsoNormal\" style=\"line-height:14.0pt\"><span lang=\"EN-GB\" style='font-size:9.0pt;font-family:\"Verdana\",sans-serif'>\u00a0</span></p>\n</td>\n<td style=\"width:16.38%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16%\">\n<p class=\"MsoNormal\" style=\"line-height:14.0pt\"><span lang=\"EN-GB\">September 2020</span></p>\n</td>\n</tr>\n</table>", "ID": "c4d51d15-e580-49d0-9c64-b7366cc1508e", "Styles": "width:98.0%;border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Text": "   ", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<tr>\n<td style=\"width:83.62%;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"83%\">\n<p class=\"MsoNormal\" style=\"margin-right:-.05pt\"><b><span lang=\"EN-GB\">Description</span></b></p>\n</td>\n<td style=\"width:16.38%;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16%\">\n<p class=\"MsoBodyText\"><b><span lang=\"EN-GB\" style=\"color:windowtext;font-style:\n  normal\">Due date</span></b></p>\n</td>\n</tr>", "ID": "57dbb60e-09e6-4b6c-bde5-0b54e674b0d5", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "c4d51d15-e580-49d0-9c64-b7366cc1508e"}, {"Element": "<td style=\"width:83.62%;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"83%\">\n<p class=\"MsoNormal\" style=\"margin-right:-.05pt\"><b><span lang=\"EN-GB\">Description</span></b></p>\n</td>", "ID": "d70f3adb-d123-42a3-83ce-626af0e9729b", "Styles": "width:83.62%;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "57dbb60e-09e6-4b6c-bde5-0b54e674b0d5"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.05pt\"><b><span lang=\"EN-GB\">Description</span></b></p>", "ID": "478a1f52-ff4d-4f77-9e96-e57fec9e41cd", "Styles": "margin-right:-.05pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d70f3adb-d123-42a3-83ce-626af0e9729b"}, {"Element": "<b><span lang=\"EN-GB\">Description</span></b>", "ID": "f14b8b3b-e528-4d5c-bc32-30773fb5367c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "478a1f52-ff4d-4f77-9e96-e57fec9e41cd"}, {"Element": "<span lang=\"EN-GB\">Description</span>", "ID": "e0379832-0941-4f2d-8751-ffeaa5aea698", "Styles": "None", "Classes": "None", "Text": "Description", "ParentId": "f14b8b3b-e528-4d5c-bc32-30773fb5367c"}, {"Element": "<td style=\"width:16.38%;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16%\">\n<p class=\"MsoBodyText\"><b><span lang=\"EN-GB\" style=\"color:windowtext;font-style:\n  normal\">Due date</span></b></p>\n</td>", "ID": "f8cff533-386c-40f2-baba-336716e2ade7", "Styles": "width:16.38%;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "57dbb60e-09e6-4b6c-bde5-0b54e674b0d5"}, {"Element": "<p class=\"MsoBodyText\"><b><span lang=\"EN-GB\" style=\"color:windowtext;font-style:\n  normal\">Due date</span></b></p>", "ID": "1edc381c-b7c6-489e-a065-20afc5be2ac1", "Styles": "None", "Classes": "['MsoBodyText']", "Text": "", "ParentId": "f8cff533-386c-40f2-baba-336716e2ade7"}, {"Element": "<b><span lang=\"EN-GB\" style=\"color:windowtext;font-style:\n  normal\">Due date</span></b>", "ID": "4ec2f187-a112-407e-812d-8fef3ae5ab9f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "1edc381c-b7c6-489e-a065-20afc5be2ac1"}, {"Element": "<span lang=\"EN-GB\" style=\"color:windowtext;font-style:\n  normal\">Due date</span>", "ID": "edb4a23d-a1c4-407b-a444-35d5e6a58dcd", "Styles": "color:windowtext;font-style:\n  normal", "Classes": "None", "Text": "Due date", "ParentId": "4ec2f187-a112-407e-812d-8fef3ae5ab9f"}, {"Element": "<tr>\n<td style=\"width:83.62%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"83%\">\n<p class=\"MsoNormal\" style=\"line-height:14.0pt\"><span lang=\"EN-GB\">MO28047\n  (PERUSE) </span></p>\n<p class=\"MsoNormal\" style=\"line-height:14.0pt\"><span lang=\"EN-GB\">A multicenter,\n  open-label, single-arm study of pertuzumab in combination with trastuzumab\n  and a taxane in first line treatment of patients with HER2- positive advanced\n  (metastatic or locally recurrent) breast cancer</span></p>\n<p class=\"MsoNormal\" style=\"line-height:14.0pt\"><span lang=\"EN-GB\" style='font-size:9.0pt;font-family:\"Verdana\",sans-serif'>\u00a0</span></p>\n</td>\n<td style=\"width:16.38%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16%\">\n<p class=\"MsoNormal\" style=\"line-height:14.0pt\"><span lang=\"EN-GB\">September 2020</span></p>\n</td>\n</tr>", "ID": "323f6a6a-b38f-4ba0-a631-0556ebc49910", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "c4d51d15-e580-49d0-9c64-b7366cc1508e"}, {"Element": "<td style=\"width:83.62%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"83%\">\n<p class=\"MsoNormal\" style=\"line-height:14.0pt\"><span lang=\"EN-GB\">MO28047\n  (PERUSE) </span></p>\n<p class=\"MsoNormal\" style=\"line-height:14.0pt\"><span lang=\"EN-GB\">A multicenter,\n  open-label, single-arm study of pertuzumab in combination with trastuzumab\n  and a taxane in first line treatment of patients with HER2- positive advanced\n  (metastatic or locally recurrent) breast cancer</span></p>\n<p class=\"MsoNormal\" style=\"line-height:14.0pt\"><span lang=\"EN-GB\" style='font-size:9.0pt;font-family:\"Verdana\",sans-serif'>\u00a0</span></p>\n</td>", "ID": "00f761f8-f279-46fa-8f88-3c062a2ece0d", "Styles": "width:83.62%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "    ", "ParentId": "323f6a6a-b38f-4ba0-a631-0556ebc49910"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:14.0pt\"><span lang=\"EN-GB\">MO28047\n  (PERUSE) </span></p>", "ID": "a277d0e3-2b52-47b4-a123-198af4dc6a7c", "Styles": "line-height:14.0pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "00f761f8-f279-46fa-8f88-3c062a2ece0d"}, {"Element": "<span lang=\"EN-GB\">MO28047\n  (PERUSE) </span>", "ID": "90f63b20-b4e7-4288-82d4-40fa300677b9", "Styles": "None", "Classes": "None", "Text": "MO28047   (PERUSE) ", "ParentId": "a277d0e3-2b52-47b4-a123-198af4dc6a7c"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:14.0pt\"><span lang=\"EN-GB\">A multicenter,\n  open-label, single-arm study of pertuzumab in combination with trastuzumab\n  and a taxane in first line treatment of patients with HER2- positive advanced\n  (metastatic or locally recurrent) breast cancer</span></p>", "ID": "b97a4404-8720-4b88-b610-e5dda7695437", "Styles": "line-height:14.0pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "00f761f8-f279-46fa-8f88-3c062a2ece0d"}, {"Element": "<span lang=\"EN-GB\">A multicenter,\n  open-label, single-arm study of pertuzumab in combination with trastuzumab\n  and a taxane in first line treatment of patients with HER2- positive advanced\n  (metastatic or locally recurrent) breast cancer</span>", "ID": "18ee514a-090c-43e3-826f-8111764e5792", "Styles": "None", "Classes": "None", "Text": "A multicenter,   open-label, single-arm study of pertuzumab in combination with trastuzumab   and a taxane in first line treatment of patients with HER2- positive advanced   (metastatic or locally recurrent) breast cancer", "ParentId": "b97a4404-8720-4b88-b610-e5dda7695437"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:14.0pt\"><span lang=\"EN-GB\" style='font-size:9.0pt;font-family:\"Verdana\",sans-serif'>\u00a0</span></p>", "ID": "80375517-bd21-4b24-9ed3-d4dc8e755aa3", "Styles": "line-height:14.0pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "00f761f8-f279-46fa-8f88-3c062a2ece0d"}, {"Element": "<span lang=\"EN-GB\" style='font-size:9.0pt;font-family:\"Verdana\",sans-serif'>\u00a0</span>", "ID": "f6749e53-5748-497e-8333-42eea5ebabbe", "Styles": "font-size:9.0pt;font-family:\"Verdana\",sans-serif", "Classes": "None", "Text": "\u00a0", "ParentId": "80375517-bd21-4b24-9ed3-d4dc8e755aa3"}, {"Element": "<td style=\"width:16.38%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16%\">\n<p class=\"MsoNormal\" style=\"line-height:14.0pt\"><span lang=\"EN-GB\">September 2020</span></p>\n</td>", "ID": "59004eec-f73d-4084-a011-9d48c73de62f", "Styles": "width:16.38%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "323f6a6a-b38f-4ba0-a631-0556ebc49910"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:14.0pt\"><span lang=\"EN-GB\">September 2020</span></p>", "ID": "59d7492d-a32b-430a-9ff5-743f1fdac3c6", "Styles": "line-height:14.0pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "59004eec-f73d-4084-a011-9d48c73de62f"}, {"Element": "<span lang=\"EN-GB\">September 2020</span>", "ID": "4324bfdc-de57-4e4f-b325-b99452dbfc1c", "Styles": "None", "Classes": "None", "Text": "September 2020", "ParentId": "59d7492d-a32b-430a-9ff5-743f1fdac3c6"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>", "ID": "eff9c42f-b72a-4668-93e5-7ac2e034a248", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": " ", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<br clear=\"all\" style=\"page-break-before:always\"/>", "ID": "96f6c005-3f52-4a45-b4b1-c371ea173a79", "Styles": "page-break-before:always", "Classes": "None", "Text": "", "ParentId": "eff9c42f-b72a-4668-93e5-7ac2e034a248"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "412a5091-8506-47bd-96c6-653c42f6440f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "55bf49e2-d049-416a-bf1d-29d13f0142dd", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "412a5091-8506-47bd-96c6-653c42f6440f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "99d41422-cd87-4473-8430-0fe2cb524fb3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0df91227-3001-4e9b-a315-263affe1bba0", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "99d41422-cd87-4473-8430-0fe2cb524fb3"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e48b032a-44ca-4264-a27a-a2c89f0a3672", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4dcae4b0-603a-4657-bad8-e1093435df47", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e48b032a-44ca-4264-a27a-a2c89f0a3672"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d25ffcf2-5f7f-40d2-971c-0d86ff3f4fae", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c1286962-96f3-4c43-a285-172a1b4ba072", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d25ffcf2-5f7f-40d2-971c-0d86ff3f4fae"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "22d0b18e-6c2a-49e8-92d3-1873a9a19fb1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "bf244dd3-da36-4f80-9486-71c978bc5709", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "22d0b18e-6c2a-49e8-92d3-1873a9a19fb1"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5b7cbce2-861a-4b4d-bc6c-ba64ac7b168f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8f47cdb5-f93c-4f01-bc0e-fbf0905eef5e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5b7cbce2-861a-4b4d-bc6c-ba64ac7b168f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d3c08c31-051c-490a-a856-33d6133944b8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e13621a6-8b36-448f-9391-2273442e98c9", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d3c08c31-051c-490a-a856-33d6133944b8"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e471b473-c1be-4214-a1a6-11fc8beff265", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "66b83172-1728-4a9f-8e29-2faefafc87ac", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e471b473-c1be-4214-a1a6-11fc8beff265"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "140aab4e-c408-49fc-884e-495829be2a89", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9629d4a0-df57-4a54-aafb-aa3b7213df0f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "140aab4e-c408-49fc-884e-495829be2a89"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7e41dee6-fdfd-4297-8d10-316958578e34", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ea216b15-57fb-4805-b8cf-b80c6cc9371f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7e41dee6-fdfd-4297-8d10-316958578e34"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "18d32678-85e2-4d4f-b1aa-8276eec40850", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "fd8fd10e-f35f-4d45-8202-0b5b2dee2225", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "18d32678-85e2-4d4f-b1aa-8276eec40850"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "cd809345-6a41-48a3-8f75-a9a5e7566edd", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3f9c7db4-1cd9-496e-b374-3c0cea9d863a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "cd809345-6a41-48a3-8f75-a9a5e7566edd"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "11951c6e-1914-4a1d-b7fd-81a26b220961", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "157c9a6f-9b4d-4eb7-aa77-f34622ca0214", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "11951c6e-1914-4a1d-b7fd-81a26b220961"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3fd3172a-55ae-491d-bbc1-8efc5afc54ed", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9b341ba8-0e20-4c64-b1e4-f1c2ec25a896", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3fd3172a-55ae-491d-bbc1-8efc5afc54ed"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5d934905-4f66-42c6-b766-f056b28fa31c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "363220e2-0c72-433f-aca7-1c37231a4ae7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5d934905-4f66-42c6-b766-f056b28fa31c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "28c2e011-b594-4633-9ba3-7df308f66573", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e316d66b-0019-4459-90fb-4b7a7d331a38", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "28c2e011-b594-4633-9ba3-7df308f66573"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "67048da3-75ed-4081-9986-3f02d73d1a0e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "398c7216-c8bb-407f-b5d7-82f563008cfc", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "67048da3-75ed-4081-9986-3f02d73d1a0e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "794836ae-d048-41b7-b8a6-bf8caae9992d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6aee5c2b-ac88-4557-87c0-53e3fea72ce2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "794836ae-d048-41b7-b8a6-bf8caae9992d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7eaeddb1-1661-4242-b36d-7805d2ac03e8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "57742c01-e24d-42c0-8c96-f46309532e60", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7eaeddb1-1661-4242-b36d-7805d2ac03e8"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "fa92bbd2-f89b-44c0-bad1-4939c432a082", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8fce0522-94e4-4147-b90a-4dc3247f3353", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "fa92bbd2-f89b-44c0-bad1-4939c432a082"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e9e0e271-b175-42de-b940-52ece8b77f65", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "38e655aa-a895-402d-adee-680ecdbe82cb", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e9e0e271-b175-42de-b940-52ece8b77f65"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0d759045-859d-42d6-ba8c-8ff9dfab54d2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c478a109-843a-49d6-a653-2f5a669e56d2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0d759045-859d-42d6-ba8c-8ff9dfab54d2"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d367511e-7ba0-4bcc-8c9b-cc3b07a94e66", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5122c3f1-cf54-4806-9b4e-e0b92ea03781", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d367511e-7ba0-4bcc-8c9b-cc3b07a94e66"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2a36181b-1852-4775-8b99-5c6b7f014500", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a1739224-0d77-42ce-b1eb-97e39dd0d3d7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2a36181b-1852-4775-8b99-5c6b7f014500"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">ANNEX\nIII</span></b></p>", "ID": "6b6c6578-3e31-4577-bab4-b66598afae40", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">ANNEX\nIII</span></b>", "ID": "b537b7f3-6985-4967-913c-131af5caec66", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "6b6c6578-3e31-4577-bab4-b66598afae40"}, {"Element": "<span lang=\"EN-GB\">ANNEX\nIII</span>", "ID": "4c7755a7-165f-4fba-b342-686dd736f629", "Styles": "None", "Classes": "None", "Text": "ANNEX III", "ParentId": "b537b7f3-6985-4967-913c-131af5caec66"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "c22a5ef7-0a6b-4362-b378-0369b7102712", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "946e692c-d270-4964-be1a-0399c913cbc5", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c22a5ef7-0a6b-4362-b378-0369b7102712"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "594383fc-8f00-42e8-bae8-ece71878791b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "946e692c-d270-4964-be1a-0399c913cbc5"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">LABELLING\nAND PACKAGE LEAFLET</span></b></p>", "ID": "498a2c52-453f-42b0-96ef-2e3c7de6adf7", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">LABELLING\nAND PACKAGE LEAFLET</span></b>", "ID": "a323429d-ba39-4af8-b50e-ddb017eb9efc", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "498a2c52-453f-42b0-96ef-2e3c7de6adf7"}, {"Element": "<span lang=\"EN-GB\">LABELLING\nAND PACKAGE LEAFLET</span>", "ID": "4d81ea8f-1a0f-457e-956a-18b259af53ff", "Styles": "None", "Classes": "None", "Text": "LABELLING AND PACKAGE LEAFLET", "ParentId": "a323429d-ba39-4af8-b50e-ddb017eb9efc"}, {"Element": "<b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span></b>", "ID": "4528a111-8996-4868-bb53-6be0a9be11d1", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>", "ID": "0d845869-9315-49f2-87df-81eb1291dd36", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": " ", "ParentId": "4528a111-8996-4868-bb53-6be0a9be11d1"}, {"Element": "<br clear=\"all\" style=\"page-break-before:always\"/>", "ID": "34f0b740-c225-4832-b7d4-1c3d3aef0ad4", "Styles": "page-break-before:always", "Classes": "None", "Text": "", "ParentId": "0d845869-9315-49f2-87df-81eb1291dd36"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "5e1a5c92-23d2-4cae-9466-a9337646cd4f", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "9c1cf218-ef7c-4e2d-8d8f-254a48e6150f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "5e1a5c92-23d2-4cae-9466-a9337646cd4f"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3d87d559-b020-4b35-9fa8-d3f713399509", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9c1cf218-ef7c-4e2d-8d8f-254a48e6150f"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "be2db06b-49b7-47a9-a0c0-5ae25bb87505", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7896dedd-8935-40c0-8e1b-e82543ede261", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "be2db06b-49b7-47a9-a0c0-5ae25bb87505"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "548143b3-e019-46bc-9b1c-39348f75bce9", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "abbd9173-df39-4093-8eae-4848eb8afaba", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "548143b3-e019-46bc-9b1c-39348f75bce9"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a1bd3304-540a-4146-8abe-c69fa5fe1007", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0b2c3eb4-1565-4e96-8a87-bc1abcff6e6f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a1bd3304-540a-4146-8abe-c69fa5fe1007"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d2bd8830-f9a0-4a75-b046-eba020db669b", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "670eca3a-21dd-4222-bd20-0ad19a810282", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d2bd8830-f9a0-4a75-b046-eba020db669b"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3145bb9d-9d7a-4be5-bb19-b7cda1fe4dcf", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3ad75c68-3f14-4076-88d7-1f2fd4045479", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3145bb9d-9d7a-4be5-bb19-b7cda1fe4dcf"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0fb3a3ec-04b1-4a95-8d1b-8a83fbc87694", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ba1c9629-0c82-4cb1-9421-edf3df2767fb", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0fb3a3ec-04b1-4a95-8d1b-8a83fbc87694"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "85595631-f9f2-48eb-8670-6ca0d042036e", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0b947611-4dc8-4c64-aac4-b45e6b9b37b1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "85595631-f9f2-48eb-8670-6ca0d042036e"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "fc25b609-acaa-4932-96be-170d19912b38", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8a0708b5-8da2-4493-a189-6f4dcc1b3f9b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "fc25b609-acaa-4932-96be-170d19912b38"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "96dce387-cc7a-4aa5-9842-b3e21178e43c", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7cc4c5ac-6d28-4135-b28a-98c1cabcd0d3", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "96dce387-cc7a-4aa5-9842-b3e21178e43c"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0f7ea65a-d9fb-4f9a-b5ca-4dc452599c5c", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "900b4555-da69-4ef5-9020-3ac00433c8cb", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0f7ea65a-d9fb-4f9a-b5ca-4dc452599c5c"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0f4154ac-3f25-4245-8a02-a028571854af", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f4caecce-23ca-480d-9d2f-851f82d07213", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0f4154ac-3f25-4245-8a02-a028571854af"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5fcffa35-4ae0-47fe-8cdb-881738419a8a", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9c1862fc-53fa-44d0-8e78-bd60ac11945b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5fcffa35-4ae0-47fe-8cdb-881738419a8a"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "07a2e879-c958-4750-a500-84cbb7a6f8cf", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d7043460-7fcc-4b13-abda-b42005959c71", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "07a2e879-c958-4750-a500-84cbb7a6f8cf"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "94e48c13-d63a-4599-b74a-de9f058bd2a8", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "11de0cc3-11ec-4b8d-a253-a4b3e1f1312b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "94e48c13-d63a-4599-b74a-de9f058bd2a8"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "00dfe2db-d43b-4028-b95f-5b4258d8de40", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "56a43ca8-98c5-4418-b607-b8fee11e8535", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "00dfe2db-d43b-4028-b95f-5b4258d8de40"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "11eeaa36-1dfe-4127-b14a-ab33de0ae6bc", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "feda1ed4-c66a-4303-ba6b-071a7cc36f84", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "11eeaa36-1dfe-4127-b14a-ab33de0ae6bc"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "51a99768-1269-4987-ade8-e7b717dddf5a", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "03131730-445c-4ca7-b48a-5d7616209a24", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "51a99768-1269-4987-ade8-e7b717dddf5a"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8ebe723f-2b62-4afc-b26b-c86ea1dae2a3", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e449b5dc-109c-4352-a299-f7e666045a22", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8ebe723f-2b62-4afc-b26b-c86ea1dae2a3"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9d25a727-f062-4f40-9de8-fdee858ce13c", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d2f6e80e-f751-4800-a958-c2b7b4028810", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9d25a727-f062-4f40-9de8-fdee858ce13c"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "cdf19266-4761-4c8b-9837-92f29b88d659", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a2f3266d-f502-4ac5-9db0-de3532367ee4", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "cdf19266-4761-4c8b-9837-92f29b88d659"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>", "ID": "64ed5e7c-d5f0-4cff-a239-4fe877c2a51f", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span>", "ID": "115381e8-f1bf-4422-8e40-6fcef3fcdf08", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "64ed5e7c-d5f0-4cff-a239-4fe877c2a51f"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>", "ID": "1c6565e8-9b28-406f-bb50-68ef5c44c844", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span>", "ID": "af25ee07-39dc-4e25-bbca-e83e2d2a7e86", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "1c6565e8-9b28-406f-bb50-68ef5c44c844"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>", "ID": "1dadc275-7f6b-454f-830b-02d7e6d98563", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span>", "ID": "b0056be6-8e12-4310-b064-cbf128e5c965", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "1dadc275-7f6b-454f-830b-02d7e6d98563"}, {"Element": "<p class=\"Annex\"><span lang=\"EN-GB\">A. LABELLING</span></p>", "ID": "2ce9b73f-e381-40b3-8f64-188a155ffc6a", "Styles": "None", "Classes": "['Annex']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">A. LABELLING</span>", "ID": "f5758cc6-cd0d-41c6-b5e9-abb1d117416f", "Styles": "None", "Classes": "None", "Text": "A. LABELLING", "ParentId": "2ce9b73f-e381-40b3-8f64-188a155ffc6a"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>", "ID": "d235f2d2-174c-49fa-aeef-470e0f96ce11", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": " ", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<br clear=\"all\" style=\"page-break-before:always\"/>", "ID": "7bb8286b-7ea7-4107-ac0e-becffb2c5062", "Styles": "page-break-before:always", "Classes": "None", "Text": "", "ParentId": "d235f2d2-174c-49fa-aeef-470e0f96ce11"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "86168f2d-35dc-463a-bcd9-e18de279cebd", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "446d3da8-9ecf-4155-b51f-52dadd6f5596", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "86168f2d-35dc-463a-bcd9-e18de279cebd"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">PARTICULARS\nTO APPEAR ON THE OUTER PACKAGING</span></b></p>\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">CARTON</span></b></p>\n</div>", "ID": "56fe3102-1b72-4af2-af31-d3b3c4c3f06e", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "    ", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">PARTICULARS\nTO APPEAR ON THE OUTER PACKAGING</span></b></p>", "ID": "f20e2d68-10ae-44ea-88e8-009613540a77", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "56fe3102-1b72-4af2-af31-d3b3c4c3f06e"}, {"Element": "<b><span lang=\"EN-GB\">PARTICULARS\nTO APPEAR ON THE OUTER PACKAGING</span></b>", "ID": "9fee5b12-5645-4671-9bbb-d53de01efe9b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f20e2d68-10ae-44ea-88e8-009613540a77"}, {"Element": "<span lang=\"EN-GB\">PARTICULARS\nTO APPEAR ON THE OUTER PACKAGING</span>", "ID": "77f4dd56-fef1-4aea-834c-52d47f1fdd5c", "Styles": "None", "Classes": "None", "Text": "PARTICULARS TO APPEAR ON THE OUTER PACKAGING", "ParentId": "9fee5b12-5645-4671-9bbb-d53de01efe9b"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "26e4ec88-58cb-47fc-a4db-7c5b9af62c18", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "56fe3102-1b72-4af2-af31-d3b3c4c3f06e"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "c2872708-ad0a-4869-af70-bdd879d1b52c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "26e4ec88-58cb-47fc-a4db-7c5b9af62c18"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8d61cab0-b4f0-4834-aa9f-385b86f91480", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c2872708-ad0a-4869-af70-bdd879d1b52c"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">CARTON</span></b></p>", "ID": "be65e736-2c32-4046-8ab3-fafb3092d38d", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "56fe3102-1b72-4af2-af31-d3b3c4c3f06e"}, {"Element": "<b><span lang=\"EN-GB\">CARTON</span></b>", "ID": "81ff29dd-eb23-4e00-96c2-0831cfa1855e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "be65e736-2c32-4046-8ab3-fafb3092d38d"}, {"Element": "<span lang=\"EN-GB\">CARTON</span>", "ID": "1e2a430d-15f9-400b-8830-be9cdf1cc033", "Styles": "None", "Classes": "None", "Text": "CARTON", "ParentId": "81ff29dd-eb23-4e00-96c2-0831cfa1855e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "67dd5a68-b66d-4550-9d49-412bb6945f91", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ddbaff7b-9aa5-42e7-bb8e-45b745e0ceb6", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "67dd5a68-b66d-4550-9d49-412bb6945f91"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "01ee2ba7-384e-4bd3-afca-c92e0ad9ee43", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "09cc6595-4567-4abb-86d1-aa2334f54dd3", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "01ee2ba7-384e-4bd3-afca-c92e0ad9ee43"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME\nOF THE MEDICINAL PRODUCT</span></b></p>\n</div>", "ID": "e7ab198e-7580-4d5d-b07a-c50783210e7a", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME\nOF THE MEDICINAL PRODUCT</span></b></p>", "ID": "898e471b-f5b1-493d-9449-2efd1a706393", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e7ab198e-7580-4d5d-b07a-c50783210e7a"}, {"Element": "<b><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME\nOF THE MEDICINAL PRODUCT</span></b>", "ID": "349ccdd1-61ce-45fa-bb62-0a2d53a13e7d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "898e471b-f5b1-493d-9449-2efd1a706393"}, {"Element": "<span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME\nOF THE MEDICINAL PRODUCT</span>", "ID": "82544967-c8ac-4b99-b0d9-cf7ac1205a24", "Styles": "None", "Classes": "None", "Text": "1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME OF THE MEDICINAL PRODUCT", "ParentId": "349ccdd1-61ce-45fa-bb62-0a2d53a13e7d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "966ff28e-d2b0-4114-9905-9c15b6aed6b0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "fb5ad77e-0383-495d-bd14-1169ab1913d9", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "966ff28e-d2b0-4114-9905-9c15b6aed6b0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Perjeta 420\u00a0mg concentrate for\nsolution for infusion</span></p>", "ID": "5a7d0a76-1336-453b-81dc-f6a5a3c68b5d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Perjeta 420\u00a0mg concentrate for\nsolution for infusion</span>", "ID": "81f0e700-071e-4ec7-b6a8-97f11fe65bc9", "Styles": "None", "Classes": "None", "Text": "Perjeta 420\u00a0mg concentrate for solution for infusion", "ParentId": "5a7d0a76-1336-453b-81dc-f6a5a3c68b5d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">pertuzumab</span></p>", "ID": "759459a1-0f98-4c59-a564-828f4c0da044", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">pertuzumab</span>", "ID": "633af3ad-0dc6-4425-81ce-39da0b505f23", "Styles": "None", "Classes": "None", "Text": "pertuzumab", "ParentId": "759459a1-0f98-4c59-a564-828f4c0da044"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d2d07279-42f1-4190-b2f5-06bb3ae3fa7e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "73c2ad41-392b-4572-bccc-2038c8f03f02", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d2d07279-42f1-4190-b2f5-06bb3ae3fa7e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a3cf222f-7e9b-4c49-ac85-be7cd85480c1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "596ffca7-34a9-4bca-8d07-32b31aaea750", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a3cf222f-7e9b-4c49-ac85-be7cd85480c1"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 STATEMENT\nOF ACTIVE SUBSTANCE(S)</span></b></p>\n</div>", "ID": "59dcd527-a2c7-4871-b0e9-8d3d6f283596", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 STATEMENT\nOF ACTIVE SUBSTANCE(S)</span></b></p>", "ID": "e26869f3-5252-451a-a055-8fa776f0acb9", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "59dcd527-a2c7-4871-b0e9-8d3d6f283596"}, {"Element": "<b><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 STATEMENT\nOF ACTIVE SUBSTANCE(S)</span></b>", "ID": "a3438c3f-6013-4369-95d7-5585d520206f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e26869f3-5252-451a-a055-8fa776f0acb9"}, {"Element": "<span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 STATEMENT\nOF ACTIVE SUBSTANCE(S)</span>", "ID": "7bed0601-db08-4fc6-87cb-61bde58334e1", "Styles": "None", "Classes": "None", "Text": "2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 STATEMENT OF ACTIVE SUBSTANCE(S)", "ParentId": "a3438c3f-6013-4369-95d7-5585d520206f"}, {"Element": "<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">\u00a0</span></i></p>", "ID": "ed73acdd-2a6e-42ba-84d4-3fac2961d49b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<i><span lang=\"EN-GB\">\u00a0</span></i>", "ID": "d6cd1a9d-5e8d-4438-8e8e-0855d1dc2a4f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ed73acdd-2a6e-42ba-84d4-3fac2961d49b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f7b0310c-1a6c-41ad-8cda-aa045cbea477", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d6cd1a9d-5e8d-4438-8e8e-0855d1dc2a4f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">One 14\u00a0ml vial contains 420\u00a0mg of\npertuzumab at a concentration of 30\u00a0mg/ml.</span></p>", "ID": "53621d95-fad4-4f47-86e1-4464087a1efe", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">One 14\u00a0ml vial contains 420\u00a0mg of\npertuzumab at a concentration of 30\u00a0mg/ml.</span>", "ID": "8f194631-09fe-4910-bb68-e334e9886610", "Styles": "None", "Classes": "None", "Text": "One 14\u00a0ml vial contains 420\u00a0mg of pertuzumab at a concentration of 30\u00a0mg/ml.", "ParentId": "53621d95-fad4-4f47-86e1-4464087a1efe"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3a96f533-7b1b-4afd-a1d8-65a3f4322759", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "eaebf6c9-eebb-4625-9642-ecfb90c30f1b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3a96f533-7b1b-4afd-a1d8-65a3f4322759"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "710d8f1b-a100-4ab3-9e8e-660f039bcaa9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c4721605-d273-4032-b37e-19329ffcc4e4", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "710d8f1b-a100-4ab3-9e8e-660f039bcaa9"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 LIST\nOF EXCIPIENTS</span></b></p>\n</div>", "ID": "ace5645a-aa84-4169-b1ce-0f2ecfee5c8b", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 LIST\nOF EXCIPIENTS</span></b></p>", "ID": "5942a103-2f18-4c56-83db-4a06daf169c3", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ace5645a-aa84-4169-b1ce-0f2ecfee5c8b"}, {"Element": "<b><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 LIST\nOF EXCIPIENTS</span></b>", "ID": "d86de2a8-1b52-4d36-ac91-bc0f66e3aa42", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "5942a103-2f18-4c56-83db-4a06daf169c3"}, {"Element": "<span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 LIST\nOF EXCIPIENTS</span>", "ID": "516aaeb4-55c6-4b01-b778-35a7f5ebf85d", "Styles": "None", "Classes": "None", "Text": "3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 LIST OF EXCIPIENTS", "ParentId": "d86de2a8-1b52-4d36-ac91-bc0f66e3aa42"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "12b47aaf-2bd2-43b3-a552-19fb69dd6a19", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a2083abc-7032-4319-9573-9973e69cd4cf", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "12b47aaf-2bd2-43b3-a552-19fb69dd6a19"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Glacial acetic acid, L-histidine, sucrose\nand polysorbate 20.</span></p>", "ID": "536c46d9-d92c-4ab9-956c-48c9cebb230f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Glacial acetic acid, L-histidine, sucrose\nand polysorbate 20.</span>", "ID": "54569973-61ff-4137-8bcf-d3623f2fad54", "Styles": "None", "Classes": "None", "Text": "Glacial acetic acid, L-histidine, sucrose and polysorbate 20.", "ParentId": "536c46d9-d92c-4ab9-956c-48c9cebb230f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Water for injections</span></p>", "ID": "8cb02184-cd93-498e-a5ee-5ee80addf7a0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Water for injections</span>", "ID": "568b6f81-67b2-48d8-a173-ca0cdd6d4305", "Styles": "None", "Classes": "None", "Text": "Water for injections", "ParentId": "8cb02184-cd93-498e-a5ee-5ee80addf7a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3ba180fa-6d2c-4f9b-be6d-f15a325ce51d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ba96e623-cdda-4ba9-83ea-767dd4c107b4", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3ba180fa-6d2c-4f9b-be6d-f15a325ce51d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c553d9ff-6f3a-46a7-9bb8-164eaab60c30", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6711706b-afe5-4eca-9941-660aba2327e6", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c553d9ff-6f3a-46a7-9bb8-164eaab60c30"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL\nFORM AND CONTENTS</span></b></p>\n</div>", "ID": "27a54ce8-2633-4e88-a990-1e5262aa5660", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL\nFORM AND CONTENTS</span></b></p>", "ID": "2f221d8b-2f6b-45bc-b63b-96edac8b75c7", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "27a54ce8-2633-4e88-a990-1e5262aa5660"}, {"Element": "<b><span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL\nFORM AND CONTENTS</span></b>", "ID": "afa7c23b-31f2-49b0-9386-bc1a23ef588b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "2f221d8b-2f6b-45bc-b63b-96edac8b75c7"}, {"Element": "<span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL\nFORM AND CONTENTS</span>", "ID": "73e27244-2234-4834-ae36-64575d598456", "Styles": "None", "Classes": "None", "Text": "4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL FORM AND CONTENTS", "ParentId": "afa7c23b-31f2-49b0-9386-bc1a23ef588b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "29aa5a41-19ef-41fe-a138-8400d37bc4c3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d0f51a3b-f634-4cdb-9e3f-5b840e3569d1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "29aa5a41-19ef-41fe-a138-8400d37bc4c3"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Concentrate for solution for infusion</span></p>", "ID": "56509f66-c091-4658-bc6a-9a37b8c1e5bb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Concentrate for solution for infusion</span>", "ID": "9241eebb-a81a-4975-944d-4422fc7fbcb1", "Styles": "None", "Classes": "None", "Text": "Concentrate for solution for infusion", "ParentId": "56509f66-c091-4658-bc6a-9a37b8c1e5bb"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">420\u00a0mg/14\u00a0ml</span></p>", "ID": "f1ae00fa-af85-4913-955f-a8b4a6095693", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">420\u00a0mg/14\u00a0ml</span>", "ID": "9e7ed54a-af37-4cf6-b68a-111ceac94f5a", "Styles": "None", "Classes": "None", "Text": "420\u00a0mg/14\u00a0ml", "ParentId": "f1ae00fa-af85-4913-955f-a8b4a6095693"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">1 x 14\u00a0ml</span></p>", "ID": "6f3c99fe-516a-46ce-ab7c-bf7702635844", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">1 x 14\u00a0ml</span>", "ID": "32f8541c-789c-45e0-a641-a836bab66956", "Styles": "None", "Classes": "None", "Text": "1 x 14\u00a0ml", "ParentId": "6f3c99fe-516a-46ce-ab7c-bf7702635844"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "28a490ed-b3ec-429c-bcbf-3f118179ce82", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ff723fd2-c072-42ae-8cfc-b96495b73bac", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "28a490ed-b3ec-429c-bcbf-3f118179ce82"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "58770188-4d36-4309-b621-8c9cbbe31adc", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "cf015e6a-13cf-473a-ad51-443b8d649542", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "58770188-4d36-4309-b621-8c9cbbe31adc"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD\nAND ROUTE(S) OF ADMINISTRATION</span></b></p>\n</div>", "ID": "922314a5-8e44-4d7c-9a1d-c5920ad7f6ca", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD\nAND ROUTE(S) OF ADMINISTRATION</span></b></p>", "ID": "a0f2e177-7f62-4d4f-99a5-a41610535dfc", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "922314a5-8e44-4d7c-9a1d-c5920ad7f6ca"}, {"Element": "<b><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD\nAND ROUTE(S) OF ADMINISTRATION</span></b>", "ID": "9fc5a25e-8226-4322-b310-9ff10225edaa", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a0f2e177-7f62-4d4f-99a5-a41610535dfc"}, {"Element": "<span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD\nAND ROUTE(S) OF ADMINISTRATION</span>", "ID": "39a27f2d-b8bd-4f31-b856-45d5e8c72a17", "Styles": "None", "Classes": "None", "Text": "5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD AND ROUTE(S) OF ADMINISTRATION", "ParentId": "9fc5a25e-8226-4322-b310-9ff10225edaa"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "685f757e-138a-4095-abcc-4a07b6edb75d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0916e15a-6ea2-4331-87a6-905db41951bf", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "685f757e-138a-4095-abcc-4a07b6edb75d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">For intravenous use after dilution</span></p>", "ID": "d3a2f712-6bf6-48ef-9238-83656732dff6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">For intravenous use after dilution</span>", "ID": "bbd543ec-ccae-47d4-a224-ab6b50999e8a", "Styles": "None", "Classes": "None", "Text": "For intravenous use after dilution", "ParentId": "d3a2f712-6bf6-48ef-9238-83656732dff6"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Do not shake</span></p>", "ID": "42f36c6c-d8e6-4010-bc52-64822733a750", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Do not shake</span>", "ID": "ab6cecc9-174b-4fe3-a99b-ba4c7ecc55e1", "Styles": "None", "Classes": "None", "Text": "Do not shake", "ParentId": "42f36c6c-d8e6-4010-bc52-64822733a750"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Read the package leaflet before use</span></p>", "ID": "b1ee61e1-aaad-4ace-82f7-295d4ad048cb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Read the package leaflet before use</span>", "ID": "97c16c88-844c-4926-bf3c-228a35b033c9", "Styles": "None", "Classes": "None", "Text": "Read the package leaflet before use", "ParentId": "b1ee61e1-aaad-4ace-82f7-295d4ad048cb"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7cf69d0e-e3c0-43cf-bda6-e7bac6b16b9a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1b0a0e27-c143-45c8-a850-0b0d751bfb41", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7cf69d0e-e3c0-43cf-bda6-e7bac6b16b9a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a4c8069f-02e1-4a9f-a8c4-dccc5ca7e7d0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "86f0160d-f207-4808-aa34-fae234a9a7d2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a4c8069f-02e1-4a9f-a8c4-dccc5ca7e7d0"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;border:none;\npadding:0in\"><b><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL WARNING THAT THE MEDICINAL\nPRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</span></b></p>\n</div>", "ID": "d087123f-b365-44d0-96ae-ae5f25152cf9", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;border:none;\npadding:0in\"><b><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL WARNING THAT THE MEDICINAL\nPRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</span></b></p>", "ID": "cc09d98e-6041-453b-8c31-4d22ec448973", "Styles": "margin-left:.5in;text-indent:-.5in;border:none;\npadding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d087123f-b365-44d0-96ae-ae5f25152cf9"}, {"Element": "<b><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL WARNING THAT THE MEDICINAL\nPRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</span></b>", "ID": "62da27d8-4343-47c1-b2c7-ae30aa8ff422", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "cc09d98e-6041-453b-8c31-4d22ec448973"}, {"Element": "<span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL WARNING THAT THE MEDICINAL\nPRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</span>", "ID": "fbc62b53-8a91-4506-8349-9447c681c76c", "Styles": "None", "Classes": "None", "Text": "6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN", "ParentId": "62da27d8-4343-47c1-b2c7-ae30aa8ff422"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8ee909de-161c-42b3-991b-9dfd237be8c4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f98b28c7-86b8-4e25-bae7-f334d1e3bd24", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8ee909de-161c-42b3-991b-9dfd237be8c4"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Keep out of the sight and reach of children</span></p>", "ID": "71aab5d5-8ea6-4e6f-a488-c193cf15616a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Keep out of the sight and reach of children</span>", "ID": "6a7e4ce1-15be-4f92-a1b7-0b4a228ff061", "Styles": "None", "Classes": "None", "Text": "Keep out of the sight and reach of children", "ParentId": "71aab5d5-8ea6-4e6f-a488-c193cf15616a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5f0a8328-073c-4eef-ac85-22f06eafc7bf", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "83117eef-1e4c-4c65-bf3e-596712959209", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5f0a8328-073c-4eef-ac85-22f06eafc7bf"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7fe9854e-aa82-4f19-963f-9448485e56e1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "624ea139-0274-4ecf-a0d9-59dee4b11436", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7fe9854e-aa82-4f19-963f-9448485e56e1"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER\nSPECIAL WARNING(S), IF NECESSARY</span></b></p>\n</div>", "ID": "a4a2654c-5ffe-49bd-a55e-919a8c99883d", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER\nSPECIAL WARNING(S), IF NECESSARY</span></b></p>", "ID": "decc0277-7a07-4d5e-a1f7-25095c75a21d", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a4a2654c-5ffe-49bd-a55e-919a8c99883d"}, {"Element": "<b><span lang=\"EN-GB\">7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER\nSPECIAL WARNING(S), IF NECESSARY</span></b>", "ID": "d269806f-f4bc-48cf-8ec0-70ddc0353b6e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "decc0277-7a07-4d5e-a1f7-25095c75a21d"}, {"Element": "<span lang=\"EN-GB\">7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER\nSPECIAL WARNING(S), IF NECESSARY</span>", "ID": "6336fecc-3946-44b3-b4b0-43d574e474ea", "Styles": "None", "Classes": "None", "Text": "7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER SPECIAL WARNING(S), IF NECESSARY", "ParentId": "d269806f-f4bc-48cf-8ec0-70ddc0353b6e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2ab92469-0bcb-495e-bc9d-14b4c42f34ab", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "77638d50-f6ab-4d78-8da4-9b2de2db5867", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2ab92469-0bcb-495e-bc9d-14b4c42f34ab"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "73558d2c-7863-4edc-b1e2-d840d634ed19", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "03394840-af3f-4c06-b1b3-09568b1b0e33", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "73558d2c-7863-4edc-b1e2-d840d634ed19"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY\nDATE</span></b></p>\n</div>", "ID": "d296f5fd-9b4f-495d-a2de-27c7d32cf51a", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY\nDATE</span></b></p>", "ID": "2a6ed42f-74f1-4e5a-9c9f-dbf36ca03449", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d296f5fd-9b4f-495d-a2de-27c7d32cf51a"}, {"Element": "<b><span lang=\"EN-GB\">8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY\nDATE</span></b>", "ID": "fdf5f11d-c6cf-41b4-8fc2-136e37f7ceeb", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "2a6ed42f-74f1-4e5a-9c9f-dbf36ca03449"}, {"Element": "<span lang=\"EN-GB\">8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY\nDATE</span>", "ID": "0ee3c8f1-7588-40a7-9327-aae77f93cc49", "Styles": "None", "Classes": "None", "Text": "8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY DATE", "ParentId": "fdf5f11d-c6cf-41b4-8fc2-136e37f7ceeb"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3c41a2fb-07d3-474b-a619-7f5f28e4c41c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f985fad3-b3a4-43de-a5d6-ba0163374acf", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3c41a2fb-07d3-474b-a619-7f5f28e4c41c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">EXP </span></p>", "ID": "027c1ab3-4c38-4446-971d-898ff315c7e1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">EXP </span>", "ID": "71a6fe4e-d50a-4d29-a046-6286cb4c7428", "Styles": "None", "Classes": "None", "Text": "EXP ", "ParentId": "027c1ab3-4c38-4446-971d-898ff315c7e1"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0e47e7d3-757c-43cd-be51-dcc842872266", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c11335be-5dbb-4c47-8a22-7cb05f4e2649", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0e47e7d3-757c-43cd-be51-dcc842872266"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b35587e8-4c62-496a-b2f7-7bfc31e69509", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "72f7f2ea-f413-4e2b-a2dd-a51290e8db38", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b35587e8-4c62-496a-b2f7-7bfc31e69509"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL STORAGE CONDITIONS</span></b></p>\n</div>", "ID": "c35de30e-a947-4801-a683-d4f9ac25776c", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL STORAGE CONDITIONS</span></b></p>", "ID": "224d0c8e-4111-4bc8-b4a2-3b3e7736d847", "Styles": "page-break-after:avoid;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c35de30e-a947-4801-a683-d4f9ac25776c"}, {"Element": "<b><span lang=\"EN-GB\">9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL STORAGE CONDITIONS</span></b>", "ID": "f42ab684-af1b-4c30-b2fb-3eb4f4088b3d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "224d0c8e-4111-4bc8-b4a2-3b3e7736d847"}, {"Element": "<span lang=\"EN-GB\">9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL STORAGE CONDITIONS</span>", "ID": "1f3ee019-2670-45ef-9a64-e4e812cba6e4", "Styles": "None", "Classes": "None", "Text": "9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL STORAGE CONDITIONS", "ParentId": "f42ab684-af1b-4c30-b2fb-3eb4f4088b3d"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "cce6ebdd-bb9c-4b48-b35a-bc70855599fe", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6a2d52ec-8c58-43d0-9c63-c53e62abd3bb", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "cce6ebdd-bb9c-4b48-b35a-bc70855599fe"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Store in a\nrefrigerator</span></p>", "ID": "aab39772-5d4c-47d5-8d44-8919c4f4c40b", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Store in a\nrefrigerator</span>", "ID": "75e8060c-a6ed-4b04-a162-c75f2c778f9f", "Styles": "None", "Classes": "None", "Text": "Store in a refrigerator", "ParentId": "aab39772-5d4c-47d5-8d44-8919c4f4c40b"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Do not\nfreeze</span></p>", "ID": "d2a9f0e0-1040-42b2-bb87-a928f9ddaf58", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Do not\nfreeze</span>", "ID": "b6405115-6486-494f-a895-bbd5ebf4e529", "Styles": "None", "Classes": "None", "Text": "Do not freeze", "ParentId": "d2a9f0e0-1040-42b2-bb87-a928f9ddaf58"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Keep the vial in the outer carton in order\nto protect from light </span></p>", "ID": "c17ac3fe-fd85-4e91-b34a-4b9c1f62b5a3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Keep the vial in the outer carton in order\nto protect from light </span>", "ID": "470bf968-b328-4116-97d8-7701d532cbba", "Styles": "None", "Classes": "None", "Text": "Keep the vial in the outer carton in order to protect from light ", "ParentId": "c17ac3fe-fd85-4e91-b34a-4b9c1f62b5a3"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "17751c22-b57c-4258-a820-e8d2845312e4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3fd26f9f-9ce2-46a4-a57a-c36e94228629", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "17751c22-b57c-4258-a820-e8d2845312e4"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0a7bd4cc-a61d-4d36-896e-bf5f8a351a8b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b44ea544-2fe6-43a6-98f0-b53c2bdf8181", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0a7bd4cc-a61d-4d36-896e-bf5f8a351a8b"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;border:none;\npadding:0in\"><b><span lang=\"EN-GB\">10.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL PRECAUTIONS FOR DISPOSAL OF\nUNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL\nPRODUCTS, IF APPROPRIATE</span></b></p>\n</div>", "ID": "bb125ca5-dda8-4dc6-b436-11090ead8faa", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;border:none;\npadding:0in\"><b><span lang=\"EN-GB\">10.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL PRECAUTIONS FOR DISPOSAL OF\nUNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL\nPRODUCTS, IF APPROPRIATE</span></b></p>", "ID": "fdb2f8c7-7aba-4e64-8a7e-55a0dbe012e8", "Styles": "margin-left:.5in;text-indent:-.5in;border:none;\npadding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "bb125ca5-dda8-4dc6-b436-11090ead8faa"}, {"Element": "<b><span lang=\"EN-GB\">10.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL PRECAUTIONS FOR DISPOSAL OF\nUNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL\nPRODUCTS, IF APPROPRIATE</span></b>", "ID": "b91dfdce-1332-4956-9c7b-679482de2d5b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "fdb2f8c7-7aba-4e64-8a7e-55a0dbe012e8"}, {"Element": "<span lang=\"EN-GB\">10.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL PRECAUTIONS FOR DISPOSAL OF\nUNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL\nPRODUCTS, IF APPROPRIATE</span>", "ID": "0d2909bf-2545-46d2-99a7-934d1a28a3e8", "Styles": "None", "Classes": "None", "Text": "10.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE", "ParentId": "b91dfdce-1332-4956-9c7b-679482de2d5b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8d9ac0e7-3283-46e1-9098-063cc833538c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c576b843-70a0-4148-9787-97418b4ec92d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8d9ac0e7-3283-46e1-9098-063cc833538c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "179c5f31-27f8-492a-8248-e149b81e4e98", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "adb5865a-eb23-4840-ada5-f21c1daa7d71", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "179c5f31-27f8-492a-8248-e149b81e4e98"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">11.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME\nAND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>\n</div>", "ID": "5a2325b2-78a8-4c69-83e0-97cc8e52df1d", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">11.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME\nAND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>", "ID": "4ae89b2a-0174-4bfe-90d1-1384183b73cd", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5a2325b2-78a8-4c69-83e0-97cc8e52df1d"}, {"Element": "<b><span lang=\"EN-GB\">11.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME\nAND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b>", "ID": "0f127ca3-b4f7-4a35-91ad-c6be48b5d2d0", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4ae89b2a-0174-4bfe-90d1-1384183b73cd"}, {"Element": "<span lang=\"EN-GB\">11.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME\nAND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span>", "ID": "d5bb748e-6970-4a67-b3ed-e3fdacd4387b", "Styles": "None", "Classes": "None", "Text": "11.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER", "ParentId": "0f127ca3-b4f7-4a35-91ad-c6be48b5d2d0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "1f5df500-61ca-48fc-b9bb-92c00411957c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "32918a4e-a6e8-4780-9870-9a8f33fba26c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1f5df500-61ca-48fc-b9bb-92c00411957c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche Registration GmbH </span></p>", "ID": "3e6f2abb-2a92-4a78-9dec-e61f81b9d941", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"DE-CH\">Roche Registration GmbH </span>", "ID": "13befc44-6e5c-4a19-a83f-bc6bacde9421", "Styles": "None", "Classes": "None", "Text": "Roche Registration GmbH ", "ParentId": "3e6f2abb-2a92-4a78-9dec-e61f81b9d941"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE-CH\">Emil-Barell-Strasse 1</span></p>", "ID": "9b1cc591-ebea-46bf-ba69-6a2eb4e3afe0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"DE-CH\">Emil-Barell-Strasse 1</span>", "ID": "15f6de6b-3e40-4447-9e14-9395a18642f2", "Styles": "None", "Classes": "None", "Text": "Emil-Barell-Strasse 1", "ParentId": "9b1cc591-ebea-46bf-ba69-6a2eb4e3afe0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE\">79639 Grenzach-Wyhlen</span></p>", "ID": "08484e66-6b37-47bc-b291-82c3196a9cff", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"DE\">79639 Grenzach-Wyhlen</span>", "ID": "2d653add-0cb8-4339-bf5f-bb524e23a533", "Styles": "None", "Classes": "None", "Text": "79639 Grenzach-Wyhlen", "ParentId": "08484e66-6b37-47bc-b291-82c3196a9cff"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Germany</span></p>", "ID": "f33d33f6-de90-4f24-b315-e334c4b4892a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Germany</span>", "ID": "1da1e636-5c81-42c0-9bf2-9a773bd698d2", "Styles": "None", "Classes": "None", "Text": "Germany", "ParentId": "f33d33f6-de90-4f24-b315-e334c4b4892a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e1a24700-f655-4a1b-9e08-042ef3413d81", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a013e1aa-d11d-43a7-908b-3841e1583a37", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e1a24700-f655-4a1b-9e08-042ef3413d81"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ad547391-9f41-4231-b4a5-68853327d791", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0899efe3-7dd8-4cba-b787-ebe5997521ca", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ad547391-9f41-4231-b4a5-68853327d791"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">12.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 MARKETING\nAUTHORISATION NUMBER(S) </span></b></p>\n</div>", "ID": "e7c6c36f-f679-4f70-b615-c14a05b7d37c", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">12.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 MARKETING\nAUTHORISATION NUMBER(S) </span></b></p>", "ID": "a503f4f9-f4f9-45c8-b405-7e4dd9f493b6", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e7c6c36f-f679-4f70-b615-c14a05b7d37c"}, {"Element": "<b><span lang=\"EN-GB\">12.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 MARKETING\nAUTHORISATION NUMBER(S) </span></b>", "ID": "4e65d501-cef2-48e0-816d-845aeb04a325", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a503f4f9-f4f9-45c8-b405-7e4dd9f493b6"}, {"Element": "<span lang=\"EN-GB\">12.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 MARKETING\nAUTHORISATION NUMBER(S) </span>", "ID": "7ce9da56-373e-4702-a223-01deb54e08aa", "Styles": "None", "Classes": "None", "Text": "12.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 MARKETING AUTHORISATION NUMBER(S) ", "ParentId": "4e65d501-cef2-48e0-816d-845aeb04a325"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6a0dd923-64fc-4760-a90c-539a3f7c38ae", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5450c7fa-e8bc-40d8-acee-5ce2b9927d7f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6a0dd923-64fc-4760-a90c-539a3f7c38ae"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">EU/1/13/813/001</span></p>", "ID": "30535b93-281e-4649-adf4-0b47350cecb3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">EU/1/13/813/001</span>", "ID": "14d6d920-74b9-4a9b-a7dc-ce22f6617e21", "Styles": "None", "Classes": "None", "Text": "EU/1/13/813/001", "ParentId": "30535b93-281e-4649-adf4-0b47350cecb3"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2cad80dd-3d8e-4afb-a923-f3e664a26c70", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a25d2e68-f21a-449d-a28f-e0accdeb4bb2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2cad80dd-3d8e-4afb-a923-f3e664a26c70"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "fd98acf9-465a-419b-a433-e9c446643ad7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "12cd2512-1f75-49af-aa40-caa8754ed783", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "fd98acf9-465a-419b-a433-e9c446643ad7"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">13.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 BATCH\nNUMBER</span></b></p>\n</div>", "ID": "edcbf6d5-8f40-4084-9acb-0823dbb73af8", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">13.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 BATCH\nNUMBER</span></b></p>", "ID": "cbff56c3-1830-4ba0-9f00-8b866a127577", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "edcbf6d5-8f40-4084-9acb-0823dbb73af8"}, {"Element": "<b><span lang=\"EN-GB\">13.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 BATCH\nNUMBER</span></b>", "ID": "734d38a7-8c19-4f25-90ec-120952ed55e0", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "cbff56c3-1830-4ba0-9f00-8b866a127577"}, {"Element": "<span lang=\"EN-GB\">13.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 BATCH\nNUMBER</span>", "ID": "eba5dc90-8cb6-4db3-978b-6207606a086d", "Styles": "None", "Classes": "None", "Text": "13.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 BATCH NUMBER", "ParentId": "734d38a7-8c19-4f25-90ec-120952ed55e0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9751bfde-f7a4-4cbc-8047-d6f003a0f5d0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e3fa3eea-9c0f-457e-82d1-8b965597e81b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9751bfde-f7a4-4cbc-8047-d6f003a0f5d0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Batch</span></p>", "ID": "9372e300-7694-418e-8925-dbaed37d35e5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Batch</span>", "ID": "4a77ccbe-94ab-4dc6-9c5c-55f79cc303e0", "Styles": "None", "Classes": "None", "Text": "Batch", "ParentId": "9372e300-7694-418e-8925-dbaed37d35e5"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "45b95b2e-3059-4dc0-9e2f-b8090376f213", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "84d648b9-b842-482a-a045-31b39a67d8a8", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "45b95b2e-3059-4dc0-9e2f-b8090376f213"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "1f7f1ee5-3713-4273-9f65-8668f55a95a6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6dac5c5a-ce04-4e4a-921a-ea6673b741ef", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1f7f1ee5-3713-4273-9f65-8668f55a95a6"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">14.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 GENERAL\nCLASSIFICATION FOR SUPPLY</span></b></p>\n</div>", "ID": "aaf84724-914a-43a1-9208-8e125b80c1ec", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">14.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 GENERAL\nCLASSIFICATION FOR SUPPLY</span></b></p>", "ID": "087685be-cec9-47ec-b423-401bbef88a6c", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "aaf84724-914a-43a1-9208-8e125b80c1ec"}, {"Element": "<b><span lang=\"EN-GB\">14.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 GENERAL\nCLASSIFICATION FOR SUPPLY</span></b>", "ID": "65550e78-9eba-4059-9bc3-df02b5f0d5b5", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "087685be-cec9-47ec-b423-401bbef88a6c"}, {"Element": "<span lang=\"EN-GB\">14.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 GENERAL\nCLASSIFICATION FOR SUPPLY</span>", "ID": "b4d4aef4-dbcb-4055-bfab-5bc7ebfb00ff", "Styles": "None", "Classes": "None", "Text": "14.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 GENERAL CLASSIFICATION FOR SUPPLY", "ParentId": "65550e78-9eba-4059-9bc3-df02b5f0d5b5"}, {"Element": "<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">\u00a0</span></i></p>", "ID": "cbbe40f3-4ce1-4cef-87db-aefa6c74c0af", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<i><span lang=\"EN-GB\">\u00a0</span></i>", "ID": "0abbc57f-d01c-408b-9a51-7bc4b173006b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "cbbe40f3-4ce1-4cef-87db-aefa6c74c0af"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8004cce9-f2e4-4d2f-b7f8-d7518c62b9c6", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0abbc57f-d01c-408b-9a51-7bc4b173006b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Medicinal product subject to medical\nprescription</span></p>", "ID": "e04c657e-a4ce-44c3-a1ff-93303f9fdca6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Medicinal product subject to medical\nprescription</span>", "ID": "6c3709e3-f136-4462-841f-ddcbcab6f0af", "Styles": "None", "Classes": "None", "Text": "Medicinal product subject to medical prescription", "ParentId": "e04c657e-a4ce-44c3-a1ff-93303f9fdca6"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d05d6495-23aa-4c86-a02e-f64e5283d456", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "cbc64318-caea-44f5-98a4-b216ce05588a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d05d6495-23aa-4c86-a02e-f64e5283d456"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "68add691-1204-40f7-bdbd-bb1ee6b47046", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4a8aedd5-5ff0-4456-ba87-4f05db6cf647", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "68add691-1204-40f7-bdbd-bb1ee6b47046"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">15.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 INSTRUCTIONS\nON USE</span></b></p>\n</div>", "ID": "25d5f0dc-f5e5-472b-9841-a8b6ae81b8db", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">15.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 INSTRUCTIONS\nON USE</span></b></p>", "ID": "6c85a017-08cf-4a7a-879a-ac4fc9490e10", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "25d5f0dc-f5e5-472b-9841-a8b6ae81b8db"}, {"Element": "<b><span lang=\"EN-GB\">15.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 INSTRUCTIONS\nON USE</span></b>", "ID": "5ae8828a-5f06-4507-946c-4a7049ca3ca2", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "6c85a017-08cf-4a7a-879a-ac4fc9490e10"}, {"Element": "<span lang=\"EN-GB\">15.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 INSTRUCTIONS\nON USE</span>", "ID": "cb1298b9-c8e2-4529-8f1e-b2ee66e29219", "Styles": "None", "Classes": "None", "Text": "15.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 INSTRUCTIONS ON USE", "ParentId": "5ae8828a-5f06-4507-946c-4a7049ca3ca2"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "bd26c00c-0a5f-4ced-8475-4df7e1512583", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b9c7f7fa-4f70-4e1e-88c4-c2ba2cef8c84", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "bd26c00c-0a5f-4ced-8475-4df7e1512583"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7e6da587-e33a-4e71-a430-fb9470370c8f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3b2f3cb1-2dd9-46d2-9e35-588cfe5106b6", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7e6da587-e33a-4e71-a430-fb9470370c8f"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">16.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 INFORMATION\nIN BRAILLE</span></b></p>\n</div>", "ID": "caefbef5-8f5d-4e7f-8d21-b827f704eb01", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">16.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 INFORMATION\nIN BRAILLE</span></b></p>", "ID": "f16688a4-99eb-4930-8739-64ff08de1003", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "caefbef5-8f5d-4e7f-8d21-b827f704eb01"}, {"Element": "<b><span lang=\"EN-GB\">16.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 INFORMATION\nIN BRAILLE</span></b>", "ID": "2537f181-bffd-43c2-8ac4-c6396ecbe59e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f16688a4-99eb-4930-8739-64ff08de1003"}, {"Element": "<span lang=\"EN-GB\">16.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 INFORMATION\nIN BRAILLE</span>", "ID": "051864f4-c1e1-4441-aa66-c3ed0113f433", "Styles": "None", "Classes": "None", "Text": "16.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 INFORMATION IN BRAILLE", "ParentId": "2537f181-bffd-43c2-8ac4-c6396ecbe59e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "90533754-f8d0-43df-afc6-7a12b16d8a5f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d044e9b0-c494-4131-89d4-3b1ff05b41f2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "90533754-f8d0-43df-afc6-7a12b16d8a5f"}, {"Element": "<p class=\"MsoNormal\"><span style=\"color:black;background:#D9D9D9\">Justification\nfor not including Braille accepted</span> </p>", "ID": "6f24c0aa-8603-4992-987f-3b911b1dd81c", "Styles": "None", "Classes": "['MsoNormal']", "Text": " ", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span style=\"color:black;background:#D9D9D9\">Justification\nfor not including Braille accepted</span>", "ID": "1f7837bd-c1ab-46a9-91f7-483a5198eeca", "Styles": "color:black;background:#D9D9D9", "Classes": "None", "Text": "Justification for not including Braille accepted", "ParentId": "6f24c0aa-8603-4992-987f-3b911b1dd81c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "28169f85-8011-4f75-bc05-485072967f19", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "23587d72-6d0c-434b-8630-c6c9321778af", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "28169f85-8011-4f75-bc05-485072967f19"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "926ddb26-91c9-4002-bccd-f396d5799dbf", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9374c7af-9ac5-439a-8f76-0916faef036a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "926ddb26-91c9-4002-bccd-f396d5799dbf"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b>17.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 UNIQUE\nIDENTIFIER \u2013 2D BARCODE</b></p>\n</div>", "ID": "c81a9899-364a-436e-ada7-210f7dadcb87", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b>17.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 UNIQUE\nIDENTIFIER \u2013 2D BARCODE</b></p>", "ID": "7186a739-2ce3-4da6-8dd6-f68490ef88bb", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c81a9899-364a-436e-ada7-210f7dadcb87"}, {"Element": "<b>17.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 UNIQUE\nIDENTIFIER \u2013 2D BARCODE</b>", "ID": "c228205e-b9c3-4b1a-9d0b-7201acdd0fc1", "Styles": "None", "Classes": "None", "Text": "17.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 UNIQUE IDENTIFIER \u2013 2D BARCODE", "ParentId": "7186a739-2ce3-4da6-8dd6-f68490ef88bb"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "68bd1d4e-41f6-4046-ab49-8f8ef5f8097a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<p class=\"MsoNormal\"><span style=\"background:lightgrey\">2D barcode carrying the\nunique identifier included.</span></p>", "ID": "51200c37-a9b5-4fab-b060-02b8d83cd42e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span style=\"background:lightgrey\">2D barcode carrying the\nunique identifier included.</span>", "ID": "e3a09abb-27a3-404e-b1d9-7d1d90d9f059", "Styles": "background:lightgrey", "Classes": "None", "Text": "2D barcode carrying the unique identifier included.", "ParentId": "51200c37-a9b5-4fab-b060-02b8d83cd42e"}, {"Element": "<p class=\"MsoNormal\"><span style=\"background:#CCCCCC\">\u00a0</span></p>", "ID": "e24720b0-2a85-4575-8ee6-cdb8c06b5751", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span style=\"background:#CCCCCC\">\u00a0</span>", "ID": "c568c1c2-1060-438a-97df-d8496c49b02d", "Styles": "background:#CCCCCC", "Classes": "None", "Text": "\u00a0", "ParentId": "e24720b0-2a85-4575-8ee6-cdb8c06b5751"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "db0572a6-ce7b-4c0f-8330-914d40c767ca", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b>18.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 UNIQUE\nIDENTIFIER - HUMAN READABLE DATA</b></p>\n</div>", "ID": "b8e26874-b8c8-4cc9-86cd-b2d63457c161", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b>18.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 UNIQUE\nIDENTIFIER - HUMAN READABLE DATA</b></p>", "ID": "bc4766ae-456a-46f3-adc4-7cb2cda0ead1", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b8e26874-b8c8-4cc9-86cd-b2d63457c161"}, {"Element": "<b>18.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 UNIQUE\nIDENTIFIER - HUMAN READABLE DATA</b>", "ID": "b8257641-38c2-4d61-ba84-d6d14c7b1f51", "Styles": "None", "Classes": "None", "Text": "18.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 UNIQUE IDENTIFIER - HUMAN READABLE DATA", "ParentId": "bc4766ae-456a-46f3-adc4-7cb2cda0ead1"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "163cae88-908d-469d-8198-dda4f154aa42", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<p class=\"MsoNormal\">PC: </p>", "ID": "1b10bc5f-ed2c-48b5-bfd8-df89001681f7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "PC: ", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<p class=\"MsoNormal\">SN: </p>", "ID": "314adea3-0541-4758-8091-593849ed4a7a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "SN: ", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<p class=\"MsoNormal\">NN: </p>", "ID": "46434e19-268f-4365-a727-7a8ee48dec7c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "NN: ", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>", "ID": "039816d9-c50d-4259-9a20-76a35af2d405", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": " ", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<br clear=\"all\" style=\"page-break-before:always\"/>", "ID": "55a909ea-0002-44c5-ae01-b7d5777070c1", "Styles": "page-break-before:always", "Classes": "None", "Text": "", "ParentId": "039816d9-c50d-4259-9a20-76a35af2d405"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3e71bf40-7981-40e1-a83d-b171ad363d3c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "cfd24de2-eeb4-4a31-8400-797914c2e032", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3e71bf40-7981-40e1-a83d-b171ad363d3c"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">MINIMUM\nPARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS</span></b></p>\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">VIAL\nLABEL</span></b></p>\n</div>", "ID": "bcac50ae-fecc-4d82-9421-d8f97b619ad1", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "    ", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">MINIMUM\nPARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS</span></b></p>", "ID": "ba616add-7079-4e52-b317-c02694997515", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "bcac50ae-fecc-4d82-9421-d8f97b619ad1"}, {"Element": "<b><span lang=\"EN-GB\">MINIMUM\nPARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS</span></b>", "ID": "39d1fdb7-147d-43af-9315-2f9dbea159e7", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ba616add-7079-4e52-b317-c02694997515"}, {"Element": "<span lang=\"EN-GB\">MINIMUM\nPARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS</span>", "ID": "369c1fa5-d1ad-41ac-931d-d0f1d6908cc8", "Styles": "None", "Classes": "None", "Text": "MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS", "ParentId": "39d1fdb7-147d-43af-9315-2f9dbea159e7"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "4dc72ff7-a291-4ea7-98e0-77cf5deb94d7", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "bcac50ae-fecc-4d82-9421-d8f97b619ad1"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "ee25b03b-0cb1-4966-930f-75f0972d7fa8", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4dc72ff7-a291-4ea7-98e0-77cf5deb94d7"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f1c1b086-261e-4159-8fec-a163177aa38e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ee25b03b-0cb1-4966-930f-75f0972d7fa8"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">VIAL\nLABEL</span></b></p>", "ID": "8017a980-55f3-447f-b3ca-88c3018e7e6f", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "bcac50ae-fecc-4d82-9421-d8f97b619ad1"}, {"Element": "<b><span lang=\"EN-GB\">VIAL\nLABEL</span></b>", "ID": "8fb050a5-1a86-4ad5-84c0-0b6b9eb355c8", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8017a980-55f3-447f-b3ca-88c3018e7e6f"}, {"Element": "<span lang=\"EN-GB\">VIAL\nLABEL</span>", "ID": "f46ec92f-7b54-4bc8-9928-b3a4000e038d", "Styles": "None", "Classes": "None", "Text": "VIAL LABEL", "ParentId": "8fb050a5-1a86-4ad5-84c0-0b6b9eb355c8"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "8beefa92-69d1-438a-b628-07fc0e5e899f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "bbf6962e-f458-4584-9e07-9d0cc5b9b87d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8beefa92-69d1-438a-b628-07fc0e5e899f"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0363e539-4277-497d-8e75-450e5faf179a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "bbf6962e-f458-4584-9e07-9d0cc5b9b87d"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "5d6be421-9499-4420-89b5-a2fb532067a3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "d2e61cc0-4c76-4dd3-aee1-bba2806422af", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "5d6be421-9499-4420-89b5-a2fb532067a3"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "35d73f2d-812c-4fc1-9f17-62c2fe940a38", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d2e61cc0-4c76-4dd3-aee1-bba2806422af"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME\nOF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p>\n</div>", "ID": "ad3bbd59-1f17-4717-a0e5-2615f2b93d0b", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME\nOF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p>", "ID": "5fedd172-22a8-4d80-a066-cd642053e1bc", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ad3bbd59-1f17-4717-a0e5-2615f2b93d0b"}, {"Element": "<b><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME\nOF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b>", "ID": "dcdd7567-971c-42dc-8d64-1797aae01369", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "5fedd172-22a8-4d80-a066-cd642053e1bc"}, {"Element": "<span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME\nOF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span>", "ID": "c749fc41-da0c-45c1-bd9d-674a87372f95", "Styles": "None", "Classes": "None", "Text": "1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION", "ParentId": "dcdd7567-971c-42dc-8d64-1797aae01369"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "46b6e048-28ed-4fc5-bfb6-c1f00ae17014", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a28ef262-d008-4161-9d47-03393994c19a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "46b6e048-28ed-4fc5-bfb6-c1f00ae17014"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Perjeta 420\u00a0mg concentrate for\nsolution for infusion</span></p>", "ID": "6bc18085-5a84-4bb6-a303-5425b7234a9a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Perjeta 420\u00a0mg concentrate for\nsolution for infusion</span>", "ID": "f869f303-5c7b-4bcf-bc26-fdfc86e94e80", "Styles": "None", "Classes": "None", "Text": "Perjeta 420\u00a0mg concentrate for solution for infusion", "ParentId": "6bc18085-5a84-4bb6-a303-5425b7234a9a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">pertuzumab</span></p>", "ID": "1dae3fb0-5c0e-4c7a-85ca-f979cce6250f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">pertuzumab</span>", "ID": "2cff3743-0e1e-4a1a-ac9a-a1937b20a5b8", "Styles": "None", "Classes": "None", "Text": "pertuzumab", "ParentId": "1dae3fb0-5c0e-4c7a-85ca-f979cce6250f"}, {"Element": "<p class=\"MsoNormal\"><span style=\"color:black;background:#D9D9D9\">IV</span></p>", "ID": "4fa43132-60a7-4913-ac04-d3b4921e8ae4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span style=\"color:black;background:#D9D9D9\">IV</span>", "ID": "41860308-781c-46c9-86a5-3208d61ec82c", "Styles": "color:black;background:#D9D9D9", "Classes": "None", "Text": "IV", "ParentId": "4fa43132-60a7-4913-ac04-d3b4921e8ae4"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "bf402e27-f545-4547-ada6-50be1ad359c8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "fb6063c9-aec4-40c7-b884-68dd06f244b7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "bf402e27-f545-4547-ada6-50be1ad359c8"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ff888b6c-3447-437d-810f-21cfbc5e6ce5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d63729ee-f823-4b43-9ef8-66bbaf0e8d55", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ff888b6c-3447-437d-810f-21cfbc5e6ce5"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD\nOF ADMINISTRATION</span></b></p>\n</div>", "ID": "5f805733-5cd2-46fa-b6c7-6ed42499f260", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD\nOF ADMINISTRATION</span></b></p>", "ID": "71c79a32-2541-440e-9bf3-d5472c37c540", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5f805733-5cd2-46fa-b6c7-6ed42499f260"}, {"Element": "<b><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD\nOF ADMINISTRATION</span></b>", "ID": "9464e012-03ce-43b1-a452-2b7c94c16645", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "71c79a32-2541-440e-9bf3-d5472c37c540"}, {"Element": "<span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD\nOF ADMINISTRATION</span>", "ID": "07282e69-d0e7-4864-b870-89bbe4975b8f", "Styles": "None", "Classes": "None", "Text": "2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD OF ADMINISTRATION", "ParentId": "9464e012-03ce-43b1-a452-2b7c94c16645"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "dfe6b323-2b36-47f4-9ae0-9f2913d58b08", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9755acb4-f8c9-4b48-ae6e-919c2125218f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "dfe6b323-2b36-47f4-9ae0-9f2913d58b08"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">For intravenous use after dilution</span></p>", "ID": "977b27f5-9a63-407d-9801-3983d0aa81c8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">For intravenous use after dilution</span>", "ID": "25c0ebe9-584d-4450-b74e-58893ab16378", "Styles": "None", "Classes": "None", "Text": "For intravenous use after dilution", "ParentId": "977b27f5-9a63-407d-9801-3983d0aa81c8"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a92eb19c-b8ac-4bdc-b0da-37f3bdf57271", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "75043e72-e7e4-46f4-8296-4c99fd9457fc", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a92eb19c-b8ac-4bdc-b0da-37f3bdf57271"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "25915d49-972d-4c64-b9fa-f6f1ded272f7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5fc0b692-24ed-4338-8e2a-6e3826eb7b71", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "25915d49-972d-4c64-b9fa-f6f1ded272f7"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY\nDATE</span></b></p>\n</div>", "ID": "17658d7c-c10c-4260-a5a6-9c4dc715efd8", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY\nDATE</span></b></p>", "ID": "98190392-2e86-4e90-bcb5-64c43daa3258", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "17658d7c-c10c-4260-a5a6-9c4dc715efd8"}, {"Element": "<b><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY\nDATE</span></b>", "ID": "83b769f6-4cdf-4cce-b73e-9afd4866347f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "98190392-2e86-4e90-bcb5-64c43daa3258"}, {"Element": "<span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY\nDATE</span>", "ID": "48bb6e7a-7c99-457e-86d7-98564c050006", "Styles": "None", "Classes": "None", "Text": "3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY DATE", "ParentId": "83b769f6-4cdf-4cce-b73e-9afd4866347f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4a3b9e45-b50a-494c-9fe4-24e690c159eb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9cf91ca4-9f44-4ccf-8811-31db1660b4ac", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4a3b9e45-b50a-494c-9fe4-24e690c159eb"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">EXP</span></p>", "ID": "d58b9c95-efdb-4bde-9844-50894fdfb485", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">EXP</span>", "ID": "5709ad4c-ac84-4f55-ab58-fa5b600173b3", "Styles": "None", "Classes": "None", "Text": "EXP", "ParentId": "d58b9c95-efdb-4bde-9844-50894fdfb485"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5143fed5-b218-434b-8cda-9c73e6c70352", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7581d6b6-478a-420c-ad57-14bac4e4bb3d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5143fed5-b218-434b-8cda-9c73e6c70352"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "db647de7-a082-4e7e-befb-48e97c5f4fa6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6d2680c7-15ca-496a-9c12-98cecf371d19", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "db647de7-a082-4e7e-befb-48e97c5f4fa6"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 BATCH\nNUMBER</span></b></p>\n</div>", "ID": "cc53b34c-81bc-4e03-922c-312b308da22c", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 BATCH\nNUMBER</span></b></p>", "ID": "e8b7d2e8-c1ac-4756-8eb4-6846ee72dca7", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "cc53b34c-81bc-4e03-922c-312b308da22c"}, {"Element": "<b><span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 BATCH\nNUMBER</span></b>", "ID": "62c0d772-3e30-4469-a21b-6a13fd431aa9", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e8b7d2e8-c1ac-4756-8eb4-6846ee72dca7"}, {"Element": "<span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 BATCH\nNUMBER</span>", "ID": "ecae9114-93db-4afb-9124-f4947349c866", "Styles": "None", "Classes": "None", "Text": "4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 BATCH NUMBER", "ParentId": "62c0d772-3e30-4469-a21b-6a13fd431aa9"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "76dcecc6-1295-4386-b9c7-c2ae89a56703", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8a1354e7-e712-48f2-9e65-514ef70d871c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "76dcecc6-1295-4386-b9c7-c2ae89a56703"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Lot</span></p>", "ID": "a75fde7d-471b-49b0-a9fe-a25daba8d639", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Lot</span>", "ID": "07639316-5dd9-4519-975b-63f1ab9b2fd8", "Styles": "None", "Classes": "None", "Text": "Lot", "ParentId": "a75fde7d-471b-49b0-a9fe-a25daba8d639"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d86b5d1f-0f98-433a-baac-1efae0b50b3a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8cabb097-44b7-4988-9e8a-e57b085221d4", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d86b5d1f-0f98-433a-baac-1efae0b50b3a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3edd4bfa-1fe9-40f9-8662-0488b7d54634", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c87945df-defb-4d1c-9d40-e09d868476f1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3edd4bfa-1fe9-40f9-8662-0488b7d54634"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 CONTENTS\nBY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>\n</div>", "ID": "f4770d17-4961-42a3-ba41-7474c2df345b", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 CONTENTS\nBY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>", "ID": "7a944f2b-189b-42c3-8e8a-d384e3beaa11", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f4770d17-4961-42a3-ba41-7474c2df345b"}, {"Element": "<b><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 CONTENTS\nBY WEIGHT, BY VOLUME OR BY UNIT</span></b>", "ID": "1738ae8e-8992-4119-950a-bb8dd0e3be40", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "7a944f2b-189b-42c3-8e8a-d384e3beaa11"}, {"Element": "<span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 CONTENTS\nBY WEIGHT, BY VOLUME OR BY UNIT</span>", "ID": "884ce1bc-afc0-4c30-8d81-87904c53a5fe", "Styles": "None", "Classes": "None", "Text": "5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT", "ParentId": "1738ae8e-8992-4119-950a-bb8dd0e3be40"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2568e8c9-5551-49cd-82e1-24c81c132d50", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4a3c9e79-acdb-4b2c-88b1-69801e4cee24", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2568e8c9-5551-49cd-82e1-24c81c132d50"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">420\u00a0mg/14\u00a0ml</span></p>", "ID": "ae9ca92c-4ca6-44a6-b23d-324b4b216bbd", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">420\u00a0mg/14\u00a0ml</span>", "ID": "d3413f75-8848-4706-9610-faf5bfc52377", "Styles": "None", "Classes": "None", "Text": "420\u00a0mg/14\u00a0ml", "ParentId": "ae9ca92c-4ca6-44a6-b23d-324b4b216bbd"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "109cbb6c-87d6-43a2-ac84-41c77473cd84", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "965f5370-37fb-462a-b956-2e4439a016ae", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "109cbb6c-87d6-43a2-ac84-41c77473cd84"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "81fd24cf-574a-46b5-9bdc-0ce8fd3cc3d9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2fe2315f-4cf7-4bba-8d63-2a2193638688", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "81fd24cf-574a-46b5-9bdc-0ce8fd3cc3d9"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER</span></b></p>\n</div>", "ID": "a86ba3ca-36ed-436e-904b-0515169bcbf6", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER</span></b></p>", "ID": "37e1da2e-b09e-48f6-bbd6-2bc35b94fba5", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a86ba3ca-36ed-436e-904b-0515169bcbf6"}, {"Element": "<b><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER</span></b>", "ID": "bcd9bdea-ef1a-4f60-88b0-61d6faf554e4", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "37e1da2e-b09e-48f6-bbd6-2bc35b94fba5"}, {"Element": "<span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER</span>", "ID": "10a31b1c-284c-4ea1-b0de-20a8f7947b96", "Styles": "None", "Classes": "None", "Text": "6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER", "ParentId": "bcd9bdea-ef1a-4f60-88b0-61d6faf554e4"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8ff7e663-7715-40b6-8117-814d1aea9dfa", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "dd77c7a2-2416-4d78-b129-fbd159194684", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8ff7e663-7715-40b6-8117-814d1aea9dfa"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>", "ID": "3a525f60-e914-43bd-bc4b-bf0d5139edb7", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": " ", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<br clear=\"all\" style=\"page-break-before:always\"/>", "ID": "a2b04634-75a0-434a-ba82-fa0dc5595605", "Styles": "page-break-before:always", "Classes": "None", "Text": "", "ParentId": "3a525f60-e914-43bd-bc4b-bf0d5139edb7"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "eee6cc76-d80e-421b-b2ea-2534a1b35fb2", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "02e9ae92-35ab-40e6-9f65-702b91cbd836", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "eee6cc76-d80e-421b-b2ea-2534a1b35fb2"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6d4c9e38-75da-44ab-8dfc-63862d1f03b4", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9047be52-9e45-4cb2-97e7-279b3dcdd04b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6d4c9e38-75da-44ab-8dfc-63862d1f03b4"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "903aac51-b5db-42aa-9b0a-aa37c1a95a73", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e9a46086-22a2-4eb0-b4f6-adc285192ace", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "903aac51-b5db-42aa-9b0a-aa37c1a95a73"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "960bb94e-7993-4042-b26e-875f724315d2", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0e4a376e-1c4f-4a71-94a6-daf178d05eda", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "960bb94e-7993-4042-b26e-875f724315d2"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8f94bafb-f714-43b0-ac9c-0ad658443fef", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "38e7b8ae-a4fb-4264-8d5f-f10eb5e16197", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8f94bafb-f714-43b0-ac9c-0ad658443fef"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c9e91f4c-14a3-489f-a43a-66fed80e5116", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f6f6b7f1-446c-4897-9d9d-ae0d7b34502e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c9e91f4c-14a3-489f-a43a-66fed80e5116"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c569e62e-61f0-428b-8386-d65e488ffdcc", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "330cdba9-036c-42ea-ba3b-cc131d5e9efa", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c569e62e-61f0-428b-8386-d65e488ffdcc"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3caaf02a-ddde-48e5-8dd3-300e69ac7aac", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "81c71fd8-23d3-46aa-8a5d-becc0223ed11", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3caaf02a-ddde-48e5-8dd3-300e69ac7aac"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "13c42ef2-685d-4566-ae9e-8bbd5ec48714", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "baab6e22-913e-46c2-80cf-94d147990f6a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "13c42ef2-685d-4566-ae9e-8bbd5ec48714"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3dfb4111-82ac-43fc-9eab-30974579f6ef", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1592c91e-2412-4de8-bdb9-c22541c88413", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3dfb4111-82ac-43fc-9eab-30974579f6ef"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "205618e8-2910-4bd6-8457-ca5763d92f78", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f4c51c5e-6c2f-47a0-9ad1-cf7555b313db", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "205618e8-2910-4bd6-8457-ca5763d92f78"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6ade1b52-8cf7-47f7-9f81-156cbbcddb3e", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5a51382a-0390-4ac0-a587-9db931d35f20", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6ade1b52-8cf7-47f7-9f81-156cbbcddb3e"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "1b5687d6-d39f-4d5a-aab8-d417efa30248", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c7f35c5e-7de7-4dde-91e6-0d9551ada3b8", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1b5687d6-d39f-4d5a-aab8-d417efa30248"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ca231fae-ae54-4107-a2c6-63f7eb625dec", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4a0b799f-94a4-40f8-bf8c-3d1f162e5f36", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ca231fae-ae54-4107-a2c6-63f7eb625dec"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0bf15dbb-091d-42a0-8986-381ab5f24dfd", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "28005f75-4141-4ef7-9068-4a318c95a6e8", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0bf15dbb-091d-42a0-8986-381ab5f24dfd"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e2b07ffd-9d5f-40f8-9ad4-b9a102f893e0", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f50ba773-a7f4-41fe-9976-2da61e3e0beb", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e2b07ffd-9d5f-40f8-9ad4-b9a102f893e0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6b9615f9-078d-47ef-b1c1-a1b2064e938d", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d1fc1e17-3e98-4364-bc23-d6125c544ef2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6b9615f9-078d-47ef-b1c1-a1b2064e938d"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0d161b8e-07b3-467e-a645-fafe6dc21d78", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "fb6508cb-f825-44bf-adf5-247ce3a0c6e1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0d161b8e-07b3-467e-a645-fafe6dc21d78"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4c3b38a3-4052-49bd-b571-0f3d32650f93", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "99e120cc-16fa-4eac-8f70-894e1e68b224", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4c3b38a3-4052-49bd-b571-0f3d32650f93"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "27540633-4947-4115-ab06-d75979262e71", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6676f070-1353-4a32-ac2b-3908d5077da8", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "27540633-4947-4115-ab06-d75979262e71"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0bb729d5-f9e9-49a6-ac8f-4002244e51c8", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "78911b34-7bb2-4173-9691-01967b5f2947", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0bb729d5-f9e9-49a6-ac8f-4002244e51c8"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "554ca66e-dcdc-474a-a907-862aabcf6a7a", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e355f360-e67a-4b75-93f3-4c7e35bf728b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "554ca66e-dcdc-474a-a907-862aabcf6a7a"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "21eebed0-24cd-42b3-98d4-15896ab33f08", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a1f63de8-a103-417e-bb58-a19da3d355c2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "21eebed0-24cd-42b3-98d4-15896ab33f08"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a49b7d00-4d12-4c12-bac9-201d2795109f", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ff3cd4e7-8ca5-4f98-b1cc-50d40983068b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a49b7d00-4d12-4c12-bac9-201d2795109f"}, {"Element": "<p class=\"Annex\"><span lang=\"EN-GB\">B. PACKAGE LEAFLET</span></p>", "ID": "1a02cba0-2a22-4d85-acd9-d46cc35e4af2", "Styles": "None", "Classes": "['Annex']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">B. PACKAGE LEAFLET</span>", "ID": "e51790d4-b98d-43a6-ac01-b6b451197bec", "Styles": "None", "Classes": "None", "Text": "B. PACKAGE LEAFLET", "ParentId": "1a02cba0-2a22-4d85-acd9-d46cc35e4af2"}, {"Element": "<b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span></b>", "ID": "f3c2630d-1ceb-4222-b863-734dd23f8a68", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>", "ID": "10b60945-0fbb-4a16-9801-857db7f18f96", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": " ", "ParentId": "f3c2630d-1ceb-4222-b863-734dd23f8a68"}, {"Element": "<br clear=\"all\" style=\"page-break-before:always\"/>", "ID": "81031e6e-9432-458a-a348-1f93f8dea073", "Styles": "page-break-before:always", "Classes": "None", "Text": "", "ParentId": "10b60945-0fbb-4a16-9801-857db7f18f96"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">Package\nLeaflet: Information for the user</span></b></p>", "ID": "40c256eb-17a9-405c-b25f-ab27c2076fbc", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">Package\nLeaflet: Information for the user</span></b>", "ID": "6d744864-e596-4aa7-9dad-ffa07afed214", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "40c256eb-17a9-405c-b25f-ab27c2076fbc"}, {"Element": "<span lang=\"EN-GB\">Package\nLeaflet: Information for the user</span>", "ID": "7f2b6d58-246f-4f15-970c-719608f73a3f", "Styles": "None", "Classes": "None", "Text": "Package Leaflet: Information for the user", "ParentId": "6d744864-e596-4aa7-9dad-ffa07afed214"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "892b3712-d3d4-4b8c-890c-7f1433143227", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "133160f3-f892-4582-94a4-0eb64bdbf112", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "892b3712-d3d4-4b8c-890c-7f1433143227"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "01cc6ee9-5f2a-475b-82bc-61a5b4a4407c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "133160f3-f892-4582-94a4-0eb64bdbf112"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">Perjeta\n420\u00a0mg concentrate for solution for infusion</span></b></p>", "ID": "44c99d6d-1020-4f9d-a9c6-d9d27b4ab857", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">Perjeta\n420\u00a0mg concentrate for solution for infusion</span></b>", "ID": "dac46dee-c102-460c-aa4a-45a73ccbb5aa", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "44c99d6d-1020-4f9d-a9c6-d9d27b4ab857"}, {"Element": "<span lang=\"EN-GB\">Perjeta\n420\u00a0mg concentrate for solution for infusion</span>", "ID": "cb99eb15-3da1-4ad2-aa35-c1da36af03c5", "Styles": "None", "Classes": "None", "Text": "Perjeta 420\u00a0mg concentrate for solution for infusion", "ParentId": "dac46dee-c102-460c-aa4a-45a73ccbb5aa"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">pertuzumab</span></p>", "ID": "d4873293-5a13-404d-9491-62bff0e74497", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">pertuzumab</span>", "ID": "ba38b1fc-39f7-4aec-954a-3e81e16bbfa7", "Styles": "None", "Classes": "None", "Text": "pertuzumab", "ParentId": "d4873293-5a13-404d-9491-62bff0e74497"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:12.0pt\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "386a8524-63e6-4f2f-892b-cea47603b263", "Styles": "text-align:center;line-height:12.0pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "327f17d9-4329-4e89-b479-c9ac9631ff47", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "386a8524-63e6-4f2f-892b-cea47603b263"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Read all of this leaflet carefully\nbefore you start being given this medicine because it contains important\ninformation for you.</span></b></p>", "ID": "0da095bf-54ba-4105-8f16-9e7284161f83", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">Read all of this leaflet carefully\nbefore you start being given this medicine because it contains important\ninformation for you.</span></b>", "ID": "5856ed4c-79a8-4b9c-a202-90c0718243e7", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "0da095bf-54ba-4105-8f16-9e7284161f83"}, {"Element": "<span lang=\"EN-GB\">Read all of this leaflet carefully\nbefore you start being given this medicine because it contains important\ninformation for you.</span>", "ID": "c90b5edb-15b5-4d05-b395-3add2a1b73bb", "Styles": "None", "Classes": "None", "Text": "Read all of this leaflet carefully before you start being given this medicine because it contains important information for you.", "ParentId": "5856ed4c-79a8-4b9c-a202-90c0718243e7"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.1pt;text-indent:-28.1pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Keep\nthis leaflet. You may need to read it again.</span></p>", "ID": "49427e4a-2046-4228-b37d-171f2ecea19d", "Styles": "margin-left:28.1pt;text-indent:-28.1pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "5282249c-a14b-4212-93e2-296da4e0fd7e", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "49427e4a-2046-4228-b37d-171f2ecea19d"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Keep\nthis leaflet. You may need to read it again.</span>", "ID": "ad6bb687-473f-4337-927e-51b425a03e12", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Keep this leaflet. You may need to read it again.", "ParentId": "49427e4a-2046-4228-b37d-171f2ecea19d"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.1pt;text-indent:-28.1pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 If you\nhave any further questions, ask your doctor or nurse. </span></p>", "ID": "9f77e705-3cac-416b-98e8-0587d14b8794", "Styles": "margin-left:28.1pt;text-indent:-28.1pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "ddb03b63-2c23-4dcb-81ef-7a3fdce217e8", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "9f77e705-3cac-416b-98e8-0587d14b8794"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 If you\nhave any further questions, ask your doctor or nurse. </span>", "ID": "1319a735-4a33-477f-b562-085000cc23dc", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 If you have any further questions, ask your doctor or nurse. ", "ParentId": "9f77e705-3cac-416b-98e8-0587d14b8794"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.1pt;text-indent:-28.1pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 If you\nget any side effects, talk to your doctor or nurse. This includes any possible\nside effects not listed in this leaflet. See section 4.</span></p>", "ID": "2ada531c-4bf8-44d0-acd4-5af1ab4d3966", "Styles": "margin-left:28.1pt;text-indent:-28.1pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "03560575-ad48-4a78-834f-74fcbc6905f1", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "2ada531c-4bf8-44d0-acd4-5af1ab4d3966"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 If you\nget any side effects, talk to your doctor or nurse. This includes any possible\nside effects not listed in this leaflet. See section 4.</span>", "ID": "70574374-4e39-4e0d-aaf7-06f6de93ba46", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. See section 4.", "ParentId": "2ada531c-4bf8-44d0-acd4-5af1ab4d3966"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a4ef882d-404a-4df7-95fb-9c4f6693f9a5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "133748c6-cbef-4aad-b39e-982be7aa6198", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a4ef882d-404a-4df7-95fb-9c4f6693f9a5"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">What is in this leaflet</span></b><span lang=\"EN-GB\">: </span></p>", "ID": "b7f8995a-8410-40c5-b985-4a7c8e0c8194", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">What is in this leaflet</span></b>", "ID": "2b0352be-47c2-4036-bcc9-445bae4bf6d1", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b7f8995a-8410-40c5-b985-4a7c8e0c8194"}, {"Element": "<span lang=\"EN-GB\">What is in this leaflet</span>", "ID": "d163d965-2166-4654-911e-6fed6b2d7422", "Styles": "None", "Classes": "None", "Text": "What is in this leaflet", "ParentId": "2b0352be-47c2-4036-bcc9-445bae4bf6d1"}, {"Element": "<span lang=\"EN-GB\">: </span>", "ID": "71a1773e-5fd7-4c19-b4f0-b66f99ef479f", "Styles": "None", "Classes": "None", "Text": ": ", "ParentId": "b7f8995a-8410-40c5-b985-4a7c8e0c8194"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "abe898c2-8490-442c-94e4-037cb76e9675", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f5a8cdc6-544a-4a3d-a87e-dbba709316fe", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "abe898c2-8490-442c-94e4-037cb76e9675"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-1.45pt;margin-bottom:\n0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What Perjeta<b> </b>is and what it is used for</span></p>", "ID": "33d05b06-fc1c-4279-884a-6c525efb8e60", "Styles": "margin-top:0in;margin-right:-1.45pt;margin-bottom:\n0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What Perjeta<b> </b>is and what it is used for</span>", "ID": "49dd85fd-7f6d-430f-a72a-afea9824b71d", "Styles": "None", "Classes": "None", "Text": "1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What Perjetais and what it is used for", "ParentId": "33d05b06-fc1c-4279-884a-6c525efb8e60"}, {"Element": "<b> </b>", "ID": "d75093b0-4073-4142-b07b-cfc927acfc00", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "49dd85fd-7f6d-430f-a72a-afea9824b71d"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-1.45pt;margin-bottom:\n0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What you need to know before you are given Perjeta</span></p>", "ID": "6b6e8eab-7be5-4d72-bca8-168e734e6619", "Styles": "margin-top:0in;margin-right:-1.45pt;margin-bottom:\n0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What you need to know before you are given Perjeta</span>", "ID": "7adbca42-6739-4540-a1b0-cb6940eba661", "Styles": "None", "Classes": "None", "Text": "2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What you need to know before you are given Perjeta", "ParentId": "6b6e8eab-7be5-4d72-bca8-168e734e6619"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-1.45pt;margin-bottom:\n0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How you are given Perjeta </span></p>", "ID": "3d387609-5016-4c63-b462-9ab5a4968471", "Styles": "margin-top:0in;margin-right:-1.45pt;margin-bottom:\n0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How you are given Perjeta </span>", "ID": "a1c34b84-5ca8-41e7-b501-5e33c1661d6d", "Styles": "None", "Classes": "None", "Text": "3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How you are given Perjeta ", "ParentId": "3d387609-5016-4c63-b462-9ab5a4968471"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-1.45pt;margin-bottom:\n0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Possible side effects</span></p>", "ID": "1adde986-6e3f-477a-a8db-2950846d229a", "Styles": "margin-top:0in;margin-right:-1.45pt;margin-bottom:\n0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Possible side effects</span>", "ID": "d0ae1041-09e9-4a98-81ad-f8f13fd91cda", "Styles": "None", "Classes": "None", "Text": "4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Possible side effects", "ParentId": "1adde986-6e3f-477a-a8db-2950846d229a"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-1.45pt;margin-bottom:\n0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How to store Perjeta</span></p>", "ID": "97ddecce-3f93-4509-83b5-1505dfcc290e", "Styles": "margin-top:0in;margin-right:-1.45pt;margin-bottom:\n0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How to store Perjeta</span>", "ID": "e9f63d4e-f399-41bc-a9a2-20c03ccaefb2", "Styles": "None", "Classes": "None", "Text": "5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How to store Perjeta", "ParentId": "97ddecce-3f93-4509-83b5-1505dfcc290e"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-1.45pt;margin-bottom:\n0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Contents of the pack and other information</span></p>", "ID": "895671fe-5e07-4df1-b457-ba3e530a31d9", "Styles": "margin-top:0in;margin-right:-1.45pt;margin-bottom:\n0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Contents of the pack and other information</span>", "ID": "bf9c958d-7e60-4aa5-b10e-351791b0eff1", "Styles": "None", "Classes": "None", "Text": "6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Contents of the pack and other information", "ParentId": "895671fe-5e07-4df1-b457-ba3e530a31d9"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9afd348e-4620-4d9d-8c40-9b2fdcf09b0b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0288368c-e366-42c5-b7bb-74422045f1be", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9afd348e-4620-4d9d-8c40-9b2fdcf09b0b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6b1d95c8-e30d-4bff-8a2e-c2d3fae0ed7f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a4135389-fa3c-4fc6-8713-4c3ef3ce7bf1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6b1d95c8-e30d-4bff-8a2e-c2d3fae0ed7f"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What Perjeta is and what it\nis used for</span></b></p>", "ID": "51508e2d-c56b-4ce9-b432-8498345890fa", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What Perjeta is and what it\nis used for</span></b>", "ID": "61d8bcdf-a694-4d2b-b4f3-9f9bc6372bc5", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "51508e2d-c56b-4ce9-b432-8498345890fa"}, {"Element": "<span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What Perjeta is and what it\nis used for</span>", "ID": "316b9f28-2c9a-45ed-b3c9-ac55b005b03a", "Styles": "None", "Classes": "None", "Text": "1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What Perjeta is and what it is used for", "ParentId": "61d8bcdf-a694-4d2b-b4f3-9f9bc6372bc5"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "d3d9048d-efa4-43fd-a90f-dc99b272c38a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "d4988f31-87d2-4086-9d4e-24d0320a49a5", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d3d9048d-efa4-43fd-a90f-dc99b272c38a"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "77006591-6d50-4140-9364-afd552b81e1e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d4988f31-87d2-4086-9d4e-24d0320a49a5"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Perjeta contains the active substance\npertuzumab and is used to treat adult patients with breast cancer when:</span></p>", "ID": "91197643-4a52-4214-af9f-874232d124e2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Perjeta contains the active substance\npertuzumab and is used to treat adult patients with breast cancer when:</span>", "ID": "23760459-f1d0-4246-ad12-716da2fe80ff", "Styles": "None", "Classes": "None", "Text": "Perjeta contains the active substance pertuzumab and is used to treat adult patients with breast cancer when:", "ParentId": "91197643-4a52-4214-af9f-874232d124e2"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 The breast cancer\nhas been identified to be of the \u201cHER2-positive\u201d form \u2013 your doctor will test\nyou for this.</span></p>", "ID": "c9aa2550-c9f4-43f2-abce-6506c4496e32", "Styles": "margin-left:.5in;text-indent:-.5in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "18ab92a3-45be-4cc7-8da0-9c4f96a5be25", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "c9aa2550-c9f4-43f2-abce-6506c4496e32"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 The breast cancer\nhas been identified to be of the \u201cHER2-positive\u201d form \u2013 your doctor will test\nyou for this.</span>", "ID": "891984a9-c0d0-441c-8964-c0fcc66e08f4", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 The breast cancer has been identified to be of the \u201cHER2-positive\u201d form \u2013 your doctor will test you for this.", "ParentId": "c9aa2550-c9f4-43f2-abce-6506c4496e32"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 The cancer has\nspread to other parts of the body such as the lungs or liver (metastasised) and\nhas not previously been treated with anticancer medicines (chemotherapy) or\nother medicines designed to attach to HER2, or else the cancer has come back in\nthe breast after previous treatment.</span></p>", "ID": "bd596c6a-a677-49f3-920d-92b1560d45de", "Styles": "margin-left:.5in;text-indent:-.5in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "1a598634-0771-4c16-bd1a-b5cc0e7e4c9a", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "bd596c6a-a677-49f3-920d-92b1560d45de"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 The cancer has\nspread to other parts of the body such as the lungs or liver (metastasised) and\nhas not previously been treated with anticancer medicines (chemotherapy) or\nother medicines designed to attach to HER2, or else the cancer has come back in\nthe breast after previous treatment.</span>", "ID": "bc8a9ff0-1fa0-409e-8954-e37818bd00b7", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 The cancer has spread to other parts of the body such as the lungs or liver (metastasised) and has not previously been treated with anticancer medicines (chemotherapy) or other medicines designed to attach to HER2, or else the cancer has come back in the breast after previous treatment.", "ParentId": "bd596c6a-a677-49f3-920d-92b1560d45de"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 The cancer has\nnot spread to other parts of the body and treatment is going to be given before\nsurgery takes place (treatment before surgery is called neoadjuvant therapy)</span></p>", "ID": "4fb3e645-fcf5-4bbf-82e3-6b85d820a0e1", "Styles": "margin-left:.5in;text-indent:-.5in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "82b22c8d-9e9d-4500-a090-4afa6fc0d1b9", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "4fb3e645-fcf5-4bbf-82e3-6b85d820a0e1"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 The cancer has\nnot spread to other parts of the body and treatment is going to be given before\nsurgery takes place (treatment before surgery is called neoadjuvant therapy)</span>", "ID": "83596c06-2874-4878-a9d5-958fba6c83df", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 The cancer has not spread to other parts of the body and treatment is going to be given before surgery takes place (treatment before surgery is called neoadjuvant therapy)", "ParentId": "4fb3e645-fcf5-4bbf-82e3-6b85d820a0e1"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 The cancer has\nnot spread to other parts of the body and treatment is going to be given after\nsurgery (treatment after surgery is called adjuvant therapy)</span></p>", "ID": "82f51a17-b32f-408b-91ee-ddab68c73aaf", "Styles": "margin-left:.5in;text-indent:-.5in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "3fe7d392-b83a-4cb1-9fbf-db6d4297e218", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "82f51a17-b32f-408b-91ee-ddab68c73aaf"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 The cancer has\nnot spread to other parts of the body and treatment is going to be given after\nsurgery (treatment after surgery is called adjuvant therapy)</span>", "ID": "724971da-e75e-4743-94e5-50522005d864", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 The cancer has not spread to other parts of the body and treatment is going to be given after surgery (treatment after surgery is called adjuvant therapy)", "ParentId": "82f51a17-b32f-408b-91ee-ddab68c73aaf"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ac5371f1-c6c8-4a65-a108-7303acbd57a3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "39f07d9f-94de-4732-bcc2-9bb7c929e59f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ac5371f1-c6c8-4a65-a108-7303acbd57a3"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">As well as Perjeta you will also receive trastuzumab\nand medicines called chemotherapy Information about these medicines is\ndescribed in separate package leaflets. Ask your doctor or nurse to give you\ninformation about these other medicines.</span></p>", "ID": "2a916a7a-552f-42d2-a6e2-cfecd77fd610", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">As well as Perjeta you will also receive trastuzumab\nand medicines called chemotherapy Information about these medicines is\ndescribed in separate package leaflets. Ask your doctor or nurse to give you\ninformation about these other medicines.</span>", "ID": "b0ffc976-3563-4305-bfcb-2ff8aa40f397", "Styles": "None", "Classes": "None", "Text": "As well as Perjeta you will also receive trastuzumab and medicines called chemotherapy Information about these medicines is described in separate package leaflets. Ask your doctor or nurse to give you information about these other medicines.", "ParentId": "2a916a7a-552f-42d2-a6e2-cfecd77fd610"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7d262a42-d262-49cb-897a-9797f541c018", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1ead8d4d-3da2-4a8d-afd1-8f9d9983de8a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7d262a42-d262-49cb-897a-9797f541c018"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">How Perjeta\nworks</span></b></p>", "ID": "0f90ad12-4a36-4943-a08f-9f23c2f630d0", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">How Perjeta\nworks</span></b>", "ID": "d6886b60-b803-447a-a3d2-979ddae372b4", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "0f90ad12-4a36-4943-a08f-9f23c2f630d0"}, {"Element": "<span lang=\"EN-GB\">How Perjeta\nworks</span>", "ID": "ab7dae20-567d-4f40-9bce-f45efa6261bf", "Styles": "None", "Classes": "None", "Text": "How Perjeta works", "ParentId": "d6886b60-b803-447a-a3d2-979ddae372b4"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "ca468d61-44d6-46ff-90c6-71b1457a263c", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "579ad2cc-da57-4ef8-b5a5-68e9bbb6bc5d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ca468d61-44d6-46ff-90c6-71b1457a263c"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a361936c-71a5-46a5-acc2-1d3bfb3307e8", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "579ad2cc-da57-4ef8-b5a5-68e9bbb6bc5d"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Perjeta is a\ntype of medicine called a \u201cmonoclonal antibody\u201d which attaches itself to\nspecific targets in your body and on the cancer cells.<b> </b></span></p>", "ID": "22daf25d-796c-454d-a1dd-ddae170cc3d9", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Perjeta is a\ntype of medicine called a \u201cmonoclonal antibody\u201d which attaches itself to\nspecific targets in your body and on the cancer cells.<b> </b></span>", "ID": "6a8200d7-9607-4a56-a691-a26f7efb6863", "Styles": "None", "Classes": "None", "Text": "Perjeta is a type of medicine called a \u201cmonoclonal antibody\u201d which attaches itself to specific targets in your body and on the cancer cells.", "ParentId": "22daf25d-796c-454d-a1dd-ddae170cc3d9"}, {"Element": "<b> </b>", "ID": "7b00935e-d6d0-4493-a7ca-0a9feab431e5", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "6a8200d7-9607-4a56-a691-a26f7efb6863"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "f7cbf63e-6aa8-4f72-b771-dc5ad9874e1c", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "94da1285-6b82-440d-96b5-a0220c08ba11", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f7cbf63e-6aa8-4f72-b771-dc5ad9874e1c"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "be0fcc17-6895-4841-ae73-ac209131d7ca", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "94da1285-6b82-440d-96b5-a0220c08ba11"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Perjeta\nrecognises and attaches to a target called \u201chuman epidermal growth factor\u00a0receptor\n2\u201d (HER2). HER2 is found in large amounts on the surface of some cancer cells\nwhere it stimulates their growth. When Perjeta attaches to the HER2 cancer\ncells, it may slow or stop the cancer cells from growing, or may kill them.</span></p>", "ID": "1b63bf40-7c32-4e07-8490-084c1e39ff97", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Perjeta\nrecognises and attaches to a target called \u201chuman epidermal growth factor\u00a0receptor\n2\u201d (HER2). HER2 is found in large amounts on the surface of some cancer cells\nwhere it stimulates their growth. When Perjeta attaches to the HER2 cancer\ncells, it may slow or stop the cancer cells from growing, or may kill them.</span>", "ID": "ee7d4fa2-5336-40df-9fba-8d48ec2b7efc", "Styles": "None", "Classes": "None", "Text": "Perjeta recognises and attaches to a target called \u201chuman epidermal growth factor\u00a0receptor 2\u201d (HER2). HER2 is found in large amounts on the surface of some cancer cells where it stimulates their growth. When Perjeta attaches to the HER2 cancer cells, it may slow or stop the cancer cells from growing, or may kill them.", "ParentId": "1b63bf40-7c32-4e07-8490-084c1e39ff97"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e0cb9310-9bb8-4b25-b359-0ce8cd5d6cce", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7b79c9ef-22d7-4298-a42e-49a774d8e965", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e0cb9310-9bb8-4b25-b359-0ce8cd5d6cce"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0e5cb426-0511-4035-8201-f0388d76b132", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d6623030-470a-4970-abee-29d54b2e110e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0e5cb426-0511-4035-8201-f0388d76b132"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What\nyou need to know before you are given Perjeta</span></b></p>", "ID": "7b43d572-0a89-4529-99e8-e0e7a022f455", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What\nyou need to know before you are given Perjeta</span></b>", "ID": "1507c2a9-7559-470c-b336-53056a05442c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "7b43d572-0a89-4529-99e8-e0e7a022f455"}, {"Element": "<span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What\nyou need to know before you are given Perjeta</span>", "ID": "9c2218cd-ec2f-44ea-b66f-63d517c5490e", "Styles": "None", "Classes": "None", "Text": "2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What you need to know before you are given Perjeta", "ParentId": "1507c2a9-7559-470c-b336-53056a05442c"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e585f88a-28ec-4485-a9dd-589c92f5d4a5", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "177edd25-6a22-46f3-9690-9e18677f8ddf", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e585f88a-28ec-4485-a9dd-589c92f5d4a5"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">You must\nnot be given Perjeta</span></b></p>", "ID": "35b1ed32-1e49-42a1-b900-5df15f1624e0", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">You must\nnot be given Perjeta</span></b>", "ID": "f81bb880-82e8-4dd1-bbf3-b349a4bbf049", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "35b1ed32-1e49-42a1-b900-5df15f1624e0"}, {"Element": "<span lang=\"EN-GB\">You must\nnot be given Perjeta</span>", "ID": "17f16cf3-7522-457e-b59b-18bd48618ce3", "Styles": "None", "Classes": "None", "Text": "You must not be given Perjeta", "ParentId": "f81bb880-82e8-4dd1-bbf3-b349a4bbf049"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9cf279c0-0568-4e5f-92db-6e92c49f2ff2", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "912ab2fd-73a7-4c76-a28c-2c10cce7db29", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9cf279c0-0568-4e5f-92db-6e92c49f2ff2"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 If you are\nallergic to pertuzumab, or to any of the other ingredients of this medicine\n(listed in section 6).</span></p>", "ID": "98f1c63f-b7ba-4284-aed6-ff8dffc29d5c", "Styles": "margin-left:.5in;text-indent:-.5in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "0738ec37-3cdf-4587-a85d-ff49268341f6", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "98f1c63f-b7ba-4284-aed6-ff8dffc29d5c"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 If you are\nallergic to pertuzumab, or to any of the other ingredients of this medicine\n(listed in section 6).</span>", "ID": "f989ac21-3087-4b75-91f4-7e88587a8867", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 If you are allergic to pertuzumab, or to any of the other ingredients of this medicine (listed in section 6).", "ParentId": "98f1c63f-b7ba-4284-aed6-ff8dffc29d5c"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "04dd57c7-2f95-4558-8ef4-f59728c97ba0", "Styles": "margin-left:.5in;text-indent:-.5in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0bc2b434-10db-4254-a445-b8a91ad6302a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "04dd57c7-2f95-4558-8ef4-f59728c97ba0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">If you are not sure, talk to your doctor or\nnurse before you are given Perjeta.</span></p>", "ID": "ebc027cf-5eaf-4104-81dd-45539ad708dd", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">If you are not sure, talk to your doctor or\nnurse before you are given Perjeta.</span>", "ID": "faf5c888-9686-4a11-bf13-82c5105d1d03", "Styles": "None", "Classes": "None", "Text": "If you are not sure, talk to your doctor or nurse before you are given Perjeta.", "ParentId": "ebc027cf-5eaf-4104-81dd-45539ad708dd"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d8148d82-1400-43f1-8ac9-2575c0434f29", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7359d456-959f-458a-a431-2d8d977d9531", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d8148d82-1400-43f1-8ac9-2575c0434f29"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Warnings\nand precautions</span></b></p>", "ID": "1024f170-6351-45d1-916f-a71acd649b9c", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">Warnings\nand precautions</span></b>", "ID": "3fdb0710-b124-43f9-b7e6-f0e76c4d3283", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "1024f170-6351-45d1-916f-a71acd649b9c"}, {"Element": "<span lang=\"EN-GB\">Warnings\nand precautions</span>", "ID": "c9f9bbed-97bc-4b9b-bbc6-3f682ea38eb3", "Styles": "None", "Classes": "None", "Text": "Warnings and precautions", "ParentId": "3fdb0710-b124-43f9-b7e6-f0e76c4d3283"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "f3d8039e-c164-4005-b750-9b245fb8a593", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "c6d28306-0a8c-4b15-a117-fcf5ca0fb0c5", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f3d8039e-c164-4005-b750-9b245fb8a593"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6a35771c-0024-401a-a4be-4a0146f29598", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c6d28306-0a8c-4b15-a117-fcf5ca0fb0c5"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Treatment with Perjeta may affect the heart.\n\u00a0Talk to your doctor or nurse before you are given Perjeta:</span></p>", "ID": "fd73166a-caa0-4bfa-8619-3115b65b8384", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Treatment with Perjeta may affect the heart.\n\u00a0Talk to your doctor or nurse before you are given Perjeta:</span>", "ID": "58f4c129-89fa-45ab-ac2e-f96284531a63", "Styles": "None", "Classes": "None", "Text": "Treatment with Perjeta may affect the heart. \u00a0Talk to your doctor or nurse before you are given Perjeta:", "ParentId": "fd73166a-caa0-4bfa-8619-3115b65b8384"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 If you have ever\nhad heart problems (such as heart failure, treatment for serious irregular\nheartbeats, uncontrolled high blood pressure, recent heart attack), your heart\nfunction will be checked before and during treatment with Perjeta and your\ndoctor will run tests to check if your heart is working properly. </span></p>", "ID": "d325961a-d89b-4c54-ab89-d47fc3c75997", "Styles": "margin-left:.5in;text-indent:-.5in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "af05bef2-2524-4f6c-b067-fa4f522adc06", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "d325961a-d89b-4c54-ab89-d47fc3c75997"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 If you have ever\nhad heart problems (such as heart failure, treatment for serious irregular\nheartbeats, uncontrolled high blood pressure, recent heart attack), your heart\nfunction will be checked before and during treatment with Perjeta and your\ndoctor will run tests to check if your heart is working properly. </span>", "ID": "4ae98953-ad7a-4282-af83-b8269a94c148", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 If you have ever had heart problems (such as heart failure, treatment for serious irregular heartbeats, uncontrolled high blood pressure, recent heart attack), your heart function will be checked before and during treatment with Perjeta and your doctor will run tests to check if your heart is working properly. ", "ParentId": "d325961a-d89b-4c54-ab89-d47fc3c75997"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 If you have ever\nhad heart problems during previous treatment with trastuzumab.</span></p>", "ID": "ad4d2a45-b1b1-46ab-9089-51aad07432f5", "Styles": "margin-left:.5in;text-indent:-.5in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "9cc45673-fb81-43f0-8311-ef1422d56af8", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "ad4d2a45-b1b1-46ab-9089-51aad07432f5"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 If you have ever\nhad heart problems during previous treatment with trastuzumab.</span>", "ID": "670c0704-6c78-4abc-83d6-e3897a16e6f6", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 If you have ever had heart problems during previous treatment with trastuzumab.", "ParentId": "ad4d2a45-b1b1-46ab-9089-51aad07432f5"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 If you have ever\nhad a chemotherapy medicine from the class called anthracyclines, e.g.\ndoxorubicin or epirubicin \u2013 these medicines can damage heart muscle and\nincrease the risk of heart problems with Perjeta.</span></p>", "ID": "6ea6fe05-9191-47d1-b5e0-59f88252a123", "Styles": "margin-left:.5in;text-indent:-.5in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "a6f0869e-d0c1-4c93-b21c-c2d100d8f3c2", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "6ea6fe05-9191-47d1-b5e0-59f88252a123"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 If you have ever\nhad a chemotherapy medicine from the class called anthracyclines, e.g.\ndoxorubicin or epirubicin \u2013 these medicines can damage heart muscle and\nincrease the risk of heart problems with Perjeta.</span>", "ID": "cd7a16e9-cb86-4940-b965-13446ffbf9c6", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 If you have ever had a chemotherapy medicine from the class called anthracyclines, e.g. doxorubicin or epirubicin \u2013 these medicines can damage heart muscle and increase the risk of heart problems with Perjeta.", "ParentId": "6ea6fe05-9191-47d1-b5e0-59f88252a123"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "af4ea97f-8342-476f-b035-c551ee22ff3e", "Styles": "margin-left:.5in;text-indent:-.5in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1a44fe58-846c-4da0-9a3b-e51ca79d84a7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "af4ea97f-8342-476f-b035-c551ee22ff3e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">If any of the above applies to you (or you\nare not sure), talk to your doctor or nurse before you are given Perjeta. See\nsection 4 \u201cSerious side effects\u201d for more details about signs of heart problems\nto look out for.</span></p>", "ID": "4da61f32-ed19-476a-a3da-7b230d27ba99", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">If any of the above applies to you (or you\nare not sure), talk to your doctor or nurse before you are given Perjeta. See\nsection 4 \u201cSerious side effects\u201d for more details about signs of heart problems\nto look out for.</span>", "ID": "d8cc3865-858f-4c4f-9adf-90740a9b4633", "Styles": "None", "Classes": "None", "Text": "If any of the above applies to you (or you are not sure), talk to your doctor or nurse before you are given Perjeta. See section 4 \u201cSerious side effects\u201d for more details about signs of heart problems to look out for.", "ParentId": "4da61f32-ed19-476a-a3da-7b230d27ba99"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4da08c15-050f-4fab-9646-65c58e1cc6cb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "36acefda-3bf0-41ec-915c-a66957adc2a2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4da08c15-050f-4fab-9646-65c58e1cc6cb"}, {"Element": "<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Infusion reactions</span></u></p>", "ID": "001f1cec-c9cf-47ff-9868-d7630fe9c04c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<u><span lang=\"EN-GB\">Infusion reactions</span></u>", "ID": "c5f099fb-7b8a-41fe-b03d-1c10fca841e1", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "001f1cec-c9cf-47ff-9868-d7630fe9c04c"}, {"Element": "<span lang=\"EN-GB\">Infusion reactions</span>", "ID": "d06cc6ea-23ed-4da1-a6a8-04877c5f7838", "Styles": "None", "Classes": "None", "Text": "Infusion reactions", "ParentId": "c5f099fb-7b8a-41fe-b03d-1c10fca841e1"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Infusion reactions, allergic or\nanaphylactic (more severe allergic) reactions can happen. Your doctor or nurse\nwill check for side effects during your infusion and for 30 to 60 minutes\nafterwards. If you get any serious reaction, your doctor may stop treatment\nwith Perjeta. Very rarely, patients have died due to anaphylactic reactions\nduring Perjeta infusion. See section 4 \u201cSerious side effects\u201d for more details\nabout infusion reactions to look out for during the infusion and thereafter. </span></p>", "ID": "5e419f59-9432-4912-83cf-8616bd2c7a42", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Infusion reactions, allergic or\nanaphylactic (more severe allergic) reactions can happen. Your doctor or nurse\nwill check for side effects during your infusion and for 30 to 60 minutes\nafterwards. If you get any serious reaction, your doctor may stop treatment\nwith Perjeta. Very rarely, patients have died due to anaphylactic reactions\nduring Perjeta infusion. See section 4 \u201cSerious side effects\u201d for more details\nabout infusion reactions to look out for during the infusion and thereafter. </span>", "ID": "3c15a90c-b522-404b-8e44-f6ce6db83c94", "Styles": "None", "Classes": "None", "Text": "Infusion reactions, allergic or anaphylactic (more severe allergic) reactions can happen. Your doctor or nurse will check for side effects during your infusion and for 30 to 60 minutes afterwards. If you get any serious reaction, your doctor may stop treatment with Perjeta. Very rarely, patients have died due to anaphylactic reactions during Perjeta infusion. See section 4 \u201cSerious side effects\u201d for more details about infusion reactions to look out for during the infusion and thereafter. ", "ParentId": "5e419f59-9432-4912-83cf-8616bd2c7a42"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "61042439-f6db-4053-af15-44949079bd42", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "07dfff35-7789-437a-bb5e-d6ce1e79ab5a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "61042439-f6db-4053-af15-44949079bd42"}, {"Element": "<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Febrile neutropenia (Low white blood\ncells with fever)</span></u></p>", "ID": "01bdb642-9ed8-4366-aac5-b805df980dff", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<u><span lang=\"EN-GB\">Febrile neutropenia (Low white blood\ncells with fever)</span></u>", "ID": "658e05c9-63fc-44ab-931c-0b6840476c9f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "01bdb642-9ed8-4366-aac5-b805df980dff"}, {"Element": "<span lang=\"EN-GB\">Febrile neutropenia (Low white blood\ncells with fever)</span>", "ID": "d58fc807-49cd-42b8-a89a-38da7709ff64", "Styles": "None", "Classes": "None", "Text": "Febrile neutropenia (Low white blood cells with fever)", "ParentId": "658e05c9-63fc-44ab-931c-0b6840476c9f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">When Perjeta is given with other cancer\ntreatments (trastuzumab and chemotherapy), the number of white blood cells may\ndrop and fever (raised temperature) may develop. If you have inflammation of\nthe digestive tract (e.g.sore mouth or diarrhoea) you may be more likely to\ndevelop this side effect.</span></p>", "ID": "2310cd5b-57c8-4fd7-ae7f-ff6c9c929c37", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">When Perjeta is given with other cancer\ntreatments (trastuzumab and chemotherapy), the number of white blood cells may\ndrop and fever (raised temperature) may develop. If you have inflammation of\nthe digestive tract (e.g.sore mouth or diarrhoea) you may be more likely to\ndevelop this side effect.</span>", "ID": "338d8e7a-21f7-43fc-a865-0eb4814bf363", "Styles": "None", "Classes": "None", "Text": "When Perjeta is given with other cancer treatments (trastuzumab and chemotherapy), the number of white blood cells may drop and fever (raised temperature) may develop. If you have inflammation of the digestive tract (e.g.sore mouth or diarrhoea) you may be more likely to develop this side effect.", "ParentId": "2310cd5b-57c8-4fd7-ae7f-ff6c9c929c37"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0e01904b-97c7-4949-b903-85d9538f961e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "856849e7-f7a4-418a-89ac-8d9ae0405cb5", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0e01904b-97c7-4949-b903-85d9538f961e"}, {"Element": "<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Diarrhoea</span></u></p>", "ID": "56883158-6dc2-45a7-8d4a-7a0188979ef2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<u><span lang=\"EN-GB\">Diarrhoea</span></u>", "ID": "1fb831f8-4c64-4334-8aea-6f407dc27334", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "56883158-6dc2-45a7-8d4a-7a0188979ef2"}, {"Element": "<span lang=\"EN-GB\">Diarrhoea</span>", "ID": "728ba5f3-e574-46dc-8c36-c5ae9c0ad38c", "Styles": "None", "Classes": "None", "Text": "Diarrhoea", "ParentId": "1fb831f8-4c64-4334-8aea-6f407dc27334"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Treatment with Perjeta may cause severe\ndiarrhoea. Patients over 65\u00a0years of age have a higher risk of diarrhoea compared\nwith patients younger than 65 years of age.</span><span lang=\"EN-GB\" style=\"color:black;background:white\"> </span><span lang=\"EN-GB\">Diarrhoea is a\ncondition where your body produces more watery stools than normal. If you\nexperience severe diarrhoea while receiving your anti-cancer treatment, your\ndoctor may start you on anti-diarrhoeal treatment and may stop your treatment\nwith Perjeta until the diarrhoea is under control. </span></p>", "ID": "19a092b1-7abc-4ac0-9196-063612af2d1b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Treatment with Perjeta may cause severe\ndiarrhoea. Patients over 65\u00a0years of age have a higher risk of diarrhoea compared\nwith patients younger than 65 years of age.</span>", "ID": "cbb9ea32-1cb8-4739-b04e-c00de099504e", "Styles": "None", "Classes": "None", "Text": "Treatment with Perjeta may cause severe diarrhoea. Patients over 65\u00a0years of age have a higher risk of diarrhoea compared with patients younger than 65 years of age.", "ParentId": "19a092b1-7abc-4ac0-9196-063612af2d1b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black;background:white\"> </span>", "ID": "f6da4515-e8bf-4dcd-8474-2da45301d106", "Styles": "color:black;background:white", "Classes": "None", "Text": " ", "ParentId": "19a092b1-7abc-4ac0-9196-063612af2d1b"}, {"Element": "<span lang=\"EN-GB\">Diarrhoea is a\ncondition where your body produces more watery stools than normal. If you\nexperience severe diarrhoea while receiving your anti-cancer treatment, your\ndoctor may start you on anti-diarrhoeal treatment and may stop your treatment\nwith Perjeta until the diarrhoea is under control. </span>", "ID": "7d262eca-fb20-4e3c-b7c6-5f3eb88cb5b0", "Styles": "None", "Classes": "None", "Text": "Diarrhoea is a condition where your body produces more watery stools than normal. If you experience severe diarrhoea while receiving your anti-cancer treatment, your doctor may start you on anti-diarrhoeal treatment and may stop your treatment with Perjeta until the diarrhoea is under control. ", "ParentId": "19a092b1-7abc-4ac0-9196-063612af2d1b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4be8efba-3519-4afa-9564-938687a4f307", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f9ca344e-d799-4fa4-8f60-b103b15bd838", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4be8efba-3519-4afa-9564-938687a4f307"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Use in children and adolescents</span></b></p>", "ID": "d013649c-9c24-4dee-b1d0-ae4eedbf785c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">Use in children and adolescents</span></b>", "ID": "233ef732-4bca-48fa-8376-92b88e7e4378", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d013649c-9c24-4dee-b1d0-ae4eedbf785c"}, {"Element": "<span lang=\"EN-GB\">Use in children and adolescents</span>", "ID": "9cdbf5a4-08a1-4255-a47c-06dcd70d10c8", "Styles": "None", "Classes": "None", "Text": "Use in children and adolescents", "ParentId": "233ef732-4bca-48fa-8376-92b88e7e4378"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Perjeta should not be given to patients under\nthe age of 18 years because there is no information on how it works in this age\ngroup.</span></p>", "ID": "dacd2426-9e48-42bd-8e27-6910aca19ccb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Perjeta should not be given to patients under\nthe age of 18 years because there is no information on how it works in this age\ngroup.</span>", "ID": "9afc3b53-4cd8-4ff9-bae8-1d66d4691326", "Styles": "None", "Classes": "None", "Text": "Perjeta should not be given to patients under the age of 18 years because there is no information on how it works in this age group.", "ParentId": "dacd2426-9e48-42bd-8e27-6910aca19ccb"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "73d19ed3-eecc-4440-a6fc-81e03fe5cf24", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "56359bb7-81c4-498f-ba50-8591311f838e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "73d19ed3-eecc-4440-a6fc-81e03fe5cf24"}, {"Element": "<p class=\"MsoNormal\" style=\"background:white\"><b><span lang=\"EN-GB\" style=\"color:black\">Use in the elderly</span></b></p>", "ID": "8eb0b2ed-a1e7-4c45-a2d9-441304a9a8da", "Styles": "background:white", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\" style=\"color:black\">Use in the elderly</span></b>", "ID": "51e1834f-95e8-40f2-837e-066661c9f588", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8eb0b2ed-a1e7-4c45-a2d9-441304a9a8da"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Use in the elderly</span>", "ID": "68256930-fc70-4be9-8ef8-7b8c67f4271b", "Styles": "color:black", "Classes": "None", "Text": "Use in the elderly", "ParentId": "51e1834f-95e8-40f2-837e-066661c9f588"}, {"Element": "<p class=\"MsoNormal\" style=\"background:white\"><span lang=\"EN-GB\" style=\"color:black\">Patients\nover 65\u00a0years of age who are treated with Perjeta are more likely to\nexperience side effects such as reduced appetite, decrease in the number of red\nblood cells, weight loss, feeling tired, loss or altered taste, weak, numb,\ntingling or prickling sensations mainly affecting the feet and legs and\ndiarrhoea, compared to patients younger than 65\u00a0years of age.</span></p>", "ID": "58468a88-88c9-4413-b302-c6c900e7702a", "Styles": "background:white", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Patients\nover 65\u00a0years of age who are treated with Perjeta are more likely to\nexperience side effects such as reduced appetite, decrease in the number of red\nblood cells, weight loss, feeling tired, loss or altered taste, weak, numb,\ntingling or prickling sensations mainly affecting the feet and legs and\ndiarrhoea, compared to patients younger than 65\u00a0years of age.</span>", "ID": "96283a14-826e-4518-a46d-c910c4f0d90b", "Styles": "color:black", "Classes": "None", "Text": "Patients over 65\u00a0years of age who are treated with Perjeta are more likely to experience side effects such as reduced appetite, decrease in the number of red blood cells, weight loss, feeling tired, loss or altered taste, weak, numb, tingling or prickling sensations mainly affecting the feet and legs and diarrhoea, compared to patients younger than 65\u00a0years of age.", "ParentId": "58468a88-88c9-4413-b302-c6c900e7702a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "030c5346-f315-44cd-9032-16c4c431e28e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "485d4402-731c-42dd-a315-09d37c4c2ff9", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "030c5346-f315-44cd-9032-16c4c431e28e"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Other medicines and Perjeta</span></b></p>", "ID": "7224f4c1-2520-4aa9-b583-39497f6e817a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">Other medicines and Perjeta</span></b>", "ID": "20eda084-899e-46cd-a10a-10be5359fb27", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "7224f4c1-2520-4aa9-b583-39497f6e817a"}, {"Element": "<span lang=\"EN-GB\">Other medicines and Perjeta</span>", "ID": "799f8df5-7e50-4ddb-85d3-0968d2ab6294", "Styles": "None", "Classes": "None", "Text": "Other medicines and Perjeta", "ParentId": "20eda084-899e-46cd-a10a-10be5359fb27"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tell your doctor or nurse if you are\ntaking, have recently taken or might take any other medicines. </span></p>", "ID": "77a9b192-db15-4378-8a10-123c9b768d5a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Tell your doctor or nurse if you are\ntaking, have recently taken or might take any other medicines. </span>", "ID": "aa59db2c-9ea1-4101-8281-6c66899a6ea9", "Styles": "None", "Classes": "None", "Text": "Tell your doctor or nurse if you are taking, have recently taken or might take any other medicines. ", "ParentId": "77a9b192-db15-4378-8a10-123c9b768d5a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e53c0422-eb50-4039-9a0f-ecda0025194c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "73d9f815-dca6-460d-876d-420aa56080c6", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e53c0422-eb50-4039-9a0f-ecda0025194c"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Pregnancy\nand breast-feeding</span></b></p>", "ID": "63190189-b0d5-4d4b-813f-22076b99157d", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">Pregnancy\nand breast-feeding</span></b>", "ID": "5bb4b5e3-88aa-4efb-b946-f42d644e3e9a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "63190189-b0d5-4d4b-813f-22076b99157d"}, {"Element": "<span lang=\"EN-GB\">Pregnancy\nand breast-feeding</span>", "ID": "0485fa9a-e7b4-4024-b659-5ce75472ef99", "Styles": "None", "Classes": "None", "Text": "Pregnancy and breast-feeding", "ParentId": "5bb4b5e3-88aa-4efb-b946-f42d644e3e9a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Before starting treatment, you must tell\nyour doctor or nurse if you are pregnant or breast-feeding, </span><span lang=\"EN-GB\">or if you </span><span lang=\"EN-GB\">think you may be pregnant<b> </b>or\nare planning to have a baby. They will advise you about the benefits and risks\nfor you and your baby of taking Perjeta while you are pregnant.</span></p>", "ID": "6c9bf4a6-645a-45da-800a-a2c86e52f534", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Before starting treatment, you must tell\nyour doctor or nurse if you are pregnant or breast-feeding, </span>", "ID": "b063aaab-40b2-4d89-a239-7530744fdda7", "Styles": "None", "Classes": "None", "Text": "Before starting treatment, you must tell your doctor or nurse if you are pregnant or breast-feeding, ", "ParentId": "6c9bf4a6-645a-45da-800a-a2c86e52f534"}, {"Element": "<span lang=\"EN-GB\">or if you </span>", "ID": "be49c8ec-fe9c-4bcd-b050-2ab634aeca35", "Styles": "None", "Classes": "None", "Text": "or if you ", "ParentId": "6c9bf4a6-645a-45da-800a-a2c86e52f534"}, {"Element": "<span lang=\"EN-GB\">think you may be pregnant<b> </b>or\nare planning to have a baby. They will advise you about the benefits and risks\nfor you and your baby of taking Perjeta while you are pregnant.</span>", "ID": "5e68173f-0f53-477e-929b-44e8c4a5f002", "Styles": "None", "Classes": "None", "Text": "think you may be pregnantor are planning to have a baby. They will advise you about the benefits and risks for you and your baby of taking Perjeta while you are pregnant.", "ParentId": "6c9bf4a6-645a-45da-800a-a2c86e52f534"}, {"Element": "<b> </b>", "ID": "1064a51a-6ac9-433b-93d4-e9bdf3e3c59a", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "5e68173f-0f53-477e-929b-44e8c4a5f002"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a6ace1ac-a36d-47da-af26-b88a9ae53812", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2d95022b-dd6c-4fbd-bea2-bc926786196a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a6ace1ac-a36d-47da-af26-b88a9ae53812"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Tell your doctor\nstraight away,<b> </b>if you get pregnant during treatment with<b> </b>Perjeta\nor during the 6 months after stopping treatment.</span></p>", "ID": "231b561a-0056-4375-9a2a-6b3e6a849092", "Styles": "margin-left:.5in;text-indent:-.5in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "727f1fa1-6170-42e2-8a61-59497d8a4a98", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "231b561a-0056-4375-9a2a-6b3e6a849092"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Tell your doctor\nstraight away,<b> </b>if you get pregnant during treatment with<b> </b>Perjeta\nor during the 6 months after stopping treatment.</span>", "ID": "9c0ad31d-a2a6-451f-8e67-f962c78940e1", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Tell your doctor straight away,if you get pregnant during treatment withPerjeta or during the 6 months after stopping treatment.", "ParentId": "231b561a-0056-4375-9a2a-6b3e6a849092"}, {"Element": "<b> </b>", "ID": "7689ce90-e142-499f-b103-1eb5b524a4fd", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "9c0ad31d-a2a6-451f-8e67-f962c78940e1"}, {"Element": "<b> </b>", "ID": "1c582520-5afc-4dd3-a1c9-fad918b675e5", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "9c0ad31d-a2a6-451f-8e67-f962c78940e1"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Ask your doctor\nabout whether you can breast-feed during or after treatment with Perjeta.</span></p>", "ID": "01a58806-3d97-4838-aefc-ed47377df580", "Styles": "margin-left:.5in;text-indent:-.5in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "8a725fb2-2b8d-4123-8999-48408fa94615", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "01a58806-3d97-4838-aefc-ed47377df580"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Ask your doctor\nabout whether you can breast-feed during or after treatment with Perjeta.</span>", "ID": "7224ef40-654c-4fd6-a83a-80797248bafd", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Ask your doctor about whether you can breast-feed during or after treatment with Perjeta.", "ParentId": "01a58806-3d97-4838-aefc-ed47377df580"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e8139f62-5a24-4a4a-a112-55a3b005b613", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ddea6bad-2eaf-4d0f-aaa1-6a63d69bf83f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e8139f62-5a24-4a4a-a112-55a3b005b613"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Perjeta may harm the unborn baby. You\nshould use effective contraception during treatment with Perjeta and for 6 months\nafter stopping treatment. Talk to your doctor about the best contraception for\nyou.</span></p>", "ID": "9a4a1284-02c5-4834-bba1-5e0460f6f545", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Perjeta may harm the unborn baby. You\nshould use effective contraception during treatment with Perjeta and for 6 months\nafter stopping treatment. Talk to your doctor about the best contraception for\nyou.</span>", "ID": "8514ccaf-b5f8-4bc6-9e2f-bc43f4de93b8", "Styles": "None", "Classes": "None", "Text": "Perjeta may harm the unborn baby. You should use effective contraception during treatment with Perjeta and for 6 months after stopping treatment. Talk to your doctor about the best contraception for you.", "ParentId": "9a4a1284-02c5-4834-bba1-5e0460f6f545"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7095fc60-6d80-45d9-822c-80656e9fdfe6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9cba37fe-7f2d-486b-b43d-6da82dcfb3bd", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7095fc60-6d80-45d9-822c-80656e9fdfe6"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Driving and using machines</span></b></p>", "ID": "3fcd8c7b-d432-46c5-8db9-870725516929", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">Driving and using machines</span></b>", "ID": "91f4d085-c672-43ab-ab66-93cf5d412e35", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3fcd8c7b-d432-46c5-8db9-870725516929"}, {"Element": "<span lang=\"EN-GB\">Driving and using machines</span>", "ID": "6d721cc5-1bba-4e38-a9a0-ca7b70741f15", "Styles": "None", "Classes": "None", "Text": "Driving and using machines", "ParentId": "91f4d085-c672-43ab-ab66-93cf5d412e35"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Perjeta may have a minor effect on you\nbeing able to drive or use machines. However, if you get any dizziness, infusion\nreactions, allergic or anaphylactic reactions, wait until these have gone away\nbefore driving or using machines.</span></p>", "ID": "74db2cce-bf15-4594-a5bb-ce72283441db", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Perjeta may have a minor effect on you\nbeing able to drive or use machines. However, if you get any dizziness, infusion\nreactions, allergic or anaphylactic reactions, wait until these have gone away\nbefore driving or using machines.</span>", "ID": "7907f6ca-db8e-4cbd-bf41-43f620a6fd70", "Styles": "None", "Classes": "None", "Text": "Perjeta may have a minor effect on you being able to drive or use machines. However, if you get any dizziness, infusion reactions, allergic or anaphylactic reactions, wait until these have gone away before driving or using machines.", "ParentId": "74db2cce-bf15-4594-a5bb-ce72283441db"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7ea5a42a-ed1d-40e5-ab81-34c152ef1e91", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1da01608-0111-4de0-a796-5f706be289a7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7ea5a42a-ed1d-40e5-ab81-34c152ef1e91"}, {"Element": "<p class=\"MsoNormal\"><b>Sodium</b> </p>", "ID": "f0b5bb93-85d0-4ca4-b26b-400c01112173", "Styles": "None", "Classes": "['MsoNormal']", "Text": " ", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b>Sodium</b>", "ID": "04b8c3bd-3e2b-41c5-af77-10ad708697a9", "Styles": "None", "Classes": "None", "Text": "Sodium", "ParentId": "f0b5bb93-85d0-4ca4-b26b-400c01112173"}, {"Element": "<p class=\"MsoNormal\">Perjeta contains less than 1\u00a0mmol of sodium per dose,\ni.e. it is essentially sodium\u2011free.</p>", "ID": "a629b73c-a5ff-438b-a375-5c6b2fbf26aa", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Perjeta contains less than 1\u00a0mmol of sodium per dose, i.e. it is essentially sodium\u2011free.", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3242b054-7c88-499e-996d-386a244c35b4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9a16e58c-c4f3-4d74-9e20-1e46a8823dd2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3242b054-7c88-499e-996d-386a244c35b4"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d1b19672-8965-445f-a90d-816722928dd6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "11d6ef2f-7338-4369-a3f9-f7caa28ff99a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d1b19672-8965-445f-a90d-816722928dd6"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How\nyou are given Perjeta</span></b></p>", "ID": "1082bf10-c1a4-499d-80d4-c56dbff70635", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How\nyou are given Perjeta</span></b>", "ID": "bdcf265f-55ce-4547-b01e-ddb3e82fe504", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "1082bf10-c1a4-499d-80d4-c56dbff70635"}, {"Element": "<span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How\nyou are given Perjeta</span>", "ID": "f242a521-73d2-44a9-9783-93ff4e2c97c3", "Styles": "None", "Classes": "None", "Text": "3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How you are given Perjeta", "ParentId": "bdcf265f-55ce-4547-b01e-ddb3e82fe504"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "d3f2c463-9e8c-4006-8b1b-513415837288", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "84f6da05-a694-4c68-b132-860ca8f7c4d7", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d3f2c463-9e8c-4006-8b1b-513415837288"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8503d933-c1a9-4f6d-a67d-963a70bcc335", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "84f6da05-a694-4c68-b132-860ca8f7c4d7"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Being\ngiven this medicine</span></b></p>", "ID": "9c8e95a5-3bdd-453d-a29a-9d314df40485", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">Being\ngiven this medicine</span></b>", "ID": "7078d2b8-c825-44b3-a3b9-30498579b184", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "9c8e95a5-3bdd-453d-a29a-9d314df40485"}, {"Element": "<span lang=\"EN-GB\">Being\ngiven this medicine</span>", "ID": "285faa1c-55c4-44d7-8fb0-0fa97e855a39", "Styles": "None", "Classes": "None", "Text": "Being given this medicine", "ParentId": "7078d2b8-c825-44b3-a3b9-30498579b184"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "ae3cc95c-c2d3-4d91-bf39-1402942d20c2", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "771cdfd4-4677-4441-a194-9af1d1fbfa1f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ae3cc95c-c2d3-4d91-bf39-1402942d20c2"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f10e1931-6567-4c4d-bc5e-63bb0b4b3dd5", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "771cdfd4-4677-4441-a194-9af1d1fbfa1f"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt;page-break-after:avoid\"><span lang=\"EN-GB\">Perjeta</span><span lang=\"EN-GB\"> will be given to you by a doctor or\nnurse in a hospital or clinic.</span></p>", "ID": "f9ac861d-f12a-4764-ab52-9f46d7f5ab7e", "Styles": "margin-right:-.1pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Perjeta</span>", "ID": "a781b751-454b-4f8a-b805-ff3af60b5149", "Styles": "None", "Classes": "None", "Text": "Perjeta", "ParentId": "f9ac861d-f12a-4764-ab52-9f46d7f5ab7e"}, {"Element": "<span lang=\"EN-GB\"> will be given to you by a doctor or\nnurse in a hospital or clinic.</span>", "ID": "3f6e10cc-7dcd-4de2-9990-f98c8df23bc6", "Styles": "None", "Classes": "None", "Text": " will be given to you by a doctor or nurse in a hospital or clinic.", "ParentId": "f9ac861d-f12a-4764-ab52-9f46d7f5ab7e"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 It is given by a\ndrip into a vein (intravenous infusion) once every three weeks.</span></p>", "ID": "00d62379-e91a-41ad-b298-d0df764c5dc1", "Styles": "margin-left:.5in;text-indent:-.5in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "542e1c27-877e-4606-8e44-366f737a15b7", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "00d62379-e91a-41ad-b298-d0df764c5dc1"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 It is given by a\ndrip into a vein (intravenous infusion) once every three weeks.</span>", "ID": "4fa162a0-a71d-44d8-8c82-b5549a313772", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 It is given by a drip into a vein (intravenous infusion) once every three weeks.", "ParentId": "00d62379-e91a-41ad-b298-d0df764c5dc1"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 The amount of\nmedicine you are given and how long the infusion will last are different for\nthe first dose and following doses. </span></p>", "ID": "8c332688-47fe-46e2-a318-07cca3194f82", "Styles": "margin-left:.5in;text-indent:-.5in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "af67851b-3e67-42dc-adbb-5385ef5f4235", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "8c332688-47fe-46e2-a318-07cca3194f82"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 The amount of\nmedicine you are given and how long the infusion will last are different for\nthe first dose and following doses. </span>", "ID": "554700cf-9ab4-4061-b6ec-3701b75db1d6", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 The amount of medicine you are given and how long the infusion will last are different for the first dose and following doses. ", "ParentId": "8c332688-47fe-46e2-a318-07cca3194f82"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 The number of\ninfusions you will be given depends on how you respond to treatment</span><span lang=\"EN-GB\"> and whether you are receiving treatment before or after surgery\n(neoadjuvant or adjuvant therapy) or for disease which has spread</span><span lang=\"EN-GB\">.</span></p>", "ID": "39315e3a-ea56-4329-b1fb-bca113a7932f", "Styles": "margin-left:.5in;text-indent:-.5in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "755388b2-33a5-40e1-9143-a38a64aae5b6", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "39315e3a-ea56-4329-b1fb-bca113a7932f"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 The number of\ninfusions you will be given depends on how you respond to treatment</span>", "ID": "6fc09f3b-53a4-4162-975a-32ab6683da17", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 The number of infusions you will be given depends on how you respond to treatment", "ParentId": "39315e3a-ea56-4329-b1fb-bca113a7932f"}, {"Element": "<span lang=\"EN-GB\"> and whether you are receiving treatment before or after surgery\n(neoadjuvant or adjuvant therapy) or for disease which has spread</span>", "ID": "645ecc5f-5aa0-4d25-8b71-e4a8af7d2ac4", "Styles": "None", "Classes": "None", "Text": " and whether you are receiving treatment before or after surgery (neoadjuvant or adjuvant therapy) or for disease which has spread", "ParentId": "39315e3a-ea56-4329-b1fb-bca113a7932f"}, {"Element": "<span lang=\"EN-GB\">.</span>", "ID": "956ca093-ab47-4606-87c6-77817fb599e8", "Styles": "None", "Classes": "None", "Text": ".", "ParentId": "39315e3a-ea56-4329-b1fb-bca113a7932f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Perjeta is given with other cancer treatments (trastuzumab\nandchemotherapy).</span></p>", "ID": "b9f5d909-7b94-4905-aea0-39beaee249d0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "37448732-0fc1-437b-8a78-60f0bdfe8121", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "b9f5d909-7b94-4905-aea0-39beaee249d0"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Perjeta is given with other cancer treatments (trastuzumab\nandchemotherapy).</span>", "ID": "e2fae9f2-1970-4a6c-8a42-0c690ae75e9b", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Perjeta is given with other cancer treatments (trastuzumab andchemotherapy).", "ParentId": "b9f5d909-7b94-4905-aea0-39beaee249d0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d76025e1-a57b-4a79-8f30-d7f0e534c588", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "21e47015-8727-4747-90da-cfa44f4e0b41", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d76025e1-a57b-4a79-8f30-d7f0e534c588"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">For the</span></b><span lang=\"EN-GB\"> <b>first\ninfusion</b>:</span></p>", "ID": "27eff23f-8aa2-4aeb-8e22-c375c855f2d5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">For the</span></b>", "ID": "ec963844-8164-4061-970f-bb94fd086da0", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "27eff23f-8aa2-4aeb-8e22-c375c855f2d5"}, {"Element": "<span lang=\"EN-GB\">For the</span>", "ID": "830894ef-45c3-42ef-80bf-c7b8f103261f", "Styles": "None", "Classes": "None", "Text": "For the", "ParentId": "ec963844-8164-4061-970f-bb94fd086da0"}, {"Element": "<span lang=\"EN-GB\"> <b>first\ninfusion</b>:</span>", "ID": "fb08b880-ba6b-4659-b6c5-59769f4397a1", "Styles": "None", "Classes": "None", "Text": " :", "ParentId": "27eff23f-8aa2-4aeb-8e22-c375c855f2d5"}, {"Element": "<b>first\ninfusion</b>", "ID": "ad825791-d991-4d8c-9a4c-1f150c105a54", "Styles": "None", "Classes": "None", "Text": "first infusion", "ParentId": "fb08b880-ba6b-4659-b6c5-59769f4397a1"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 You will be given\n840\u00a0mg of Perjeta over 60 minutes. Your doctor or nurse will check for\nside effects during your infusion and for 60 minutes afterwards.</span></p>", "ID": "0be205de-8aac-4e4e-9cb0-727cc15cd02d", "Styles": "margin-left:.5in;text-indent:-.5in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "8f8dda60-0330-4d84-91b6-75938f1a8760", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "0be205de-8aac-4e4e-9cb0-727cc15cd02d"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 You will be given\n840\u00a0mg of Perjeta over 60 minutes. Your doctor or nurse will check for\nside effects during your infusion and for 60 minutes afterwards.</span>", "ID": "c3d092b1-75df-4c55-973b-d409ce8577ae", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 You will be given 840\u00a0mg of Perjeta over 60 minutes. Your doctor or nurse will check for side effects during your infusion and for 60 minutes afterwards.", "ParentId": "0be205de-8aac-4e4e-9cb0-727cc15cd02d"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 You will also be\ngiven trastuzumab and chemotherapyl.</span></p>", "ID": "8867c3d3-38a6-485b-af7c-b4b1b06295a7", "Styles": "margin-left:.5in;text-indent:-.5in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "be2de962-e22b-48e8-92e2-2941056146be", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "8867c3d3-38a6-485b-af7c-b4b1b06295a7"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 You will also be\ngiven trastuzumab and chemotherapyl.</span>", "ID": "7a15c8ff-896b-40c3-b6fd-ee1d5dfd9373", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 You will also be given trastuzumab and chemotherapyl.", "ParentId": "8867c3d3-38a6-485b-af7c-b4b1b06295a7"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a756e6b2-cf2d-428f-aa74-4f5536a9e4de", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b5a57953-5686-46ae-b930-91dfa6145d20", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a756e6b2-cf2d-428f-aa74-4f5536a9e4de"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">For all\nfollowing infusions</span></b><span lang=\"EN-GB\">, if the first infusion was well\ntolerated:</span></p>", "ID": "6b4b7fec-31c9-4d0f-9e83-fd818ad257f9", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">For all\nfollowing infusions</span></b>", "ID": "55d4ff8d-80c1-4f8c-8758-6f668fa9331a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "6b4b7fec-31c9-4d0f-9e83-fd818ad257f9"}, {"Element": "<span lang=\"EN-GB\">For all\nfollowing infusions</span>", "ID": "3b70d645-f830-4fea-be23-dbe864fd7dfe", "Styles": "None", "Classes": "None", "Text": "For all following infusions", "ParentId": "55d4ff8d-80c1-4f8c-8758-6f668fa9331a"}, {"Element": "<span lang=\"EN-GB\">, if the first infusion was well\ntolerated:</span>", "ID": "be6a9184-68e8-4ee7-8804-6c69261f0a16", "Styles": "None", "Classes": "None", "Text": ", if the first infusion was well tolerated:", "ParentId": "6b4b7fec-31c9-4d0f-9e83-fd818ad257f9"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;page-break-after:\navoid\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 You\nwill be given 420\u00a0mg of Perjeta over 30 to 60 minutes. Your doctor or\nnurse will check for side effects during your infusion and for 30 to 60 minutes\nafterwards.</span></p>", "ID": "4dd92ff6-c661-407c-9c4b-2b3ff0a67174", "Styles": "margin-left:.5in;text-indent:-.5in;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "2fb32af3-b27d-43d8-af39-bfafc53a9f06", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "4dd92ff6-c661-407c-9c4b-2b3ff0a67174"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 You\nwill be given 420\u00a0mg of Perjeta over 30 to 60 minutes. Your doctor or\nnurse will check for side effects during your infusion and for 30 to 60 minutes\nafterwards.</span>", "ID": "db65f6f2-76d2-4192-ac27-4379b1833ea3", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 You will be given 420\u00a0mg of Perjeta over 30 to 60 minutes. Your doctor or nurse will check for side effects during your infusion and for 30 to 60 minutes afterwards.", "ParentId": "4dd92ff6-c661-407c-9c4b-2b3ff0a67174"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;page-break-after:\navoid\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 You\nwill also be given trastuzumab and chemotherapy.</span></p>", "ID": "2d23a51e-c8e6-4457-8862-aba777b4f5c9", "Styles": "margin-left:.5in;text-indent:-.5in;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "c2d62088-73fb-4ebe-9412-caec9e978a8f", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "2d23a51e-c8e6-4457-8862-aba777b4f5c9"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 You\nwill also be given trastuzumab and chemotherapy.</span>", "ID": "21707a46-2360-483a-bf54-a8e21619255d", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 You will also be given trastuzumab and chemotherapy.", "ParentId": "2d23a51e-c8e6-4457-8862-aba777b4f5c9"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a3759422-07ad-4002-8928-d5d41630a194", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1f6c682b-432f-4afb-91da-200ce8b6ca8d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a3759422-07ad-4002-8928-d5d41630a194"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">For further information on dosing of trastuzumab\nand chemotherapy (which can cause side effects as well), please refer to the package\nleaflet for these products. If you have questions about these medicines, please\nask your doctor or nurse. </span></p>", "ID": "f19002cd-b5da-49a3-92d6-ffb9d7224354", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">For further information on dosing of trastuzumab\nand chemotherapy (which can cause side effects as well), please refer to the package\nleaflet for these products. If you have questions about these medicines, please\nask your doctor or nurse. </span>", "ID": "2786d0ca-186b-40d3-bcae-981733b604da", "Styles": "None", "Classes": "None", "Text": "For further information on dosing of trastuzumab and chemotherapy (which can cause side effects as well), please refer to the package leaflet for these products. If you have questions about these medicines, please ask your doctor or nurse. ", "ParentId": "f19002cd-b5da-49a3-92d6-ffb9d7224354"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b63c5431-16b8-46fd-b504-3148f6f68707", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4fde4f36-c08e-4965-b1ae-7112ff0c7ba4", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b63c5431-16b8-46fd-b504-3148f6f68707"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">If you forget to have Perjeta</span></b></p>", "ID": "52e0afc7-2b9f-4cb0-ac7c-4ac8a1b56c4c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">If you forget to have Perjeta</span></b>", "ID": "764382b0-9470-41c6-9f0a-5d745088e13f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "52e0afc7-2b9f-4cb0-ac7c-4ac8a1b56c4c"}, {"Element": "<span lang=\"EN-GB\">If you forget to have Perjeta</span>", "ID": "69eb21ac-c1b6-426e-83d4-92f81c7c4e33", "Styles": "None", "Classes": "None", "Text": "If you forget to have Perjeta", "ParentId": "764382b0-9470-41c6-9f0a-5d745088e13f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">If you forget or miss your appointment to\nreceive Perjeta</span><span lang=\"EN-GB\"> </span><span lang=\"EN-GB\">make another\nappointment as soon as possible. If it has been 6 weeks or more since your last\nvisit</span><span lang=\"EN-GB\"> a </span><span lang=\"EN-GB\">higher Perjeta dose of\n840\u00a0mg will be given to you.</span></p>", "ID": "e750f75f-7859-48fb-a602-06635fdccd38", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">If you forget or miss your appointment to\nreceive Perjeta</span>", "ID": "0b5502ea-8d46-4538-9a86-09b98a16fb4e", "Styles": "None", "Classes": "None", "Text": "If you forget or miss your appointment to receive Perjeta", "ParentId": "e750f75f-7859-48fb-a602-06635fdccd38"}, {"Element": "<span lang=\"EN-GB\"> </span>", "ID": "f86ed902-ba2a-4835-9dfe-eaf32522b22f", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "e750f75f-7859-48fb-a602-06635fdccd38"}, {"Element": "<span lang=\"EN-GB\">make another\nappointment as soon as possible. If it has been 6 weeks or more since your last\nvisit</span>", "ID": "282385af-5827-4358-a4d8-3396c49200c6", "Styles": "None", "Classes": "None", "Text": "make another appointment as soon as possible. If it has been 6 weeks or more since your last visit", "ParentId": "e750f75f-7859-48fb-a602-06635fdccd38"}, {"Element": "<span lang=\"EN-GB\"> a </span>", "ID": "150bc9bb-d5e1-4c94-8f82-31fb965ba7fb", "Styles": "None", "Classes": "None", "Text": " a ", "ParentId": "e750f75f-7859-48fb-a602-06635fdccd38"}, {"Element": "<span lang=\"EN-GB\">higher Perjeta dose of\n840\u00a0mg will be given to you.</span>", "ID": "06892b18-0af8-4812-a46e-c8865568bd9c", "Styles": "None", "Classes": "None", "Text": "higher Perjeta dose of 840\u00a0mg will be given to you.", "ParentId": "e750f75f-7859-48fb-a602-06635fdccd38"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d322a6e9-c291-44da-b0bb-3cf2aa4c34b3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "570a7991-6495-4d21-b7a3-6a92affa3c2d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d322a6e9-c291-44da-b0bb-3cf2aa4c34b3"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">If you stop having Perjeta</span></b></p>", "ID": "ee100d33-be2e-42a6-90cf-4d2d4857a5a9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">If you stop having Perjeta</span></b>", "ID": "b074f9f5-b9d5-4b2a-9810-2f97820f0adc", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ee100d33-be2e-42a6-90cf-4d2d4857a5a9"}, {"Element": "<span lang=\"EN-GB\">If you stop having Perjeta</span>", "ID": "fdcc8307-f5fc-487d-8ea2-b71cb78a2c66", "Styles": "None", "Classes": "None", "Text": "If you stop having Perjeta", "ParentId": "b074f9f5-b9d5-4b2a-9810-2f97820f0adc"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Do not stop having this medicine without\ntalking to your doctor first. It is important that you are given all the\ninfusions that have been recommended.</span></p>", "ID": "7f5e00bb-d7b1-45c2-bc23-d78c1a234262", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Do not stop having this medicine without\ntalking to your doctor first. It is important that you are given all the\ninfusions that have been recommended.</span>", "ID": "5fde0680-43b6-4e0a-8cee-07c6ba3ce2ff", "Styles": "None", "Classes": "None", "Text": "Do not stop having this medicine without talking to your doctor first. It is important that you are given all the infusions that have been recommended.", "ParentId": "7f5e00bb-d7b1-45c2-bc23-d78c1a234262"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7e4f4cf0-3ee6-457c-aad8-36e1f6f28158", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3d9fbd1f-22a6-4de7-a7a7-986376651e5c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7e4f4cf0-3ee6-457c-aad8-36e1f6f28158"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">If you have any further questions on the\nuse of this medicine, ask your doctor or nurse.</span></p>", "ID": "ce562284-e542-4f6f-81b0-a04b11b5327c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">If you have any further questions on the\nuse of this medicine, ask your doctor or nurse.</span>", "ID": "33977b04-e5ec-478d-8156-6f2638427eab", "Styles": "None", "Classes": "None", "Text": "If you have any further questions on the use of this medicine, ask your doctor or nurse.", "ParentId": "ce562284-e542-4f6f-81b0-a04b11b5327c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f4f5f030-58b0-49db-bb28-f02aba69a244", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c5afdb63-11df-4183-85eb-f09064658ae5", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f4f5f030-58b0-49db-bb28-f02aba69a244"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "05ed6e98-e458-4b24-8619-c5f24f2627b6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0a6ef87b-8800-4e38-8de0-3a0784017f13", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "05ed6e98-e458-4b24-8619-c5f24f2627b6"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Possible\nside effects</span></b></p>", "ID": "c1a01684-7537-4bfb-9316-144eaf3eaeec", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Possible\nside effects</span></b>", "ID": "75264ccf-d2d0-4d0d-a421-904444c3a72c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c1a01684-7537-4bfb-9316-144eaf3eaeec"}, {"Element": "<span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Possible\nside effects</span>", "ID": "586b21c8-c8df-4b9e-8159-0c52c700712b", "Styles": "None", "Classes": "None", "Text": "4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Possible side effects", "ParentId": "75264ccf-d2d0-4d0d-a421-904444c3a72c"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "44c3c537-2a9a-4431-828c-d7fe5cb70e23", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1c55a56f-a39d-4138-a60c-884386887449", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "44c3c537-2a9a-4431-828c-d7fe5cb70e23"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Like all\nmedicines, this medicine can cause side effects, although not everybody gets\nthem.</span></p>", "ID": "4b3cc31a-af18-430e-bb73-4eaf2d6a35f6", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Like all\nmedicines, this medicine can cause side effects, although not everybody gets\nthem.</span>", "ID": "9b84e2e0-fe9d-4f9a-8529-c0d26a806011", "Styles": "None", "Classes": "None", "Text": "Like all medicines, this medicine can cause side effects, although not everybody gets them.", "ParentId": "4b3cc31a-af18-430e-bb73-4eaf2d6a35f6"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "794706ff-c373-4c23-b498-623a8e9bae13", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "808178d9-5908-4d79-bf28-41fd165d5abd", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "794706ff-c373-4c23-b498-623a8e9bae13"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Serious\nside effects</span></b></p>", "ID": "d7b10dd0-5146-4008-ac4a-5476e9e388d4", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">Serious\nside effects</span></b>", "ID": "c4be649b-637f-4920-a969-2a346949282d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d7b10dd0-5146-4008-ac4a-5476e9e388d4"}, {"Element": "<span lang=\"EN-GB\">Serious\nside effects</span>", "ID": "2d6e5957-057e-435c-967d-2c9d2fc294df", "Styles": "None", "Classes": "None", "Text": "Serious side effects", "ParentId": "c4be649b-637f-4920-a969-2a346949282d"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Tell a\ndoctor or nurse straight away, if you notice any of the following side effects:\n</span></b></p>", "ID": "88440ea1-013b-4f78-9428-c343a04162f0", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">Tell a\ndoctor or nurse straight away, if you notice any of the following side effects:\n</span></b>", "ID": "fafb3060-9a8f-4330-a524-1adbfaebc832", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "88440ea1-013b-4f78-9428-c343a04162f0"}, {"Element": "<span lang=\"EN-GB\">Tell a\ndoctor or nurse straight away, if you notice any of the following side effects:\n</span>", "ID": "0c2b5e51-f937-457a-aa81-3deb7a3badb4", "Styles": "None", "Classes": "None", "Text": "Tell a doctor or nurse straight away, if you notice any of the following side effects: ", "ParentId": "fafb3060-9a8f-4330-a524-1adbfaebc832"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Very severe or\npersistent diarrhoea (7 or more stools per day).</span></p>", "ID": "7bffe4b0-b4c9-4b28-ab59-4db65ab948f1", "Styles": "margin-left:.5in;text-indent:-.5in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "8f06e1c0-0676-4926-8ad6-99bdbc9abd4b", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "7bffe4b0-b4c9-4b28-ab59-4db65ab948f1"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Very severe or\npersistent diarrhoea (7 or more stools per day).</span>", "ID": "8d5e17cc-7820-497b-8285-d08efa24f5db", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Very severe or persistent diarrhoea (7 or more stools per day).", "ParentId": "7bffe4b0-b4c9-4b28-ab59-4db65ab948f1"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 A decrease in the\nnumber or low amount of white blood cells (shown in a blood test), with or\nwithout fever, which may increase the risk of an infection.</span></p>", "ID": "35deec90-02ca-49dd-b8fe-885055b8e4e2", "Styles": "margin-left:.5in;text-indent:-.5in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "bdbe046d-bbb1-4e7d-8161-74dee7c0f09b", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "35deec90-02ca-49dd-b8fe-885055b8e4e2"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 A decrease in the\nnumber or low amount of white blood cells (shown in a blood test), with or\nwithout fever, which may increase the risk of an infection.</span>", "ID": "7ac0a134-7dd5-4eec-8bce-069d9be3ce16", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 A decrease in the number or low amount of white blood cells (shown in a blood test), with or without fever, which may increase the risk of an infection.", "ParentId": "35deec90-02ca-49dd-b8fe-885055b8e4e2"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Infusion\nreactions with symptoms that can either be mild or more severe and may include\nfeeling sick (nausea), fever, chills, feeling tired, headache, loss of appetite,\njoint and muscle pains, and hot flushes. </span></p>", "ID": "7d248aba-e89e-4c1a-893e-59f31ef926fc", "Styles": "margin-left:.5in;text-indent:-.5in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "3d98491e-1da1-4497-a009-47b4682868e6", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "7d248aba-e89e-4c1a-893e-59f31ef926fc"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Infusion\nreactions with symptoms that can either be mild or more severe and may include\nfeeling sick (nausea), fever, chills, feeling tired, headache, loss of appetite,\njoint and muscle pains, and hot flushes. </span>", "ID": "b40d313d-49b8-4a83-9a41-d728fb5f6b93", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Infusion reactions with symptoms that can either be mild or more severe and may include feeling sick (nausea), fever, chills, feeling tired, headache, loss of appetite, joint and muscle pains, and hot flushes. ", "ParentId": "7d248aba-e89e-4c1a-893e-59f31ef926fc"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span><span lang=\"EN-GB\">Allergic and anaphylactic (more severe allergic) reactions with symptoms\nthat may include swelling of your face and throat, with difficulty </span><span lang=\"EN-GB\">in </span><span lang=\"EN-GB\">breathing. Very rarely, patients have\ndied due to anaphylactic reactions during Perjeta infusion.\u00a0 </span></p>", "ID": "0b45299c-f9a1-410a-b9dd-12f800f392ee", "Styles": "margin-left:.5in;text-indent:-.5in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "a394f9c0-b814-4c6b-bde5-100259d324cb", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "0b45299c-f9a1-410a-b9dd-12f800f392ee"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span>", "ID": "9aac2aac-662e-402a-bcaf-f0af73caeef6", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "0b45299c-f9a1-410a-b9dd-12f800f392ee"}, {"Element": "<span lang=\"EN-GB\">Allergic and anaphylactic (more severe allergic) reactions with symptoms\nthat may include swelling of your face and throat, with difficulty </span>", "ID": "5496a559-5ec4-4c20-8f95-09a4cc495b46", "Styles": "None", "Classes": "None", "Text": "Allergic and anaphylactic (more severe allergic) reactions with symptoms that may include swelling of your face and throat, with difficulty ", "ParentId": "0b45299c-f9a1-410a-b9dd-12f800f392ee"}, {"Element": "<span lang=\"EN-GB\">in </span>", "ID": "aad934b4-065b-470c-8fee-856a2a0a4737", "Styles": "None", "Classes": "None", "Text": "in ", "ParentId": "0b45299c-f9a1-410a-b9dd-12f800f392ee"}, {"Element": "<span lang=\"EN-GB\">breathing. Very rarely, patients have\ndied due to anaphylactic reactions during Perjeta infusion.\u00a0 </span>", "ID": "43e0ac11-a1da-42e1-a92f-4fdb8cc8d8ac", "Styles": "None", "Classes": "None", "Text": "breathing. Very rarely, patients have died due to anaphylactic reactions during Perjeta infusion.\u00a0 ", "ParentId": "0b45299c-f9a1-410a-b9dd-12f800f392ee"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Heart problems\n(heart failure) with symptoms that can include cough, shortness of breath, and\nswelling (fluid retention) in your legs or arms. </span></p>", "ID": "429b529a-8af4-4932-9bc2-eb4f25e1ef19", "Styles": "margin-left:.5in;text-indent:-.5in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "4af11712-3866-473b-aa99-288658666e0f", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "429b529a-8af4-4932-9bc2-eb4f25e1ef19"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Heart problems\n(heart failure) with symptoms that can include cough, shortness of breath, and\nswelling (fluid retention) in your legs or arms. </span>", "ID": "d6d5c33e-7655-4d78-96f4-18714c357fe9", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Heart problems (heart failure) with symptoms that can include cough, shortness of breath, and swelling (fluid retention) in your legs or arms. ", "ParentId": "429b529a-8af4-4932-9bc2-eb4f25e1ef19"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span><span lang=\"EN-GB\">Tumour lysis syndrome (a condition which may happen when cancer\ncells die quickly, causing changes in blood levels of </span>minerals and\nmetabolites shown in a blood test). S<span lang=\"EN-GB\">ymptoms may include\nkidney problems (weakness, shortness of breath, fatigue and confusion), heart\nproblems (fluttering of the heart of a faster or slower heartbeat), seizures,\nvomiting or diarrhoea and tingling in the mouth, hands or feet</span></p>", "ID": "743b8445-1cf0-4bd9-9d42-03eed106923f", "Styles": "margin-left:.5in;text-indent:-.5in", "Classes": "['MsoNormal']", "Text": "minerals and metabolites shown in a blood test). S", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "04845a55-f1bf-4f5b-8dcf-babf55b15689", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "743b8445-1cf0-4bd9-9d42-03eed106923f"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span>", "ID": "0bd4af72-bed9-41a2-a73a-0a4106a9a864", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "743b8445-1cf0-4bd9-9d42-03eed106923f"}, {"Element": "<span lang=\"EN-GB\">Tumour lysis syndrome (a condition which may happen when cancer\ncells die quickly, causing changes in blood levels of </span>", "ID": "273a79a6-c0f5-467e-ac10-5dd3e20b0cd0", "Styles": "None", "Classes": "None", "Text": "Tumour lysis syndrome (a condition which may happen when cancer cells die quickly, causing changes in blood levels of ", "ParentId": "743b8445-1cf0-4bd9-9d42-03eed106923f"}, {"Element": "<span lang=\"EN-GB\">ymptoms may include\nkidney problems (weakness, shortness of breath, fatigue and confusion), heart\nproblems (fluttering of the heart of a faster or slower heartbeat), seizures,\nvomiting or diarrhoea and tingling in the mouth, hands or feet</span>", "ID": "1248994b-a2d9-4c94-bd56-60bb5c3c3e75", "Styles": "None", "Classes": "None", "Text": "ymptoms may include kidney problems (weakness, shortness of breath, fatigue and confusion), heart problems (fluttering of the heart of a faster or slower heartbeat), seizures, vomiting or diarrhoea and tingling in the mouth, hands or feet", "ParentId": "743b8445-1cf0-4bd9-9d42-03eed106923f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "09f39b9b-ca9a-415d-8d01-2fae48bd223b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2eb7b548-d24b-4465-917b-24b48fe99cf5", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "09f39b9b-ca9a-415d-8d01-2fae48bd223b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tell a doctor or nurse straight away, if\nyou notice any of the side effects above. </span></p>", "ID": "78395a4d-6cc9-4ea0-a833-888571fe9907", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Tell a doctor or nurse straight away, if\nyou notice any of the side effects above. </span>", "ID": "d108f7bc-a5be-4654-aa81-7a5eb3ac6dd0", "Styles": "None", "Classes": "None", "Text": "Tell a doctor or nurse straight away, if you notice any of the side effects above. ", "ParentId": "78395a4d-6cc9-4ea0-a833-888571fe9907"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4bee8ae3-3fc1-4a22-9bf3-1777fbc0aeab", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "85fde9a1-a41f-4598-8635-bbc7ff31f380", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4bee8ae3-3fc1-4a22-9bf3-1777fbc0aeab"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Other side effects include:</span></b></p>", "ID": "29266035-6daa-459a-b333-78e2f55a2d79", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">Other side effects include:</span></b>", "ID": "a27acb05-7155-4655-b7f5-f43aa7a60eff", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "29266035-6daa-459a-b333-78e2f55a2d79"}, {"Element": "<span lang=\"EN-GB\">Other side effects include:</span>", "ID": "eef6f1cb-eaf3-49ee-a87d-334c4f239f78", "Styles": "None", "Classes": "None", "Text": "Other side effects include:", "ParentId": "a27acb05-7155-4655-b7f5-f43aa7a60eff"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "36c9e966-6a2b-47bc-bd1e-bea90f4d098d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2503af8e-17d1-4bb5-a18c-93c77c10672b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "36c9e966-6a2b-47bc-bd1e-bea90f4d098d"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Very common (may affect more than 1 in\n10 people):</span></b></p>", "ID": "b15b0495-ac1d-4b41-922c-ce23f4400430", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">Very common (may affect more than 1 in\n10 people):</span></b>", "ID": "a1327be8-f7dc-4392-b9ee-c2941f28d097", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b15b0495-ac1d-4b41-922c-ce23f4400430"}, {"Element": "<span lang=\"EN-GB\">Very common (may affect more than 1 in\n10 people):</span>", "ID": "9b46b281-2025-4daa-a94d-f82d60bf9c24", "Styles": "None", "Classes": "None", "Text": "Very common (may affect more than 1 in 10 people):", "ParentId": "a1327be8-f7dc-4392-b9ee-c2941f28d097"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Diarrhoea</span></p>", "ID": "a555aba7-4da7-4e2a-b822-7c8dd0cae0f1", "Styles": "margin-left:.5in;text-indent:-.5in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "1715ef67-fe39-4020-b8a9-3dda5460c4f7", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "a555aba7-4da7-4e2a-b822-7c8dd0cae0f1"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Diarrhoea</span>", "ID": "0e310f65-8665-442f-850e-07cc5a7040df", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Diarrhoea", "ParentId": "a555aba7-4da7-4e2a-b822-7c8dd0cae0f1"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Hair loss</span></p>", "ID": "716dc2e6-dda4-486a-bb9c-1c764ec2acde", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "064d1054-0a51-4676-93aa-4a201a556088", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "716dc2e6-dda4-486a-bb9c-1c764ec2acde"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Hair loss</span>", "ID": "24aad25e-4d1d-421b-891c-67fc980e48e4", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Hair loss", "ParentId": "716dc2e6-dda4-486a-bb9c-1c764ec2acde"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Feeling sick or being tired</span></p>", "ID": "13657a43-8318-43fc-8761-0caa8a8c97f4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "38242213-c6f5-40d6-82bc-5c6d6fd83fab", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "13657a43-8318-43fc-8761-0caa8a8c97f4"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Feeling sick or being tired</span>", "ID": "619bb67a-b092-4709-bb4c-cd4b5534c720", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Feeling sick or being tired", "ParentId": "13657a43-8318-43fc-8761-0caa8a8c97f4"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Rash</span></p>", "ID": "95684090-60db-4c6e-92f9-c4f61a92dcca", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "cdce6e0a-a22a-4dc6-9d63-bdd1787f03e5", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "95684090-60db-4c6e-92f9-c4f61a92dcca"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Rash</span>", "ID": "b2ee3c2e-7acb-489f-b8e1-d1abfba6bdb0", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Rash", "ParentId": "95684090-60db-4c6e-92f9-c4f61a92dcca"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Inflammation of your digestive tract (e.g. sore mouth)</span></p>", "ID": "6990b547-fb7e-4786-836f-ae59cf168806", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "06e3971b-a8de-4cf1-b635-dec4d7ec4b88", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "6990b547-fb7e-4786-836f-ae59cf168806"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Inflammation of your digestive tract (e.g. sore mouth)</span>", "ID": "205700f1-c5eb-400d-a704-4604087fb0c2", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Inflammation of your digestive tract (e.g. sore mouth)", "ParentId": "6990b547-fb7e-4786-836f-ae59cf168806"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Decrease in the number of red blood cells \u2013 shown in a\nblood test</span></p>", "ID": "fd8c829e-dcc8-4d9f-8bdf-8e6d121f4c68", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "8799a571-ea34-487b-8b0c-26e2825fd634", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "fd8c829e-dcc8-4d9f-8bdf-8e6d121f4c68"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Decrease in the number of red blood cells \u2013 shown in a\nblood test</span>", "ID": "b48cc951-37e4-458e-ae70-a4b7792ed3f7", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Decrease in the number of red blood cells \u2013 shown in a blood test", "ParentId": "fd8c829e-dcc8-4d9f-8bdf-8e6d121f4c68"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Joint or muscle pain, muscle weakness</span></p>", "ID": "d391d86b-fed3-4df3-a0f6-5a0a46a079fb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "735e846c-7f61-4716-b1ce-e764b2a21cfa", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "d391d86b-fed3-4df3-a0f6-5a0a46a079fb"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Joint or muscle pain, muscle weakness</span>", "ID": "040d9c00-22ef-498d-bf76-427f7c94bf2d", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Joint or muscle pain, muscle weakness", "ParentId": "d391d86b-fed3-4df3-a0f6-5a0a46a079fb"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Constipation</span></p>", "ID": "f56775ef-fdac-4db1-904b-bedb0d24f559", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "d19a9c27-5eb3-47ce-a2dd-b2d7e9637454", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "f56775ef-fdac-4db1-904b-bedb0d24f559"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Constipation</span>", "ID": "d26ce3cc-98fb-446a-8007-4e2341d03add", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Constipation", "ParentId": "f56775ef-fdac-4db1-904b-bedb0d24f559"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Reduced appetite</span></p>", "ID": "291ab8b0-811e-4c14-b7f1-11cf90219cc3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "349fa4a0-dd51-4240-8edb-f5a8e004d56b", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "291ab8b0-811e-4c14-b7f1-11cf90219cc3"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Reduced appetite</span>", "ID": "da2c7eb1-cbb0-4f16-94d3-14ee893cb03b", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Reduced appetite", "ParentId": "291ab8b0-811e-4c14-b7f1-11cf90219cc3"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Loss of or altered taste</span></p>", "ID": "47396414-1d92-401e-a1d2-e324f74954ba", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "b9991d0c-d4f2-4107-b2f1-22db7168f664", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "47396414-1d92-401e-a1d2-e324f74954ba"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Loss of or altered taste</span>", "ID": "752f7e90-ccef-4147-9c84-bcc546b39321", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Loss of or altered taste", "ParentId": "47396414-1d92-401e-a1d2-e324f74954ba"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Fever </span></p>", "ID": "e006b9f5-f2ab-439b-b4a7-9d9398973b75", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "5121cbaa-2e5b-4c14-9b70-bf881cc214a4", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "e006b9f5-f2ab-439b-b4a7-9d9398973b75"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Fever </span>", "ID": "7064d270-e96e-4a7c-bae4-5075028ac63d", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Fever ", "ParentId": "e006b9f5-f2ab-439b-b4a7-9d9398973b75"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Swollen ankles or other body parts due to your body\nretaining too much water</span></p>", "ID": "c68e5cf8-6027-4d26-9ee8-37d5eed823e5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "74abad34-b758-463d-9847-1499f95fcfb2", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "c68e5cf8-6027-4d26-9ee8-37d5eed823e5"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Swollen ankles or other body parts due to your body\nretaining too much water</span>", "ID": "7f0a7845-99cc-4680-87c4-346a3c40c10a", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Swollen ankles or other body parts due to your body retaining too much water", "ParentId": "c68e5cf8-6027-4d26-9ee8-37d5eed823e5"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Not being able to\nsleep</span></p>", "ID": "680a9999-5421-4223-bbe9-3e7917f2f284", "Styles": "margin-left:.5in;text-indent:-.5in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "c7e46bb9-b254-43a5-9a07-d71f3a074e33", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "680a9999-5421-4223-bbe9-3e7917f2f284"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Not being able to\nsleep</span>", "ID": "45527241-a63e-4b03-b31d-c310f29cb515", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Not being able to sleep", "ParentId": "680a9999-5421-4223-bbe9-3e7917f2f284"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Hot flushes </span></p>", "ID": "3e676110-b5be-4598-8c4b-fb912686e59b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "f46aa740-14f5-4908-bd6a-9b302f1bb592", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "3e676110-b5be-4598-8c4b-fb912686e59b"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Hot flushes </span>", "ID": "df6b8644-8285-4849-a83f-1203909017b9", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Hot flushes ", "ParentId": "3e676110-b5be-4598-8c4b-fb912686e59b"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Weak, numb,\ntingling or prickling sensations mainly affecting the feet and legs </span></p>", "ID": "e6109a59-e5bd-4ff3-82a8-1f9ca6326636", "Styles": "margin-left:.5in;text-indent:-.5in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "6fd4b86c-f1bc-455c-a743-e6e4aef44701", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "e6109a59-e5bd-4ff3-82a8-1f9ca6326636"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Weak, numb,\ntingling or prickling sensations mainly affecting the feet and legs </span>", "ID": "9c51a303-3156-46e4-bc20-ede81f90cad3", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Weak, numb, tingling or prickling sensations mainly affecting the feet and legs ", "ParentId": "e6109a59-e5bd-4ff3-82a8-1f9ca6326636"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Nose bleeds</span></p>", "ID": "ef1c609d-ef8e-4397-98a9-4c998c4e47f0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "a0ab9d42-781a-4209-a47b-f8b6f1308425", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "ef1c609d-ef8e-4397-98a9-4c998c4e47f0"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Nose bleeds</span>", "ID": "61b1a753-062f-4f28-b3aa-027eb0a207f9", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Nose bleeds", "ParentId": "ef1c609d-ef8e-4397-98a9-4c998c4e47f0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Cough</span></p>", "ID": "be089872-ab2b-4cc8-9be0-f45ba14ef886", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "68eb1acf-28d5-41b1-8ee3-f9aa161c690d", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "be089872-ab2b-4cc8-9be0-f45ba14ef886"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Cough</span>", "ID": "b32381da-5e27-4fbb-8b62-271a9a4716f1", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Cough", "ParentId": "be089872-ab2b-4cc8-9be0-f45ba14ef886"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Heartburn</span></p>", "ID": "feca4866-4de7-4a61-946f-61282405cd04", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "32f4c550-199f-4c59-93cb-d5b1bbcbcda8", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "feca4866-4de7-4a61-946f-61282405cd04"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Heartburn</span>", "ID": "7955d4a2-d7ea-4449-8619-b683319d0743", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Heartburn", "ParentId": "feca4866-4de7-4a61-946f-61282405cd04"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Dry, itchy or acne like skin</span></p>", "ID": "e4dde239-2cbc-4fc3-9684-acbb92300656", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "72a58a77-5a5d-4a13-809a-3faaf7f0653e", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "e4dde239-2cbc-4fc3-9684-acbb92300656"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Dry, itchy or acne like skin</span>", "ID": "6018d278-ed17-4c9b-97f9-44a00a2bb5fb", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Dry, itchy or acne like skin", "ParentId": "e4dde239-2cbc-4fc3-9684-acbb92300656"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Nail problems </span></p>", "ID": "7138ccd3-87bb-4779-89b0-b08187d5ed93", "Styles": "margin-left:.5in;text-indent:-.5in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "11e636bf-9896-40c2-89ce-6d608d9141c4", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "7138ccd3-87bb-4779-89b0-b08187d5ed93"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Nail problems </span>", "ID": "9aa4db24-133b-4eda-bfd3-902b20c31804", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Nail problems ", "ParentId": "7138ccd3-87bb-4779-89b0-b08187d5ed93"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Sore throat, red, sore or runny nose, flu-like symptoms\nand fever</span></p>", "ID": "27ad8891-45dc-441c-8c25-781b193763b9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "7e87f557-c7e1-4cee-b5ca-9e2eb77c6394", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "27ad8891-45dc-441c-8c25-781b193763b9"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Sore throat, red, sore or runny nose, flu-like symptoms\nand fever</span>", "ID": "22ed65a0-c2be-4740-9c3d-1371f50db82a", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Sore throat, red, sore or runny nose, flu-like symptoms and fever", "ParentId": "27ad8891-45dc-441c-8c25-781b193763b9"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Producing more tears</span></p>", "ID": "ba8316f4-e281-465c-9434-6609a681652c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "bfb9c499-5987-439e-b9c0-6a5981bb1d36", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "ba8316f4-e281-465c-9434-6609a681652c"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Producing more tears</span>", "ID": "83e798dd-85e8-4745-963c-d24ac5410436", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Producing more tears", "ParentId": "ba8316f4-e281-465c-9434-6609a681652c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Fever associated with dangerously low levels of a type of\nwhite blood cell (neutrophils)</span></p>", "ID": "3c5f8bd4-a9a1-469e-8683-c3427ed9d25b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "c0dd42f3-473c-4484-9ab3-75c057ca001d", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "3c5f8bd4-a9a1-469e-8683-c3427ed9d25b"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Fever associated with dangerously low levels of a type of\nwhite blood cell (neutrophils)</span>", "ID": "6e5caaf1-cbcf-4664-adc7-43c5a53643f8", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Fever associated with dangerously low levels of a type of white blood cell (neutrophils)", "ParentId": "3c5f8bd4-a9a1-469e-8683-c3427ed9d25b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Pain in the body, arms, legs, and belly</span></p>", "ID": "d4fa2e99-3dd5-4c2b-b4c9-5e94bf7c1320", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "78cce54c-b8e6-4123-b1b3-ec014a885502", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "d4fa2e99-3dd5-4c2b-b4c9-5e94bf7c1320"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Pain in the body, arms, legs, and belly</span>", "ID": "1a03de7c-a3d1-46ea-9fb8-5e34b15b664f", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Pain in the body, arms, legs, and belly", "ParentId": "d4fa2e99-3dd5-4c2b-b4c9-5e94bf7c1320"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Shortness of breath</span></p>", "ID": "13d4caf9-845c-4359-9d7b-0f6071277931", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "da4cf12f-6010-4c85-bb48-7da50a5a33fb", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "13d4caf9-845c-4359-9d7b-0f6071277931"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Shortness of breath</span>", "ID": "17bd477e-464c-48b4-8f61-68e925e45c6c", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Shortness of breath", "ParentId": "13d4caf9-845c-4359-9d7b-0f6071277931"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Feeling dizzy</span></p>", "ID": "6d91c1fa-fe68-4f8c-ba95-cf72719ebe53", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "7c926dfd-5c12-421e-9068-8156c862b476", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "6d91c1fa-fe68-4f8c-ba95-cf72719ebe53"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Feeling dizzy</span>", "ID": "8c722044-276d-4ed1-b5dc-e4ed13c2dc18", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Feeling dizzy", "ParentId": "6d91c1fa-fe68-4f8c-ba95-cf72719ebe53"}, {"Element": "<p class=\"MsoNormal\"><b><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></b></p>", "ID": "c87ae044-16d9-4a60-8ded-62ab76981f3c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></b>", "ID": "fa22a33b-5b9c-461c-a5dd-5057777fc38b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c87ae044-16d9-4a60-8ded-62ab76981f3c"}, {"Element": "<u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u>", "ID": "754e9707-c008-4190-8866-1520e013184f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "fa22a33b-5b9c-461c-a5dd-5057777fc38b"}, {"Element": "<span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span>", "ID": "ed6d7f8c-0847-4802-b7ce-9a5a5cebf22c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "754e9707-c008-4190-8866-1520e013184f"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "e2b3dd69-d54f-407d-8605-22a4f7bb25d4", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "ed6d7f8c-0847-4802-b7ce-9a5a5cebf22c"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Common (may affect up to 1 in 10\npeople):</span></b></p>", "ID": "5ebdb26a-9e48-4101-9077-5460be85fab0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">Common (may affect up to 1 in 10\npeople):</span></b>", "ID": "3623e880-c5ca-4d5b-8e81-53b9c221af41", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "5ebdb26a-9e48-4101-9077-5460be85fab0"}, {"Element": "<span lang=\"EN-GB\">Common (may affect up to 1 in 10\npeople):</span>", "ID": "bcec27bb-533d-4cec-8662-2e89ee9b80e7", "Styles": "None", "Classes": "None", "Text": "Common (may affect up to 1 in 10 people):", "ParentId": "3623e880-c5ca-4d5b-8e81-53b9c221af41"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 A feeling of\nnumbness, prickling or tingling in feet or hands; sharp jabbing, throbbing,\nfreezing or burning pain; feeling pain from something which should not be\npainful such as a light touch; less able to feel changes in heat or cold; loss\nof balance or coordination</span></p>", "ID": "ff0dce58-2bf7-4350-b8ef-5f147cf0da90", "Styles": "margin-left:.5in;text-indent:-.5in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "0928b78f-627a-4ac4-8954-ac9dff79999d", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "ff0dce58-2bf7-4350-b8ef-5f147cf0da90"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 A feeling of\nnumbness, prickling or tingling in feet or hands; sharp jabbing, throbbing,\nfreezing or burning pain; feeling pain from something which should not be\npainful such as a light touch; less able to feel changes in heat or cold; loss\nof balance or coordination</span>", "ID": "3b7be3ad-3b60-4bb9-8865-4f6d7bca65aa", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 A feeling of numbness, prickling or tingling in feet or hands; sharp jabbing, throbbing, freezing or burning pain; feeling pain from something which should not be painful such as a light touch; less able to feel changes in heat or cold; loss of balance or coordination", "ParentId": "ff0dce58-2bf7-4350-b8ef-5f147cf0da90"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Inflammation of the nail bed where the nail and skin meet </span></p>", "ID": "1e0f67c4-85c6-4f54-8135-0a0c746b26ca", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "8156439c-5adf-4b9b-8dc8-7a0aa5109b65", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "1e0f67c4-85c6-4f54-8135-0a0c746b26ca"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Inflammation of the nail bed where the nail and skin meet </span>", "ID": "cb9ca9c9-b2f0-46a2-ac25-8b44cf00f79d", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Inflammation of the nail bed where the nail and skin meet ", "ParentId": "1e0f67c4-85c6-4f54-8135-0a0c746b26ca"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Infection of the ear, nose or throat</span></p>", "ID": "55717a28-26cb-4a61-a53b-b76e96fe6a32", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "f726d5bf-56ef-4571-90c5-4808a4ad8ad1", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "55717a28-26cb-4a61-a53b-b76e96fe6a32"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Infection of the ear, nose or throat</span>", "ID": "1d3543fc-3480-40d5-bd40-bb9bb865393a", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Infection of the ear, nose or throat", "ParentId": "55717a28-26cb-4a61-a53b-b76e96fe6a32"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:37.1pt;text-indent:-37.1pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Condition\nin which the left ventricle of the heart is functionally impaired with or\nwithout symptoms </span></p>", "ID": "038b5bb4-5c9c-4cb1-a9cd-e2a499ac63d9", "Styles": "margin-left:37.1pt;text-indent:-37.1pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "129b0263-e4c6-411f-9bf8-3a9f975541d2", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "038b5bb4-5c9c-4cb1-a9cd-e2a499ac63d9"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Condition\nin which the left ventricle of the heart is functionally impaired with or\nwithout symptoms </span>", "ID": "0a6074f4-3149-4a27-83b7-0262cff258ed", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Condition in which the left ventricle of the heart is functionally impaired with or without symptoms ", "ParentId": "038b5bb4-5c9c-4cb1-a9cd-e2a499ac63d9"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2bf51069-5753-4256-aea6-ecbd40f36427", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d0d938e2-c113-4422-8eaf-b7f2fee74b31", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2bf51069-5753-4256-aea6-ecbd40f36427"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Uncommon (may affect up to 1 in 100 people):</span></b></p>", "ID": "4fc6aa44-2f84-4329-8e0d-26964457d400", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">Uncommon (may affect up to 1 in 100 people):</span></b>", "ID": "4d4d692e-4000-47d8-8391-49da21319c5c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4fc6aa44-2f84-4329-8e0d-26964457d400"}, {"Element": "<span lang=\"EN-GB\">Uncommon (may affect up to 1 in 100 people):</span>", "ID": "f9e429e5-599c-4bba-b415-8391a7494448", "Styles": "None", "Classes": "None", "Text": "Uncommon (may affect up to 1 in 100 people):", "ParentId": "4d4d692e-4000-47d8-8391-49da21319c5c"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span><span lang=\"EN-GB\">Chest symptoms such as a dry cough or breathlessness </span><span lang=\"EN-GB\">(possible signs of interstitial lung disease, a condition of damage\nto the tissues around the air sacs in the lungs)</span></p>", "ID": "daf70f51-f266-486f-a56b-923eef0d14b6", "Styles": "margin-left:.5in;text-indent:-.5in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "e354869f-a91a-4e26-815e-ad94e9bde86b", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "daf70f51-f266-486f-a56b-923eef0d14b6"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span>", "ID": "8d6429be-512d-4837-ac4e-2b57f09a55cb", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "daf70f51-f266-486f-a56b-923eef0d14b6"}, {"Element": "<span lang=\"EN-GB\">Chest symptoms such as a dry cough or breathlessness </span>", "ID": "95b71445-7f1a-4c9e-8e86-e8e213ed1b0e", "Styles": "None", "Classes": "None", "Text": "Chest symptoms such as a dry cough or breathlessness ", "ParentId": "daf70f51-f266-486f-a56b-923eef0d14b6"}, {"Element": "<span lang=\"EN-GB\">(possible signs of interstitial lung disease, a condition of damage\nto the tissues around the air sacs in the lungs)</span>", "ID": "78dd2d16-52af-43da-96c1-d5feed8dd25c", "Styles": "None", "Classes": "None", "Text": "(possible signs of interstitial lung disease, a condition of damage to the tissues around the air sacs in the lungs)", "ParentId": "daf70f51-f266-486f-a56b-923eef0d14b6"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Fluid around the lungs causing difficulty in breathing</span></p>", "ID": "4fdb038f-5be9-4bf9-b99b-ac8db55c5ec0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "2b1d9b87-b742-4209-8614-e31a7380b425", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "4fdb038f-5be9-4bf9-b99b-ac8db55c5ec0"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Fluid around the lungs causing difficulty in breathing</span>", "ID": "a30d61f7-ca42-4438-93b8-6a5e14467ad9", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Fluid around the lungs causing difficulty in breathing", "ParentId": "4fdb038f-5be9-4bf9-b99b-ac8db55c5ec0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "721d2903-fdc2-49c3-886b-fd0ea4420c12", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "adbe618e-c894-4d21-a87c-086182e09d45", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "721d2903-fdc2-49c3-886b-fd0ea4420c12"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">If you experience any of the above symptoms\nafter treatment with Perjeta has been stopped, you should consult your doctor\nimmediately and inform him or her that you have previously been treated with\nPerjeta.</span></p>", "ID": "6e6bf882-dae9-46c2-b313-e82ceb87c522", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">If you experience any of the above symptoms\nafter treatment with Perjeta has been stopped, you should consult your doctor\nimmediately and inform him or her that you have previously been treated with\nPerjeta.</span>", "ID": "a2479d5f-4c68-4ce0-b513-9f71a0f6d83b", "Styles": "None", "Classes": "None", "Text": "If you experience any of the above symptoms after treatment with Perjeta has been stopped, you should consult your doctor immediately and inform him or her that you have previously been treated with Perjeta.", "ParentId": "6e6bf882-dae9-46c2-b313-e82ceb87c522"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ed9c2a9d-833f-49f2-a9e1-83bacd59cb11", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "886db0fe-5e9a-4415-a269-0a4d852b7492", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ed9c2a9d-833f-49f2-a9e1-83bacd59cb11"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Some of the side effects which you get may\nbe due to your breast cancer. If you are given Perjeta with trastuzumab and\nchemotherapy at the same time, some side effects may also be due to these other\nmedicines.</span></p>", "ID": "e8c0221e-260e-46ed-9214-46cc340401f5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Some of the side effects which you get may\nbe due to your breast cancer. If you are given Perjeta with trastuzumab and\nchemotherapy at the same time, some side effects may also be due to these other\nmedicines.</span>", "ID": "8bc698ef-b0db-43f7-b2dc-225a95615dd4", "Styles": "None", "Classes": "None", "Text": "Some of the side effects which you get may be due to your breast cancer. If you are given Perjeta with trastuzumab and chemotherapy at the same time, some side effects may also be due to these other medicines.", "ParentId": "e8c0221e-260e-46ed-9214-46cc340401f5"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c94abefa-7ee2-415f-8211-a2b578a4baaa", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "35ca5dc5-6a36-4aed-a3e1-b6ddc61be5dd", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c94abefa-7ee2-415f-8211-a2b578a4baaa"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Reporting\nof side effects</span></b></p>", "ID": "a28e630a-c0f5-44cc-bfc9-9a76d6f9761c", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">Reporting\nof side effects</span></b>", "ID": "69afa55b-80c6-4555-9a14-74ddac8c6e5f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a28e630a-c0f5-44cc-bfc9-9a76d6f9761c"}, {"Element": "<span lang=\"EN-GB\">Reporting\nof side effects</span>", "ID": "a1dacf32-c844-450e-84dd-7ef214913045", "Styles": "None", "Classes": "None", "Text": "Reporting of side effects", "ParentId": "69afa55b-80c6-4555-9a14-74ddac8c6e5f"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">If you get\nany side effects, talk to your doctor or nurse. This includes any possible side\neffects not listed in this leaflet. </span><span lang=\"EN-GB\">You can also report\nside effects directly via </span><span lang=\"EN-GB\" style=\"background:lightgrey\">the\nnational reporting system listed in </span><a href=\"https://www.ema.europa.eu/documents/template-form/appendix-v-adverse-drug-reaction-reporting-details_en.doc\"><span lang=\"EN-GB\" style=\"background:lightgrey\">Appendix V</span><span lang=\"EN-GB\">.</span></a><span lang=\"EN-GB\"> By reporting side effects you can help provide more information on\nthe safety of this medicine.</span></p>", "ID": "e02d3d64-1aa4-4c4e-93a2-a915f91a8ad1", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">If you get\nany side effects, talk to your doctor or nurse. This includes any possible side\neffects not listed in this leaflet. </span>", "ID": "d16ae13b-e7c7-483c-a118-8a0623116468", "Styles": "None", "Classes": "None", "Text": "If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. ", "ParentId": "e02d3d64-1aa4-4c4e-93a2-a915f91a8ad1"}, {"Element": "<span lang=\"EN-GB\">You can also report\nside effects directly via </span>", "ID": "39724021-90d6-40f5-bf1f-587422d2de46", "Styles": "None", "Classes": "None", "Text": "You can also report side effects directly via ", "ParentId": "e02d3d64-1aa4-4c4e-93a2-a915f91a8ad1"}, {"Element": "<span lang=\"EN-GB\" style=\"background:lightgrey\">the\nnational reporting system listed in </span>", "ID": "09a58bfc-8d67-4ffe-8e71-66a7966db927", "Styles": "background:lightgrey", "Classes": "None", "Text": "the national reporting system listed in ", "ParentId": "e02d3d64-1aa4-4c4e-93a2-a915f91a8ad1"}, {"Element": "<a href=\"https://www.ema.europa.eu/documents/template-form/appendix-v-adverse-drug-reaction-reporting-details_en.doc\"><span lang=\"EN-GB\" style=\"background:lightgrey\">Appendix V</span><span lang=\"EN-GB\">.</span></a>", "ID": "994ad285-d74f-4b1c-b46b-0e755f6470e2", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e02d3d64-1aa4-4c4e-93a2-a915f91a8ad1"}, {"Element": "<span lang=\"EN-GB\" style=\"background:lightgrey\">Appendix V</span>", "ID": "2f180af2-df78-40ac-a687-98bc595fddae", "Styles": "background:lightgrey", "Classes": "None", "Text": "Appendix V", "ParentId": "994ad285-d74f-4b1c-b46b-0e755f6470e2"}, {"Element": "<span lang=\"EN-GB\">.</span>", "ID": "16fb4fb2-e002-4c8c-bcb9-39247da83648", "Styles": "None", "Classes": "None", "Text": ".", "ParentId": "994ad285-d74f-4b1c-b46b-0e755f6470e2"}, {"Element": "<span lang=\"EN-GB\"> By reporting side effects you can help provide more information on\nthe safety of this medicine.</span>", "ID": "0b7949ce-0481-4371-b030-28686255e733", "Styles": "None", "Classes": "None", "Text": " By reporting side effects you can help provide more information on the safety of this medicine.", "ParentId": "e02d3d64-1aa4-4c4e-93a2-a915f91a8ad1"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "08819f1b-247c-4e56-bc6d-9a984cc4de1d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "814a3925-ce95-4aa7-9aaf-27c4e51164f1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "08819f1b-247c-4e56-bc6d-9a984cc4de1d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "85366f94-69e3-4045-acd7-443ffe99ea9f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9b278f1a-dd4b-433f-bf96-ddf17f600818", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "85366f94-69e3-4045-acd7-443ffe99ea9f"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How\nto store Perjeta</span></b></p>", "ID": "49487fd4-8f0e-4c8c-8705-69721c1283f1", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How\nto store Perjeta</span></b>", "ID": "ee0910fc-cdf3-4f8a-8bb8-a0dc1398f884", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "49487fd4-8f0e-4c8c-8705-69721c1283f1"}, {"Element": "<span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How\nto store Perjeta</span>", "ID": "691a4991-f33f-45ac-b6c0-1f1c1d7bb49f", "Styles": "None", "Classes": "None", "Text": "5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How to store Perjeta", "ParentId": "ee0910fc-cdf3-4f8a-8bb8-a0dc1398f884"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "c336f04a-639c-444f-9355-030005dd0044", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "7457e9aa-4415-41d0-9bbb-ec325ae33d76", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c336f04a-639c-444f-9355-030005dd0044"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8ec4b981-d00e-485e-bd1c-b4a1932730f1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7457e9aa-4415-41d0-9bbb-ec325ae33d76"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Perjeta will\nbe stored by the health professionals at the hospital or clinic. The storage\ndetails </span></p>", "ID": "8045e729-963f-4ce9-880b-4b68002bd6dd", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Perjeta will\nbe stored by the health professionals at the hospital or clinic. The storage\ndetails </span>", "ID": "b430e795-da0d-44f3-8fb4-715e86f9b7f3", "Styles": "None", "Classes": "None", "Text": "Perjeta will be stored by the health professionals at the hospital or clinic. The storage details ", "ParentId": "8045e729-963f-4ce9-880b-4b68002bd6dd"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">are as\nfollows:</span></p>", "ID": "abccf8f7-2ef0-4f1c-908c-9542e580974d", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">are as\nfollows:</span>", "ID": "bf8a2688-8707-41e9-b951-916fb08ea74f", "Styles": "None", "Classes": "None", "Text": "are as follows:", "ParentId": "abccf8f7-2ef0-4f1c-908c-9542e580974d"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Keep this\nmedicine out of the sight and reach of children.</span></p>", "ID": "6d3ad0bd-fdf1-4274-bfa8-64461fc096d2", "Styles": "margin-left:.5in;text-indent:-.5in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "59982b23-20ee-40fd-ba68-9a00fba1ce26", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "6d3ad0bd-fdf1-4274-bfa8-64461fc096d2"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Keep this\nmedicine out of the sight and reach of children.</span>", "ID": "3ef9216c-594c-4c5c-98eb-fe67c00b2790", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Keep this medicine out of the sight and reach of children.", "ParentId": "6d3ad0bd-fdf1-4274-bfa8-64461fc096d2"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Do not use this\nmedicine after the expiry date which is stated on the outer carton after EXP.\nThe expiry date refers to the last day of that month.</span></p>", "ID": "8b275526-0085-4f07-8298-355a9302230e", "Styles": "margin-left:.5in;text-indent:-.5in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "49cc216a-0c69-4ad4-b5d5-118b3e1ce292", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "8b275526-0085-4f07-8298-355a9302230e"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Do not use this\nmedicine after the expiry date which is stated on the outer carton after EXP.\nThe expiry date refers to the last day of that month.</span>", "ID": "663bdf05-22e9-48e6-b4a0-ed44384b3906", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Do not use this medicine after the expiry date which is stated on the outer carton after EXP. The expiry date refers to the last day of that month.", "ParentId": "8b275526-0085-4f07-8298-355a9302230e"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Store in a\nrefrigerator (2\u00b0C-8\u00b0C). </span></p>", "ID": "4b780abc-847e-4631-ad2f-164c5e315aab", "Styles": "margin-left:.5in;text-indent:-.5in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "74c5748f-d6ec-46d4-9e62-fbdb63596fd8", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "4b780abc-847e-4631-ad2f-164c5e315aab"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Store in a\nrefrigerator (2\u00b0C-8\u00b0C). </span>", "ID": "fd26de70-05d5-416a-a853-450e2d9081e1", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Store in a refrigerator (2\u00b0C-8\u00b0C). ", "ParentId": "4b780abc-847e-4631-ad2f-164c5e315aab"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Do not freeze.</span></p>", "ID": "f660d6c2-6be0-4d42-aa33-0ce362633f6b", "Styles": "margin-left:.5in;text-indent:-.5in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "de7272e0-7d9d-4afe-8dd5-14232d1d025b", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "f660d6c2-6be0-4d42-aa33-0ce362633f6b"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Do not freeze.</span>", "ID": "144dbd29-44bb-4806-974e-85d3b025426d", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Do not freeze.", "ParentId": "f660d6c2-6be0-4d42-aa33-0ce362633f6b"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Keep the vial in\nthe outer carton in order to protect from light.</span></p>", "ID": "f0a74489-5609-43d1-aeef-01e320d03329", "Styles": "margin-left:.5in;text-indent:-.5in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "793dd732-f171-4f0c-bb81-97a497770b51", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "f0a74489-5609-43d1-aeef-01e320d03329"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Keep the vial in\nthe outer carton in order to protect from light.</span>", "ID": "506ae3fd-4dc1-4924-9f95-88e78fb6c3cb", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Keep the vial in the outer carton in order to protect from light.", "ParentId": "f0a74489-5609-43d1-aeef-01e320d03329"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Do not use this\nmedicine if you notice any particles in the liquid or it is the wrong colour\n(please see section 6). </span></p>", "ID": "b58c627d-6652-4c2a-b614-8f8d22f4d1d5", "Styles": "margin-left:.5in;text-indent:-.5in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "3b79b60a-ae57-4c0e-8409-4b7161586ad9", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "b58c627d-6652-4c2a-b614-8f8d22f4d1d5"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Do not use this\nmedicine if you notice any particles in the liquid or it is the wrong colour\n(please see section 6). </span>", "ID": "3848c7e2-eb7f-485f-89d0-90e24c0cfa10", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Do not use this medicine if you notice any particles in the liquid or it is the wrong colour (please see section 6). ", "ParentId": "b58c627d-6652-4c2a-b614-8f8d22f4d1d5"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Do not throw away\nany medicines via wastewater or household waste. Ask your pharmacist how to\nthrow away medicines you no longer use. These measures will help to protect the\nenvironment.</span></p>", "ID": "cfc9123e-d012-4c38-b519-9ee0e3f8a25d", "Styles": "margin-left:.5in;text-indent:-.5in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "8288e6b8-61ae-4c82-8d6f-bbe6e48d4c6e", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "cfc9123e-d012-4c38-b519-9ee0e3f8a25d"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Do not throw away\nany medicines via wastewater or household waste. Ask your pharmacist how to\nthrow away medicines you no longer use. These measures will help to protect the\nenvironment.</span>", "ID": "7cbce60e-e063-4cab-a7a9-1193c9d59d68", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.", "ParentId": "cfc9123e-d012-4c38-b519-9ee0e3f8a25d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "1dab5d6a-567b-4cb6-b8c8-9e811481f331", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9a306647-34cd-45dd-8a8a-b724cf4bbed4", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1dab5d6a-567b-4cb6-b8c8-9e811481f331"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "cae80126-8bba-4cf9-a9cf-957a1ace3f43", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e5a93ae0-2081-443a-9a01-d5034d0c712d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "cae80126-8bba-4cf9-a9cf-957a1ace3f43"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Contents of the pack and\nother information</span></b></p>", "ID": "94621391-8ec6-4ff8-bd3a-212105cdb5eb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Contents of the pack and\nother information</span></b>", "ID": "c8d32acd-0888-4aa3-915b-8b9062519b16", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "94621391-8ec6-4ff8-bd3a-212105cdb5eb"}, {"Element": "<span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Contents of the pack and\nother information</span>", "ID": "e503e4a0-c172-4702-b226-1d847ff28633", "Styles": "None", "Classes": "None", "Text": "6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Contents of the pack and other information", "ParentId": "c8d32acd-0888-4aa3-915b-8b9062519b16"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "86475db7-e9a4-47eb-aeb8-a02be46b01a2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "4ff43e50-05e4-4cf0-8b56-44bff847a41e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "86475db7-e9a4-47eb-aeb8-a02be46b01a2"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f3a1cad4-8c41-47b0-9ef6-c2f2147eed6a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4ff43e50-05e4-4cf0-8b56-44bff847a41e"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">What Perjeta contains</span></b></p>", "ID": "90bf7c30-0108-4efc-9bda-214cf6374a33", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">What Perjeta contains</span></b>", "ID": "6113dfc2-27ad-4092-a6ed-e7687cc337e4", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "90bf7c30-0108-4efc-9bda-214cf6374a33"}, {"Element": "<span lang=\"EN-GB\">What Perjeta contains</span>", "ID": "d7f5ddc9-7e0d-4c80-9c9c-0ac0bc18eff8", "Styles": "None", "Classes": "None", "Text": "What Perjeta contains", "ParentId": "6113dfc2-27ad-4092-a6ed-e7687cc337e4"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 The active\nsubstance is pertuzumab. Each vial contains a total of 420\u00a0mg pertuzumab\nat a concentration of 30\u00a0mg/ml</span></p>", "ID": "e6478430-a612-48d8-b241-64561101ee14", "Styles": "margin-left:.5in;text-indent:-.5in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "7a37ec33-aba2-4fd7-8179-5e3499accef1", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "e6478430-a612-48d8-b241-64561101ee14"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 The active\nsubstance is pertuzumab. Each vial contains a total of 420\u00a0mg pertuzumab\nat a concentration of 30\u00a0mg/ml</span>", "ID": "95d55c5c-76a2-40f3-b7c2-7b23b64a9afa", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 The active substance is pertuzumab. Each vial contains a total of 420\u00a0mg pertuzumab at a concentration of 30\u00a0mg/ml", "ParentId": "e6478430-a612-48d8-b241-64561101ee14"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 The other\ningredients are glacial acetic acid, L-histidine, sucrose, polysorbate 20 and\nwater for injections</span></p>", "ID": "134ae8e8-1599-4ffe-83ae-1a02c8a3585b", "Styles": "margin-left:.5in;text-indent:-.5in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "40f2c78d-e979-46fb-9975-d6da0c89daa5", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "134ae8e8-1599-4ffe-83ae-1a02c8a3585b"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 The other\ningredients are glacial acetic acid, L-histidine, sucrose, polysorbate 20 and\nwater for injections</span>", "ID": "90464d27-c520-443e-b279-43c20c785300", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 The other ingredients are glacial acetic acid, L-histidine, sucrose, polysorbate 20 and water for injections", "ParentId": "134ae8e8-1599-4ffe-83ae-1a02c8a3585b"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d54240be-b962-4195-9ff2-d95ab6796ac4", "Styles": "margin-left:.5in;text-indent:-.5in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "702a52a9-529a-483c-b7d8-32174db0cb8f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d54240be-b962-4195-9ff2-d95ab6796ac4"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">What Perjeta\nlooks like and contents of the pack</span></b></p>", "ID": "e8232a40-58dc-4742-9a86-a1231a64907c", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">What Perjeta\nlooks like and contents of the pack</span></b>", "ID": "5030dcea-7b7b-48bf-9638-8edc12c42ef8", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e8232a40-58dc-4742-9a86-a1231a64907c"}, {"Element": "<span lang=\"EN-GB\">What Perjeta\nlooks like and contents of the pack</span>", "ID": "2ae6c711-4ab6-4c23-bb49-e93a44402e52", "Styles": "None", "Classes": "None", "Text": "What Perjeta looks like and contents of the pack", "ParentId": "5030dcea-7b7b-48bf-9638-8edc12c42ef8"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Perjeta is a\nconcentrate for solution for infusion. It is a clear to slightly pearly\n(opalescent), colourless to pale yellow liquid. It is supplied in a glass vial\ncontaining 14\u00a0ml concentrate.</span></p>", "ID": "36eb6096-ec78-4967-8cf7-3be20ef1f241", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Perjeta is a\nconcentrate for solution for infusion. It is a clear to slightly pearly\n(opalescent), colourless to pale yellow liquid. It is supplied in a glass vial\ncontaining 14\u00a0ml concentrate.</span>", "ID": "8c68a052-d6b4-4289-b035-92b5c2d26a9e", "Styles": "None", "Classes": "None", "Text": "Perjeta is a concentrate for solution for infusion. It is a clear to slightly pearly (opalescent), colourless to pale yellow liquid. It is supplied in a glass vial containing 14\u00a0ml concentrate.", "ParentId": "36eb6096-ec78-4967-8cf7-3be20ef1f241"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Each pack\ncontains one vial.</span></p>", "ID": "4241f3d9-352f-4893-8403-239682632870", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Each pack\ncontains one vial.</span>", "ID": "12e683fd-0302-4813-9480-111373cc8f4e", "Styles": "None", "Classes": "None", "Text": "Each pack contains one vial.", "ParentId": "4241f3d9-352f-4893-8403-239682632870"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0e29067d-d656-4b86-95f6-e45ff29c829e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1530e340-82ce-4f51-9d78-4a9647245750", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0e29067d-d656-4b86-95f6-e45ff29c829e"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Marketing\nAuthorisation Holder</span></b></p>", "ID": "f5caee4d-1a22-4bfe-90d8-f07bc2ee2f7d", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">Marketing\nAuthorisation Holder</span></b>", "ID": "c61427b6-655a-4c95-8519-f099658de395", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f5caee4d-1a22-4bfe-90d8-f07bc2ee2f7d"}, {"Element": "<span lang=\"EN-GB\">Marketing\nAuthorisation Holder</span>", "ID": "74c0a871-fdd0-4afd-b718-314dc6e0a289", "Styles": "None", "Classes": "None", "Text": "Marketing Authorisation Holder", "ParentId": "c61427b6-655a-4c95-8519-f099658de395"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Roche Registration GmbH </span></p>", "ID": "84025d10-a61d-4841-8034-d77b4fd72406", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Roche Registration GmbH </span>", "ID": "0c335479-93b3-45c5-a504-dd5da7dd5c99", "Styles": "None", "Classes": "None", "Text": "Roche Registration GmbH ", "ParentId": "84025d10-a61d-4841-8034-d77b4fd72406"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Emil-Barell-Strasse 1</span></p>", "ID": "3bcfdd4a-4e4d-41a7-ad51-4366f339a7da", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Emil-Barell-Strasse 1</span>", "ID": "4e944dc3-7e13-406f-8e51-fcde41d457e3", "Styles": "None", "Classes": "None", "Text": "Emil-Barell-Strasse 1", "ParentId": "3bcfdd4a-4e4d-41a7-ad51-4366f339a7da"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">79639 Grenzach-Wyhlen</span></p>", "ID": "8a4106b7-52d7-4ed0-adbd-a342241dbb40", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">79639 Grenzach-Wyhlen</span>", "ID": "4e13482f-0ddf-400c-b50b-19a253510bcd", "Styles": "None", "Classes": "None", "Text": "79639 Grenzach-Wyhlen", "ParentId": "8a4106b7-52d7-4ed0-adbd-a342241dbb40"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Germany</span></p>", "ID": "6c5f4205-975e-47b9-9858-27facc1e761c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Germany</span>", "ID": "2656bbce-f98e-427c-90b1-d615b539e9c3", "Styles": "None", "Classes": "None", "Text": "Germany", "ParentId": "6c5f4205-975e-47b9-9858-27facc1e761c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c4634897-4490-400d-a3b1-4988cbc806de", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f2651c7c-c052-44a0-9f2f-2746dbfc4fde", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c4634897-4490-400d-a3b1-4988cbc806de"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Manufacturer</span></b></p>", "ID": "2848070a-4f74-4ef4-ba97-bb5ba88505f2", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">Manufacturer</span></b>", "ID": "9a0552c0-d7fc-4eb4-9a0c-2271404ae67d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "2848070a-4f74-4ef4-ba97-bb5ba88505f2"}, {"Element": "<span lang=\"EN-GB\">Manufacturer</span>", "ID": "bbe61ee2-95f6-494d-8d90-4beb6c1228ce", "Styles": "None", "Classes": "None", "Text": "Manufacturer", "ParentId": "9a0552c0-d7fc-4eb4-9a0c-2271404ae67d"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"DE\" style=\"color:black\">Roche Pharma AG </span></p>", "ID": "a8ed6b19-1705-49b9-9071-2804df84e7aa", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"DE\" style=\"color:black\">Roche Pharma AG </span>", "ID": "c37c14bd-6677-4ef1-8b63-329e612d6c24", "Styles": "color:black", "Classes": "None", "Text": "Roche Pharma AG ", "ParentId": "a8ed6b19-1705-49b9-9071-2804df84e7aa"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"DE-CH\" style=\"color:black\">Emil-Barell-Strasse 1</span></p>", "ID": "9b22a706-e976-467b-b2ed-16c24fb6687d", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"DE-CH\" style=\"color:black\">Emil-Barell-Strasse 1</span>", "ID": "697abbff-a17b-4361-8449-a3a923bc8f85", "Styles": "color:black", "Classes": "None", "Text": "Emil-Barell-Strasse 1", "ParentId": "9b22a706-e976-467b-b2ed-16c24fb6687d"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">D-79639\nGrenzach-Wyhlen</span></p>", "ID": "4a92be59-9618-4b9a-9bd5-6c232a5bcf04", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">D-79639\nGrenzach-Wyhlen</span>", "ID": "6070ed71-0709-4e91-ae5c-40e2321d8d9d", "Styles": "None", "Classes": "None", "Text": "D-79639 Grenzach-Wyhlen", "ParentId": "4a92be59-9618-4b9a-9bd5-6c232a5bcf04"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Germany </span></p>", "ID": "e5638e59-7cd6-4f66-9500-f80a11764ba8", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Germany </span>", "ID": "0ecc6181-f931-4b90-9b18-e8a41f5cdf5f", "Styles": "None", "Classes": "None", "Text": "Germany ", "ParentId": "e5638e59-7cd6-4f66-9500-f80a11764ba8"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e41ceade-d2fe-4b36-85c5-6e90afaee543", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5901958a-4b68-4cb4-be48-d82046e03d07", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e41ceade-d2fe-4b36-85c5-6e90afaee543"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">For any information about this medicine,\nplease contact the local representative of the Marketing Authorisation Holder:</span></p>", "ID": "604e6597-2bfa-4a8d-9ec4-8fa6cb9c02a2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">For any information about this medicine,\nplease contact the local representative of the Marketing Authorisation Holder:</span>", "ID": "9df16121-25e7-4712-8565-4bb19a2b82bc", "Styles": "None", "Classes": "None", "Text": "For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:", "ParentId": "604e6597-2bfa-4a8d-9ec4-8fa6cb9c02a2"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "04bcf731-f571-4e05-bd7b-bffaae61cc92", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9ae3a2be-d686-4f07-9f9c-b466f323f96c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "04bcf731-f571-4e05-bd7b-bffaae61cc92"}, {"Element": "<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse\">\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"FR-CH\">Belgi\u00eb/Belgique/Belgien</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"FR-CH\">N.V. Roche S.A.</span></p>\n<p class=\"MsoNormal\"><span lang=\"FR\">T\u00e9l/Tel: +32 (0) 2 525 82 11</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"FR\">\u00a0</span></b></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">Lietuva</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">UAB \u201cRoche Lietuva\u201d</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Tel: +370 5 2546799</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">\u00a0</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><b><span lang=\"EN-GB\">\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u0420\u043e\u0448</span><span lang=\"EN-GB\"> </span><span lang=\"EN-GB\">\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f</span><span lang=\"EN-GB\"> </span><span lang=\"EN-GB\">\u0415\u041e\u041e\u0414</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u0422\u0435\u043b</span>: +359\n  2\u00a0818 44 44</p>\n<p class=\"MsoNormal\">\u00a0</p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">Luxembourg/Luxemburg</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">(Voir/siehe Belgique/Belgien)</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">\u010cesk\u00e1 republika</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche s. r. o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">Tel: +420 - 2 20382111</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">\u00a0</span></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE\">Magyarorsz\u00e1g</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">Roche (Magyarorsz\u00e1g) Kft.</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">Tel: +36 - 23 446 800</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"DE\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Danmark</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Roche a/s</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tlf: +45 - 36 39 99 99</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Malta</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">(See Ireland)</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">Deutschland</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche Pharma AG</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Tel: +49 (0) 7624 140</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">\u00a0</span></b></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">Nederland</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche Nederland B.V.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +31 (0) 348 438050</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"IT\">Eesti</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Roche Eesti O\u00dc</span></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Tel: + 372 - 6 177 380</span></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Norge</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Roche Norge AS</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tlf: +47 - 22 78 90 00</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u0395\u03bb\u03bb\u03ac\u03b4\u03b1</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Roche (Hellas) A.E. </span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u03a4\u03b7\u03bb: +30 210 61 66 100</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">\u00d6sterreich</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche Austria GmbH</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Tel: +43 (0) 1 27739</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"ES\">Espa\u00f1a</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"ES\">Roche Farma S.A.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +34 - 91 324 81 00</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Polska</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche Polska Sp.z o.o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +48 - 22 345 18 88</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">France</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Roche</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">T\u00e9l: +33\u00a0 (0)1 47 61 40 00</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"PT-BR\">Portugal</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"PT-BR\">Roche Farmac\u00eautica Qu\u00edmica, Lda</span></p>\n<p class=\"MsoNormal\"><span lang=\"PT-BR\">Tel: +351 - 21 425 70 00</span></p>\n<p class=\"MsoNormal\"><span lang=\"PT-BR\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">Hrvatska</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche d.o.o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: + 385 1 47 22 333</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"IT\">Rom\u00e2nia</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Roche Rom\u00e2nia S.R.L.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +40 21 206 47 01</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Ireland</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Roche Products (Ireland) Ltd.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +353 (0) 1 469 0700</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Slovenija</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Roche farmacevtska dru\u017eba d.o.o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +386 - 1 360 26 00</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"PT-BR\">\u00cdsland </span></b></p>\n<p class=\"MsoNormal\"><span lang=\"PT-BR\">Roche a/s</span></p>\n<p class=\"MsoNormal\"><span lang=\"PT-BR\">c/o Icepharma hf</span></p>\n<p class=\"MsoNormal\"><span lang=\"PT-BR\">S\u00edmi: +354 540 8000</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"PT-BR\">\u00a0</span></b></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DA\">Slovensk\u00e1 republika </span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DA\">Roche Slovensko, s.r.o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +421 - 2 52638201</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"IT\">Italia</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Roche S.p.A.</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Tel: +39 - 039 2471</span></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">Suomi/Finland</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche Oy<span style=\"layout-grid-mode:\n  line\"> </span></span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Puh/Tel: +358 (0) 10 554 500</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">K</span></b><b><span lang=\"EN-GB\">\u03cd\u03c0\u03c1\u03bf\u03c2</span></b><span lang=\"EN-GB\" style=\"font-size:10.0pt\"> </span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u0393</span><span lang=\"DE-CH\">.</span><span lang=\"EN-GB\">\u0391</span><span lang=\"DE-CH\">.</span><span lang=\"EN-GB\">\u03a3\u03c4\u03b1\u03bc\u03ac\u03c4\u03b7\u03c2</span><span lang=\"DE-CH\"> &amp; </span><span lang=\"EN-GB\">\u03a3\u03b9\u03b1</span><span lang=\"EN-GB\"> </span><span lang=\"EN-GB\">\u039b\u03c4\u03b4</span><span lang=\"DE-CH\">.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u03a4\u03b7\u03bb: +357 - 22 76 62 76</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Sverige</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Roche AB</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +46 (0) 8 726 1200</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"IT\">Latvija</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Roche Latvija SIA</span></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Tel: +371 - 6 7039831</span></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">United Kingdom</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Roche Products Ltd.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +44 (0) 1707 366000</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n</table>", "ID": "0a577017-8419-45b1-b78f-e2d8c5de4fd9", "Styles": "border-collapse:collapse", "Classes": "['MsoNormalTable']", "Text": "                ", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"FR-CH\">Belgi\u00eb/Belgique/Belgien</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"FR-CH\">N.V. Roche S.A.</span></p>\n<p class=\"MsoNormal\"><span lang=\"FR\">T\u00e9l/Tel: +32 (0) 2 525 82 11</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"FR\">\u00a0</span></b></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">Lietuva</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">UAB \u201cRoche Lietuva\u201d</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Tel: +370 5 2546799</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">\u00a0</span></b></p>\n</td>\n</tr>", "ID": "cb815444-f877-4c4d-90c9-cfb35061c68f", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "0a577017-8419-45b1-b78f-e2d8c5de4fd9"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"FR-CH\">Belgi\u00eb/Belgique/Belgien</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"FR-CH\">N.V. Roche S.A.</span></p>\n<p class=\"MsoNormal\"><span lang=\"FR\">T\u00e9l/Tel: +32 (0) 2 525 82 11</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"FR\">\u00a0</span></b></p>\n</td>", "ID": "d3ccbbc5-585c-4234-a268-7f79228afd94", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "cb815444-f877-4c4d-90c9-cfb35061c68f"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"FR-CH\">Belgi\u00eb/Belgique/Belgien</span></b></p>", "ID": "8afa1bde-2dc7-4002-a907-d9088f2acc47", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d3ccbbc5-585c-4234-a268-7f79228afd94"}, {"Element": "<b><span lang=\"FR-CH\">Belgi\u00eb/Belgique/Belgien</span></b>", "ID": "615b1f90-d59f-4977-8e31-f4f22acf2620", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8afa1bde-2dc7-4002-a907-d9088f2acc47"}, {"Element": "<span lang=\"FR-CH\">Belgi\u00eb/Belgique/Belgien</span>", "ID": "376b5077-d86e-4288-a9cf-72ecef216c0a", "Styles": "None", "Classes": "None", "Text": "Belgi\u00eb/Belgique/Belgien", "ParentId": "615b1f90-d59f-4977-8e31-f4f22acf2620"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"FR-CH\">N.V. Roche S.A.</span></p>", "ID": "a6e7b442-260a-4831-a787-ca7c6050b970", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d3ccbbc5-585c-4234-a268-7f79228afd94"}, {"Element": "<span lang=\"FR-CH\">N.V. Roche S.A.</span>", "ID": "be39cff2-daa7-49be-884e-40a18f87b1c6", "Styles": "None", "Classes": "None", "Text": "N.V. Roche S.A.", "ParentId": "a6e7b442-260a-4831-a787-ca7c6050b970"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"FR\">T\u00e9l/Tel: +32 (0) 2 525 82 11</span></p>", "ID": "f031d8f0-ce03-44df-854f-6702cca667cb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d3ccbbc5-585c-4234-a268-7f79228afd94"}, {"Element": "<span lang=\"FR\">T\u00e9l/Tel: +32 (0) 2 525 82 11</span>", "ID": "d3853a07-eecb-40f2-9fd3-550262ac994d", "Styles": "None", "Classes": "None", "Text": "T\u00e9l/Tel: +32 (0) 2 525 82 11", "ParentId": "f031d8f0-ce03-44df-854f-6702cca667cb"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"FR\">\u00a0</span></b></p>", "ID": "9416751f-9024-4288-8c8f-bf88d8d55611", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d3ccbbc5-585c-4234-a268-7f79228afd94"}, {"Element": "<b><span lang=\"FR\">\u00a0</span></b>", "ID": "c07f1199-2cb7-4e90-8c4d-d6a14081767e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "9416751f-9024-4288-8c8f-bf88d8d55611"}, {"Element": "<span lang=\"FR\">\u00a0</span>", "ID": "c42f209f-30b9-4cb1-b530-5e4e0e4b6aed", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c07f1199-2cb7-4e90-8c4d-d6a14081767e"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">Lietuva</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">UAB \u201cRoche Lietuva\u201d</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Tel: +370 5 2546799</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">\u00a0</span></b></p>\n</td>", "ID": "89435d6c-f00e-4dea-a820-ceba5633705e", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "cb815444-f877-4c4d-90c9-cfb35061c68f"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">Lietuva</span></b></p>", "ID": "a354a4c3-9718-47f0-ae04-5a7f6efaa570", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "89435d6c-f00e-4dea-a820-ceba5633705e"}, {"Element": "<b><span lang=\"DE-CH\">Lietuva</span></b>", "ID": "a5e6abb2-3815-4589-a4ae-b39cf5858432", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a354a4c3-9718-47f0-ae04-5a7f6efaa570"}, {"Element": "<span lang=\"DE-CH\">Lietuva</span>", "ID": "c29af534-033b-4aa8-ad62-7620164c88de", "Styles": "None", "Classes": "None", "Text": "Lietuva", "ParentId": "a5e6abb2-3815-4589-a4ae-b39cf5858432"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE-CH\">UAB \u201cRoche Lietuva\u201d</span></p>", "ID": "b04aae8e-56e1-4bf6-9d1c-9c3a063bc783", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "89435d6c-f00e-4dea-a820-ceba5633705e"}, {"Element": "<span lang=\"DE-CH\">UAB \u201cRoche Lietuva\u201d</span>", "ID": "4218e466-7c47-4605-ac72-dbf4f95c42e1", "Styles": "None", "Classes": "None", "Text": "UAB \u201cRoche Lietuva\u201d", "ParentId": "b04aae8e-56e1-4bf6-9d1c-9c3a063bc783"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE-CH\">Tel: +370 5 2546799</span></p>", "ID": "31e7f1fd-96b6-4625-b61b-90ce1bd5042f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "89435d6c-f00e-4dea-a820-ceba5633705e"}, {"Element": "<span lang=\"DE-CH\">Tel: +370 5 2546799</span>", "ID": "be604f5c-a263-4e52-a8f9-5d6a5b1345a6", "Styles": "None", "Classes": "None", "Text": "Tel: +370 5 2546799", "ParentId": "31e7f1fd-96b6-4625-b61b-90ce1bd5042f"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">\u00a0</span></b></p>", "ID": "e31b8748-257d-4edc-af99-508ed05f9a64", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "89435d6c-f00e-4dea-a820-ceba5633705e"}, {"Element": "<b><span lang=\"DE-CH\">\u00a0</span></b>", "ID": "e03bea4d-6850-413a-9431-336a7891a21d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e31b8748-257d-4edc-af99-508ed05f9a64"}, {"Element": "<span lang=\"DE-CH\">\u00a0</span>", "ID": "7095f1de-447a-492f-934e-9d50996258db", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e03bea4d-6850-413a-9431-336a7891a21d"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><b><span lang=\"EN-GB\">\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u0420\u043e\u0448</span><span lang=\"EN-GB\"> </span><span lang=\"EN-GB\">\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f</span><span lang=\"EN-GB\"> </span><span lang=\"EN-GB\">\u0415\u041e\u041e\u0414</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u0422\u0435\u043b</span>: +359\n  2\u00a0818 44 44</p>\n<p class=\"MsoNormal\">\u00a0</p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">Luxembourg/Luxemburg</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">(Voir/siehe Belgique/Belgien)</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">\u00a0</span></p>\n</td>\n</tr>", "ID": "84ce8e7c-4ccf-4dd5-904c-e93688f24e89", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "0a577017-8419-45b1-b78f-e2d8c5de4fd9"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><b><span lang=\"EN-GB\">\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u0420\u043e\u0448</span><span lang=\"EN-GB\"> </span><span lang=\"EN-GB\">\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f</span><span lang=\"EN-GB\"> </span><span lang=\"EN-GB\">\u0415\u041e\u041e\u0414</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u0422\u0435\u043b</span>: +359\n  2\u00a0818 44 44</p>\n<p class=\"MsoNormal\">\u00a0</p>\n</td>", "ID": "3f38e735-3cea-415f-8df4-d829ed94a0b8", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "84ce8e7c-4ccf-4dd5-904c-e93688f24e89"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><b><span lang=\"EN-GB\">\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f</span></b></p>", "ID": "8bf7c65c-44f8-4953-a332-0458386736d5", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "3f38e735-3cea-415f-8df4-d829ed94a0b8"}, {"Element": "<b><span lang=\"EN-GB\">\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f</span></b>", "ID": "5ca178a4-8db5-4817-a536-63c2da74ee08", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8bf7c65c-44f8-4953-a332-0458386736d5"}, {"Element": "<span lang=\"EN-GB\">\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f</span>", "ID": "6c339759-c809-4131-8dba-86eb73f2f3ab", "Styles": "None", "Classes": "None", "Text": "\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f", "ParentId": "5ca178a4-8db5-4817-a536-63c2da74ee08"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u0420\u043e\u0448</span><span lang=\"EN-GB\"> </span><span lang=\"EN-GB\">\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f</span><span lang=\"EN-GB\"> </span><span lang=\"EN-GB\">\u0415\u041e\u041e\u0414</span></p>", "ID": "0124264a-d012-4b70-8d28-e6c3e9b3d057", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "3f38e735-3cea-415f-8df4-d829ed94a0b8"}, {"Element": "<span lang=\"EN-GB\">\u0420\u043e\u0448</span>", "ID": "bc64640c-22a3-4a94-ab2e-befa11e48cdd", "Styles": "None", "Classes": "None", "Text": "\u0420\u043e\u0448", "ParentId": "0124264a-d012-4b70-8d28-e6c3e9b3d057"}, {"Element": "<span lang=\"EN-GB\"> </span>", "ID": "cc6760c2-5312-4074-8c14-0c97051b1f5c", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "0124264a-d012-4b70-8d28-e6c3e9b3d057"}, {"Element": "<span lang=\"EN-GB\">\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f</span>", "ID": "d570ce1f-d524-4823-91f7-c82fd7092cb6", "Styles": "None", "Classes": "None", "Text": "\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f", "ParentId": "0124264a-d012-4b70-8d28-e6c3e9b3d057"}, {"Element": "<span lang=\"EN-GB\"> </span>", "ID": "c2bb0f2a-f7fe-4353-b93f-e09e2c9a064f", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "0124264a-d012-4b70-8d28-e6c3e9b3d057"}, {"Element": "<span lang=\"EN-GB\">\u0415\u041e\u041e\u0414</span>", "ID": "960bfca8-d4a6-4c5b-8e3b-21a5b05d8e5e", "Styles": "None", "Classes": "None", "Text": "\u0415\u041e\u041e\u0414", "ParentId": "0124264a-d012-4b70-8d28-e6c3e9b3d057"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u0422\u0435\u043b</span>: +359\n  2\u00a0818 44 44</p>", "ID": "30a84e7e-b4d0-48ad-a8d2-4329ab8da95a", "Styles": "None", "Classes": "['MsoNormal']", "Text": ": +359   2\u00a0818 44 44", "ParentId": "3f38e735-3cea-415f-8df4-d829ed94a0b8"}, {"Element": "<span lang=\"EN-GB\">\u0422\u0435\u043b</span>", "ID": "a38f1137-41ae-45a3-b43e-87a82272afa9", "Styles": "None", "Classes": "None", "Text": "\u0422\u0435\u043b", "ParentId": "30a84e7e-b4d0-48ad-a8d2-4329ab8da95a"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "e94398b5-078a-4e88-8131-4e1527f0aca5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "3f38e735-3cea-415f-8df4-d829ed94a0b8"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">Luxembourg/Luxemburg</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">(Voir/siehe Belgique/Belgien)</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">\u00a0</span></p>\n</td>", "ID": "e7e654f2-c956-47fb-bb3c-f1266a8a88d9", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "    ", "ParentId": "84ce8e7c-4ccf-4dd5-904c-e93688f24e89"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">Luxembourg/Luxemburg</span></b></p>", "ID": "7aa0eb6e-1a32-4f16-8ea2-64f9acf13926", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e7e654f2-c956-47fb-bb3c-f1266a8a88d9"}, {"Element": "<b><span lang=\"DE-CH\">Luxembourg/Luxemburg</span></b>", "ID": "f2a680ed-a7c9-46e6-be9d-0e640a50fde4", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "7aa0eb6e-1a32-4f16-8ea2-64f9acf13926"}, {"Element": "<span lang=\"DE-CH\">Luxembourg/Luxemburg</span>", "ID": "f6aa0341-ea0e-4c8f-80e9-be29a40e38fe", "Styles": "None", "Classes": "None", "Text": "Luxembourg/Luxemburg", "ParentId": "f2a680ed-a7c9-46e6-be9d-0e640a50fde4"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE-CH\">(Voir/siehe Belgique/Belgien)</span></p>", "ID": "c705e421-cff9-46ca-b18a-5b50859f1188", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e7e654f2-c956-47fb-bb3c-f1266a8a88d9"}, {"Element": "<span lang=\"DE-CH\">(Voir/siehe Belgique/Belgien)</span>", "ID": "d1827261-19bd-4dba-85f6-ec2ebe3aeb7c", "Styles": "None", "Classes": "None", "Text": "(Voir/siehe Belgique/Belgien)", "ParentId": "c705e421-cff9-46ca-b18a-5b50859f1188"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE-CH\">\u00a0</span></p>", "ID": "b1e9554d-c61e-47a3-a07a-13ce6af13848", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e7e654f2-c956-47fb-bb3c-f1266a8a88d9"}, {"Element": "<span lang=\"DE-CH\">\u00a0</span>", "ID": "456b8e03-e451-4f7f-9147-751d21a50f3c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b1e9554d-c61e-47a3-a07a-13ce6af13848"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">\u010cesk\u00e1 republika</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche s. r. o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">Tel: +420 - 2 20382111</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">\u00a0</span></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE\">Magyarorsz\u00e1g</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">Roche (Magyarorsz\u00e1g) Kft.</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">Tel: +36 - 23 446 800</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"DE\">\u00a0</span></p>\n</td>\n</tr>", "ID": "2f71bdb8-56ed-4203-8aa9-3faa3b35dcfd", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "0a577017-8419-45b1-b78f-e2d8c5de4fd9"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">\u010cesk\u00e1 republika</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche s. r. o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">Tel: +420 - 2 20382111</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">\u00a0</span></p>\n</td>", "ID": "02bec85f-91cd-4b59-aeec-04f5f47c2ebb", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "2f71bdb8-56ed-4203-8aa9-3faa3b35dcfd"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">\u010cesk\u00e1 republika</span></b></p>", "ID": "6fc325bd-4e9b-4e77-90af-14d9bd405aa0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "02bec85f-91cd-4b59-aeec-04f5f47c2ebb"}, {"Element": "<b><span lang=\"DE-CH\">\u010cesk\u00e1 republika</span></b>", "ID": "5c6b2a11-8b4e-44dc-b56a-3dacd5f4b726", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "6fc325bd-4e9b-4e77-90af-14d9bd405aa0"}, {"Element": "<span lang=\"DE-CH\">\u010cesk\u00e1 republika</span>", "ID": "6821fdaa-b744-4791-8ed1-9d99b23164d6", "Styles": "None", "Classes": "None", "Text": "\u010cesk\u00e1 republika", "ParentId": "5c6b2a11-8b4e-44dc-b56a-3dacd5f4b726"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche s. r. o.</span></p>", "ID": "e6f96cd4-d279-4510-a39c-a2b24aac9790", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "02bec85f-91cd-4b59-aeec-04f5f47c2ebb"}, {"Element": "<span lang=\"DE-CH\">Roche s. r. o.</span>", "ID": "d5c8bd33-e136-49c7-8ee3-7bf01431f382", "Styles": "None", "Classes": "None", "Text": "Roche s. r. o.", "ParentId": "e6f96cd4-d279-4510-a39c-a2b24aac9790"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE\">Tel: +420 - 2 20382111</span></p>", "ID": "d6279a0c-b53b-4280-b285-7c65a799a69c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "02bec85f-91cd-4b59-aeec-04f5f47c2ebb"}, {"Element": "<span lang=\"DE\">Tel: +420 - 2 20382111</span>", "ID": "41197803-98f8-4ffc-86a0-2a7df1b0ddb9", "Styles": "None", "Classes": "None", "Text": "Tel: +420 - 2 20382111", "ParentId": "d6279a0c-b53b-4280-b285-7c65a799a69c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE\">\u00a0</span></p>", "ID": "7e14ec09-4d68-43bd-b24b-d7d839b0d303", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "02bec85f-91cd-4b59-aeec-04f5f47c2ebb"}, {"Element": "<span lang=\"DE\">\u00a0</span>", "ID": "c5c71da9-46a4-440f-ab6a-d382eb17d456", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7e14ec09-4d68-43bd-b24b-d7d839b0d303"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE\">Magyarorsz\u00e1g</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">Roche (Magyarorsz\u00e1g) Kft.</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">Tel: +36 - 23 446 800</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"DE\">\u00a0</span></p>\n</td>", "ID": "5dd3e5d6-eb2b-46ac-bab3-a0973e3ba920", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "2f71bdb8-56ed-4203-8aa9-3faa3b35dcfd"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"DE\">Magyarorsz\u00e1g</span></b></p>", "ID": "c1d6b9b9-1cea-4902-85b8-2c11743ca650", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5dd3e5d6-eb2b-46ac-bab3-a0973e3ba920"}, {"Element": "<b><span lang=\"DE\">Magyarorsz\u00e1g</span></b>", "ID": "78e88319-1ff8-42d0-94a3-e3352d7ae5ca", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c1d6b9b9-1cea-4902-85b8-2c11743ca650"}, {"Element": "<span lang=\"DE\">Magyarorsz\u00e1g</span>", "ID": "1fee3496-d992-42cf-b6d2-7307107c89a1", "Styles": "None", "Classes": "None", "Text": "Magyarorsz\u00e1g", "ParentId": "78e88319-1ff8-42d0-94a3-e3352d7ae5ca"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE\">Roche (Magyarorsz\u00e1g) Kft.</span></p>", "ID": "d211f065-a9c5-4308-9ae8-d7021af7cafd", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5dd3e5d6-eb2b-46ac-bab3-a0973e3ba920"}, {"Element": "<span lang=\"DE\">Roche (Magyarorsz\u00e1g) Kft.</span>", "ID": "d6e1b1c7-b718-4dec-8071-3b1c212747cc", "Styles": "None", "Classes": "None", "Text": "Roche (Magyarorsz\u00e1g) Kft.", "ParentId": "d211f065-a9c5-4308-9ae8-d7021af7cafd"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE\">Tel: +36 - 23 446 800</span></p>", "ID": "34ad05e8-d52b-4d33-955c-b6eb024bc8d7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5dd3e5d6-eb2b-46ac-bab3-a0973e3ba920"}, {"Element": "<span lang=\"DE\">Tel: +36 - 23 446 800</span>", "ID": "978657a4-40bc-4488-81c8-3c603c7c95fe", "Styles": "None", "Classes": "None", "Text": "Tel: +36 - 23 446 800", "ParentId": "34ad05e8-d52b-4d33-955c-b6eb024bc8d7"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"DE\">\u00a0</span></p>", "ID": "19ea80dd-fb83-40a9-bbb3-3bca6445d6b7", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5dd3e5d6-eb2b-46ac-bab3-a0973e3ba920"}, {"Element": "<span lang=\"DE\">\u00a0</span>", "ID": "efb28453-83e3-4b7f-a8d8-6bd8757bda9c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "19ea80dd-fb83-40a9-bbb3-3bca6445d6b7"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Danmark</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Roche a/s</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tlf: +45 - 36 39 99 99</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Malta</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">(See Ireland)</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "a847fa12-3188-43c6-a158-e9a8efcc359f", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "0a577017-8419-45b1-b78f-e2d8c5de4fd9"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Danmark</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Roche a/s</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tlf: +45 - 36 39 99 99</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>", "ID": "8f037161-03c6-4659-b37d-29719617728d", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "a847fa12-3188-43c6-a158-e9a8efcc359f"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Danmark</span></b></p>", "ID": "17e9582c-9812-491b-9f63-71330ba991f1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8f037161-03c6-4659-b37d-29719617728d"}, {"Element": "<b><span lang=\"EN-GB\">Danmark</span></b>", "ID": "df751f6e-2f26-400a-8389-d3d539ec5e82", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "17e9582c-9812-491b-9f63-71330ba991f1"}, {"Element": "<span lang=\"EN-GB\">Danmark</span>", "ID": "7c3310fb-30c9-40e2-b999-b57baebcb3d6", "Styles": "None", "Classes": "None", "Text": "Danmark", "ParentId": "df751f6e-2f26-400a-8389-d3d539ec5e82"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Roche a/s</span></p>", "ID": "09ac29b5-7a81-42f9-9383-e8a95e8e39f3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8f037161-03c6-4659-b37d-29719617728d"}, {"Element": "<span lang=\"EN-GB\">Roche a/s</span>", "ID": "ebc6b24d-1ae6-43ff-be8f-ad286407403d", "Styles": "None", "Classes": "None", "Text": "Roche a/s", "ParentId": "09ac29b5-7a81-42f9-9383-e8a95e8e39f3"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tlf: +45 - 36 39 99 99</span></p>", "ID": "a980b723-e517-48cf-ac08-800c59374299", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8f037161-03c6-4659-b37d-29719617728d"}, {"Element": "<span lang=\"EN-GB\">Tlf: +45 - 36 39 99 99</span>", "ID": "b99f0118-09a5-47f0-ac4b-bfa3b0bb3be5", "Styles": "None", "Classes": "None", "Text": "Tlf: +45 - 36 39 99 99", "ParentId": "a980b723-e517-48cf-ac08-800c59374299"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "aec59c33-3b85-460f-b058-743c179d7887", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8f037161-03c6-4659-b37d-29719617728d"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "ea6420e3-f2e7-4274-9317-79e3b317116d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "aec59c33-3b85-460f-b058-743c179d7887"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7b7945f5-b807-4159-88c5-42f08aaab351", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ea6420e3-f2e7-4274-9317-79e3b317116d"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Malta</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">(See Ireland)</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "b1c8e515-c86f-4d36-bba5-004a32f94cca", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "    ", "ParentId": "a847fa12-3188-43c6-a158-e9a8efcc359f"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Malta</span></b></p>", "ID": "95f354a0-b124-4399-873c-12cdbebd80f2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1c8e515-c86f-4d36-bba5-004a32f94cca"}, {"Element": "<b><span lang=\"EN-GB\">Malta</span></b>", "ID": "f0233e33-1f3f-4c74-8497-26b179edeefd", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "95f354a0-b124-4399-873c-12cdbebd80f2"}, {"Element": "<span lang=\"EN-GB\">Malta</span>", "ID": "56ce7a48-45a1-41f5-ae07-0c453cbc4bc3", "Styles": "None", "Classes": "None", "Text": "Malta", "ParentId": "f0233e33-1f3f-4c74-8497-26b179edeefd"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">(See Ireland)</span></p>", "ID": "67c7d8a9-ab12-41fa-884c-dee0cdb46aa2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1c8e515-c86f-4d36-bba5-004a32f94cca"}, {"Element": "<span lang=\"EN-GB\">(See Ireland)</span>", "ID": "fc0230b7-76cd-4ba3-92ec-90ce022e916c", "Styles": "None", "Classes": "None", "Text": "(See Ireland)", "ParentId": "67c7d8a9-ab12-41fa-884c-dee0cdb46aa2"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f3716499-9b80-4ee2-8c33-15cde0e1c0b2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1c8e515-c86f-4d36-bba5-004a32f94cca"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b12b5135-ba5f-4586-84b4-95e7422c4d7a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f3716499-9b80-4ee2-8c33-15cde0e1c0b2"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">Deutschland</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche Pharma AG</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Tel: +49 (0) 7624 140</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">\u00a0</span></b></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">Nederland</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche Nederland B.V.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +31 (0) 348 438050</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "2bb91908-4258-4d83-905b-66bddface23f", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "0a577017-8419-45b1-b78f-e2d8c5de4fd9"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">Deutschland</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche Pharma AG</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Tel: +49 (0) 7624 140</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">\u00a0</span></b></p>\n</td>", "ID": "93f0a5bc-38c4-41ce-8f66-59049f809767", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "2bb91908-4258-4d83-905b-66bddface23f"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">Deutschland</span></b></p>", "ID": "bae6b746-a237-4698-ad51-ff8cbcd0d072", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "93f0a5bc-38c4-41ce-8f66-59049f809767"}, {"Element": "<b><span lang=\"DE-CH\">Deutschland</span></b>", "ID": "dbdbf7cb-8be4-4c90-8e96-6ae438c9ef38", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "bae6b746-a237-4698-ad51-ff8cbcd0d072"}, {"Element": "<span lang=\"DE-CH\">Deutschland</span>", "ID": "7e159d56-4920-4815-a870-4d92a6f27888", "Styles": "None", "Classes": "None", "Text": "Deutschland", "ParentId": "dbdbf7cb-8be4-4c90-8e96-6ae438c9ef38"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche Pharma AG</span></p>", "ID": "5441596a-d49c-4e4c-9d18-27c39700a630", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "93f0a5bc-38c4-41ce-8f66-59049f809767"}, {"Element": "<span lang=\"DE-CH\">Roche Pharma AG</span>", "ID": "f0822585-9140-421f-b308-433bf8d8b55e", "Styles": "None", "Classes": "None", "Text": "Roche Pharma AG", "ParentId": "5441596a-d49c-4e4c-9d18-27c39700a630"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE-CH\">Tel: +49 (0) 7624 140</span></p>", "ID": "3e6335de-1d19-4aac-b196-2f154e2ef882", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "93f0a5bc-38c4-41ce-8f66-59049f809767"}, {"Element": "<span lang=\"DE-CH\">Tel: +49 (0) 7624 140</span>", "ID": "fbf81ad5-2682-4c07-912a-7e8be2c0b088", "Styles": "None", "Classes": "None", "Text": "Tel: +49 (0) 7624 140", "ParentId": "3e6335de-1d19-4aac-b196-2f154e2ef882"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">\u00a0</span></b></p>", "ID": "77497d0e-8e84-4140-8e33-11d5b2906c46", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "93f0a5bc-38c4-41ce-8f66-59049f809767"}, {"Element": "<b><span lang=\"DE-CH\">\u00a0</span></b>", "ID": "ec46d8fb-abe8-4069-9804-d305b31511ce", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "77497d0e-8e84-4140-8e33-11d5b2906c46"}, {"Element": "<span lang=\"DE-CH\">\u00a0</span>", "ID": "f26edccc-975c-4564-a0a7-e5162c90e0b8", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ec46d8fb-abe8-4069-9804-d305b31511ce"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">Nederland</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche Nederland B.V.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +31 (0) 348 438050</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "4c6ad460-a260-4978-b1b3-68aadadc4a18", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "2bb91908-4258-4d83-905b-66bddface23f"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">Nederland</span></b></p>", "ID": "dc9c0917-2653-4a17-b5b4-18764627c39f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4c6ad460-a260-4978-b1b3-68aadadc4a18"}, {"Element": "<b><span lang=\"DE-CH\">Nederland</span></b>", "ID": "c7934d95-39e8-4c1b-974e-8e497021bf27", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "dc9c0917-2653-4a17-b5b4-18764627c39f"}, {"Element": "<span lang=\"DE-CH\">Nederland</span>", "ID": "b7f5a8e8-2c3e-44ad-82f2-2494a3427f64", "Styles": "None", "Classes": "None", "Text": "Nederland", "ParentId": "c7934d95-39e8-4c1b-974e-8e497021bf27"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche Nederland B.V.</span></p>", "ID": "7db71d74-ca2e-44b4-a204-a174a4288be7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4c6ad460-a260-4978-b1b3-68aadadc4a18"}, {"Element": "<span lang=\"DE-CH\">Roche Nederland B.V.</span>", "ID": "91c96e29-ac80-4012-b5c1-5aa1399d5520", "Styles": "None", "Classes": "None", "Text": "Roche Nederland B.V.", "ParentId": "7db71d74-ca2e-44b4-a204-a174a4288be7"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +31 (0) 348 438050</span></p>", "ID": "3568db74-9241-43c3-8bfe-f9528ec6aa23", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4c6ad460-a260-4978-b1b3-68aadadc4a18"}, {"Element": "<span lang=\"EN-GB\">Tel: +31 (0) 348 438050</span>", "ID": "8c6b7f2b-7038-490f-9cd6-d1524cafa1de", "Styles": "None", "Classes": "None", "Text": "Tel: +31 (0) 348 438050", "ParentId": "3568db74-9241-43c3-8bfe-f9528ec6aa23"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "94712b8f-1c45-4bae-845c-266c446383fa", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4c6ad460-a260-4978-b1b3-68aadadc4a18"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a6f825b9-af12-4100-bae3-a451b1c85a6a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "94712b8f-1c45-4bae-845c-266c446383fa"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"IT\">Eesti</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Roche Eesti O\u00dc</span></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Tel: + 372 - 6 177 380</span></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Norge</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Roche Norge AS</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tlf: +47 - 22 78 90 00</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "6da6f4a4-7fca-4e4a-bdc0-e1a4963b190a", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "0a577017-8419-45b1-b78f-e2d8c5de4fd9"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"IT\">Eesti</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Roche Eesti O\u00dc</span></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Tel: + 372 - 6 177 380</span></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">\u00a0</span></p>\n</td>", "ID": "04dacd31-4335-41ae-b903-c635253e9c18", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "6da6f4a4-7fca-4e4a-bdc0-e1a4963b190a"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"IT\">Eesti</span></b></p>", "ID": "562325d1-dbc4-4612-a86c-515c394954de", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "04dacd31-4335-41ae-b903-c635253e9c18"}, {"Element": "<b><span lang=\"IT\">Eesti</span></b>", "ID": "4c7eb6eb-61ff-43ba-837e-910dcd21c5cd", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "562325d1-dbc4-4612-a86c-515c394954de"}, {"Element": "<span lang=\"IT\">Eesti</span>", "ID": "35e806f3-6bd2-495b-8c6b-a41de4e2dc2f", "Styles": "None", "Classes": "None", "Text": "Eesti", "ParentId": "4c7eb6eb-61ff-43ba-837e-910dcd21c5cd"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"IT\">Roche Eesti O\u00dc</span></p>", "ID": "031033d4-f1f4-49b4-9a9d-34186ff29769", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "04dacd31-4335-41ae-b903-c635253e9c18"}, {"Element": "<span lang=\"IT\">Roche Eesti O\u00dc</span>", "ID": "4b5c07d5-64cc-4b77-a2f3-011c5d7827ed", "Styles": "None", "Classes": "None", "Text": "Roche Eesti O\u00dc", "ParentId": "031033d4-f1f4-49b4-9a9d-34186ff29769"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"IT\">Tel: + 372 - 6 177 380</span></p>", "ID": "8b095cef-3c52-4843-b1ad-bd74c73b4412", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "04dacd31-4335-41ae-b903-c635253e9c18"}, {"Element": "<span lang=\"IT\">Tel: + 372 - 6 177 380</span>", "ID": "7058f554-7eaf-449c-9d41-c60cbf148c8f", "Styles": "None", "Classes": "None", "Text": "Tel: + 372 - 6 177 380", "ParentId": "8b095cef-3c52-4843-b1ad-bd74c73b4412"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"IT\">\u00a0</span></p>", "ID": "2b233254-aa78-4c6f-941a-d226150e5a3d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "04dacd31-4335-41ae-b903-c635253e9c18"}, {"Element": "<span lang=\"IT\">\u00a0</span>", "ID": "9bda68e4-daf1-40d1-b024-2256638bf0e8", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2b233254-aa78-4c6f-941a-d226150e5a3d"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Norge</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Roche Norge AS</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tlf: +47 - 22 78 90 00</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "39f07847-85fb-45f5-99e7-3824726c338b", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "6da6f4a4-7fca-4e4a-bdc0-e1a4963b190a"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Norge</span></b></p>", "ID": "48220fa2-ec60-4368-b8b2-ab6af6c4a5be", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "39f07847-85fb-45f5-99e7-3824726c338b"}, {"Element": "<b><span lang=\"EN-GB\">Norge</span></b>", "ID": "8a222f16-ac71-4fa6-bc5e-1c55416b8d88", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "48220fa2-ec60-4368-b8b2-ab6af6c4a5be"}, {"Element": "<span lang=\"EN-GB\">Norge</span>", "ID": "b69a6491-f6ed-4e20-a9c8-44a6ae1de541", "Styles": "None", "Classes": "None", "Text": "Norge", "ParentId": "8a222f16-ac71-4fa6-bc5e-1c55416b8d88"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Roche Norge AS</span></p>", "ID": "f04affae-1a1d-49e6-bb4b-ea1ad63522a4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "39f07847-85fb-45f5-99e7-3824726c338b"}, {"Element": "<span lang=\"EN-GB\">Roche Norge AS</span>", "ID": "004a96b7-ac89-4cee-8eb0-0fdcb1741ab8", "Styles": "None", "Classes": "None", "Text": "Roche Norge AS", "ParentId": "f04affae-1a1d-49e6-bb4b-ea1ad63522a4"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tlf: +47 - 22 78 90 00</span></p>", "ID": "3975c4e4-5821-4b3c-b271-900cfcb8feb5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "39f07847-85fb-45f5-99e7-3824726c338b"}, {"Element": "<span lang=\"EN-GB\">Tlf: +47 - 22 78 90 00</span>", "ID": "7648f215-d84f-4299-8129-6a50b95ee045", "Styles": "None", "Classes": "None", "Text": "Tlf: +47 - 22 78 90 00", "ParentId": "3975c4e4-5821-4b3c-b271-900cfcb8feb5"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9366f13e-b33f-4be3-af53-a184ea65ad89", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "39f07847-85fb-45f5-99e7-3824726c338b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a64a07ca-49b7-4015-a913-e6e2ea26d311", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9366f13e-b33f-4be3-af53-a184ea65ad89"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u0395\u03bb\u03bb\u03ac\u03b4\u03b1</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Roche (Hellas) A.E. </span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u03a4\u03b7\u03bb: +30 210 61 66 100</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">\u00d6sterreich</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche Austria GmbH</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Tel: +43 (0) 1 27739</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">\u00a0</span></p>\n</td>\n</tr>", "ID": "f7c8b8eb-6145-4876-81fb-fe75843e6f16", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "0a577017-8419-45b1-b78f-e2d8c5de4fd9"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u0395\u03bb\u03bb\u03ac\u03b4\u03b1</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Roche (Hellas) A.E. </span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u03a4\u03b7\u03bb: +30 210 61 66 100</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "cf5c17a0-582c-4ca6-93f3-a85979711c54", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "f7c8b8eb-6145-4876-81fb-fe75843e6f16"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u0395\u03bb\u03bb\u03ac\u03b4\u03b1</span></b></p>", "ID": "39eb6bad-6569-41e1-8ead-837e31d54ebe", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "cf5c17a0-582c-4ca6-93f3-a85979711c54"}, {"Element": "<b><span lang=\"EN-GB\">\u0395\u03bb\u03bb\u03ac\u03b4\u03b1</span></b>", "ID": "c2d614bd-bb1c-4117-a7e5-258b5ab68e2a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "39eb6bad-6569-41e1-8ead-837e31d54ebe"}, {"Element": "<span lang=\"EN-GB\">\u0395\u03bb\u03bb\u03ac\u03b4\u03b1</span>", "ID": "4abde0a7-15aa-42bd-8bd3-cefb62a93819", "Styles": "None", "Classes": "None", "Text": "\u0395\u03bb\u03bb\u03ac\u03b4\u03b1", "ParentId": "c2d614bd-bb1c-4117-a7e5-258b5ab68e2a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Roche (Hellas) A.E. </span></p>", "ID": "6c30ac51-db50-4d87-bafd-49ca7d4f2c38", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "cf5c17a0-582c-4ca6-93f3-a85979711c54"}, {"Element": "<span lang=\"EN-GB\">Roche (Hellas) A.E. </span>", "ID": "9ebdd349-0eee-4db4-a87e-701404055e56", "Styles": "None", "Classes": "None", "Text": "Roche (Hellas) A.E. ", "ParentId": "6c30ac51-db50-4d87-bafd-49ca7d4f2c38"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u03a4\u03b7\u03bb: +30 210 61 66 100</span></p>", "ID": "d65cb64d-4b30-4e7f-b5f4-0c61896d4f56", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "cf5c17a0-582c-4ca6-93f3-a85979711c54"}, {"Element": "<span lang=\"EN-GB\">\u03a4\u03b7\u03bb: +30 210 61 66 100</span>", "ID": "4c83f16a-cd99-4aad-80ae-01d7ccc3dc2c", "Styles": "None", "Classes": "None", "Text": "\u03a4\u03b7\u03bb: +30 210 61 66 100", "ParentId": "d65cb64d-4b30-4e7f-b5f4-0c61896d4f56"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0d787537-7e99-48c3-89ec-d3306891e801", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "cf5c17a0-582c-4ca6-93f3-a85979711c54"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2a981837-5c0b-495c-b816-41bd020b23bb", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0d787537-7e99-48c3-89ec-d3306891e801"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">\u00d6sterreich</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche Austria GmbH</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Tel: +43 (0) 1 27739</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">\u00a0</span></p>\n</td>", "ID": "b1dfa816-dd0a-46b7-8d60-065d63b50dc6", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "f7c8b8eb-6145-4876-81fb-fe75843e6f16"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">\u00d6sterreich</span></b></p>", "ID": "897e36fd-dd00-4b8b-91f7-3889662f9287", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1dfa816-dd0a-46b7-8d60-065d63b50dc6"}, {"Element": "<b><span lang=\"DE-CH\">\u00d6sterreich</span></b>", "ID": "3d27d5cf-bd02-4f37-b23b-e636325e5393", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "897e36fd-dd00-4b8b-91f7-3889662f9287"}, {"Element": "<span lang=\"DE-CH\">\u00d6sterreich</span>", "ID": "14dbf537-91e1-43bf-b60f-781a0983e831", "Styles": "None", "Classes": "None", "Text": "\u00d6sterreich", "ParentId": "3d27d5cf-bd02-4f37-b23b-e636325e5393"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche Austria GmbH</span></p>", "ID": "c25bf9b7-c4ab-4ebe-9e2e-79aa9d65b858", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1dfa816-dd0a-46b7-8d60-065d63b50dc6"}, {"Element": "<span lang=\"DE-CH\">Roche Austria GmbH</span>", "ID": "89eb94de-e8ee-43d8-9832-0f823a25bc8b", "Styles": "None", "Classes": "None", "Text": "Roche Austria GmbH", "ParentId": "c25bf9b7-c4ab-4ebe-9e2e-79aa9d65b858"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE-CH\">Tel: +43 (0) 1 27739</span></p>", "ID": "41d3f3bf-4c96-418b-bd29-1e2ee66e9436", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1dfa816-dd0a-46b7-8d60-065d63b50dc6"}, {"Element": "<span lang=\"DE-CH\">Tel: +43 (0) 1 27739</span>", "ID": "f63b04df-a3cd-463b-b1e3-ea90788ff528", "Styles": "None", "Classes": "None", "Text": "Tel: +43 (0) 1 27739", "ParentId": "41d3f3bf-4c96-418b-bd29-1e2ee66e9436"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE-CH\">\u00a0</span></p>", "ID": "a441fb3b-3fa7-48d8-91a7-20afdbd0d259", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1dfa816-dd0a-46b7-8d60-065d63b50dc6"}, {"Element": "<span lang=\"DE-CH\">\u00a0</span>", "ID": "80004716-a0c2-4aab-855e-d1416cfd1d91", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a441fb3b-3fa7-48d8-91a7-20afdbd0d259"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"ES\">Espa\u00f1a</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"ES\">Roche Farma S.A.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +34 - 91 324 81 00</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Polska</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche Polska Sp.z o.o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +48 - 22 345 18 88</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "8af104a2-4535-4b4c-9f4a-f5c3eb333389", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "0a577017-8419-45b1-b78f-e2d8c5de4fd9"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"ES\">Espa\u00f1a</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"ES\">Roche Farma S.A.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +34 - 91 324 81 00</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "a591e552-072b-4a02-931f-f458e6b5d4d6", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "8af104a2-4535-4b4c-9f4a-f5c3eb333389"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"ES\">Espa\u00f1a</span></b></p>", "ID": "f57e93bb-d480-499b-98fd-f0915e470890", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a591e552-072b-4a02-931f-f458e6b5d4d6"}, {"Element": "<b><span lang=\"ES\">Espa\u00f1a</span></b>", "ID": "a99d678e-0184-44fc-9b1a-456bafeadf28", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f57e93bb-d480-499b-98fd-f0915e470890"}, {"Element": "<span lang=\"ES\">Espa\u00f1a</span>", "ID": "44739251-2fe8-4ea0-aa09-becd2c788cb4", "Styles": "None", "Classes": "None", "Text": "Espa\u00f1a", "ParentId": "a99d678e-0184-44fc-9b1a-456bafeadf28"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"ES\">Roche Farma S.A.</span></p>", "ID": "c12736fd-e138-44c3-9038-dbf31f396394", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a591e552-072b-4a02-931f-f458e6b5d4d6"}, {"Element": "<span lang=\"ES\">Roche Farma S.A.</span>", "ID": "c25584c6-950a-4db3-b033-33183e4f598d", "Styles": "None", "Classes": "None", "Text": "Roche Farma S.A.", "ParentId": "c12736fd-e138-44c3-9038-dbf31f396394"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +34 - 91 324 81 00</span></p>", "ID": "938eb219-07a0-4179-bef2-7fb6910ab381", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a591e552-072b-4a02-931f-f458e6b5d4d6"}, {"Element": "<span lang=\"EN-GB\">Tel: +34 - 91 324 81 00</span>", "ID": "08b0ae41-030a-4b58-bea9-9c916a2679e7", "Styles": "None", "Classes": "None", "Text": "Tel: +34 - 91 324 81 00", "ParentId": "938eb219-07a0-4179-bef2-7fb6910ab381"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d6770aeb-6721-4e26-a3f0-f17f7f5da9e3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a591e552-072b-4a02-931f-f458e6b5d4d6"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "79089dbf-0102-4ae7-b705-196f3b17f30f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d6770aeb-6721-4e26-a3f0-f17f7f5da9e3"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Polska</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche Polska Sp.z o.o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +48 - 22 345 18 88</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "5f08191a-57a3-402e-9136-7b913f268a5d", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "8af104a2-4535-4b4c-9f4a-f5c3eb333389"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Polska</span></b></p>", "ID": "67343765-c2bd-4ed0-a16c-0da3639471af", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5f08191a-57a3-402e-9136-7b913f268a5d"}, {"Element": "<b><span lang=\"EN-GB\">Polska</span></b>", "ID": "6728d234-fcb1-4186-90e1-7fbca251a459", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "67343765-c2bd-4ed0-a16c-0da3639471af"}, {"Element": "<span lang=\"EN-GB\">Polska</span>", "ID": "b74a1f9a-a9cc-4e48-abd4-501821e8a16a", "Styles": "None", "Classes": "None", "Text": "Polska", "ParentId": "6728d234-fcb1-4186-90e1-7fbca251a459"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche Polska Sp.z o.o.</span></p>", "ID": "8d0f1d02-b6e3-41c1-8890-538bd2c58935", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5f08191a-57a3-402e-9136-7b913f268a5d"}, {"Element": "<span lang=\"DE-CH\">Roche Polska Sp.z o.o.</span>", "ID": "aadb2d32-aa40-4f3f-9a5e-e8bd217c43cf", "Styles": "None", "Classes": "None", "Text": "Roche Polska Sp.z o.o.", "ParentId": "8d0f1d02-b6e3-41c1-8890-538bd2c58935"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +48 - 22 345 18 88</span></p>", "ID": "f492756e-4318-4498-9f00-523f0554bdee", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5f08191a-57a3-402e-9136-7b913f268a5d"}, {"Element": "<span lang=\"EN-GB\">Tel: +48 - 22 345 18 88</span>", "ID": "2b4e2901-c144-4e08-add7-fa2974279547", "Styles": "None", "Classes": "None", "Text": "Tel: +48 - 22 345 18 88", "ParentId": "f492756e-4318-4498-9f00-523f0554bdee"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3ea7bee5-5764-41d1-96ac-763a23bc2348", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5f08191a-57a3-402e-9136-7b913f268a5d"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9c3aa130-30b7-4efc-8426-e8ebf16326a5", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3ea7bee5-5764-41d1-96ac-763a23bc2348"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">France</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Roche</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">T\u00e9l: +33\u00a0 (0)1 47 61 40 00</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"PT-BR\">Portugal</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"PT-BR\">Roche Farmac\u00eautica Qu\u00edmica, Lda</span></p>\n<p class=\"MsoNormal\"><span lang=\"PT-BR\">Tel: +351 - 21 425 70 00</span></p>\n<p class=\"MsoNormal\"><span lang=\"PT-BR\">\u00a0</span></p>\n</td>\n</tr>", "ID": "ff04276b-f85d-457f-a929-7d56c01b3713", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "0a577017-8419-45b1-b78f-e2d8c5de4fd9"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">France</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Roche</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">T\u00e9l: +33\u00a0 (0)1 47 61 40 00</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>", "ID": "ee2a7653-6f73-4c1e-a701-950639591a3e", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "ff04276b-f85d-457f-a929-7d56c01b3713"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">France</span></b></p>", "ID": "377d8981-7eb2-41fe-9267-e2ab21ea89bc", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ee2a7653-6f73-4c1e-a701-950639591a3e"}, {"Element": "<b><span lang=\"EN-GB\">France</span></b>", "ID": "8df82fd3-71d3-4b9b-aef7-c489fd199ab4", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "377d8981-7eb2-41fe-9267-e2ab21ea89bc"}, {"Element": "<span lang=\"EN-GB\">France</span>", "ID": "580928bb-5c32-4a98-9e49-81e1b3216724", "Styles": "None", "Classes": "None", "Text": "France", "ParentId": "8df82fd3-71d3-4b9b-aef7-c489fd199ab4"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Roche</span></p>", "ID": "073245e6-9297-4883-9e4b-cd4fbc09c81d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ee2a7653-6f73-4c1e-a701-950639591a3e"}, {"Element": "<span lang=\"EN-GB\">Roche</span>", "ID": "d6d07ad5-d9ef-4740-8dac-cf41a755c44a", "Styles": "None", "Classes": "None", "Text": "Roche", "ParentId": "073245e6-9297-4883-9e4b-cd4fbc09c81d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">T\u00e9l: +33\u00a0 (0)1 47 61 40 00</span></p>", "ID": "0b68a650-4d25-4e27-8e5f-bd80461e45dc", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ee2a7653-6f73-4c1e-a701-950639591a3e"}, {"Element": "<span lang=\"EN-GB\">T\u00e9l: +33\u00a0 (0)1 47 61 40 00</span>", "ID": "8b6eaae7-48ce-4057-b0cc-0cb57cb4710e", "Styles": "None", "Classes": "None", "Text": "T\u00e9l: +33\u00a0 (0)1 47 61 40 00", "ParentId": "0b68a650-4d25-4e27-8e5f-bd80461e45dc"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "d780aca6-4301-4d24-bf00-04032cfcca07", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ee2a7653-6f73-4c1e-a701-950639591a3e"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "9489ca38-c8f4-4fca-b5bd-c996fdf604ec", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d780aca6-4301-4d24-bf00-04032cfcca07"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "fac2f1bb-43b3-4620-9e08-20543cc68617", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9489ca38-c8f4-4fca-b5bd-c996fdf604ec"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"PT-BR\">Portugal</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"PT-BR\">Roche Farmac\u00eautica Qu\u00edmica, Lda</span></p>\n<p class=\"MsoNormal\"><span lang=\"PT-BR\">Tel: +351 - 21 425 70 00</span></p>\n<p class=\"MsoNormal\"><span lang=\"PT-BR\">\u00a0</span></p>\n</td>", "ID": "18c1b1f8-fa4d-4e81-918e-c3841bcdd6d0", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "ff04276b-f85d-457f-a929-7d56c01b3713"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"PT-BR\">Portugal</span></b></p>", "ID": "7efe3222-19f0-4c88-a4d0-f957ebefaeae", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c1b1f8-fa4d-4e81-918e-c3841bcdd6d0"}, {"Element": "<b><span lang=\"PT-BR\">Portugal</span></b>", "ID": "ebea1129-3dce-4208-aab7-17654398f9c0", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "7efe3222-19f0-4c88-a4d0-f957ebefaeae"}, {"Element": "<span lang=\"PT-BR\">Portugal</span>", "ID": "0d904fc1-dbe8-49ca-9cad-207132a4bd86", "Styles": "None", "Classes": "None", "Text": "Portugal", "ParentId": "ebea1129-3dce-4208-aab7-17654398f9c0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"PT-BR\">Roche Farmac\u00eautica Qu\u00edmica, Lda</span></p>", "ID": "d33125c8-cae9-4362-9672-b661506a426f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c1b1f8-fa4d-4e81-918e-c3841bcdd6d0"}, {"Element": "<span lang=\"PT-BR\">Roche Farmac\u00eautica Qu\u00edmica, Lda</span>", "ID": "ba91ff39-ee31-4847-a27a-b253e6811936", "Styles": "None", "Classes": "None", "Text": "Roche Farmac\u00eautica Qu\u00edmica, Lda", "ParentId": "d33125c8-cae9-4362-9672-b661506a426f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"PT-BR\">Tel: +351 - 21 425 70 00</span></p>", "ID": "f3e762e6-ec8a-473c-8213-9eab281e84f0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c1b1f8-fa4d-4e81-918e-c3841bcdd6d0"}, {"Element": "<span lang=\"PT-BR\">Tel: +351 - 21 425 70 00</span>", "ID": "a93e6786-c2db-4b3f-9825-39249f6112d1", "Styles": "None", "Classes": "None", "Text": "Tel: +351 - 21 425 70 00", "ParentId": "f3e762e6-ec8a-473c-8213-9eab281e84f0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"PT-BR\">\u00a0</span></p>", "ID": "e6cad56d-a107-4f5a-b660-314718bcf29e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c1b1f8-fa4d-4e81-918e-c3841bcdd6d0"}, {"Element": "<span lang=\"PT-BR\">\u00a0</span>", "ID": "9ff46ca5-a823-42d4-a289-6833c9b8ed40", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e6cad56d-a107-4f5a-b660-314718bcf29e"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">Hrvatska</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche d.o.o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: + 385 1 47 22 333</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"IT\">Rom\u00e2nia</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Roche Rom\u00e2nia S.R.L.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +40 21 206 47 01</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "d4670ef5-9201-4068-9025-a6422d063c62", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "0a577017-8419-45b1-b78f-e2d8c5de4fd9"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">Hrvatska</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche d.o.o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: + 385 1 47 22 333</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "8b80fad9-283f-4768-a024-7e6750de8047", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "d4670ef5-9201-4068-9025-a6422d063c62"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">Hrvatska</span></b></p>", "ID": "556601d0-4537-4722-8bd5-3fd60c901464", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8b80fad9-283f-4768-a024-7e6750de8047"}, {"Element": "<b><span lang=\"DE-CH\">Hrvatska</span></b>", "ID": "42527d5e-97df-4c13-b793-01e11f7ea431", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "556601d0-4537-4722-8bd5-3fd60c901464"}, {"Element": "<span lang=\"DE-CH\">Hrvatska</span>", "ID": "10748847-da2b-401c-8903-5b3467b3ca61", "Styles": "None", "Classes": "None", "Text": "Hrvatska", "ParentId": "42527d5e-97df-4c13-b793-01e11f7ea431"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche d.o.o.</span></p>", "ID": "e1d659c2-bff0-4925-8932-525f7219feaa", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8b80fad9-283f-4768-a024-7e6750de8047"}, {"Element": "<span lang=\"DE-CH\">Roche d.o.o.</span>", "ID": "9a7897c8-4528-4200-9393-f20f6c49bb4f", "Styles": "None", "Classes": "None", "Text": "Roche d.o.o.", "ParentId": "e1d659c2-bff0-4925-8932-525f7219feaa"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: + 385 1 47 22 333</span></p>", "ID": "b0d6e02e-364c-4f25-880a-6ecf23b218b9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8b80fad9-283f-4768-a024-7e6750de8047"}, {"Element": "<span lang=\"EN-GB\">Tel: + 385 1 47 22 333</span>", "ID": "170e83cf-1d05-4665-9775-f5d6f90e4b58", "Styles": "None", "Classes": "None", "Text": "Tel: + 385 1 47 22 333", "ParentId": "b0d6e02e-364c-4f25-880a-6ecf23b218b9"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "492ae254-db62-4ade-b101-00bca06e2d65", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8b80fad9-283f-4768-a024-7e6750de8047"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0d37a81c-ce4c-4b8d-819e-cfe7b23cb94d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "492ae254-db62-4ade-b101-00bca06e2d65"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"IT\">Rom\u00e2nia</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Roche Rom\u00e2nia S.R.L.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +40 21 206 47 01</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "dcf74db3-b8c7-4368-9abc-9d3d78b225c7", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "d4670ef5-9201-4068-9025-a6422d063c62"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"IT\">Rom\u00e2nia</span></b></p>", "ID": "254e20e8-bc9f-449f-be7b-90a64e27eab3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "dcf74db3-b8c7-4368-9abc-9d3d78b225c7"}, {"Element": "<b><span lang=\"IT\">Rom\u00e2nia</span></b>", "ID": "85883f49-7a47-47be-b98f-a9ac51dca1dd", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "254e20e8-bc9f-449f-be7b-90a64e27eab3"}, {"Element": "<span lang=\"IT\">Rom\u00e2nia</span>", "ID": "8e2b0d7c-3051-4940-8c6b-ee00db069b6b", "Styles": "None", "Classes": "None", "Text": "Rom\u00e2nia", "ParentId": "85883f49-7a47-47be-b98f-a9ac51dca1dd"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"IT\">Roche Rom\u00e2nia S.R.L.</span></p>", "ID": "7ad4fe38-d528-49f7-8131-3f807bd4942c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "dcf74db3-b8c7-4368-9abc-9d3d78b225c7"}, {"Element": "<span lang=\"IT\">Roche Rom\u00e2nia S.R.L.</span>", "ID": "a540f6bf-9009-4c17-9245-591fe2bcd50d", "Styles": "None", "Classes": "None", "Text": "Roche Rom\u00e2nia S.R.L.", "ParentId": "7ad4fe38-d528-49f7-8131-3f807bd4942c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +40 21 206 47 01</span></p>", "ID": "4d739a7d-507c-4aaf-869d-804c83313484", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "dcf74db3-b8c7-4368-9abc-9d3d78b225c7"}, {"Element": "<span lang=\"EN-GB\">Tel: +40 21 206 47 01</span>", "ID": "9a8070f3-4ec2-4c1b-b8d2-84b68a72ad95", "Styles": "None", "Classes": "None", "Text": "Tel: +40 21 206 47 01", "ParentId": "4d739a7d-507c-4aaf-869d-804c83313484"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9cfe27a9-83f3-4a2d-a776-5646d76c2318", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "dcf74db3-b8c7-4368-9abc-9d3d78b225c7"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "436a0197-8e71-42f7-9b22-4787cb0454c7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9cfe27a9-83f3-4a2d-a776-5646d76c2318"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Ireland</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Roche Products (Ireland) Ltd.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +353 (0) 1 469 0700</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Slovenija</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Roche farmacevtska dru\u017eba d.o.o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +386 - 1 360 26 00</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n</tr>", "ID": "4e73e5bb-fa37-4151-bac4-5066572ecec8", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "0a577017-8419-45b1-b78f-e2d8c5de4fd9"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Ireland</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Roche Products (Ireland) Ltd.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +353 (0) 1 469 0700</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>", "ID": "d7d23058-a9f0-40b9-9966-0245ee56996e", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "4e73e5bb-fa37-4151-bac4-5066572ecec8"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Ireland</span></b></p>", "ID": "431e5d37-f582-4616-828d-521a83d919e2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7d23058-a9f0-40b9-9966-0245ee56996e"}, {"Element": "<b><span lang=\"EN-GB\">Ireland</span></b>", "ID": "41b6f490-5478-4f0f-b597-dd42f4181cb6", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "431e5d37-f582-4616-828d-521a83d919e2"}, {"Element": "<span lang=\"EN-GB\">Ireland</span>", "ID": "e6a63d6e-9f10-4983-a655-9d90a7bd5f22", "Styles": "None", "Classes": "None", "Text": "Ireland", "ParentId": "41b6f490-5478-4f0f-b597-dd42f4181cb6"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Roche Products (Ireland) Ltd.</span></p>", "ID": "a1c589b3-28e0-4ed6-a6d7-a4449b2b6656", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7d23058-a9f0-40b9-9966-0245ee56996e"}, {"Element": "<span lang=\"EN-GB\">Roche Products (Ireland) Ltd.</span>", "ID": "7eb0a115-b669-4ee3-bd5f-14da9bc9e0de", "Styles": "None", "Classes": "None", "Text": "Roche Products (Ireland) Ltd.", "ParentId": "a1c589b3-28e0-4ed6-a6d7-a4449b2b6656"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +353 (0) 1 469 0700</span></p>", "ID": "bebb3cd9-a24e-4145-a053-f1b109a83729", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7d23058-a9f0-40b9-9966-0245ee56996e"}, {"Element": "<span lang=\"EN-GB\">Tel: +353 (0) 1 469 0700</span>", "ID": "259d3676-95e7-47e2-8d99-a2125db67ff9", "Styles": "None", "Classes": "None", "Text": "Tel: +353 (0) 1 469 0700", "ParentId": "bebb3cd9-a24e-4145-a053-f1b109a83729"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "441dbc11-2a40-4987-89b3-305be7c0f993", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7d23058-a9f0-40b9-9966-0245ee56996e"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "6bd6a0fe-096e-4e97-89d2-f27c768769bd", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "441dbc11-2a40-4987-89b3-305be7c0f993"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f605b9f8-0638-4c72-acf1-291ba335f65a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6bd6a0fe-096e-4e97-89d2-f27c768769bd"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Slovenija</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Roche farmacevtska dru\u017eba d.o.o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +386 - 1 360 26 00</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>", "ID": "dbbbfeb8-9f46-49a9-ad70-affea63a20fe", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "4e73e5bb-fa37-4151-bac4-5066572ecec8"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Slovenija</span></b></p>", "ID": "6c82d9b7-a461-4fe2-a45d-51f5c225047a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "dbbbfeb8-9f46-49a9-ad70-affea63a20fe"}, {"Element": "<b><span lang=\"EN-GB\">Slovenija</span></b>", "ID": "bdaf0446-3368-4575-927e-31a0dbb1ca5d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "6c82d9b7-a461-4fe2-a45d-51f5c225047a"}, {"Element": "<span lang=\"EN-GB\">Slovenija</span>", "ID": "abf70c21-20a4-4c98-88f2-d453cbcfafd3", "Styles": "None", "Classes": "None", "Text": "Slovenija", "ParentId": "bdaf0446-3368-4575-927e-31a0dbb1ca5d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Roche farmacevtska dru\u017eba d.o.o.</span></p>", "ID": "3906ea83-3c89-4419-8f08-ef8f3923f217", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "dbbbfeb8-9f46-49a9-ad70-affea63a20fe"}, {"Element": "<span lang=\"EN-GB\">Roche farmacevtska dru\u017eba d.o.o.</span>", "ID": "ef13f235-2706-4b6a-92b4-29101a570b97", "Styles": "None", "Classes": "None", "Text": "Roche farmacevtska dru\u017eba d.o.o.", "ParentId": "3906ea83-3c89-4419-8f08-ef8f3923f217"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +386 - 1 360 26 00</span></p>", "ID": "ba9ca8e7-a9e6-483b-9fab-cc39b93d54b3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "dbbbfeb8-9f46-49a9-ad70-affea63a20fe"}, {"Element": "<span lang=\"EN-GB\">Tel: +386 - 1 360 26 00</span>", "ID": "9aba3183-06c3-4fc1-ac51-62f64fffcc0a", "Styles": "None", "Classes": "None", "Text": "Tel: +386 - 1 360 26 00", "ParentId": "ba9ca8e7-a9e6-483b-9fab-cc39b93d54b3"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "35b470c7-aba1-4e74-86ce-15f47f96f5da", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "dbbbfeb8-9f46-49a9-ad70-affea63a20fe"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "00072dd3-5b7e-4673-aa91-cf240af3802c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "35b470c7-aba1-4e74-86ce-15f47f96f5da"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "eabbaae4-6435-42b6-921c-7737a394f01c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "00072dd3-5b7e-4673-aa91-cf240af3802c"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"PT-BR\">\u00cdsland </span></b></p>\n<p class=\"MsoNormal\"><span lang=\"PT-BR\">Roche a/s</span></p>\n<p class=\"MsoNormal\"><span lang=\"PT-BR\">c/o Icepharma hf</span></p>\n<p class=\"MsoNormal\"><span lang=\"PT-BR\">S\u00edmi: +354 540 8000</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"PT-BR\">\u00a0</span></b></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DA\">Slovensk\u00e1 republika </span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DA\">Roche Slovensko, s.r.o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +421 - 2 52638201</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "e230ae66-2c93-4374-b6e4-4e464123a314", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "0a577017-8419-45b1-b78f-e2d8c5de4fd9"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"PT-BR\">\u00cdsland </span></b></p>\n<p class=\"MsoNormal\"><span lang=\"PT-BR\">Roche a/s</span></p>\n<p class=\"MsoNormal\"><span lang=\"PT-BR\">c/o Icepharma hf</span></p>\n<p class=\"MsoNormal\"><span lang=\"PT-BR\">S\u00edmi: +354 540 8000</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"PT-BR\">\u00a0</span></b></p>\n</td>", "ID": "eec5a1bb-41be-41ad-aa4b-844f921457c1", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "      ", "ParentId": "e230ae66-2c93-4374-b6e4-4e464123a314"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"PT-BR\">\u00cdsland </span></b></p>", "ID": "47dd8c2a-f5f5-4642-b899-02a2d68c627d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "eec5a1bb-41be-41ad-aa4b-844f921457c1"}, {"Element": "<b><span lang=\"PT-BR\">\u00cdsland </span></b>", "ID": "c4b5c87b-244a-431d-a5bb-234c77c88930", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "47dd8c2a-f5f5-4642-b899-02a2d68c627d"}, {"Element": "<span lang=\"PT-BR\">\u00cdsland </span>", "ID": "571945c2-2bcc-4a89-9f31-4381bf3d30cf", "Styles": "None", "Classes": "None", "Text": "\u00cdsland ", "ParentId": "c4b5c87b-244a-431d-a5bb-234c77c88930"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"PT-BR\">Roche a/s</span></p>", "ID": "f6b69e2f-e91f-4afe-9738-5e934ff6181b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "eec5a1bb-41be-41ad-aa4b-844f921457c1"}, {"Element": "<span lang=\"PT-BR\">Roche a/s</span>", "ID": "7f9ae40e-ed23-4435-8d45-63ad42db794d", "Styles": "None", "Classes": "None", "Text": "Roche a/s", "ParentId": "f6b69e2f-e91f-4afe-9738-5e934ff6181b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"PT-BR\">c/o Icepharma hf</span></p>", "ID": "a52206cc-60d0-45ef-b4da-a68858ef2c16", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "eec5a1bb-41be-41ad-aa4b-844f921457c1"}, {"Element": "<span lang=\"PT-BR\">c/o Icepharma hf</span>", "ID": "4e4f787b-c5ae-4ae3-aaed-9d4ec278e3d3", "Styles": "None", "Classes": "None", "Text": "c/o Icepharma hf", "ParentId": "a52206cc-60d0-45ef-b4da-a68858ef2c16"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"PT-BR\">S\u00edmi: +354 540 8000</span></p>", "ID": "4dbd202a-249c-4798-a8d9-7797499ff6b0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "eec5a1bb-41be-41ad-aa4b-844f921457c1"}, {"Element": "<span lang=\"PT-BR\">S\u00edmi: +354 540 8000</span>", "ID": "d2a0756e-5c6b-466f-97ac-8ae45effacec", "Styles": "None", "Classes": "None", "Text": "S\u00edmi: +354 540 8000", "ParentId": "4dbd202a-249c-4798-a8d9-7797499ff6b0"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"PT-BR\">\u00a0</span></b></p>", "ID": "eb929d3f-a75b-4782-934f-c7e9a3339829", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "eec5a1bb-41be-41ad-aa4b-844f921457c1"}, {"Element": "<b><span lang=\"PT-BR\">\u00a0</span></b>", "ID": "bc9d1601-1790-41d8-adb8-a2ed32761406", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "eb929d3f-a75b-4782-934f-c7e9a3339829"}, {"Element": "<span lang=\"PT-BR\">\u00a0</span>", "ID": "f8f89307-e9e3-4ff0-86b1-b330af3c8988", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "bc9d1601-1790-41d8-adb8-a2ed32761406"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DA\">Slovensk\u00e1 republika </span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DA\">Roche Slovensko, s.r.o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +421 - 2 52638201</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "0a722e31-af2f-4f2a-b79b-0a327b87bf31", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "e230ae66-2c93-4374-b6e4-4e464123a314"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"DA\">Slovensk\u00e1 republika </span></b></p>", "ID": "e016bc77-6d21-4ab8-9bf1-2a832efb5122", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0a722e31-af2f-4f2a-b79b-0a327b87bf31"}, {"Element": "<b><span lang=\"DA\">Slovensk\u00e1 republika </span></b>", "ID": "b8d6d4db-7b63-476f-bfc1-1618de2ecdc9", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e016bc77-6d21-4ab8-9bf1-2a832efb5122"}, {"Element": "<span lang=\"DA\">Slovensk\u00e1 republika </span>", "ID": "6cf4c984-8825-49b2-8d4f-291028758cb0", "Styles": "None", "Classes": "None", "Text": "Slovensk\u00e1 republika ", "ParentId": "b8d6d4db-7b63-476f-bfc1-1618de2ecdc9"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DA\">Roche Slovensko, s.r.o.</span></p>", "ID": "9a1aa8af-8662-48d1-8de0-df0d1df6fe93", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0a722e31-af2f-4f2a-b79b-0a327b87bf31"}, {"Element": "<span lang=\"DA\">Roche Slovensko, s.r.o.</span>", "ID": "fbfdc08d-edbb-4e00-9cb8-8d3ddd0d01e5", "Styles": "None", "Classes": "None", "Text": "Roche Slovensko, s.r.o.", "ParentId": "9a1aa8af-8662-48d1-8de0-df0d1df6fe93"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +421 - 2 52638201</span></p>", "ID": "0b924ead-44ca-4142-8ae8-db10db45aca1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0a722e31-af2f-4f2a-b79b-0a327b87bf31"}, {"Element": "<span lang=\"EN-GB\">Tel: +421 - 2 52638201</span>", "ID": "2c60fee7-0ece-4a77-972a-f9cdd55ce871", "Styles": "None", "Classes": "None", "Text": "Tel: +421 - 2 52638201", "ParentId": "0b924ead-44ca-4142-8ae8-db10db45aca1"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "336c6004-5544-4277-b5f6-d7e8a1e7c3f0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0a722e31-af2f-4f2a-b79b-0a327b87bf31"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ef049c29-7b71-42f8-9e8d-8736dc3536e8", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "336c6004-5544-4277-b5f6-d7e8a1e7c3f0"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"IT\">Italia</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Roche S.p.A.</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Tel: +39 - 039 2471</span></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">Suomi/Finland</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche Oy<span style=\"layout-grid-mode:\n  line\"> </span></span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Puh/Tel: +358 (0) 10 554 500</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">\u00a0</span></p>\n</td>\n</tr>", "ID": "e7f98990-2e11-42c9-9eab-9a249d74396d", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "0a577017-8419-45b1-b78f-e2d8c5de4fd9"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"IT\">Italia</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Roche S.p.A.</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Tel: +39 - 039 2471</span></p>\n</td>", "ID": "ec0ad380-6fad-43dd-be87-9cded064ad4b", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "    ", "ParentId": "e7f98990-2e11-42c9-9eab-9a249d74396d"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"IT\">Italia</span></b></p>", "ID": "3e2e359d-7ad7-475c-a494-3e79ffd8a668", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ec0ad380-6fad-43dd-be87-9cded064ad4b"}, {"Element": "<b><span lang=\"IT\">Italia</span></b>", "ID": "36ca26bd-6162-4647-9c71-5b8bdd3684f2", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3e2e359d-7ad7-475c-a494-3e79ffd8a668"}, {"Element": "<span lang=\"IT\">Italia</span>", "ID": "33702a63-6332-4162-a674-465cc8dcd6df", "Styles": "None", "Classes": "None", "Text": "Italia", "ParentId": "36ca26bd-6162-4647-9c71-5b8bdd3684f2"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"IT\">Roche S.p.A.</span></p>", "ID": "7063aff0-569a-45d6-836f-7329ee816ca2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ec0ad380-6fad-43dd-be87-9cded064ad4b"}, {"Element": "<span lang=\"IT\">Roche S.p.A.</span>", "ID": "12fe5880-c5c0-48ab-be83-b0f5d9d282f4", "Styles": "None", "Classes": "None", "Text": "Roche S.p.A.", "ParentId": "7063aff0-569a-45d6-836f-7329ee816ca2"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE-CH\">Tel: +39 - 039 2471</span></p>", "ID": "f0406581-6853-48aa-b8f0-aaa00061a4b4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ec0ad380-6fad-43dd-be87-9cded064ad4b"}, {"Element": "<span lang=\"DE-CH\">Tel: +39 - 039 2471</span>", "ID": "fd9ca692-cee9-4942-98b7-89781e51f902", "Styles": "None", "Classes": "None", "Text": "Tel: +39 - 039 2471", "ParentId": "f0406581-6853-48aa-b8f0-aaa00061a4b4"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">Suomi/Finland</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche Oy<span style=\"layout-grid-mode:\n  line\"> </span></span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Puh/Tel: +358 (0) 10 554 500</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">\u00a0</span></p>\n</td>", "ID": "fd774825-10d4-4474-b363-e183f6ab8e42", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "e7f98990-2e11-42c9-9eab-9a249d74396d"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">Suomi/Finland</span></b></p>", "ID": "2b705fb2-8ca8-4da6-9139-0dbf181597cc", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "fd774825-10d4-4474-b363-e183f6ab8e42"}, {"Element": "<b><span lang=\"DE-CH\">Suomi/Finland</span></b>", "ID": "ef2def96-5377-4e2e-8767-f86502e2c8de", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "2b705fb2-8ca8-4da6-9139-0dbf181597cc"}, {"Element": "<span lang=\"DE-CH\">Suomi/Finland</span>", "ID": "36e7fc08-4e8d-4898-b676-646e08c3a17e", "Styles": "None", "Classes": "None", "Text": "Suomi/Finland", "ParentId": "ef2def96-5377-4e2e-8767-f86502e2c8de"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche Oy<span style=\"layout-grid-mode:\n  line\"> </span></span></p>", "ID": "df34b423-18e4-4588-a4b5-ea276540983d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "fd774825-10d4-4474-b363-e183f6ab8e42"}, {"Element": "<span lang=\"DE-CH\">Roche Oy<span style=\"layout-grid-mode:\n  line\"> </span></span>", "ID": "d1e5994e-723f-48f1-bc6e-a2a16337a426", "Styles": "None", "Classes": "None", "Text": "Roche Oy", "ParentId": "df34b423-18e4-4588-a4b5-ea276540983d"}, {"Element": "<span style=\"layout-grid-mode:\n  line\"> </span>", "ID": "13a68e51-97ff-4133-a8b2-36edfb6d8d33", "Styles": "layout-grid-mode:\n  line", "Classes": "None", "Text": " ", "ParentId": "d1e5994e-723f-48f1-bc6e-a2a16337a426"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE-CH\">Puh/Tel: +358 (0) 10 554 500</span></p>", "ID": "425638f1-f006-4c2f-acbe-55a2f8ff4148", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "fd774825-10d4-4474-b363-e183f6ab8e42"}, {"Element": "<span lang=\"DE-CH\">Puh/Tel: +358 (0) 10 554 500</span>", "ID": "e603d60d-a081-4763-b4e6-86c37fa99143", "Styles": "None", "Classes": "None", "Text": "Puh/Tel: +358 (0) 10 554 500", "ParentId": "425638f1-f006-4c2f-acbe-55a2f8ff4148"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE-CH\">\u00a0</span></p>", "ID": "e29b6410-3e2e-4ccc-8112-3560bd651267", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "fd774825-10d4-4474-b363-e183f6ab8e42"}, {"Element": "<span lang=\"DE-CH\">\u00a0</span>", "ID": "17be7072-c112-46ad-8419-9ecc18d8519d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e29b6410-3e2e-4ccc-8112-3560bd651267"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">K</span></b><b><span lang=\"EN-GB\">\u03cd\u03c0\u03c1\u03bf\u03c2</span></b><span lang=\"EN-GB\" style=\"font-size:10.0pt\"> </span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u0393</span><span lang=\"DE-CH\">.</span><span lang=\"EN-GB\">\u0391</span><span lang=\"DE-CH\">.</span><span lang=\"EN-GB\">\u03a3\u03c4\u03b1\u03bc\u03ac\u03c4\u03b7\u03c2</span><span lang=\"DE-CH\"> &amp; </span><span lang=\"EN-GB\">\u03a3\u03b9\u03b1</span><span lang=\"EN-GB\"> </span><span lang=\"EN-GB\">\u039b\u03c4\u03b4</span><span lang=\"DE-CH\">.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u03a4\u03b7\u03bb: +357 - 22 76 62 76</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Sverige</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Roche AB</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +46 (0) 8 726 1200</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "74b3eefd-1e36-4326-b41d-5acceb0c1738", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "0a577017-8419-45b1-b78f-e2d8c5de4fd9"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">K</span></b><b><span lang=\"EN-GB\">\u03cd\u03c0\u03c1\u03bf\u03c2</span></b><span lang=\"EN-GB\" style=\"font-size:10.0pt\"> </span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u0393</span><span lang=\"DE-CH\">.</span><span lang=\"EN-GB\">\u0391</span><span lang=\"DE-CH\">.</span><span lang=\"EN-GB\">\u03a3\u03c4\u03b1\u03bc\u03ac\u03c4\u03b7\u03c2</span><span lang=\"DE-CH\"> &amp; </span><span lang=\"EN-GB\">\u03a3\u03b9\u03b1</span><span lang=\"EN-GB\"> </span><span lang=\"EN-GB\">\u039b\u03c4\u03b4</span><span lang=\"DE-CH\">.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u03a4\u03b7\u03bb: +357 - 22 76 62 76</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>", "ID": "3212349e-87e4-4334-9e9c-c60a74fb0d11", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "74b3eefd-1e36-4326-b41d-5acceb0c1738"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">K</span></b><b><span lang=\"EN-GB\">\u03cd\u03c0\u03c1\u03bf\u03c2</span></b><span lang=\"EN-GB\" style=\"font-size:10.0pt\"> </span></p>", "ID": "8bd79dde-7c25-42d5-8c4b-3356c2e15b0a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "3212349e-87e4-4334-9e9c-c60a74fb0d11"}, {"Element": "<b><span lang=\"DE-CH\">K</span></b>", "ID": "744d24a5-fcac-47f7-b80f-0460a9628607", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8bd79dde-7c25-42d5-8c4b-3356c2e15b0a"}, {"Element": "<span lang=\"DE-CH\">K</span>", "ID": "206eb1b9-f43e-42d7-997b-3731350d39c6", "Styles": "None", "Classes": "None", "Text": "K", "ParentId": "744d24a5-fcac-47f7-b80f-0460a9628607"}, {"Element": "<b><span lang=\"EN-GB\">\u03cd\u03c0\u03c1\u03bf\u03c2</span></b>", "ID": "f25953a2-eae9-4cf5-a089-bfa13fb054e2", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8bd79dde-7c25-42d5-8c4b-3356c2e15b0a"}, {"Element": "<span lang=\"EN-GB\">\u03cd\u03c0\u03c1\u03bf\u03c2</span>", "ID": "54a887c7-5234-4124-b2b8-e03487a40c3d", "Styles": "None", "Classes": "None", "Text": "\u03cd\u03c0\u03c1\u03bf\u03c2", "ParentId": "f25953a2-eae9-4cf5-a089-bfa13fb054e2"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\"> </span>", "ID": "af2af594-42e7-4397-8ff4-6c07b7a1ba7f", "Styles": "font-size:10.0pt", "Classes": "None", "Text": " ", "ParentId": "8bd79dde-7c25-42d5-8c4b-3356c2e15b0a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u0393</span><span lang=\"DE-CH\">.</span><span lang=\"EN-GB\">\u0391</span><span lang=\"DE-CH\">.</span><span lang=\"EN-GB\">\u03a3\u03c4\u03b1\u03bc\u03ac\u03c4\u03b7\u03c2</span><span lang=\"DE-CH\"> &amp; </span><span lang=\"EN-GB\">\u03a3\u03b9\u03b1</span><span lang=\"EN-GB\"> </span><span lang=\"EN-GB\">\u039b\u03c4\u03b4</span><span lang=\"DE-CH\">.</span></p>", "ID": "fdd656be-1edf-4c3c-9fb6-65f1373aa1e4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "3212349e-87e4-4334-9e9c-c60a74fb0d11"}, {"Element": "<span lang=\"EN-GB\">\u0393</span>", "ID": "9f59c693-d14b-49ab-8b7e-a5af46ef5ba7", "Styles": "None", "Classes": "None", "Text": "\u0393", "ParentId": "fdd656be-1edf-4c3c-9fb6-65f1373aa1e4"}, {"Element": "<span lang=\"DE-CH\">.</span>", "ID": "d033398c-f251-4d45-8d82-edf3fe33eacf", "Styles": "None", "Classes": "None", "Text": ".", "ParentId": "fdd656be-1edf-4c3c-9fb6-65f1373aa1e4"}, {"Element": "<span lang=\"EN-GB\">\u0391</span>", "ID": "1bb72be9-00c6-4603-963b-f076a0eb7aa7", "Styles": "None", "Classes": "None", "Text": "\u0391", "ParentId": "fdd656be-1edf-4c3c-9fb6-65f1373aa1e4"}, {"Element": "<span lang=\"DE-CH\">.</span>", "ID": "9536f583-9958-44c6-b8cd-966923f462b1", "Styles": "None", "Classes": "None", "Text": ".", "ParentId": "fdd656be-1edf-4c3c-9fb6-65f1373aa1e4"}, {"Element": "<span lang=\"EN-GB\">\u03a3\u03c4\u03b1\u03bc\u03ac\u03c4\u03b7\u03c2</span>", "ID": "69f36458-177c-4a7b-a157-8276ca520122", "Styles": "None", "Classes": "None", "Text": "\u03a3\u03c4\u03b1\u03bc\u03ac\u03c4\u03b7\u03c2", "ParentId": "fdd656be-1edf-4c3c-9fb6-65f1373aa1e4"}, {"Element": "<span lang=\"DE-CH\"> &amp; </span>", "ID": "006f035e-ae97-4a9f-b390-f321176ff41c", "Styles": "None", "Classes": "None", "Text": " & ", "ParentId": "fdd656be-1edf-4c3c-9fb6-65f1373aa1e4"}, {"Element": "<span lang=\"EN-GB\">\u03a3\u03b9\u03b1</span>", "ID": "bc752a02-b0fe-48f1-a8f6-5848edab0f51", "Styles": "None", "Classes": "None", "Text": "\u03a3\u03b9\u03b1", "ParentId": "fdd656be-1edf-4c3c-9fb6-65f1373aa1e4"}, {"Element": "<span lang=\"EN-GB\"> </span>", "ID": "72f84621-142c-4bee-b5a8-0e114f324f57", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "fdd656be-1edf-4c3c-9fb6-65f1373aa1e4"}, {"Element": "<span lang=\"EN-GB\">\u039b\u03c4\u03b4</span>", "ID": "ed9f74da-354f-4b65-b912-1c09b8d0e700", "Styles": "None", "Classes": "None", "Text": "\u039b\u03c4\u03b4", "ParentId": "fdd656be-1edf-4c3c-9fb6-65f1373aa1e4"}, {"Element": "<span lang=\"DE-CH\">.</span>", "ID": "e36a674e-2aa7-4c4f-91e3-1f4481fe68cc", "Styles": "None", "Classes": "None", "Text": ".", "ParentId": "fdd656be-1edf-4c3c-9fb6-65f1373aa1e4"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u03a4\u03b7\u03bb: +357 - 22 76 62 76</span></p>", "ID": "7a0be3a1-15cd-4299-89d7-a8804a85e9ef", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "3212349e-87e4-4334-9e9c-c60a74fb0d11"}, {"Element": "<span lang=\"EN-GB\">\u03a4\u03b7\u03bb: +357 - 22 76 62 76</span>", "ID": "ecaaa72b-5a37-484a-8035-51c57d5d517c", "Styles": "None", "Classes": "None", "Text": "\u03a4\u03b7\u03bb: +357 - 22 76 62 76", "ParentId": "7a0be3a1-15cd-4299-89d7-a8804a85e9ef"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "13302991-ae9a-4f0f-bae1-1daabcde384f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "3212349e-87e4-4334-9e9c-c60a74fb0d11"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "82757220-73b6-4f0d-924e-5ad63171b632", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "13302991-ae9a-4f0f-bae1-1daabcde384f"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "22b054b8-4ec5-4488-b495-b1666a6b60bb", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "82757220-73b6-4f0d-924e-5ad63171b632"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Sverige</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Roche AB</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +46 (0) 8 726 1200</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "20cd7efe-6ce8-4e2a-b9cd-7c8e89f33cee", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "74b3eefd-1e36-4326-b41d-5acceb0c1738"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Sverige</span></b></p>", "ID": "62a88597-dfe5-45c2-a0df-998252914a7a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "20cd7efe-6ce8-4e2a-b9cd-7c8e89f33cee"}, {"Element": "<b><span lang=\"EN-GB\">Sverige</span></b>", "ID": "c4ad3c0a-db3c-464f-a90e-96e873b4cc06", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "62a88597-dfe5-45c2-a0df-998252914a7a"}, {"Element": "<span lang=\"EN-GB\">Sverige</span>", "ID": "f6d703ae-3ca3-4827-b688-937ee2a3d36d", "Styles": "None", "Classes": "None", "Text": "Sverige", "ParentId": "c4ad3c0a-db3c-464f-a90e-96e873b4cc06"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Roche AB</span></p>", "ID": "1f168ee9-b6c9-4d2d-a5d9-0ba8f2ae0b16", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "20cd7efe-6ce8-4e2a-b9cd-7c8e89f33cee"}, {"Element": "<span lang=\"EN-GB\">Roche AB</span>", "ID": "3c2dec83-81c3-475d-940d-7d47caec64b0", "Styles": "None", "Classes": "None", "Text": "Roche AB", "ParentId": "1f168ee9-b6c9-4d2d-a5d9-0ba8f2ae0b16"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +46 (0) 8 726 1200</span></p>", "ID": "72fea00a-5eb9-4b64-b83d-5ee3e7327eab", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "20cd7efe-6ce8-4e2a-b9cd-7c8e89f33cee"}, {"Element": "<span lang=\"EN-GB\">Tel: +46 (0) 8 726 1200</span>", "ID": "105046d4-2df3-438a-9a79-455950dcc1da", "Styles": "None", "Classes": "None", "Text": "Tel: +46 (0) 8 726 1200", "ParentId": "72fea00a-5eb9-4b64-b83d-5ee3e7327eab"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "72b934ec-c0c8-4595-b4cc-535d6ed7535c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "20cd7efe-6ce8-4e2a-b9cd-7c8e89f33cee"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ace83427-93d6-464e-b3cf-11abc213ae14", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "72b934ec-c0c8-4595-b4cc-535d6ed7535c"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"IT\">Latvija</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Roche Latvija SIA</span></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Tel: +371 - 6 7039831</span></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">United Kingdom</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Roche Products Ltd.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +44 (0) 1707 366000</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "41f0c84a-53c2-4fad-bbb2-39500a1ea28a", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "0a577017-8419-45b1-b78f-e2d8c5de4fd9"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"IT\">Latvija</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Roche Latvija SIA</span></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Tel: +371 - 6 7039831</span></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">\u00a0</span></p>\n</td>", "ID": "bab51b8b-2143-49b0-8dda-889921a9b9c7", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "41f0c84a-53c2-4fad-bbb2-39500a1ea28a"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"IT\">Latvija</span></b></p>", "ID": "dea190e6-e6fa-422c-be3e-dd48213f250c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "bab51b8b-2143-49b0-8dda-889921a9b9c7"}, {"Element": "<b><span lang=\"IT\">Latvija</span></b>", "ID": "c3af8503-c33a-4c5c-88be-8d2ac5b0507b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "dea190e6-e6fa-422c-be3e-dd48213f250c"}, {"Element": "<span lang=\"IT\">Latvija</span>", "ID": "b20794c7-0bb9-453a-ab72-7ef141b25a65", "Styles": "None", "Classes": "None", "Text": "Latvija", "ParentId": "c3af8503-c33a-4c5c-88be-8d2ac5b0507b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"IT\">Roche Latvija SIA</span></p>", "ID": "7e82eae6-6740-475b-82a2-582715ffa048", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "bab51b8b-2143-49b0-8dda-889921a9b9c7"}, {"Element": "<span lang=\"IT\">Roche Latvija SIA</span>", "ID": "e95e0d91-078f-4a03-9950-73dd4964fac9", "Styles": "None", "Classes": "None", "Text": "Roche Latvija SIA", "ParentId": "7e82eae6-6740-475b-82a2-582715ffa048"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"IT\">Tel: +371 - 6 7039831</span></p>", "ID": "df185854-12f7-440e-8cb3-aa9f59635823", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "bab51b8b-2143-49b0-8dda-889921a9b9c7"}, {"Element": "<span lang=\"IT\">Tel: +371 - 6 7039831</span>", "ID": "33252d37-f365-4d34-99cd-7e0aff389936", "Styles": "None", "Classes": "None", "Text": "Tel: +371 - 6 7039831", "ParentId": "df185854-12f7-440e-8cb3-aa9f59635823"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"IT\">\u00a0</span></p>", "ID": "25a6cb6a-68fc-421e-b0dd-73d2c7dea2ac", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "bab51b8b-2143-49b0-8dda-889921a9b9c7"}, {"Element": "<span lang=\"IT\">\u00a0</span>", "ID": "231ab196-1b28-4f60-85b0-cd798919a622", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "25a6cb6a-68fc-421e-b0dd-73d2c7dea2ac"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">United Kingdom</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Roche Products Ltd.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +44 (0) 1707 366000</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "0a62e62d-ad2b-4b2d-b498-3cef68216f63", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "41f0c84a-53c2-4fad-bbb2-39500a1ea28a"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">United Kingdom</span></b></p>", "ID": "18a1518c-6881-4f76-9163-000736b9219b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0a62e62d-ad2b-4b2d-b498-3cef68216f63"}, {"Element": "<b><span lang=\"EN-GB\">United Kingdom</span></b>", "ID": "7d48a411-7cc3-428b-bbce-45b5f35121be", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "18a1518c-6881-4f76-9163-000736b9219b"}, {"Element": "<span lang=\"EN-GB\">United Kingdom</span>", "ID": "5ba34201-0741-4f8e-bca3-d5f5a33b85be", "Styles": "None", "Classes": "None", "Text": "United Kingdom", "ParentId": "7d48a411-7cc3-428b-bbce-45b5f35121be"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Roche Products Ltd.</span></p>", "ID": "0f958fbd-c383-4d98-bcd1-95e2e6144dff", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0a62e62d-ad2b-4b2d-b498-3cef68216f63"}, {"Element": "<span lang=\"EN-GB\">Roche Products Ltd.</span>", "ID": "feee4505-ca48-4e1c-b19d-eb65dbf132fc", "Styles": "None", "Classes": "None", "Text": "Roche Products Ltd.", "ParentId": "0f958fbd-c383-4d98-bcd1-95e2e6144dff"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +44 (0) 1707 366000</span></p>", "ID": "4a802d0e-f2e8-4447-94be-9b808cd4999d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0a62e62d-ad2b-4b2d-b498-3cef68216f63"}, {"Element": "<span lang=\"EN-GB\">Tel: +44 (0) 1707 366000</span>", "ID": "c2d68ad7-0d5c-4ada-be85-67031842824f", "Styles": "None", "Classes": "None", "Text": "Tel: +44 (0) 1707 366000", "ParentId": "4a802d0e-f2e8-4447-94be-9b808cd4999d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b7d08e59-526b-4bbf-8e3a-e7f773e74f3d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0a62e62d-ad2b-4b2d-b498-3cef68216f63"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "59cc4adf-39ad-4cdd-ad09-aa1593c306e2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b7d08e59-526b-4bbf-8e3a-e7f773e74f3d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "55de1976-cef8-4b12-8c0e-1719627b2579", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "06eddb74-91ef-4bd3-9cf5-bf31d04f8ecf", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "55de1976-cef8-4b12-8c0e-1719627b2579"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">This\nleaflet was last revised in. </span></b></p>", "ID": "330cc0e0-0458-4b63-b83a-e53fae18c6d7", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">This\nleaflet was last revised in. </span></b>", "ID": "7aeeccd9-e039-41d9-8943-2230c66904e2", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "330cc0e0-0458-4b63-b83a-e53fae18c6d7"}, {"Element": "<span lang=\"EN-GB\">This\nleaflet was last revised in. </span>", "ID": "e8e5dfd1-2f2e-458e-9c6a-942be0c0f6da", "Styles": "None", "Classes": "None", "Text": "This leaflet was last revised in. ", "ParentId": "7aeeccd9-e039-41d9-8943-2230c66904e2"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "a9c6c9b3-0163-459c-ac4b-21d7a8e4fba6", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "0363f17e-eb03-4844-b2f5-cba2a600e066", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a9c6c9b3-0163-459c-ac4b-21d7a8e4fba6"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "186a7d13-6fe5-46e5-b8c6-e924c21cdfc3", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0363f17e-eb03-4844-b2f5-cba2a600e066"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-1.4pt\"><span lang=\"EN-GB\">Detailed\ninformation on this medicine is available on the European Medicines Agency web\nsite: http://www.ema.europa.eu </span></p>", "ID": "b4e093a0-6a49-4a0c-b557-2e4d962a2375", "Styles": "margin-right:-1.4pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span lang=\"EN-GB\">Detailed\ninformation on this medicine is available on the European Medicines Agency web\nsite: http://www.ema.europa.eu </span>", "ID": "d49841ff-63a3-4b8c-af91-3b6ac4160a26", "Styles": "None", "Classes": "None", "Text": "Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu ", "ParentId": "b4e093a0-6a49-4a0c-b557-2e4d962a2375"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:6.0pt;margin-bottom:0in;\nmargin-left:6.35pt;margin-bottom:.0001pt;text-autospace:none\"><span style=\"color:black\">\u00a0</span></p>", "ID": "799899de-afe1-4e51-8f1c-92a191667f84", "Styles": "margin-top:0in;margin-right:6.0pt;margin-bottom:0in;\nmargin-left:6.35pt;margin-bottom:.0001pt;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1556562-cce0-4cdc-9a84-e7791a4be2a1"}, {"Element": "<span style=\"color:black\">\u00a0</span>", "ID": "e379d72f-78b1-4931-bfc5-4958ed23e30a", "Styles": "color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "799899de-afe1-4e51-8f1c-92a191667f84"}]}